

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION
2018 FINAL PROGRAM



38TH ANNUAL MEETING AND SCIENTIFIC SESSIONS

NICE, FRANCE

APRIL 11 – 14, 2018

ISHLT 2018 ACADEMIES

APRIL 10, 2018

[ABOUT ISHLT](#)

[2017-2018 BOARD OF DIRECTORS](#)

[ISHLT STAFF](#)

[2018 ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE](#)

[2018 ABSTRACT REVIEWERS](#)

[ISHLT COMMITTEES ROSTERS](#)

[Corporate Development Committee](#)
[Education Committee](#)
[Governance Committee](#)
[Grants and Awards Committee](#)
[International and Inter-Society Coordination Committee \(I2C2\)](#)
[ISHLT Mechanically Assisted Circulatory Support \(IMACS®\) Registry Steering Committee](#)
[International DCD Registry Steering Committee](#)
[International Pediatric Heart Failure Registry \(IPHFR\) Steering Committee](#)
[International Thoracic Transplant Registry Steering Committee](#)
[Journal of Heart and Lung Transplantation \(JHLT\) Editorial Board](#)
[Registries and Databases Committee](#)
[Standards and Guidelines Committee](#)
[Links Newsletter Editorial Staff](#)

[ISHLT SCIENTIFIC COUNCIL OPERATING BOARDS](#)

[Basic Science and Translational Research](#)
[Chronic Thromboembolic Pulmonary Hypertension](#)
[Heart Failure and Transplantation](#)
[Infectious Diseases](#)
[Junior Faculty and Trainee](#)
[Mechanical Circulatory Support](#)
[Nursing, Health Sciences and Allied Health](#)
[Pathology](#)
[Pediatric Thoracic Transplantation and Heart Failure](#)
[Pharmacy and Pharmacology](#)
[Pulmonary Hypertension](#)
[Pulmonary Transplantation](#)

[PAST PRESIDENTS](#)

[PAST PROGRAM CHAIRS](#)

[JOURNAL AND LINKS NEWSLETTER EDITORS](#)

[REGISTRY MEDICAL DIRECTORS](#)

[ISHLT AWARD RECIPIENTS](#)

[OUTSTANDING ACHIEVEMENT AWARDS:](#)

[ISHLT Pioneer Award](#)
[ISHLT Lifetime Achievement Award](#)
[ISHLT Lifetime Service Award](#)
[Emeritus Membership](#)

[GRANTS AND SCHOLARSHIPS:](#)

[ISHLT Norman E. Shumway Career Development Award](#)
[ISHLT Joel D. Cooper Career Development Award](#)
[ISHLT Nursing Research Grant Award](#)
[ISHLT Research Fellowship Award](#)
[ISHLT Transplant Registry Early Career Award](#)
[ISHLT/Bayer Pulmonary Hypertension Research Grant Award](#)

[ISHLT/O.H. Frazier Award in MCS Translational Research Sponsored by Medtronic](#)
[ISHLT Branislav Radovancevic Memorial Fellowship Grant \(Supported by Thoratec\)](#)
[ISHLT International Traveling Scholarship Award](#)
[ISHLT Leach-Abramson-Imhoff Links Travel Awards](#)

ABSTRACT AWARDS:

[Philip K. Caves Award](#)
[Nursing, Health Sciences & Allied Health Excellence in Research Award](#)
[Early Career Scientist Award](#)
[JFTC Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award](#)
[ISHLT Branislav Radovancevic Memorial Best MCSD Paper Award \(Supported by Thoratec\)](#)

ACCREDITATION INFORMATION / CONTINUING MEDICAL EDUCATION INFORMATION

UNRESTRICTED EDUCATIONAL GRANTS

COMMERCIAL SUPPORT

ANNUAL MEETING HIGHLIGHTS

[Basic Science and Translational Research](#)
[Heart Failure and Transplantation](#)
[Infectious Diseases](#)
[Lung Transplantation](#)
[Mechanical Circulatory Support](#)
[Nursing, Health Sciences and Allied Health](#)
[Pathology](#)
[Pediatric Thoracic Transplantation and Heart Failure](#)
[Pharmacy and Pharmacology](#)
[Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Hypertension](#)

CONVENTION CENTER FLOOR PLANS

[First Floor](#)
[Second Floor](#)
[Third Floor](#)

ACRONYMS

SCIENTIFIC COUNCIL MEETINGS & RECEPTIONS

SCHEDULE AT A GLANCE

[Monday, April 9, 2018](#)
[Tuesday, April 10, 2018](#)
[Wednesday, April 11, 2018](#)
[Thursday, April 12, 2018](#)
[Friday, April 13, 2018](#)
[Saturday, April 14, 2018](#)

WEDNESDAY, APRIL 11, 2018 ANNUAL MEETING SCIENTIFIC PROGRAM

[ORAL SESSION 01: Stop It Without Bleeding: Mechanisms of Stroke in MCS](#)
[ORAL SESSION 02: Thinking Inside The Box: DCD Donation and Ex-vivo Heart Perfusion](#)
[ORAL SESSION 03: Novel Insights About Antibodies in Lung Transplantation](#)
[ORAL SESSION 04: Immunosuppression in Heart Transplantation: Lessons Learned](#)
[ORAL SESSION 05: Don't Go Breaking My Heart: The Assessment, Treatment and Implications of Psychosocial Risk Factors](#)
[ORAL SESSION 06: Building a Better Transplant](#)
[ORAL SESSION 07: Cutting Edge CTEPH: From Metabolomics to Surgical Technique](#)
[OPENING PLENARY SESSION](#)
[SYMPOSIUM 01: The Devil Wears Prada - The Role of the RV in Advanced Heart Failure and LVADs](#)
[SYMPOSIUM 02: Adult Congenital Heart Disease: Reaching the Summit](#)
[SYMPOSIUM 03: Chronic Lung Allograft Dysfunction \(CLAD\): Where Are We Now?](#)

[SYMPOSIUM 04: Cardio-Oncology: A Tale of Two Problems](#)
[SYMPOSIUM 05: The Young and the Restless: Unique Challenges in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults](#)
[SYMPOSIUM 06: Novel Tools in Transplant Research \(Say You Want a Revolution...\)](#)
[SYMPOSIUM 07: The Devil is in the Details - Nuances in CTEPH](#)
[ORAL SESSION 08: Four Liters and Fingers Crossed: ECMO - Management and Outcomes](#)
[ORAL SESSION 09: The Pressure is On! Assessment and Role of Blood Pressure in MCS](#)
[ORAL SESSION 10: Mechanisms of Allograft Injury after Lung Transplantation](#)
[ORAL SESSION 11: Predictable or Inevitable? Complications of Heart Transplantation](#)
[ORAL SESSION 12: The Leading Edge: Novel Practices in Patient Care Pathways](#)
[ORAL SESSION 13: Early Career Scientist Award in Transplantation](#)
[ORAL SESSION 14: Reading Tea Leaves - Heart Failure Prediction Risks](#)
[MINI ORAL 01: Mechanical Circulatory Support: ECMO](#)
[MINI ORAL 02: Heart Transplantation: Outcomes](#)
[MINI ORAL 03: Lung Transplantation, Pulmonary Hypertension and CTEPH](#)
[MINI ORAL 04: Mechanical Circulatory Support: Thrombosis](#)
[MINI ORAL 05: Pediatric Thoracic Transplantation](#)
[MINI ORAL 06: Heart Failure & Transplantation: Outcomes and Antibodies](#)

THURSDAY, APRIL 12, 2018 ANNUAL MEETING SCIENTIFIC PROGRAM

[SYMPOSIUM 08: A Forgotten Organ - The Vascular System on Continuous Flow LVAD Support](#)
[SYMPOSIUM 09: "The Heat Is On" - Great Debates in Heart Transplantation](#)
[SYMPOSIUM 10: Cardiothoracic Transplantation: Too Frail to Rock and Roll, Too Young to Die](#)
[SYMPOSIUM 11: Cystic Fibrosis in Lung Transplantation: Controversial Topics](#)
[SYMPOSIUM 12: CTEPH: Challenges in Intervention Decision Making](#)
[SYMPOSIUM 13: A Day in the Life: The Pathologist as a Member of the Thoracic Transplant Team](#)
[SYMPOSIUM 14: Old Cells New Tricks: Updates on Transplant Immunology](#)
[ORAL SESSION 16: It's Leaking But Nobody Cares: Valvular Disease in MCS](#)
[SYMPOSIUM 15: We Never Stop Learning: 50th Anniversary of Heart Transplantation](#)
[ORAL SESSION 17: The New Frontier: Hepatitis C and Other Viruses](#)
[SYMPOSIUM 16: JHLT at ISHLT: The Year in a Capsule](#)
[ORAL SESSION 18: Mining the Tissue Biopsy: Molecular Signals of Rejection](#)
[ORAL SESSION 19: Improving Lung Transplant Outcomes Through Science](#)
[SYMPOSIUM 17: Rapid Update on MCS Complications and Management: The Unpublished](#)
[SYMPOSIUM 18: It's Electric! Electrophysiologic Management of the LVAD Patient](#)
[SYMPOSIUM 19: Antibody-Mediated Rejection After Lung Transplantation – 2018](#)
[SYMPOSIUM 20: Malignancy in Transplantation: Too Much, Too Early or Too Little, Too Late?](#)
[SYMPOSIUM 21: Great Debates in the Management of PAH: Genetics, Bridge to Lung Transplant, and Goal Directed Therapy](#)
[SYMPOSIUM 22: Cytomegalovirus \(CMV\) in Thoracic Organ Transplantation - A Changing Landscape](#)
[SYMPOSIUM 23: Too Little or Too Much: Controversies in Monitoring After Pediatric Thoracic Transplantation](#)
[ORAL SESSION 20: See One, Do One, Teach One: Novel Management Strategies in MCS](#)
[ORAL SESSION 21: Right and Wrong: The Impact of the Right Ventricle After LVAD](#)
[ORAL SESSION 22: Trials and Treatments in Lung Transplantation](#)
[ORAL SESSION 23: Getting to the Heart and Lung of the Matter: Drugs in Thoracic Transplant](#)
[ORAL SESSION 24: Walking the Tightrope in Heart Transplantation: Outcomes in High Risk Population](#)
[ORAL SESSION 25: Philip K. Caves Award Candidate Presentations](#)
[ORAL SESSION 26: The Perfect Match: Donor and Recipient Effects on Pediatric Thoracic Outcomes](#)
[MINI ORAL 07: Mechanical Circulatory Support: Surgical Techniques](#)
[MINI ORAL 08: Heart Transplantation: PGD and CAV](#)
[MINI ORAL 09: Lung Transplantation: Allograft Function](#)
[MINI ORAL 10: Mechanical Circulatory Support, Pharmacy & Pharmacology](#)
[MINI ORAL 11: Nursing, Health Science & Allied Health, Pediatrics](#)
[MINI ORAL 12: Basic Science & Translational Research](#)

FRIDAY, APRIL 13, 2018 ANNUAL MEETING SCIENTIFIC PROGRAM

[ORAL SESSION 27: How Sick is Too Sick? The Impact of Frailty and Cognitive Function in LVADs](#)
[ORAL SESSION 28: Just Pacing Myself! Electrophysiology and Mechanical Support](#)
[ORAL SESSION 29: Lung Donation after Circulatory Death - Current Status](#)

[ORAL SESSION 30: Infection: Achille's Heel of Mechanical Circulatory Support](#)
[ORAL SESSION 31: Spotlight on a Heart Transplant Donor](#)
[ORAL SESSION 32: Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best](#)
[SYMPOSIUM 24: Retransplantation in the Child to Young Adult - History Repeating Itself?](#)
[PLENARY SESSION: Moving Cardiothoracic Transplantation Forward](#)
[SYMPOSIUM 25: Crashing and Burning: Cardiogenic Shock and Short-term MCS](#)
[SYMPOSIUM 26: Can My Lung Transplant Candidate Take This Medication? What to Do with the New Drugs for Lung Failure](#)
[SYMPOSIUM 27: DCD Lungs - Expanding Utilization](#)
[SYMPOSIUM 28: First Days of a New Life: Management After Heart Transplant](#)
[SYMPOSIUM 29: Joint ISHLT/ESC Symposium: Pulmonary Hypertension Due to Left Heart Disease: When RIGHT Meets LEFT](#)
[SYMPOSIUM 30: Joint ISHLT/TTS-TID Symposium: Infectious Challenges Around the World - Common Threads](#)
[SYMPOSIUM 31: Pediatric Heart Failure: MCS, ICU Care, and Early Graft Dysfunction](#)
[ORAL SESSION 33: We Are Here to Pump...You Up! Exercise in MCS](#)
[ORAL SESSION 34: Getting It Right From the Start: LVAD Implant and Device Failure](#)
[ORAL SESSION 35: Out of Body Experiences: Ten Years of EVLP](#)
[ORAL SESSION 36: Antibodies and Rejection in Heart Transplantation: Donor Cells Tell No Lies](#)
[ORAL SESSION 37: New Treatment Paradigms in Pulmonary Hypertension](#)
[ORAL SESSION 38: Hot Topics in Infectious Diseases](#)
[ORAL SESSION 39: All Is Not Lost: Improving Outcomes in Children with a Failing Heart](#)
[MINI ORAL 13: Mechanical Circulatory Support: Bleeding](#)
[MINI ORAL 14: Lung Transplantation: Organ Allocation and Candidate Selection](#)
[MINI ORAL 15: Heart Transplantation: Donor Issues](#)
[MINI ORAL 16: Basic Science and Infectious Disease Issues](#)

SATURDAY, APRIL 14, 2018 ANNUAL MEETING SCIENTIFIC PROGRAM

[ORAL SESSION 40: Riding the Wave: Hemodynamics in MCS](#)
[ORAL SESSION 41: Crunching the Numbers: Improving Outcomes in Heart Transplantation](#)
[ORAL SESSION 42: Lung Allocation: New Rules and Old Age](#)
[ORAL SESSION 43: A Road Less Traveled: Alternative Mechanisms and Treatments for Heart Failure](#)
[ORAL SESSION 44: The Battle for Hearts, Lungs, Minds and Money](#)
[ORAL SESSION 45: Live Long and Prosper: Long-term Outcomes After Pediatric Heart Transplant](#)
[PLENARY SESSION](#)
[ORAL SESSION 46: Flight Plan: Planning the LVAD Implant](#)
[ORAL SESSION 47: A Melange of Outcomes in Heart Transplantation](#)
[ORAL SESSION 48: Procedures and Standards in Lung Transplantation](#)
[ORAL SESSION 49: Rocket Fuel and Scaffolding: Alternative Bridges to Heart Transplantation](#)
[ORAL SESSION 50: What is Really Going On in The Lung Transplant](#)
[ORAL SESSION 51: I'm at Risk! Outcomes and Novel Risk Stratification in Pulmonary Hypertension](#)

WEDNESDAY, APRIL 11, 2018 – POSTER SESSION 1

[Basic Science and Translational Research](#)
[Economics, Ethics, Public Policy](#)
[Junior Faculty Clinical Case Reports](#)
[Lung Transplantation](#)
[Mechanical Circulatory Support](#)
[Nursing, Health Sciences, Allied Health](#)
[Pathology](#)
[Pharmacy and Pharmacology](#)

THURSDAY, APRIL 12, 2018 – POSTER SESSION 2

[Heart Failure](#)
[Heart Transplantation](#)
[Infectious Diseases](#)
[Junior Faculty Clinical Case Reports](#)
[Mechanical Circulatory Support](#)
[Pediatric Transplantation](#)

FRIDAY, APRIL 13, 2018 – POSTER SESSION 3

[Heart Transplantation](#)
[Lung Transplantation](#)
[Mechanical Circulatory Support](#)
[Pulmonary Hypertension and CTEPH](#)

POSTER MAPS

POSTER SESSION 1, WEDNESDAY

[Gallieni 1-2](#)
[Agora 2](#)
[Agora 3](#)
[Muses/Euterpe](#)

POSTER SESSION 2, THURSDAY

[Gallieni 1-2](#)
[Agora 3](#)
[Muses/Euterpe](#)

POSTER SESSION 3, FRIDAY

[Gallieni 1-2](#)
[Agora 3](#)
[Muses/Euterpe](#)

ISHLT ACADEMY: CORE COMPETENCIES IN HEART FAILURE AND CARDIAC TRANSPLANTATION

ISHLT ACADEMY: CORE COMPETENCIES IN LUNG TRANSPLANTATION

ISHLT ACADEMY: CORE COMPETENCIES IN MECHANICAL CIRCULATORY SUPPORT

ISHLT ACADEMY: MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT

ISHLT ACADEMY: MASTER CLASS IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

AFFILIATE EVENTS

CORPORATE EVENTS AND INDUSTRY THEATER LISTINGS

EXHIBIT HALL FLOOR PLAN

2018 EXHIBITORS AND BOOTH NUMBERS

2018 EXHIBITOR PRODUCT DESCRIPTIONS

FUTURE ANNUAL MEETINGS

ABOUT ISHLT

ISHLT Mission

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

The purposes of the Society are:

1. Promoting the association of persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences;
2. Encouraging and stimulating basic and clinical research in heart and lung transplantation and end-stage heart and lung disease, and promoting new therapeutic strategies;
3. Holding scientific meetings featuring presentations and discussions relevant to heart and lung transplantation and the treatment of end-stage heart and lung disease;
4. Sponsoring a scientific journal for the publication of manuscripts related to these disciplines;
5. Maintaining an international registry for heart and lung transplantation;
6. Awarding research grants and establishing endowments for the study of heart and lung transplantation and end-stage heart and lung disease, when funds are available and without jeopardizing the financial well-being of the organization; and
7. Sponsoring and conducting educational activities and providing educational resources, which promote expert development and improve standards of care in advanced heart and lung disease, heart and lung transplantation, and relevant medical and device therapies.

Society Origins and Description

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3000 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators, and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

2017-2018 BOARD OF DIRECTORS

Andrew J. Fisher, FRCP, PhD, President, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Jeffrey J. Teuteberg, MD, President-Elect, Stanford University School of Medicine, Stanford, CA, United States
Mary R. Johnson, MD, Past President, University of Wisconsin, Madison, WI, United States
Joseph Rogers, MD, Treasurer, Duke University Medical Center, Durham, NC, United States
Lara Danziger-Isakov, MD, MPH, Secretary, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States
Kevin Chan, MD, Director, University of Michigan Health System, Ann Arbor, MI, United States
Jason D. Christie, MD, Director, University of Pennsylvania, Philadelphia, PA, United States
Jennifer Cowger, MD, MS, Director, Henry Ford Hospitals, Detroit, MI, United States
Teresa De Marco, MD, FACC, Director, University of California San Francisco, San Francisco, CA, United States
Tobias Deuse, MD, PhD, Director, University of California at San Francisco, San Francisco, CA, United States
Howard J. Eisen, MD, Director, Drexel University College of Medicine, Philadelphia, PA, United States
Stephan M. Ensminger, MD, DPhil, Director, Ruhr-University Bochum, Bad Oeynhausen, Germany
Daniel J. Goldstein, MD, Director, Montefiore Medical Center, Bronx, NY, United States
Peter M. Hopkins, FRACP, Director, The Prince Charles Hospital, Brisbane, Australia
Michael G. Petty, PhD, RN, CNS, Director, University of Minnesota Medical Center, Minneapolis, MN, United States
Dirk Van Raemdonck, MD, PhD, Director, University Hospital Gasthuisberg, Leuven, Belgium

Ex Officio Board Members

Amanda W. Rowe, ISHLT Executive Director

ISHLT STAFF

Amanda W. Rowe
Executive Director

Jennifer Coy
Deputy Executive Director of Professional Education and Meetings

Lisa Edwards
Director of Meetings

Lee Ann Mills
Director of Finance and Operations

Susie Newton
Programs and Services Manager

Megan Barrett
Programs and Services Assistant

Justin Hickman
Finance and Operations Assistant

Phyllis Glenn
Administrative Assistant

14673 Midway Road, Suite 200
Addison, TX 75001
Phone: 972-490-9495
Fax: 972-490-9499
www.ishlt.org

ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

◆Symposium Planning Committee

★Abstract Selection Committee

Christian Benden, MD FCCP, University Hospital Zurich, Zurich, Switzerland, 2018 Scientific Program Chair ◆★
Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, UK, ISHLT President ◆★
Lara Danziger-Isakov, MD, MPH, Children's Hospital Medical Center, Cincinnati, OH, United States, 2019 Scientific Program Chair ◆★
Jeffrey J. Teuteberg, MD, Stanford University, Palo Alto, CA, United States, 2017 Scientific Program Chair ◆★
Francisco Arabia, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, United States ★
Saima Aslam, MD, UCSD, San Diego, United States ◆★
Raymond Benza, MD, Allegheny General Hospital, Pittsburgh, PA, United States ◆★
Alexander Bernhardt, MD, University Heart Center Hamburg, Hamburg, Germany ◆★
Nancy Blumenthal, CRNP, University of Pennsylvania, Philadelphia, PA, United States ★
Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada ★
Agnieszka Ciarka, MD, KU Leuven, Leuven, Belgium ★
Stephen Clark, FRCS, Freeman Hospital, Newcastle Upon Tyne, UK ★
Rachel Crackett, MSc, Freeman Hospital, Newcastle Upon Tyne, UK ◆★
Marcelo Cypel, MD, University of Toronto, Toronto, ON, Canada ★
Kyle Dawson, PharmD, MBA, BCPS, University of Kentucky, Lexington, KY, United States ★
Teresa De Marco, MD, UCSF, San Francisco, CA, United States ◆★
Howard Eisen, MD, Drexel University College of Medicine, Philadelphia, PA, United States ◆★
Sitaramesh Emani, MD, The Ohio State University, Columbus, OH, United States ★
Melanie Everitt, MD, Children's Hospital Colorado, Aurora, CO, United States ◆★
Savitri Fedson, MD, Baylor College of Medicine, Houston, TX, United States ★
Rochelle Gellatly, PharmD, The Alfred Hospital, Melbourne, Australia ◆★
Ranny Goldwasser, MD, University Children's Hospital Heidelberg, Heidelberg, Germany ◆★
Mark Greer, MB Bch, Hannover Medical School, Hannover, Germany ★
Matthew Hartwig, MD, Duke University, Durham, NC, United States ◆★
Are Martin Holm, MD, PhD, Oslo University Hospital, Oslo, Norway ◆★
Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, United States ◆★
Jason Katz, MD, MHS, University of North Carolina, Chapel Hill, NC, United States ★
Mary Keebler, MD, Vanderbilt University, Nashville, TN, United States ★
Ahmet Kilic, MD, The Ohio State University, Columbus, OH, United States ★
Ivan Knezevic, MD, University Clinical Center, Ljubljana, Slovenia ★
Antonio Loforte, MD, PhD, University of Bologna, Bologna, Italy ★
Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, Australia ◆★
Marco Masetti, MD, University of Bologna, Bologna, Italy ★
Mandeep Mehra, MD, MBBS, FACC, FACP, Brigham & Women's Hospital, Boston, MA, United States ◆★
Joshua Mooney, MD, Stanford University, Palo Alto, CA, United States ★
Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia ◆★
Sanem Nalbantgil, MD, Ege University Tip Hospital, Izmir, Turkey ◆★
Alexandra Rice, FRCPath, Royal Brompton Hospital, London, UK ◆★
Mace Schuurmans, MD, University of Zurich, Zurich, Switzerland ★
Ashish Shah, MD, Vanderbilt University, Nashville, TN, United States ★
Michael Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States ◆★
Jorge Silva Enciso, MD, UCSD, San Diego, CA, United States ◆★
Marc Simon, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States ◆★
Melinda Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, ON, Canada ★

Carmela Tan, MD, Cleveland Clinic, Cleveland, OH, United States ♦★
Mitesh Thakrar, MD, University of Calgary, Calgary, AB, Canada ♦★
Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN, United States ★
Marian Urban, MD, Freeman Hospital, Newcastle Upon Tyne, UK ♦★
Stijn Verleden, PhD, KU Leuven, Leuven, Belgium ♦★
Christopher Wigfield, MD, FRCS, Advocate Christ Medical Center, Chicago, IL, United States ♦★
Keith Wille, MD, MSPH, University of Alabama, Birmingham, AL, United States ♦★
Quincy Young, PhD, RPsych, St. Paul's Hospital, Vancouver, BC, Canada ♦★

ABSTRACT REVIEWERS

Sirtaz Adaty, MD, University of Chicago, Chicago, IL, United States
Clemens Aigner, MD, Ruhrlandklinik, Essen, Germany
Peta Alexander, MBBS, Boston Children's Hospital, Boston, MA, United States
Hakim Ali, MD, Duke University, Durham, NC, United States
Amal Alotaibi, MBBS, University of Texas Medical Branch, Galveston, TX, United States
Cristiano Amarelli, MD, Monaldi Hospital, Napoli, Italy
Amrut Ambardekar, MD, University of Colorado, Aurora, CO, United States
Antonio Amodeo, MD, Bambino Gesù Pediatric Hospital, Rome, Italy
Samantha Anthony, PhD, Hospital for Sick Children, Toronto, ON, Canada
Christina Aquilante, PharmD, University of Colorado, Aurora, CO, United States
Pavan Atluri, MD, University of Pennsylvania, Philadelphia, PA, United States
John-David Aubert, MD, Lausanne University Hospital, Lausanne, Switzerland
William Auger, MD, UCSD Medical Center, San Diego, CA, United States
Sanjeet Singh Avtaar Singh, MSc, Golden Jubilee National Hospital, Glasgow, United Kingdom
Estela Azeka, MD, InCor/University of Sao Paulo, Sao Paulo, Brazil
Roberto Badagliacca, MD, PhD, Sapienza University of Rome, Rome, Italy
Dipanjan Banerjee, MD, Stanford University, Palo Alto, CA, United States
Aditya Bansal, MD, Ochsner Clinic Foundation, New Orleans, LA, United States
David Baran, MD, Sentara Heart Hospital, Norfolk, VA, United States
Jay Baumwol, FRACP, Fiona Stanley Hospital, Murdoch, Australia
Jennifer Beckman, ARNP, University of Washington, Seattle, WA, United States
Jürgen Behr, MD, Hospital of the University of Munich, Munich, Germany
Lavanya Bellumkonda, MD, Yale University, New Haven, CT, United States
Alberto Benazzo, MD, Medical University of Vienna, Vienna, Austria
Mark Benzimra, FRACP, St. Vincent's Hospital, Sydney, Australia
Christian Bermudez, MD, University of Pennsylvania, Philadelphia, PA, United States
Alejandro Bertolotti, MD, Favalaro Foundation, Buenos Aires, Argentina
Pramod Bonde, MD, FACS, Yale University, New Haven, CT, United States
Karen Booth, MBChB, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Gerard Boyle, MD, Cleveland Clinic Children's, Cleveland, OH, United States
Andrew Boyle, MD, Thomas Jefferson University, Philadelphia, PA, United States
Olivier Brugiere, MD, PhD, Hopital Bichat, Paris, France
Patrick Bruneval, MD, University Paris Descartes, Paris, France
Fay Burrows, BPharm, St. Vincent's Hospital, Sydney, Australia
Ryan Butts, MD, UT Southwestern, Dallas, TX, United States
Marco Caccamo, DO, West Virginia University, Morgantown, WV, United States
Fiorella Calabrese, MD, University of Padova, Padova, Italy
Silvia Campos, MD, InCor/University of Sao Paulo, Sao Paulo, Brazil
Edward Cantu, MD, University of Pennsylvania, Philadelphia, PA, United States
Adrian Carlson, PharmD, University of Utah, Salt Lake City, UT, United States
Kevin Carney, MSN, CRNP, CCTC, Temple University, Philadelphia, PA, United States
Chesney Castleberry, MD, Washington University, St. Louis, MO, United States
Sandra Chaparro, MD, University of Miami, Miami, FL, United States
Richard Cheng, MD, University of Washington Medical Center, Seattle, WA, United States
Laveena Chhatwani, MD, Stanford University, Palo Alto, CA, United States
Dawn Christensen, MS, CRNP, Innovative Program Solutions, Pine Grove, PA, United States
Jose Cifrian, PhD, Hospital University Marques Valdecilla, Santander, Spain
Adam Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA, United States
Erin Coglianese, MD, Massachusetts General Hospital, Boston, MA, United States
Robert Cole, MD, Emory University, Atlanta, GA, United States

Monica Colvin, MD, MS, FAHA, University of Michigan, Ann Arbor, MI, United States
Pamela Combs, PhD, RN, University of Chicago, Chicago, IL, United States
Carol Conrad, MD, Lucile Packard Children's Hospital, Palo Alto, CA, United States
Jennifer Conway, MD, Stollery Children's Hospital, Edmonton, AB, Canada
Jennifer Cook, MD, University of Arizona, Tucson, AZ, United States
Hannah Copeland, MD, University of Mississippi Medical Center, Jackson, MS, United States
William Cornwell, MD, University of Colorado, Aurora, CO, United States
Paul Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Andrew Courtwright, MD, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
Jennifer Cowger, MD, MS, Henry Ford Hospitals, Detroit, MI, United States
Maria Crespo, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, United States
Sourbha Dani, MD, Eastern Maine Medical Center, Bangor, ME, United States
Todd Dardas, MD, University of Washington, Seattle, WA, United States
Hiroshi Date, MD, Kyoto University, Kyoto, Japan
Nicolaas de Jonge, MD, PhD, University Medical Center, Utrecht, Netherlands
Michel De Pauw, PhD, Ghent University Hospital, Ghent, Belgium
Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden
Eugene DePasquale, MD, UCLA Medical Center, Los Angeles, CA, United States
Tobias Deuse, MD, UCSF Medical Center, San Francisco, CA, United States
Ravi Dhingra, MD, MPH, University of Wisconsin, Madison, WI, United States
Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, United States
Esme Dijke, PhD, University of Alberta, Edmonton, AB, Canada
Daniel Dilling, MD, Loyola University Medical Center, Maywood, IL, United States
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada
Karen Doucette, MD, University of Alberta, Edmonton, AB, Canada
Stavros Drakos, MD, PhD, University of Utah School of Medicine, Salt Lake City, UT, United States
Hilary DuBrock, MD, Mayo Clinic, Rochester, MN, United States
Anique Ducharme, MD, Montreal Heart Institute, Montreal, QC, Canada
Ignacio Echenique, MD, Cleveland Clinic, Weston, FL, United States
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, United States
Thomas Egan, MD, MSc, University of North Carolina, Chapel Hill, NC, United States
Frank Enseleit, MD, University Hospital, Zurich, Switzerland
Stephan Ensminger, MD, DPhil, Heart & Diabetes Center NRW, Bad Oeynhausen, Germany
Christopher Ensor, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
John Entwistle, MD, PhD, Thomas Jefferson University, Philadelphia, PA, United States
Eric Epailly, MD, University Hospital, Strasbourg, France
Michele Estabrook, MD, Washington University, St. Louis, MO, United States
Gregory Ewald, MD, Washington University, St. Louis, MO, United States
Elie Fadel, MD, Hopital Marie Lannelongue, Le Plessis Robinson, France
Christine Falk, MD, Hannover Medical School, Hannover, Germany
Maryjane Farr, MD, Columbia University Medical Center, New York, NY, United States
Marta Farrero, MD, PhD, Hospital Clinic, Barcelona, Spain
Carol Farver, MD, Cleveland Clinic, Cleveland, OH, United States
Marny Fedrigo, PhD, University of Padua, Padua, Italy
Brian Feingold, MD, MS, Children's Hospital of Pittsburgh, Pittsburgh, PA, United States
Veronica Franco, MD, The Ohio State University, Columbus, OH, United States
Meg Fregoso, MSN, Inova Fairfax Hospital, Falls Church, VA, United States
Maria Frigerio, MD, A. O. Niguarda Ca' Granda, Milan, Italy
Norihide Fukushima, PhD, National Cerebral and Cardiovascular Center, Osaka, Japan
Erik Fung, MB ChB PhD, Prince of Wales Hospital, Shatin, Hong Kong
Sonia Garg, MD, UT Southwestern, Dallas, TX, United States
Patricia Ging, MSc, Mater Misericordiae, Dublin, Ireland
Michael Givertz, MD, Brigham & Women's Hospital, Boston, MA, United States

Allan Glanville, MD, St. Vincent's Hospital, Sydney, Australia
Martin Goddard, FRCPath, Papworth Hospital, Cambridge, United Kingdom
Lee Goldberg, MD, MPH, University of Pennsylvania, Philadelphia, PA, United States
Samuel Goldfarb, MD, Children's Hospital of Philadelphia, Philadelphia, PA, United States
Livia Goldraich, MD, MSc, Hospital de Clinicas, Porto Alegre, Brazil
Daniel Goldstein, MD, Montefiore Medical Center, Bronx, NY, United States
Mardi Gombert-Maitland, MD, Inova Fairfax Hospital, Falls Church, VA, United States
José González-Costello, MD, Hospital University de Bellvitge, Barcelona, Spain
Jeffrey Gossett, MD, UCSF Medical Center, San Francisco, CA, United States
Umesh Goswami, MD, University of Minnesota, Minneapolis, MN, United States
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany
Kate Gould, FRCPath, FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Kathleen Grady, PhD, Northwestern University, Chicago, IL, United States
Aric Gregson, MD, UCLA Medical Center, Los Angeles, CA, United States
Cynthia Gries, MD, Florida Hospital, Orlando, FL, United States
Paolo Antonio Grossi, MD, PhD, University of Insubria, Varese, Italy
Maya Guglin, MD, PhD, University of Kentucky, Lexington, KY, United States
Dipankar Gupta, MD, UF College of Medicine, Gainesville, FL, United States
Ramsey Hachem, MD, Washington University, St. Louis, MO, United States
Denis Hadjiladis, MD, University of Pennsylvania, Philadelphia, PA, United States
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, United States
Elizabeth Hammond, MD, University of Utah School of Medicine, Salt Lake City, UT, United States
Ayesha Hasan, MD, The Ohio State University, Columbus, OH, United States
Chris Hayward, MD, St. Vincent's Hospital, Sydney, Australia
Christian Heim, MD, PhD, University of Erlangen-Nuremberg, Nuremberg, Germany
Jaime Hernandez Montfort, MD, MPH, Baystate Medical Center, Northampton, MA, United States
Brian Houston, MD, Medical University of South Carolina, Charleston, SC, United States
Eileen Hsich, MD, Cleveland Clinic, Cleveland, OH, United States
Chih-Hsin Hsu, MD, PhD, National Cheng Kung University Hospital, Tainan, Taiwan
Howard Huang, MD, Baylor University Medical Center, Dallas, TX, United States
Charles Huddleston, MD, St. Louis School of Medicine, St. Louis, MO, United States
Christine Hui, PharmD, UCSF Medical Center, San Francisco, CA, United States
Sharon Hunt, MD, Stanford University, Palo Alto, CA, United States
Ilhan Inci, MD, University Hospital, Zurich, Switzerland
Amanda Ingemi, PharmD, Sentara Norfolk General Hospital, Norfolk, VA, United States
Claire Irving, MBChB, MRCPCH, MD, Children's Hospital Westmead, Sydney, Australia
Debra Isaac, MD, University of Calgary, Calgary, AB, Canada
Miriam Jacob, MD, Cleveland Clinic, Cleveland, OH, United States
Jama Jahanyar, MD, PhD, Mayo Clinic, Rochester, MN, United States
Jeffrey Javidfar, MD, Emory University School of Medicine, Atlanta, GA, United States
George Javorsky, MBBS, FRACP, Prince Charles Hospital, Brisbane, Australia
Christine Jensen, RN, MSN, St. Joseph Medical Center, Lynden, WA, United States
Ranjit John, MD, University of Minnesota, Minneapolis, MN, United States
Mary Johnson, MD, University of Wisconsin, Madison, WI, United States
Jonathan Johnson, MD, Mayo Clinic, Rochester, MN, United States
Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, United States
Sung-Ho Jung, MD, PhD, Asan Medical Center, Seoul, South Korea
Colleen Juricek, University of Chicago Medical Center, Chicago, IL, United States
Stephen Juvet, MD, PhD, University Health Network, Toronto, ON, Canada
Annemarie Kaan, MCN, RN, St. Paul's Hospital, Vancouver, BC, Canada
Forum Kamdar, MD, PhD, University of Minnesota, Minneapolis, MN, United States
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, United States
Nandkishore Kapadia, MCH, PhD, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

Shalika Katugaha, MD, Inova Fairfax Hospital, Falls Church, VA, United States
Jamie Kennedy, MD, University of Virginia, Charlottesville, VA, United States
Ron Kerman, PhD, Baylor College of Medicine, Houston, TX, United States
Umit Kervan, MD, University of Health Science, Ankara, Turkey
Feras Khaliel, MD, PhD, King Faisal Hospital and Research Center, Riyadh, Saudi Arabia
Sanjeev Khulbey, MCH, CVTS, Apollo Hospital, Hyderabad, India
Kiran Khush, MD, Stanford University, Palo Alto, CA, United States
Michael Kiernan, MD, Tufts Medical Center, Boston, MA, United States
Kyung-Hee Kim, PhD, Sejong General Hospital, Kyung-gi do, South Korea
Miae Kim, PharmD, MS, Brigham & Women's Hospital, Boston, MA, United States
Richard Kirk, FRCP, FRCPC, UT Southwestern, Dallas, TX, United States
Charles Klodell, MD, University of Florida, Gainesville, FL, United States
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, United States
Takushi Kohmoto, MD, PhD, MBA, University of Wisconsin, Madison, WI, United States
Robert Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
Evan Kransdorf, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, United States
A. Sasha Krupnick, MD, University of Virginia, Charlottesville, VA, United States
Jasleen Kukreja, MD, UCSF Medical Center, San Francisco, CA, United States
Johanna Kwakkel-van Erp, PhD, University Medical Center, Utrecht, Netherlands
Jose Luis Lambert Rodriguez, PhD, Hospital University Central de Asturias, Oviedo, Spain
Brandon Larsen, MD, PhD, Mayo Clinic, Rochester, MN, United States
Jacob Lavee, MD, Sheba Medical Center, Tel Hashomer, Israel
Adrian C Lawrence, MD, University of Minnesota, Minneapolis, MN, United States
Jerome Le Pavec, MD, Hopital Marie Lannelongue, Le Plessis Robinson, France
Erika Lease, MD, University of Washington Medical Center, Seattle, WA, United States
Sangjin Lee, MD, Spectrum Health, Grand Rapids, MI, United States
Amanda Leech, RN, BSN, CPTC, University of Pennsylvania Medical Center, Philadelphia, PA, United States
Anthony Lemaire, MD, Robert Wood Johnson Medical Center, Princeton, NJ, United States
Karl Lemstrom, MD, PhD, University of Helsinki, Helsinki, Finland
Clive Lewis, MD, PhD, Papworth Hospital, Cambridge, United Kingdom
Brian Lima, MD, North Shore University Hospital, Roslyn, NY, United States
Kimberly Lin, MD, Children's Hospital of Philadelphia, Philadelphia, PA, United States
Me-Linh Luong, MD, Hopital St. Luc-Montreal University, Montreal, QC, Canada
Haifa Lyster, MSc, Royal Brompton & Harefield NHS Trust, Middlesex, United Kingdom
Guy MacGowan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
George Mallory, MD, Baylor College of Medicine, Houston, TX, United States
Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN, United States
Jiri Maly, MD, PhD, IKEM, Prague, Czech Republic
Pradeep Mammen, MD, UT Southwestern, Dallas, TX, United States
Charles Marboe, MD, Columbia University Medical Center, New York, NY, United States
Fabiana Marcondes-Braga, PhD, Heart Institute, Sao Jose dos Campos, Brazil
Sofia Masri, MD, University of Washington Medical Center, Seattle, WA, United States
H. Todd Massey, MD, Thomas Jefferson University, Philadelphia, PA, United States
Leann Matura, PhD, RN, University of Pennsylvania Medical Center, Philadelphia, PA, United States
Jeremy Mazurek, MD, University of Pennsylvania Medical Center, Philadelphia, PA, United States
David McGiffin, FRACS, The Alfred Hospital, Melbourne, Australia
Dana McGlothlin, MD, Kaiser Permanente, San Francisco, CA, United States
Colleen McIlvennan, University of Colorado, Denver, CO, United States
Scott McKenzie, MBBS, FRACP, Prince Charles Hospital, Brisbane, Australia
Bruno Meiser, MD, University Munich/Grosshadern, Munich, Germany
Vojtech Melenovsky, MD, PhD, IKEM, Prague, Czech Republic
Olaf Mercier, MD, PhD, Hopital Marie Lannelongue, Le Plessis Robinson, France
Anna Meyer, MD, Leipzig Heart Center, Leipzig, Germany

Oliver Miera, MD, German Heart Center, Berlin, Germany
Elina Minami, MD, University of Washington Medical Center, Seattle, WA, United States
Omar Mohamedaly, MD, Duke University, Durham, NC, United States
Selma Mohammed, MD, PhD, MedStar Washington Hospital Center, Washington, DC, United States
Thalachallour Mohanakumar, PhD, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States
Martha Mooney, MD, Sentara Norfolk Transplant Center, Norfolk, VA, United States
Jeffrey Morgan, MD, Texas Heart Institute/Baylor College of Medicine, Houston, TX, United States
Alanna Morris, MD, MSc, Emory University School of Medicine, Atlanta, GA, United States
Francesco Moscato, PhD, Medical University of Vienna, Vienna, Austria
Michael Mulligan, MD, University of Washington School of Medicine, Seattle, WA, United States
Jayan Nagendran, MD, PhD, University of Alberta, Edmonton, AB, Canada
Takeshi Nakatani, MD, PhD, Maki Hospital, Osaka, Japan
Deipanjani Nandi, MD, Nationwide Children's Hospital/OSU, Columbus, OH, United States
Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Johan Nilsson, MD, PhD, Lund University and Skane University Hospital, Lund, Sweden
Minoru Ono, MD, PhD, University of Tokyo, Tokyo, Japan
Isabelle Opitz, MD, University Hospital, Zurich, Switzerland
Mustafa Ozbaran, MD, Ege University, Izmir, Turkey
Robert Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA, United States
Walter Pae, MD, Penn State Hershey Medical Center, Hershey, PA, United States
Francis Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, United States
Scott Palmer, MD, MHS, Duke University, Durham, NC, United States
Amit Parulekar, MD, Baylor College of Medicine, Houston, TX, United States
Hamang Patel, MD, Ochsner Medical Center, New Orleans, LA, United States
Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, United States
Chet Patel, MD, Duke University, Durham, NC, United States
Caroline Patterson, MD, Papworth Hospital, Cambridge, United Kingdom
Simon Pecha, MD, University Heart Center Hamburg, Hamburg, Germany
Carlo Pellegrini, MD, PhD, University of Pavia, Pavia, Italy
Matthias Peltz, MD, UT Southwestern, Dallas, TX, United States
David Peng, MD, University of Michigan, Ann Arbor, MI, United States
Joanna Pepke-Zaba, PhD, Papworth Hospital, Cambridge, United Kingdom
Michael Perch, MD, Rigshospitalet, Copenhagen, Denmark
Michael Pham, MD, California Pacific Medical Center, San Francisco, CA, United States
Sean Pinney, MD, Mount Sinai Hospital, New York, NY, United States
Matthew Pipeling, MD, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
Gregor Poglajen, PhD, University Medical Center, Ljubljana, Slovenia
Evgenij Potapov, MD, PhD, German Heart Center, Berlin, Germany
Luciano Potena, MD, PhD, Bologna University Hospital, Bologna, Italy
Stephanie Pouch, MD, Emory University, Atlanta, GA, United States
Kriti Puri, MD, Texas Children's Hospital/Baylor College of Medicine, Houston, TX, United States
Adam Putschoegl, DO, Mayo Clinic, Rochester, MN, United States
Eugenia Raichlin, MD, Loyola University Medical Center, Maywood, IL, United States
Amresh Raina, MD, Allegheny General Hospital, Pittsburgh, PA, United States
Rajalingam Raja, PhD, UCSF Medical Center, San Francisco, CA, United States
Indranee Rajapreyar, MD, University of Alabama at Birmingham, Birmingham, AL, United States
Aaron Ranasinghe, MD, University Hospital Birmingham, Birmingham, United Kingdom
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada
Ravikumar Ratnagiri, MD, Gleanagles Global Hospital, Chennai, India
Ashwin Ravichandran, MD, St. Vincent Heart Center, Indianapolis, IN, United States
Anna Reed, MD, Royal Brompton & Harefield NHS Trust, Harefield, United Kingdom
Bruno Reichart, MD, LMU Munich, Munich, Germany
Zdenka Reinhardt, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Cecile Robinson, University Hospital, Zurich, Switzerland
Nicola Robinson Smith, RN, MSN, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Desiree Robson, BSc (Hons), St. Vincent's Hospital, Sydney, Australia
Anja Roden, MD, Mayo Clinic, Rochester, MN, United States
Eulalia Roig, MD, PhD, Hospital Sant Pau, Barcelona, Spain
David Rosenthal, MD, Stanford University, Palo Alto, CA, United States
Joseph Rossano, MD, The Children's Hospital, Philadelphia, PA, United States
Antoine Roux, MD, PhD, Foch Hospital, Suresnes, France
Diyar Saeed, MD, PhD, Dusseldorf University Hospital, Dusseldorf, Germany
Omar Saeed, MD, Montefiore Medical Center, Bronx, NY, United States
Zeenat Safdar, MD, Houston Methodist Hospital, Houston, TX, United States
Satoshi Saito, MD, PhD, University of Washington, Seattle, WA, United States
Christopher Salerno, MD, St. Vincent Heart Center, Indianapolis, IN, United States
Elena Sandoval, MD, Hospital Clinic, Barcelona, Spain
Joanna Schaenman, MD, PhD, UCLA Medical Center, Los Angeles, CA, United States
Marc Schechter, MD, Cincinnati Children's Hospital, Cincinnati, OH, United States
Sarah Schettle, PA-C, Mayo Clinic, Rochester, MN, United States
Thomas Schlöglhofer, BSc, Medical University of Vienna, Vienna, Austria
Bastian Schmack, University Hospital Heidelberg, Heidelberg, Germany
Christof Schmid, MD, University Hospital, Regensburg, Germany
Jan Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany
Sonja Schrepfer, MD, PhD, UCSF Medical Center, San Francisco, CA, United States
Stephan Schubert, MD, German Heart Center, Berlin, Germany
Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Christian Schulze, MD, PhD, University Hospital, Jena, Germany
Martin Schweiger, MD, PhD, Children's Hospital, Zurich, Switzerland
Javier Segovia, MD, PhD, Hospital Puerta de Hierro, Madrid, Spain
Craig Selzman, MD, University of Utah, Salt Lake City, UT, United States
Palak Shah, MD, MS, Inova Heart & Vascular Institute, Falls Church, VA, United States
Keyur Shah, MD, Virginia Commonwealth University, Richmond, VA, United States
Kavita Sharma, MD, Johns Hopkins School of Medicine, Baltimore, MD, United States
Ciara Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, United States
Aleem Siddique, MBBS, University of Nebraska Medical Center, Omaha, NE, United States
Jonathan Singer, MD, UCSF Medical Center, San Francisco, CA, United States
Tajinder Singh, MD, Boston Children's Hospital, Boston, MA, United States
Sakima Smith, MD, The Ohio State University, Columbus, OH, United States
Cristy Smith, MD, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States
Jacqueline Smits, PhD, Eurotransplant, Leiden, Netherlands
Laurie Snyder, MD, Duke University, Durham, NC, United States
Behzad Soleimani, MD, Penn State Hershey Medical Center, Hershey, PA, United States
Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany
Joshua Sparks, MD, University of Louisville, Louisville, KY, United States
Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT, United States
Michael Stokes, MBBS, FRACP, Royal Adelaide Hospital, Wayville, Australia
Benjamin Sun, MD, Minneapolis Heart Institute, Minneapolis, MN, United States
Hiroo Takayama, MD, Columbia University Medical Center, New York, NY, United States
Wilson Tang, MD, Cleveland Clinic, Cleveland, OH, United States
Benjamin Tarrant, B.Physio, The Alfred Hospital, Melbourne, Australia
Mustafa Toma, MD, University of British Columbia, Vancouver, BC, Canada
Rade Tomic, MD, University of Minnesota, Minneapolis, MN, United States
Veli Topkara, MD, Columbia University Medical Center, New York, NY, United States
Laurens Tops, MD, PhD, Leiden University Medical Center, Leiden, Netherlands
Dirk Troitzsch, PhD, Aarhus University Hospital, Dessau-Rosslau, Denmark

Fabio M Turazza, MD, Ospedale Niguarda, Milano, Italy
Patricia Uber, PharmD, Virginia Commonwealth University, Richmond, VA, United States
Walt Uber, PharmD, Medical University of South Carolina, Charleston, SC, United States
Nir Uriel, MD, University of Chicago, Chicago, IL, United States
Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada
Jean-Luc Vachieri, MD, Erasme University Hospital, Brussels, Belgium
Vincent Valentine, MD, University of Alabama at Birmingham, Birmingham, AL, United States
Nicole Valenzuela, PhD D(ABHI), UCLA Medical Center, Los Angeles, CA, United States
Bart Vanaudenaerde, PhD, KU Leuven, Leuven, Belgium
Erik Verschuuren, MD, PhD, University Medical Center, Groningen, Netherlands
Wickii Vigneswaran, MD, MBA, Loyola University Medical Center, Maywood, IL, United States
Andre Vincentelli, MD, PhD, CHU Lille, Lille, France
Jan von der Thüsen, MD, PhD, Erasme Medical Center, Rotterdam, Netherlands
Robin Vos, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
Bojan Vrtovec, MD, PhD, UKC Ljubljana, Ljubljana, Slovenia
Florian Wagner, MD, University Heart Center Hamburg, Hamburg, Germany
Rajat Walia, MD, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States
Richard Wampler, MD, Oregon Health Sciences University, Loomis, CA, United States
Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany
Andre Wasler, MD, Medical University, Graz, Austria
Katharina Wassilew, Dscmed MHBA, Rigshospitalet, Copenhagen, Denmark
Robert Weintraub, MBBS, Royal Children's Hospital, Parkville, Australia
Shawn West, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, United States
Helen Whitford, MBBS, FRACP, The Alfred Hospital, Melbourne, Australia
Mark Wigger, MD, Vanderbilt University Medical Center, Nashville, TN, United States
Markus Wilhelm, MD, University Hospital, Zurich, Switzerland
Cameron Wolfe, MBBS(Hons), MPH, Duke University, Durham, NC, United States
Yoshito Yamada, PhD, University Hospital, Zurich, Switzerland
Stephanie Yerkovich, PhD, Prince Charles Hospital, Brisbane, Australia
Roger Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO, United States
Melana Yuzefpolskaya, MD, Columbia University Medical Center, New York, NY, United States
Tomasz Zielinski, MD, Institute of Cardiology, Warsaw, Poland

ISHLT COMMITTEES

CORPORATE DEVELOPMENT COMMITTEE

Joseph Rogers, MD, Chair
Andrew J. Fiser, FRCP, PhD, ISHLT President
Jeffrey J. Teuteberg, MD, President-Elect
Amanda Rowe, ISHLT Executive Director

EDUCATION COMMITTEE

Christopher H. Wigfield, MD, FRCS(C/TH), Director of Educational Affairs
Mardi Gomberg-Maitland, MD, MSc, Committee Vice Chair
Jennifer Cowger, MD, MS, Board of Directors Liaison
Amanda Rowe, ISHLT Executive Director

Additional Committee Members

David Baran, MD
Goran Dellgren, MD, PhD
Howard J. Eisen, MD
Lorriana Leard, MD
Donna M. Mancini, MD
Anna Reed, MD

GOVERNANCE COMMITTEE

Maryl R. Johnson, MD, Chair
Andrew J. Fisher, FRCP, PhD, ISHLT President
Jeffrey J. Teuteberg, MD, President-Elect
Joseph Rogers, MD, Treasurer

At Large Members

Duane Davis, MD, MBA, Past President
David O. Taylor, MD, Past President
Stuart C. Sweet, MD, PhD, Past Secretary/Treasurer

GRANTS AND AWARDS COMMITTEE

Stephan M. Ensminger, MD, DPhil, Co-Chair & Board of Directors Liaison
Kathleen Grady, PhD, APN, FAAN, Co-Chair
Daniel Kreisel, MD, PhD, Co-Chair
Louise M. Fuller, PT, Nursing, Health Sciences & Allied Health Research Grant Awards
Josef Stehlik, MD, MPH, Transplant Registry Early Career Awards

INTERNATIONAL AND INTER-SOCIETY COORDINATION COMMITTEE (I2C2)

Howard J. Eisen, MD, FAHA, FACC, FACP, Chair
Maryl R. Johnson, MD, Board of Directors Liaison
David O. Taylor, MD, Standards & Guidelines Committee Chair
Christopher H. Wigfield, MD, FRCS(C/Th), Director of Educational Affairs
Joseph Rogers, MD, Finance Committee Chair
Josef Stehlik, MD, MPH, Thoracic Registry Medical Director

Councils

Ciara Shaver, MD, PhD, Basic Science & Translational Research Council
Alejandro Bertolotti, Heart Failure & Transplantation Council
Fernanda Silveira, Infectious Disease Council
Hirsch S. Mehta, Junior Faculty & Trainee Council
Rasha Adams, RN, Nursing, Health Sciences & Allied Health Council
Annalisa Angelini, MD, Pathology Council
James D. St. Louis, MD, Pediatric Thoracic Transplantation & Heart Failure Council

Douglas L. Jennings, PharmD, Pharmacy & Pharmacology Council
Manreet Kanwar, MD, Pulmonary Hypertension Council
Denis Hadjiliadis, MD, Pulmonary Transplantation Council

Ad Hoc Members

Jacob Lavee, MD
Lori J. West, MD, DPhil

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS®) REGISTRY INTERIM STEERING COMMITTEE

Daniel J. Goldstein, Chair
Jennifer Cowger, MD, MS, Vice Chair for Data Studies
Jeffrey J. Teuteberg, MD, Board of Directors Liaison
Bart Meyns, MD, EUROMACS Representative
Takeshi Nakatani, MD, PhD, JMACS Representative
Steven Shaw, MBChB, MRCP, PhD, UK Representative
Amanda W. Rowe, ISHLT Executive Director
Rongbing Xie, MPH, Statistician

INTERNATIONAL DCD REGISTRY STEERING COMMITTEE

Dirk Van Raemdonck, MD, PhD, Chair
Wida S. Cherikh, PhD, Biostatistician
Jeffrey J. Teuteberg, MD, Board of Directors Liaison

Active Participating Centers (LUNG)

Allan R. Glanville, MBBS, MD, FRACP
Michael T. Musk, MBBS
Peter M. Hopkins, FRACP
Gregory I. Snell, MD
Marcelo Cypel, MD
Shaf Keshavjee, MD, FRCSC
Michiel E. Erasmus, MD, PhD
Marshall I. Hertz, MD
Roger D. Yusen, MD, MPH
Kenneth R. McCurry, MD, FACS
Frank D'Ovidio, MD, PhD

Starting Up Centers (Heart)

Stephen R. Large, FRCS
Steven SL Tsui, MD, FRCS
Kumud K. Dhital, MD, PhD
Peter MacDonald, MD, PhD

INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY (IPHFR) STEERING COMMITTEE

Anne I. Dipchand, MD, Chair
Jeffrey J. Teuteberg, MD, Board of Directors Liaison
Scott Auerbach, MD
Estela Azeka, MD
Wida S. Cherikh, PhD
Richard Kirk, FRCP, FRCPCH
Beth Kaufman, MD
Aliessa Barnes, MD
David Peng, MD
Philip Thrush, MD
Jennifer Conway, MD
Warren Zuckerman, MD

INTERNATIONAL THORACIC TRANSPLANT REGISTRY STEERING COMMITTEE

Josef Stehlik, MD, MPH, Medical Director & Chair
Jeffrey J. Teuteberg, MD, Board of Directors Liaison

Associate Medical Directors

Kiran K. Khush, MD, Adult Heart (Sept 2021)
Daniel C. Chambers, MBBS, MRCP, FRACP, MD, Adult Lung/Heart-Lung (Sept 2021)
Joseph W. Rossano, MD, Pediatric Heart (Sept 2019)
Samuel B. Goldfarb, MD, Pediatric Lung/Heart-Lung (Sept 2018)

Additional Members

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Outcomes (Sept 2018)
Bruno M. Meiser, MD, OEO Relations (Sept 2018)
Wida S. Cherikh, PhD, Biostatistics
Anna Kucheryavaya, MD, Assistant Biostatistician

JOURNAL FOR HEART AND LUNG TRANSPLANTATION (JHLT) EDITORIAL BOARD

Mandeep R. Mehra, MD, MBBS, FACC, FACP, Editor-in-Chief
Patricia A. Uber, PharmD, Executive Editor
Hilary Campbell, Journal Office Coordinator
Maria Rosa Costanzo, MD, Consulting Editor (Editor Emeritus 1995-1999)
James K. Kirklin, MD, Consulting Editor (Editor Emeritus 2000-2009)

Editorial Board Consultants

Annalisa Angelini, MD (Italy)
William R. Auger, MD (USA)
David A. Baran, MD (USA)
Christian Benden, MD (Switzerland)
Christian A. Bermudez, MD (USA)
Charles E. Canter, MD (USA)
Pablo Castro, MD (Chile)
Jean Connors (USA)
Paul A. Corris, MB, FRCP (UK)
Kevin P. Daly, MD (USA)
John Dark, MB, FRCS (UK)
Kyle L. Dawson, PharmD, MBA, BCPS (USA)
S.W. Denfield, MD (USA)
Mary Amanda Dew, PhD (USA)
Fabienne Dobbels, MSc, PhD (Belgium)
Thomas M. Egan, MD, MSC (USA)
Howard Eisen, MD (USA)
Roger W. Evans, PhD (USA)
Andrew J. Fisher, FRCP, PhD (UK)
Robert Frantz, MD (USA)
Allan R. Glanville, MBBS, MD, FRACP (Australia)
Daniel J. Goldstein, MD (USA)
Paolo Grossi, MD, PhD (Italy)
Margaret Hannan, MD (Ireland)
Marius M. Hoepfer (Germany)
Peter M. Hopkins, FRACP (Australia)
Valluvan Jeevanandam, MD (USA)
Maryl R. Johnson, MD (USA)
Shaf Keshavjee, MD, FRCSC (Canada)
Kiran Kaur Khush, MD (USA)
Richard Kirk, FRCP, FRCPCH (UK)
Jon Kobashigawa, MD (USA)
Neal K. Lakdawala, MD (USA)
Lorriana Leard, MD (USA)
JoAnn Lindenfeld, MD (USA)
Peter MacDonald, MD, PhD (Australia)

Stanley I. Martin, MD (USA)
Tereza Martinu, MD (Canada)
Bruno Meiser, MD (Germany)
Thalachallour Mohanakumar, PhD (USA)
David Morales, MD (USA)
Ivan Netuka, MD, PhD (Czech Republic)
Francis Pagani, MD, PhD (USA)
Sean P. Pinney, MD (USA)
Jeffery L. Platt, MD (USA)
Evgenij V. Potapov, MD, PhD (Germany)
Luciano Potena, MD, PhD (Italy)
Joseph G. Rogers, MD (USA)
Heather J. Ross, MD, MHSc, FRCPC (Canada)
Lewis Rubin, MD (USA)
Stephan Schueler, MD, PhD, FRCS (UK)
Martin Schweiger, MD (Switzerland)
Keyur B. Shah, MD (USA)
Jacqueline M. Smits, MD, PhD (The Netherlands)
Josef Stehlik, MD, MPH (USA)
Jeffrey J. Teuteberg, MD (USA)
Jean Luc Vachiery, MD (Belgium)
Hector O. Ventura, MD (USA)
Geert Verleden, MD, PhD (Belgium)
Robin Vos, MD, PhD (Belgium)
Aaron Waxman, MD, PhD (USA)
Lori J. West, MD, DPhil (Canada)
Roger D. Yusen, MD, MPH (USA)
Michael Zakliczynski, MD (Poland)

REGISTRIES AND DATABASES COMMITTEE

Josef Stehlik, MD, MPH, Chair (July 2022)
Jeffrey J. Teuteberg, MD, Board of Directors Liaison
Wida S. Cherikh, PhD, Biostatistician for the International Thoracic, International Pediatric Heart Failure, and Donation After Cardiac Death (DCD) Registries
Daniel J. Goldstein, MD, IMACS Registry Committee Chair
Rongbing Xie, MPH, IMACS Registry Biostatistician
Anne I. Dipchand, MD, International Pediatric Heart Failure Registry Committee Chair
Dirk Van Raemdonck, MD, PhD, International Donation after Cardiac Death (DCD) Registry Committee Chair
Roger D. Yusen, MD, MPH, Additional Member

STANDARDS AND GUIDELINES COMMITTEE

David O. Taylor, MD, Chair
Peter Hopkins, FRACP, Vice Chair
Teresa De Marco, MD, FACC, Board of Directors Liaison
Megan Barrett, ISHLT Staff Liaison

Council Workforce Leaders

Keshava Rajagopal, MD, PhD, Basic Science & Translational Research Council
Hannah Copeland, MD, Heart Failure & Transplantation Council
Valentina Stosor, MD, Infectious Disease Council
Agnieszka Ciarka, MD, Junior Faculty & Trainee Council
David A. D'Alessandro, MD, Mechanical Circulatory Support Council
Colleen Juricek, Nursing, Health Sciences & Allied Health Council
Anja C. Roden, MD, Pathology Council
Steven Kindel, MD, Pediatric Thoracic Transplantation & Heart Failure Council
Kevin Daly, MD, Pediatric Thoracic Transplantation & Heart Failure Council
Robert L. Page, II, Pharm D, MS, Pharmacy & Pharmacology Council
Oksana Shlobin, MD, Pulmonary Hypertension Council
Erika D. Lease, MD, Pulmonary Transplantation Council

LINKS NEWSLETTER EDITORIAL STAFF

Vincent Valentine, MD, Editor
Megan Barrett, Managing Editor

Senior Associate Editors

Pamela Combs, PhD, RN
Paul Corris, MB, FRCP
John Dark, MB, FRCS
Roger Evans, PhD
Allan Glanville, MBBS, MD, FRACP
Maryl Johnson, MD

Associate Editors

Manreet Kanwar, MD, Cardiology
Claudius Mahr, DO, Cardiology
Joshua Mooney, MD, Junior Faculty & Trainee
Stephanie Pouch, MD, Infectious Disease
Emily Stimpson, MSN, FN, CCTC, Nursing, Health Sciences & Allied Health
Maryanne R. Chrisant, MD, Pediatrics
Daniel F. Dilling, MD, Pulmonary Transplantation

International Correspondents Board

Zargham Ahmadi, MD (Iran)
Javier Carbone, MD, PhD (Spain)
Marco Masetti, MD, PhD (Italy)
Andreas Zuckermann, MD (Austria)

Council Communications Liaisons

Howard J. Eisen, MD, Basic Science & Translational Research Council
David P. Nelson, MD, Heart Failure & Transplantation Council
Saima Aslam, MD, MS, Infectious Diseases Council
Jorge Silva Enciso, MD, Junior Faculty & Trainee Council
Evgenij Potapov, MD, PhD, Mechanical Circulatory Support Council
Kirsten Diegel, RD, LDN, Nursing, Health Sciences & Allied Health Council
Jill Giordano, MA, MSW, LCSW, Nursing, Health Sciences & Allied Health Council
Brandon Larsen, MD, PhD, Pathology Council
Martin Schweiger, Pediatric Thoracic Transplantation and Heart Failure Council
Ed Horn, PharmD, BCPS, Pharmacy & Pharmacology Council
Amresh Raina, MD, Pulmonary Hypertension Council
Jussi Tikkanen, MD, PhD, Pulmonary Transplantation Council

ISHLT SCIENTIFIC COUNCIL OPERATING BOARDS

BASIC SCIENCE AND TRANSLATIONAL RESEARCH

Edward Cantu, III, MD, Chair
Joshua M. Diamond, MD, Vice Chair
Sonja Schrepfer, MD, PhD, Past Chair
Stephan M. Ensminger, MD, DPhil, Board of Directors Liaison
Mary Porteous, MD, Education Committee Workforce Leader
Ciara M. Shaver, MD, PhD, I2C2 Workforce Leader
Keshava Rajagopal, MD, PhD, Standards & Guidelines Committee Workforce Leader
Doris A. Taylor, PhD, Senior Advisor
Jeffrey L. Platt, MD, Senior Advisor
Howard J. Eisen, MD, FAHA, FACC, FACP, ISHLT Links Newsletter Liaison
Pradeep P. A. Mammen, MD, FACC, FAHA, Heart Failure & Transplantation Council Liaison
Aric Gregson, MD, Infectious Diseases Council Liaison
Simon Pecha, MD, Junior Faculty & Trainee Council Liaison
J. Michael DiMaio, MD, Mechanical Circulatory Support Council Liaison
Monica Horn, RN, CCRN, CCTC, Nursing, Health Sciences & Allied Health Council Liaison
Annalisa Angelini, MD, Pathology Council Liaison
Aaron B. Waxman, MD, PhD, Pulmonary Hypertension Council Liaison
Pablo G. Sanchez, MD, PhD, Pulmonary Transplantation Council Liaison

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

William R. Auger, MD, Chair
Marc De Perrot, MD, Vice Chair-Elect
Jason D. Christie, MD, Board of Directors Liaison
Manreet Kanwar, MD, Education Workforce Leader

HEART FAILURE AND TRANSPLANTATION

Michael Pham, MD, MPH, Chair
Jignesh K. Patel, MD, PhD, Vice Chair
Marta Farerro, MD, PhD, Vice Chair-Elect
Monica M. Colvin, MD, Past Chair
Howard J. Eisen, MD, FAHA, FACC, FACP, Board of Directors Liaison
Daniel H. Kim, MD, Education Committee Workforce Leader
Alejandro Bertolotti, MD, I2C2 Workforce Leader
Hannah Copeland, MD, Standards & Guidelines Committee Workforce Leader
David P. Nelson, MD, ISHLT Links Newsletter Liaison
Pradeep P.A. Mammen, MD, FACC, FAHA, Basic Science & Translational Research Council Liaison
Natasha Altman, MD, Junior Faculty & Trainee Council Liaison
Marco Masetti, MD, PhD, Junior Faculty & Trainee Council Liaison
Edith Boyes, MSN, FNP-BC, CHFNP, Nursing, Health Sciences & Allied Health Council Liaison

INFECTIOUS DISEASES

Me-Linh Luong, MD, Chair
Saima Aslam, MD, MS, Vice Chair-Elect
Paolo A. Grossi, MD, PhD, Past Chair
Joseph Rogers, MD, Board of Directors Liaison
Joanna Schaenman, MD, PhD, Education Committee Workforce Leader
Fernanda Silveira, MD, I2C2 Workforce Leader
Valentina Stosor, MD, Standards & Guidelines Committee Workforce Leader
Saima Aslam, MD, MS, ISHLT Links Newsletter Liaison
Aric Gregson, MD, Basic Science & Translational Research Council Liaison
Ignacio A. Echenique, MD, Junior Faculty & Trainee Council Liaison

JUNIOR FACULTY AND TRAINEE

Keyur B. Shah, MD, Chair
Evan P. Kransdorf, MD, PhD, Vice Chair
Martin Schweiger, MD, Vice Chair-Elect
Eugene C. DePasquale, MD, Past Chair
Mary Johnson, MD, Board of Directors Liaison
Martin Schweiger, MD, Education Workforce Leader
Hirsch S. Mehta, MD, I2C2 Workforce Leader
Agnieszka Ciarka, MD, Standards & Guidelines Committee Workforce Leader
Jorge Silva Enciso, MD, ISHLT Links Newsletter Liaison
Simon Pecha, MD, Basic Science & Translational Research Council Liaison
Natasha Altman, MD, Heart Failure & Transplantation Council Liaison
Marco Masetti, MD, PhD, Heart Failure & Transplantation Council Liaison
Ignacio Echenique, MD, Infectious Diseases Council Liaison
Jaime Hernandez Montfort, MD, MPH, Mechanical Circulatory Support Liaison
Feras Khaliel, MD, PhD, Mechanical Circulatory Support Council Liaison
Colleen K. McIlvennan, Nursing, Health Sciences & Allied Health Council Liaison
Claire A. Irving, MBChB, MRCPCH, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison
Ann Punnoose, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison
Marco A. Caccamo, MD, Pulmonary Hypertension Council Liaison
Joshua J. Mooney, MD, Pulmonary Transplantation Council Liaison
Darko Vucicevic, MD, International Liaison

MECHANICAL CIRCULATORY SUPPORT

Nir Uriel, MD, Chair
Simon Maltais, MD, PhD, Vice Chair
Stephan Schueler, MD, PhD, FRCS, Past Chair
Tobias Deuse, MD, PhD, Board of Directors Liaison
Diyar Saeed, MD, PhD, Education Committee Workforce Leader
David A. D'Alessandro, MD, Standards & Guidelines Committee Workforce Leader
Evgenij V. Potapov, MD, ISHLT Links Newsletter Liaison
Dawn M. Christensen, MS, CRNP, VAD Coordinator Liaison
J. Michael DiMaio, MD, Basic Science & Translational Research Council Liaison
Jaime Hernandez Montfort, MD, MPH, Junior Faculty & Trainee Council Liaison
Feras Khaliel, MD, PhD, Junior Faculty & Trainee Council Liaison
Jennifer A. Beckman, MSN-FNP, RN, CHFN, Nursing, Health Sciences & Allied Health Council Liaison
Angela Lorts, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison

NURSING, HEALTH SCIENCES AND ALLIED HEALTH

Kevin Carney, MSN, CRNP, CCTC, Chair
Pamela S. Combs, PhD, RN, Vice Chair
Caron Burch, RN, MSN, FNP, CCTC, Vice Chair-Elect
Samantha J. Anthony, PhD, MSW, Past Chair
Michael G. Petty, PhD, RN, CCNS, CNS, Board of Directors Liaison
Caron Burch, RN, MSN, FNP, CCTC, Education Workforce Leader
Rasha Adam, RN, I2C2 Workforce Leader
Colleen Juricek, Standards & Guidelines Committee Workforce Leader
Louise M. Fuller, PT, Grants & Award Committee Workforce Leader
Kirsten Diegel, RD, LDN, ISHLT Links Newsletter Liaison
Jill Giordano, MA, MSW, LCSW, Links Newsletter Liaison
Monica Horn, RN, CCRN, CCTC, Basic Science & Translational Research Council Liaison
Edith Boyes, MSN, FNP-BC, CHFN, Heart Failure & Transplantation Council Liaison
Colleen McIlvennan, Junior Faculty & Trainee Council Liaison
Jennifer A. Beckman, MSN-FNP, RN, CHFN, Mechanical Circulatory Support Council Liaison
Jodie Lantz, CNS, Pediatric Thoracic Transplantation & Heart Failure Council Liaison
Rachel M. Crackett, MSc, Pulmonary Hypertension Council Liaison
Nicole Davis, BSN, MPH, CCTC, Pulmonary Transplantation Council Liaison

PATHOLOGY

Robert F. Padera, MD, PhD, Chair
Fiorella Calabrese, MD, Vice Chair
Martin J. Goddard, FRCS, MRCPa, Past Chair
Dirk Van Raemdonck, MD, PhD, Board of Directors Liaison
Annalisa Angelini, MD, I2C2 Workforce Leader
Anja C. Roden, MD, Standards & Guidelines Committee Workforce Leader
Brandon T. Larsen, MD, PhD, ISHLT Links Newsletter Liaison
Annalisa Angelini, MD, Basic Science & Translational Research Council Liaison

PEDIATRIC THORACIC TRANSPLANTATION AND HEART FAILURE

Brian Feingold, MD, MS, Chair
Carol K. Conrad, MD, Vice Chair
Tajinder P. Singh, MD, MSc, Past Chair
Kevin Chan, MD, Board of Directors Liaison
Beth Kaufman, MD, Education Committee Workforce Leader
James D. St. Louis, MD, I2C2 Workforce Leader
Steven Kindel, MD, Standards & Guidelines Committee Workforce Leader
Kevin Daly, MD, Standards & Guidelines Committee Workforce Leader
Ryan Butts, MD, Pediatric Heart Failure Workforce Leader
Marc Schechter, MD, Pediatric Lung Transplant Workforce Leader
Martin Schweiger, MD, ISHLT Links Newsletter Liaison
Claire Irving, MBChB, MRCPCH, Junior Faculty & Trainee Council Liaison
Ann Punnoose, MD, Junior Faculty & Trainee Council Liaison
Angela Lorts, MD, Mechanical Circulatory Support Council Liaison
Jodie Lantz, CNS, Nursing, Health Sciences & Allied Health Council Liaison

PHARMACY AND PHARMACOLOGY

Adam B. Cochrane, PharmD, MPH, Chair
Haifa Lyster, MSc, Vice Chair
Walter Uber, PharmD, Past Chair
Daniel J. Goldstein, MD, Board of Directors Liaison
Tam Khuu, PharmD, BCPS, Education Committee Workforce Leader
Douglas L. Jennings, PharmD, I2C2 Workforce Leader
Robert L. Page, II, PharmD, MS, Standards & Guidelines Committee Workforce Leader
Edward Horn, PharmD, BCPS, ISHLT Links Newsletter Liaison

PULMONARY HYPERTENSION

Dana P. McGlothlin, MD, Chair
Jean-Luc Vachiery, MD, Vice Chair
Ioana Preston, MD, Vice Chair-Elect
Mardi Gomberg-Maitland, MD, MSc, Past Chair
Teresa De Marco, MD, FACC, Board of Directors Liaison
Ioana Preston, MD, Education Workforce Leader
Manreet Kanwar, MD, I2C2 Workforce Leader
Oksana A. Shlobin, MD, FACC, Standards & Guidelines Committee Workforce Leader
Amresh Raina, MD, ISHLT Links Newsletter Liaison
Aaron B. Waxman, MD, PhD, Basic Science & Translational Research Council Liaison
Marco A. Caccamo, MD, Junior Faculty & Trainee Council Liaison
Rachel M. Crackett, MSc, Nursing, Health Sciences & Allied Health Council Liaison

PULMONARY TRANSPLANTATION

Cynthia J. Gries, MD, MSc, Chair
Ramsey R. Hachem, MD, Vice Chair
Glen P. Westall, FRACP, PhD, Vice Chair-Elect
Michael Mulligan, MD, Past Chair
Peter M. Hopkins, FRACP, Board of Directors Liaison

Lorriana E. Leard, MD, Education Committee Workforce Leader
Denis Hadjiliadis, MD, I2C2 Workforce Leader
Erika D. Lease, MD, Standards & Guidelines Committee Workforce Leader
Jonathan P. Singer, MD, MS, Quality of Life Workforce Leader
Jussi Tikkanen, MD, PhD, ISHLT Links Newsletter Liaison
Pablo G. Sanchez, MD, PhD, Basic Science & Translational Research Council Liaison
Joshua J. Mooney, MD, Junior Faculty & Trainee Council Liaison
Nicole Davis, BSN, MPH, CCTC, Nursing, Health Sciences & Allied Health Council Liaison

PAST PRESIDENTS

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD
2000-2001	Anne Keogh, MBBS, MD
2001-2002	James B. Young, MD
2002-2003	Stephan Schueler, MD
2003-2004	Jon Kobashigawa, MD
2004-2005	Alec Patterson, MD
2005-2006	Mark L. Barr, MD
2006-2007	Robert C. Robbins, MD
2007-2008	Paul A. Corris, MB FRCP
2008-2009	Mandeep R. Mehra, MD
2009-2010	James K. Kirklin, MD
2010-2011	John Dark, MB, FRCS
2011-2012	Lori J. West, MD, DPhil
2012-2013	David O. Taylor, MD
2013-2014	Allan R. Glanville, MBBS, MD, FRACP
2014-2015	Hermann Reichenspurner, MD, PhD
2015-2016	Duane Davis, MD, MBA
2016-2017	Maryl Johnson, MD

PAST PROGRAM CHAIRS

1981	San Francisco, CA	Edward B. Stinson, MD and Michael L. Hess, MD
1982	Phoenix, AZ	Jack Copeland, MD
1983	New Orleans, LA	Jack Copeland, MD
1984	New York, NY	Jack Copeland, MD
1985	Anaheim, CA	Bartley Griffith, MD
1986	New York, NY	Terence A. H. English
1987	New Orleans, LA	John C. Baldwin, MD
1988	Los Angeles, CA	John C. Baldwin, MD
1989	Munich, Germany	Joel D. Cooper, MD
1990	San Diego, CA	D. Glenn Pennington, MD
1991	Paris, France	John B. O'Connell, MD
1992	San Diego, CA	Eric A. Rose, MD
1993	Boca Raton, FL	Maria Rosa Costanzo, MD
1994	Venice, Italy	John Wallwork, MBChB, FRCS
1995	San Francisco, CA	Leslie W. Miller, MD
1996	New York, NY	William A. Baumgartner, MD
1997	London, England	Stephan Schueler, MD
1998	Chicago, IL	James B. Young, MD
1999	San Francisco, CA	Mark L. Barr, MD
2000	Osaka, Japan	Jon Kobashigawa, MD
2001	Vancouver, Canada	David O. Taylor, MD
2002	Washington, DC	Robert C. Robbins, MD
2003	Vienna, Austria	Bruce R. Rosengard, MD
2004	San Francisco, CA	Mandeep R. Mehra, MD
2005	Philadelphia, PA	Shaf Keshavjee, MD
2006	Madrid, Spain	John Dark, MB, FRCS
2007	San Francisco, CA	Duane Davis, MD
2008	Boston, MA	Lori J. West, MD, DPhil
2009	Paris, France	Randall C. Starling, MD, MPH
2010	Chicago, IL	Hermann Reichenspurner, MD, PhD
2011	San Diego, CA	Richard N. Pierson, III, MD
2012	Prague, Czech Republic	Stuart C. Sweet, MD, PhD
2013	Montreal, Canada	Allan R. Glanville, MBBS, MD, FRACP
2014	San Diego, CA	Jason D. Christie, MD
2015	Nice, France	Andreas Zuckermann, MD
2016	Washington, DC	Andrew J. Fisher, FRCP, PhD
2017	San Diego, CA	Jeffrey J. Teuteberg, MD

EDITORS

JOURNAL OF HEART AND LUNG TRANSPLANTATION

1981-1985	Jacques G. Losman, MD
1986-1994	Michael P. Kaye, MD
1995-1999	Maria Rosa Costanzo, MD
2000-2009	James K. Kirklin, MD
2010-Present	Mandeep R. Mehra, MD

LINKS NEWSLETTER

2008-2011	David S. Feldman, MD, PhD
2011-Present	Vincent G. Valentine, MD

MEDICAL DIRECTORS

INTERNATIONAL REGISTRY FOR HEART AND LUNG TRANSPLANTATION

1987-1993	Michael P. Kaye, MD
1993-2001	Jeffrey D. Hosenpud, MD
2001-2012	Marshall I. Hertz, MD
2012-Present	Josef Stehlik, MD, PhD

ISHLT AWARD RECIPIENTS

OUTSTANDING ACHIEVEMENT AWARDS:

ISHLT PIONEER AWARD

2000 Christiaan Barnard, MD
Joel D. Cooper, MD
Norman E. Shumway, MD
2002 Michael DeBakey, MD
Bruce A. Reitz, MD
2006 Leonard L. Bailey, MD
2008 Richard E. Lower, MD
2009 Christian E. A. Cabrol, MD
2011 Elizabeth Hammond, MD
2013 Jack G. Copeland, MD
2015 Bruno Reichart, MD
2016 Sir Roy Calne, FRCP, FRCS, FRS

ISHLT LIFETIME ACHIEVEMENT AWARD

1996 Norman Shumway, MD
1999 Keith Reemtsma, MD
2004 Sir Magdi Yacoub, MD
2010 Margaret Billingham, MD
2012 Sharon Hunt, MD
2014 Sir Terence English, KBE, FRCS
2016 Adrian Kantrowitz, MD
Jean Kantrowitz, MPH
2018 O. Howard Frazier, MD

ISHLT LIFETIME SERVICE AWARD

1996 Michael P. Kaye, MD
1997 Jacques G. Losman, MD

EMERITUS MEMBERSHIP

Margaret D. Allen, MD
Christian Cabrol, MD
Sir Terence English, KBE, FRCS
Albert J. Guerraty, MD
Sharon A. Hunt, MD
Carl V. Leier, MD
Bruno Reichart, MD
Marlene Rose, PhD
John Wallwork, FRCS
Elaine M. Winkel, MD
Prof. Magdi Yacoub, MD

GRANTS AND SCHOLARSHIPS:

ISHLT NORMAN E. SHUMWAY CAREER DEVELOPMENT AWARD

2000 Gordon D. Wu, MD (supported by Roche)
2002 Anthony Azakie, MD (supported by Roche)
2004 Allan M. Ramirez, MD (supported by Novartis Pharma)
2006 Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)
2008 Glen Westall, MD, PhD (supported by Roche)
2010 Sonja Schrepfer, MD, PhD (supported by Astellas)
2012 Tereza Martinu, MD, PhD

- 2014 Keshava Rajagopal, MD, PhD
- 2015 Xingan Wang, MD, PhD
- 2016 Stephen Juvet, MD, PhD, FRCPC
- 2017 Nicole Valenzuela, PhD, D(ABHI)
- 2018 David Schibilsky, MD

ISHLT JOEL D. COOPER CAREER DEVELOPMENT AWARD

- 2017 Keki Blasara, MD
- 2018 Brian Wong, PhD

ISHLT NURSING RESEARCH GRANT AWARD

- 1997 Eileen Collins, RN, PhD
- 1998 Katherine St. Clair, RN, MSN
- 1999 Jeanne Salyer, PhD
- 2000 Nancy M. Albert, MSN, RN
- 2001 Lynn Doering, RN, DNSc
- 2002 Annette J. De Vito Dabbs, RN, MN, PhD
- 2003 Diane H. Leloudis, RN, MSN
Janet E. Madill, PhD
- 2004 Deidre E. Logan, PhD
- 2005 Annemarie F. Kaan, MCN
- 2006 Thierry Troosters, PhD
- 2007 Mi-Kyung Song, PhD
- 2008 Stacey M. Pollock-BarZiv, PhD
- 2009 Jane MacIver, RN, MSc
- 2010 Heike Spaderna, PhD
Gerdi Weidner, PhD
- 2011 Christiane Kugler, PhD (supported by CSL Behring)
Hilde Bollen, RN
- 2012 Lut Berben, PhD, RN (supported by CSL Behring)
Connie White-Williams, PhD, RN, FAAN
- 2013 Jo Wray, PhD
Jane Haines, DNP, RN, CMSRN
- 2014 Lea Ann Matura, PhD, RN
- 2015 JiYeon Choi, PhD, RN
- 2016 Mohammad Alrawashdeh, BSN, MSN
- 2016 Melissa Cousino, PhD (Jointly Funded by Enduring Hearts)
- 2017 Samantha Anthony, PhD, MSW
- 2018 Martha Abshire, PhD, RN
Mary Amanda Dew, PhD

ISHLT RESEARCH FELLOWSHIP AWARD

- 1995 Frances L. Johnson, MD (supported by Ortho-Biotech)
- 1996 Tuija S. Ikonen, MD (supported by Roche)
Andrew F. Pierre, MD (supported by Ortho-Biotech)
- 1997 Jonathan Chen, MD (supported by Roche)
Alyssa M. Krasinskas, MD (supported by Astellas)
Owen T. Lawrence, MD (supported by Ortho-Biotech)
Anne K. Raisanen-Sokolowski, MD (supported by Roche)
- 1998 Kelly S.A. Blair, MD (supported by Roche)
A.M. El Gamel, MD (supported by Roche)
Christine L. Lau, MD (supported by Wyeth-Ayerst)
Scott D. Ross, MD
Margaret L. Schwarze, MD (supported by Novartis)
- 1999 George Juang, MD (supported by Novartis)
Sivasai Krovvidi, PhD (supported by Roche)
Satoshi Saito, MD (supported by Novartis)
Donald Wong, PhD (supported by Roche)

2000 Richard S. Lee, MD (supported by Novartis)
 Christopher H. Wigfield, FRCS (supported by Roche)

2001 Arnar Geirsson, MD (supported by Roche)
 Matteo Vatta, PhD (supported by Roche)

2002 Ruediger Hoebelt, MD (supported by Roche)

2003 Ewout J. van den Bos, MD (supported by Astellas)
 Felix Fernandez, MD (supported by Roche)

2004 Christian A. Gleissner, MD (supported by Astellas)
 Tsuyoshi Shoji, MD, PhD (supported by Actelion)
 Kendra N. Taylor, PhD (supported by Roche)
 Monica Zwierzchonieuska, MD (supported by XDx)

2005 Ryan C. Fields, MD (supported by Chiron)
 Arne Neyrinck, MD (supported by Astellas)
 Ahmad Saad, MD (supported by Roche)

2006 Rachel L. Anderson, MBBS (supported by Roche)
 Zhaohui Li, PhD (supported by Transmedics)
 Heather E. Merry, MD (supported by Encysive)
 Edward N. Seung, PhD (supported by XDx)
 Matthew J. Weiss, MD (supported by Novartis)

2007 J. Raymond Fitzpatrick, III, MD (supported by Encysive)
 Howard J. Huang, MD (supported by Transmedics)
 Mylvaganam Jeyakanthan, MD (supported by XDx)
 Timothy M. Millington, MD (supported by Novartis)
 Satish N. Nadig, MD (supported by Roche)
 Takeshi Oyaizu, MD, PhD (supported by Actelion)
 Sonja Schrepfer, MD (supported by Astellas)

2008 Jonathan Choy, PhD (supported by XDx)
 Satoshi Itoh, MD (supported by Transmedics)
 Tereza Martinu, MD (supported by Novartis)
 Deepti Saini, PhD (supported by Gilead)
 Atsushi Shiozaki, MD, PhD (supported by Astellas)
 Seiichiro Sugimoto, MD, PhD (supported by Roche)

2009 Hua Shen, MD, PhD (supported by Astellas)
 Tobias Deuse, MD, PhD (supported by Novartis)
 Masahiro Miyajima, MD, PhD (supported by XDx)
 Shin Hirayama, MD, PhD (supported by Gilead)

2010 Esme Dijke, PhD (supported by Novartis)
 Smita Sihag, MD (supported by Genentech)
 Sumiharu Yamamoto, MD (supported by Gilead)
 Khurram Shahzad, MD (supported by United Therapeutics)
 Nina Pilat, MSc, PhD (supported by XDx)

2011 Alejandro Bribriescio, MD (supported by Astellas)
 Alexey Dashkevich, MD (supported by XDx)
 Patricia E. de Almeida, DVM, MS, PhD
 Tiago Machuca, MD, PhD

2012 Stephen C. Juvet, MD, FRCPC
 Maria Lucia L. Madariga, MD
 Jessica H. Spahn, PhD
 Konstantinos Malliaras, PhD

2013 Nikolaos Diakos, MD
 Raymond Givens, MD, PhD
 Pablo Sanchez, MD, PhD

2014 Charles Evans, MD
 Christine Lin, MD
 Stijn Verleden, PhD

2015 Jonathan Merola, MD

2016 Hsi-Min Hsaio, PhD
 Nikolas Skartsis, MD, PhD
 Corey Tabit, MD, MBA, MPH

2017 Ramiro Fernandez, MD

2018 Ei Miyamoto, MD

ISHLT TRANSPLANT REGISTRY EARLY CAREER AWARD

(formerly Junior Faculty Award)

- 2007 Beth D. Kaufman, MD
2008 Cynthia Gries, MD, MSc
Scott Halpern, MD, PhD
Josef Stehlik, MD, MPH
2010 Jennifer Conway, MD, FRCPC
Kiran K. Khush, MD, MAS
2011 Jose Nativi, MD
2012 Erin M. Lowery, MD
Omar E. Wever-Pinzon, MD
2013 Chesney Castleberry, MD
Eugene DePasquale, MD
Aaron Healy, MD
2014 Marian Urban, MD
Miranda Paraskeva, MBBS
Hrishikesh Kulkarni, MD
Agnieszka Ciarka, MD, PhD
2015 Livia Goldraich, MD, MSc
Deipanjan Nandi, MD, MSc
Evan Kransdorf, MD, PhD
Manreet Kanwar, MD
Natasha Loghmanpour, PhD
Alexander Bernhardt, MD
Jong-Chan Youn, MD, PhD
2016 Sai Bhagra, MBBS, MRCP
Forum Kamdar, MD
Marco Masetti, MD, PhD
Joshua Mooney, MD
Edit Nagy, MD, PhD
2017 Laith Alshwabkeh, MD, MSc
Yuka Furuya, MD
Christian Heim, MD
Monique Robinson, MBBS, MRCP, DPhil
Lorenzo Zaffiri, MD, PhD
2018 Hakim Ali, MD
Daniel Reichart, MD
Laneshia Tague, MD, MSCI
Amanda Vest, MBBS, MPH
Michael Yaoyao Yin, MD

ISHLT/BAYER PULMONARY HYPERTENSION RESEARCH GRANT AWARD

- 2014 Benjamin Freed, MD

ISHLT/HEARTWARE AWARD FOR TRANSLATIONAL RESEARCH IN MCS

- 2014 Leigh Reardon, MD
2015 Alexander Bernhardt, MD

ISHLT/O.H. FRAZIER AWARD IN MCS TRANSLATIONAL RESEARCH Sponsored by Medtronic

- 2016 Todd Dardas, MD, MS
2017 Yasuhiro Shudo, MD, PhD
2018 Kavitha Muthiah, MBChB, PhD, FRACP

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT (supported by Thoratec)

- 2009 Sasa D. Borovic, MD
2010 Iki Adachi, MD
2012 Antigone Koliopoulou, MD
2014 Masahiro Ono, MD, PhD

ISHLT INTERNATIONAL TRAVELING SCHOLARSHIP AWARD

- 2011** Stephanie T. Yerkovich, PhD
Sarah E. Gilpin, PhD
Kimberly M. Derkatz, BNSc
Jennifer Conway, MD, FRCPC
- 2012** Ramin E. Beygui, MD
Kevin C. Carney, MSN
Alexandre Souza Cauduro, MD
Esme Dijke, PhD
Ana Belen Mendez, MD
David Schibilsky, MD
Aleem Siddique, MBBS
Amparo Solé, MD, PhD
Manon Huibers, MSc
Daniel R. Goldstein, MD
Laveena Munshi, MD, FRCPC
Marco Masetti, MD
Rochelle M. Gellatly, PScPharm, ACPR, PharmD
- 2013** Alison Gareau, MSc
Erin Schumer, MD, MS
Bojan Vrtovec, MD, PhD
Marsha Renikunta, PhD (student)
Katie Morley, BA(Hons), RCN, MA
Ali Yeginsu, MD
Fabrizio Gandolfo, MD
Marian Urban, MD
Alexander Bernhardt, MD
Victor Rossel, MD
Mohammed Quader, MD
- 2014** Marny Fedrigo, MD, PhD
Zachary Kon, MD
Evgenios Neofytou, MD
Dong, Wang, MD
Stephen Clark, DM, FRCS
Caroline Patterson, BMBS, BMedSci, MRCP
Tahaunty Pena, MD
- 2015** Oisín O'Connell, MD, MRCPI
Lucas Van Aelst, MD, PhD
Arezu Aliabadi, MD
Timothy Sladden, MBBS, BVSc
Bao Tran, MD
L G Saptharishi, MD, DM
Allison Carroll, MD
Akshay Pendyal, MD
Stefania Paolillo, MD, PhD
Soumitra Sinha Roy, MD
- 2016** Lucas Van Aelst, MD, PhD
Espeed Khoshin, MB ChB, MD, FRCS
- 2017** Amit Adlakha, MBChB, MRCP, FFICM
In-Cheol Kim, MD, PhD
Sanjeev Kumar Khulbey, MBBS, MS, MCH
Antonios Kourliouros, PhD, FRCS (CTh)
Mrinalini Krishnan, MD
Simon Pecha, MD
Kuruswamy Prasad, MD, DM
Ann Punnoose, MD
Adam Putschoegl, DO
Jong-Chan Young, MD, PhD

ISHLT LEACH-ABRAMSON-IMHOFF LINKS TRAVEL AWARDS

- 2012** Tereza Martinu, MD, Writer of the Year
Stanley I. Martin, MD, First Runner-Up
Luciano Potena, MD, PhD, First Runner-Up
Nancy P. Blumenthal, CRNP, Honorable Mention
Bronwyn J. Levvey, RN, Honorable Mention
Javier Carbone, MD, PhD, Honorable Mention
Stavros G. Drakos, MD, Honorable Mention
Daniel F. Dilling, MD, Honorable Mention
- 2013** Michele Estabrook, MD, Writer of the Year
Melanie Everitt, MD, First Runner-Up
Christina Migliore, MD, First Runner-Up
Veronica Franco, MD, Honorable Mention
Manreet Kanwar, MD, Honorable Mention
Luciano Potena, MD, PhD, Honorable Mention
Macé Schuurmans, MD, Honorable Mention
Jeffrey J. Teuteberg, MD, Honorable Mention
- 2014** Christopher R. Ensor, PharmD, BCPS-CV, Writer of the Year
Amanda Ingemi, PharmD, First Runner-Up
Simon Urschel, MD, Honorable Mention
- 2015** Pamela S. Combs, PhD, RN, Writer of the Year
Manreet Kanwar, MD, First Runner-Up
Oveimar De la Cruz, MD, Honorable Mention
Heather T. Henderson, MD, Honorable Mention
Simon Urschel, MD, Honorable Mention
Erin Wells, RN, BSN, CPN, Honorable Mention
- 2016** Kyle Dawson, PharmD, MBA, BCPS, Writer of the Year
Adam Cochrane, PharmD, BCPS, First Runner-Up
Christa Kirk, PharmD, First Runner-Up
Angela Velleca, RN, BSN, CCTC, Honorable Mention
Erin Wells, RN, BSN, CPN, Honorable Mention
- 2017** Quincy Young, PhD, RPsych, Writer of the Year
Monica Horn, RN, First Runner-Up
Melissa Cousino, PhD, Honorable Mention
Erin Wells, RN, BSN, CPN, Honorable Mention
- 2018** Erin Wells, RN, BSN, Writer of the Year
Martin Schweiger, MD, First Runner-Up
Adam Cochrane, Honorable Mention
Pamela S. Combs, Honorable Mention
Kyle Dawson, PharmD, MBA, BCPS, Honorable Mention
Joshua Mooney, MD, Honorable Mention

ABSTRACT AWARDS:

PHILIP K. CAVES AWARD

- 1983** Robbin G. Cohen, MD
1984 Hermann Reichensperner, MD
1985 Michael A. Breda, MD
1986 Stuart J. Knechtle, MD
1987 Wim Van Der Bij, MD
1988 Charles D. Fraser, Jr., MD
1989 A.M. Wood, MD
1990 Andres J. Duncan, MD
1991 A. Jiminez, MD
1992 David P. Kapelanski, MD
1993 David Marshman, MD
1994 Jobst Winter, MD
Alain Chapelier, MD
1995 Elizabeth A. Davis, MD
1996 Moninder S. Bhabra, MD

1997 Simon D. Eiref, MD
1998 Carla C. Baan, MD
1999 Joerg Koglin, MD
2000 Michael P. Fischbein, MD
2001 Alexander S. Krupnick, MD
2002 Peter Blaha, MD
2003 Sigrid Sandner, MD
2004 M.D. Peterson, MD
2005 Sigrid Sandner, MD
Frank D'Ovidio, MD
2006 Gregor Warnecke, MD
2007 Heather E. Merry, MD
2008 Satish N. Nadig, MD
2009 Howard Huang, MD
2010 Tobias Deuse, MD, PhD
2011 Ankit Bharat, MD
2012 Simo Syrjälä, MD
2013 Alexey Dashkevich, MD
2014 Jessica Spahn
2015 Simon Pecha, MD
2016 Corey E. Tabit, MD
2017 Stephen Chiu, MD

NURSING AND SOCIAL SCIENCES EXCELLENCE IN RESEARCH AWARD

2005 Mary Amanda Dew, PhD
2006 Kathleen L. Grady, PhD, RN
2007 Christiane Kugler, PhD
2008 Annette DeVito Dabbs, RN, PhD
2009 Connie White-Williams, MSN
2010 Bronwyn Levvey, RN
2011 Samantha J. Anthony, PhD, MSW
2012 Kate Hayes, MPhysio (Cardio)
2013 Jane Haines, DNP, RN, CMSRN
2014 Louise Fuller, PT
2015 Catherine Murks, PhD, APN
2016 Fabienne Dobbels, MSc, PhD
2017 Maral Bakir, RN, PHN

EARLY CAREER SCIENTIST AWARD

2017 His-Min Hsiao, PhD

JFTC CLINICAL CASE DILEMMAS IN THORACIC TRANSPLANTATION BEST PRESENTATION AWARD

2011 Michelle M. Kittleson, MD, PhD
2012 Erin Albers, MD
2013 Mustafa Ahmed, MD
2014 Lauren Sacha
2015 Ankit Bharat, MD
2016 Yasufumi Goda, MD
2017 Robert Gottlieb, MD, PhD

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCS ABSTRACT AWARD (supported by Thoratec)

2009 Nishant Shah, MD
2010 Jose N. Nativi, MD
2012 Arun Raghav Mahankali Sridhar, MD, MPH
2013 Claire Watkins, MD
2014 Jason O. Robertson, MD

CONTINUING MEDICAL EDUCATION INFORMATION

ACCME Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and allied health professionals.

CME Credit Designation Statement

ISHLT designates this live activity for a maximum of 29 AMA PRA Category 1 Credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

ABTC Accreditation

The ABTC Board of Governors has granted a total of 29 Category 1 Continuing Education Points for Transplant Certification (CEPTC) to the International Society for Heart & Lung Transplantation's ISHLT 38th Annual Meeting and Scientific Sessions.

Nurses and Pharmacists

Accreditation Statement – In support of improving patient care, this activity has been planned and implemented by Amedco and the International Society for Heart & Lung Transplantation. Amedco is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco designates this live activity for a maximum of 29 contact hours for nurses and 17 contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Educational Objectives

Because of the rapid advances in patient health care in general and end-stage heart and lung disease management in particular, professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in the field. This meeting is designed to address their needs.

Educational Goals

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.

Target Audience

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in the care and treatment of patients with end-stage heart and lung disease. The audience for this program includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators, and other allied health and social science professionals engaged in the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.

Learning Objectives

1. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management, and patient management for the treatment of patients suffering from end-stage heart and lung disease.
2. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies, outcome implications, and psychosocial management strategies for patients with end-stage heart and lung failure.
3. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding emerging technologies, medical advances, and the clinical applications of basic science models of end-stage heart and lung disease management and prevention.

UNRESTRICTED EDUCATIONAL GRANTS

The International Society for Heart and Lung Transplantation extends its heartfelt gratitude to the following companies for their unrestricted educational grants in the support of the Thirty-Eighth Annual Meeting and Scientific Sessions.

Actelion
Medtronic
Abbott

COMMERCIAL SUPPORT

The International Society for Heart and Lung Transplantation is grateful for the support of the following companies for the Society and its endeavors in 2018:

Tier 1

Medtronic

Tier 2

Abbott
Actelion

Tier 3

Gilead Sciences
Bayer/Merck

Tier 4

Transmedics
XVIVO
CareDx
One Lambda (Thermo Fisher)

ANNUAL MEETING HIGHLIGHTS

Basic Science and Translational Research

The ISHLT returns to Nice in 2018. As the French say, “c’est si bon” (that is so good). So taking French in high school and college has some utility after all. Come to Nice for the beautiful vistas, the fine beaches, excellent museums, great food (it is France after all) and the ISHLT Annual Meeting. The crème de la crème of the meeting will be the BSTR Symposia. Participants will be provided with sound and selective updates in applied science and novel research methods relevant for scientists and specialists in heart and lung transplantation as well as allied professionals. This year’s foci will appraise the “evolution” of our understanding of cell population subsets in immune processes and their interactions. Amaze your friends with the knowledge you acquire in **OLD CELLS NEW TRICKS: Updates in Transplant Immunology**. The second emphasis will be on the emerging tools currently tackling research challenges to produce a “revolution” in translational science. You will learn about these in **Novel Tools in Transplant Research (Say You Want a Revolution...)**. So come one, come all to the ISHLT in Nice and be amazed. After all, why do you think they call it nice?

Heart Failure and Transplantation

This year’s heart symposia will feature a diverse range of topics appealing to a broad audience of cardiologists, surgeons, nurses and allied health care professionals, focusing on practical aspects surrounding heart transplantation and providing perspectives to hotly debated controversies in our daily clinical practice. **We Never Stop Learning: 50th Anniversary of Heart Transplantation** will wind back the clock to the early days of heart transplantation with its surgical challenges, changes in patient selection, evolution of immunosuppression, developing and refining the definition of rejection, as well as the role ISHLT played in its advancement. The session will also include the unique experience of the longest surviving heart transplant recipient in the world. **Adult Congenital Heart Disease: Reaching the Summit** will bring an exciting set of lectures dedicated to the growing population of patients with congenital diseases surviving to adulthood. **Cardio-Oncology: A Tale of Two Problems** will discuss the challenging problem of concurrent heart failure and oncological disease. **Too Frail to Rock and Roll, Too Young to Die** will delve into the role of frailty in heart transplantation. The very clinically oriented symposium, **First Days of a New Life: Management After Heart Transplantation**, will focus on practical issues relative to pre-transplant optimization, ICU post-transplant haemodynamic and rhythm management, and optimal management of early graft failure. Our program highlight will be **“The Heat Is On”- Great Debates in Heart Transplantation**, where brief case presentations by junior faculty will set the stage for each debate by expert faculty with the audience declaring a winner. Controversial debate topics include utilization of donors with low ejection fraction, Hepatitis C positive status, and the value of desensitization strategies in the highly allosensitized heart transplant candidate. This session will further engage the audience with a final panel discussion. We hope the lessons learned during this year’s meeting will have a lasting positive impact on your clinical practice.

Infectious Diseases

We have an exciting meeting in store for our Infectious Diseases (ID) colleagues and ID “wannabes”. For the first time, we have partnered with the Transplant Infectious Diseases section of The Transplantation Society to bring you the **ISHLT/TTS-TID Joint Symposium: Infectious Challenges Around the World - Common Threads**. This unique symposium will assemble internationally renowned transplant ID physicians to discuss a diverse range of issues including arboviral infections, cryptococcosis, CMV guidelines, multi-drug resistant pathogens, donor screening and parasitic infections. The multidisciplinary symposium **Cytomegalovirus (CMV) in Thoracic Organ Transplantation - A Changing Landscape** will tackle different aspects of CMV including the continuum between viremia and disease, use of immunoglobulins, duration of prophylaxis, immunoassays, management strategies for difficult cases and pharmacology/toxicity of the drugs used to treat CMV. The program includes a smattering of ID in other symposia - hepatitis C organ debate, overview of mechanical circulatory support infections, *Aspergillus* in cystic fibrosis patients, and talks on microbiome/virome in lung transplant recipients.

Lung Failure and Transplantation

This year at the ISHLT conference, five symposia will address hot topics in lung transplantation. The scarcity of organs available for transplant remains a challenge in lung transplantation and using organs procured by donation after circulatory death (DCD) may be a way to increase the number of available organs. **DCD Lungs – Expanding Utilization** will address some of the challenges and controversies related to establishing a DCD program. The impact of novel antifibrotic drugs and drugs for patients with CF on the perioperative care and postoperative follow-up of lung transplant recipients will be discussed in **Can My Lung Transplant Recipient Take This Medication** and, in separate talks, traditional drugs such as neurotropic drugs and the use of anticoagulation will be addressed. **Cystic Fibrosis in Lung Transplantation: Controversial Topics**, will address clinical, pharmacological, surgical and other challenges specific to CF patients. **Antibody-Mediated Rejection After Lung Transplantation – 2018** will discuss some of the uncertainties

and controversies of AMR as a cause of allograft rejection. How are HLA-antibodies detected? What are the pathological findings in AMR? How should AMR be treated? Finally, the greatest challenge to long term success after lung transplantation is the development of chronic lung allograft dysfunction (CLAD). There are still many unknowns regarding the diagnosis, risk factors, phenotypes and treatment of this condition. These issues will be examined in **Chronic Lung Allograft Dysfunction (CLAD): Where Are We?** In summary, these five LUNG symposia at the ISHLT 2018 will present scientific data and expert opinions of high clinical relevance to everyone who works in the field of lung transplantation.

Mechanical Circulatory Support

If you are interested in MCS, you are in for a terrific experience at the Nice 2018 meeting with five dedicated symposia offering a wide range of MCS topics. **A Forgotten Organ - The Vascular System on Continuous Flow LVAD Support** will feature a primer on the vascular physiology and the impact of low pulsatility on angiogenesis, renal function, and cerebral autoregulation. The right ventricle continues to vex our field and we will delve into the impact of RV dysfunction on exercise physiology and end-organ function, define the best modalities to characterize RV function and discuss novel medical and surgical approaches to its treatment in **The Role of the RV in Advanced Heart Failure and LVADs**. One of the hottest topics in MCS is the interface of pacing technologies and LVADs and this will be discussed in detail in **It's Electric! Electrophysiologic Management of the LVAD Patient** where we will debate the merits of intra-operative VT ablation and the benefits of resynchronization therapy after LVAD. The emerging role of short term MCS in cardiogenic shock, decision making in patients with shock and the transition to durable support will be the centerpiece of the **Crashing and Burning: Cardiogenic Shock and Short-Term MCS**. Lastly, don't miss the cutting-edge talks on MCS complications in **Rapid Update on MCS Complications and Management: The Unpublished** which will offer the latest twists on anticoagulation and pump optimization in addition to the most recent insights into the management of common problems such as stroke, infection and hemolysis. In this rapidly expanding field, we are excited to bring you the latest insights into non-pulsatile physiology as well as many expert tips on how to optimize results with current MCS technology. See you in Nice!

Nursing and Allied Health

Nursing and Allied Health sessions will kick off the annual conference on Wednesday in Nice so plan to arrive early! Transplant teams are faced daily with complex, ethically-loaded decisions. Such decisions are even more challenging and distressing when the patient at hand is a young person. **The Young and the Restless: Unique Issues in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults** will highlight common challenging decisions faced by providers, and review the evidence base related to such decisions. Novel patient-reported data on end-of-life care preferences and clinically derived tools for improving practice will be shared. The symposium will conclude with a complex case presentation of a young adult presenting for re-transplantation which highlights the issues uncovered in previous presentations. Audience participation will be encouraged during a question and answer period with the panel of presenters. The multi-disciplinary symposium, **Too Frail to Rock and Roll, Too Young to Die**, will examine frailty in cardiothoracic transplantation and mechanical support. With health care becoming ever more complex, the issue of frailty needs to be addressed and more fully understood. Presentations of the assessment of frailty and pharmacological issues in the frail will be included, rounded out by an exploration of shared decision making and multidisciplinary considerations for the older candidate and recipient, including a focus on cognition and mood.

Pathology

The pathologist plays a key role in the thoracic transplant team. Through case discussions, **A Day in the Life: The Pathologist as a Member of the Thoracic Transplant Team** will focus on the contribution of the pathologist to patient care, quality assurance and research. Lectures will explore some of the diagnostic difficulties faced by pathologists in the assessment of native and transplanted organs, and how these may be resolved by multidisciplinary teamwork and new advances including molecular pathology.

Pediatrics

Pediatric thoracic transplantation requires expertise in acute and chronic multi-organ failure and mechanical support both before and after transplantation. In Nice, attendees will find an array of topics that span the continuum of care for pediatric patients. **Pediatric Heart Failure: MCS, ICU Care and Early Graft Failure** will cover the evaluation and treatment of the failing heart before and after heart transplant. Topics will include the treatment of acute heart failure while awaiting heart transplant and care in the ICU after transplantation. Short-term circulatory support, management of the positive crossmatch patient, and early graft failure are a few of the highly-anticipated talks. **Retransplantation in the Child to Young Adult - History Repeating Itself?** will address the challenges of decision-making in the pediatric heart or lung transplant recipient with graft failure. When is the right time and who is the right patient for re-transplantation? And don't meander on the Riviera while missing **Too Little or Too Much: Controversies in Monitoring After Pediatric**

Thoracic Transplantation. These great debates will interrogate the questions around routine invasive monitoring in pediatric heart recipients and lung recipients. Be sure to schedule time for ***The Young and the Restless: Unique Challenges in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults*** which will include discussions of adherence, transition and communication tools. These topics will be distinctly applicable to our patient population and will be tackled by leading experts in the field. In addition to these pediatric symposia, don't overlook the many other symposia of interest to pediatric thoracic transplant attendees throughout the program.


Pharmacy and Pharmacology

Malignancy has significant effects in thoracic transplant, both limiting listing options and causing morbidity and mortality after transplantation. As such, management questions exist in post-transplant malignancy. What are the risk factors for developing malignancy post-transplant and how do we modify them? What is the role of anti-CMV prophylaxis with respect to EBV reactivation? Is there a period during and after chemotherapy where risk of rejection fluctuates? What immunosuppressants have heightened roles after successful treatment? These questions will be tackled in ***Malignancy in Transplantation: Too Much, Too Early or Too Little, Too Late?*** We will discuss the approach to the thoracic transplant recipient who has risk factors for developing cancer post transplant or who has already developed cancer after transplantation. This session will appeal to all members of ISHLT who work with thoracic transplant recipients.

Pulmonary Hypertension and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)


Pulmonary hypertension and the grand début of the CTEPH Council is sure to be a show stopper with 4 symposia at the ISHLT Scientific Sessions in Nice! The ISHLT is partnering with the European Society of Cardiology (ESC) this year for a joint symposium in which experts in the field from both Societies will take a unique and hard look at ***Pulmonary Hypertension Due to Left Heart Disease: When RIGHT Meets LEFT***. In ***Great Debates in the Management of PAH: Genetics, Bridge to Lung Transplant, and Goal Directed Therapy***, experts will go head to head on provocative questions at the cutting edge of care through a series of three pro-con debates. Debaters will take on genomics vs. proteomics to guide therapy, the use of ECLS vs. atrial septostomy, and a sure to be lively debate of the REVEAL scoring system vs. the ESC goal-directed therapy approach in PAH. And for CTEPH, thought leaders will be discussing risk factors and disease evolution, along with the latest developments in diagnosis and therapies available to patients in ***The Devil is in the Details - Nuances in CTEPH***. More controversial topics will be addressed in ***CTEPH: Challenges in Intervention Decision Making***. Case presentations will provide the stimulus for debates focused on distal vessel CTEPH, on what to do for patients with symptomatic chronic thromboembolic disease without pulmonary hypertension at rest, and on the emerging role of balloon pulmonary angioplasty vis-à-vis pulmonary endarterectomy.

CONVENTION CENTER
FLOOR PLANS
FIRST FLOOR




CONVENTION CENTER
FLOOR PLANS

SECOND FLOOR



CONVENTION CENTER
FLOOR PLANS
THIRD FLOOR



ACRONYMS

To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for. These codes are explained as follows:

BSTR	Basic Science and Translational Research
EEP	Economics, Ethics, Public Policy
HF	Heart Failure (Adult)
HTX	Heart Transplantation (Adult)
ID	Infectious Diseases
LBCS	Late Breaking Clinical Science
LTX	Lung Transplantation (Adult)
MCS	Mechanical Circulatory Support (Adult)
NHSAH	Nursing, Health Science, and Allied Health
PATH	Pathology
PEDS	Pediatrics
PHARM	Pharmacy and Pharmacology
PH	Pulmonary Hypertension

SCIENTIFIC COUNCIL MEETINGS

Council

Basic Science and Translational Research
Chronic Thromboembolic Pulmonary Hypertension
Heart Failure & Transplantation
Infectious Diseases
Junior Faculty and Trainees
Mechanical Circulatory Support
Nursing, Health Science, and Allied Health
Pathology
Pediatric Thoracic Transplantation & Heart Failure
Pharmacy and Pharmacology
Pulmonary Hypertension
Pulmonary Transplantation

Meeting Date and Location

Wed, Apr 11, 7:15 – 8:15 AM (Clio/Thalie/Erato)
Wed, Apr 11, 7:15 - 8:15 AM (Athena)
Fri, Apr 13, 7:15 - 8:15 AM (Clio/Thalie/Erato)
Fri, Apr 13, 7:15 - 8:15 AM (Gallieni 5)
Fri, Apr 13, 7:15 - 8:15 AM (Uranie/Calliope)
Thurs, Apr 12, 7:15 - 8:15 AM (Athena)
Wed, Apr 11, 7:15 - 8:15 AM (Uranie/Calliope)
Thurs, Apr 12, 7:15 - 8:15 AM (Hermes)
Fri, Apr 13, 7:15 - 8:15 AM (Hermes)
Wed, Apr 11, 7:15 - 8:15 AM (Hermes)
Thurs, Apr 12, 7:15 - 8:15 AM (Uranie/Calliope)
Thurs, Apr 12, 7:15 - 8:15 AM (Clio/Thalie/Erato)

COUNCIL NETWORKING RECEPTIONS

In response to feedback from Council members requesting more opportunities for networking at the ISHLT Annual Meetings, we are excited to announce the following Council receptions planned in association with respective evening poster sessions:

Council

Basic Science and Translational Research
Chronic Thromboembolic Pulmonary Hypertension
Heart Failure & Transplantation
Infectious Diseases
Junior Faculty and Trainees
Mechanical Circulatory Support
Nursing, Health Science, and Allied Health
Pathology
Pediatric Thoracic Transplantation & Heart Failure
Pharmacy and Pharmacology
Pulmonary Hypertension
Pulmonary Transplantation

Reception Date and Location

Wed, Apr 11, 6:15 PM – 7:15 PM (Agora 2)
Fri, Apr 13, 6:15 - 7:15 PM (Gallieni 1-2/Mykonos)
Thurs, Apr 12, 6:15 - 7:15 PM (Muses)
Thurs, Apr 12, 6:15 - 7:15 PM (Gallieni 1-2/Mykonos)
Wed, Apr 11, 6:15 - 7:15 PM (Agora 3)
Wed, Apr 11, 6:15 - 7:15 PM (Muses)
Wed, Apr 11, 6:15 - 7:15 PM (Gallieni 1-2/Mykonos)
Wed, Apr 11, 6:15 - 7:15 PM (Agora 2)
Thurs, Apr 12, 6:15 - 7:15 PM (Agora 3)
Wed, Apr 11, 6:15 - 7:15 PM (Agora 2)
Fri, Apr 13, 6:15 - 7:15 PM (Gallieni 1-2/Mykonos)
Fri, Apr 13, 6:15 - 7:15 PM (Euterpe)

SCHEDULE AT A GLANCE

All meetings and activities will take place at The Acropolis Congress Centre, Nice, France, unless otherwise specified. All papers will be presented in English. Please check the ISHLT web site (www.isHLT.org) for updates. This Final Program reflects the latest session schedule and room assignments.

MONDAY, APRIL 9, 2018

4:00 PM - 7:00 PM

Academy Registration Open (Agora 1)

Speaker Ready Room Open (*Academy Faculty Only*) (Hermes Lounge)

TUESDAY, APRIL 10, 2018

7:00 AM - 3:00 PM

Academy Registration Open (Agora 1)

7:00 AM - 7:00 PM

Speaker Ready Room Open (Hermes Lounge)

Exhibitor Registration Open (Agora 1)

7:55 AM - 5:30 PM

ISHLT ACADEMY: Core Competencies in Heart Failure and Cardiac Transplantation (Mediterranee ABC)

7:55 AM - 5:45 PM

ISHLT ACADEMY: Core Competencies in Lung Transplantation (Hermes)

8:00 AM - 5:30 PM

ISHLT ACADEMY: Core Competencies in Mechanical Circulatory Support (Athena)

8:00 AM - 1:00 PM

ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Clio, Thalie)

8:00 AM - 2:00 PM

ISHLT Board of Directors Meeting (Gallieni 4)

2:00 PM - 5:00 PM

ISHLT Board/Committee/Council Leadership Orientation (Gallieni 5)

2:00 PM - 7:00 PM

ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Clio, Thalie)

ISHLT ACADEMY: Master Class in Chronic Thromboembolic Pulmonary Hypertension (Erato, Uranie)

4:00 PM - 7:00 PM

Annual Meeting Registration Open (Agora 1)

5:00 PM - 6:00 PM

I2C2 Committee Meeting (Gallieni 5)

Standards & Guidelines Committee Meeting (Gallieni 7)

5:00 PM - 7:00 PM

Press Office Open (Gallieni 6)

International Thoracic Organ Transplant Registry Steering Committee Meeting (Gallieni 4)

WEDNESDAY, APRIL 11, 2018

7:00 AM - 10:00 AM

Poster Session 1 Mount (Muses, Euterpe, Agora 2, Agora 3, Gallieni 1-2)

7:00 AM - 7:00 PM

Annual Meeting Registration Open (Agora 1)

Speaker Ready Room Open (Hermes Lounge)

7:15 AM - 8:15 AM

Chronic Thromboembolic Pulmonary Hypertension Scientific Council Meeting (Athena)

Basic Science and Translational Research Scientific Council Meeting (Clio/Thalie/Erato)

Nursing, Health Science and Allied Health Scientific Council Meeting (Uranie/Caliope)

Pharmacy and Pharmacology Scientific Council Meeting (Hermes)

DCD Registry Steering Committee Meeting (Gallieni 7)

IMAC Registry Committee Meeting (Gallieni 4)

7:15 AM - 8:30 AM

International Engagement Committee Meeting (Gallieni Conference Office 5)

8:00 AM - 8:30 AM

Coffee and Croissants (Rhodes Exhibit Hall)

8:00 AM - 7:15 PM

Exhibit Hall Open (Rhodes Exhibit Hall)

8:30 AM - 10:00 AM

ORAL SESSION 01: Stop It Without Bleeding: Mechanisms of Stroke in MCS (Apollon)

(MCS, HF, NNSAH, PHARM)

ORAL SESSION 02: Thinking Inside The Box: DCD Donation and Ex-vivo Heart Perfusion (Athena)

(HTX, BSTR, EEP, HF, MCS, NNSAH, PATH)

ORAL SESSION 03: Novel Insights About Antibodies in Lung Transplantation (Mediterranee ABC)

(LTX, BSTR, PATH)

ORAL SESSION 04: Immunosuppression in Heart Transplantation: Lessons Learned (Clio/Thalie/Erato)

(HTX, BSTR, EEP, HF, ID, NNSAH, PATH, PHARM)

ORAL SESSION 05: Don't Go Breaking My Heart: The Assessment, Treatment and Implications of Psychosocial Risk Factors (Uranie/Caliope)

(NNSAH, HF, HTX, MCS)

ORAL SESSION 06: Building a Better Transplant (Hermes)

(BSTR, HTX, MCS, PATH)

ORAL SESSION 07: Cutting Edge CTEPH: From Metabolomics to Surgical Technique (Mediterranee 6)

(CTEPH, BSTR, MCS, PH)

9:00 AM - 7:00 PM

Press Office Open (Gallieni 6)

10:00 AM - 10:30 AM

Coffee Break (Rhodes Exhibit Hall)

10:00 AM - 7:15 PM

Poster Hall Open (Muses, Euterpe, Agora 2, Agora 3, Gallieni 1-2)

10:30 AM - 12:30 PM

Opening Plenary Session (Apollon)

(ALL)

12:30 PM - 2:00 PM

Lunch Break

Junior Faculty Mentor Lunch Meeting (Gallieni 5)

12:45 PM - 1:45 PM

Exhibit Hall Closed (Rhodes Exhibit Hall)

2:00 PM - 4:00 PM

SYMPOSIUM 01: The Devil Wears Prada - The Role of the RV in Advanced Heart Failure and LVADs (Apollon)
(MCS, HF/HTX, NNSAH, PEDS, PH, PHARM)

SYMPOSIUM 02: Adult Congenital Heart Disease: Reaching the Summit (Athena)
(HF/HTX, PEDS)

SYMPOSIUM 03: Chronic Lung Allograft Dysfunction (CLAD): Where Are We Now? (Mediterranee ABC)
(LF/LTX, BSTR, ID, NNSAH, PATH, PEDS, PHARM)

SYMPOSIUM 04: Cardio-Oncology: A Tale of Two Problems (Clio/Thalie/Erato)
(HF/HTX, MCS, NNSAH, PEDS, PHARM)

SYMPOSIUM 05: The Young and the Restless: Unique Challenges in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults (Uranie/Caliope)
(NNSAH, HF/HTX, LF/LTX, MCS, PEDS)

SYMPOSIUM 06: Novel Tools in Transplant Research (Say You Want a Revolution...) (Hermes)
(BSTR, HF/HTX, ID, LF/LTX, PATH, PHARM)

SYMPOSIUM 07: The Devil is in the Details - Nuances in CTEPH (Mediterranee 6)
(CTEPH, LF/LTX, PH)

4:00 PM - 4:30 PM

Coffee Break (Rhodes Exhibit Hall)

4:30 PM - 6:00 PM

ORAL SESSION 08: Four Liters and Fingers Crossed: ECMO - Management and Outcomes (Apollon)
(MCS)

ORAL SESSION 09: The Pressure is On! Assessment and Role of Blood Pressure in MCS (Athena)
(MCS, NNSAH, PHARM, PH)

ORAL SESSION 10: Mechanisms of Allograft Injury after Lung Transplantation (Mediterranee ABC)
(LTX, BSTR, PATH)

ORAL SESSION 11: Predictable or Inevitable? Complications of Heart Transplantation (Clio/Thalie/Erato)
(HTX, BSTR, HF, NNSAH, PATH)

ORAL SESSION 12: The Leading Edge: Novel Practices in Patient Care Pathways (Uranie/Caliope)
(NNSAH, HF, HTX, LTX, MCS)

ORAL SESSION 13: Early Career Scientist Award in Transplantation (Hermes)
(BSTR, HTX, LTX, PATH)

ORAL SESSION 14: Reading Tea Leaves - Heart Failure Prediction Risks (Mediterranee 6)
(HF, HTX, MCS, PHARM)

6:00 PM - 7:15 PM

Exhibit Hall Opening Reception (Rhodes Exhibit Hall)

6:15 PM - 7:15 PM

MINI ORAL 01: Mechanical Circulatory Support: ECMO (Athena)
(MCS, HTX, PHARM)

MINI ORAL 02: Heart Transplantation: Outcomes (Mediterranee ABC)
(HTX, BSTR, EEP, HF, MCS, PHARM)

MINI ORAL 03: Lung Transplantation, Pulmonary Hypertension and CTEPH (Clio/Thalie/Erato)
(LTX, CTEPH, HF, PH)

MINI ORAL 04: Mechanical Circulatory Support: Thrombosis (Uranie/Caliope)
(MCS, PHARM)

MINI ORAL 05: Pediatric Thoracic Transplantation (Hermes)
(PEDS, HF, HTX, ID, MCS, NHSAH, PHARM)

MINI ORAL 06: Heart Failure & Transplantation: Outcomes and Antibodies (Mediterranee 6)
(HF, BSTR, EEP, HTX, MCS, NHSAH, PATH)

COUNCIL NETWORKING RECEPTIONS:

Mechanical Circulatory Support (Muses)

Nursing, Health Science and Allied Health (Gallieni 1-2/Mykonos)

Basic Science and Translational Research (Agora 2)

Pathology (Agora 2)

Pharmacy and Pharmacology (Agora 2)

Junior Faculty and Trainee (Agora 3)

POSTER SESSION 1:

Basic Science and Translational Research (Agora 2)
(BSTR, HF, HTX, ID, LTX, MCS, PATH, PEDS, PH)

Economics, Ethics, Public Policy (Muses)
(EEP, HF, HTX, LTX, MCS, NHSAH)

Junior Faculty Clinical Case Reports (Agora 3)
(ALL)

Lung Transplantation (Euterpe)
(LTX, BSTR, LTX, PHARM)

Mechanical Circulatory Support (Muses)
(MCS)

Nursing, Health Sciences, Allied Health (Gallieni 1-2)
(NHSAH, HF, HTX, LTX, MCS)

Pathology (Agora 2)
(PATH, BSTR, HTX, LTX)

Pharmacy and Pharmacology (Agora 2)
(PHARM, BSTR, HF, HTX, LTX, MCS, NHSAH)

7:15 PM - 8:00 PM

Poster Session 1 Removal (Muses, Euterpe, Agora 2, Agora 3, Gallieni 1-2)

THURSDAY, APRIL 12, 2018

7:00 AM - 7:00 PM

**Annual Meeting Registration Open (Agora 1)
Speaker Ready Room Open (Hermes Lounge)**

7:15 AM - 8:15 AM

**Mechanical Circulatory Support Scientific Council Meeting (Athena)
Pulmonary Transplantation Scientific Council Meeting (Clio/Thalie/Erato)
Pulmonary Hypertension Scientific Council Meeting (Uranie/Caliope)
Pathology Scientific Council Meeting (Hermes)
International Pediatric Heart Failure Registry Steering Committee Meeting (Gallieni 4)**

8:00 AM - 8:30 AM

Coffee and Croissants (Rhodes Exhibit Hall)

8:00 AM - 7:15 PM

Exhibit Hall Open (Rhodes Exhibit Hall)

8:30 AM - 10:00 AM

Poster Session 2 Mount (Muses Nord, Euterpe, Agora 3, Gallieni 1-2)

8:30 AM - 10:30 AM

**SYMPOSIUM 08: A Forgotten Organ - The Vascular System on Continuous Flow LVAD Support (Apollon)
(MCS, HF/HTX)**

SYMPOSIUM 09: "The Heat Is On" - Great Debates in Heart Transplantation (Athena)

(HF/HTX, ID, MCS, NHSAH, PATH, PEDS, PHARM)

SYMPOSIUM 10: Cardiothoracic Transplantation: Too Frail to Rock and Roll, Too Young to Die (Mediterranee ABC)

(HF/HTX, EEP, LTX, NHSAH, PEDS, PHARM)

SYMPOSIUM 11: Cystic Fibrosis in Lung Transplantation: Controversial Topics (Clio/Thalie/Erato)

(LF/LTX, ID, NHSAH, PEDS, PHARM)

SYMPOSIUM 12: CTEPH: Challenges in Intervention Decision Making (Uranie/Caliope)

(CTEPH, LF/LTX, PH)

SYMPOSIUM 13: A Day in the Life: The Pathologist as a Member of the Thoracic Transplant Team (Hermes)

(PATH, EEP, HF/HTX, LF/LTX, MCS, NHSAH, PEDS, PHARM)

SYMPOSIUM 14: Old Cells New Tricks: Updates on Transplant Immunology (Mediterranee 6)

(BSTR, HF/HTX, LF/LTX, PATH)

9:00 AM - 7:00 PM

Press Office Open (Gallieni 6)

10:30 AM - 11:00 AM

Coffee Break (Rhodes Exhibit Hall)

10:30 AM - 7:15 PM

Poster Hall Open (Muses, Euterpe, Agora 3, Gallieni 1-2)

11:00 AM - 12:30 PM

ORAL SESSION 15: The Final Frontier? Bleeding in MCS (Apollon)

(MCS, NHSAH, PHARM)

ORAL SESSION 16: It's Leaking But Nobody Cares: Valvular Disease in MCS (Athena)

(MCS, HF, NHSAH, PATH)

SYMPOSIUM 15: We Never Stop Learning: 50th Anniversary of Heart Transplantation (Mediterranee ABC)
(HF/HTX, BSTR, ID, NNSAH, PATH, PEDS, PHARM)

ORAL SESSION 17: The New Frontier: Hepatitis C and Other Viruses (Clio/Thalie/Erato)
(ID, HTX, LTX, MCS, PHARM,)

SYMPOSIUM 16: JHLT at ISHLT: The Year in a Capsule (Uranie/Caliope)
(ALL)

ORAL SESSION 18: Mining the Tissue Biopsy: Molecular Signals of Rejection (Hermes)
(PATH, BSTR, HTX, LTX)

ORAL SESSION 19: Improving Lung Transplant Outcomes Through Science (Mediterranee 6)
(BSTR, LTX, PATH)

12:30 PM - 2:00 PM

Lunch Break

JHLT Editorial Board Lunch Meeting (Gallieni 5)

12:45 PM - 1:45 PM

Exhibit Hall Closed (Rhodes Exhibit Hall)

2:00 PM - 4:00 PM

SYMPOSIUM 17: Rapid Update on MCS Complications and Management: The Unpublished (Apollon)
(MCS, HF/HTX, ID, NNSAH, PHARM)

SYMPOSIUM 18: It's Electric! Electrophysiologic Management of the LVAD Patient (Athena)
(MCS, HF/HTX, NNSAH, PEDS)

SYMPOSIUM 19: Antibody-Mediated Rejection After Lung Transplantation - 2018 (Mediterranee ABC)
(LF/LTX, BSTR, PATH, PEDS)

SYMPOSIUM 20: Malignancy in Transplantation: Too Much, Too Early or Too Little, Too Late? (Hermes)
(PHARM, BSTR, HF/HTX, ID, LF/LTX, NNSAH, PATH, PEDS)

SYMPOSIUM 21: Great Debates in the Management of PAH: Genetics, Bridge to Lung Transplant, and Goal Directed Therapy (Uranie/Caliope)
(PH, HF/HTX, LF/LTX, MCS, PEDS, PHARM)

SYMPOSIUM 22: Cytomegalovirus (CMV) in Thoracic Organ Transplantation - A Changing Landscape (Clio/Thalie/Erato)

(ID, BSTR, HF/HTX, LF/LTX, NNSAH, PATH, PEDS, PHARM)

SYMPOSIUM 23: Too Little or Too Much: Controversies in Monitoring After Pediatric Thoracic Transplantation (Mediterranee 6)

(PEDS, ID, LF/LTX)

4:00 PM - 4:30 PM

Coffee Break (Rhodes Exhibit Hall)

2019 Symposium Planning Committee Meeting (Gallieni 5)

4:30 PM - 6:00 PM

ORAL SESSION 20: See One, Do One, Teach One: Novel Management Strategies in MCS (Apollon)
(MCS, NNSAH, PEDS)

ORAL SESSION 21: Right and Wrong: The Impact of the Right Ventricle After LVAD (Athena)
(MCS, NNSAH, PH)

ORAL SESSION 22: Trials and Treatments in Lung Transplantation (Mediterranee ABC)

(LTX, PHARM)

ORAL SESSION 23: Getting to the Heart and Lung of the Matter: Drugs in Thoracic Transplant (Clio/Thalie/Erato)

(PHARM, HTX, ID, LTX, NHSAH)

ORAL SESSION 24: Walking the Tightrope in Heart Transplantation: Outcomes in High Risk Population (Uranie/Caliope)

(HTX, BSTR, EEP, HF, MCS, NHSAH, PATH, PEDS)

ORAL SESSION 25: Philip K. Caves Award Candidate Presentations (Hermes)

(BSTR, HTX, LTX, PATH)

ORAL SESSION 26: The Perfect Match: Donor and Recipient Effects on Pediatric Thoracic Outcomes (Mediterranee 6)

(PEDS, EEP, HTX, LTX, NHSAH)

6:00 PM - 7:00 PM

Past President's Meeting (Gallieni 4)

6:00 PM - 7:15 PM

Wine and Cheese Reception (Rhodes Exhibit Hall)

6:15 PM - 7:15 PM

MINI ORAL 07: Mechanical Circulatory Support: Surgical Techniques (Athena)

(MCS, NHSAH)

MINI ORAL 08: Heart Transplantation: PGD and CAV (Mediterranee ABC)

(HTX, BSTR, EEP, HF, NHSAH, PATH)

MINI ORAL 09: Lung Transplantation: Allograft Function (Clio/Thalie/Erato)

(LTX, PATH)

MINI ORAL 10: Mechanical Circulatory Support, Pharmacy & Pharmacology (Uranie/Caliope)

(PHARM, BSTR, HTX, LTX, MCS, PEDS)

MINI ORAL 11: Nursing, Health Science & Allied Health, Pediatrics (Hermes)

(NHSAH, HF, HTX, LTX, MCS, PEDS)

MINI ORAL 12: Basic Science & Translational Research (Mediterranee 350)

(BSTR, HTX, LTX, MCS, PATH)

COUNCIL NETWORKING RECEPTIONS:

Heart Failure and Transplantation (Muses)

Infectious Diseases (Gallieni 1-2/Mykonos)

Pediatric Thoracic Transplantation and Heart Failure (Agora 3)

POSTER SESSION 2:

Heart Failure (Muses)

(HF, HTX, MCS, PHARM, PH)

Heart Transplantation (Muses)

(HTX, BSTR, EEP, HF, ID, MCS, NHSAH, PATH, PHARM, PH)

Infectious Diseases (Gallieni 1-2)

(ID, HTX, LTX, MCS, PEDS)

Junior Faculty Clinical Case Reports (Agora 3)

(ALL)

Mechanical Circulatory Support (Euterpe)
(MCS)

Pediatric Transplantation (Agora 3)
(PEDS, HF, HTX, ID, LTX, MCS, PHARM)

7:00 PM - 8:00 PM

Poster Session 2 Removal (Muses, Euterpe, Agora 3, Gallieni 1-2)

FRIDAY, APRIL 13, 2018

7:00 AM - 7:00 PM

Annual Meeting Registration Open (Agora 1)

Speaker Ready Room Open (Hermes Lounge)

7:15 AM - 8:15 AM

Heart Failure and Transplantation Scientific Council Meeting (Clio/Thalie/Erato)

Junior Faculty and Trainee Scientific Council Meeting (Uranie/Caliope)

Pediatric Thoracic Transplantation and Heart Failure Scientific Council Meeting (Hermes)

Infectious Diseases Scientific Council Meeting (Gallieni 7)

Grants and Awards Committee Meeting (Gallieni Conference Office 5)

8:00 AM - 8:30 AM

Coffee and Croissants (Rhodes Exhibit Hall)

8:00 AM - 6:30 PM

Exhibit Hall Open (Rhodes Exhibit Hall)

8:30 AM - 10:00 AM

ORAL SESSION 27: How Sick is Too Sick? The Impact of Frailty and Cognitive Function in LVADs (Apollon)

(MCS, HF, NHSAA, PHARM)

ORAL SESSION 28: Just Pacing Myself! Electrophysiology and Mechanical Support (Athena)

(MCS, BSTR, HF, NHSAA, PHARM)

ORAL SESSION 29: Lung Donation after Circulatory Death - Current Status (Mediterranee ABC)

(LTX, EEP)

ORAL SESSION 30: Infection: Achille's Heel of Mechanical Circulatory Support (Clio/Thalie/Erato)

(ID, HTX, MCS)

ORAL SESSION 31: Spotlight on a Heart Transplant Donor (Uranie/Caliope)

(HTX)

ORAL SESSION 32: Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best (Hermes)

(ALL)

SYMPOSIUM 24: Retransplantation in the Child to Young Adult - History Repeating Itself? (Mediterranee 6)

(PEDS, EEP, HF/HTX, LF/LTX, MCS, NHSAA, PHARM)

Poster Session 3 Mount (Muses, Euterpe, Agora 3, Gallieni 1-2)

9:00 AM - 7:00 PM

Press Office Open (Gallieni 6)

10:00 AM - 10:30 AM

Coffee Break (Rhodes Exhibit Hall)

Annual Business Meeting (Apollon)

10:30 AM - 7:15 PM

Poster Hall Open (Muses Nord, Euterpe, Agora 3, Gallieni 1-2)

10:30 AM - 12:30 PM

Plenary Session: Moving Cardiothoracic Transplantation Forward (Apollon)

(ALL)

12:30 PM - 2:00 PM

Lunch Break

12:45 PM - 1:45 PM

Exhibit Hall Closed (Rhodes Exhibit Hall)

2:00 PM - 4:00 PM

SYMPOSIUM 25: Crashing and Burning: Cardiogenic Shock and Short-term MCS (Apollon)

(MCS, HF/HTX, NNSAH, PEDS, PHARM)

SYMPOSIUM 26: Can My Lung Transplant Candidate Take This Medication? What to Do with the New Drugs for Lung Failure (Athena)

(LF/LTX, BSTR, ID, NNSAH, PEDS, PHARM)

SYMPOSIUM 27: DCD Lungs- Expanding Utilization (Mediterranee ABC)

(LF/LTX, NNSAH)

SYMPOSIUM 28: First Days of a New Life: Management After Heart Transplant (Clio/Thalie/Erato)

(HF/HTX, MCS, PHARM, PH)

SYMPOSIUM 29: Joint ISHLT/ESC Symposium: Pulmonary Hypertension Due to Left Heart Disease: When RIGHT Meets LEFT (Uranie/Caliope)

(PH, BSTR, HF/HTX, NNSAH, PATH, PEDS, PHARM)

SYMPOSIUM 30: Joint ISHLT/TTS-TID Symposium: Infectious Challenges Around the World - Common Threads (Hermes)

(ID, EEP, HF/HTX, LF/LTX, NNSAH, PEDS, PHARM)

SYMPOSIUM 31: Pediatric Heart Failure: MCS, ICU Care, and Early Graft Dysfunction (Mediterranee 6)

(PEDS, HF/HTX, MCS)

4:00 PM - 4:30 PM

Coffee Break (Rhodes Exhibit Hall)

4:30 PM - 6:00 PM

ORAL SESSION 33: We Are Here to Pump...You Up! Exercise in MCS (Apollon)

(MCS, HF, NNSAH, PHARM)

ORAL SESSION 34: Getting It Right From the Start: LVAD Implant and Device Failure (Athena)

(MCS)

ORAL SESSION 35: Out of Body Experiences: Ten Years of EVLP (Mediterranee ABC)

(LTX)

ORAL SESSION 36: Antibodies and Rejection in Heart Transplantation: Donor Cells Tell No Lies (Clio/Thalie/Erato)

(HTX, BSTR, EEP, HF, NNSAH, PATH)

ORAL SESSION 37: New Treatment Paradigms in Pulmonary Hypertension (Uranie/Caliope)

(PH, HF, MCS, PHARM)

ORAL SESSION 38: Hot Topics in Infectious Diseases (Hermes)

(ID, HTX, LTX, MCS)

ORAL SESSION 39: All Is Not Lost: Improving Outcomes in Children with a Failing Heart (Mediterranee 6)

(PEDS, HF, HTX, MCS, NHSAH)

6:00 PM - 6:30 PM

Wine and Cheese Reception (Rhodes Exhibit Hall)

6:15 PM - 7:15 PM

MINI ORAL 13: Mechanical Circulatory Support: Bleeding (Athena)

(MCS, PHARM)

MINI ORAL 14: Lung Transplantation: Organ Allocation and Candidate Selection (Clio/Thalie/Erato)

(LTX)

MINI ORAL 15: Heart Transplantation: Donor Issues (Uranie/Calioppe)

(HTX, BSTR, EEP, NHSAH, PATH)

MINI ORAL 16: Basic Science and Infectious Disease Issues (Hermes)

(ID, BSTR, HTX, LTX, MCS)

COUNCIL NETWORKING RECEPTIONS:

Pulmonary Hypertension (Gallieni 1-2/Mykonos)

Chronic Thromboembolic Pulmonary Hypertension (Gallieni 1-2/Mykonos)

Pulmonary Transplantation (Euterpe)

POSTER SESSION 3:

Heart Transplantation (Muses Foyer/Corridor)

(HTX)

Lung Transplantation (Euterpe)

(LTX)

Mechanical Circulatory Support (Agora 3)

(MCS)

Pulmonary Hypertension and CTEPH (Gallieni 1-2)

(PH, BSTR, CTEPH, HF, LTX, MCS, NHSAH, PATH, PHARM)

7:00 PM - 8:00 PM

Poster Session 3 Removal (Muses, Euterpe, Agora 3, Gallieni 1-2)

8:00 PM - 9:30 PM

ISHLT President's Cocktail Reception (Le Negresco Palace)

SATURDAY, APRIL 14, 2018

7:30 AM - 12:15 PM

Annual Meeting Registration Open (Agora 1)

7:30 AM - 2:00 PM

Speaker Ready Room Open (Hermes Lounge)

8:00 AM - 8:15 AM

Morning Coffee (Hermes Foyer/Mykonos Lounge)

8:15 AM - 9:45 AM

ORAL SESSION 40: Riding the Wave: Hemodynamics in MCS (Athena)
(MCS, HTX)

ORAL SESSION 41: Crunching the Numbers: Improving Outcomes in Heart Transplantation (Mediterranee ABC)
(HTX, BSTR, EEP, HF, ID, NHSAH, PATH, PHARM)

ORAL SESSION 42: Lung Allocation: New Rules and Old Age (Clio/Thalie/Erato)
(LTX, EEP)

ORAL SESSION 43: A Road Less Traveled: Alternative Mechanisms and Treatments for Heart Failure (Uranie/Caliope)
(HF, BSTR, HTX, MCS, PHARM)

ORAL SESSION 44: The Battle for Hearts, Lungs, Minds and Money (Hermes)
(EEP, HF, HTX, LTX, MCS, NHSAH)

ORAL SESSION 45: Live Long and Prosper: Long-term Outcomes After Pediatric Heart Transplant (Mediterranee 6)
(PEDS, HTX, NHSAH, PHARM)

9:45 AM - 10:00 AM

Coffee Break (Hermes Foyer/Mykonos Lounge)

10:00 AM - 12:00 PM

Plenary Session (Athena)
(ALL)

12:00 PM - 12:15 PM

Coffee Break (Hermes Foyer/Mykonos Lounge)

12:15 PM - 1:45 PM

ORAL SESSION 46: Flight Plan: Planning the LVAD Implant (Athena)
(MCS, NHSAH, PHARM, PH)

ORAL SESSION 47: A Melange of Outcomes in Heart Transplantation (Mediterranee ABC)
(HTX, BSTR, EEP, HF, MCS, NHSAH, PATH)

ORAL SESSION 48: Procedures and Standards in Lung Transplantation (Clio/Thalie/Erato)
(LTX, BSTR, PATH)

ORAL SESSION 49: Rocket Fuel and Scaffolding: Alternative Bridges to Heart Transplantation (Uranie/Caliope)
(HF, HTX, PHARM)

ORAL SESSION 50: What is Really Going On in The Lung Transplant (Hermes)
(BSTR, LTX, PATH)

ORAL SESSION 51: I'm at Risk! Outcomes and Novel Risk Stratification in Pulmonary Hypertension (Mediterranee 6)
(PH, HF)

2:00 PM - 7:30 PM

ISHLT Board of Directors Meeting (Gallieni 1-2)

WEDNESDAY, APRIL 11, 2018

8:30 AM - 10:00 AM

ORAL SESSION 01: Stop It Without Bleeding: Mechanisms of Stroke in MCS

Location: Apollon

Target Audience: MCS, HF, NNSAH, PHARM

Chairs: Andre R Simon, MD, PhD, and Sangjin Lee, MD

8:30 AM (1) Blood Pressure Management Ameliorates the Severity of Neurological Events; J. J. Teuteberg¹, J. G. Rogers², C. A. Milano², M. S. Kiernan³, G. S. Couper³, S. W. Boyce⁴, C. Mahr⁵, N. A. Mokadam⁵, T. A. Vassiliades⁶, F. D. Pagani⁷. ¹Stanford University, Stanford, CA, ²Duke University, Durham, NC, ³Tufts Medical Center, Boston, MA, ⁴MedStar Health, Washington, DC, ⁵University of Washington, Seattle, WA, ⁶Medtronic, Framingham, MA, ⁷University of Michigan, Ann Arbor, MI

8:45 AM (2) Quantifying the Devastation From Stroke During Support With Continuous Flow Pumps: An Intermacs Analysis; J. K. Kirklín¹, D. C. Naftel¹, S. L. Myers¹, F. D. Pagani², L. W. Stevenson³, R. L. Kormos⁴, P. C. Colombo⁵. ¹Kirklín Institute for Research in Surgical Outcomes (KIRSO), University of Alabama at Birmingham, Birmingham, AL, ²University of Michigan, Ann Arbor, MI, ³Vanderbilt University, Nashville, TN, ⁴University of Pittsburgh Medical Center, Heart and Vascular Institute, Pittsburgh, PA, ⁵Columbia University Medical Center, New York, NY

9:00 AM (3) Neurocognitive Deficits are Prevalent in Ambulatory Patients Living with Left Ventricular Assist Devices; M. R. Robinson¹, H. Khalid², L. Meece¹, S. Al-Kindi¹, M. Zacharias¹, C. El Amm¹, M. Ginwalla¹, M. Moghbelli¹, R. Benatti¹, G. H. Oliveira¹. ¹Cardiology, Univeristy Hopsitals Cleveland Medical Center, Cleveland, OH, ²Internal Medicine, Univeristy Hopsitals Cleveland Medical Center, Cleveland, OH

9:15 AM (4) Risk of Thromboembolic Events Among Heart Transplant Recipients Bridged with Durable Mechanical Circulatory Support Devices Receiving Anticoagulation Reversal Agents at Time of Transplant; J. D. Moretz¹, J. Lindenfeld¹, A. S. Shah², M. A. Wigger¹, K. H. Schlendorf¹, M. E. Keebler¹, M. R. Danter², S. B. Sacks¹, H. Ooi¹, D. M. Brinkley¹, S. K. Zalawadiya¹. ¹Advanced Heart Failure and Transplant, Vanderbilt University Medical Center, Nashville, TN, ²Dept of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN

9:30 AM (5) Development of New Algorithms for Early Detection of Pump Thrombosis by Analysis of HeartWare LVAD Log Files; N. Reiss¹, F. Mueller-von Aschwege², T. Schmidt¹, C. Feldmann³, J. Schmitto³, A. Hein², J. Glitza². ¹Clinical Research, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, ²OFFIS Institute, Oldenburg, Germany, ³Hannover Medical School, Hannover, Germany

9:45 AM (6) Stroke After LVAD: Does Age Matter? A Sex-based Analysis; V. Blumer¹, G. A. Hernandez², M. Ortiz³, V. Mehta¹, S. Chaparro¹. ¹University of Miami, Miami, FL, ²Vanderbilt University, Nashville, TN, ³Universidad Central de Venezuela, Caracas, Venezuela, Bolivarian Republic of

8:30 AM - 10:00 AM

ORAL SESSION 02: Thinking Inside The Box: DCD Donation and Ex-vivo Heart Perfusion

Location: Athena

Target Audience: HTX, BSTR, EEP, HF, MCS, NHSAH, PATH

Chairs: Stephen R. Large, MB MA MS F, and Kumud K Dhital, BM.BCh, FRCS-CTh, FRACS, PhD

8:30 AM (7) Non Ischemic Heart Preservation; J. Nilsson¹, V. Jernryd¹, G. Qin¹, S. Nozohoor¹, D. C. Goncalves², S. Ragnarsson¹, A. Paskevicius¹, M. Johansson¹, J. Warheim¹, P. Höglund³, T. Sjöberg¹, S. Steen¹. ¹*Clinical Sciences Lund, Cardiothoracic Surgery, Lund University, Skane University Hospital, Lund, Sweden*, ²*Clinical Sciences Lund, Anesthesiology, Lund University, Skane University Hospital, Lund, Sweden*, ³*Laboratory Medicine, Lund, Clinical Chemistry and Pharmacology, Lund University, Skane University Hospital, Lund, Sweden*

8:45 AM (8) Early Outcomes from DCD Heart Transplantation: A Single Centre Experience; A. Page, S. Messer, V. Hudson, E. Pavlushkov, M. Berman, J. Dunning, J. Parameshwar, Y. Abu-Omar, M. Goddard, S. Bhagra, S. Pettit, C. Lewis, A. Kydd, K. Valchanov, B. Parizkova, S. Colah, D. Jenkins, C. Sudarshan, P. Catarino, A. Ali, S. Tsui, S. Large. *Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom*

9:00 AM (9) Donation After Circulatory Death (DCD) Heart Transplantation in Australia: An Update of Current Practises and Outcomes; H. Chew, M. Connellan, A. Iyer, S. Scheuer, E. Granger, C. Hayward, A. Jabbour, P. Jansz, A. Keogh, E. Kotlyar, P. Spratt, P. Macdonald, K. Dhital. *Heart Lung Clinic, St Vincent's Hospital, Sydney, Australia*

9:15 AM (10) Midterm Followup of Heart Transplantation With Ex vivo Normothermic Preservation Using Extended Criteria Donor Hearts; D. García Sáez¹, B. Zych¹, P. N. Mohite¹, C. T. Bowles¹, F. De Robertis¹, B. Mahesh¹, U. Stock¹, T. Bahrami¹, O. Maunz², N. Banner³, F. Riesgo Gil³, O. Dar³, A. R. Simon¹. ¹*Dept of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield Hospital NHS Foundation Trust, Harefield, London, United Kingdom*, ²*Dept of Perfusion, Royal Brompton and Harefield NHS Foundation Trust, London, UK, Harefield, London, United Kingdom*, ³*Dept of Heart Failure and Transplant Medicine, Royal Brompton and Harefield Hospital NHS Foundation Trust, Harefield, London, United Kingdom*

9:30 AM (11) Prolonged Donation Withdrawal Ischaemic Time (DWIT) Does Not Impact on DCD Heart Transplant Outcomes; S. Messer, A. Page, M. Berman, S. Tsui, S. Large. *Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom*

9:45 AM (12) Post-Transplant Assessment of Donation after Circulatory Death (DCD) Cardiac Allografts with MRI - An Update; E. Pavlushkov¹, A. Page¹, S. Messer¹, A. Kydd¹, Y. Abu-Omar¹, A. Ali¹, M. Berman¹, P. Catarino¹, J. Dunning¹, D. Jenkins¹, S. Bhagra¹, C. Lewis¹, J. Parameshwar¹, S. Pettit¹, C. Sudarshan¹, S. Tsui¹, S. Large¹, K. Tweed². ¹*Cardiothoracic Transplantation, Papworth Hospital, Cambridge, United Kingdom*, ²*Radiology, Papworth Hospital, Cambridge, United Kingdom*

8:30 AM - 10:00 AM

ORAL SESSION 03: Novel Insights About Antibodies in Lung Transplantation

Location: Mediterranean ABC

Target Audience: LTX, BSTR, PATH

Chairs: Amparo Sole, MD, PhD, and Christophe Pison, MD, PhD

8:30 AM (13) *Is the New ISHLT Criteria for Pulmonary Antibody-mediated Rejection Also a Severity Indicator?*; S. Agbor-Enoh¹, [A. Cochrane](#)², A. Jackson³, I. Tunc⁴, P. Shah⁵, Z. Cao⁶, A. Brown⁷, I. Timofte⁶, A. Marishta⁸, M. Jang⁸, S. Gorham⁸, Y. Yang⁸, U. Fideli⁸, A. Iacono⁶, S. Nathan⁹, J. Orens¹⁰, H. Valantine¹. ¹Nat'l Inst. of Health, Bethesda, MD, ²Pharmacy Dept, Inova Fairfax Hospital, Falls Church, VA, ³Immunogenetic Laboratory, Johns Hopkins Hospital, Baltimore, MD, ⁴Bioinformatics and Computation Core, National Heart, Lung, and Blood Institute, Nat'l Inst. of Health, Bethesda, MD, ⁵Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, ⁶Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD, ⁷Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Falls Church, VA, ⁸Laboratory of Transplant Genomics, Nat'l Inst. of Health, Bethesda, MD, ⁹Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Falls Church, VA, ¹⁰pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD

8:45 AM (14) *Risk Factors for the Development of Donor-specific Antibodies and Their Impact on Outcomes After Lung Transplantation*; K. Tsui¹, P. Aguilar¹, D. Byers¹, R. Yusen¹, Y. Furuya¹, L. Tague¹, A. Gelman², V. Puri², D. Kreisel², E. Trulock¹, R. Hachem¹. ¹Pulmonary/Critical Care, Washington University, St Louis, MO, ²Cardiothoracic Surgery, Washington University, St Louis, MO

9:00 AM (15) *Antibody-mediated Rejection: Should We Wait for Clinical Diagnosis?*; S. Agbor-Enoh¹, A. Jackson², G. Berry³, A. Cochrane⁴, I. Tunc⁵, M. Jang¹, K. Bhatti¹, A. Marishta¹, S. Gorham¹, Y. Yang¹, U. Fideli¹, J. Zhu¹, M. Pirooznia⁵, D. Grimm⁶, H. Luikart⁶, P. Shah⁷, I. Timofte⁸, A. Iacono⁸, Z. Cao⁹, A. W. Brown¹⁰, P. Shah¹¹, J. Orens⁷, C. Marboe¹², S. Nathan¹⁰, K. Khush⁶, H. Valantine¹. ¹Laboratory of Transplant Genomics, Nat'l Inst. of Health, Bethesda, MD, ²Immunogenetic Laboratory, Johns Hopkins Hospital, Baltimore, MD, ³Dept of Pathology, Stanford University School of Medicine, Palo Alto, CA, ⁴Pharmacy Dept, Inova Fairfax Hospital, Falls Church, VA, ⁵Bioinformatics and Computation Core, National Heart, Lung, and Blood Institute, Nat'l Inst. of Health, Bethesda, MD, ⁶Division of Cardiology, Stanford School of Medicine, Palo Alto, CA, ⁷Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, ⁸Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD, ⁹Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Bethesda, MD, ¹⁰Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Falls Church, VA, ¹¹Division of Cardiology, Inova Fairfax Hospital, Falls Church, VA, ¹²Dept of Pathology, New York Presbyterian Hospital, New York, NY

9:15 AM (16) *Elevated Donor-Derived Cell-Free DNA (ddcfDNA) as an Early Risk Factor for the Development and Persistence of De Novo Donor Specific HLA Antibody*; [A. M. Jackson](#)¹, A. B. Cochrane², S. Nathan³, A. W. Brown², P. Shah¹, J. Orens¹, A. Iacono⁴, I. Timofte⁴, S. Agbor-Enoh⁵, H. Valantine⁶. ¹Medicine, Johns Hopkins University, Baltimore, MD, ²Medicine, Inova Fairfax Hospital, Fairfax, VA, ³Medicine, Inova Fairfax Hospital, Fairfax, MD, ⁴Medicine, University of Maryland Medical Center, Baltimore, MD, ⁵Medicine, National Heart, Lung and Blood Institute, Baltimore, MD, ⁶Medicine, National Heart, Lung and Blood Institute, Baltimore, VA

9:30 AM (17) *Important HLA and Non-HLA Pre-Transplant Determinantes Associated with the Development of De Novo Donor Specific Antibody After Lung Transplantation*; A. Zhang¹, R. Pei², D. Thomas¹, Y. Sun³, M. Budev⁴. ¹Pathology & Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, ²R&D Dept, Thermo Fisher Scientific, Woodland Hills, CA, ³Avalon Medical University, Curaçao, Netherlands Antilles, ⁴Pulmonary Medicine, Cleveland Clinic, Cleveland, OH

9:45 AM (18) *Feasibility of Avoiding Higher Risk Epitope and Allele HLA Mismatch to Reduce de novo Donor Specific Antibody (dnDSA) in Lung Transplantation*; [R. Zamel](#)¹, J. McCaughan², A. Hirji³, M. Cypel⁴, L. G. Singer⁴, S. Keshavjee⁴, K. Tinckam², J. Tikkanen⁴. ¹Latner Thoracic Research Laboratories, University Health Network, Toronto, ON, Canada, ²Dept of Medicine - Nephrology, University Health Network, Toronto, ON, Canada, ³Respirology, University of Alberta, Edmonton, AB, Canada, ⁴Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

8:30 AM - 10:00 AM

ORAL SESSION 04: Immunosuppression in Heart Transplantation: Lessons Learned

Location: Clio/Thalie/Erato

Target Audience: HTX, BSTR, EEP, HF, ID, NHSAH, PATH, PHARM

Chairs: Jon A Kobashigawa, MD, and Sanjeet Singh Avtaar Singh, MRCS, MSc

8:30 AM (19) Multicenter Study to Determine Up to 5 Year Clinical Outcome of Heart Transplant Recipient Receiving Rituximab Versus Placebo Outcomes in Subjects Previously Randomized in the CTOT-11 Study; R. C. Starling¹, B. Armstrong², Y. R. Morrison³, M. H. Sayegh⁴, A. Chandraker⁵. ¹Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ²Rho Federal Systems Division, Rho Federal Systems Division, Chapel Hill, NC, ³Transplantation Branch, NIH, Rockville, MD, ⁴Internal Medicine, American University of Beirut, Beirut, Lebanon, ⁵Nephrology, Brigham and Womens Hospital, Boston, MA

8:45 AM (20) Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance (Schedule): Results After 6 Years of Follow-up; A. K. Andreassen. Oslo University Hospital, Oslo, Norway

9:00 AM (21) TICTAC 10: Ten Year Follow-up of the Tacrolimus in Combination Tacrolimus Alone Compared Trial; D. A. Baran¹, S. Kapoor², S. Vijaykumar², C. Gidea², M. Camacho², M. J. Zucker². ¹Advanced Heart Failure and Transplant, Sentara Heart Hospital, Norfolk, VA, ²Newark Beth Israel Medical Center, Newark, NJ

9:15 AM (22) Clinical Outcomes Associated With mTORi Initiation in Adult Heart Transplant: An ISHLT Registry Analysis; J. G. Duero Posada¹, Y. Moayed², M. Alhussein¹, S. Bhagra³, S. Fan⁴, C. Manlhiot⁵, J. Stehlik⁶, A. I. Dipchand⁴, H. J. Ross⁵. ¹Cardiology, University Health Network, Toronto, ON, Canada, ²Cardiology, Stanford University, Palo Alto, CA, ³Cardiothoracic Transplantation, Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, United Kingdom, ⁴Cardiology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Cardiology, Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ⁶Cardiology, University of Utah School of Medicine, Salt Lake City, UT

9:30 AM (23) Quantiferon Monitor Assay Identifies Over-Immunosuppressed Patients with Adverse Outcomes After Heart Transplantation: Towards the Definition of a Phenotype of Immune Frailty; L. Potena¹, A. Gaudenzi¹, A. Chiereghin², L. Borgese¹, A. Brighenti¹, G. Piccirilli², M. Masetti¹, L. Giovannini¹, S. Boschi¹, T. Lazzarotto², F. Grigioni¹. ¹Cardiology, University of Bologna, Bologna, Italy, ²Microbiology, University of Bologna, Bologna, Italy

9:45 AM (24) 5-Year Outcome of Renal Function with Patients on Renal-Sparing Protocol After Heart Transplantation; J. Patel, M. Johl, M. Kittleson, L. Czer, S. Dimbil, R. Levine, N. Musto, D. H. Chang, M. Hamilton, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

8:30 AM - 10:00 AM

ORAL SESSION 05: Don't Go Breaking My Heart: The Assessment, Treatment and Implications of Psychosocial Risk Factors

Location: Uranie/Calliope

Target Audience: NHSAH, HF, HTX, MCS

Chairs: Annemarie Kaan, MCN, RN, and Christiane Kugler, PhD

8:30 AM (25) *Variability in Depressive Symptoms and Its Multilevel Correlates in Heart Transplant Recipients: Results From the International Cross-sectional BRIGHT Study*; N. Duerinckx¹, S. De Geest², K. Denhaerynckx², L. Berben², J. Vanhaecke³, C. Russell⁴, R. Helmy², M. Crespo-Leiro⁵, F. Dobbels⁶. ¹KU Leuven, UZ Leuven, Leuven, Belgium, ²University of Basel, Basel, Switzerland, ³University Hospitals of Leuven, Leuven, Belgium, ⁴University of Missouri, Kansas City, MO, ⁵Hospital Universitario A Coruña, Coruña, Spain, ⁶KU Leuven, Leuven, Belgium

8:45 AM (26) *Pre-transplant Distress and Risk of Early Death in UK Cardiothoracic Transplant Recipients*; Z. G. Malpus, A. Diallo, Z. Lawrence, E. Karimi, R. Venkateswaran, M. AlAloul. Cardiothoracic Transplant Unit, Manchester University NHS Foundation Trust, Manchester, United Kingdom

9:00 AM (27) *Psychosocial Assessment for LVAD Candidates: A National Survey*; M. J. Clancy¹, A. B. Jessop¹, H. J. Eisen². ¹Mayes College of Health Policy, University of the Sciences, Philadelphia, PA, ²Division of Cardiology, Drexel University, Philadelphia, PA

9:15 AM (28) *Psychosocial Risk in LVAD Candidates: Preliminary Evaluation of Validity and Reliability of mPACT*; M. C. Maltby¹, M. P. Flattery¹, J. Salyer², S. R. Weinland¹, K. B. Shah¹. ¹Pauley Heart Center, VCU Health System, Richmond, VA, ²Adult Health & Nursing Systems, VCU School of Nursing, Richmond, VA

9:30 AM (29) *Predictors of Posttraumatic Growth Post Lung Transplant*; S. Airdrie¹, L. Stopa¹, A. Reed², M. Sanchez³. ¹Psychology, University of Southampton, Southampton, United Kingdom, ²Faculty of Medicine, National Heart Lung Institute, Imperial College, London, United Kingdom, ³Psychological Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom

9:45 AM (30) *PTSD Following Heart and Lung Transplant: Outcome of Those Receiving Trauma-Focused Cognitive Behavioral Therapy*; L. Painter, I. S. Fontanilla. Transplant Psychology, Auckland City Hospital, Auckland, New Zealand

8:30 AM - 10:00 AM

ORAL SESSION 06: Building a Better Transplant

Location: Hermes

Target Audience: BSTR, HTX, MCS, PATH

Chairs: Kyung-Hee Kim, and Tobias Deuse, MD, PhD

8:30 AM (31) Mitochondrial Transplantation Prolongs Cold Preservation Time in Murine Cardiac Transplantation; K. Moskowitsova¹, K. Liu², B. Shin¹, G. F. Ramirez-Barbieri¹, A. Guariento¹, D. Blitzer¹, D. B. Cowan³, J. K. Thedsanamoorthy³, R. Yao³, A. Orfany¹, G. Visner², P. J. del Nido¹, J. D. McCully¹. ¹Cardiac Surgery, Boston Children's Hospital and Harvard Medical School, Boston, MA, ²Pulmonary and Respiratory diseases, Boston Children's Hospital and Harvard Medical School, Boston, MA, ³Anesthesiology, Boston Children's Hospital and Harvard Medical School, Boston, MA

8:45 AM (218) Intracoronary Implantation of Post-GCSF Stimulation Circulation-derived Autologous CD34+ Cells Reverses Cardiac Remodeling in Patients With End-stage Diffuse Coronary Artery Disease (CAD) - Phase I Early and Long-term Results; F. Lee, H. Lu, P. Sung, Y. Chen, K. Chen, K. Lin, S. Ko, T. Huang, S. Leu, M. Lee, H. Yip. Chang Gung Mem Hosp, Kaohsiung, Taiwan

9:00 AM (33) Knockout of the M33 Receptor Gene in Murine Cytomegalovirus is Associated With Decreased Levels of Cardiac Allograft Vasculopathy in a Murine Aortic Transplant Model; C. Heim¹, N. Fritz¹, T. Stamminger², A. Gocht¹, M. Ramsperger-Gleixner¹, S. M. Ensminger³, M. Weyand¹. ¹Dept of Cardiac Surgery, University of Erlangen, Erlangen, Germany, ²Dept of Virology, University of Erlangen, Erlangen, Germany, ³Dept of Cardiac Surgery, HDZ NRW, Bad Oeynhausen, Germany

9:15 AM (35) Primary LV Unloading with a Trans-valvular Axial Flow Pump Reduces Infarct Size by Increasing Myocardial Levels of Stromal Derived Factor One Alpha (SDF-1a) in Acute Myocardial Infarction and Limits the Development of Ischemic Heart Failure; M. L. Esposito, L. Reyelt, X. Qiao, Y. Zhang, K. Morine, S. Annamalai, C. Bogins, P. Natov, A. Patel, E. Rowin, R. H. Karas, N. K. Kapur. Tufts Medical Center, Boston, MA

9:30 AM (36) Pre-Transplant Serum Exosome Proteomics Differentiates Right and Left Ventricular Primary Graft Dysfunction; B. Fine¹, E. Chen², G. Lebreton³, S. Restaino¹, J. Taupin⁴, E. Zorn⁵, M. Farr¹, P. C. Colombo¹, P. Leprince³. ¹Cardiology, Columbia University, New York, NY, ²Proteomics, Columbia University, New York, NY, ³Thoracic And Cardiovascular Surgery, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Immunology, Hôpital Saint-Louis, Paris, France, ⁵Immunology, Columbia University, New York, NY

9:45 AM (220) Variable Cell-free DNA Characteristics With Different Acute Rejection Phenotypes; S. Agbor-Enoh¹, i. Tunc², M. Jang¹, S. Gorhan¹, A. Marishta¹, U. Fideli¹, Y. Yang¹, K. Bhatti¹, H. Luikart³, M. Pirooznia², J. Zhu², K. Khush³, H. Valentine¹. ¹Laboratory of Transplant Genomics, Nat'l Inst. of Health, Bethesda, MD, ²Bioinformatics and Computation Core, National Heart, Lung, and Blood Institute, Nat'l Inst. of Health, Bethesda, MD, ³Division of Cardiology, Stanford University School of Medicine, Palo Alto, CA

8:30 AM - 10:00 AM

ORAL SESSION 07: Cutting Edge CTEPH: From Metabolomics to Surgical Technique

Location: Mediterranean 6

Target Audience: CTEPH, BSTR, MCS, PH

Chairs: Robert J. Moraca, MD, and David P. Jenkins, FRCS

8:30 AM (37) *Pre-PTE Pulmonary Artery Elastance, Right Ventricular Elastance, and RV-PA Coupling Predict Post-Operative Length of Stay and Hemodynamics*; F. Contijoch¹, D. Wong², S. Igata², A. McDivitt Mizzell², W. Auger², A. DeMaria², D. Blanchard², A. Waheed³, T. Bachman³, M. Simon³, M. Pinsky⁴. ¹*Bioengineering, UC San Diego, La Jolla, CA*, ²*Medicine, UC San Diego, La Jolla, CA*, ³*Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA*, ⁴*Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA*

8:45 AM (38) *Metabolomics Analysis in Chronic Thromboembolic Pulmonary Hypertension*; G. A. Heresi¹, I. Haddadin², J. R. Bartholomew³, M. Gomes³, R. Renapurkar², N. G. Smedira⁴, R. A. Dweik¹. ¹*Respiratory Institute, Cleveland Clinic, Cleveland, OH*, ²*Imaging Institute, Cleveland Clinic, Cleveland, OH*, ³*Vascular Medicine, Cleveland Clinic, Cleveland, OH*, ⁴*Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH*

9:00 AM (39) *A Comparison of Short Term Outcomes of Minimally Invasive versus Sternotomy Pulmonary Thromboendarterectomy*; J. R. Higgins¹, N. H. Kim², K. Kerr², T. Fernandez², D. Poch², M. Madani¹. ¹*Cardiothoracic Surgery, UCSD Medical Center, La Jolla, CA*, ²*Pulmonary Medicine, UCSD Medical Center, La Jolla, CA*

9:15 AM (40) *Impact on Outcomes with Extra-Corporeal Life Support (ECLS) After Complicated Pulmonary Thrombo-Endarterectomy*; H. Nair. *Anesthesiology, Narayana Institute of Cardiac Sciences, Bangalore, India*

9:30 AM (41) *Pulmonary Endarterectomy: Relationship Between Total Reopened Branches and Outcomes*; M. Pin, B. Vanini, A. Sciortino, V. Grazioli, V. Merli, A. Celentano, I. Parisi, C. Klersy, G. Silvaggio, C. Monterosso, M. Salati, C. Pellegrini, B. Cattadori, A. D'Armini. *Policlinico San Matteo, Policlinico San Matteo, Pavia, Italy*

9:45 AM (42) *The Incidence and Identification of Chronic Thromboembolic Disease in Patients Presenting with Acute Pulmonary Embolism*; L. DiChiacchio, C. Pasrija, F. Boulos, J. Jeudy, Z. Kon. *University of Maryland Medical Center, Baltimore, MD*

10:30 AM - 12:30 PM

PLENARY 1: Opening Plenary Session

Location: Apollon

Target Audience: ALL

Chairs: Christian Benden, MD, FCCP, and Andrew J Fisher, PhD, FRCP

10:30 AM Welcome/Program Chair Report

Christian Benden, MD, FCCP, University Hospital Zurich, Zurich, Switzerland

10:40 AM Thoracic Registry Report

Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

10:55 AM MCSD Registry Reports

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

11:05 AM JHLT Editor's Report

Mandeep R Mehra, MD, MBBS, FACC, FACP, Brigham and Women's Hospital, Boston, MA, USA

11:15 AM Presidential Address

Andrew J Fisher, PhD FRCP, Newcastle University, Newcastle Upon Tyne, United Kingdom

11:30 AM (43) Molecular Diagnosis of Rejection Phenotypes in 889 Heart Transplant Biopsies: The INTERHEART

Study; J. Reeve¹, D. H. Kim², M. G. Crespo-Leiro³, J. Kobashigawa⁴, L. Potena⁵, M. Deng⁶, M. Cadeiras⁶, E. C. Depasquale⁶, P. Bruneval⁷, A. Lopy⁸, P. Macdonald⁹, A. Zuckermann¹⁰, A. A. Aliabadi¹⁰, J. Goekler¹⁰, P. F. Halloran¹.
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁴Cedars-Sinai Heart Institute, Beverly Hills, CA, ⁵University of Bologna, Bologna, Italy, ⁶Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁷Hôpital Européen Georges Pompidou, Paris, France, ⁸Hôpital Necker, Paris, France, ⁹The Victor Chang Cardiac Research Institute, Sydney, Australia, ¹⁰Medical University of Vienna, Vienna, Austria

11:45 AM Interactive Discussant for Presentation 43

Lori J West, MD, D.Phil, University of Alberta, Edmonton, AB, Canada

11:50 AM (44) Benefits of Early Everolimus-Based Quadruple Immunosuppression Early After Lung Transplantation - Results of 4EVERLUNG, a Prospective Randomized Multicenter Trial; J. Gottlieb¹, C. Neurohr², J. Müller-Quernheim³, H. Wirtz⁴, B. Sill⁵, H. Wilkens⁶, V. Besa⁷, C. Knosalla⁸, M. Junge⁹, C. Capusan⁹, M. Strüber⁴. ¹Dpt.

Respiratory Medicine OE6870, Hannover Medical School, Hannover, Germany, ²Medizinische Klinik und Poliklinik V Großhadern, LMU, München, Germany, ³Medizinische Klinik Pneumologie, Universitätsklinikum, Freiburg, Germany, ⁴Innere Medizin/Abteilung Pneumologie, Universitätsklinikum, Leipzig, Germany, ⁵Klinik für Herz-und Gefäßchirurgie, UKE, Hamburg, Germany, ⁶Innere Medizin V, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany, ⁷Westdeutsches Zentrum für Lungentransplantation, Ruhrlandklinik, Essen, Germany, ⁸Deutsches Herzzentrum, Berlin, Germany, ⁹Novartis Pharma, Nürnberg, Germany

12:05 PM Interactive Discussant for Presentation 44

Roger D. Yusen, MD, MPH, Washington Univ Sch Med, St. Louis, MO, USA

12:10 PM Lifetime Achievement Award Laudation

Robert L Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

12:25 PM Lifetime Achievement Award Acceptance

O. Howard Frazier, MD, Texas Heart Institute, Houston, TX, USA

2:00 PM - 4:00 PM

SYMPOSIUM 01: The Devil Wears Prada - The Role of the RV in Advanced Heart Failure and LVADs

Location: Apollon

Target Audience: MCS, HF/HTX, NNSAH, PEDS, PH, PHARM

Chairs: Sanem Nalbantgil, MD, and Francis D Pagani, MD, PhD

Session Summary: The rise of MCS has brought a lot of attention to the usually "forgotten" RV. This close scrutiny is driven by lack of options for durable RVAD support and worse outcome associated with RV failure. As MCS technology advances and complications decline, less sick patients will be offered therapy. The following question arises: Should we shift our focus from LV-centric approach to RV-centric one, pulling surgical trigger early on, to prevent major short and long-term consequences for our patients? A panel discussion with all speakers will conclude this session.

2:00 PM *Pathogenesis of RV Failure Due to Left Heart Disease*

Ryan Tedford, MD, FACC, FAHA, Medical University of South Carolina, Charleston, SC, USA

2:12 PM *The Importance of Exercise Physiology in the Assessment of RV Function in Heart Failure Patients*

Marco Guazzi, MD, University of Milano, Milano, Italy

2:24 PM *Defining Biventricular Failure: What is the Best Modality?*

Maria G Crespo-Leiro, MD, Hospital Univ A Coruna, La Coruna, Spain

2:36 PM *Systemic Venous Congestion From RV Failure as a Fundamental Stimulus for Dysfunction and Damage of Vital Organs*

Paolo C Colombo, MD, Columbia University, New York, NY, USA

2:48 PM *Non-Surgical Treatment of RV Failure Post LVAD*

Sandra Eifert, MD, LMU University clinic Munich, Dept. of cardiac surgery Germany, Munich, Germany

3:00 PM *CASE PRESENTATION: Unexpected RV Failure with Persistent Pulmonary Hypertension Following LVAD: What Now?*

Steven Hsu, MD, Johns Hopkins University, Baltimore, MD, USA

3:05 PM *Drug Therapies for Pulmonary Hypertension are Needed to Target the Right Ventricle*

Marc A Simon, MD, University of Pittsburgh, Pittsburgh, PA, USA

3:17 PM *Surgical Treatment of RV Failure Post LVAD*

Francis D Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA

3:29 PM *Pulsatile BiVAD: Reality or Fantasy?*

Arjang Ruhparwar, MD, PhD, University of Heidelberg, Heidelberg, Germany

3:41 PM *Panel Discussion*

2:00 PM - 4:00 PM

SYMPOSIUM 02: Adult Congenital Heart Disease: Reaching the Summit

Location: Athena

Target Audience: HF/HTX, PEDS

Chairs: Michael Burch, MD, and Monica M Colvin, MD

Session Summary: The aim of this session is to discuss assessment, management and outcome of ACHD patients from the time of referral for cardiac transplantation, as opposed to the well described time points of listing and transplant. Speakers will describe the population and address specific considerations required when managing these patients particularly those which are different from acquired heart disease. Options for those not suitable for transplant and alternatives to transplant will also be discussed.

2:00 PM *Transplant Assessment of Adult Congenital Heart Disease Patients: Who, When and By Whom*

David S Crossland, MRCPCH, Freeman Hospital, Newcastle upon Tyne, United Kingdom

2:20 PM Q&A

2:24 PM *Presentation and Management of Cardiogenic Shock in the Single Ventricle*

Joseph W. Rossano, MD, The Children's Hospital, Philadelphia, PA, USA

2:44 PM Q&A

2:48 PM *Pain for How Much Gain? Non-transplant Strategies and Bridging to Candidacy in Adult Congenital Heart Disease Patients*

Lucy S Roche, MD, University of Toronto, Toronto, ON, Canada

3:08 PM Q&A

3:12 PM *The Liver, the Kidneys and Everything Else! Assessing Non-Thoracic Organs for Suitability for Heart Transplant*

Stephan Schubert, MD, Deutsches Herzzentrum Berlin, Berlin, Germany

3:32 PM Q&A

3:36 PM *Planning the Plumbing: Anatomical Limitations and How to Address Them*

Antonio Amodeo, MD, Pediatric Hospital Bambino Gesù, Rome, Italy

3:56 PM Q&A

2:00 PM - 4:00 PM

SYMPOSIUM 03: Chronic Lung Allograft Dysfunction (CLAD): Where Are We Now?

Location: Mediterranean ABC

Target Audience: LF/LTX, BSTR, ID, NNSAH, PATH, PEDS, PHARM

Chairs: Cynthia J Gries, MD, MSc, and Are Martin Holm, MD, PhD

Session Summary: The pathogenesis of CLAD involves both alloimmune and non-alloimmune pathways. This multi-council forum will present up-to-date knowledge about the pathobiology of CLAD phenotypes including new paradigms of pathophysiology, host-pathogen interactions, the impact of lung microbiome and pulmonary infections upon innate immunity and their impact on CLAD development, diagnosis using more sensitive pulmonary function parameters, radiographic and pathological correlates, and therapeutic strategies.

2:00 PM *Is It CLAD or Is It Something Else: Why Does Lung Function Decline After Transplant?*

Robin Vos, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

2:15 PM Q&A

2:20 PM *Non-Infectious Risk Factors for CLAD*

Adrian C Lawrence, MD, MACM, University of Minnesota, Minneapolis, MN, USA

2:35 PM Q&A

2:40 PM *Biomarkers for CLAD: Are Cellular and Molecular Analyses Useful for the Clinician?*

Johanna Kwakkel-van Erp, MD, PhD, University Medical Center, Utrecht, Netherlands

2:55 PM Q&A

3:00 PM *The Impact of the Lung Microbiome and Pulmonary Infections Upon the Development of CLAD*

Andrew J Fisher, FRCP, PhD, Newcastle University, Newcastle Upon Tyne, United Kingdom

3:15 PM Q&A

3:20 PM *Subtypes of CLAD: Where Are We Now?*

Jamie L Todd, MD, Duke University Medical Center, Durham, NC, USA

3:35 PM Q&A

3:40 PM *Treatment Options in CLAD: A Story of Hope or Evidence?*

Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

3:55 PM Q&A

2:00 PM - 4:00 PM

SYMPOSIUM 04: Cardio-Oncology: A Tale of Two Problems

Location: Clio/Thalie/Erato

Target Audience: HF/HTX, MCS, NNSAH, PEDS, PHARM

Chairs: Jennifer N. Gray, PharmD, and Sofia C Masri, MD

Session Summary: This session will focus on cardiac risk in cancer patients, including: (1) Risks of the newer agents (including fulminant myocarditis with checkpoint inhibitors), (2) Balancing risk of cardiac complications when treating cancer, (3) Use of temporary and durable MCS in setting of increased risk of infection and bleeding, (4) Timing of heart transplant and post-transplant outcomes in cancer, and (5) Role of heart transplant in AL (light chain) amyloid.

2:00 PM *Cardio Toxicity in Cancer: The Frontier Beyond Anthracyclines*

Douglas L. Jennings, PharmD, Columbia University Medical Center, New York, NY, USA

2:20 PM *Treating Heart Failure in Cancer Patients: How Do We Balance Cardio Toxicity with Cancer Risk?*

Guilherme H Oliveira, MD, University Hospitals Case Medical Center, Cleveland, OH, USA

2:40 PM *Medical and Mechanical Heart Failure Therapies in Cancer Therapeutics Related Cardiomyopathies*

Meike Rybczynski, MD, University Heart Centre Hamburg, Hamburg, Germany

3:00 PM *Survivors of Cancer: Is This a Contraindication to Transplant?*

Charles E. Canter, MD, St Louis Children's Hospital, St. Louis, MO, USA

3:20 PM *Advanced Therapies in AL Amyloidosis: Is This a Good Idea?*

Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

3:40 PM *Panel Discussion*

2:00 PM - 4:00 PM

SYMPOSIUM 05: The Young and the Restless: Unique Challenges in Cardiothoracic Transplantation and Mechanical Support from Children to Young Adults

Location: Uranie/Calliope

Target Audience: NNSAH, HF/HTX, LF/LTX, MCS, PEDS

Chairs: Liz Painter, MA, MSc, and Quincy Young, PhD, RPsych

Session Summary: This session will address: 1) challenges in transitioning from pediatrics to the adult setting, 2) how to manage non-adherence in youth and young adults, 3) best practices in managing frailty, 4) data on youth preferences regarding end of life discussions and review tips on how to best approach those conversations. The challenging issues discussed by presenters will be highlighted in a complex clinical case presentation of a young adult presenting for re-transplantation. Audience participation and panel discussion will be encouraged in the last 15 minutes of the symposium.

2:00 PM *It's So Hard to Say Goodbye: Transitioning from the Pediatric to the Adult Setting*

Jo Wray, PhD, Great Ormond Street Hospital, London, United Kingdom

2:15 PM *Prehabbing and Rehabbing: What Can We Do for the Frail Patient at Any Age?*

Louise M Fuller, PT, Alfred Hospital, Melbourne, Australia

2:30 PM *You are Not the Boss of Me! Managing Non-Adherence in Adolescents and Young Adults in Cardiothoracic Transplantation and Mechanical Support*

Samantha J Anthony, PhD, MSW, Hospital for Sick Children, Toronto, ON, Canada

2:45 PM *Dying to Talk about Death? Adolescent and Young Adult Preferences for Advance Care Planning and End of Life Discussions*

Melissa Cousino, PhD, CS Mott Children's Hospital, Ann Arbor, MI, USA

3:00 PM *Communication Tools for Goals of Care Conversations*

Elizabeth Blume, MD, Boston Children's Hospital, Boston, MA, USA

3:15 PM *Education and Employment After Cardiothoracic Transplantation or Mechanical Support*

Michael Petty, PhD, RN, CNS, University of Minnesota, Minneapolis, MN, USA

3:30 PM *So, Should We Do This Again? Re-Transplantation of the Medically and Psychosocially Complex Young Adult*

Mustafa Toma, MD, University of British Columbia, Vancouver, BC, Canada

3:45 PM *Panel Discussion*

2:00 PM - 4:00 PM

SYMPOSIUM 06: Novel Tools in Transplant Research (Say You Want a Revolution...)

Location: Hermes

Target Audience: BSTR, HF/HTX, ID, LF/LTX, PATH, PHARM

Chairs: Sonja Schrepfer, MD, PhD, and Christopher H Wigfield, MD

Session Summary: New tools and techniques in clinical immunology are redefining what is possible. We will explore some of the cutting-edge research tools that are fueling research into heart and lung transplantation, including advanced microscopy, cytometry, immune monitoring, RNA sequencing, proteomics, microbiome profiling, and genome-wide association studies. Exciting possibilities will be tempered with practical considerations on how to use these techniques to advance your research career.

2:00 PM *If Tissue is the Issue...*

Daniel Kreisel, MD, PhD, Washington University School of Medicine, St. Louis, MO, USA

2:15 PM Q&A

2:20 PM *Scrutinizing the Immune System*

Marilia Cascalho, MD, PhD, University of Michigan, Ann Arbor, MI, USA

2:35 PM Q&A

2:40 PM *What's in the DNA?*

Bart Vanaudenaerde, MD, Katholieke Universiteit, Leuven, Belgium

2:55 PM Q&A

3:00 PM *Should We Act Based on the DNA?*

Nancy Reinsmoen, PhD, Cedars-Sinai Health System, Los Angeles, CA, USA

3:15 PM Q&A

3:20 PM *Epigenetics, MicroRNA, Transcriptome*

Thalachallour Mohanakumar, PhD, St. Joseph's Hospital and MC, Phoenix, AZ, USA

3:35 PM Q&A

3:40 PM *Microbiome and Virome*

Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

3:55 PM Q&A

2:00 PM - 4:00 PM

SYMPOSIUM 07: The Devil is in the Details - Nuances in CTEPH

Location: Mediterranean 6

Target Audience: CTEPH, LF/LTX, PH

Chairs: Marc De Perrot, MD, and Irene Lang, MD

Session Summary: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is one of the commonest subsets of PH, and potentially curable. It is of utmost importance to familiarize the audience with key characteristics of the condition, including risk factors and details of diagnostic imaging. With a rising number of providers focusing on managing patients with CTEPH, patient selection and appropriateness of diagnosis remains key in predicting clinical outcomes post interventions.

2:00 PM *Acute Pulmonary Embolism to CTEPH - Understanding the Pathway*

Frederikus A Klok, MD, Leiden University Medical Center, Leiden, Netherlands

2:15 PM Q&A

2:20 PM *Diagnostic Imaging to Adequately Assess Thrombus Burden in CTEPH*

Nicholas Screatton, MD, Papworth Hospital, London, United Kingdom

2:35 PM Q&A

2:40 PM *CTEPH Outcomes - Insights from Registries*

Kim Kerr, MD, UCSD Medical Center, San Diego, CA, USA

2:55 PM Q&A

3:00 PM *Medical Management in CTEPH*

Manreet V Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA

3:15 PM Q&A

3:20 PM *Evolving Approach to Pulmonary Endarterectomy: Unraveling the Distal Vessels*

Andrea M D'Armini, MD, Foundation IRCCS Policlinico San Matteo, Pavia, Italy

3:35 PM Q&A

3:40 PM *CTEPH - The Great Mimic*

Gustavo Heresi, MD, Cleveland Clinic foundation, Cleveland, OH, USA

3:55 PM Q&A

4:30 PM - 6:00 PM

ORAL SESSION 08: Four Liters and Fingers Crossed: ECMO - Management and Outcomes

Location: Apollon

Target Audience: MCS

Chairs: Jose Gonzalez-Costello, MD, and Ranjit John, MD

4:30 PM (45) Percutaneous Unloading of the Left Ventricle During Extracorporeal Membrane Oxygenation in Cardiogenic Shock - Ongoing Experience from a High-Volume Centre; B. Schrage¹, M. Becher¹, M. Schwarzl¹, H. Grahn¹, G. Söffker², E. Lubos¹, A. Bernhardt³, H. Reichenspurner³, S. Blankenberg¹, D. Westermann¹. ¹Dept of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany, ²Dept of Intensive Care Medicine, University Heart Center Hamburg, Hamburg, Germany, ³Dept of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

4:45 PM (46) Extracorporeal Membrane Oxygenation as a Bridge to Heart Transplant versus Left Ventricular Assist Device: Analysis of a Multicenter, Nationwide Database; Z. Shah¹, V. Vuddanda², M. Yin¹, O. Wever-Pinzon¹, J. Nativi-Nicolau¹, S. Drakos¹, A. Kfoury³, J. Fang¹, J. Stehlik¹. ¹University of Utah Medical Center, Salt Lake City, UT, ²Department of Public Health, Harvard Medical School, Boston, MA, ³Intermountain Medical Center, Salt Lake City, UT

5:00 PM (47) Long-term Outcome of Patients Bridged to Recovery After Short-term Mechanical Circulatory Support for Cardiogenic Shock; Y. Cheng¹, A. R. Garan², H. Takayama¹, M. Ando¹, J. Han¹, P. A. Kurlansky¹, M. Yuzefpolskaya², P. C. Colombo², Y. Naka¹, K. Takeda¹. ¹Division of Cardiothoracic Surgery, Dept of Surgery, New York Presbyterian Hospital, New York, NY, ²Division of Cardiology, New York Presbyterian Hospital, New York, NY

5:15 PM (48) Extracorporeal Membrane Oxygenation to Transplant Survival: Past, Present and Future; M. Y. Kamath, N. Bellam, M. Moore, A. Salimbanon, A. Chang, A. Nsair, M. Cadeiras, M. Kwon, A. Ardehali, E. Depasquale. UCLA, Los Angeles, CA

5:30 PM (49) Early Elevated Plasma Free Hemoglobin Predicts Occurrence of Thromboembolic Stroke during Venoarterial Extracorporeal Membrane Oxygenation Support; O. Saeed¹, W. Jackobleff², T. Chinnadurai¹, S. Forest², S. Rangasamy¹, S. Madan¹, M. Aljoudi¹, Y. Xia³, S. R. Patel¹, S. Vukelic¹, D. B. Sims¹, J. Shin¹, H. H. Billett¹, D. J. Goldstein², U. P. Jorde¹. ¹Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, ²Cardiothoracic Surgery, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, ³Surgery, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY

5:45 PM (50) Is Cerebral Near-infrared Spectroscopy Monitoring Predictive of Neurological Injury During ECMO?; S. Liem, N. Cavarocchi, H. Hirose. Surgery, Thomas Jefferson University, Philadelphia, PA

4:30 PM - 6:00 PM

ORAL SESSION 09: The Pressure is On! Assessment and Role of Blood Pressure in MCS

Location: Athena

Target Audience: MCS, NNSAH, PHARM, PH

Chairs: Brent C Lampert, DO, and Jason N Katz, MD, MHS

4:30 PM (51) Estimation of Mean Arterial Pressure in HeartMate II Patients Using Doppler Blood Pressure and Pump Speed; A. Pinsino¹, F. Castagna², E. J. Stöhr³, B. J. McDonnell⁴, J. R. Cockcroft⁴, M. Tiburcio¹, L. Effner¹, A. R. Garan¹, V. K. Topkara¹, K. Takeda¹, H. Takayama¹, Y. Naka¹, R. T. Demmer⁵, M. Yuzefpolskaya¹, P. C. Colombo¹.
¹Columbia University, New York, NY, ²Columbia University, Yale Bridgeport Hospital, New York, Bridgeport, NY, ³Columbia University, Cardiff Metropolitan University, New York, NY, ⁴Cardiff Metropolitan University, Cardiff, United Kingdom, ⁵University of Minnesota, Columbia University, New York, NY

4:45 PM (52) Systolic Blood Pressure and Outcomes in Patients on Continuous Flow LVAD Support: An INTERMACS Analysis; J. A. Cowger¹, T. Chamogeorgakis², J. Borgi², G. Grafton³, Y. Selektor³, H. Nemeh², C. Williams³, C. Tita³, D. Lanfear³. ¹Henry Ford Health System, Detroit, MI, ²Cardiothoracic Surgery, Henry Ford Health System, Detroit, MI, ³Cardiology, Henry Ford Health System, Detroit, MI

5:00 PM (53) Blood Pressure Control as a Risk Factor for Stroke in LVAD Patients- Single Center Experience; N. S. Clarke¹, R. Vela¹, J. Pruszyński¹, M. Drazner², L. C. Huffman¹, M. Peltz¹. ¹Cardiovascular and Thoracic Surgery, University of Texas Southwestern, Dallas, TX, ²Internal Medicine, University of Texas Southwestern, Dallas, TX

5:15 PM (54) Risk Predictors for Ischemic Stroke in CF-LVAD Patients by Pump Flow Type; M. Kanwar¹, L. Lohmueller², R. Kormos³, S. Bailey¹, C. McIlvannan⁴, S. Murali¹, J. Antaki². ¹Allegheny General Hospital, Pittsburgh, PA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Colorado, Denver, CO

5:30 PM (55) Predictive Value of Mean Arterial Pressure Versus Systolic Blood Pressure and Visit-To-Visit Blood Pressure Variability for Stroke and Pump Thrombosis in HeartMate II Patients; A. Pinsino¹, F. Castagna¹, J. Z. Willey¹, A. M. Zuver¹, M. A. Flannery¹, B. Cagliostro¹, J. R. Cockcroft², A. R. Garan¹, V. K. Topkara¹, H. Takayama¹, K. Takeda¹, Y. Naka¹, R. T. Demmer³, P. C. Colombo¹, M. Yuzefpolskaya¹. ¹Columbia University, New York, NY, ²Cardiff Metropolitan University, Cardiff, United Kingdom, ³University of Minnesota, Columbia University, New York, NY

5:45 PM (56) Increased Aortic Stiffness is Associated with Higher Rates of Stroke, GI-bleeding and Pump Thrombosis in Continuous-Flow Left Ventricular Assist Device Patients; H. Rosenblum¹, A. Pinsino¹, R. T. Demmer¹, P. C. Colombo¹, M. Yuzefpolskaya¹, A. R. Garan¹, V. K. Topkara¹, A. Gaudig¹, M. T. Pineda¹, Y. Naka¹, H. Takayama¹, K. Takeda¹, F. Castagna², J. Z. Willey¹, B. J. McDonnell¹, J. R. Cockcroft¹, E. J. Stöhr¹. ¹Columbia University, New York, NY, ²Columbia University/Yale New Haven Bridgeport, New York, NY

4:30 PM - 6:00 PM

ORAL SESSION 10: Mechanisms of Allograft Injury after Lung Transplantation

Location: Mediterranean ABC

Target Audience: LTX, BSTR, PATH

Chairs: Angela Koutsokera, MD, PhD, and Jonathan D'Cunha, MD

4:30 PM (57) Clinically-unrecognized Allograft Injury is Common After Lung Transplantation; S. Agbor-Enoh¹, I. Tunc², S. Gorham¹, M. Jang¹, U. Fideli¹, A. Marishta¹, J. Zhu², M. Pirooznia², Y. Yang¹, A. Davis¹, D. Grimm³, Z. Cao⁴, H. Luikart³, P. Shah⁵, I. Timofte⁴, A. W. Brown⁶, A. Iacono⁴, S. Nathan⁷, J. Orens⁵, K. Khush³, H. Valentine¹. ¹Laboratory of Transplant Genomics, Nat'l Inst. of Health, Bethesda, MD, ²Bioinformatics and Computation Core, National Heart, Lung, and Blood Institute, Nat'l Inst. of Health, Bethesda, MD, ³Division of Cardiology, Stanford School of Medicine, Palo Alto, CA, ⁴Pulmonary and Critical Care Medicine, University of Maryland Medical Center, Baltimore, MD, ⁵Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, ⁶Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Fall Church, VA, ⁷Pulmonary and Critical Care Medicine, Inova Fairfax Hospital, Falls Church, VA

4:45 PM (58) Impact of Carbon Dioxide Tension on Survival After Lung Transplantation for Pulmonary Fibrosis; M. A. Villavicencio¹, A. L. Axtell¹, A. G. Fiedler¹, E. Heng¹, Y. Raz², I. P. Neuringer², S. I. Melnitchouk¹, G. Tolis¹, D. A. D'Alessandro¹, T. A. Astor². ¹Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ²Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA

5:00 PM (59) Neutrophil Extracellular Traps in Human Ex Vivo Lung Perfusion as a Biomarker of Lung Injury; L. Calderone¹, A. Mariscal¹, A. Sage¹, S. Juvet¹, T. Martinu¹, M. Khan², M. Cypel¹, M. Liu¹, N. Palaniyar², S. Keshavjee¹. ¹University Health Network, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada

5:15 PM (60) High Frequencies of Regulatory T Cells Are Associated with Less Chronic Lung Allograft Dysfunction in Cystic Fibrosis Patients After Combined Lung and Liver Transplantation; J. Salman, A. Knoefel, T. Siemieni, F. Lus, W. Sommer, M. Avsar, C. Kuehn, A. Haverich, F. Lehner, T. Igor, G. Warnecke. Hannover Medical School, Hannover, Germany

5:30 PM (61) Increasing Frequency of CD127^{low} Regulatory Cells Early After Lung Transplantation Improves Freedom From Chronic Lung Allograft Rejection and Graft Survival in 673 Patients; F. Ius¹, A. Knoefel¹, J. Salman¹, W. Sommer¹, T. Nakagiri¹, T. Siemieni¹, C. Kuehn¹, M. Avsar¹, D. Bobylev¹, R. Poyanmehr¹, D. Boethig¹, T. Welte², A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Respiratory Medicine, Hannover Medical School, Hannover, Germany

5:45 PM (62) Exosomes With Lung Self-antigens, α 1Tubulin and Collagen V, as Biomarker for Bronchiolitis Obliterans Syndrome Following Human Lung Transplantation; T. Mohanakumar¹, M. Gunasekaran¹, M. Sharma¹, S. Elnahas¹, S. Biswas Roy¹, R. Hachem², R. Bremner¹, M. Smith¹. ¹Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ²Washington University School of Medicine, St. Louis, MO

4:30 PM - 6:00 PM

ORAL SESSION 11: Predictable or Inevitable? Complications of Heart Transplantation

Location: Clio/Thalie/Erato

Target Audience: HTX, BSTR, HF, NNSAH, PATH

Chairs: Debra L Isaac, MD, and David A Baran, MD

4:30 PM (63) *Assessing the Predictive Validity of ISHLT's Primary Graft Dysfunction Classification Instrument*; F. Foroutan¹, C. Alba¹, J. Krakovsky¹, S. Chih², G. H. Guyatt³, H. Ross¹. ¹Cardiology, Toronto General Hospital, Toronto, ON, Canada, ²Cardiology, Ottawa Heart Institute, Ottawa, ON, Canada, ³Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

4:45 PM (64) *Association Between Common Measures of Graft Function and Mortality Post Heart Transplant (HT)*; F. Foroutan¹, H. J. Ross¹, A. Malik¹, G. H. Guyatt², C. Alba¹. ¹Cardiology, Toronto General Hospital, Toronto, ON, Canada, ²Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

5:00 PM (65) *ST2 as a Marker of Primary Graft Dysfunction*; A. Galeone¹, S. Varnous¹, J. Salem², G. Lebreton¹, G. Coutance¹, J. Hulot², P. Leprince¹. ¹Dept of Thoracic and Cardiovascular Surgery, La Pitié-Salpêtrière Hospital, Paris, France, ²Dept of Pharmacology, CIC Paris-Est 1421, Institute of Cardiometabolism and Nutrition (ICAN), Pitié-Salpêtrière Hospital, Paris, France

5:15 PM (66) *Pre-transplant Macrophage Cholesterol Efflux Capacity is Associated With Angiographic Cardiac Allograft Vasculopathy in a Multi-center Observational Study*; A. Javaheri¹, E. Novak¹, K. Lavine¹, D. J. Rader², R. Starling³, A. K. Chandraker⁴, D. Baran⁵, P. S. Heeger⁶, J. Stehlik on behalf of CTOT18 investigators⁷. ¹Medicine, Washington University of Saint Louis, Saint Louis, MO, ²Medicine, University of Pennsylvania, Philadelphia, PA, ³Medicine, Cleveland Clinic, Cleveland, OH, ⁴Medicine, Harvard Medical School, Boston, MA, ⁵Medicine, Sentara Advanced Heart Failure Center, Norfolk, VA, ⁶Medicine, Mount Sinai School of Medicine, New York, NY, ⁷Medicine, University of Utah, Salt Lake City, UT

5:30 PM (67) *The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Allograft Vasculopathy in De-Novo Heart Transplant Recipients: Results of the Schedule Trial after 6 Years*; S. Arora¹, K. Karason², F. Gustafsson³, H. Eiskjær⁴, G. Rådegran⁵, L. Aaberge¹, E. Gude¹, D. Solbu⁶, G. Dellgren², A. K. Andreassen¹, L. Gullestad¹. ¹Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ²Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Cardiology, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Cardiology, Skejby University Hospital, Aarhus, Denmark, ⁵Cardiology, Skåne University Hospital, Lund, Sweden, ⁶Novartis Norge, Oslo, Norway

5:45 PM (68) *A Novel Risk Prediction Model for PTLD in the Post Cardiac Transplantation Population: A UNOS Database Analysis*; N. Nair¹, S. Yang², E. Gongora³. ¹Division of Cardiology, Dept of Internal Medicine, Texas Tech health Sciences Center, Lubbock, TX, ²Dept of Internal Medicine, Texas Tech health Sciences Center, Lubbock, TX, ³Cardiothoracic Surgery, Memorial Cardiac and Vascular Institute, Hollywood, FL

4:30 PM - 6:00 PM

ORAL SESSION 12: The Leading Edge: Novel Practices in Patient Care Pathways

Location: Uranie/Calliope

Target Audience: NNSAH, HF, HTX, LTX, MCS

Chairs: Nicola Robinson Smith, RN, and Kevin C Carney, MSN, CRNP, CCTC

4:30 PM (69) *Assessing the Need for Palliative Care in LVAD and HTX Patients*; F. Strangl¹, A. Ullrich², A. Bernhardt³, M. Barten³, C. Bokemeyer², S. Blankenberg¹, H. Reichenspurner³, K. Oechsle², M. Rybczynski¹. ¹*Dept of Cardiology, University Heart Center Hamburg-Eppendorf, Hamburg, Germany*, ²*Dept of Oncology, Hematology and Bone Marrow Transplantation, Palliative Care Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany*, ³*Dept of Cardiac Surgery, University Heart Center Hamburg-Eppendorf, Hamburg, Germany*

4:45 PM (70) *IPADS and LVADS: VAD Coordinator Telemonitoring*; A. Luke, C. Castillo, M. Taveras, T. Chinnadurai, S. Rangasamy, D. Goldstein, U. Jorde, S. Patel. *Mechanical Circulatory Support, Montefiore Medical Center, Bronx, NY*

5:00 PM (71) *Clinicians' Acceptance of Interactive Health Technologies for Self-Management among Patients with Chronic Cardiopulmonary Disorders*; M. Alrawashdeh¹, R. Zomak², S. Al-Zaiti¹, S. Sereika¹, B. Parmanto³, A. DeVito Dabbs¹. ¹*School of Nursing, University of Pittsburgh, Pittsburgh, PA*, ²*Cardiothoracic Transplant Program, University of Pittsburgh Medical Center, Pittsburgh, PA*, ³*School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, PA*

5:15 PM (72) *Pilot Experience with a Novel Bluetooth Tablet-Based Technology for Home Monitoring and Education After Lung Transplantation*; F. A. Schenkel, S. Ganesh, J. O'Conner, R. Sadeghi, M. Bembi, M. Duong, M. L. Barr, A. E. Hackmann. *Keck Medical Center of USC, Los Angeles, CA*

5:30 PM (73) *Outcomes of Telehealth Assessment of Lung Transplant Candidates*; A. Sidhu, R. Colman, J. Tikkanen, M. Binnie, C. Chaparro, S. Keshavjee, L. G. Singer. *Toronto Lung Transplant Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada*

5:45 PM (74) *Impact of a Mobile Health Intervention on Long-term Nonadherence in Lung Transplantation*; E. M. Rosenberger¹, M. Dew¹, A. F. DiMartini¹, J. M. Pilewski¹, A. J. DeVito Dabbs². ¹*School of Medicine, University of Pittsburgh UPMC, Pittsburgh, PA*, ²*School of Nursing, University of Pittsburgh UPMC, Pittsburgh, PA*

4:30 PM - 6:00 PM

ORAL SESSION 13: Early Career Scientist Award Candidate Presentations

Location: Hermes

Target Audience: BSTR, HTX, LTX, PATH

Chairs: Edward Cantu, MD, and Karl B Lemstrom, MD, PhD

4:30 PM (75) Dynamics of Transient Populations of the Human Respiratory Virome After Lung Transplantation; A. B. Mitchell¹, B. Mourad¹, L. Morgan², B. Oliver³, A. R. Glanville⁴. ¹Molecular Biology, University of Technology, Sydney, Naremburn, Australia, ²Thoracic Medicine, Concord Clinical School, University of Sydney, Concord, Australia, ³Cellular and Molecular Biology, Woolcock Institute of Medical Research, Glebe, Australia, ⁴Lung Transplantation, St Vincent's Hospital, Sydney, Darlinghurst, Australia

4:48 PM (76) MicroRNAs Signature in Heart Transplant Enhances Diagnosis of Different Types of Acute Rejection; A. Di Francesco¹, M. Fedrigo¹, D. Santovito², F. De Pascale³, C. Castellani¹, G. Toscano¹, G. Feltrin¹, A. Fraiese¹, A. Nocco⁴, E. Benazzi⁴, G. Thiene¹, G. Valle³, A. Schober², G. Gerosa¹, A. Angelini¹. ¹Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ²Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University (LMU) Munich, Muenchen, Germany, ³CRIBI Biotechnology Centre, University of Padova, Padova, Italy, ⁴Organ and Tissue Transplantation Immunology, Fondazione IRCSS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy

5:06 PM (77) CD4 T Cells, Foreign Protein and CD22 Control Antibody Response to Non-Self Blood Group A-Antigen in A-Transgenic Mice; I. Adam¹, B. Motyka², J. Pearcey², K. Tao², L. West³. ¹Medical Microbiology & Immunology, University of Alberta, Edmonton, AB, Canada, ²Pediatrics, University of Alberta, Edmonton, AB, Canada, ³Medical Microbiology & Immunology, Pediatrics, surgery, University of Alberta, Edmonton, AB, Canada

5:24 PM (78) Time and Perfusate Dependent Molecular Repair Response During Ex Vivo Lung Perfusion; N. S. Aboelnazar¹, P. Dromparis², S. Wagner², S. Himmat¹, C. W. White³, S. Hatami¹, B. Adam², M. Mengel⁴, D. H. Freed⁵, J. Nagendran⁵. ¹Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada, ²Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada, ³Cardiac Surgery, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada, ⁴Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, ⁵Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada

5:42 PM (79) Lysophosphatidic Acid Drives Recruitment and Fibroblastic Differentiation of Mesenchymal Stromal Cells in Chronic Lung Allograft Dysfunction; K. A. Sinclair, M. E. Tan, T. M. Sladden, P. M. Hopkins, B. J. O'Sullivan, D. C. Chambers. School of Medicine, Univeristy of Queensland, Brisbane, Australia

4:30 PM - 6:00 PM

ORAL SESSION 14: Reading Tea Leaves - Heart Failure Prediction Risks

Location: Mediterranean 6

Target Audience: HF, HTX, MCS, PHARM

Chairs: Sharon Chih, MD, and Savitri Fedson, MD

4:30 PM (80) Natriuretic Doses of Mineralocorticoid Receptor Antagonists in Outpatients With Acute Decompensated Heart Failure; H. Rosenblum¹, R. Aponte Medina¹, P. Trinh¹, J. Fried¹, R. T. Demmer², J. Radhakrishnan¹, M. Yuzefpolskaya¹, R. Bijou¹, V. K. Topkara¹, P. C. Colombo¹, A. Masoumi¹. ¹Columbia University, New York, NY, ²University of Minnesota, Columbia University, New York, NY

4:45 PM (81) Predictors of Systolic Heart Failure and Mortality Following Orthotopic Liver Transplantation: A Single-center Cohort; T. Doctorian, H. Kim, D. Narasimha, T. Khachatryan, A. Desai, D. Estevez, K. Jutzy, A. Hilliard, I. Abudayyeh, L. Stoletniy, P. Baron, A. Sakr. Loma Linda University, Loma Linda, CA

5:00 PM (82) A Novel Readmission Risk Score is Highly Predictive of Mortality after Heart Failure Admission; R. Cogswell¹, A. Rhodes², T. Alexy¹, J. Shultz¹, C. Martin¹, T. Freitag¹, L. Wick¹, R. John³. ¹Medicine, University of Minnesota, Minneapolis, MN, ²Fairview Health Services, University of Minnesota, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN

5:15 PM (83) Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support (SUSTAIN-IT): Baseline Findings; K. L. Grady¹, A. Andrei², L. Pollan², H. Shi², H. Adam², A. Kao³, D. Pham¹, M. Dew⁴, R. Kormos⁵, E. Hsich⁶, W. Cotts⁷, S. LaRue⁸, S. V. Pamboukian⁹, F. Pagani¹⁰, M. Petty¹¹, B. Lampert¹², M. Johnson¹³, M. Murray¹⁴, J. Spertus¹⁵, J. K. Kirklin¹⁶, S. C. Collum¹, C. Yancy¹⁷. ¹Surgery / Division of Cardiac Surgery, Northwestern University, Chicago, IL, ²Surgery / BCVI Clinical Trials Unit, Northwestern University, Chicago, IL, ³Medicine, University of Missouri-Kansas City, Kansas-City, MO, ⁴Psychiatry, University of Pittsburgh, Pittsburgh, PA, ⁵Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine, Cleveland Clinic, Cleveland, OH, ⁷Medicine, Advocate Christ Medical Center, Oak Lawn, IL, ⁸Medicine, Washington University, St. Louis, MO, ⁹Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Cardiac Surgery, University of Michigan, Ann Arbor, MI, ¹¹Surgery, University of Minnesota Medical Center, Minneapolis, MN, ¹²Medicine, Ohio State University, Columbus, OH, ¹³Medicine, University of Wisconsin, Madison, WI, ¹⁴Cardiothoracic Surgery, University of Wisconsin, Madison, WI, ¹⁵Medicine, University of Missouri Kansas City, Kansas City, MO, ¹⁶Surgery, University of Alabama Birmingham, Birmingham, AL, ¹⁷Medicine / Division of Cardiology, Northwestern University, Chicago, IL

5:30 PM (84) Discordance Between Clinical and Invasive Assessment of Hemodynamics in Patients with Decompensated Heart Failure; N. Narang¹, R. Kalathiyia², L. Laffin², B. Chung², A. Nguyen², M. R. Costanzo³, T. Imamura², G. Kim², J. Raikhelkar², N. Sarswat², S. Kalantari², V. Jeevanandam⁴, G. T. Sayer², N. Uriel². ¹University of Chicago Medical Center, Chicago, IL, ²Cardiology, University of Chicago Medical Center, Chicago, IL, ³Cardiology, Edwards Hospital Center, Naperville, IL, ⁴Cardiac Surgery, University of Chicago Medical Center, Chicago, IL

5:45 PM (85) Pulmonary Artery Catheterization is Associated with Mortality Decline over Time in Cardiogenic Shock Compared to Patients with Acute Decompensated Heart Failure; G. A. Hernandez¹, A. Lemor², V. Blumer³, C. Rueda¹, S. Zalawadiya¹, L. W. Stevenson¹, J. Lindenfeld¹. ¹Advanced Heart Failure and Transplant, Vanderbilt University, Nashville, TN, ²Dept of Internal Medicine, Icahn School of Medicine at Mount Sinai St Luke's – Mount Sinai West Hospital, New York City, NY, ³Depart, University of Miami - Jackson Memorial Hospital, Miami, FL

6:15 PM - 7:15 PM

MINI ORAL 01: Mechanical Circulatory Support: ECMO

Location: Athena

Target Audience: MCS, HTX, PHARM

Chairs: Pavan Atluri, MD, and Susan Joseph, MD

6:15 PM (86) *Extra-Corporeal Membrane Oxygenation (ECMO) as a Bridge to A Long-Term, Implantable Left Ventricular Assist Device*; H. Lamba, J. Marcano, C. Kurihara, M. Kawabori, T. Sugiura, A. Santiago, F. H. Cheema, A. Alnajar, A. Civatello, R. Delgado, L. Simpson, A. Nair, G. Letsou, R. Ghanta, T. Rosengart, O. Frazier, J. Morgan, J. K. George, S. Chatterjee. *Baylor College of Med, Houston, TX*

6:20 PM (87) *Optimal Hemodynamics During LVAD Support Are Associated with Reduced Hemocompatibility-related Adverse Events*; T. Imamura¹, J. Raikhelkar¹, N. Sarswat¹, S. Kalantari¹, C. Murks¹, D. Rodgers¹, C. Juricek¹, G. Kim¹, M. Costanzo¹, T. Ota¹, T. Song¹, V. Jeevanandam¹, U. Jorde², D. Burkhoff³, G. Sayer¹, N. Uriel¹. ¹*University of Chicago, Chicago, IL*, ²*Montefiore Medical Center, New York, NY*, ³*Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY*

6:25 PM (88) *Highly Accurate Continuous Blood Pressure Measurement in LVAD Patients with a Non-Invasive, Non-Oscillometric Wearable Device: A Pilot Study*; G. Sayer¹, G. H. Kim², D. Rodgers², B. Chung², A. Nguyen¹, N. Narang¹, J. Raikhelkar², S. Kalantari², N. Sarswat², V. Jeevanandam³, N. Uriel². ¹*University of Chicago, Chicago, IL*, ²*Cardiology, University of Chicago, Chicago, IL*, ³*Cardiac Surgery, University of Chicago, Chicago, IL*

6:30 PM (89) *Novel Minimally Invasive Surgical Approach for Refractory Cardiogenic Shock: A Hemodynamic Comparison With Current Percutaneous Strategies*; O. Akanni¹, A. R. Garan², H. Takayama¹, J. Han¹, P. A. Kurlansky¹, D. H. Burkhoff², M. Yuzefpolskaya², P. C. Colombo², Y. Naka¹, K. Takeda¹. ¹*Dept of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY*, ²*Dept of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY*

6:35 PM (90) *Pulmonary Dynamic Compliance for Prediction of Mortality in Adult Severe Acute Respiratory Distress Syndrome Treated With Venovenous Extracorporeal Membrane Oxygenation*; K. Zoeller, U. Owolabi, J. Trivedi, M. Slaughter, V. van Berkel, K. Adkins. *Cardiovascular and Thoracic Surgery, Univ of Louisville, Louisville, KY*

6:40 PM (91) *Higher Age and Lower BMI Are Stronger Predictors of Mortality For Females Than Males on VA ECMO*; M. Leacche¹, N. K. Manandhar Shrestha², S. V. Jovinge², T. Boeve¹. ¹*Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI*, ²*Fredrik Meijer Heart and Vascular Institute, Fredrik Meijer Heart and Vascular Institute, Grand Rapids, MI*

6:45 PM (92) *Identifying Appropriate Durable VAD Candidates in Patients with Venovenous Extracorporeal Membrane Oxygenation: Can We Identify the "Point of No Return"?*; D. Saeed¹, A. Loforte², F. Pappalardo³, M. Attisani⁴, M. Morshuis⁵, D. Zimpfer⁶, F. Ramjankhan⁷, U. Jorde⁸, R. Wieloch¹, A. Albert¹, A. Lichtenberg¹. ¹*Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany*, ²*Cardiovascular Surgery, Bologna University, Bologna, Italy*, ³*Cardiovascular Surgery, San Raffaele Hospital, Milan, Italy*, ⁴*Cardiovascular Surgery, University of Turin, Turin, Italy*, ⁵*Cardiothoracic and Vascular Surgery, Herz und Diabetes Zentrum NRW, Bad Oeynhausen, Germany*, ⁶*Cardiovascular Surgery, Medical University Vienna, Vienna, Austria*, ⁷*Dept of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands*, ⁸*Dept of Cardiology, Albert Einstein College of Medicine, New York, NY*

6:50 PM (93) *The Impact of Age on In-hospital Mortality With Extracorporeal Membrane Oxygenation Use in Cardiogenic Shock*; M. Chung¹, Y. Zhao², J. B. Strom², C. Shen², R. Yeh². ¹*Dept of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA*, ²*Dept of Medicine, Beth Israel Deaconess Medical Center, Boston, MA*

6:55 PM (94) *Effects of Percutaneous LVAD Support on Right Ventricular Load and Adaptation Acutely and Over Time*; J. P. Yourshaw¹, C. Armstrong², P. Mishra², D. Steinberg¹, B. Ramu¹, M. Craig¹, A. Van Bakel¹, R. J. Tedford¹, B. A. Houston¹. ¹*Cardiology, Medical University of South Carolina, Charleston, SC*, ²*Internal Medicine, Medical University of South Carolina, Charleston, SC*

7:00 PM (95) *Impact of Ongoing CPR on VA ECMO Outcomes*; K. J. Fujita, A. P. Rabenstein, R. Chiu, F. Seifert, A. J. McLarty. *Stony Brook University, Stony Brook, NY*

7:05 PM (96) Neuron-Specific-Enolase as a Predictor of Overall and Neurological Outcome After Cardiopulmonary Resuscitation in Patients with VA-ECMO; B. Schrage¹, N. Rübsamen¹, M. Becher¹, M. Schwarzl¹, H. Grahn¹, G. Söffker², E. Lubos¹, A. Bernhardt³, H. Reichenspurner³, S. Blankenberg¹, D. Westermann¹. ¹*Dept of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany,* ²*Dept of Intensive Care Medicine, University Heart Center Hamburg, Hamburg, Germany,* ³*Dept of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany*

7:10 PM (97) Extracorporeal Membrane Oxygenation for Cardiogenic Shock: National trends in the United States 2008-2012; A. Arora, A. Amin, A. Tsangaris. *Rutgers New Jersey Medical School, Newark, NJ*

6:15 PM - 7:15 PM

MINI ORAL 02: Heart Transplantation: Outcomes

Location: Mediterranean ABC

Target Audience: HTX, BSTR, EEP, HF, MCS, PHARM

Chairs: Fabiana G Marcondes-Braga, MD, PhD, and Robert T Cole, MD

6:15 PM (98) Pulmonary Artery Decoupling Further Enhances Discriminatory Power of Pulmonary Vascular Resistance in Patients Bridged to Transplant with Left Ventricular Assist Devices; L. K. Truby¹, A. R. Garan¹, R. Givens¹, H. Takayama¹, M. Yuzefpolskaya¹, K. Takeda¹, F. Latif¹, S. Restaino¹, Y. Naka¹, P. C. Colombo¹, M. Farr¹, N. Uriel², V. K. Topkara¹. ¹Columbia University, New York, NY, ²University of Chicago, Chicago, IL

6:20 PM (99) Patterns of Gene Expression in High GEP Score Samples Correlated with Clinical Factors in the Outcomes AlloMap Registry; S. P. Pinney¹, R. N. Woodward², J. Sinsky², M. Machrus², J. A. Kobashigawa³. ¹Cardiology, Mount Sinai Health System, New York, NY, ²CareDx, Brisbane, CA, ³Cedars-Sinai Heart Institute, Los Angeles, CA

6:25 PM (100) Frailty Predicts Mortality After Heart Transplantation; S. Offen, S. Jha, M. Connellan, K. Dhital, E. Granger, M. Harkness, C. Hayward, A. Jabbour, P. Jansz, E. Kotlyar, E. Montgomery, K. Muthiah, P. Newton, A. Smith, P. Spratt, P. Macdonald. *Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Darlinghurst, Australia*

6:30 PM (101) Center Effect on Long-term Post-transplant Survival Among Currently Active United States Heart Transplant Centers; T. P. Singh¹, K. Gauvreau². ¹Boston Children's Hospital, Boston, MA, ²Cardiology, Boston Children's Hospital, Boston, MA

(102) WITHDRAWN

6:35 PM (863) Outcomes of the Cardiac Transplantation with Opioid Overdose Donors; K. Oh¹, J. Fertel¹, D. B. Sims¹, J. J. Shin¹, O. Saeed¹, S. Murthy¹, S. Vukelic¹, S. Forest², D. Goldstein², U. P. Jorde¹, S. R. Patel¹. ¹Dept of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, ²Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY

6:40 PM (103) Heart Transplantation in Patients with Active Prostate Cancer; Are We Denying a Life Saving Therapy Due to an Indolent Tumor?; J. Raikhelkar¹, M. Pham², T. Riley¹, C. Murks¹, J. Powers¹, M. Reilly¹, L. Lourenco³, B. Chung¹, A. Nguyen¹, N. Narang¹, S. Kalantari¹, N. Sarswat¹, G. Kim¹, G. Zagaja⁴, G. Sayer¹, N. Uriel¹. ¹Cardiology, University of Chicago, Chicago, IL, ²Cardiology, California Pacific Medical Center, San Francisco, CA, ³Pharmacy Services, University of Chicago, Chicago, IL, ⁴Surgery, University of Chicago, Chicago, IL

6:45 PM (104) Gender Mismatch in NonVAD Patients Doesn't Negatively Affect Heart Transplant Survival; Y. Itoda, T. Okamoto, H. Niikawa, K. S. Ayyat, K. R. McCurry. *Dept of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH*

6:50 PM (105) Older Donors Into Older Recipients: Still Contentious But Reasonable; M. Rafiei, J. Patel, M. Kittleson, L. Czer, D. H. Chang, S. Dimbil, R. Levine, E. Kransdorf, A. Hage, F. Esmailian, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

6:55 PM (106) Increase in DCD Donation in the United States May Adversely Impact DBD Heart Transplantation: Retrospective Analysis of a Limited UNOS Dataset; M. Farr¹, J. Lindower², S. Taylor², U. Jorde³, L. Chen⁴, A. Gass⁵, L. Truby¹, S. DeLair², S. Pinney⁶. ¹Columbia University Medical Center, New York, NY, ²New York Cardiothoracic Transplant Consortium, Albany, NY, ³Montefiore Medical Center, Bronx, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵Westchester Medical Center, Valhalla, NY, ⁶Mount Sinai Medical Center, New York, NY

7:00 PM (107) DCD Heart Retrieval Does Not Compromise Other Donor Organs: The UK Experience; A. Page¹, S. Messer¹, J. Bunnett², J. Mehew², E. Wong², M. Berman¹, A. Simon³, R. Venkateswaran⁴, P. Catarino¹, G. Oniscu⁵, S. Tsui¹, S. Large¹. ¹Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, ²NHS Blood and Transplant, Bristol, United Kingdom, ³Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, ⁴University Hospital South Manchester NHS Foundation Trust, Manchester, United Kingdom, ⁵Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

7:05 PM (108) Variability of Both Raw and Transformed Gene Expression Profile Scores Predict Adverse Events Post Heart Transplant: The Mid America Experience; S. R. Beauchamp¹, K. R. Carl¹, K. F. Kennedy², B. A. Austin³, M. P. Everley³, T. M. Khumri³, S. L. Lawhorn³, A. Magalski³, B. W. Sperry³, D. Vodnala³, A. M. Borkon⁴, G. Dryton¹, A. Kao³. ¹Surgery, Saint Luke's Hospital, Kansas City, MO, ²Cardiology, Saint Luke's Hospital, Kansas City, MO, ³Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO, ⁴Surgery, Mid America Heart & Lung Surgeons, Kansas City, MO

7:10 PM (109) The Risk of pAMR 1H After Heart Transplantation: Is It Bad?; J. Patel, M. Kittleson, L. Czer, D. H. Chang, E. Kransdorf, S. Dimbil, R. Levine, S. Sana, M. Hamilton, F. Esmailian, D. Luthringer, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

6:15 PM - 7:15 PM

MINI ORAL 03: Lung Transplantation, Pulmonary Hypertension and CTEPH

Location: Clio/Thalie/Erato

Target Audience: LTX, CTEPH, HF, PH

Chairs: Veronica Franco, MD, and Wiebke Sommer, MD

6:15 PM (110) Endothelial to Mesenchymal Transition (EndMT) Occurs in Lungs Secondary to Heart Failure in a Non Ischemic Cardiomyopathy Mouse Model; F. Hussain, A. S. Solbes, A. Guha, R. Barrios, K. A. Youker, A. Bhimaraj. *Heart Failure Division, Houston Methodist Hospital, Houston, TX*

6:20 PM (111) Mitochondrial Respiratory Function is Impaired in the Setting of Right Ventricular Remodeling Induced by Pressure Overload; P. Noly¹, J. Piquereau², J. arthur-Ataam³, M. Coblenz³, J. Guihaire³, E. Fadel³, O. Mercier³. ¹Montreal Heart Institute, Montreal, QC, Canada, ²UMR-S 1180 INSERM, Chatenay-Malabry, France, ³Research and Innovation Unit, ISERM U999, Le Plessis Robinson, France

6:25 PM (112) Endothelin-1 Derived from the Pulmonary Endarterectomy Specimen Could Play a Major Role in Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension; Y. Zhao, M. Ding, L. Dong, Y. Yao, I. Wu, J. Granton, M. de Perrot. *University Health Network, University Health Network, Toronto, ON, Canada*

6:30 PM (113) Initial Combination Therapy With Riociguat and Ambrisentan in Pulmonary Arterial Hypertension: A Prospective Open-label Study; M. V. Thakrar, J. C. Weatherald, R. A. Varughese, D. S. Helmersen, C. Lydell, N. Fine, N. Hirani. *University of Calgary, Calgary, AB, Canada*

6:35 PM (114) Right Ventricular Dysfunction in Group 3 PH: Male Gender is Associated With RV-PA Uncoupling; L. Rose¹, K. W. Prins¹, S. L. Archer², M. Pritzker¹, E. K. Weir¹, T. Thenappan¹. ¹Cardiovascular Division, University of Minnesota, Minneapolis, MN, ²Dept of Medicine, Queen's University, Kingston, ON, Canada

6:40 PM (115) Abnormal Invasive Pulmonary Hemodynamics Predict Outcomes in Exercising Patients; A. Jose¹, C. King², E. Welt³, O. A. Shlobin², A. Brown², S. Aryal², N. Weir², S. D. Nathan². ¹George Washington Hospital, Washington, DC, ²Inova Fairfax Hospital, Falls Church, VA, ³Georgetown University Hospital, Washington, DC

6:45 PM (116) Portable Normothermic Perfusion for Critical Marginal Graft Use: A Clinical-Pathological Comparison with Standard Marginal Donors Stored with Cold Preservation; M. Schiavon¹, G. Faggi², G. Marulli¹, P. Feltracco³, A. Rebusso¹, D. Azzolina⁴, F. Lunardi⁵, E. Faccioli¹, E. Verderi¹, E. Cozzi⁶, F. Calabrese⁵, F. Rea¹. ¹Cardiac, thoracic and vascular sciences, University of Padua, Padova, Italy, ²Istitution of Anaesthesia, Padua Hospital, Padova, Italy, ³Istitution of Anaesthesia, University of Padua, Padova, Italy, ⁴Statistics Unit, Cardiac, thoracic and vascular sciences, University of Padua, Padova, Italy, ⁵Pathologic Unit, Cardiac, thoracic and vascular sciences, University of Padua, Padova, Italy, ⁶Immunology Unit, Cardiac, thoracic and vascular sciences, University of Padua, Padova, Italy

6:50 PM (117) Modified Surgical Technique of Normothermic Ex-Vivo Perfusion Reduces Cold Ischemic Time in Lung Transplantation During the EXPAND Trial; M. A. Villavencio¹, A. L. Axtell¹, A. G. Fiedler¹, E. E. Heng¹, S. E. Kilmarx¹, N. Roy¹, M. Funamoto¹, T. Astor², S. Melnitchouk¹, D. A. D'Alessandro¹, G. Tolis¹, T. M. Sundt¹. ¹Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ²Dept of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA

6:55 PM (118) The Intent or Performance of EVLP on Donor Lungs in the United States: National Trends and OPO Variability; K. M. Chan¹, R. R. Lehman², T. P. Whelan³, K. Uccellini⁴, R. J. Carrico². ¹Division of Pulmonary and Critical Care Medicine, Michigan Medicine, Ann Arbor, MI, ²Research, United Network for Organ Sharing, Richmond, VA, ³Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, ⁴Policy, United Network for Organ Sharing, Richmond, VA

7:00 PM (119) A Near Point of Care Test for Interleukin 1B During Human Ex-Vivo Lung Perfusion; A. S. Andreasson¹, W. Laroy², J. H. Dark¹, A. J. Fisher¹. ¹Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ²MyCartis NV, Gent, Belgium

7:05 PM (120) Predictors of Donor Utilization in Lung Transplantation; E. Singh¹, F. Zafar², C. Towe², D. L. Morales², R. Bryant², J. K. Steger², J. Tweddell², M. G. Schecter². ¹University of Cincinnati, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH

7:10 PM (121) ISHLT Consensus on Standardization of Bronchoalveolar Lavage in Lung Transplantation; T. Martinu¹, A. Koutsokera¹, C. Benden², E. Cantu³, D. Chambers⁴, M. Cypel¹, J. Edelman⁵, A. Emtiazjoo⁶, A. Fisher⁷, J. Greenland⁸, D. Hayes, Jr.⁹, D. Hwang¹⁰, B. C. Keller¹¹, E. D. Lease¹², M. Perch¹³, M. Sato¹⁴, J. Todd¹⁵, S. Verleden¹⁶, J. von der Thüsen¹⁷, S. Weight¹⁸, S. Keshavjee¹, .. On behalf of the BAL Standardization Workgroup¹. ¹Lung Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada, ²Lung Transplant Program, University Hospital Zurich, Zurich, Switzerland, ³Dept of Surgery, University Hospital of Pennsylvania, Philadelphia, PA, ⁴Lung Transplant Program, The Prince Charles Hospital, Brisbane, Australia, ⁵Lung Transplant Program, Puget Sound VAMC, Seattle, WA, ⁶Lung Transplant Program, University of Florida, Gainesville, FL, ⁷Lung Transplant Program, Freeman Hospital, Newcastle, United Kingdom, ⁸Lung Transplant Program, University of California, San Francisco, CA, ⁹Lung Transplant Program, Nationwide Children's Hospital, Columbus, OH, ¹⁰Dept of Pathology, Toronto General Hospital, UHN, Toronto, ON, Canada, ¹¹Lung Transplant Program, Wexner Medical Center, The Ohio State University, Columbus, OH, ¹²Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Washington, WA, ¹³Lung Transplant Program, Rigshospitalet, Copenhagen, Denmark, ¹⁴Dept of Surgery, University of Tokyo, Tokyo, Japan, ¹⁵Lung Transplant Program, Durham University Medical Center, Durham, NC, ¹⁶Laboratory of Pulmonology, Katholieke Universiteit, Leuven, Belgium, ¹⁷Dept of Pathology, Erasmus Medical Center, Rotterdam, Netherlands, ¹⁸Lung Transplant Program, UCLA, Los Angeles, CA

6:15 PM - 7:15 PM

MINI ORAL 04: Mechanical Circulatory Support: Thrombosis

Location: Uranie/Calliope

Target Audience: MCS, PHARM

Chairs: Andrew J Boyle, MD, and Mustafa Toma, MD

6:15 PM (122) Feasibility, Efficacy and Safety of Fibrinogen Guided Very Low Dose Multi-Day Thrombolytics in the Management of LVAD Thrombosis; A. S. Cruz-Solbes, B. Hannawi, M. Achi, J. Amione-Guerra, E. Karanja, B. Trachtenberg, A. Bhimaraj, J. Estep, G. Torre-Amione, I. Hussain, M. Park, B. Bruckner, A. Guha. *Methodist DeBaakey Heart Center, Houston Methodist Hospital, Houston, TX*

6:20 PM (123) An Analysis of Preceding Signals and Treatment Strategies of VAD Thrombus in the ENDURANCE and ENDURANCE SUPPLEMENTAL Trials; F. D. Pagani¹, S. S. Najjar², U. P. Jorde³, J. J. Teuteberg⁴, R. L. Kormos⁵, R. Starling⁶, J. D. Rich⁷, T. A. Vassiliades⁸, S. W. Boyce². ¹University of Michigan, Ann Arbor, MI, ²MedStar Health, Washington, DC, ³Montefiore Medical Center, Bronx, NY, ⁴Stanford University, Stanford, CA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Cleveland Clinic, Cleveland, OH, ⁷Northwestern, Chicago, IL, ⁸Medtronic, Framingham, MA

6:25 PM (124) Increased Pump Speed is Associated with Reduced Rates of Stroke on HeartMate II LVAD Support; J. N. Schultz¹, R. Cogswell², M. Prtzyker², E. Missov², K. Liao³, J. Misialek², R. John³. ¹Dept of Medicine, University of Minnesota, Minneapolis, MN, ²Dept of Cardiology, University of Minnesota, Minneapolis, MN, ³Dept of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

6:30 PM (125) Hemocompatibility of an Ambulatory Counterpulsation Circulatory Assist System; V. Jeevanandam, D. Onsager, T. Song, T. Ota, C. Juricek LaBuhn, T. Lammy, S. Patel-Raman, G. Sayer, G. Kim, S. Kalantari, N. Uriel. *University of Chicago Medicine, Chicago, IL*

6:35 PM (126) Detection of LVAD Pump Thrombus Using Intraventricular Flow Dynamics; R. Montes, S. Salim, V. Vu, K. May-Newman. *Bioengineering, San Diego State University, San Diego, CA*

6:40 PM (127) Validity of a Novel Institutional Method to Analyze and Display HeartWare HVAD Log Files; Y. Lin¹, A. Ambardekar², L. A. Allen², C. Pierce³, A. Brieke², E. Benton², J. C. Cleveland¹, J. D. Pal¹. ¹Surgery, University of Colorado, Aurora, CO, ²Medicine, University of Colorado, Aurora, CO, ³University of Colorado Hospital, Aurora, CO

6:45 PM (128) High Thromboembolic Event Rate in Patients Supported With an Impella CP Device With an Anti-Xa Level of Less Than 0.1 u/mL; S. Batra¹, H. Kamran², T. Lech¹, J. Montgomery¹, D. Venesy¹, R. Patten¹, S. Shah¹. ¹Cardiology, Lahey Hospital & Med Ctr, Burlington, MA, ²Internal Medicine, Lahey Hospital & Med Ctr, Burlington, MA

6:50 PM (129) 4D Flow MRI in 3D Printed Models of Aorta Grafted With a Ventricular Assist Device Allows Detailed Embolic Trajectory Analysis; O. Amili¹, F. Coletti¹, R. MacIver². ¹Aerospace Engineering and Mechanics, University of Minnesota, Minneapolis, MN, ²Cardiac Surgery, Childrens Hospitals and Clinics of Minnesota, Minneapolis, MN

6:55 PM (130) Mobilization of ECMO Patients with Various Cannulation Configurations; E. Colclough¹, S. Ramsey², P. Barrett², E. Sheffield², J. Webster², D. Dean². ¹CT Surgery, Cardiovascular Critical Care, Piedmont Heart, Atlanta, GA, ²Advanced Heart Failure, Piedmont Heart, Atlanta, GA

7:00 PM (131) Time Spent Out of Mean Arterial Blood Pressure (MAP) Goal Correlates With Adverse Events in Patients on Left Ventricular Assist Device; A. Khan, E. Sultanik, M. Racherla, E. Sorensen, H. Voorhees, L. Dees, E. Feller, D. Kaczorowski, Z. Kon, V. Ton. *University of Maryland School of Medicine, Baltimore, MD*

7:05 PM (132) Treatment of Pump Thrombosis With Low Dose Thrombolytic Therapy in Heartware HVAD Left Ventricular Assist Devices: Single Center Experience; E. Demir¹, S. Nalbantgil¹, P. Öztürk², C. Sahutoglu³, Ç. Engin², T. Yagdi¹, M. Özbaran¹. ¹Cardiology, Ege University Medicine Faculty, İzmir, Turkey, ²Cardiovascular surgery, Ege University Medicine Faculty, İzmir, Turkey, ³Anesthesiology, Ege University Medicine Faculty, İzmir, Turkey

7:10 PM (133) Clinical Profile of Patients with Late Stroke after Left Ventricular Assist Device Implantation; J. Nnanabu, D. Rodgers, N. Sarswat, J. Raikhelkar, G. Kim, S. Kalantari, T. Ota, T. Song, C. Juricek, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*

6:15 PM - 7:15 PM

MINI ORAL 05: Pediatric Thoracic Transplantation

Location: Hermes

Target Audience: PEDS, HF, HTX, ID, MCS, NNSAH, PHARM

Chairs: Bart L. Rottier, MD, and Jacqueline M. Lamour, MD

6:15 PM (134) Increasing Use of Exceptions After Changes to Pediatric Heart Allocation; A. M. Robinson¹, W. T. Mahle², R. R. Davies³. ¹United Network for Organ Sharing, Richmond, VA, ²Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, GA, ³Pediatric Cardiothoracic Surgery, UT Southwestern - Children's Health Dallas, Dallas, TX

6:20 PM (135) Poor Outcomes on the Waiting List for Pediatric Lung Retransplant Patients Listed in Low Volume Centers; B. B. Scully¹, J. S. Heinle¹, M. L. Kueht¹, E. D. McKenzie², G. B. Mallory³, E. Melicoff³, A. Rana¹. ¹Surgery, Baylor College of Medicine, Houston, TX, ²Surgery, Emory College of Medicine, Atlanta, GA, ³Pulmonology and Pediatrics, Baylor College of Medicine, Houston, TX

6:25 PM (136) Worse Survival After Heart Transplantation in Children With Heterotaxy Syndrome; A. M. Khan¹, E. Pahl¹, E. Pruitt², J. K. Kirklin³, E. Azeka⁴, P. G. Rusconi⁵, S. Guan⁶, A. P. Barnes⁷, S. Blensdorf¹, M. D. Everitt⁸. ¹Cardiology, Ann and Robert H. Lurie Children's Hospital, Chicago, IL, ²University of Alabama at Birmingham, Birmingham, AL, ³Surgery, University of Alabama at Birmingham, Birmingham, AL, ⁴Cardiology, University of Sao Paulo Medical School, Sao Paulo, Brazil, ⁵Miller School of Medicine, University of Miami, Miami, FL, ⁶Division of Cardiovascular and Thoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Missouri-Kansas City School of Medicine, Kansas City, MO, ⁸Pediatric Cardiology, Children's Hospital Colorado, Aurora, CO

6:30 PM (137) Prolonged Management in Donors with Reduced Ejection Fraction is a Risk Factor for Graft Loss in Pediatric Heart Transplantation; N. Singh¹, C. Grosshuesch², W. Johnson², N. DeVogel², Z. Yin², T. Wang², S. Kindel¹, R. Woods¹. ¹Herma Heart Institute, Children's Hospital of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI

6:35 PM (138) Mycophenolic Acid Trough Levels Underestimate Drug Exposure in Pediatric Heart Transplant Patients; J. Pak¹, T. Herzog², T. Nemeth¹, N. Jorgensen³, J. Friedland-Little⁴, B. Hong⁴, E. Albers⁴, M. Kemna⁴, Y. Law⁴. ¹Pharmacy, Seattle Children's Hospital, Seattle, WA, ²Pediatrics, Seattle Children's Hospital, Seattle, WA, ³Dept of Biostatistics, University of Washington, Seattle, WA, ⁴Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA

6:40 PM (139) What is the Risk of Rejection Following Subtherapeutic CNI Levels After Heart Transplantation?; S. Kerr¹, N. Jorgensen², B. Hong³, J. Friedland-Little³, E. Albers³, Y. Law³, M. Kemna³. ¹Univ of Washington, School of Medicine, Seattle, WA, ²Univ of Washington, Dept of Biostatistics, Seattle, WA, ³Seattle Children's Hospital, Seattle, WA

6:45 PM (140) Poor Out-patient Clinic Appointment Compliance is a Predictor of Post-Heart Transplant Mortality in Children; J. Dentel, B. Keeshan, J. Grijalva, Y. Law, J. Chen, D. M. McMullan. Seattle Children's Hospital, Seattle, WA

6:50 PM (141) Alteration of the Intestinal Microbiome in Pediatric Heart Transplant Patients is Associated with Diarrhea; J. A. Spinner¹, S. W. Denfield¹, R. Luna², M. Balderas³, W. J. Dreyer¹, S. Devaraj². ¹Pediatrics, Baylor College of Medicine, Houston, TX, ²Pathology & Immunology, Baylor College of Medicine, Houston, TX, ³Pathology, Baylor College of Medicine, Houston, TX

6:55 PM (142) The Effect of Infectious Complications During Ventricular Assist Device Use on Outcomes of Pediatric Heart Transplantation; S. R. Auerbach¹, E. Pruitt², T. T. Bradford³, M. J. Bock⁴, E. R. Skipper⁵, R. S. Cantor², D. A. Koehl², K. Butler⁶, J. C. Alejos⁷, R. E. Edens⁸, J. K. Kirklin². ¹Pediatrics, Div of Cardiology, Univ of Colorado Anschutz Medical Campus, Aurora, CO, ²Dept of Cardiovascular Surgery, Univ of Alabama at Birmingham, Birmingham, AL, ³Pediatrics, Div of Cardiology, Univ of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, AR, ⁴Pediatrics, Div of Cardiology, Loma Linda Univ Children's Hosp, Loma Linda, CA, ⁵Dept of Thoracic and Cardiovascular Surgery, Carolinas Medical Center, Charlotte, NC, ⁶Children's Hosp Colorado, Heart Institute, Aurora, CO, ⁷Pediatrics, Div of Cardiology, UCLA, Mattel Children's Hosp, Los Angeles, CA, ⁸Pediatrics, Div of Cardiology, Univ of Iowa, Iowa City, IA

7:00 PM (143) Nutritional Rehabilitation of Pediatric Patients on Ventricular Assist Device Support; S. A. Hollander¹, L. Schultz², K. Dennis², A. M. Hollander³, S. Rizzuto³, J. E. Murray⁴, D. N. Rosenthal¹, C. S. Almond¹. ¹Pediatrics (Cardiology), Stanford University, Palo Alto, CA, ²Nutrition Services, Lucile Packard Children's Hospital Stanford, Palo Alto, CA, ³Rehabilitation Services, Lucile Packard Children's Hospital Stanford, Palo Alto, CA, ⁴Solid Organ Transplant Services, Lucile Packard Children's Hospital Stanford, Palo Alto, CA

7:05 PM (144) *Using HeartWare Device in Paediatric Patients with Left Ventricular Heart Failure as Bridge to Transplantation Provides Improved Outcomes and Better Quality of Life: UK Based Experience*; A. Khushnood¹, A. R. Armada², Z. Reinhardt², T. Chila², F. De Rita², T. Hsia¹, A. Karimova¹, M. Fenton¹, M. Burch¹. ¹*Heart Transplantation, Great Ormond Street Hospital, London, United Kingdom*, ²*Heart Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom*

7:10 PM (145) *Novel Virtual Reality Techniques Improve Virtual Implantation of Total Artificial Heart in the Pediatric Population*; R. A. Moore, N. Szugye, F. Zafar, C. Villa, R. Bryant III, M. Taylor, A. Lorts, D. Morales. *The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

6:15 PM - 7:15 PM

MINI ORAL 06: Heart Failure and Transplantation: Outcomes and Antibodies

Location: Mediterranean 6

Target Audience: HF, BSTR, EEP, HTX, MCS, NNSAH, PATH

Chairs: Eugenia Raichlin, MD, and Javier Segovia, MD, PhD

6:15 PM (146) Elevated Panel Reactive Antibodies in Patients Bridged to Heart Transplantation with Ventricular Assist Devices; A. Iyengar¹, M. Caceres Polo², O. Kwon², E. Adams¹, L. Reardon², J. Schaeenman², M. Kwon², A. Ardehali², E. DePasquale². ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of California - Los Angeles, Los Angeles, CA

6:20 PM (147) Admission and In-hospital Mortality Trends of Heart Failure Patients in the United States from 2001-2014; A. Briasoulis¹, E. Akintoye², C. Inampudi¹, P. Alvarez¹, T. Ando², J. K. Bhama³. ¹Dept of Internal Medicine-Cardiology, Univ of Iowa Hosp, Iowa City, IA, ²Dept of Internal Medicine-Cardiology, Wayne State Univ, Harper Hosp/ Detroit Med Ctr, Detroit, MI, ³Dept of Internal Medicine-Cardiothoracic Surgery, Univ of Iowa Hosp, Iowa City, IA

6:25 PM (148) Trends of Admission and Hospital Outcomes of Acute Myocarditis. Insight from the U.S. Nationwide Inpatient Sample 2010-2014; V. Blumer¹, G. A. Hernandez², M. Ortiz³, C. Rueda², J. Lindenfeld², S. V. Chaparro⁴. ¹Dept of Internal Medicine, University of Miami - Jackson Memorial Hospital, Miami, FL, ²Advanced Heart Failure and Transplant, Vanderbilt University, Nashville, TN, ³Universidad Central de Venezuela, Caracas, Venezuela, Bolivarian Republic of, ⁴Division of Cardiology, University of Miami, Miller School of Medicine, Miami, FL

6:30 PM (149) Normal Serum Lactic Acid is Discordant with Shock in Advanced Heart Failure Patients; N. Narang¹, L. Laffin¹, R. Kalathiya¹, B. Chung¹, A. Nguyen¹, M. R. Costanzo², T. Imamura¹, S. Kalantari¹, G. H. Kim¹, J. Raikhelkar¹, N. Sarswat¹, V. Jeevanandam³, G. Sayer¹, N. Uriel¹. ¹Cardiology, University of Chicago Medical Center, Chicago, IL, ²Cardiology, Edwards Hospital Center, Naperville, IL, ³Cardiac Surgery, University of Chicago Medical Center, Chicago, IL

6:35 PM (150) Association of Comorbid Conditions and Quality of Life in Ambulatory Heart Failure Patients: A Report From REVIVAL; T. Cascino¹, A. Lala², J. Stehlik³, M. Palardy¹, S. Pamboukian⁴, M. Kittleson⁵, G. A. Ewald⁶, M. M. Mountis⁷, D. A. Horstmannshof⁸, S. W. Robinson⁹, D. C. Haas¹⁰, U. Jorde¹¹, R. Forde-McLean¹², S. Khalatbari¹, C. A. Spino¹, W. C. Taddei-Peters¹³, K. L. Grady¹⁴, D. L. Mann⁶, G. C. Stewart¹⁵, K. D. Aaronson¹. ¹Univ of Michigan, Ann Arbor, MI, ²Mount Sinai Hospital, New York, NY, ³Univ of Utah, Salt Lake City, UT, ⁴Univ of Alabama, Birmingham, AL, ⁵Cedars Sinai Med Ctr, Los Angeles, CA, ⁶Washington Univ, St. Louis, MO, ⁷Cleveland Clinic Foundation, Cleveland, OH, ⁸INTEGRIS, Oklahoma City, OK, ⁹Univ of Maryland, Baltimore, MD, ¹⁰Abington Hospital-Jefferson Health, Abington, PA, ¹¹Montefiore Med Ctr, Bronx, NY, ¹²Univ of Pennsylvania, Philadelphia, PA, ¹³National Heart, Lung, and Blood Institute, Bethesda, MD, ¹⁴Northwestern Univ, Chicago, IL, ¹⁵Brigham and Women's Hospital, Boston, MA

6:40 PM (151) Incidence and Impact of Late Right Heart Failure After Continuous-flow Left Ventricular Assist Device Implantation; C. Kurihara, M. Kawabori, A. Critsinelis, T. Sugiura, A. B. Civitello, L. Simpson, J. K. George, R. M. Delgado, A. P. Nair, G. Loor, O. H. Frazier, J. A. Morgan. Baylor College of Medicine, Houston, TX

6:45 PM (152) Effect of Cardiac Rehabilitation on Muscle Mass, Muscle Strength, and Exercise Tolerance in Patients with Heart Failure; K. Kim¹, S. Kim², S. Lee¹, S. Hong¹. ¹Sejong General Hospital, Seoul, Korea, Republic of, ²Dept of Rehabilitation, Sejong General Hospital, Seoul, Korea, Republic of

6:50 PM (153) Outcomes in Patients Bridged to Long-term Continuous Flow Left Ventricular Assist Devices Using Short-term Impella Device; C. Kurihara, M. Kawabori, T. Sugiura, A. Critsinelis, L. Simpson, J. K. George, R. M. Delgado, A. P. Nair, L. Gabriel, O. H. Frazier, J. A. Morgan, A. B. Civitello. Baylor College of Medicine, Houston, TX

6:55 PM (154) Profiles of Ambulatory Advanced Heart Failure: A Report from the REVIVAL Registry; M. Kittleson¹, J. D. Estep², M. Palardy³, N. Gilotra⁴, P. Shah⁵, A. V. Ambardekar⁶, J. Thibodeau⁷, G. A. Ewald⁸, M. M. Mountis⁹, S. W. Robinson¹⁰, K. Shah¹¹, S. Khalatbari³, C. A. Spino³, J. Baldwin¹², N. Jeffries¹², D. L. Mann⁸, L. W. Stevenson¹³, K. D. Aaronson³, G. C. Stewart¹⁴. ¹Cedars-Sinai Heart Institute, Los Angeles, CA, ²Houston Methodist Research Institute, Houston, TX, ³Univ of Michigan, Ann Arbor, MI, ⁴Johns Hopkins Hospital, Baltimore, MD, ⁵Inova Heart and Vascular Institute, Falls Church, VA, ⁶Univ of Colorado, Aurora, CO, ⁷Univ of Texas Southwestern Medical Center, Dallas, TX, ⁸Washington Univ, St. Louis, MO, ⁹Cleveland Clinic Foundation, Cleveland, OH, ¹⁰Univ of Maryland, Baltimore, MD, ¹¹Virginia Commonwealth University, Richmond, VA, ¹²National Heart, Lung, and Blood Institute, Bethesda, MD, ¹³Vanderbilt Univ, Nashville, TN, ¹⁴Brigham and Women's Hospital, Boston, MA

7:00 PM (155) Frailty Screening in Advanced Heart Failure Patients Provided Multidimensional Prognostic Information and Disease Management Strategies; K. Fan, M. Wong, K. Cheng, C. Chow, K. Au. *Cardiac Medical Unit, Grantham Hospital, Aberdeen, Hong Kong*

7:05 PM (156) Highly Sensitized Heart Transplant Recipients Have Similar Outcomes Irrespective of Pre-transplant Ventricular Assist Device Implantation; C. D. Fraser, X. Zhou, J. T. Magruder, A. Suarez Pierre, C. Lui, R. S. Higgins, R. S. Higgins, A. Kilic. *Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD*

7:10 PM (157) The Role of Non-HLA Antibody to Angiotensin-II Type 1 Receptor in Patients Bridged to Heart Transplant Using Continuous Flow Ventricular Assist Device; V. Q. Chau¹, M. Flattery¹, K. Desai¹, P. Uber¹, P. M. Kimball², K. B. Shah¹. ¹*Pauley Heart Center, Virginia Commonwealth University, Richmond, VA*, ²*Transplant Surgery, Virginia Commonwealth University, Richmond, VA*

THURSDAY, APRIL 12, 2018

8:30 AM - 10:30 AM

SYMPOSIUM 08: A Forgotten Organ - The Vascular System on Continuous Flow LVAD Support

Location: Apollon

Target Audience: MCS, HF/HTX

Chairs: James Antaki, PhD, and Anna L Meyer, MD

Session Summary: The purpose of this symposium is to review the impact of Continuous Flow (CF) LVAD physiology on the vascular system. The symposium will start with a primer on vascular physiology. It will follow with sessions on new data regarding larger artery stiffness and cerebral autoregulation during CF LVAD. The fourth session will offer a fresh perspective on bleeding with a focus on AVM development. The last session will explore changes in the peripheral vasculature and endothelial dysfunction during CF LVAD.

8:30 AM *The ABCs of Low Pulsatile Flow - A Primer on Vascular Physiology*

Karen May-Newman, PhD, San Diego State University, San Diego, CA, USA

8:42 AM Q&A

8:47 AM *Is Aortic Stiffness the Missing Link Between Large Vessel Vascular Disease and Continuous Flow LVAD support?*

Amrut V Ambardekar, M.D., University of Colorado, Aurora, CO, USA

8:59 AM Q&A

9:04 AM *Carotid Mechanoreceptors, Sympathetic Neural Activity and Cerebral Autoregulation*

David W Markham, MD, Emory St. Joseph Hospital, Atlanta, GA, USA

9:16 AM Q&A

9:21 AM *Differential Effects of Pulsatile vs Non-Pulsatile Flow on the Renal Vasculature*

Meredith A Brisco-Bacik, MD, MSCE, FACC, Temple University, Philadelphia, PA, USA

9:33 AM Q&A

9:38 AM *Maladaptation of the Peripheral Vasculature During Continuous Flow LVAD - Restoration of Cardiac Output Does Not Equal Normal Exercise Capacity*

Finn Gustafsson, MD, Rigshospitalet, Copenhagen, Denmark

9:50 AM Q&A

9:55 AM *An Acquired Vasculopathy - A New Paradigm in Continuous Flow LVAD Related Arteriovenous Malformation Bleeding*

Snehal R Patel, MD, Montefiore Medical Center, Bronx, NY, USA

10:07 AM Q&A

10:12 AM *Mechanisms of Angiogenesis During Continuous Flow LVAD Support*

Gabriel Sayer, MD, University of Chicago, Chicago, IL, USA

10:24 AM Q&A

8:30 AM - 10:30 AM

SYMPOSIUM 09: "The Heat Is On" - Great Debates in Heart Transplantation

Location: Athena

Target Audience: HF/HTX, ID, MCS, NHSAH, PATH, PEDS, PHARM

Chairs: Jon A Kobashigawa, MD, and Teresa De Marco, MD

Session Summary: This session will provide a forum for debate and discussion on controversial questions in heart transplantation, including selection of donors and management of allosensitized patients. Each debate will start with 5-minute case presented by a junior faculty member. The chairs will then poll the audience with a simple yes, no, or maybe question with a show of hands. This will be followed by 15 minutes PRO and 15 minutes CON debate by senior faculty members. The Chairs will subsequently poll the audience again, and declare the winner. A panel discussion with all speakers will conclude this session.

8:30 AM CASE PRESENTATION: A Young Donor with Brain Injury and Low Ejection Fraction

Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA

8:35 AM QUICK AUDIENCE POLL led by session co-chairs

8:36 AM DEBATE (Pro): "Come As You Are"- Low Ejection Fraction Donors Should Be Used for Heart Transplantation

Ulrich Jorde, MD, Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, USA

8:51 AM DEBATE (Con): "Come As You Are" - Low Ejection Fraction Donors Should Be Used for Heart Transplantation

Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Hamburg, Germany

9:06 AM FOLLOW-UP AUDIENCE POLL led by session co-chairs

9:10 AM CASE PRESENTATION: A Young Hep C Positive Donor

Karen L Booth, MBChB, Freeman Hospital, Newcastle upon Tyne, United Kingdom

9:15 AM QUICK AUDIENCE POLL led by session co-chairs

9:16 AM DEBATE (Pro): "You Can't Always Get What You Want"- Hep C Donors Should Be Used in Heart Transplantation

JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

9:31 AM DEBATE (Con): "You Can't Always Get What You Want"- Hep C Donors Should Be Used in Heart Transplantation

Michael G Ison, MD, MS, Northwestern University Feinberg SoM, Chicago, IL, USA

9:46 AM FOLLOW-UP AUDIENCE POLL led by session co-chairs

9:50 AM CASE PRESENTATION: A Diabetic, Allosensitized Patient on LVAD Awaiting Heart and Kidney Transplantation

Van N Selby, MD, UCSF Medical Center, San Francisco, CA, USA

9:55 AM QUICK AUDIENCE POLL by the session co-chairs

9:56 AM DEBATE (Pro): "Living on a Prayer" - Highly Allosensitized Patients on LVAD as Bridge to Transplantation Should Undergo Desensitization

Jignesh K. Patel, MD, PhD, Cedars Sinai Heart Institute, Los Angeles, CA, USA

10:11 AM DEBATE (Con): "Living on a Prayer" - Highly Allosensitized Patients on LVAD as Bridge to Transplantation Should Undergo Desensitization

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

10:26 AM FOLLOW-UP AUDIENCE POLL led by session co-chairs

8:30 AM - 10:30 AM

SYMPOSIUM 10: Cardiothoracic Transplantation: Too Frail to Rock and Roll, Too Young to Die

Location: Mediterranean ABC

Target Audience: HF/HTX, EEP, LTX, NNSAH, PEDS, PHARM

Chairs: Maria G Crespo-Leiro, MD, and Margaret Fregoso, NP

Session Summary: Selection criteria for advanced heart & lung failure therapies have continued to evolve. Most centers have strict age limits. Despite this, there are more than 2000 heart & lung transplants in adults = 70 years of age. As the population ages, criteria for transplant may need to be reconsidered. This symposium serves to more closely examine the older population & considerations for advanced therapies including immunologic considerations, frailty, multiorgan dysfunction, ethical considerations.

8:30 AM *Definition of Frailty and Adapting Frailty Measures for Solid Organ Transplant*

Geetha Bhat, MD, Advocate Christ Medical Center, Oak Lawn, IL, USA

8:45 AM *Pathophysiology and Risk Factors of Frailty*

Peter MacDonald, MD, PhD, St. Vincent's Hospital, Sydney, Australia

9:00 AM *Reversing Frailty*

Savitri Fedson, MD, Baylor College of Medicine, Houston, TX, USA

9:15 AM *Pharmacology in the Frail Patient*

Steven P Ivulich, BPharm, Alfred Hospital, Melbourne, Australia

9:30 AM *The Right Stuff: Shared Decision Making in End-Stage Illness*

Rachel Crackett, MSc, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

9:45 AM *Multidisciplinary Considerations for the Frail Candidate and Recipient: Cognition and Mood*

Rose DeRosa, PA-C, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

10:00 AM *Panel Discussion*

8:30 AM - 10:30 AM

SYMPOSIUM 11: Cystic Fibrosis in Lung Transplantation: Controversial Topics

Location: Clio/Thalie/Erato

Target Audience: LF/LTX, ID, NNSAH, PEDS, PHARM

Chairs: Cecilia Chaparro, MD, and Monique Malouf, FRACP

Session Summary: This session will discuss important issues surrounding the care of cystic fibrosis patients before and after lung transplantation such as nutritional optimization strategies, colon cancer screening and indication for liver-lung transplantation; CF transplantation outcome, timing for transplantation referral and re-listing; Surgical and perioperative issues specific to CF; Management of important infectious pathogens; Strategies to improve efficacy/ minimize toxicity of antimicrobial drugs

8:30 AM *When Is It Time for Transplant in Cystic Fibrosis?*

Jasvir S. Parmar, PhD, FRCP, Papworth Hospital, Cambridge, United Kingdom

8:45 AM Q&A

8:50 AM *Keep Calm and Call the Surgeon: Surgical Perspective of Lung Transplant in Cystic Fibrosis*

Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada

9:05 AM Q&A

9:10 AM *The Cystic Fibrosis Gut*

Denis Hadjilias, MD, University of Pennsylvania, Philadelphia, PA, USA

9:25 AM Q&A

9:30 AM *What Comes Around Stays Around: Dealing with Pre- and Post-Transplant Aspergillus*

Me-Linh Luong, MD, St. Luc Hospital, Montreal, QC, Canada

9:45 AM Q&A

9:50 AM *Optimizing Antimicrobials in Cystic Fibrosis: What's Too Little, What's Too Much*

Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland

10:05 AM Q&A

10:10 AM *Lung Transplantation in Cystic Fibrosis Patients: Who Should not be Transplanted?*

Walter Weder, MD, University Hospital Zurich, Zurich, Switzerland

10:25 AM Q&A

8:30 AM - 10:30 AM

SYMPOSIUM 12: CTEPH: Challenges in Intervention Decision Making

Location: Uranie/Calliope

Target Audience: CTEPH, LF/LTX, PH

Chairs: Elie Fadel, MD, and William Auger, MD

Session Summary: This symposium will focus on the key challenges in decision making that physicians face in managing a rising number of patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) – especially those with 'early' disease and those with severe, distal disease. Presented in a debate format, this symposium highlights the advantages and disadvantages of each approach in a case based discussion.

8:30 AM CASE PRESENTATION: A Male Patient with Distal CTEPH

Mark Toshner, MD, Papworth Hospital, Cambridge, United Kingdom

8:35 AM DEBATE (Pro): Distal Vessel CTEPH: "The Scalpel is Mightier than the Balloon"

Michael M Madani, MD, UCSD Medical Center, San Diego, CA, USA

8:50 AM DEBATE (Con): Distal Vessel CTEPH: "The Scalpel is Mightier than the Balloon"

Irene Lang, MD, Medical University of Vienna, Vienna, Austria

9:05 AM Debate Rebuttal (Pro)

Michael M Madani, MD, UCSD Medical Center, San Diego, CA, USA

9:10 AM Debate Rebuttal (Con)

Irene Lang, MD, Medical University of Vienna, Vienna, Austria

9:15 AM CASE PRESENTATION: Female Patient with Chronic Thromboembolic Disease (CTED)

Mithun Chakravarthy, MD, Allegheny General Hospital, Pittsburgh, PA, USA

9:20 AM DEBATE (Pro): Early Intervention in CTED: A Stitch in Time Saves Nine

Isabelle Opitz, MD, University Hospital Zurich, Zurich, Switzerland

9:35 AM DEBATE (Con): Early Intervention in CTED: A Stitch in Time Saves Nine

Joanna Pepke-Zaba, MD, Papworth Hospital, Cambridge, United Kingdom

9:50 AM Debate Rebuttal (Pro)

Isabelle Opitz, MD, University Hospital Zurich, Zurich, Switzerland

9:55 AM Debate Rebuttal (Con)

Joanna Pepke-Zaba, PhD, FRCP, Papworth Hospital, Cambridge, United Kingdom

10:00 AM Balloon Pulmonary Angioplasty: Is It Complementary or an Alternative to Pulmonary Thrombo-Endarectomy?

Olaf Mercier, MD, Centre Chirurgical Marie Lannelongue, Fontenay aux roses, France

10:15 AM Should Balloon Pulmonary Angioplasty be Combined with Pulmonary Thrombo-Endarectomy?

Hiroshi Matsubara, MD, PhD, Okayama Medical Center, Okayama, Japan

8:30 AM - 10:30 AM

SYMPOSIUM 13: A Day in the Life: The Pathologist as a Member of the Thoracic Transplant Team

Location: Hermes

Target Audience: PATH, EEP, HF/HTX, LF/LTX, MCS, NNSAH, PEDS, PHARM

Chairs: Martin J Goddard, FRCS, MRCPa, and Charles C Marboe, MD

Session Summary: The pathologist plays an important clinical role in the care of a thoracic transplant patient. The session will follow two patients (one heart and one lung) through the stages of pre-transplant diagnosis, the transplant itself, post-transplant follow-up and ultimately re-transplantation or death. The role of the pathologist in his/her clinical and scientific role will be emphasized at each stage of the process.

8:30 AM *Evaluating the Native Heart and Mechanical Support Device (MCS: What's Gone Wrong?)*

Robert Padera, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

8:42 AM Q&A

8:47 AM *Call the Pathologist: The Diagnostic Dilemma in the Failing Cardiac Allograft*

Katharina Wassilew, MD, University of Copenhagen, Copenhagen, Denmark

8:59 AM Q&A

9:04 AM *Cardiologist's Perspective*

Mazen Hanna, MD, Cleveland Clinic, Cleveland, OH, USA

9:16 AM Q&A

9:21 AM *Evaluating the Explanted Lungs: The Unexpected Diagnosis*

Doris Rassi, MD, Papworth Hospital, Cambridge, United Kingdom

9:33 AM Q&A

9:38 AM *Call the Pathologist: The Diagnostic Dilemma in the Failing Lung Allograft*

Fiorella Calabrese, MD, University of Padua, Padua, Italy

9:50 AM Q&A

9:55 AM *Pulmonologist's Perspective*

Are Martin Holm, MD, PhD, Oslo University Hospital, Oslo, Norway

10:07 AM Q&A

10:12 AM *Closing the Loop: What the Post-Mortem Offers the Clinician and the Family*

Gregory Fishbein, MD, UCLA Medical Center, Los Angeles, CA, USA

10:24 AM Q&A

8:30 AM - 10:30 AM

SYMPOSIUM 14: Old Cells New Tricks: Updates on Transplant Immunology

Location: Mediterranean 6

Target Audience: BSTR, HF/HTX, LF/LTX, PATH

Chairs: Stijn Verleden, PhD, and Tereza Martinu, MD, PhD

Session Summary: Graft-specific responses involve a coordinated effort between multiple immune cell types. Exciting advances in transplant immunology are providing insights into these complex interactions that will affect both present and future care for heart and lung allograft recipients. This session will highlight cutting edge transplant immunology research into T, B, and NK lymphocytes and neutrophils, and describe how available therapies affect the cells.

8:30 AM *Immunosuppression Strategies and Innate Immunity*

Daniel R Goldstein, MD, University of Michigan, Ann Arbor, MI, USA

8:45 AM Q&A

8:50 AM *Coming Soon to an Allograft Near You: Regulatory T Cell Immunotherapy*

Gregor Warnecke, PhD, Hannover Medical School, Hannover, Germany

9:05 AM Q&A

9:10 AM *Natural Killer (NK) Cells: Friend or Foe?*

John R Greenland, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

9:25 AM Q&A

9:30 AM *Macrophages and Dendritic Cells: Inside the Control Center*

Carla C Baan, PhD, Erasmus Medical Center, Rotterdam, Netherlands

9:45 AM Q&A

9:50 AM *Targeting Rejection by Targeting B Cells*

Lori J West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

10:05 AM Q&A

10:10 AM *Alloimmunity: And Don't Forget the Neutrophils!*

Andrew Gelman, PhD, Washington University, St. Louis, MO, USA

10:25 AM Q&A

11:00 AM - 12:30 PM

ORAL SESSION 15: The Final Frontier? Bleeding in MCS

Location: Apollon

Target Audience: MCS, NNSAH, PHARM

Chairs: Ulrich Jorde, MD, and Thomas Schlöglhofer, BSc

11:00 AM (158) Increased Bleeding Risk in LVAD Patients with Elevated Angiotensin-2 and TNF- α : Analysis of the PREVENT Multicenter Study; G. H. Kim¹, G. Sayer¹, J. Ransom², M. Keebler³, J. Katz⁴, A. Kilic⁵, J. Lindenfeld³, G. Egnaczyk⁶, P. Shah⁷, A. Brieke⁸, J. Walenga⁹, D. Crandall¹⁰, D. Farrar¹⁰, K. Sundareswaran¹⁰, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Baptist Health Heart and Transplant Institute, Little Rock, AR, ³Vanderbilt University, Nashville, TN, ⁴University of North Carolina, Chapel Hill, NC, ⁵Ohio State University, Columbus, OH, ⁶Christ Hospital, Cincinnati, OH, ⁷Inova Heart and Vascular Institute, Falls Church, VA, ⁸University of Colorado, Aurora, CO, ⁹Loyola University Medical Center, Maywood, IL, ¹⁰Abbott (Formerly St. Jude Medical), Chicago, IL

11:15 AM (159) Angiodysplastic Lesions in the Gastrointestinal Tract of Heart Failure Patients Predates Post LVAD Bleeding; S. R. Patel, J. Kwah, H. Rosenberg, T. Chinnadurai, O. Saeed, M. Gibber, D. J. Goldstein, U. P. Jorde. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

11:30 AM (160) Discontinuation of Aspirin in Heartmate 3 Left Ventricular Assist Device; S. Lim, A. Ranasinghe, N. Howell. University Hospital Birmingham, Birmingham, United Kingdom

11:45 AM (161) Minimal Anticoagulation Evaluation To Augment Hemocompatibility - The MAGENTUM 1 Study; J. Netuka¹, P. Ivák², Z. Tučanová², S. Gregor¹, O. Szárszoi², P. Sood³, J. Rimsans⁴, J. M. Connors⁵, M. R. Mehra⁶. ¹Institute for Clinical & Experimental Medicine, Prague, Czech Republic, ²Dept of Cardiovascular Surgery, Institute for Clinical & Experimental Medicine, Prague, Czech Republic, ³Global Clinical Affairs, Heart Failure, Abbott, Burlington, MA, ⁴Dept of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Heart and Vascular Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

12:00 PM (162) Pre-Operative Pectoralis Muscle Quantity and Attenuation by Computed Tomography are Predictive of Recurrent Gastrointestinal Bleeding on Left Ventricular Assist Device Support; R. Cogswell¹, R. John², J. Shultz³, C. Martin¹, T. Thenappan¹, F. Kamdar¹, C. P. Earthman⁴, L. M. Teigen⁴. ¹Dept of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, ²Dept of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN, ³Dept of Medicine, University of Minnesota, Minneapolis, MN, ⁴Food Science and Nutrition, University of Minnesota, St. Paul, MN

12:15 PM (163) Pre-Operative Tricuspid Regurgitation and Right Ventricular Enlargement are Associated with Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices; M. Liebo¹, Z. Hussain¹, S. Malik², R. Zolty², H. Ilias Basha¹, A. Heroux¹, B. Lowes², E. Raichlin¹. ¹Medicine, Loyola University Medical Center, Maywood, IL, ²Medicine, University of Nebraska Medical Center, Omaha, NE

11:00 AM - 12:30 PM

ORAL SESSION 16: It's Leaking But Nobody Cares: Valvular Disease in MCS

Location: Athena

Target Audience: MCS, HF, NNSAH, PATH

Chairs: Pascal N LePrince, MD, PhD, and Shelley Hall, MD

11:00 AM (164) Valvular Regurgitation Affects Hemodynamic Predictors of Right Ventricular Failure After Left Ventricular Assist Device Implantation; R. M. Wehbe¹, A. Tibrewala¹, J. E. Wilcox¹, K. Ghafourian¹, A. S. Anderson¹, R. Harap², J. Tomasko², J. Nakano², A. Churyla², D. T. Pham², J. D. Rich¹, E. Vorovich¹. ¹*Division of Cardiology, Dept of Medicine, Northwestern University, Chicago, IL*, ²*Division of Cardiac Surgery, Dept of Surgery, Northwestern University, Chicago, IL*

11:15 AM (165) The Effect of Concomitant Mitral Valve Procedures for Severe Mitral Valve Regurgitation During Left Ventricular Assist Device Implantation; M. Kawabori, C. Kurihara, A. Critsinelis, T. Sugiura, R. M. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, T. K. Rosengart, O. H. Frazier, J. A. Morgan. *Texas Heart Institute/ Baylor College of Medicine. Cardiothoracic Transplant and Circulatory Support, Houston, TX*

11:30 AM (166) Impact of Concomitant Mitral Valve Surgery for Mitral Regurgitation During LVAD Implantation: Systematic Review and Meta-Analysis; J. Choi¹, J. G. Luc², E. Moncho Escrivà³, K. Phan⁴, S. A. Rizvi¹, S. Patel¹, J. W. Entwistle¹, R. J. Morris¹, H. T. Massey¹, V. Tchantchaleishvili¹. ¹*Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA*, ²*University of Alberta, Edmonton, AB, Canada*, ³*University of Granada, Granada, Spain*, ⁴*University of New South Wales, Sydney, Australia*

11:45 AM (167) Natural History of Mild Aortic Insufficiency at the Time of Left Ventricular Assist Device Implantation for Heartmate II and HVAD; M. Kawabori, C. Kurihara, R. T. Conyer, T. Sugiura, R. M. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, T. K. Rosengart, O. H. Frazier, J. A. Morgan. *Texas Heart Institute/ Baylor College of Medicine, Texas Heart Institute/ Baylor College of Medicine, Houston, TX*

12:00 PM (168) De Novo Aortic Insufficiency on Left Ventricular Assist Device Support: An Analysis of the INTERMACS Registry; L. K. Truby, H. Takayama, A. Garan, K. Takeda, R. Givens, M. Yuzefpolskaya, P. C. Colombo, Y. Naka, V. K. Topkara. *Columbia University, New York, NY*

12:15 PM (169) TAVR is an Effective and Durable Treatment Modality for Symptomatic Aortic Insufficiency in LVAD Patients; A. Yehya¹, V. Rajagopal¹, C. Meduri¹, J. Kauten², M. Brown², L. Dean¹, J. Webster¹, A. Krishnamoorthy¹, T. Hrobowski¹, D. Dean¹. ¹*Advanced Heart Failure, Piedmont Heart, Atlanta, GA*, ²*Cardiac Surgery, Piedmont Heart, Atlanta, GA*

11:00 AM - 12:30 PM

ORAL SESSION 17: The New Frontier: Hepatitis C and Other Viruses

Location: Clio/Thalie/Erato

Target Audience: ID, HTX, LTX, MCS, PHARM

Chairs: Paolo A Grossi, MD, PhD, and Robin K. Avery, MD

11:00 AM (170) Heart and Heart-Kidney Transplantation from Hepatitis C Virus (HCV) Positive Donors into HCV-Negative Recipients; S. Aslam, M. Mariski, G. Pretorius, E. Adler. *University of California, San Diego, San Diego, CA*

11:15 AM (171) Breaking the Viral Spiral: Changing how you C Hepatitis; T. E. Miller, E. Mitchell, A. DeVore, J. Schroder, C. B. Patel. *Transplant Services, Duke Univ Med Ctr, Durham, NC*

11:30 AM (172) Early Experience With the Use of Hepatitis C Antibody-positive, Nucleic Acid Testing-negative Donors in Lung Transplantation; M. S. Mulvihill¹, M. L. Cox¹, J. Watson¹, L. ElLaissi², C. R. Wolfe³, A. Gray³, M. G. Hartwig¹. ¹*Dept of Surgery, Duke University, Durham, NC*, ²*Duke Transplant Center, Duke University, Durham, NC*, ³*Dept of Medicine, Duke University, Durham, NC*

11:45 AM (173) Unexplained Persistent Hepatitis C Seropositivity (Hepc Ab+Ve) in the Absence of Viremia in Lung Transplant LTX Recipients from Hepc Ab+Ve/Nucleic Acid Test Negative (NAT-Ve) Donors Associated with Excellent Clinical Outcomes and Implications for Future Practice; O. C. smibert¹, J. S. Doyle¹, D. Pilcher², M. A. Paraskeva³, G. I. Snell³. ¹*Infectious Diseases, Alfred Hospital, Melbourne, Australia*, ²*Intensive Care, Alfred Hospital, Melbourne, Australia*, ³*Lung transplant service, Alfred Hospital, Melbourne, Australia*

12:00 PM (174) Hepatitis E Virus Infection in Lung Transplant Recipients; G. Ambrocio¹, M. Aguilar Perez², R. Laporta², M. Lázaro², A. Avellón³, G. Arán-Tohá⁴, N. Martos Gisbert², M. Ussetti Gil². ¹*Section of Pulmonary Medicine, Philippine General Hospital-University of Philippines, Manila, Philippines*, ²*Section of Pulmonary Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Spain*, ³*Section of Microbiology, Instituto de Salud Carlos III, Madrid, Spain*, ⁴*Section of Microbiology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain*

12:15 PM (175) The Prevalence of Hepatitis E Virus Infections and Ribavirin Therapy in Heart Transplant Recipients; K. Okamura¹, K. Nawata¹, M. Kimura¹, O. Kinoshita¹, A. Masuzawa¹, H. Yamauchi¹, Y. Hirata¹, Y. Owada², Y. Oshiro³, H. Okamoto⁴, N. Ohkohchi³, M. Ono¹. ¹*Cardiac Surgery, The University of Tokyo Hospital, Bunkyo-ku Tokyo, Japan*, ²*Cardiac Surgery, University of Tsukuba, Tsukuba, Ibaraki, Japan*, ³*University of Tsukuba, Tsukuba, Ibaraki, Japan*, ⁴*Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan*

11:00 AM - 12:30 PM

ORAL SESSION 18: Mining the Tissue Biopsy: Molecular Signals of Rejection

Location: Hermes

Target Audience: PATH, BSTR, HTX, LTX

Chairs: E Rene Rodriguez, MD, and Alexandra Rice, FRCPath

11:00 AM (176) Validation of Donor-derived Cell-free DNA to Detect Heart-transplant Rejection; H. Valantine¹, P. Shah², K. Shah³, S. Hsu⁴, E. Feller⁵, M. Rodrigo⁶, S. Najjar⁶, U. Fideli¹, S. Gorham¹, A. Marishta¹, Y. Yang¹, M. Jang¹, I. Tunc¹, S. Agbor-Enoh¹. ¹Laboratory of Transplant Genomics, Nat'l Inst. of Health, Bethesda, MD, ²division of Cardiology, Inova Fairfax Hospital, Falls Church, VA, ³Division of Cardiology, Virginia Commonwealth University, Richmond, VA, ⁴Division of Cardiology, Johns Hopkins Hospital, Baltimore, MD, ⁵Division of Cardiology, University of Maryland Medical Center, Baltimore, MD, ⁶Division of Cardiology, Medstar Washington Hospital Center, Washington, DC

11:15 AM (177) RT-MLPA as a New Tool for the Molecular Diagnosis of Allograft Rejection in Formalin Paraffin-embedded Endomyocardial Biopsies; N. Adam¹, G. Coutance¹, F. Drieux², P. Vially², M. Rabant¹, A. Gay³, E. Epailly⁴, C. Toquet⁵, P. Rouvier¹, A. François³, P. Bruneval¹, J. Duong Van Huyen¹. ¹Assistance Publique Hopitaux de Paris, Paris, France, ²Centre Henri Becquerel, Rouen, France, ³Hôpital Charles Nicolle, Rouen, France, ⁴CHRU Strasbourg, Strasbourg, France, ⁵CHU Nantes, Nantes, France

11:30 AM (178) By Molecular Analysis, Many ISHLT Histologic Rejection Diagnoses Are Associated With Molecular Injury, Not Molecular Rejection; J. Reeve¹, D. H. Kim², M. G. Crespo-Leiro³, J. Kobashigawa⁴, L. Potena⁵, M. Deng⁶, M. Cadeiras⁶, E. C. Depasquale⁶, P. Bruneval⁷, A. Loupy⁸, P. Macdonald⁹, A. Zuckermann¹⁰, A. Z. Aliabadi¹⁰, J. Goekler¹⁰, P. F. Halloran¹. ¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁴Cedars-Sinai Heart Institute, Beverly Hills, CA, ⁵University of Bologna, Bologna, Italy, ⁶Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁷Hôpital Européen Georges Pompidou, Paris, France, ⁸Hôpital Necker, Paris, France, ⁹The Victor Chang Cardiac Research Institute, Sydney, Australia, ¹⁰Medical University of Vienna, Vienna, Austria

11:45 AM (179) Phosphorylated P70 S6 Kinase and S6 Ribosomal Protein Value as Diagnostic Marker of Antibody-mediated Rejection in Lung Allografts: A Multicenter Study; F. Calabrese¹, F. Lunardi¹, J. Le Pavec², P. Dorfmueller², M. Ivanovic³, T. Pena³, K. Wassilew⁴, M. Perch⁴, S. Hirschi⁵, M. Chenard⁵, D. Neil⁶, A. Montero-Fernandez⁷, A. Rice⁷, E. Cozzi¹, P. Tellaroli¹, F. Rea¹, D. J. Levine⁸, M. Goddard⁹. ¹Univ of Padova Medical School, Padova, Italy, ²Marie Lannelongue Hospital, Le Plessis Robinson, France, ³Univ of Iowa, Iowa City, IA, ⁴Univ Hospital of Copenhagen, Copenhagen, Denmark, ⁵Univ Hospital of Strasbourg, Strasbourg, France, ⁶Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁷Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom, ⁸Univ of Texas Health Science Center, San Antonio, TX, ⁹Papworth Hospital NHS Trust, Cambridge, United Kingdom

12:00 PM (180) Molecular Diagnosis of Rejection Phenotypes in Lung Transplant Biopsies: Initial Findings of the INTERLUNG Study; K. Halloran¹, M. D. Parkes¹, J. Chang¹, K. Famulski¹, J. Reeve¹, R. Hachem², P. Jaksch³, S. Juvet⁴, S. Keshavjee⁴, W. Klepetko³, D. Kreisel², A. Loupy⁵, A. Roux⁶, E. P. Trulock², G. Snell⁷, I. Timofte⁸, G. Westall⁷, P. Halloran¹. ¹Univ of Alberta, Edmonton, AB, Canada, ²Washington Univ School of Medicine in St. Louis, St. Louis, MO, ³Medical Univ of Vienna, Vienna, Austria, ⁴Univ of Toronto, Toronto, ON, Canada, ⁵Necker Hospital, Paris, France, ⁶Foch Hospital, Paris, France, ⁷Alfred Hospital, Melbourne, Australia, ⁸Univ of Maryland, Baltimore, MD

12:15 PM (181) Molecular Detection of Rejection-like Changes in Proximal Bronchial Mucosal Lung Transplant Biopsies: Initial Findings of the INTERLUNG Study; K. Halloran¹, M. D. Parkes¹, J. Chang¹, K. Famulski¹, J. Reeve¹, R. Hachem², S. Juvet³, S. Keshavjee³, D. Kreisel², G. Snell⁴, E. P. Trulock², I. Timofte⁵, G. Westall⁴, P. Halloran¹. ¹Univ of Alberta, Edmonton, AB, Canada, ²Washington Univ School of Medicine in St. Louis, St. Louis, MO, ³Univ of Toronto, Toronto, ON, Canada, ⁴Alfred Hospital, Melbourne, Australia, ⁵Univ of Maryland, Baltimore, MD

11:00 AM - 12:30 PM

ORAL SESSION 19: Improving Lung Transplant Outcomes Through Science

Location: Mediterranean 6

Target Audience: BSTR, LTX, PATH

Chairs: Daniel Chambers, MBBS, MRCP, FRACP, MD, and Arne Neyrinck, MD, PhD

11:00 AM (182) *Alpha 1 Antitrypsin to Prevent Ischemia Reperfusion Injury in a Pig Lung Transplant Survival Model*; A. Mariscal¹, L. Caldarone², M. Chen², M. Cypel², J. Tikkanen², M. Liu², S. Keshavjee². ¹UHN, Toronto Lung Transplant Program, Toronto, ON, Canada, ²UHN, Toronto Lung Transplant Program, Toronto, ON, Canada

11:15 AM (183) *Repeated Episodes of Airway Inflammation Augment Acute Rejection and Fibrosis in a Mouse Lung Transplant Model*; T. Watanabe¹, K. Boonstra¹, M. Horie², C. Konoeda¹, Z. Guan¹, M. Maxim¹, D. Hwang³, M. Liu¹, S. Keshavjee¹, S. Juvet¹, T. Martinu¹. ¹Latner Thoracic Surgery Research Laboratories, Toronto Lung Transplant Program / University Health Network, Toronto, ON, Canada, ²Joint Dept of Medical Imaging, University Health Network, Toronto, ON, Canada, ³Dept of Pathology, University Health Network, Toronto, ON, Canada

11:30 AM (184) *Impact of Primary Graft Dysfunction on Allograft T Cell Chimerism Following Lung Transplantation*; M. E. Snyder¹, T. Connors², L. Benvenuto¹, L. Shah¹, H. Robbins¹, J. Hook¹, F. D'Ovidio³, M. Bacchetta³, J. R. Sonett¹, S. Arcasoy³, D. L. Farber³. ¹Medicine, Columbia University Medical Center, New York, NY, ²Pediatrics, Columbia University Medical Center, New York, NY, ³Surgery, Columbia University Medical Center, New York, NY

11:45 AM (185) *Linking Early Humoral Sensitization in Lung Transplant Recipients with Even Earlier Cellular Alloreactivity in Humanized Mice*; T. Siemeni¹, A. Knöfel¹, F. Ius¹, J. Salman¹, N. Madrahimov¹, W. Sommer¹, M. Avsar¹, K. Jansson¹, C. Kühn¹, C. Falk², I. Tudorache¹, A. Haverich¹, G. Warnecke¹. ¹Hannover HTTG, Hannover, Germany, ²Institute of transplant immunology, Hannover, Germany

12:00 PM (186) *Emphysema Induces Lung-Specific Autoantibodies that Exacerbate Ischemia Reperfusion Injury Post-Lung Transplantation*; K. J. Patel¹, Q. Cheng², D. P. Allen¹, S. Stephenson², M. Goddard³, S. N. Nadig¹, C. Atkinson². ¹Surgery, Medical University of South Carolina, Charleston, SC, ²Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, ³Transplantation, Papworth Hospital NHS Foundation Trust, Cambridgeshire, United Kingdom

12:15 PM (187) *Leukocytes from Lung Transplant Recipients with Severe Primary Graft Dysfunction Adoptively Transfer Alloreactivity to Vessel Grafts Trans Vivo*; A. Knoefel, T. Siemeni, N. Madrahimov, W. Sommer, M. Avsar, F. Ius, K. Jansson, L. Ahrend, J. Salman, C. Kuehn, I. Tudorache, A. Haverich, C. Falk, G. Warnecke. HTTG, MHH, Hannover, Germany

11:00 AM - 12:30 PM

SYMPOSIUM 15: We Never Stop Learning: 50th Anniversary of Heart Transplantation

Location: Mediterranean ABC

Target Audience: HF/HTX, BSTR, ID, NNSAH, PATH, PEDS, PHARM

Chairs: Maryl R Johnson, MD, and Hermann Reichenspurner, MD, PhD

Session Summary: Heart transplantation has evolved from a highly specialized procedure performed at only a handful of centers to a routine treatment option for end-stage heart failure. This session will highlight the historical milestones in surgical techniques, immunosuppression, pathology interpretation, and recipient management that have helped to define the field over the past 50 years.

11:00 AM *Second Chances: How I Spent the Past 38 Years with My New Heart*

Brent Evje, Fairdale, ND, USA

11:15 AM *Replacing the Heart: The Early Days of Heart Transplantation*

Sir Terence English, KBE, FRCS, Oxford, United Kingdom

11:30 AM *Heart-to-Heart: Patient Selection for Heart Transplantation*

Marco Masetti, MD, Malpighi University Hospital, Bologna, Italy

11:45 AM *Protect My Heart: The Evolution of Immunosuppression*

Robert L Page, PharmD, MSPH, University of Colorado, Denver, CO, USA

12:00 PM *A Piece of My Heart: Developing and Refining Pathologic Grading of Rejection*

Elizabeth H Hammond, MD, Intermountain Healthcare/University of Utah, Salt Lake City, UT, USA

12:15 PM *Our Community: The Role of ISHLT in Advancing Heart Transplant Knowledge*

Sharon A. Hunt, MD, Stanford University, Stanford, CA, USA

11:00 AM - 12:30 PM

SYMPOSIUM 16: JHLT at ISHLT: The Year in a Capsule

Location: Uranie/Calliope

Target Audience: ALL

Chairs: Evan P Kransdorf, MD, PhD, and Fabienne Dobbels, MSc, PhD

Session Summary: This session will highlight the most exciting publications in JHLT over the past year, each paper followed by a discussion by one of the senior editorial consultants of the journal to relate the presented articles to the greater body of published literature and discuss how they advance our understanding in the field. Due to time limits the presented papers for each talk will STRICTLY be limited to FOUR selected papers.

11:00 AM *JHLT Best Papers of the Year*

Patricia A Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

11:10 AM *Highlights of Heart Transplantation and Mechanical Circulatory Support*

Jorge Silva Enciso, MD, UCSD Medical Center, San Diego, CA, USA

11:25 AM *Expert Senior Discussant in Heart Transplantation and MCS*

Jeffrey J Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, USA

11:30 AM *Highlights of Lung Transplantation*

Gustavo Parrilla, MD, Hospital University Fundación Favaloro, Favaloro, Argentina

11:45 AM *Expert Senior Discussant in Lung Transplantation*

Tereza Martinu, MD, Toronto General Hospital, Toronto, Canada

11:50 AM *Highlights of Pediatric Heart and Lung Transplantation*

Claire Irving, MD, Children's Hospital Westmead, Westmead, Australia

12:05 PM *Expert Senior Discussant in Pediatric Heart and Lung Transplantation*

Richard Kirk, FRCP, FRCPCH, UT Southwestern Medical Center, Dallas, TX, USA

12:10 PM *Highlights of Pulmonary Hypertension*

Mitesh V Thakrar, MD, University of Calgary, Calgary, AB, Canada

12:25 PM *Expert Senior Discussant in Pulmonary Hypertension*

Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

2:00 PM - 4:00 PM

SYMPOSIUM 17: Rapid Update on MCS Complications and Management: The Unpublished

Location: Apollon

Target Audience: MCS, HF/HTX, ID, NHSAH, PHARM

Chairs: Bastian Schmack, MD, and Aly El Banayosy, MD

Session Summary: Mechanical Circulatory Support management is constantly evolving. While serious adverse events such as bleeding, thrombosis, stroke and RV failure are now recognized, comprehensive prevention and treatment strategies have either not been developed or are in constant flux.

2:00 PM *Anticoagulation Approaches in MCS - New Developments?*

Andre Vincentelli, MD, PhD, CHU de Lille, Lille, France

2:10 PM Q&A

2:15 PM *Hemolysis in Continuous Flow LVAD Patients: When Is It Clinically Relevant?*

Omar Saeed, MD, Montefiore Medical Center, Bronx, NY, USA

2:25 PM Q&A

2:30 PM *Pathophysiology and Management of Stroke in Continuous Flow LVAD Patients*

Joshua Z Willey, MD, MAS, Columbia University, New York, NY, USA

2:40 PM Q&A

2:45 PM *How to Assess Aortic Insufficiency and Its Clinical Relevance During Continuous Flow LVAD Support? Implications for Management*

Jennifer A Cowger, MD, MS, St. Vincent Heart Center, Indianapolis, IN, USA

2:55 PM Q&A

3:00 PM *Dealing with the Bugs - Chronic LVAD Infections During Destination Therapy Support*

Saima Aslam, MD, MS, UCSD Medical Center, San Diego, CA, USA

3:10 PM Q&A

3:15 PM *Device Optimization - Invasive or Noninvasive*

Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

3:25 PM Q&A

3:30 PM *Pulmonary Artery Sensors and LVAD: First Step to a SmartPump*

Nir Uriel, MD, University of Chicago, Chicago, IL, USA

3:40 PM Q&A

3:45 PM *Ancillary Procedures During LVAD Placement Prevent Long-Term Complications: Myth or Reality?*

Evgenij V Potapov, MD, PhD, Berlin Heart Center, Berlin, Germany

3:55 PM Q&A

2:00 PM - 4:00 PM

SYMPOSIUM 18: It's Electric! Electrophysiologic Management of the LVAD Patient

Location: Athena

Target Audience: MCS, HF/HTX, NNSAH, PEDS

Chairs: Jan Schmitto, MD, PhD, and Brian Houston, MD

Session Summary: As the population of LVAD patients grows (largely due to increased use of destination therapy devices), the management of the accompanying electrophysiologic complications and devices becomes increasingly important. In this session, the speakers will tackle topics including the prevention and treatment of ventricular tachyarrhythmias, the implications and treatment of atrial fibrillation, and a pro/con debate regarding the utility of cardiac resynchronization therapy (CRT) in VAD patients.

2:00 PM *An Ounce of Prevention: Intra-Operative Approach to Ventricular Tachycardia in LVAD*

James D Bergin, MD, University of Virginia Health Science Center, Charlottesville, VA, USA

2:15 PM Q&A

2:20 PM *Approach to Ventricular Tachycardia in LVAD Patients - A Pound of Cure: Invasive Management of Ventricular Tachycardia After VAD Implantation*

Joshua D Moss, MD, UCSF Medical Center, San Francisco, CA, USA

2:35 PM Q&A

2:40 PM *Atrial Fibrillation in the LVAD Patient: Pest or Problem?*

Kavitha Muthiah, MBChB, PhD, St. Vincent's Hospital, Sydney, Australia

2:55 PM Q&A

3:00 PM *The Shocking Truth: Utility Of and Programming For the Implantable Cardioverter Defibrillator After LVAD*

Simon Pecha, MD, University Hospital Hamburg, Hamburg, Germany

3:15 PM Q&A

3:20 PM *DEBATE (Pro): Cardiac Resynchronization Therapy is Beneficial in LVAD Patients*

Melana Yuzefpolskaya, MD, Columbia University, New York, NY, USA

3:35 PM *DEBATE (Con): Cardiac Resynchronization Therapy is Beneficial in LVAD Patients*

Emma Birks, MD, PhD, University of Louisville, Louisville, KY, USA

3:50 PM *Debate Rebuttal (Pro)*

Melana Yuzefpolskaya, MD, Columbia University, New York, NY, USA

3:55 PM *Debate Rebuttal (Con)*

Emma Birks, MD, PhD, University of Louisville, Louisville, KY, USA

2:00 PM - 4:00 PM

SYMPOSIUM 19: Antibody-Mediated Rejection After Lung Transplantation - 2018

Location: Mediterranean ABC

Target Audience: LF/LTX, BSTR, PATH, PEDS

Chairs: Deborah Levine, MD, and Christian Benden, MD, FCCP

Session Summary: AMR after lung transplantation is an increasingly recognized form of rejection that often results in allograft failure. Since the Society developed a standardized definition in 2016, the community has had increasing experience in AMR, however numerous questions regarding the diagnosis and management persist. The purpose of this session is to provide clinicians and researchers with the latest update on HLA antibody testing, pathology, clinical management, and future diagnostics.

2:00 PM *HLA Antibody Testing - 2018*

Adriana Zeevi, PhD, University of Pittsburgh, Pittsburgh, PA, USA

2:20 PM *Pathology of Pulmonary AMR*

Desley Neil, FRCPath, Queen Elizabeth Hospital, Birmingham, United Kingdom

2:40 PM *Treatment of AMR in Lung Transplantation*

Olivier Brugière, MD, PhD, Hôpital Bichat, Paris, France

3:00 PM *DEBATE: We Should Treat De Novo DSA (Pro)*

Ramsey Hachem, MD, Washington University, St. Louis, MO, USA

3:15 PM *DEBATE: We Should Treat De Novo DSA (Con)*

Allan R Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

3:30 PM *Debate Rebuttal (Pro)*

Ramsey Hachem, MD, Washington University, St. Louis, MO, USA

3:35 PM *Debate Rebuttal (Con)*

Allan R Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

3:40 PM *Panel Discussion*

2:00 PM - 4:00 PM

SYMPOSIUM 20: Malignancy in Transplantation: Too Much, Too Early or Too Little, Too Late?

Location: Hermes

Target Audience: PHARM, BSTR, HF/HTX, ID, LF/LTX, NHSAH, PATH, PEDS

Chairs: Haifa Lyster, MSc, and Andreas Zuckermann, MD

Session Summary: The session will cover malignancy after transplantation focusing on causes, epidemiology, effective treatments, and risks associated with immunosuppression minimization.

2:00 PM *The Root of All Evil: Pathophysiology/Epidemiology of Malignancy in Transplant*

Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

2:20 PM Q&A

2:24 PM *The Bad Actor: the Role of Epstein-Barr Virus (EBV) Reactivation in the Development of Post-Transplant Lympho-Proliferative Disease*

Erik Verschuuren, MD, PhD, University Medical Center, Groningen, Netherlands

2:44 PM Q&A

2:48 PM *Treatment of Malignancy - More Than Just CHOPping Away at Cancer*

Nicole Kaiser, PharmD, BCOP, Children's Hospital Colorado, Aurora, CO, USA

3:08 PM Q&A

3:12 PM *Lurking in the Shadows: Risk of Rejection or Graft Failure Before, During, and After Chemotherapy*

Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, Australia

3:32 PM Q&A

3:36 PM *Looking Back and Moving Forward - Immunosuppression Before and After Cancer*

Edward Horn, PharmD, Allegheny General Hospital, Pittsburgh, PA, USA

3:56 PM Q&A

2:00 PM - 4:00 PM

SYMPOSIUM 21: Great Debates in the Management of PAH: Genetics, Bridge to Lung Transplant, and Goal Directed Therapy

Location: Uranie/Calliope

Target Audience: PH, HF/HTX, LF/LTX, MCS, PEDS, PHARM

Chairs: Ioana Preston, MD, and Oksana A Shlobin, MD

Session Summary: This symposium focuses on current challenges in decision making that physicians face in managing PAH patients in the setting of increased genetic/proteomic awareness, bridge to lung transplant, and management algorithms through a series of pro-con debates and didactic lectures.

2:00 PM DEBATE (Pro): Gene vs. Product: Genetic Testing and Not Proteomics is the Path Forward to Realize Personalized Management of PAH

Anna Hemnes, MD, Vanderbilt University, Nashville, TN, USA

2:15 PM DEBATE (Con): Gene vs. Product: Genetic Testing and Not Proteomics is the Path Forward to Realize Personalized Management of PAH

Evelyn M Horn, MD, Weill Cornell Medical Center, New York, NY, USA

2:30 PM Debate Rebuttal (Pro)

Anna Hemnes, MD, Vanderbilt University, Nashville, TN, USA

2:35 PM Debate Rebuttal (Con)

Evelyn M Horn, MD, Weill Cornell Medical Center, New York, NY, USA

2:40 PM DEBATE (Pro): Early Application of ECLS is the Preferred Bridge to Lung Transplantation for PAH

Clemens Aigner, MD, Ruhrlandklinik - University Essen, Essen, Germany

2:55 PM DEBATE (Con): Early Application of ECLS is the Preferred Bridge to Lung Transplantation for PAH

Erika Berman-Rosenzweig, MD, Columbia University, New York, NY, USA

3:10 PM Debate Rebuttal (Pro)

Clemens Aigner, MD, Medical University of Vienna, Vienna, Austria

3:15 PM Debate Rebuttal (Con)

Erika Berman Rosenzweig, MD, Columbia University, New York, NY, USA

3:20 PM DEBATE (Pro): The ERS/ESC Risk Profiles are Superior to the REVEAL Calculator for Providing Goal Directed Therapy in PAH

C. Dario Vizza, MD, University of Rome, Rome, Italy

3:35 PM DEBATE (Con): The ERS/ESC Risk Profiles are Superior to the REVEAL Calculator for Providing Goal Directed Therapy in PAH

Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA

3:50 PM Debate Rebuttal (Pro)

C. Dario Vizza, MD, University of Rome, Rome, Italy

3:55 PM Debate Rebuttal (Con)

Raymond L Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA

2:00 PM - 4:00 PM

SYMPOSIUM 22: Cytomegalovirus (CMV) in Thoracic Organ Transplantation - A Changing Landscape

Location: Clio/Thalie/Erato

Target Audience: ID, BSTR, HF/HTX, LF/LTX, NNSAH, PATH, PEDS, PHARM

Chairs: Aric Gregson, MD, and Macé M Schuurmans, MD

Session Summary: Cytomegalovirus (CMV) continues to present diagnostic and therapeutic challenges for clinicians caring for thoracic organ transplant recipients. Advances in CMV detection, such as quantitative PCR, have introduced uncertainties about when to initiate and cease therapy. Newer CMV immunoassays may change how we manage CMV. Prolonged prophylactic strategies with valganciclovir have reduced disease incidence, but present new challenges, including resistant and potentially untreatable CMV disease.

2:00 PM *How Many Copies Do We Need? Viremia, Disease, and Everything In Between*

Jutta K Preiksaitis, MD, University of Alberta, Edmonton, AB, Canada

2:15 PM Q&A

2:20 PM *Counting Spots: The Use of CMV Immunoassays*

Kovi Levin, MD, The Alfred Hospital, Melbourne, Australia

2:35 PM Q&A

2:40 PM *CMV Immunoglobulins: When, Where and Why?*

Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

2:55 PM Q&A

3:00 PM *Prophylaxis Duration: Are We There Yet?*

Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital, Cincinnati, OH, USA

3:15 PM Q&A

3:20 PM *Resistance and Challenging Infections: Time to Get Creative*

Robin Avery, MD, Johns Hopkins University, Baltimore, MD, USA

3:35 PM Q&A

3:40 PM *Skirting the Abyss: Drug Toxicities*

Kyle Dawson, MBA, BCPS, University of Kentucky, Lexington, KY, USA

3:55 PM Q&A

2:00 PM - 4:00 PM

SYMPOSIUM 23: Too Little or Too Much: Controversies in Monitoring After Pediatric Thoracic Transplantation

Location: Mediterranean 6

Target Audience: PEDS, ID, LF/LTX

Chairs: Ranny Goldwasser, MD, and Melinda P. Solomon, MD, FRCPC

Session Summary: Due to the small number of thoracic transplants in children, interventions and monitoring are extrapolated from adult and other solid organ transplant protocols. How imaging studies, biopsy, and routine cardiac catheterization or bronchoscopy examinations affect long term morbidities and mortality in children is unclear. In this session, experts in the field of pediatric thoracic transplantation will debate the impact of routine post-transplant care on long term morbidities and outcome.

2:00 PM *Emerging Biomarkers in Pediatric Thoracic Transplantation*

Kevin P Daly, MD, Boston Children's Hospital, Boston, MA, USA

2:20 PM *DEBATE (Pro): Bronchoscopy is the Gold Standard*

Brigitte Willemse, MD, University Medical Center, Groningen, Netherlands

2:35 PM *DEBATE (Con): Bronchoscopy is the Gold Standard*

Marc Schechter, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA

2:50 PM *Debate Rebuttal (Pro)*

Brigitte W Willemse, MD, PhD, University Medical Center, Groningen, Netherlands

2:55 PM *Debate Rebuttal (Con)*

Marc G Schechter, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA

3:15 PM *DEBATE (Pro): Cardiac Catheterization is the Gold Standard*

Daphne T. Hsu, MD, Children's Hospital Montefiore, Bronx, NY, USA

3:00 PM *DEBATE (Con): Cardiac Catheterization is the Gold Standard*

Brian Feingold, MD, MS, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

3:30 PM *Debate Rebuttal (Pro)*

Daphne T Hsu, MD, Children's Hospital Montefiore, Bronx, NY, USA

3:35 PM *Debate Rebuttal (Con)*

Brian Feingold, MD, MS, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

3:40 PM *Panel Discussion*

4:30 PM - 6:00 PM

ORAL SESSION 20: See One, Do One, Teach One: Novel Management Strategies in MCS

Location: Apollon

Target Audience: MCS, NNSAH, PEDS

Chairs: Antonio Loforte, MD, and Joshua Z Willey, MD, MAS

(188) WITHDRAWN

4:30 PM (1246) Less Invasive Left Ventricular Assist Device Implantation - 5-Year Survival and Post Transplant Outcomes; J. Riebandt¹, R. Moayedifar¹, D. Wiedemann¹, T. Schlöglhofer², K. Dimitrov¹, A. Rajek³, G. Laufer¹, D. Zimpfer¹. ¹Cardiac Surgery, Medical Univ Vienna, Vienna, Austria, ²Medical Physics and Biomedical Engineering, Medical Univ Vienna, Vienna, Austria, ³Anesthesia, General Intensive Care and Pain Management, Medical Univ Vienna, Vienna, Austria

4:45 PM (189) The Impact of VAD Clinical Course on Post-Transplant Survival: A Merged Intermacs and OPTN Data Project; J. A. Tallaj¹, S. V. Pamboukian¹, D. C. Naftel², S. L. Myers², W. S. Cherikh³, J. K. Kirklin². ¹Cardiovascular Disease, Univ of Alabama at Birmingham, Birmingham, AL, ²Univ of Alabama at Birmingham, Birmingham, AL, ³Research Dept, United Network for Organ Sharing, Richmond, VA

5:00 PM (190) Impact of the Thoracotomy Implant Approach on Average Length of Stay and Rehospitalizations in the HVAD LATERAL Trial; M. Strueber¹, A. Cheung², N. A. Mokadam³, G. Weiselthaler⁴, S. Lee⁵, T. Boeve⁵, S. Maltais⁶, V. Pretorius⁷, M. Danter⁸, T. A. Vassiliades⁹, E. McGee¹⁰. ¹Beth Israel Medical Center, Newark, NJ, ²University of British Columbia, Vancouver, BC, Canada, ³University of Washington, Seattle, WA, ⁴University of California San Francisco, San Francisco, CA, ⁵Spectrum Health, Grand Rapids, MI, ⁶Mayo Clinic, Rochester, NY, ⁷University of California San Diego, San Diego, CA, ⁸Vanderbilt University Medical Center, Nashville, TN, ⁹Medtronic, Framingham, MA, ¹⁰Loyola University Medical Center, Maywood, IL

5:15 PM (191) Clinical Outcomes with Heartmate 3™ Left Ventricular Assist Device as Treatment for Advanced Heart Failure: 12-Month Outcomes from the ELEVATE Registry; M. Morshuis¹, J. Garbade², D. Zimpfer³, S. Shaw⁴, J. Lavee⁵, F. Gustafsson⁶, S. Lim⁷, F. Beyersdorf⁸, L. Damme⁹, D. Saeed¹⁰. ¹Cardiothoracic Surgery, Heart and Diabetic Center NRW, Bad Oeynhausen, Germany, ²Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany, ³Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ⁴Transplant Center, University Hospital of South Manchester NHS Trust, Manchester, United Kingdom, ⁵Heart Transplantation Unit, Leviev Heart Center, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Dept of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁷Dept of Cardiology, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁸Medical Faculty, University Heart Center Freiburg, Freiburg, Germany, ⁹Abbott, Abbott, Chicago, IL, ¹⁰Cardiovascular Surgery, University Hospital of Duesseldorf, Düsseldorf, Germany

5:30 PM (192) A Multidisciplinary Continuous Support Heart Team Approach Improves Survival in Continuous Flow LVAD Recipients; A. M. Shah¹, D. Sims¹, S. Madan¹, N. Siddiqi¹, A. Luke¹, O. Saeed¹, S. Patel¹, S. Murthy¹, J. Shin¹, S. Watts¹, W. Jakobleff², S. Forest², S. Vukelic¹, D. Belov¹, Y. Puius³, G. Minamoto³, V. Muggia³, A. Carlese⁴, S. Leung⁴, M. Rahmanian⁴, J. Leff⁵, D. Goldstein², U. Jorde¹. ¹Division of Cardiology, Montefiore Medical Center, Bronx, NY, ²Division of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Bronx, NY, ³Division of Infectious Disease, Montefiore Medical Center, Bronx, NY, ⁴Division of Critical Care Medicine, Montefiore Medical Center, Bronx, NY, ⁵Division of Cardiothoracic Anesthesia, Montefiore Medical Center, Bronx, NY

5:45 PM (193) Ambulatory Counterpulsation with a Minimally Invasive Circulatory Assist Device - Expanding Indications and Extending Support; V. Jeevanandam, T. Song, T. Ota, D. Onsager, C. Juricek LaBuhn, T. Lammy, S. Patel-Raman, G. Sayer, G. Kim, S. Kalantari, N. Uriel. University of Chicago Medicine, Chicago, IL

4:30 PM - 6:00 PM

ORAL SESSION 21: Right and Wrong: The Impact of the Right Ventricle After LVAD

Location: Athena

Target Audience: MCS, NNSAH, PH

Chairs: Michael S Kiernan, MD, and Jeffrey J Teuteberg, MD

4:30 PM (194) Outcomes After Isolated Durable Right Ventricular Assist Device; E. Y. Birati¹, E. Grandin², M. Seigerman³, A. Padegimas¹, F. Cabezas², J. A. Mazurek¹, M. S. Kiernan⁴, N. K. Kapur⁴, G. H. Oliveira⁵, F. D. Pagani⁶, D. C. Naftel⁷, J. J. Teuteberg⁸, R. L. Kormos⁹, J. Kirklin¹⁰, P. Atluri¹¹, M. A. Acker¹¹, J. Rame¹. ¹Cardiology, University of Pennsylvania, Philadelphia, PA, ²Cardiology, Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, Boston, MA, ³Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Cardiology, Tufts Medical Center, Boston, MA, ⁵Cardiology, University Hospitals, Cleveland, OH, ⁶Cardiothoracic Surgery, University of Michigan School of Medicine, Ann Arbor, MI, ⁷School of Public Health, University of Alabama Birmingham, Birmingham, AL, ⁸Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁰Cardiothoracic Surgery, University of Alabama Birmingham School of Medicine, Birmingham, PA, ¹¹Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA

4:45 PM (195) Chemokine Receptor Regulation in Mechanical Circulatory Support to Predict RV Failure and Mortality is Dependent on Etiology; A. Nayak¹, C. Neill², R. L. Kormos³, L. Lagazzi³, I. Halder⁴, C. McTiernan⁴, J. Larsen², J. Teuteberg³, T. N. Bachman³, K. Hanley-Yanez⁴, D. M. McNamara³, M. A. Simon³. ¹UPMC Presbyterian, Pittsburgh, PA, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, ³UPMC Heart and Vascular Institute, Pittsburgh, PA, ⁴UPMC Vascular Medicine Institute, Pittsburgh, PA

5:00 PM (196) Outcomes in Late Right Heart Failure after LVAD: A Contemporary Analysis of the New Intermacs 4.0 Definition; J. E. Rame¹, E. Y. Birati¹, J. Teuteberg², E. W. Grandin³, P. Atluri⁴, M. Kiernan⁵, G. H. Oliveira⁶, S. L. Myers⁷, D. C. Naftel⁷, F. D. Pagani⁸, R. L. Kormos⁹, J. K. Kirklin⁷. ¹Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ²Cardiovascular Medicine, Stanford University, Palo Alto, CA, ³Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, ⁵Cardiovascular Center, Tufts Medical Center, Boston, MA, ⁶Division of Cardiology, University Hospital, Cleveland, OH, ⁷Dept of Surgery, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Cardiothoracic Surgery, University of Michigan School of Medicine, Ann Arbor, MI, ⁹Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA

5:15 PM (197) Predictors for Right Ventricular Failure After Bridge to Left Ventricular Assist Device by Extracorporeal Life Support; D. Tsyganenko, F. Hennig, F. Kaufmann, C. Starck, F. Schönrrath, V. Falk, M. Müller, T. Krabatsch, E. Potapov. Dept of Cardiothoracic and Vascular Surgery, DHZB, Berlin, Germany

5:30 PM (198) The Global Experience With Biventricular Support Using Two HeartMate 3 Ventricular Assist Devices; J. Lavee¹, J. Mulzer², T. Krabatsch², S. Marasco³, D. McGiffin³, J. Garbade⁴, J. D. Schmitto⁵, D. Zimpfer⁶, E. V. Potapov². ¹Leviev Heart Center, Sheba Medical Center Tel Aviv University, Tel Aviv, Israel, ²Cardiac, Thoracic and Vascular Surgery, German Heart Center, Berlin, Germany, ³Cardiothoracic Surgery & Transplantation, The Alfred, Melbourne, Australia, ⁴University of Leipzig Heart Center, Leipzig, Germany, ⁵Dept. of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, ⁶Dept. of Cardiac Surgery, Medical University Vienna, Vienna, Austria

5:45 PM (199) Minimally Invasive Left Ventricular Assist Device Implantation is Associated with Decreased Postoperative Right Ventricular Failure; C. Pasrija¹, M. A. Sawan¹, E. Sorensen², H. Voorhees², L. Wang³, F. M. Boulos¹, L. DiChiacchio¹, V. Ton³, E. Feller³, D. J. Kaczorowski¹, B. P. Griffith¹, S. M. Pham⁴, Z. N. Kon¹. ¹Division of Cardiac Surgery, University of Maryland, Baltimore, MD, ²Division of Clinical Engineering, University of Maryland Medical Center, Baltimore, MD, ³Medicine, University of Maryland, Baltimore, MD, ⁴Cardiothoracic Surgery, Mayo Clinic, Jacksonville, FL

4:30 PM - 6:00 PM

ORAL SESSION 22: Trials and Treatments in Lung Transplantation

Location: Mediterranean ABC

Target Audience: LTX, PHARM

Chairs: Geert M Verleden, MD, PhD, and Christian A Bermudez, MD

4:30 PM (200) A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation (NCT01915082); R. Vos, A. Van Herck, B. M. Vanaudenaerde, S. E. Verleden, D. E. Van Raemdonck, A. Frick, A. P. Neyrinck, G. M. Verleden. *University Hospitals Leuven, Leuven, Belgium*

4:45 PM (201) A Randomized Controlled Trial of Naloxone for Optimization of Hypoxemia in Lung Donors; R. Dhar¹, A. Paramesh², G. Marklin³. ¹Neurology, Washington University in St. Louis School of Medicine, St Louis, MO, ²Surgery, Tulane University, New Orleans, LA, ³Mid-America Transplant, St Louis, MO

5:00 PM (202) Improved Lung Preservation in the Organ Care System in a Porcine Transplantation Setting Modelled After the INSPIRE Trial Triggers a Proregulatory T Cell Phenotype; J. Salman, R. Sanz, T. Siemeni, K. Jansson, A. Knoefel, F. Ius, W. Sommer, k. Hoeffler, A. Haverich, I. Tudorache, C. Falk, G. Warnecke. *hannover medical school, Hannover, Germany*

5:15 PM (203) Human Leukocyte Antigen Allosensitization in Patients Bridged to Lung Transplantation with Extracorporeal Membrane Oxygenation; A. Courtwright¹, M. Molina², L. Gardo¹, V. N. Ahya¹, J. D. Christie¹, J. M. Diamond¹, D. Hadjiliadis¹, J. Lee¹, N. Patel¹, M. Porteous¹, E. Cantu², M. Crespo¹, C. Bermudez². ¹Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, ²Dept of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

5:30 PM (204) Influence of an IgM-enriched Intravenous Immunoglobulin-based Treatment on Regulatory T Cells in Patients with Donor Specific Antibodies After Lung Transplantation; F. Ius¹, W. Sommer¹, A. Knoefel¹, J. Salman¹, T. Nakagiri¹, T. Siemeni¹, C. Kuehn¹, M. Avsar¹, D. Bobylev¹, R. Poyanmehr¹, T. Welte², A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Respiratory Medicine, Hannover Medical School, Hannover, Germany

5:45 PM (205) Anastomotic Outcomes in Idiopathic Pulmonary Fibrosis Patients Receiving Anti-Fibrotic Therapy: Experience of the Australian Lung Transplant Collaborative; J. Mackintosh¹, M. Munsif², C. Thomson³, M. Musk⁴, G. Snell², A. Glanville³, D. Chambers¹, P. Hopkins¹. ¹Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia, ²Lung Transplant Service, The Alfred, Melbourne, Australia, ³Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, ⁴Lung Transplant Unit, Royal Perth Hospital, Perth, Australia

4:30 PM - 6:00 PM

ORAL SESSION 23: Getting to the Heart and Lung of the Matter: Drugs in Thoracic Transplant

Location: Clio/Thalie/Erato

Target Audience: PHARM, HTX, ID, LTX, NNSAH

Chairs: Michael Shullo, PharmD, and Fay S Burrows, BPharm

4:30 PM (206) *Polymorphisms in the KCNJ11 Gene are Associated with New Onset Diabetes After Lung Transplantation*; E. Henriksen¹, D. R. Calabrese², R. Florez¹, K. W. Dewey¹, C. Hui¹, L. Leard², J. Singer², S. Hays², J. Kukreja³, J. Golden², J. R. Greenland⁴. ¹University of California San Francisco, San Francisco, CA, ²Division of Pulmonology, University of California San Francisco, San Francisco, CA, ³Dept of Surgery, University of California San Francisco, San Francisco, CA, ⁴VA Health Care System, San Francisco, CA

4:45 PM (207) *Effect of Marijuana Exposure on Calcineurin Inhibitor Dose to Trough Ratios in Heart Transplant Recipients*; C. Shakowski¹, S. Freedman², K. Schwarz¹, R. L. Page II³. ¹Dept of Pharmacy, University of Colorado Hospital, Aurora, CO, ²Dept of Pharmacy, University of Maryland Medical Center, Baltimore, MD, ³Dept of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy, Aurora, CO

5:00 PM (208) *Outcomes Associated With Mammalian Target of Rapamycin (mTOR) Inhibitors in Heart Transplant Recipients: A Meta-analysis*; N. Lange¹, W. L. Baker², M. Shullo³, F. Latif¹, S. Restaino¹, K. Takeda¹, H. Takayama¹, Y. Naka¹, M. Farr¹, P. Colombo¹, D. L. Jennings¹. ¹Columbia University Medical Center, New York, NY, ²University of Connecticut, Storrs, CT, ³University of Pittsburgh Medical Center, Pittsburgh, PA

5:15 PM (209) *Optimizing Immunosuppression: Steroid Weaning Strategies in Heart Transplant (HT)*; T. Khuu, M. Kamath, J. Smith, J. Fuentes, M. Cadeiras, A. Nsair, A. Baas, L. Sweet, S. Fraschilla, D. Cruz, M. Moore, M. C. Deng, A. Ardehali, E. C. DePasquale. UCLA, Los Angeles, CA

5:30 PM (210) *Effect of Everolimus and CNI Reduction on Rejection, CLAD, and Death in Thoracic Transplant Recipients*; R. A. Cartus¹, C. J. Iasella¹, C. A. Moore¹, M. R. Morrell¹, J. Hayanga², N. Shigemura³, A. Zeevi¹, J. F. McDyer¹, C. R. Ensor¹. ¹University of Pittsburgh, Pittsburgh, PA, ²West Virginia University, Morgantown, WV, ³Temple University, Philadelphia, PA

5:45 PM (211) *Stabilization of Lung Function and Survival Improvement By Aerosolized Liposomal Cyclosporine A (L-CsA) for Bronchiolitis Obliterans Syndrome*; A. Iacono¹, M. Wijesinha², K. Rajagopal³, N. Murdock¹, T. Hughes¹, S. McGee¹, I. Timofte⁴, J. Kim⁴, J. Rinaldi¹, M. Terrin². ¹Shock Trauma and Transplantation, University of Maryland, Baltimore, MD, ²Epidemiology, University of Maryland, Baltimore, MD, ³Cardiac Surgery, Memorial Hermann Hospital, Houston, TX, ⁴Medicine, Division of Pulmonary & Critical Care Medicine, University of Maryland, Baltimore, MD

4:30 PM - 6:00 PM

ORAL SESSION 24: Walking the Tightrope in Heart Transplantation: Outcomes in High Risk Population

Location: Uranie/Calliope

Target Audience: HTX, BSTR, EEP, HF, MCS, NHSAH, PATH, PEDS

Chairs: Joseph Rogers, MD, and Eulalia Roig, MD

4:30 PM (212) *Optimizing Outcomes after Heart Transplantation in Patients with Cardiac Amyloidosis - A Single Center Analysis of 48 Patients in 2 Eras*; M. M. Kreusser¹, A. V. Kristen¹, S. O. Schönland², P. Blum¹, B. Schmack³, A. Ruhparwar³, U. Hegenbart², H. A. Katus¹, P. W. Raake¹. ¹Cardiology, University of Heidelberg, Heidelberg, Germany, ²Hematology, University of Heidelberg, Heidelberg, Germany, ³Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

4:45 PM (213) *Cardiac Transplantation with Delayed Autologous Stem Cell Transplant in Patients with Cardiac Amyloidosis*; B. H. Trachtenberg¹, R. Araujo-Gutierrez¹, K. Rammurti², L. Rice², A. Bhimaraj¹, A. Guha¹, M. H. Park¹, I. Hussain¹, E. E. Suarez¹, B. Bruckner¹, J. D. Estep¹. ¹DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX, ²Hematology, Houston Methodist Hospital, Houston, TX

5:00 PM (214) *Heart Transplant Outcomes in Patients Listed for Kidney Transplant*; M. Y. Kamath, J. Wilson, N. Bassi, S. Fraschilla, A. Iyengar, M. Moore, S. Shah, D. Vucicevic, K. Pandya, M. Deng, A. Ardehali, E. Depasquale. UCLA, Los Angeles, CA

5:15 PM (215) *Outcomes in Heart Transplantation for Adults with Congenital Heart Disease- Contemporary Analysis and Development of a Risk Model - ReDoT Score*; M. R. Robinson¹, J. Rossano², W. Cherikh³, A. Kucheryavaya³, G. H. Oliveira¹, J. Stehlik⁴. ¹Cardiology, University Hospitals Cleveland Medical Center, Cleveland, OH, ²Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ³United Network of Organ Sharing, Richmond, VA, ⁴Cardiology, University of Utah Health, Salt Lake, UT

5:30 PM (216) *Pregnancy Outcomes in 91 Female Heart Transplant Recipients*; L. R. Punnoose¹, L. A. Coscia², D. P. Armenti², S. Costantinescu², M. J. Moritz². ¹Cardiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Transplant Pregnancy Registry International, Gift of Life Institute, Philadelphia, PA

5:45 PM (217) *Pre-Transplant Estimated Glomerular Filtration Rate Less Than 40 Provides Similar Risks of Post-transplant Mortality Both in LVAD and Non-LVAD Heart Transplant Recipients*; M. Cevasco, M. Ando, H. Takayama, P. A. Kurlansky, A. R. Garan, V. K. Topkara, M. Yuzefpolskaya, P. C. Colombo, M. Farr, Y. Naka, K. Takeda. Columbia University Medical Center, New York, NY

4:30 PM - 6:00 PM

ORAL SESSION 25: Philip K. Caves Award Candidate Presentations

Location: Hermes

Target Audience: BSTR, HTX, LTX, PATH

Chairs: Stephan M Ensminger, MD, DPhil, and Kathleen L Grady, PhD, APN, FAAN

4:30 PM (32) *Human Thrombomodulin Expression Confers Prolonged Graft Survival over Costimulation Blockade Alone in a Pig-to-Baboon Heterotopic Cardiac Xenotransplant Model*; L. DiChiacchio¹, A. Singh¹, J. Chan², P. Corcoran², B. Lewis¹, M. Thomas², D. Ayares³, K. Horvath², K. Horvath², M. Mohiuddin¹. ¹University of Maryland Medical Center, Baltimore, MD, ²Cardiothoracic Surgery Research Program/National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, ³Revivicor, Inc, Blacksburg, VA

4:45 PM (219) *Donor HLA-G Single Nucleotide Polymorphisms Predict Post-lung Transplant Mortality*; J. Lazarte¹, J. Ma², T. Martinu², L. Levy², W. Klement², M. White², J. Pelling², Z. Guan², S. Azad², J. Tikkanen², V. Rao³, G. Tomlinson², D. Delgado³, S. Keshavjee², S. Juvet². ¹Medicine, University Health Network, Toronto, ON, Canada, ²Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ³Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada

5:00 PM (34) *Heart En Bloc Thymus Cotransplantation in NHPs Controls Cellular but not Humoral Alloreactivity*; J. O., W. Sommer, K. Pruner, J. T. Paster, I. M. Hanekamp, A. Dehnadi, I. Rosales, R. N. Smith, R. B. Colvin, G. Benichou, J. S. Allan, J. C. Madsen. Center for Transplantation Sciences, MGH, Boston, MA

5:15 PM (221) *Dectin-1 Genotypes are Associated with Decreased CLAD-Free Survival in Lung Transplant Recipients*; D. R. Calabrese¹, T. Chong², J. Singer¹, D. Torgerson², S. Hays¹, J. Golden¹, J. Kukreja³, J. R. Greenland⁴. ¹Division of Pulmonology, University of California San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³Dept of Surgery, University of California San Francisco, San Francisco, CA, ⁴VA Health Care System, San Francisco, CA

5:30 PM (222) *Pre-transplant Ex Vivo Recipient-derived Regulatory T Cell Therapy of the Lung Allograft*; E. Miyamoto, T. Martinu, A. Ohsumi, K. Boonstra, B. Joe, M. Liu, M. Cypel, S. Keshavjee, S. Juvet. Latner Thoracic Surgery Research Laboratories, Toronto, ON, Canada

5:45 PM (223) *Tolerance to A-Antigen After Treatment of Infant or Adult Mice with MHC-Matched A-Expressing Blood Cells*; J. Fersovich¹, B. Motyka², B. Lamarche¹, M. Sosniuk¹, I. Adam², J. Pearcey², K. Tao², C. W. Cairo³, P. J. Cowan⁴, L. J. West². ¹Dept Pediatrics, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, ²Dept Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, ³Dept Chemistry, University of Alberta, Edmonton, AB, Canada, ⁴Immunology Research Centre, University of Alberta, Melbourne, Australia

4:30 PM - 6:00 PM

ORAL SESSION 26: The Perfect Match: Donor and Recipient Effects on Pediatric Thoracic Outcomes

Location: Mediterranean 6

Target Audience: PEDS, EEP, HTX, LTX, NNSAH

Chairs: Carol K Conrad, MD, and Brian Feingold, MD, MS

4:30 PM (224) Incidence, Predictors and Outcomes of Severe Primary Graft Dysfunction in Pediatric Heart Transplant Recipients; E. L. Profita¹, K. Gauvreau¹, P. Rycus², R. Thiagarajan¹, T. P. Singh¹. ¹Dept of Cardiology, Boston Children's Hospital, Boston, MA, ²ELSO Registry, University of Michigan, Ann Arbor, MI

4:45 PM (225) Number of Refusals Due to Donor Quality Does Not Impact Lung Transplantation Outcomes; E. Singh¹, M. G. Schechter², C. Towe², R. Rizwan², R. Bryant III², J. Tweddell², J. K. Steger², D. L. Morales², F. Zafar². ¹University of Cincinnati, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH

5:00 PM (226) Donor to Recipient Predicted Total Lung Capacity Ratio Matching Predicts Survival after Lung Transplantation in Pre-Adolescent Patients; C. D. Fraser¹, X. Zhou¹, J. C. Grimm¹, A. Suarez Pierre¹, J. T. Magruder¹, C. Lui¹, E. L. Bush¹, N. Hibino¹, L. A. Vricella¹, C. Merlo². ¹Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD, ²Dept of Medicine, The Johns Hopkins Hospital, Baltimore, MD

5:15 PM (227) A Novel Recipient Risk Score to Predict 1-Year Mortality in Pediatric Heart Transplantation; C. D. Fraser, J. C. Grimm, X. Zhou, C. Lui, A. Suarez Pierre, T. C. Crawford, J. T. Magruder, M. L. Jacobs, N. Hibino, L. A. Vricella. Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD

5:30 PM (228) Non-standard Donor Organs in Pediatric Lung Transplantation Have No Negative Impact on Recipients Outcome; W. Sommer¹, F. Ius¹, N. Schwerk², C. Müller², D. Bobylev¹, C. Kühn¹, M. Avsar¹, J. Salman¹, T. Siemeni¹, A. Horke¹, A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, ²Pediatric Pneumology, Hannover Medical School, Hannover, Germany

5:45 PM (229) A New Combined Model for End-Stage Liver Disease Excluding INR (CMELD-XI) Score Better Predicts Pediatric Heart Transplant Outcomes; S. Choudhry¹, K. E. Hosek¹, S. W. Denfield¹, J. F. Price¹, A. G. Cabrera¹, H. P. Tunuguntla¹, V. R. Dharnidharka², C. E. Canter², W. J. Dreyer¹. ¹Texas Children's Hospital, Baylor College of Medicine, Houston, TX, ²Washington University School of Medicine, Saint Louis, MO

6:15 PM - 7:15 PM

MINI ORAL 07: Mechanical Circulatory Support: Surgical Techniques

Location: Athena

Target Audience: MCS, NNSAH

Chairs: Mustafa Ozbaran, MD, and Vivek Rao, MD, PhD

6:15 PM (230) Minimally-invasive Implantation of a Centrifugal Continuous-flow Left Ventricular Assist Device is Associated With Decreased Early Right Ventricular Failure; M. Psotka¹, V. Selby², M. Janmohamed², T. De Marco², L. Klein², G. Wieselthaler³. ¹Advanced Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA, ²Cardiology, UCSF, San Francisco, CA, ³Cardiothoracic Surgery, UCSF, San Francisco, CA

(231) WITHDRAWN

6:20 PM (1231) Changes in Metabolic Profiles Following Left Ventricular Assist Device Implantation; A. Nguyen¹, T. Imamura¹, B. Chung¹, N. Narang¹, L. Holzhauser¹, C. LaBuhn¹, D. Rodgers¹, T. Ota¹, T. Song¹, M. Costanzo², S. Kalantari¹, N. Sarswat¹, J. Raikhelkar¹, G. Kim¹, V. Jeevanandam¹, G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Advocate Medical Group, Chicago, IL

6:25 PM (232) Relation Between Intraventricular HVAD Position and Pump Thrombosis; P. Aigner¹, T. Schloeglhofer², L. Plunger³, D. Beitzke⁴, A. Wielandner⁴, H. Schima², D. Wiedemann⁵, D. Zimpfer⁵, F. Moscato¹. ¹Center for Medical Physics and Biomedical Engineering, Medical Univ of Vienna, Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria, ²Center for Medical Physics and Biomedical Engineering, Dept of Cardiac Surgery, Medical Univ of Vienna, Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria, ³Center for Medical Physics and Biomedical Engineering, Medical Univ of Vienna, Vienna, Austria, ⁴Dept of Radiology and Nuclear Medicine, Medical Univ of Vienna, Vienna, Austria, ⁵Dept of Cardiac Surgery, Medical Univ of Vienna, Vienna, Austria

6:30 PM (233) Early and Late Outcomes of Subcostal Exchange of HeartMate II Left Ventricular Assist Device: A Word of Caution; S. N. Yu, H. Takayama, J. Han, A. R. Garan, V. K. Topkara, M. Yuzefpolskaya, P. C. Colombo, Y. Naka, K. Takeda. Columbia University Medical Center, New York, NY

6:35 PM (234) A Comparison of Surgical Outcomes for LVAD Implantation by Minimally Invasive Surgery and Conventional Sternotomy; S. D. Miller¹, A. W. Cheung², J. Hong², J. G. Bashir², M. J. Kearns¹. ¹Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada, ²Dept of Surgery, University of British Columbia, Vancouver, BC, Canada

6:40 PM (235) Simplified, Less-Invasive LVAD Implantation in Redo Patients; M. O. Zembala, R. Antonczyk, J. Waszak, T. Niklewski, T. Wolny, M. Zembala. Cardiac Surgery and Transplantology, Silesian Center For Heart Disease, Zabrze, Poland

6:45 PM (236) Post-Heart-Transplant Outcome Following Successful Bridge to Heart Transplantation With CentriMag BiVAD Support; D. Schibilsky, A. Page, M. Zhu, P. Kaul, S. Messer, S. Bhagra, A. Kydd, S. Petit, C. Lewis, M. Berman, A. Ali, Y. Abu-Omar, P. Catarino, C. Sudarshan, D. Jenkins, J. Dunning, J. Parameshwar, S. Tsui. Dept of Transplantation, Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, United Kingdom

6:50 PM (237) Inflow Cannula Position is Associated with Improvement in Mitral Regurgitation After Left Ventricular Assist Device Implantation; C. Pasrija¹, E. Sorensen², M. A. Sawan³, H. Voorhees², D. Tran¹, L. Wang³, L. DiChiacchio¹, V. Ton³, E. Feller³, B. P. Griffith¹, Z. N. Kon¹, D. J. Kaczorowski¹. ¹Division of Cardiac Surgery, University of Maryland, Baltimore, MD, ²Division of Clinical Engineering, University of Maryland Medical Center, Baltimore, MD, ³Medicine, University of Maryland, Baltimore, MD

6:55 PM (238) Survival Factors for Patients With Biventricular Failure on CentriMag Biventricular Support as Bridge to Decision or Transplant; R. Yanagida¹, M. Camacho¹, A. Okoh², C. Gidea³, M. Strueber¹, M. J. Zucker³. ¹Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, NJ, ²Surgery, Newark Beth Israel Medical Center, Newark, NJ, ³Medicine, Newark Beth Israel Medical Center, Newark, NJ

7:00 PM (239) Use of Protek Duo Cannula (RVAD) for Percutaneous Support in Various Clinical Settings. A Safe and Effective Option; J. A. Gomez-Abraham¹, S. Brann¹, V. Aggarwal², B. O'Neill², R. Alvarez², E. Hamad², Y. Toyoda¹. ¹Cardiothoracic Surgery, Temple University School of Medicine Div of Cardiothoracic Surgery, Philadelphia, PA, ²Cardiology, Temple University School of Medicine Div of Cardiothoracic Surgery, Philadelphia, PA

7:05 PM (240) Berlin Heart Outcomes in Single Ventricle Patients: Where are we Now?; J. C. Dykes¹, M. S. Bleiweis², K. Maeda³, S. Chen¹, D. N. Rosenthal¹, C. Tjossem⁴, J. Murray⁵, C. S. Almond¹. ¹*Pediatrics, Stanford University, Palo Alto, CA*, ²*Cardiothoracic Surgery, University of Florida, Gainesville, FL*, ³*Cardiothoracic Surgery, Stanford University, Palo Alto, CA*, ⁴*Berlin Heart, Woodlands, TX*, ⁵*Pediatrics, Lucile Packard Children's Hospital, Palo Alto, CA*

7:10 PM (241) Survival and Readmission Rates Following LVAD Exchange; T. Imamura, D. Rodgers, A. Nguyen, B. Chung, N. Narang, L. Holzhauser, C. Juricek, T. Ota, T. Song, G. Kim, J. Raikhelkar, S. Kalantari, N. Sarswat, V. Jeevanandam, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*

6:15 PM - 7:15 PM

MINI ORAL 08: Heart Transplantation: PGD and CAV

Location: Mediterranean ABC

Target Audience: HTX, BSTR, EEP, HF, NNSAH, PATH

Chairs: Bruno M. Meiser, MD, and Livia Goldraich, MD

6:15 PM (242) Donor Plasma VEGF as a Biomarker for Early Graft Failure After Heart Transplantation; E. Holmström¹, R. Tuuminen¹, R. Krebs¹, E. Rouvinen¹, A. Nykänen², K. Lemström². ¹Transplantation Laboratory, University of Helsinki, Helsinki, Finland, ²Transplantation Laboratory, Cardiothoracic Surgery, Helsinki University Hospital, Helsinki, Finland

6:20 PM (243) Validation of a Model to Predict Primary Graft Dysfunction (PGD) after Adult Heart Transplantation in the United Kingdom; S. Avtaar Singh¹, N. Banner², S. Rushton³, C. Berry⁴, N. Al-Attar¹. ¹Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, ²Cardiology and Mechanical Circulatory Support, Harefield Hospital, London, United Kingdom, ³Cardiothoracic Advisory Group Statistician, National Health Service Blood and Transplant, Bristol, United Kingdom, ⁴Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

6:25 PM (244) Impact of ISHLT Left Ventricular Primary Graft Dysfunction on Survival After Heart Transplant; J. J. Martinez, M. Peltz, J. E. Pruszynski, L. C. Huffman, P. Bajona, M. A. Wait, J. S. Murala, M. E. Jessen, W. S. Ring. Cardiothoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX

6:30 PM (245) Proinflammatory Cytokines as Biomarkers for Severe Primary Graft Dysfunction After Heart Transplantation; E. Holmström¹, R. Tuuminen¹, S. Syrjälä¹, R. Krebs¹, E. Rouvinen¹, A. Nykänen², K. Lemström². ¹Transplantation Laboratory, University of Helsinki, Helsinki, Finland, ²Cardiothoracic Surgery, Helsinki University Hospital, Helsinki, Finland

6:35 PM (246) Discontinuing Amiodarone Treatment Prior to Heart Transplant May Lower Incidence of Severe Primary Graft Dysfunction; B. Hoemann, H. Takayama, M. Wright, D. L. Jennings, J. Han, S. Restaino, P. C. Colombo, M. Farr, Y. Naka, K. Takeda. Columbia University College of Physicians and Surgeons, New York City, NY

6:40 PM (247) Comparison of Predictors and Outcomes of Severe LV and RV Primary Graft Dysfunction in Heart Transplant Recipients; J. A. Fried¹, L. Truby¹, S. Restaino¹, G. Rubin¹, K. Clerkin¹, K. Takeda², H. Takayama², M. Farr¹, Y. Naka², P. C. Colombo¹, B. Fine¹. ¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY

6:45 PM (248) Intracoronary Intimal Thickness in Recipients of Hepatitis C-Positive Donor Hearts; S. Zalawadiya¹, J. Lindenfeld¹, E. Haddad², M. Wigger¹, M. Danter³, M. Keebler¹, M. Brinkley¹, J. Menachem¹, S. B. Sacks¹, H. Ooi¹, R. Perri⁴, C. Chung⁴, J. Awad⁴, S. Smith¹, R. Hayes¹, H. O'Dell⁴, C. Darragh⁵, S. Ruzevich-Scholl¹, K. Schlendorf¹. ¹Heart failure and transplantation, Vanderbilt University Medical Center, Nashville, TN, ²Cardiovascular medicine, Vanderbilt University Medical Center, Nashville, TN, ³Cardiothoracic surgery, Vanderbilt University Medical Center, Nashville, TN, ⁴Gastroenterology and hepatology, Vanderbilt University Medical Center, Nashville, TN, ⁵Vanderbilt University Medical Center, Nashville, TN

6:50 PM (249) Detecting Early Cardiac Allograft Vasculopathy Using Highly Automated 3D Coronary Optical Coherence Tomography Segmentation Analysis; M. Pazdernik¹, Z. Chen², H. Bedanova³, J. Kautzner¹, V. Melenovsky¹, V. Karmazin¹, I. Malek¹, A. Tomasek³, E. Ozabalova³, J. Krejci⁴, J. Franekova¹, A. Wahle², H. Zhang², T. Kovarnik⁵, M. Sonka². ¹IKEM, Prague, Czech Republic, ²Dept of Biomedical Imaging, The University of Iowa, Iowa City, IA, ³Cardiovascular and Transplantation Surgery, Brno, Czech Republic, ⁴Dept of Cardiovascular Diseases, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic, ⁵2nd Dept of Internal Medicine, Dept of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

6:55 PM (250) Human Immunodeficiency Virus (HIV), Heart Transplantation And Mechanical Circulatory Support (MCS : Where Do We Stand?; S. Madan¹, S. R. Patel¹, K. Patel², D. B. Sims¹, O. Saeed¹, S. Forest³, W. Jakobleff³, S. Murthy¹, J. J. Shin¹, D. J. Goldstein³, U. P. Jorde¹. ¹Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

7:00 PM (251) Induction Immunosuppressive Therapy in Cardiac Transplantation: A Systematic Review and Meta-analysis; A. Briasoulis¹, C. Inampudi¹, P. Alvarez¹, D. C. Voruganti², T. Ando³, J. K. Bhama⁴. ¹Dept of Internal Medicine - Cardiology, University of Iowa Hospitals and Clinics, Iowa, IA, ²Dept of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa, IA, ³Dept of Internal Medicine - Cardiology, Wayne State University, Harper hospital/ Detroit Medical Center, Division of Cardiology, Detroit, MI, ⁴Dept of Surgery - Cardiothoracic surgery, University of Iowa Hospitals and Clinics, Iowa, IA

(252) PROMOTED TO ORAL

7:05 PM (886) Donor Simvastatin Treatment Alters the Gene Expression Profile of Human Cardiac Allografts During Ischemia and Reperfusion; R. Krebs¹, M. Kankainen², E. Holmström¹, J. Lukac¹, T. Ojala², P. Mattila², A. Nykänen¹, K. Lemström¹. ¹Transplantation Laboratory, University of Helsinki, Helsinki, Finland, ²Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

7:10 PM (253) Panel Reactive Antibodies and Outcomes Following Heart Transplantation in Adults with Congenital Heart Disease; L. Alshawabkeh¹, T. P. Singh², A. R. Opotowsky³, W. S. Cherikh⁴, A. Y. Kucheryavaya⁴, M. J. Landzberg³, M. A. Curry⁴, J. W. Rossano⁵, M. M. Givertz⁶. ¹Cardiovascular Medicine, University of California San Diego and Brigham & Women's Hospital, Harvard Medical School, La Jolla, CA, ²Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ³Cardiovascular Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁴United Network for Organ Sharing, Richmond, VA, ⁵Cardiology, Children's Hospital of Philadelphia, University of Pennsylvania, PA, ⁶Division of Cardiovascular Medicine, Dept of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

6:15 PM - 7:15 PM

MINI ORAL 09: Lung Transplantation: Allograft Function

Location: Clio/Thalie/Erato

Target Audience: LTX, PATH

Chairs: Michael Perch, MD, and Gundeep S Dhillon, MD

6:15 PM (254) Importance of Donor Hypoxemia in Lung Transplantation: A Comprehensive Analysis of Serial Blood Gases; R. Daulton¹, C. Towe², M. M. Hossain³, M. Schechter², R. Bryant III¹, D. L. Morales¹, F. Zafar¹.

¹Cardiothoracic Surgery, Children 's Hospital Med Ctr, Cincinnati, OH, ²Pulmonology, Children 's Hospital Med Ctr, Cincinnati, OH, ³Biostatistics and Epidemiology, Children 's Hospital Med Ctr, Cincinnati, OH

6:20 PM (255) CD8 T Effector Memory T Cells as Predictive Biomarker of Severe Acute Rejection in Lung

Transplantation; J. Irure¹, M. Á. Ballesteros², D. Merino³, D. Iturbe⁴, V. Mora⁴, S. Fernández-Rozas⁴, R. Mons⁵, E. Asensio¹, J. J. Gómez-Román⁶, J. Cifrián⁴, M. López-Hoyos¹, D. San Segundo¹. ¹Immunology, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Intensive Care, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain, ³University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁴Pneumology, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁵Surgery, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁶Pathology, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain

6:25 PM (256) Pitfalls in the Real-World Diagnosis and Management of Clinical Antibody Mediated Rejection of

the Lung; D. Abelson¹, A. Awford¹, S. Garnett², M. Plit¹, A. Havryk¹, R. Pearson¹, M. Benzimra¹, M. A. Malouf¹, A. Rigby¹, A. R. Glanville¹. ¹Lung Transplantation Unit, St Vincent's Hospital, Sydney, Australia, ²Integrative Biomedical Sciences, University of Capetown, Capetown, South Africa

6:30 PM (257) Treatment of Antibody Mediated Rejection in Lung Transplantation : Impact of Antibody Depletion

Strategy; J. Le Pavec¹, A. Hanna¹, J. Taupin², P. Pradère¹, S. Feuillet¹, A. Crutu¹, F. Leroy Ladurie¹, D. Fabre¹, O. Mercier¹, S. Mussot¹, E. Fadel¹, F. Lunardi³, P. Dorfmueller¹, F. Calabrese³. ¹Service de chirurgie thoracique, Hôpital Marie Lannelongue, Le Plessis Robinson, France, ²Service d'histocompatibilité, Hôpital Saint Louis, Paris, France, ³Dept of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy

6:35 PM (258) Observations on the Early Natural History of Auto- and Allospecific Antibodies After Lung

Transplantation; D. Abelson, A. Mullin, M. Benzimra, A. Havryk, L. B. Honeysett, M. A. Malouf, M. Plit, A. R. Glanville. Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia

6:40 PM (259) Long-term Results of an IgM-enriched Human Immunoglobulin-based Therapy for Early Donor

Specific Antibodies After Lung Transplantation; F. Ius¹, W. Sommer¹, M. Verboom², M. Hallensleben², J. Salman¹, T. Siemeni¹, C. Kuehn¹, M. Avsar¹, D. Bobylev¹, R. Poyanmehr¹, N. Schwerk³, C. Mueller³, A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Transfusion Medicine, Hannover Medical School, Hannover, Germany, ³Paediatrics, Hannover Medical School, Hannover, Germany

6:45 PM (260) Extracorporeal Photopheresis as Treatment Option of Chronic Lung Allograft Dysfunction. Is ECP

the Therapy of the Future?; A. Benazzo¹, M. Landl², M. Mockenhuber¹, S. Schwarz¹, G. O. Murakoezy¹, C. O. Lambers¹, B. Moser¹, K. Hoetzenecker¹, J. O. Matilla Siguenza¹, G. O. Lang¹, S. Taghavi¹, W. Klepetko¹, P. Jaksch¹. ¹Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ²Thoracic Surgery, Medical University of Vienna, Wien, Austria

6:50 PM (261) Impact of Neutropenia on Survival in Lung Transplant Recipients Receiving Mycophenolate for

Immunosuppression; L. K. Tague¹, D. Byers¹, R. Hachem¹, A. Krupnick², D. Kreisel³, A. Gelman³. ¹Dept of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University in St. Louis, Saint Louis, MO, ²Dept of Surgery, Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA, ³Dept of Surgery, Division of Cardiothoracic Surgery, Washington University in St. Louis, Saint Louis, MO

6:55 PM (262) Eosinophils on Transbronchial Biopsies Are Predictive of Reduced Survival After Lung

Transplantation; D. R. Darley¹, J. Ma², P. Fiset¹, D. M. Hwang³, W. Klement¹, R. Zamel¹, S. Azad¹, J. M. Tikkanen¹, L. G. Singer¹, G. Tomlinson⁴, T. Martinu¹. ¹Lung Transplant, Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, ON, Canada, ²Lung Transplant, Biostatistics Research Unit, University Health Network, Toronto, ON, Canada, ³Pathology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada, ⁴Biostatistics Research Unit, Biostatistics Research Unit, University Health Network, Toronto, ON, Canada

7:00 PM (263) A Prospective Study of Coagulation Profile in Lung Transplantation; B. Saez-Gimenez¹, V. Cortina², M. Ramón¹, H. Sintés¹, C. Berastegui¹, M. Lopez-Meseguer¹, V. Monforte¹, C. Bravo¹, A. Santamaria¹, A. Roman³. ¹Lung - Transplant Unit, Hospital Vall Hebron, Barcelona, Spain, ²Hemostasis and Thrombosis Unit, Hospital Vall Hebron, Barcelona, Spain, ³Lung -Transplant Unit, Hospital Vall Hebron. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES)., Barcelona, Spain

7:05 PM (264) Donor Derived Cell Free DNA is Elevated With Pathogens That are Risk Factors For Chronic Lung Allograft Dysfunction; P. Shah¹, M. Rohly², A. Brown³, I. Timofte⁴, M. Nayyar⁵, A. Gandhi⁶, N. Kim⁶, A. Joshi⁷, A. Iacono⁴, S. Nathan³, R. Avery⁷, J. Orens⁸, S. Agbor-Enoh⁹, H. Valantine⁹. ¹Genomic Research Alliance for Transplantation (GRAfT), Johns Hopkins University, Baltimore, MD, ²Columbus State University, Athens, GA, ³GRAfT, Inova Fairfax Hospital, Fairfax, VA, ⁴GRAfT, University of Maryland, Baltimore, MD, ⁵University of Virginia, Charlottesville, VA, ⁶University of Maryland, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD, ⁸GRAfT, Johns Hopkins University, Baltimore, MD, ⁹GRAfT, National Institute of Health, Bethesda, MD

7:10 PM (265) Sustained Reduction in FEV1 Decline After Cessation of Extracorporeal Photopheresis; C. M. Shaver¹, A. Dunatchik², S. G. Norfolk¹, J. E. Loyd¹, M. P. Steele³, I. M. Robbins¹. ¹Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Veterans Affairs Administration, Salisbury, NC

6:15 PM - 7:15 PM

MINI ORAL 10: Mechanical Circulatory Support, Pharmacy & Pharmacology

Location: Uranie/Calliope

Target Audience: PHARM, BSTR, HTX, LTX, MCS, PEDS

Chairs: Christina Aquilante, PharmD, and Peter J Bergin, MBBS, FRACP

6:15 PM (266) *Direct Acting Oral Anticoagulant Utilization, Safety and Efficacy in Heart Transplant (HT)*; N. Bellam¹, M. Kamath¹, E. C. DePasquale¹, J. G. Smith², J. Fuentes², R. Ardehali¹, A. S. Baas¹, M. Cadeiras¹, M. Deng¹, M. H. Kwon³, A. Ardehali³, A. Nsair¹, T. Khuu². ¹Medicine - Cardiology, UCLA, Los Angeles, CA, ²Transplant Services, UCLA, Los Angeles, CA, ³Surgery - CardioThoracic, UCLA, Los Angeles, CA

6:20 PM (267) *Rapid High Dose Vaccine Series: Increasing Immunity to Hepatitis B in Lung Transplant Candidates*; M. A. Bowen, A. B. Cochrane, L. N. Albergottie-Barnes, A. Brown. Inova Lung Transplant Program, Inova Fairfax Hosp, Falls Church, VA

6:25 PM (268) *Thrombotic Events With PSI Based Immunosuppression in Cardiac Transplantation*; O. Witkowski¹, J. J. Teuteberg², A. Althouse³, M. Shullo⁴. ¹Pharmacy, The Ohio State Univ Wexner Med Ctr, Columbus, OH, ²Stanford Univ, Stanford, CA, ³Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴West Virginia Univ Medicine, Morgantown, WV

6:30 PM (269) *Safety and Efficacy of Rabbit Anti-Thymocyte Globulin Induction in Pediatric Patients Undergoing Cardiac Transplantation*; M. L. Sell¹, A. L. Haney¹, K. Sprott¹, A. Burnette², H. Henderson², A. Savage². ¹Pharmacy, Medical Univ of South Carolina, Charleston, SC, ²Pediatric Cardiology, Medical Univ of South Carolina, Charleston, SC

6:35 PM (270) *Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Lung Transplant Recipients: Short-Term Effects on Renal Function and Diabetic Parameters*; L. Godinas, L. Hulst, R. Vos, B. M. Vanaudenaerde, S. E. Verleden, D. E. Van Raemdonck, A. P. Neyrinck, G. M. Verleden. Univ Hosps Leuven, Leuven, Belgium

6:40 PM (271) *Effect of ABCC2 Polymorphisms on Tacrolimus Disposition in Heart Transplant Recipients*; K. Oreschak¹, K. M. Deininger¹, A. V. Ambardekar¹, R. L. Page II¹, J. Lindenfeld², C. L. Aquilante¹. ¹Univ of Colorado, Aurora, CO, ²Vanderbilt Univ, Nashville, TN

6:45 PM (272) *Impaired Baseline Renal Function May Not Influence Long Term Renal Function and Survival After LVAD Implantation*; H. Smail¹, H. A. Hassan², C. T. Bowles¹, U. Stock¹, P. Mohite¹, G. Benedetti¹, D. Garcia-saez¹, B. Zych¹, M. Hussain¹, A. Jothidasan¹, M. Motagudo-vera¹, M. Balakrishnan¹, F. De Robertis¹, A. R. Simon¹. ¹Cardiothoracic Transplantation and Mechanical Support, Harefield Hosp, Harefield, United Kingdom, ²Cardiothoracic Surgery, Menoufia Univ Hosp, Menoufia, Egypt

6:50 PM (273) *Pre-Cannulation IL-10 Levels Predict Who Will Develop Acute Kidney Injury on VA-ECMO*; M. Leacche, T. Boeve, S. Fitch, T. Timek, N. K. Manandhar Shresta, P. Wilton, G. Marco, S. Jovinge. Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI

6:55 PM (274) *LVAD Patients with CKD: Are Two Organs Better than One?*; M. Y. Kamath, A. Salimbangon, A. Chang, E. Moreno, M. Cadeiras, M. Deng, T. Khuu, A. Nsair, A. Ardehali, M. Kwon, E. Depasquale. UCLA, Los Angeles, CA

7:00 PM (275) *Predictors of Dialysis Dependent Renal Failure in Patients Requiring Total Artificial Heart Support*; K. Desai, D. G. Tang, M. Quader, E. J. Sawey, I. Tchoukina, L. Thacker, V. Kasirajan, K. B. Shah. Virginia Commonwealth Univ Health System, Richmond, VA

7:05 PM (276) *Failure to Improve Renal Function Following VAD Placement Predicts Renal Injury and Chronic Kidney Disease Following Cardiac Transplant*; S. A. Hollander¹, E. Pruitt², S. M. Sutherland³, R. S. Cantor², J. Kirklin², W. J. Ravekes⁴, R. Ameduri⁵, M. Chrisant⁶, T. Hoffman⁷, I. Lytrivi⁸, J. Conway⁹. ¹Pediatrics (Cardiology), Stanford Univ, Palo Alto, CA, ²Univ of Alabama at Birmingham, Birmingham, AL, ³Pediatrics (Nephrology), Stanford Univ, Palo Alto, CA, ⁴Johns Hopkins Univ School of Medicine (MDJH), Baltimore, MD, ⁵Univ of Minnesota Children's Hosp, Minneapolis, MN, ⁶Joe DiMaggio Children's Hosp, Hollywood, FL, ⁷Univ of North Carolina, Chapel Hill, NC, ⁸The Mount Sinai Medical Center, New York, NY, ⁹Univ of Alberta, Edmonton, AB, Canada

7:10 PM (277) *Reduced Pulsatility During Continuous Flow Left Ventricular Assist Device Does Not Affect Kidney Function*; M. Gallo, C. L. Valadon, J. R. Trivedi, M. S. Slaughter. *Dept of Cardiovascular and Thoracic Surgery, Univ of Louisville, Louisville, KY*

6:15 PM - 7:15 PM

MINI ORAL 11: Nursing, Health Science & Allied Health, Pediatrics

Location: Hermes

Target Audience: NNSAH, HF, HTX, LTX, MCS, PEDS

Chairs: Annette J. Devito Dabbs, PhD, RN, and Melanie D Everitt, MD

6:15 PM (278) *Reduced Body Weight, Improved Physical Activity and Healthier Eating with Fitness Intensive Therapy (Get FIT) vs. Get FIT+: A Feasibility Study*; L. S. Evangelista¹, M. Cacciata¹, D. Lombardo², A. Stromberg¹.
¹Sue & Bill Gross School of Nursing, Univ of California Irvine, Irvine, CA, ²School of Medicine, Univ of California Irvine, Irvine, CA

6:20 PM (279) *Acute Inpatient Rehabilitation Facilitates Post-Implant Recovery of High-Risk LVAS Recipients*; E. N. Lyons, K. A. Frankel, D. C. Turno, L. Coakley, M. Hickey, F. Melanson, K. Montoya, E. Olanda, D. S. Medina, M. R. Mehra, S. K. Singh, M. M. Givertz, G. C. Stewart. *Brigham & Women's Hosp, Boston, MA*

6:25 PM (280) *High-Intensity Interval Training Improves Exercise Performance in Patients with LVAD*; M. Alvarez Villela, T. Chinnadurai, K. Salkey, A. Furlani, M. Yanamandala, A. Luke, C. Castillo, M. Taveras, D. Sims, O. Saeed, J. Shin, I. Pina, U. Jorde, S. Patel. *Cardiology, Montefiore Medical Center, New York, NY*

6:30 PM (281) *A Single Centre UK Experience of Incorporating Urgently Listed Inotrope and Ventricular Assist Device Patients into a Cardiac Rehabilitation Programme Pre-Transplant*; H. Probert, J. Copping, A. Bachtler, G. Donovan, C. O'Sullivan. *Cardiac Rehab, Harefield Hosp, Harefield, United Kingdom*

6:35 PM (282) *Frailty Assessment in Lung Transplant Candidates: The Use of the Short Performance Physical Battery*; A. L. Carswell¹, C. L. Pereira¹, A. M. Roberts¹, M. A. Sanchez¹, M. R. Carby², A. R. Simon², A. K. Reed².
¹Rehabilitation and Therapies, Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom, ²Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom

6:40 PM (283) *Acute Skeletal Muscle Wasting and Relation to Physical Function in Patients Requiring Extracorporeal Membrane Oxygenation (ECMO)*; K. Hayes¹, A. E. Holland², V. A. Pellegrino³, S. Mathur⁴, C. L. Hodgson⁵. ¹Physiotherapy Dept, Alfred Hosp, Melbourne, Australia, ²Discipline of Physiotherapy, La Trobe Univ, Melbourne, Australia, ³Intensive Care Dept, Alfred Hosp, Melbourne, Australia, ⁴Dept of Physical Therapy, Univ of Toronto, Toronto, ON, Canada, ⁵Australian and New Zealand Intensive Care Research Ctr, Monash Univ, Melbourne, Australia

6:45 PM (284) *Early and Continued Improvement in Cognition in Response to Left Ventricular Assist Device Implantation*; C. S. Lee¹, K. L. Grady², J. M. Gelow³, C. V. Chien⁴, S. O. Hiatt¹, J. O. Mudd³. ¹School of Nursing, OHSU, Portland, OR, ²Feinberg School of Medicine, Northwestern Univ, Evanston, IL, ³Knight Cardiovascular Institute, OHSU, Portland, OR, ⁴REX Healthcare, Univ of North Carolina, Raleigh, NC

6:50 PM (285) *Changes in Sexual Activity Among Patients Supported With an Implantable Left Ventricular Assist Device in Japan*; N. P. Kato¹, Y. Kagami², M. Nemoto², M. Endo², M. Hatano¹, M. Ono³, T. Jaarsma⁴, K. Kinugawa⁵.
¹Therapeutic Strategy for Heart Failure, Univ of Tokyo, Tokyo, Japan, ²Organ Transplantation, Univ of Tokyo Hosp, Tokyo, Japan, ³Cardiovascular Surgery, Univ of Tokyo, Tokyo, Japan, ⁴Social and Welfare Studies, Linköping Univ, Linköping, Sweden, ⁵The Second Dept of Internal Medicine, Univ of Toyama, Toyama, Japan

6:55 PM (286) *Frailty: Does it Predict Length of Stay in Hosp Post Lung Transplant*; A. F. Jackson¹, L. Painter², I. S. Fontanilla², C. A. Lewis³. ¹Physiotherapy Dept, Green Lane Clinical Centre, Auckland, New Zealand, ²Transplant Psychology, Auckland City Hosp, Auckland, New Zealand, ³Lung Transplant, Auckland City Hosp, Auckland, New Zealand

7:00 PM (287) *Impact of Genotype on Boys with Duchenne Muscular Dystrophy*; K. Gambetta¹, C. Wittlieb-Weber², M. Bock³, C. Villa⁴, J. Johnson⁵, A. Lal⁶, K. Schumacher⁷, S. Law⁸, S. Deshpande⁹, S. West¹⁰, J. Friedland-Little¹¹, I. Lytrivi¹², R. Butts¹³, C. Cunningham¹⁴, K. R. Knecht¹⁵, M. McCullough¹⁶. ¹Lurie Children's Hosp, Chicago, IL, ²Univ of Rochester Med Ctr, Rochester, NY, ³Loma Linda Univ, Loma Linda, CA, ⁴Cincinnati Children's Hosp, Cincinnati, OH, ⁵Mayo Clinic, Rochester, MN, ⁶Primary Children's Hosp Univ of Utah, Salt Lake City, UT, ⁷CS Mott Children's Hosp, Ann Arbor, MI, ⁸Columbia Univ, New York, NY, ⁹Emory Children's Hosp, Atlanta, GA, ¹⁰Children's Hosp of Pittsburgh, Pittsburgh, PA, ¹¹Seattle Children's Hosp, Seattle, WA, ¹²Mount Sinai Med Ctr, New York, NY, ¹³UT Southwestern Dallas

Children's Hosp, Dallas, TX, ¹⁴Univ of Alberta, Edmonton, AB, ¹⁵Arkansas Children's Hosp, Little Rock, AR, ¹⁶Univ of Virginia, Charlottesville, VA

7:05 PM (288) Utilization and Outcomes for BiVADs in Pedimacs Patients; R. Butts¹, D. Sutcliffe¹, R. Davies¹, R. Jaquiss¹, T. Pirolli¹, M. Bano¹, R. Morrow², A. Gao¹, S. Zhang¹, R. Kirk¹. ¹Univ of Texas Southwestern, Dallas, TX, ²Children's Medical Center of Dallas, Dallas, TX

7:10 PM (289) Incidence of Treatable Ventricular Arrhythmias After VAD Placement in Children; S. J. Wilkens¹, C. S. Almond¹, S. Chen¹, S. R. Ceresnak¹, J. M. Murray¹, J. Dykes¹, K. S. Motonaga¹, D. N. Rosenthal¹, C. Tjossem², A. M. Dubin¹. ¹Pediatric Cardiology, Stanford Univeristy, Lucile Packard Children's Hosp, Palo Alto, CA, ²Berlin Heart Inc, The Woodlands, TX

6:15 PM - 7:15 PM

MINI ORAL 12: Basic Science & Translational Research

Location: Meditteranee 6

Target Audience: BSTR, HTX, LTX, MCS, PATH

Chairs: Pradeep P.A. Mammen, MD, FACC, FAHA, and Joshua Diamond, MD

6:15 PM (290) Higher FiO₂ and Elevated Cell-Free Hemoglobin Augment the Risk of Primary Graft Dysfunction Through Direct Effects on Lung Vascular Permeability; C. M. Shaver, N. Wickersham, J. B. McNeil, S. R. Landstreet, J. A. Bastarache, L. B. Ware. *Allergy, Pulmonary, & Critical Care Medicine, Vanderbilt Univ Medical Center, Nashville, TN*

6:20 PM (291) Inhibition of Neutrophil Serine Proteases by Alpha 1 Antitrypsin During Storage Preserves Primary Graft Functions of Transplanted Murine Donor Lungs; C. Morrone. *Comprehensive Pulmonary Center, CPC/ILBD and Helmholtz Zentrum Munich, Munich, Germany*

6:25 PM (292) Two-Day Lung Preservation Followed by Lung Transplantation in a Large Animal Model Using Novel Extracellular Oxygen Carrier; A. Ali¹, Y. Watanabe¹, M. Galasso¹, W. Stansfield², T. Watanabe¹, K. Ramandan¹, M. Chen¹, R. P. Ribeiro¹, H. Gokhale¹, A. Gazzalle¹, T. Waddell¹, M. Liu¹, S. Keshavjee¹, M. Cypel¹. ¹*Thoracic Surgery, University Health Network, Toronto, ON, Canada*, ²*Cardiac Surgery, University Health Network, Toronto, ON, Canada*

6:30 PM (293) Tolerance Induction by Delayed Non-Myeloablative Irradiation in a Large Animal Lung Transplantation Model; K. Jansson, K. S. Hacker, J. Pichler, W. Sommer, J. Salman, M. Avsar, T. Siemeni, A. Knöfel, L. Ahrens, A. Haverich, G. Warnecke. *Cardiac-, Thoracic-, Transplantation- and Vascular Surgery, Medical School Hannover, Hannover, Germany*

6:35 PM (294) Regulatory T Cells Induce Persistent Acceptance by IL-2 Complexes after Mouse Lung Transplantation; Y. Yamada¹, D. Impellizzieri², J. Jang¹, T. Nguyen², U. Karakus², I. Inci¹, I. Yoshino³, C. Benden⁴, W. Weder¹, W. Jungraithmayr⁵, O. Boyman². ¹*Dept of Thoracic Surgery, Univ Hosp Zurich, Zurich, Switzerland*, ²*Dept of Immunology, Univ Hosp Zurich, Zurich, Switzerland*, ³*Dept of General Thoracic Surgery, Chiba Univ Graduate Sch of Med, Chiba, Japan*, ⁴*Dept of Pulmonology, Univ Hosp Zurich, Zurich, Switzerland*, ⁵*Dept of Thoracic Surgery, Brandenburg Med Sch, Neuruppin, Germany*

6:40 PM (295) Taci Polymorphisms Associated with Cardiac Allograft Rejection; M. Barbosa¹, E. Farkash², J. Platt¹, M. Cascalho¹. ¹*Surgery, Microbiology and Immunology, Univ of Michigan Hosp, Ann Arbor, MI*, ²*Pathology, Univ of Michigan Hosp, Ann Arbor, MI*

6:45 PM (296) Targeting Glucose Metabolism During Ex vivo Lung Perfusion Improves Lung Preservation and Post Transplant Lung Function; K. Noda¹, S. Tane¹, J. D'Cunha¹, J. D. Luketich¹, N. Shigemura². ¹*Dept of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA*, ²*Cardiovascular Surgery, Temple University, Philadelphia, PA*

6:50 PM (297) Is Cold Storage Possible in DCD Heart Transplantation? A Pre-Clinical Study; R. Ribeiro, J. Alvarez, F. Yu, M. Adamson, G. Rugeri, E. Paradiso, V. Bisoondath, C. Serrick, M. Meineri, V. Rao, M. V. Badiwala. *Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada*

6:55 PM (298) Advanced Heart Failure Patients With Left Ventricular Assist Devices and Heart Transplantation Have Altered Oral Microbial Diversity Alongside Endotoxemia, Inflammation and Oxidative Stress; M. Yuzefpolskaya¹, R. T. Demmer², D. Onat¹, M. Nasiri¹, P. Trinh¹, A. M. Zuver¹, A. Pinsino¹, E. A. Royzman¹, A. R. Garan¹, V. K. Topkara¹, H. Takayama¹, K. Takeda¹, Y. Naka¹, M. A. Farr¹, A. Uhlemann¹, P. C. Colombo¹. ¹*Cardiology, Columbia University, New York, NY*, ²*Cardiology, University of Minnesota, Columbia University, New York, NY*

7:00 PM (299) PDGF Receptor Blockade is Associated With Decreased Development of Cardiac Allograft Vasculopathy in a Murine Aortic Transplant Model; C. Heim¹, A. Gocht¹, J. Distler², B. Spriewald², M. Ramsperger-Gleixner¹, M. Weyand¹, S. M. Ensminger³. ¹*Dept of Cardiac Surgery, University of Erlangen, Erlangen, Germany*, ²*Dept of Medicine, University of Erlangen, Erlangen, Germany*, ³*Dept of Cardiac Surgery, HDZ NRW, Bad Oeynhausen, Germany*

7:05 PM (300) Heart Transplant Tolerance Induction in Mice: Understanding the Complex Interplay Between Tolerizing Cells and Host Immune System by Systematic Depletion of Effector Cells; R. A. Bascom, K. Tao, L. J. West. *University of Alberta, Edmonton, AB, Canada*

7:10 PM (301) Modification of Complement Activity in Donor Lungs with Cigarette Smoke Exposure History Improves Post-Lung Transplantation Outcomes; K. J. Patel¹, Q. Cheng¹, D. P. Allen¹, S. Esckilsen¹, M. Goddard², S. N. Nadig¹, C. Atkinson³. ¹Surgery, Medical University of South Carolina, Charleston, SC, ²Transplantation, Papworth Hospital NHS Foundation Trust, Cambridgeshire, United Kingdom, ³Microbiology and Immunology, Medical University of South Carolina, Charleston, SC

FRIDAY, APRIL 13, 2018

8:30 AM - 10:00 AM

ORAL SESSION 27: How Sick is Too Sick? The Impact of Frailty and Cognitive Function in LVADs

Location: Apollon

Target Audience: MCS, HF, NNSAH, PHARM

Chairs: Mary E Keebler, MD, and Larry Allen, MD, MHS

8:30 AM (302) Ventricular Assist Device May Enhance Learning in End Stage Heart Failure; M. Karahan¹, S. Kocabeyoglu¹, U. Kervan¹, D. Sert¹, E. Aygun¹, M. Tola², B. Demirkan³, E. Bakar⁴, S. Mungan⁵, O. Kursun⁵, Z. Catav¹, M. Pac¹. ¹Cardiovascular Surgery, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ²Radiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ³Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ⁴Psychology, Ufuk University, Ankara, Turkey, ⁵Neurology, Ankara Numune Hospital, Ankara, Turkey

8:45 AM (303) Predictors of Postoperative Vasoplegia in Patients Receiving Left Ventricular Assist Devices; J. Han¹, A. Pinsino², E. Royzman², A. Gaudig², M. Mabasa², H. Takayama¹, P. A. Kurlansky¹, A. R. Garan², V. Topkara², Y. Naka¹, K. Takeda¹, P. C. Colombo², M. Yuzefpolskaya². ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, ²Division of Cardiology, Columbia University Medical Center, New York, NY

9:00 AM (304) Survival in Intermacs 1 & 2 Patients After LVAD Therapy: Does Chronicity of Heart Failure Matter?; J. L. Guidi¹, G. Troutman², E. Y. Birati³, J. Wald³, A. Fox³, J. Ortega-Legaspi³, C. Bermudez⁴, J. Horak⁵, J. Gutsche⁵, C. Justice⁴, D. Guarracino⁴, W. Shay⁴, P. A. Atluri⁴, M. A. Acker⁴, J. Rame¹. ¹Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, ³Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA

9:15 AM (305) Reversibility of Fried's Physical Frailty Domains Post- Ventricular-Assist Device Implantation Among Patients with Advanced Heart Failure; S. R. Jha¹, D. Robson¹, P. Jansz¹, P. Spratt¹, E. Granger¹, K. Dhital¹, M. Connellan¹, C. Hayward¹, K. Muthiah¹, A. Jabbour¹, E. Kotlyar¹, E. Montgomery¹, P. J. Newton², P. S. Macdonald¹. ¹Heart & Lung Transplant Clinic, St. Vincent's Hospital Sydney, Sydney, Australia, ²Nursing Research Center, Western Sydney University, Sydney, Australia

9:30 AM (306) The Impact of Frailty on Post-Bridge-to-Transplant Ventricular Assist Device (VAD) Outcomes; S. Jha¹, D. Robson¹, E. Montgomery¹, C. S. Hayward¹, P. Newton², P. C. Jansz¹, P. MacDonald³. ¹Heart Transplant Unit, St. Vincent's Hospital, Sydney, Australia, ²Nursing, University of Western Sydney, Sydney, Australia, ³St. Vincent's Hospital, Sydney, Australia

9:45 AM (307) Further Improvement of Exercise Capacity One Year After Implantation of a Cf- Left Ventricular Assist Device; S. Felix¹, M. Oerlemans¹, F. Ramjankhan², M. Buijsrogge², H. Kirkels¹, N. de Jonge¹. ¹Cardiology, UMC Utrecht, Netherlands, Utrecht, Netherlands, ²Cardiothoracic surgery, UMC Utrecht, Netherlands, Utrecht, Netherlands

8:30 AM - 10:00 AM

ORAL SESSION 28: Just Pacing Myself! Electrophysiology and Mechanical Support

Location: Athena

Target Audience: MCS, BSTR, HF, NNSAH, PHARM

Chairs: Jerry D Estep, MD, and Maria Frigerio, MD

8:30 AM (308) Atrial Fibrillation Burden in Patients with Left Ventricular Assist Devices: Analysis from ICDs; M. A. Brisco-Bacik¹, P. Eckman², B. Lima³, A. Bansal⁴, I. Gosev⁵, R. Aggerwal⁶, Y. Nabutovsky⁶, S. M. Joseph⁷. ¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Minneapolis Heart Institute, Minneapolis, MN, ³North Shore University Hospital, Manhasset, NY, ⁴Ochsner, New Orleans, LA, ⁵University of Rochester, Rochester, NY, ⁶Abbott Medical, Sylmar, CA, ⁷Baylor University Medical Center in Dallas, Dallas, TX

8:45 AM (309) Evaluation of the CHADS₂, CHA₂DS₂-VAsc, and R₂CHADS₂ Risk Assessment Scores in Continuous Flow LVADs; A. Santiago, H. Lamba, A. Alnajar, F. H. Cheema, J. Hyak, R. Conyer, M. Kim, B. Chou, A. Nair, S. Oberton, R. K. Ghanta, J. George, Z. A. Taimeh, A. Civatello, O. Frazier, J. Morgan. Baylor College of Med, Houston, TX

9:00 AM (310) Implication of Appropriate ICD Shock on Mortality After Continuous Flow LVAD; B. Omery¹, R. Pedersen², N. Sulemanjee², T. E. Hastings², O. Cheema², E. Roberts², F. X. Downey³, J. D. Crouch³, V. Thohan². ¹Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Center, Milwaukee, WI, ²Tendick Clinic for Advanced Heart Failure Therapies, Aurora St. Luke's Medical Center, Milwaukee, WI, ³Aurora Cardiovascular Surgical Services, Aurora St. Luke's Medical Center, Milwaukee, WI

9:15 AM (311) Cardiac Resynchronization Therapy and Outcomes in Patients With Left Ventricular Assist Devices: A Systematic Review and Meta-analysis; D. C. Voruganti¹, A. Briasoulis², P. Alvarez², V. Cotarlan³, J. K. Bhama⁴, M. C. Giudici². ¹Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, ²Internal Medicine, Division of Cardiology, University of Iowa Hospitals and Clinics, Iowa City, IA, ³Internal Medicine, Division of Cardiology, University of Cincinnati, Cincinnati, OH, ⁴Division of Cardiothoracic Surgery, Dept of General Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA

9:30 AM (312) Improved Exercise Performance and Quality of Life with Right Ventricular Pacing Over Biventricular Pacing in LVAD Patients; B. Chung¹, J. Grinstein², G. Sayer¹, G. Kim¹, N. Sarswat¹, J. Raikhelkar¹, S. Kalantari¹, A. Nguyen¹, N. Narang¹, M. R. Costanzo³, U. Jorde⁴, D. Burkhoff⁵, C. LaBuhn⁶, V. Jeevanandam⁶, R. Lang¹, N. Uriel¹. ¹Cardiology, University of Chicago, Chicago, IL, ²Cardiology, MedStar Washington Hospital Center, Washington, DC, ³Cardiology, Edward-Elmhurst Health, Naperville, IL, ⁴Cardiology, Montefiore Medical Center, Bronx, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Cardiac Surgery, University of Chicago, Chicago, IL

9:45 AM (313) Atrial Fibrillation is Associated With Early Right Ventricular Failure Post-LVAD; S. Koh, O. O. Braun, M. Brambatti, P. Kim, H. Tran, V. Pretorius, E. Adler, J. Silva Enciso. University of California San Diego, La Jolla, CA

8:30 AM - 10:00 AM

ORAL SESSION 29: Lung Donation after Circulatory Death - Current Status

Location: Mediterranean ABC

Target Audience: LTX, EEP

Chairs: Inga Leuckfeld, MD, and Ilhan Inci, MD

8:30 AM (314) *The ISHLT 2017 Updated DCD Registry Report*; D. E. Van Raemdonck¹, S. Keshavjee², B. Levvey³, G. Snell⁴, M. E. Erasmus⁵, W. S. Cherikh⁶, A. Y. Kucheryavaya⁶, J. Stehlik⁷, K. R. McCurry⁸, A. Glanville⁹, F. D'Ovidio¹⁰, M. Hertz¹¹, I. Inci¹², P. Hopkins¹³, R. Walia¹⁴, G. A. Patterson¹⁵, R. D. Yusen¹⁶, D. Mason¹⁷, M. Musk¹⁸, D. F. Dilling¹⁹, P. Camp²⁰, M. Cypel². ¹Thoracic Surgery, Univ Hosps Leuven, Leuven, Belgium, ²Thoracic Surgery, The Toronto General Hosp & Hosp for Sick Children, Toronto, ON, Canada, ³Nursing, Alfred Hosp, Melbourne, Australia, ⁴Pulmonology, Alfred Hosp, Melbourne, Australia, ⁵CardioThoracic Surgery, Universitair Medisch Centrum, Groningen, Netherlands, ⁶United Network for Organ Sharing, Richmond, VA, ⁷Cardiology, Univ of Utah, Salt Lake City, UT, ⁸CardioThoracic Surgery, Cleveland Clinic, Cleveland, OH, ⁹Pneumology, St Vincent's Hosp, Sydney, Australia, ¹⁰Thoracic Surgery, Columbia Univ Medical Center, New York, NY, ¹¹Pulmonology, Univ of Minnesota Medical Center, Minneapolis, MN, ¹²Thoracic Surgery, Univ Hosp Zurich, Zurich, Switzerland, ¹³Thoracic Surgery, Prince Charles Hosp, Brisbane, Australia, ¹⁴Pulmonology, St. Joseph 's Hosp & Medical Center, Phoenix, AZ, ¹⁵CardioThoracic Surgery, Barnes Jewish Hosp Washington Univ, St Louis, MO, ¹⁶Pulmonology, Barnes Jewish Hosp Washington Univ, St Louis, MO, ¹⁷CardioThoracic Surgery, Baylor Univ Medical Center, Dallas, TX, ¹⁸Pulmonology, Fiona Stanley Hosp, Palmyra DC, Australia, ¹⁹Pulmonology, Loyola Univ Medical Centre, Maywood, IL, ²⁰Thoracic Surgery, Brigham & Women's Hosp, Boston, MA

8:45 AM (315) *Chronic Lung Allograft Dysfunction (CLAD): Donation after Circulatory Death (DCD) vs Donation After Brain Death (DBD) - The First 10 Years*; G. I. Snell, B. Levvey, H. Whitford, L. Kovi, T. Williams, S. Kotecha, D. McGiffin, G. Westall, M. Paraskeva. *Lung Transplant Service, Alfred Hospital, Melbourne, Australia*

9:00 AM (316) *10 Years on: The Significant Impact of Controlled Donation after Circulatory Death (DCD) Lung Donors on Lung Transplant LTX Opportunities and Outcomes*; B. J. Levvey, G. P. Westall, M. Paraskeva, H. M. Whitford, K. Levin, S. Kotecha, J. Hobson, A. Henriksen, Y. Cristiano, T. J. Williams, D. McGiffin, G. I. Snell. *Lung Transplant Service, Alfred Hospital, Melbourne, Australia*

9:15 AM (317) *A Comparison of Inflammatory Profiles in Donor Lungs Following Donation After Brain-Death (DBD) and Donation After Circulatory Death (DCD)*; M. I. Morrison, A. S. Andreasson, W. E. Scott III, A. J. Fisher, J. H. Dark. *Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom*

9:30 AM (318) *Low Partial Pressures of Oxygen in Circulatory Death Donors is Associated with Decreased Survival in Lung Transplant Recipients*; A. G. Fiedler¹, A. L. Axtell¹, E. Heng¹, A. Osho¹, S. I. Melnitchouk¹, D. A. D'Alessandro¹, G. Tolis¹, T. Astor², Y. Raz², I. P. Neuringer², M. A. Villavicencio¹. ¹Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ²Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA

9:45 AM (319) *Prone Positioning Attenuates Lung Injury During Warm Ischemia in a Large Animal Controlled Donation after Cardiac Death Model*; Y. Watanabe¹, M. Galasso¹, T. Watanabe¹, A. Ali¹, H. H. Chan², R. Qaqish¹, C. Summers¹, K. Ramadan¹, R. V. Ribeiro¹, Y. Zhang¹, A. Gazzalle¹, T. K. Waddell¹, M. Liu¹, S. Keshavjee¹, L. Del Sorbo³, M. Cypel¹. ¹Latner Thoracic Surgery Research Laboratories, Univ Health Network, Univ of Toronto, Toronto, ON, Canada, ²Guided Therapeutics, TECHNA Institute, Univ Health Network, Univ of Toronto, Toronto, ON, Canada, ³InterDeptal Division of Critical Care Medicine, Univ Health Network, Univ of Toronto, Toronto, ON, Canada

8:30 AM - 10:00 AM

ORAL SESSION 30: Infection: Achille's Heel of Mechanical Circulatory Support

Location: Clio/Thalie/Erato

Target Audience: ID, HTX, MCS

Chairs: Shahid Husain, MD, MS, and Martha L. Mooney, MD, FACP

8:30 AM (320) *Microbial Biofilm Formation and Migration on Ventricular Assist Device Drivelines: Implications for Infection*; Y. Qu¹, D. C. McGiffin², C. E. Kure², B. Ozcelik³, H. Thissen³, J. F. Fraser⁴, A. Y. Peleg¹. ¹Dept of Infectious Diseases, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia, ²Cardiothoracic Surgery, The Alfred Hospital, Prahran, Australia, ³CSIRO Manufacturing, CSIRO, Clayton, Australia, ⁴Critical Care Research Group & Adult Intensive Care Service, The Prince Charles Hospital, Brisbane, Australia

8:45 AM (321) *The Impact of Left Ventricular Assist Device Infections on Post Cardiac Transplant Survival: A Meta-analysis*; D. Chahal, A. Sepehry, H. Nazzari, A. J. Wright, M. Toma. University of British Columbia, Vancouver, BC, Canada

9:00 AM (322) *Bloodstream Infections in Left Ventricular Assist Device Recipients Awaiting Transplantation*; A. Kyvernitakis¹, O. Pappas², D. Farmakiotis³, E. T. Horn⁴, R. L. Benza², S. H. Bailey⁴, R. Agarwal². ¹Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ²Cardiovascular Disease, Allegheny General Hospital, Pittsburgh, PA, ³Infectious Diseases, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, ⁴Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, PA

9:15 AM (323) *Telemonitoring of Driveline Exit Site for Early Detection of Relevant Driveline Infections*; N. Reiss¹, S. Jansen², N. Luneburg², C. Feldmann³, R. Wendl³, J. Schmitto³, R. Neubert². ¹Clinical Research, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, ²Target Holding, Groningen, Netherlands, ³Hannover Medical School, Hannover, Germany

9:30 AM (324) *Antimicrobial Prophylaxis for Left Ventricular Assist Device Implantation: Comparing Infection Rates with Single or Multiple Drug Regimens*; S. A. Schubert¹, L. T. Yarboro¹, J. S. Green², R. J. Cogswell³, J. L. Kennedy⁴. ¹Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA, ²Infectious Disease and International Medicine, University of Minnesota, Minneapolis, MN, ³Cardiovascular Medicine, University of Minnesota, Minneapolis, MN, ⁴Cardiovascular Medicine, University of Virginia, Charlottesville, VA

9:45 AM (325) *Hepatitis C Virus Antibody Formation After LVAD Implantation*; D. B. Sims¹, S. Rangasamy¹, S. Murthy¹, S. Forest², S. Vukelic¹, O. Saeed¹, J. Shin¹, S. Patel¹, D. Goldstein², U. P. Jorde¹. ¹Cardiology, Montefiore Medical Center, Bronx, NY, ²Cardiac Surgery, Montefiore Medical Center, Bronx, NY

8:30 AM - 10:00 AM

ORAL SESSION 31: Spotlight on a Heart Transplant Donor

Location: Uranie/Calliope

Target Audience: HTX

Chairs: Marian Urban, MD, and David C McGiffin, MB, BS, FRACS

8:30 AM (326) *Prevalence, Characteristics and Prognostic Impact of Wall Motion Abnormalities in Brain-dead Cardiac Donors With Transient Left Ventricular Systolic Dysfunction (LVSD)*; S. Madan¹, S. R. Patel¹, O. Saeed¹, O. Buhari², S. Forest³, W. Jakobleff³, S. Murthy¹, J. Shin¹, D. J. Goldstein³, D. B. Sims¹, U. P. Jorde¹. ¹Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

8:45 AM (327) *Cardiac Transplantation From Non-viremic Hepatitis C Donors*; S. R. Patel, O. Saeed, D. Sims, J. J. Shin, S. Murthy, S. Vukelic, C. Nucci, J. Reinus, S. Madan, E. Borukhov, S. Forest, W. Jakobleff, D. J. Goldstein, U. P. Jorde. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

9:00 AM (328) *Forgotten Women: Use of Female Donors and Survival Outcomes*; D. A. Baran¹, H. Copeland², J. Copeland³, C. Gidea⁴, M. Camacho⁵. ¹Advanced Heart Failure and Transplant, Sentara Heart Hospital, Norfolk, VA, ²University of Mississippi Medical Center, Jackson, MS, ³University of Arizona, Tucson, AZ, ⁴Newark Beth Israel Medical Center, Newark, NJ, ⁵Newark Beth Israel Medical Center, Newark, NJ

9:15 AM (329) *Interaction Between Ischemic Interval and Donor Age on Adult Heart Transplant Outcomes in the Modern Era*; M. M. John¹, T. P. Martens¹, N. W. Hasaniya¹, B. Jabo², A. J. Razzouk¹, L. L. Bailey¹, D. G. Rabkin¹. ¹Cardiovascular and Thoracic Surgery, Loma Linda University Medical Center, Loma Linda, CA, ²Research Consulting Group, School of Public Health, Loma Linda University Medical Center, Loma Linda, CA

9:30 AM (330) *Regional Variation and Outcomes of Thoracic Organ Transplantation from Drug Overdose*; X. Zhou¹, C. D. Fraser¹, A. Suarez-Pierre¹, C. Lui¹, A. Kilic¹, C. M. Sciortino², R. S. Higgins¹, K. J. Zehr¹. ¹Johns Hopkins Hospital, Baltimore, MD, ²University of Pittsburgh Medical Center, Pittsburgh, PA

9:45 AM (331) *Implications of the Refusal of Increased Risk Donor Offers on Waitlist Survival in Heart Transplantation*; M. S. Mulvihill¹, M. A. Bishawi¹, M. L. Cox¹, A. A. Osho², C. B. Patel³, M. G. Hartwig¹, C. A. Milano¹, J. N. Schroder¹. ¹Dept of Surgery, Duke University, Durham, NC, ²Dept of Surgery, Massachusetts General Hospital, Boston, MA, ³Dept of Medicine, Duke University, Durham, NC

8:30 AM - 10:00 AM

ORAL SESSION 32: Junior Faculty Clinical Case Dilemmas: The Best of the Best

Location: Hermes

Target Audience: ALL

Chairs: Joshua Mooney, MD, and Agnieszka Ciarka

8:30 AM (332) Case of Combined Heart-Kidney Transplant from Hepatitis C (+) Donor to a HCV (-) Recipient; N. Wettersten, H. Tran, V. Pretorius, S. Aslam, E. Adler. *University of California, San Diego, La Jolla, CA*

8:35 AM Expert Discussant (Heart Failure/Transplantation)

Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA

8:40 AM Discussion

8:45 AM (333) Post Transplant Lymphoproliferative Disease in Two Recipients From a Single Donor, Donor Derived Disease?; O. Shtraichman, A. Umterman, D. Rosengarten, D. Shitenberg, Y. Shostak, M. R. Kramer. *Pulmonary Institute, Rabin Medical Center Belinson Campus, Petach Tikva, Israel*

8:50 AM Expert Discussant (Lung Failure/Transplantation)

Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA

8:55 AM Discussion

9:00 AM (334) Vasculitis Mimicking Chronic Thromboembolic Pulmonary Hypertension; V. N. Selby¹, N. K. Tarango², M. Janmohamed¹, N. H. Kim³, T. De Marco¹. ¹Cardiology, University of California, San Francisco, San Francisco, CA, ²Nursing, UCSF, San Francisco, CA, ³Pulmonary and Critical Care Medicine, UCSD, La Jolla, CA

9:05 AM Expert Discussant (Pulmonary Hypertension)

Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

9:10 AM Discussion

9:15 AM (335) Third Party HLA Antibody as a Surrogate Marker for Treatment of Non-HLA AMR; T. K. Roberts¹, J. Sparks². ¹Dept of Pathology, University of Louisville, Louisville, KY, ²Dept of Pediatrics, Cardiology, University of Louisville, Louisville, KY

9:20 AM Expert Discussant (Pediatrics)

Lori J. West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

9:25 AM Discussion

9:30 AM (336) An Under-Recognized Cause of Malnutrition After Lung Transplant; M. Howsare¹, D. R. Nunley¹, V. Van Berkel², A. Ramirez¹. ¹Pulmonary, Critical Care, and Sleep Medicine, University of Louisville, Louisville, KY, ²Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

9:35 AM Expert Discussant (Infectious Diseases)

Erika D. Lease, MD, University of Washington, Seattle, WA, USA

9:40 AM Discussion

9:45 AM (337) Pseudoconstriction Secondary to Epicardial Pacing Following HeartWare Left Ventricular Assist Device (HVAD) Implant; A. L. French, R. Kociol. *Advanced Heart Failure and Transplant Cardiology, Beth Israel Deaconess Medical Center, Boston, MA*

9:50 AM Expert Discussant (Mechanical Circulatory Support)

Jan D. Schmitto, MD, PhD, Hannover Medical School, Hannover, Germany

9:55 AM Discussion

8:30 AM - 10:00 AM

SYMPOSIUM 24: Retransplantation in the Child to Young Adult - History Repeating Itself?

Location: Mediterranean 6

Target Audience: PEDS, EEP, HF/HTX, LF/LTX, MCS, NNSAH, PHARM

Chairs: Susan W. Denfield, MD, and Stuart Sweet, MD

Session Summary: Re-transplantation remains a clinical challenge in children and young adults. The demographics of primary transplantation have changed affecting retransplantation. Current outcomes of retransplantation, as well as the timing of retransplant work up, indications, contraindications and comorbidities affecting heart or lung retransplant will be reviewed as well as support strategies while listed for retransplant. The ethics of retransplantation will be discussed. A panel discussion with all speakers will conclude this session.

8:30 AM Thoracic Retransplantation - Population at Risk and Outcomes

Zdenka Reinhardt, MD, Freeman Hospital, Newcastle upon Tyne, United Kingdom

8:45 AM When Should the Cardiac Transplant Patient Be Considered for Retransplant?

Elfriede Pahl, MD, Lurie Children's Hospital, Chicago, IL, USA

9:00 AM Trials and Tribulations of Supporting the Cardiac Transplant Patient to Retransplant

Jennifer Conway, MD, Alberta Health Services, Edmonton, AB, Canada

9:15 AM When Should the Lung Transplant Patient Be Considered for Retransplant?

Ernestina Melicoff-Portillo, MD, Texas Children's Hospital, Houston, TX, USA

9:30 AM Should Anyone Be Considered for Retransplantation – Ethical Issues

Beth Kaufman, MD, Stanford University, Stanford, CA, USA

9:45 AM Panel Discussion

10:30 AM - 12:30 PM

PLENARY 2: Plenary Session: Moving Cardiothoracic Transplantation Forward

Location: Apollon

Target Audience: ALL

Chairs: Lori J West, MD, DPhil, and Allan R Glanville, MBBS, MD, FRACP

10:30 AM *New Technologies to Advance Future Transplant Patient Care*

Stefan Schneeberger, MD, Innsbruck Medical University, Innsbruck, Austria

10:50 AM (338) *Right Ventricular Remodeling in Chronic Thrombo-Embolic Pulmonary Hypertension; S.*

Guimaron¹, J. Guihaire¹, M. Amsallem¹, J. Athur-Ataam¹, A. Amato-Gauberville², M. Isorni², L. Mabile³, A. Potier⁴, S. Arthur-Ataam¹, P. Dorfmueller¹, L. Lamrani¹, P. Deleuze⁵, S. Mussot⁶, E. Fadel⁶, O. Mercier⁶. ¹Research and Innovation Unit Research Lab, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ²Dept of Radiology, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ³Dept of Nuclear Medicine and Radiology, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ⁴Dept of Cardiology, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ⁵Adult Cardiac Surgery, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France, ⁶Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France

11:05 AM *Interactive Discussant for Presentation 338*

William Auger, MD, University of California San Diego Medical Center, La Jolla, CA, USA

11:10 AM *Transplant Registries to Improve Results: ItRelates to Research, Regulation, Reporting and Reimbursement*

David Reich, MD, FACS, Drexel University College of Medicine, Philadelphia, PA, USA

11:30 AM (339) *Outcome and Primary Endpoint Results From a Prospective Multi-center Study of Myocardial Recovery Using LVADs: Remission from Stage D Heart Failure (RESTAGE-HF); E. J. Birks¹, S. G. Drakos², B. D.*

Lowes³, S. R. Patel⁴, C. Selzman⁵, M. S. Slaughter⁶, P. Alturi⁷, D. Goldstein⁸, J. Um⁹, C. Cunningham¹⁰, K. B. Margulies¹¹, J. Stehlik², R. Starling¹², D. Farrar¹³, E. Rame¹¹. ¹Dept of Cardiovascular Medicine, Univ of Louisville, Louisville, KY, ²Dept of Cardiovascular Medicine, Univ of Utah, Salt Lake City, UT, ³Dept of Cardiovascular Medicine, Univ of Nebraska, Omaha, NE, ⁴Dept of Cardiovascular Medicine, Montefiore Medical Center, New York, NY, ⁵Dept of Cardiothoracic Surgery, Univ of Utah, Salt Lake City, UT, ⁶Dept of Cardiovascular Surgery, Univ of Louisville, Louisville, KY, ⁷Dept of Cardiovascular Surgery, Univ of Pennsylvania, Philadelphia, PA, ⁸Dept of Cardiovascular Surgery, Montefiore, New York, NY, ⁹Dept of Cardiovascular Surgery, Univ of Nebraska, Omaha, NE, ¹⁰Clinical Trials Unit, Univ of Louisville, Louisville, KY, ¹¹Dept of Cardiovascular Medicine, Univ of Pennsylvania, Philadelphia, PA, ¹²Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH, ¹³Medical Affairs, Abbott, Pleasanton, CA

11:45 AM *Interactive Discussant for Presentation 339*

Guy A MacGowan, MD, FACC, FRCPI, Freeman Hospital, Newcastle upon Tyne, United Kingdom

11:50 AM *Tissue-Engineered Matrix to Generate Organs*

Simon P Hoerstrup, MD, PhD, IREM, University of Zurich, Zurich, Switzerland

12:10 PM (340) *Transplanting Thoracic Organs from Hepatitis C Positive Donors to Hepatitis C Uninfected*

Recipients; A. E. Woolley¹, S. K. Singh², H. R. Mallidi³, M. M. Givertz⁴, H. J. Goldberg⁵, M. R. Mehra⁴, L. L. Coakley⁴, A. E. Kuzstos¹, K. Chen¹, J. Fanikos⁶, D. Harrington⁷, P. C. Camp⁸, L. R. Baden¹. ¹Infectious Diseases, Brigham and Women's Hospital, Boston, MA, ²Cardiac and Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, ³Thoracic and Cardiac Surgery, Brigham and Women's Hospital, Boston, MA, ⁴Cardiology, Brigham and Women's Hospital, Boston, MA, ⁵Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁶Pharmacy, Brigham and Women's Hospital, Boston, MA, ⁷Dana Farber Cancer Institute and Harvard TH Chan School of Public Health, Boston, MA, ⁸Thoracic Surgery, Brigham and Women's Hospital, Boston, MA

12:25 PM *Interactive Discussant for Presentation 340*

Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

2:00 PM - 4:00 PM

SYMPOSIUM 25: Crashing and Burning: Cardiogenic Shock and Short-term MCS

Location: Apollon

Target Audience: MCS, HF/HTX, NNSAH, PEDS, PHARM

Chairs: Jaime A Hernandez Montfort, MD MPH, and Stephan Schueler, MD, PhD, FRCS

Session Summary: Despite recent advances in the treatment of end-stage heart failure, cardiogenic shock remains a challenging condition. Short-term mcs is increasingly being used as a bridge to decision making in patients with refractory cardiogenic shock. The aim of this symposium is to review the clinical data on cardiogenic shock and the outcome. The use of mcs with particular emphasis on ECMO will be discussed. Patient selection, timing of device implantation, bridging to decision making under short-term mcs will be evaluated.

2:00 PM *Do We Need a New Classification for Cardiogenic Shock?*

J. Eduardo Rame, MD, Penn Heart and Vascular Center, Philadelphia, PA, USA

2:15 PM Q&A

2:20 PM *Counterpulsation Response in Low-Output Heart Failure: Secondary Shock Prevention?*

Jerry D Estep, MD, The Methodist Hospital, Houston, TX, USA

2:35 PM Q&A

2:40 PM *Door to...Recovery! Contemporary Treatment of Acute Myocardial Infarction Maximizing Potential for Myocardial Recovery*

Navin K Kapur, MD, Tufts Medical Center, Boston, MA, USA

2:55 PM Q&A

3:00 PM *Decision-Making in Complex Cardiogenic Shock: The Surgeon's View*

Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

3:15 PM Q&A

3:20 PM *Veno-Arterial ECMO: Indications and Surveillance*

Shelley A. Hall, MD, Baylor University Medical Center, Dallas, TX, USA

3:35 PM Q&A

3:40 PM *Weaning from ECMO*

Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

3:55 PM Q&A

2:00 PM - 4:00 PM

SYMPOSIUM 26: Can My Lung Transplant Candidate Take This Medication? What to Do with the New Drugs for Lung Failure

Location: Athena

Target Audience: LF/LTX, BSTR, ID, NNSAH, PEDS, PHARM

Chairs: Keith M Wille, MD, MSPH, and Michael Durheim, MD

Session Summary: With the introduction of new medications for lung failure, concerns have surfaced about their preoperative safety and some programs restrict their use in candidates. This creates clinical quandaries revolving around assessing risk of disease progression vs. preoperative risks of using such medications. Debate also exists whether to continue to use some of these medications after the transplant. We will discuss some of the more common and controversial examples.

2:00 PM *Use of Anticoagulation or Anti-Platelet Therapy While Waiting: Can It Be Done Safely?*

Matthew G Hartwig, MD, Duke University Medical Center, Durham, NC, USA

2:15 PM Q&A

2:20 PM *Is it Safe to Use mTOR Inhibition (Sirolimus or Everolimus) While Awaiting Lung Transplantation in Lymphangiomyomatosis (LAM)?*

Daniel F Dilling, MD, Loyola University Medical Center, Chicago, IL, USA

2:35 PM Q&A

2:40 PM *Planning for the Far Side: Antimicrobial Agents in Patients on the Wait List for Lung Transplantation*

Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia

2:55 PM Q&A

3:00 PM *Are the Novel Antifibrotic Medications Safe for Use in Candidates for Lung Transplantation?*

Hilary J Goldberg, MD, Brigham & Women's Hospital, Boston, MA, USA

3:15 PM Q&A

3:20 PM *Lumacaftor/Ivacaftor Use Before and After Transplant in Cystic Fibrosis: Is It Indicated?*

Adam B Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA

3:35 PM Q&A

3:40 PM *Analgesia and Neuropharmacology: What is Acceptable in Lung Transplant Candidates*

Linda Stuckey Fitzgerald, PharmD, BCPS, University of Michigan Hospital, Ann Arbor, MI, USA

3:55 PM Q&A

2:00 PM - 4:00 PM

SYMPOSIUM 27: DCD Lungs- Expanding Utilization

Location: Mediterranean ABC

Target Audience: LF/LTX, NNSAH

Chairs: Aleem Siddique, MBBS, and John Dark, MB, FRCS

Session Summary: Ample data has accrued on the outcomes with DCD lungs demonstrating equivalence with DBD donors. Yet DCD lung utilization remains low outside of well-established centers. This session will attempt to breakdown some of the barriers to broader utilization and describe strategies that have proven to be successful while highlighting lessons that we can all learn from. A panel discussion with all speakers will conclude this session.

2:00 PM *Establishing a DCD Program*

Dirk E Van Raemdonck, MD, PhD, University Hospitals Leuven, Leuven, Belgium

2:20 PM *Uncontrolled DCD: Can We Use It for Lung Transplant and How?*

Thomas M. Egan, MD, MSC, UNC School of Medicine, Chapel Hill, NC, USA

2:40 PM *Which Potential DCD Donor Will Progress to Donation? Measures to Predict and Optimize Resources*

Peter M Hopkins, FRACP, Prince Charles Hospital, Brisbane, Australia

3:00 PM *DEBATE (Pro): We Need EVLP to Use Lungs from DCD*

Andre R Simon, MD, PhD, Harefield Hospital, London, United Kingdom

3:15 PM *DEBATE (Con): We Need EVLP to Use Lungs from DCD*

Kumud K Dhital, MD, PhD, St. Vincent's Hospital, Sydney, Australia

3:30 PM *Debate Rebuttal (Pro)*

Andre R Simon, MD, PhD, Harefield Hospital, London, United Kingdom

3:35 PM *Debate Rebuttal (Con)*

Kumud K Dhital, MD, PhD, St. Vincent's Hospital, Sydney, Australia

3:40 PM *Panel Discussion*

2:00 PM - 4:00 PM

SYMPOSIUM 28: First Days of a New Life: Management After Heart Transplant

Location: Clio/Thalie/Erato

Target Audience: HF/HTX, MCS, PHARM, PH

Chairs: Marta Farrero Torres, MD, PhD, and Michael Pham, MD

Session Summary: This session will focus on four important aspects of peri-operative care: pre-op optimization, post-transplant haemodynamics, post-transplant rhythm disturbances and early graft dysfunction. Each topic will start with case presentation with several open-ended questions that will lead to a lecture. A panel discussion with all speakers will conclude this session.

2:00 PM CASE PRESENTATION: Patient with Co-Morbidities on LVAD Awaiting Heart Transplantation: What Should We Be Doing?

Jorge Silva Enciso, MD, UCSD Medical Center, San Diego, CA, USA

2:05 PM Preparing for Heart Transplantation: Are You Ready to Rumble?

Anique Ducharme, MD, MSC, Montreal Heart Institute, Montreal, QC, Canada

2:25 PM CASE PRESENTATION: A Patient Immediately Post Heart Transplant in ICU with PH, Vasoplegia, and Renal Failure on Multiple Vasoactive Agents: Now What?

Munir S Janmohamed, MD, UCSF Medical Center, San Francisco, CA, USA

2:30 PM Managing the Immediate Post-Transplant Patient: It's All About the Volume, It's All About the Pressure

Jason N Katz, MD, MHS, University of North Carolina, Chapel Hill, NC, USA

2:50 PM CASE PRESENTATION: A Thin Patient on LVAD as Bridge to Transplantation Early Post-Transplant with Bradycardia, Intermittent Atrial Fibrillation and Prolonged ITU Stay

Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria

2:55 PM And the Beat Goes On: Managing the Immediate Post-Transplant Patient: Rhythm, Pulse, Fuel and Movement!

David A. Hormuth, MD, Indiana University Health Physicians, Indianapolis, IN, USA

3:15 PM CASE PRESENTATION: A Patient in ICU with Primary Graft Dysfunction on ECMO and CRRT: God Help Us!

Mitchell Psotka, MD PhD, UCSF Medical Center, San Francisco, CA, USA

3:20 PM The Heart is Not Working... Don't Panic

Javier Segovia, MD, PhD, Hospital Puerta De Hierro, Madrid, Spain

3:40 PM Panel Discussion

2:00 PM - 4:00 PM

SYMPOSIUM 29: Joint ISHLT/ESC Symposium: Pulmonary Hypertension Due to Left Heart Disease: When RIGHT Meets LEFT

Location: Uranie/Calliope

Target Audience: PH, BSTR, HF/HTX, NNSAH, PATH, PEDS, PHARM

Chairs: Irene Lang, MD, and Stephan Rosenkranz, MD

Session Summary: This session, supported by a collaborative effort with the European Society of Cardiology (ESC), will discuss and debate the latest advances in PH due to left heart diseases, the leading cause of PH, after the World Symposium on PH held in Nice (Feb 25th to March 1st 2018). A panel discussion with all speakers will conclude this session.

2:00 PM *From Nice 2013 to Nice 2018: Same Venue but Some Changes*

Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

2:15 PM *The PH-HFpEF Phenome: Redefining the Disease*

Sanjiv J. Shah, MD, Northwestern University, Chicago, IL, USA

2:30 PM *The Failing Right Heart in Left Heart Diseases: Any Different from What We See in PAH?*

Stephan Rosenkranz, MD, University Heart Center, Cologne, Germany

2:45 PM *Provocative Testing in the Cath Lab to Unmask Pulmonary Hypertension Due to Left Heart Disease*

Susanna Mak, MD, PhD, Mount Sinai Hospital, Toronto, ON, Canada

3:00 PM *DEBATE (Pro): PH Due to LHD Should Not Be Treated with Vasodilators*

Nazzareno Galiè, MD, Prof., Bologna University Hospital, Bologna, Italy

3:15 PM *DEBATE (Con): PH Due to LHD Should Not Be Treated with Vasodilators*

Mardi Gomberg-Maitland, MD, Inova Fairfax, Falls Church, VA, USA

3:30 PM *Debate Rebuttal (Pro)*

Nazzareno Galiè, MD, Bologna University Hospital, Bologna, Italy

3:35 PM *Debate Rebuttal (Con)*

Mardi Gomberg-Maitland, MD, Inova Fairfax, Falls Church, VA, USA

3:40 PM *Panel Discussion*

2:00 PM - 4:00 PM

SYMPOSIUM 30: Joint ISHLT/TTS-TID Symposium: Infectious Challenges Around the World - Common Threads

Location: Hermes

Target Audience: ID, EEP, HF/HTX, LF/LTX, NHSAH, PEDS, PHARM

Chairs: Clarisse Machado, MD, and Michael G Ison, MD MS

Session Summary: This symposium draws experts from ISHLT and the international Transplant Infectious Diseases (TID) section of The Transplantation Society (TTS) to create a joint symposium which addresses important and timely topics in Infectious Diseases.

2:00 PM *What's All the Fuss? Emerging Arboviral Infections*

Clarisse Machado, MD, University of São Paulo, São Paulo, Brazil

2:15 PM Q&A

2:20 PM *Cryptococcus: A Perennial Problem*

John W Baddley, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL, USA

2:35 PM Q&A

2:40 PM *The Latest and Greatest in the Prevention and Management of CMV*

Camille Kotton, MD, Massachusetts General Hospital, Boston, MA, USA

2:55 PM Q&A

3:00 PM *Time to Man the Global Barricades: Multi-Drug Resistant Organisms on the March*

Stephanie Pouch, MD, Emory University, Atlanta, GA, USA

3:15 PM Q&A

3:20 PM *To Screen or Not to Screen: That is the Question! Global Donor Screening Issues*

Ban Hock Tan, MD, Singapore General Hospital, Singapore, Malaysia

3:35 PM Q&A

3:40 PM *Parasitic Cases: Hot Bugs in a Warming World*

Joanna M Schaeenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

3:55 PM Q&A

2:00 PM - 4:00 PM

SYMPOSIUM 31: Pediatric Heart Failure: MCS, ICU Care, and Early Graft Dysfunction

Location: Mediterranean 6

Target Audience: PEDS, HF/HTX, MCS

Chairs: Estela Azeka, MD, and Holger W. Buchholz, MD

Session Summary: The goal of this session is to gain a better understanding of the evaluation and treatment of the failing heart in the intensive care unit setting. This will include discussions on evaluation and treatment of acute heart failure in both cardiomyopathy and congenital heart disease, care of patients on mechanical circulatory support while awaiting heart transplant and care in the ICU after transplantation.

2:00 PM *Short-Term Mechanical Support for Children: A Bridge Across Troubled Waters*

Katsuhide Maeda, MD, Stanford University, Stanford, CA, USA

2:15 PM Q&A

2:20 PM *Pushing the Limits of Organ Acceptance: Take It or Leave It*

Farhan Zafar, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

2:35 PM Q&A

2:40 PM *Anesthesia and ICU Considerations in the First 24 Hours: Best Day of My Life*

Martin Schweiger, MD, PhD, Children's Hospital Zurich, Zurich, Switzerland

2:55 PM Q&A

3:00 PM *Non-Cardiac Organ Dysfunction After Heart Transplant in Children and Adults with Congenital Heart Disease: Don't You Forget About Me*

Kimberly Lin, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

3:15 PM Q&A

3:20 PM *Proceed with Caution After Positive Crossmatch: Breaking In a Brand New Broken Heart*

Steven A. Webber, MBChB, Monroe Carrell Jr. Children's Hospital, Nashville, TN, USA

3:35 PM Q&A

3:40 PM *It Just Needs a Little Time: Graft Failure After Heart Transplant*

Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

3:55 PM Q&A

4:30 PM - 6:00 PM

ORAL SESSION 33: We Are Here to Pump...You Up! Exercise in MCS

Location: Apollon

Target Audience: MCS, HF, NNSAH, PHARM

Chairs: Shashank S Desai, MD, and Douglas A. Horstmanshof, MD

4:30 PM (341) Continuous-flow LVAD Therapy: A 'Forme-fruste' of Diastolic Heart Failure; P. Jain¹, K. Muthiah¹, A. Jabbour¹, E. Kotlyar¹, A. Keogh¹, D. Robson¹, P. Jansz¹, S. Nanayakkara², J. Mariani², P. Macdonald¹, C. Hayward¹, D. Kaye². ¹Heart failure and transplant unit, St Vincent's Hospital, Sydney, Australia, ²Heart failure-transplant unit, The Alfred Hospital, Melbourne, Australia

4:45 PM (342) LVAD Pump Speed Increase is Associated with Improvement of Cardiac Output, O₂ Kinetic and O₂ Muscle Extraction; S. Paolillo¹, C. Vignati², A. Apostolo², N. Bonini², F. M. Righini², G. Gerosa³, T. Bottio⁴, V. Tarzia⁴, J. Bejko⁴, P. Agostoni². ¹IRCCS SDN, Napoli, Italy, ²Centro Cardiologico Monzino, IRCCS, Milan, Italy, ³Cardiac Surgery Unit, Dept. of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁴Cardiac Surgery Unit, Dept. of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

5:00 PM (343) Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated With a Continuous Flow Left Ventricular Assist Device: A Multicentre Study; K. K. Mirza¹, M. H. Jung¹, K. Cuomo², S. Russell³, F. Gustafsson¹. ¹Dept of Cardiology, Rigshospitalet, Copenhagen, Denmark, ²Johns Hopkins Hospital, Baltimore, MD, ³Dept of Medicine, Duke University School of Medicine, Durham, NC

5:15 PM (344) Development of Exercise Capacity in LVAD Patients During Inpatient Cardiac Rehabilitation Depending on Exercise Tolerance at the Time of Admission; N. Reiss¹, S. Mommertz¹, S. Schulte-Eistrup², J. Sindermann³, T. Schmidt¹. ¹Clinical Research, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, ²Dept of Cardiac Surgery, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, ³Cardiac Rehabilitation, Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany

5:30 PM (345) Right Atrial and Ventricular Ejection Fractions at Rest Measured by Cardiac CT Predict Right Heart Function During Exercise But Do Not Determine Exercise Capacity in LVAD Recipients; K. K. Mirza, M. H. Jung, P. E. Sigvardsen, K. Kofoed, K. Rossing, F. Gustafsson. Dept of Cardiology, Rigshospitalet, Copenhagen, Denmark

5:45 PM (346) Ventricular Fibrosis and Other Factors Influencing Exercise Tolerance in LVAD Patients; M. Racherla¹, J. Heath¹, E. Sorensen¹, H. Voorhees¹, L. Dees¹, E. Feller¹, D. Kaczorowski¹, Z. Kon¹, S. Russell², V. Ton¹. ¹University of Maryland School of Medicine, Baltimore, MD, ²Duke University School of Medicine, Durham, NC

4:30 PM - 6:00 PM

ORAL SESSION 34: Getting It Right From the Start: LVAD Implant and Device Failure

Location: Athena

Target Audience: MCS

Chairs: Ahmet Kilic, MD, and Evgenij V Potapov, MD, PhD

4:30 PM (347) Evaluation of HeartWare HVAD Appearance on Serial Chest Radiographs: Pump Position and Migration Influence Adverse Outcomes; C. M. Pietras¹, S. Maltais², V. Tchantchaleishvili³, S. Poddi², S. M. Dunlay², R. C. Daly², F. D. Pagani⁴, J. M. Stulak². ¹Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, ²Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ³Division of Cardiovascular Surgery, Thomas Jefferson University, Philadelphia, PA, ⁴Division of Cardiovascular Surgery, University of Michigan, Ann Arbor, MI

4:45 PM (348) Worldwide Experience of Adult Patients with Small Body Size Supported by a Continuous-Flow Left Ventricular Assist Device - An IMACS Analysis; S. Lee¹, R. Xie², K. Lemstrom³, M. G. Dickinson¹, T. Boeve¹, M. Leacche¹, J. Cowger⁴, T. de By⁵, J. K. Kirklin². ¹Spectrum Health, Grand Rapids, MI, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Henry Ford Hospital, Detroit, MI, ⁵EUROMACS, EACTS House, Windsor, United Kingdom

5:00 PM (349) HVAD Thrombosis - Searching for the Source; F. Kaufmann, C. Hörmandinger, E. Potapov, T. Krabatsch, V. Falk. German Heart Center Berlin, Berlin, Germany

5:15 PM (350) A Single Center Experience: Four Cases of Late Twisting of Outflow Grafts in HeartMate 3; M. Mueller, J. Mulzer, C. Hoermandinger, F. Kaufmann, S. Dreyse, V. Falk, E. Potapov. Surgery, DHZB, Berlin, Germany

5:30 PM (351) Alternative Outflow Graft Placement During Thoracotomy Implant of the HVAD System for the Treatment of Advanced Heart Failure; D. Zimpfer¹, J. D. Schmitto², V. Horvath³, S. Klotz⁴, U. Kervan⁵, M. Pac⁵, J. C. Roussel⁶. ¹Medical University Vienna, Vienna, Austria, ²Hannover Medical School, Hannover, Germany, ³Center of Cardiovascular and Transplant Surgery, Prague, Czech Republic, ⁴University Hospital Luebeck, Luebeck, Germany, ⁵Turkiye Yuksek Ihtisas Education & Research Hospital, Ankara, Turkey, ⁶University of Nantes, Nantes, France

5:45 PM (352) Evidence for Subclinical, Progressive Outflow Graft Stenosis in Patients With Heartware HVAD; P. Jain, D. Robson, P. Jansz, C. Hayward. Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia

4:30 PM - 6:00 PM

ORAL SESSION 35: Out of Body Experiences: Ten Years of EVLP

Location: Mediterranean ABC

Target Audience: LTX

Chairs: Marcelo Cypel, MD, and Goran Dellgren, MD, PhD

4:30 PM (353) Results of the OCS Lung EXPAND International Trial Using Portable Normothermic OCS Lung Perfusion System (OCS) to Recruit and Evaluate Extended Criteria Donor (ECD) Lungs; G. Loo¹, G. Warnecke², M. Villavicencio³, M. Smith⁴, J. Kukreja⁵, A. Ardehali⁶, M. Hartwig⁷, M. Daneshmand⁷, M. Hertz⁸, A. Haverich², J. Madsen³, D. Van Raemdonck⁹. ¹Surgery, University of Minnesota, Minneapolis, MN, ²Hannover Medical School, Hannover, Germany, ³Massachusetts General Hospital, Boston, MA, ⁴St. Joseph's Medical Center, Phoenix, AZ, ⁵University of California San Francisco Medical Center (UCSF), San Francisco, CA, ⁶UCLA Medical Center, Los Angeles, CA, ⁷Duke University Medical Center, Durham, NC, ⁸University of Minnesota, Minneapolis, MN, ⁹Leuven University Hospital, Leuven, Belgium

4:45 PM (354) Negative Impact of Ischemia on Short and Long Term Outcomes in Standard Criteria Double Lung Transplants Prospective Evidence from the OCS Lung INSPIRE International Trial Results; G. Warnecke¹, D. Van Raemdonck², J. Kukreja³, M. Smith⁴, G. Loo⁵, F. Rea⁶, G. Massard⁷, F. De Robertis⁸, J. Nagendran⁹, J. Moradiellos¹⁰, K. Dhital¹¹, C. Knosalla¹², C. Bermudez¹³, S. Tsui¹⁴, J. Madsen¹⁵, I. Wang¹⁶, K. McCurry¹⁷, T. Deuse¹⁸, P. Thomas¹⁹, I. Tudorache¹, B. Wiegmann¹, M. Schiavon⁶, F. Calabrese⁶, N. Santelmo⁷, A. Olland⁷, P. Falcoz⁷, A. Varela¹⁰, M. Hertz⁵, A. Simon⁸, H. Resichenspurner¹⁸, A. Haverich¹, A. Ardehali²⁰. ¹Hannover Medical School, Hannover, Germany, ²Leuven University Hospital, Leuven, Belgium, ³University of California San Francisco Medical Center (UCSF), San Francisco, CA, ⁴St. Joseph's Medical Center, Phoenix, AZ, ⁵University of Minnesota Medical Center, Minneapolis, MN, ⁶University of Padua Hospital, Padua, Italy, ⁷University Hospital of Strasbourg, Strasbourg, France, ⁸Harefield Hospital, London, United Kingdom, ⁹University of Alberta Medical Center, Edmonton, AB, Canada, ¹⁰University Puerta de Hierro Hospital, Madrid, Spain, ¹¹St. Vincent's Hospital, Sydney, Australia, ¹²German Heart Institute, Berlin, Germany, ¹³University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, ¹⁴Papworth Hospital, Cambridge, United Kingdom, ¹⁵Massachusetts General Hospital, Boston, MA, ¹⁶Indiana University Health Methodist Hospital, Indianapolis, IN, ¹⁷Cleveland Clinic Foundation, Cleveland, OH, ¹⁸Hamburg University Hospital, Hamburg, Germany, ¹⁹University Hospitals of Marseille, Marseille, France, ²⁰UCLA Medical Center, Los Angeles, CA

5:00 PM (355) Ex-Vivo Lung Perfusion in Donation After Circulatory Death Lung Transplantation Increases Donor Utilization: Analysis of the NOVEL Extension Trial; B. A. Whitson¹, B. Shukrallah¹, M. S. Mulligan², J. D'Cunha³, M. Daneshmand⁴, T. Wozniak⁵, Z. Kon⁶, T. Machuca⁷, M. Jessen⁸, P. Sanchez³, E. Cantu⁹. ¹Dept of Surgery, Wexner Med Ctr, Columbus, OH, ²University of Washington, Seattle, WA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Duke, Raleigh, NC, ⁵Indiana University, Indianapolis, IN, ⁶University of Maryland, Baltimore, MD, ⁷University of Florida, Gainesville, FL, ⁸University of Texas Southwestern, Dallas, TX, ⁹University of Pennsylvania, Philadelphia, PA

5:15 PM (356) A Novel Parameter of Lung Evaluation Utilizing PaO₂/FiO₂ Difference at the Different FiO₂ in Ex Vivo Lung Perfusion; H. Niikawa¹, T. Okamoto¹, K. S. Ayyat¹, Y. Itoda¹, J. Hata², K. R. McCurry¹. ¹Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ²General Anesthesiology, Cleveland Clinic, Cleveland, OH

5:30 PM (357) Long Term Outcomes of Ex Vivo Lung Perfusion: A Single Center 10 Year Experience; C. Divithotawela, M. Cypel, S. Azad, L. Singer, M. Binnie, C. Chaparro, C. Chow, T. Martinu, S. Juvet, S. Keshavjee, J. Tikkanen. Toronto Lung Transplant Program, Toronto, ON, Canada

5:45 PM (358) Ex-vivo Lung Perfusion - 10 Year Follow-up of the First Performed Double LTX With Marginal Donor Lungs Evaluated Using EVLP; M. Fakhro, J. Andreasson, L. Pierre, R. Ingemansson, S. Lindstedt. Cardiothoracic Surgery, Lund University, Lund, Sweden

4:30 PM - 6:00 PM

ORAL SESSION 36: Antibodies and Rejection in Heart Transplantation: Donor Cells Tell No Lies

Location: Clio/Thalie/Erato

Target Audience: HTX, BSTR, EEP, HF, NHSAA, PATH

Chairs: Fabio M Turazza, MD, and Kiran Khush, MD, MAS

4:30 PM (359) Donor-Derived Cell-Free DNA in D-OAR, a Real World, Clinical Use Heart Transplant Population; J. A. Kobashigawa¹, S. Pinney², K. K. Khush³, M. Shullo⁴, D. Hiller⁵, R. N. Woodward⁵, S. Scott⁵, J. Sninsky⁵, J. P. Yee⁵, J. Teuteberg³. ¹Cedars-Sinai Heart Institute, Los Angeles, CA, ²Cardiology, Mount Sinai Health System, New York, NY, ³Stanford University, Stanford, CA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵CareDx, Brisbane, CA

(360) WITHDRAWN

4:45 PM (252) Donor Specific Antibodies in Heart Transplantation: Do Clinicians Need to do Something Always?; Y. Moayed¹, J. A. McCaughan², J. G. Duero Posada³, M. Alhussein³, L. A. Goldraich⁴, K. Runeckles⁵, S. Fan⁵, F. Foroutan⁶, C. Manhiot⁵, S. Kozusko³, A. C. Alba³, A. I. Dipchand⁷, K. Tinckam², H. J. Ross³. ¹Medicine, Stanford University, Palo Alto, CA, ²HLA laboratory and Dept of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada, ³Medicine, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Division of Cardiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵Biostatistics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Biostatistics and Epidemiology, McMaster University, Hamilton, ON, Canada, ⁷Medicine, Division of Cardiology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

5:00 PM (361) The Evolving (In)significance of Panel Reactive Antibody on Cardiac Transplantation Outcomes in the Modern Era; J. J. Chung¹, A. Thomasson², C. W. Chen¹, C. Pietras¹, A. C. Gaffey¹, J. Han¹, M. A. Acker¹, E. Y. Birati³, P. Atluri¹. ¹Surgery, University of Pennsylvania, Philadelphia, PA, ²Penn Transplant Institute, University of Pennsylvania, Philadelphia, PA, ³Medicine, University of Pennsylvania, Philadelphia, PA

5:15 PM (362) Development of Rejection Risk Prediction Model by Routine Monitoring for De-novo Donor Specific Antibodies After Heart Transplantation; K. WONG¹, B. Smith², T. Taner³, S. Kushwaha¹, B. Edwards¹, M. Gandhi⁴, W. Kremers², R. Daly³, N. Pereira⁵. ¹Dept of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, ³Dept of Surgery, Mayo Clinic, Rochester, MN, ⁴Dept of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁵Dept of Cardiovascular Disease; Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN

5:30 PM (363) Patients Bridged to Transplant with Durable LVAD Support Have a Higher Risk of Post-Transplant De Novo Donor Specific Antibodies; R. T. Cole¹, J. Minto², L. Bogar³, H. Miller², A. Morris¹, D. Gupta¹, A. Smith¹, J. Vega⁴, S. Laskar¹, K. Bhatt¹, P. Shah⁵. ¹Cardiology, Emory Univ Sch of Med, Atlanta, GA, ²George Washington University School of Medicine, Washington D.C., DC, ³Cardiothoracic Surgery, Inova Heart and Vascular Institute, Falls Church, VA, ⁴Cardiothoracic Surgery, Emory Univ Sch of Med, Atlanta, GA, ⁵Inova Heart and Vascular Institute, Falls Church, VA

5:45 PM (364) It's HLA-DR Not HLA-DQ Donor-specific Antibody That is Correlated to CAV After Heart Transplant; M. Olymbios, M. Kittleson, J. Patel, L. Czer, D. H. Chang, S. Dimbil, R. Levine, M. Curry, B. Azarbal, A. Hage, D. Ramzy, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

4:30 PM - 6:00 PM

ORAL SESSION 37: New Treatment Paradigms in Pulmonary Hypertension

Location: Uranie/Calliope

Target Audience: PH, HF, MCS, PHARM

Chairs: Marc A. Simon, MD, and Dana McGlothlin, MD

4:30 PM (365) Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function; R. L. Benza¹, P. A. Corris², J. R. Klinger³, D. Langleben⁴, R. Naeije⁵, G. Simonneau⁶, C. Vizza⁷, H. Wirtz⁸, M. Patarroyo-Aponte⁹, M. Chang¹⁰, P. Colorado¹¹, C. Meier¹⁰, D. Busse¹², M. M. Hoeper¹³. ¹Allegheny Gen Hosp, Pittsburgh, PA, ²Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom, ³Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, ⁴Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁵Dept of Cardiology, Erasme University Hospital, Brussels, Belgium, ⁶Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre, France, ⁷Dept of Cardiovascular and Respiratory Sciences, Sapienza University of Rome, Rome, Italy, ⁸Dept of Respiratory Medicine, University of Leipzig, Leipzig, Germany, ⁹Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, ¹⁰Global Medical Affairs, Bayer AG, Berlin, Germany, ¹¹Global Clinical Development, Bayer AG, Barcelona, Spain, ¹²Chrestos Concept GmbH & Co. KG, Essen, Germany, ¹³Clinic for Respiratory Medicine, Hannover Medical School, member of the German Center for Lung Research (DZL), Hannover, Germany

4:45 PM (366) Rates of Hospitalization Associated with the Use of Aldosterone Receptor Antagonists in Patients with Pulmonary Arterial Hypertension; M. E. Corkish¹, L. T. Devine², M. M. Clarke¹, B. P. Murray¹, I. B. Hollis¹, L. J. Rose-Jones¹. ¹University of North Carolina Medical Center, Chapel Hill, NC, ²Massachusetts General Hospital, Boston, MA

5:00 PM (367) OPUS Registry: Switching to Macitentan From Other Endothelin Receptor Antagonists (ERAs); A. Ravichandran¹, R. Channick², K. M. Chin³, N. H. Kim⁴, M. Brand⁵, M. Selej⁶, V. V. McLaughlin⁷. ¹St. Vincent Heart Center, Indianapolis, IN, ²Massachusetts General Hospital, Boston, MA, ³UT Southwestern Medical Center, Dallas, TX, ⁴University of California San Diego, La Jolla, CA, ⁵Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ⁶Actelion Pharmaceuticals US, Inc, South San Francisco, CA, ⁷University of Michigan, Ann Arbor, MI

5:15 PM (368) Characteristics of Patients With CTD-associated PAH Treated With Selexipag in the Real-world Setting: Interim Data From the SPHERE Registry; K. B. Highland¹, H. W. Farber², N. H. Kim³, K. M. Chin⁴, A. R. Hemnes⁵, M. M. Chakinala⁶, C. Zhao⁷, M. Keating⁷, B. Hartline⁷, V. McLaughlin⁸. ¹Cleveland Clinic, Cleveland, OH, ²Boston University School of Medicine, Boston, MA, ³University of California San Diego Medical Center, San Diego, CA, ⁴University of Texas, Southwestern Medical Center, Dallas, TX, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Actelion Pharmaceuticals US, Inc., South San Francisco, CA, ⁸University of Michigan Medical Center, Ann Harbor, MI

5:30 PM (369) Intravenous Treprostinil Delivered by Implantable Pump for the Treatment of Pulmonary Arterial Hypertension - Report of First 11 Cases; D. Rosengarten¹, B. D. Fox², R. G. Balmor¹, A. Balenky¹, N. Natif², A. Unterman¹, A. Avriel³, Y. Adir⁴, M. J. Segel⁵, M. R. Kramer¹. ¹Rabin medical center, Petach tikva, Israel, ²Assaf Harofeh, Rishon-Le-Zion, Israel, ³Soroka medical center, Beer sheva, Israel, ⁴Carmel medical center, Haifa, Israel, ⁵Sheba medical center, Ramat gan, Israel

5:45 PM (370) LVAD Does Not Improve Outcomes in Patients with Pulmonary Hypertension after Heart Transplantation; C. R. Brown¹, F. N. Khurshan¹, Z. Chen¹, P. Zamani², J. A. Mazurek², F. H. McCarthy¹, M. A. Acker¹, N. D. Desai¹, J. Rame². ¹Division of Cardiac Surgery, University of Pennsylvania, Philadelphia, PA, ²Cardiovascular Division, University of Pennsylvania, Philadelphia, PA

4:30 PM - 6:00 PM

ORAL SESSION 38: Hot Topics in Infectious Diseases

Location: Hermes

Target Audience: ID, HTX, LTX, MCS

Chairs: Cameron R Wolfe, MBBS MPH, and Orla Morrissey, MD

4:30 PM (371) Mortality Outcomes Related to Multi-drug Resistant Organisms in Cystic Fibrosis Lung Transplant Recipients: An International Society of Heart and Lung Transplantation (ISHLT) Registry Study; C. Lay¹, N. Law¹, A. M. Holm², C. Benden³, S. Aslam¹. ¹University of California, San Diego, San Diego, CA, ²Oslo University Hospital, Oslo, Norway, ³University Hospital Zurich, Zurich, Switzerland

4:45 PM (372) A Phase 2b Randomized Controlled Trial of Presatovir, an Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Lung Transplant (LT) Recipients; J. Gottlieb¹, F. Torres², T. Haddad³, G. Dhillon⁴, D. F. Dilling⁵, C. Knoop⁶, R. Rampolla⁷, R. Walia⁸, V. Ahya⁹, R. Kessler¹⁰, D. P. Mason¹¹, M. Budev¹², C. Neurohr¹³, A. R. Glanville¹⁴, R. Jordan¹⁵, D. Porter¹⁵, M. T. McKeivitt¹⁵, P. German¹⁵, Y. Guo¹⁵, J. W. Chien¹⁵, T. R. Watkins¹⁵, M. Zamora¹⁶. ¹Hannover Medical School, Hannover, Germany, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Tampa General Hospital, Tampa, FL, ⁴Stanford University Medical Center, Stanford, CA, ⁵Loyola University Chicago, Maywood, IL, ⁶Erasmee University Hospital, Brussels, Belgium, ⁷Ochsner Clinic Foundation, New Orleans, LA, ⁸St. Joseph's Hospital and Medical Center, Phoenix, AZ, ⁹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁰University of Strasbourg, Strasbourg, France, ¹¹Baylor University Medical Center, Dallas, TX, ¹²Cleveland Clinic Foundation, Cleveland, OH, ¹³University of Munich, Munich, Germany, ¹⁴St. Vincent's Hospital, Darlinghurst, Australia, ¹⁵Gilead Sciences Inc., Foster City, CA, ¹⁶University of Colorado at Denver Health Sciences Center, Aurora, CO

5:00 PM (373) Bacteriophage Treatment in a Lung Transplant Recipient; S. Aslam¹, G. Yung¹, J. Dan¹, S. Reed¹, M. LeFebvre¹, C. Logan¹, R. Taplitz¹, N. Law¹, E. Golts¹, K. Afshar¹, S. Lehman², S. Morales², C. Furr², F. Rosas², A. Gaidamaka², I. Bilinsky², P. Grint², B. Biswas³, C. Duplessis³, T. Hamilton³, R. Schooley¹. ¹University of California San Diego, San Diego, CA, ²AmpliPhi Biosciences Corporation, San Diego, CA, ³Naval Medical Research Center, Fort Detrick, MD

5:15 PM (374) Using Ultraviolet C Irradiation as a Sterilization Method for Organ Perfusion Systems; M. Galasso, A. Patel, C. Summers, R. Ribeiro, Y. Zhang, A. Ali, A. Gazzalle, M. Liu, S. Keshavjee, M. Cypel. *Thoracic Surgery, Latner Thoracic Surgery Laboratories - University Health Network, Toronto, ON, Canada*

5:30 PM (375) Chagas' Disease Reactivation after Heart Transplant: Update on New Immunosuppression Era; I. W. Campos, L. F. Seguro, C. R. Andrade, F. G. Marcondes-Braga, L. P. Soares, M. S. Avila, S. Mangini, M. C. Galante, F. A. Gaiotto, T. Strabelli, F. Bacal. *Heart Institute (InCor), São Paulo, Brazil*

5:45 PM (376) Defining Severe Secondary Antibody Deficiency in Heart and Lung Transplantation; J. Carbone¹, I. Sousa², J. Cifrian³, M. Gomez-Sanchez⁴, R. Laporta⁵, M. Crespo-Leiro⁶, C. Bravo⁷, L. Almenar⁸, A. Sole⁹, G. Rabago¹⁰, J. Segovia¹¹, A. de Pablos¹², J. Lopez¹³, S. Mirabet¹⁴, J. Navarro¹, E. Sarmiento¹. ¹Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pneumology, Hospital Marques de Valdecilla, Santander, Spain, ⁴Cardiology, Hospital Universitario Doce de Octubre, Madrid, Spain, ⁵Pneumology, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁶Cardiology, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁷Pneumology, Hospital Valle de Hebron, Barcelona, Spain, ⁸Cardiology, Hospital Universitario La Fe, Valencia, Spain, ⁹Pneumology, Hospital Universitario La Fe, Valencia, Spain, ¹⁰Heart Surgery, Clínica Universitaria de Navarra, Navarra, Spain, ¹¹Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹²Pneumology, Hospital Universitario Doce de Octubre, Madrid, Spain, ¹³Cardiology, Hospital Clínico Universitario, Valladolid, Spain, ¹⁴Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

4:30 PM - 6:00 PM

ORAL SESSION 39: All Is Not Lost: Improving Outcomes in Children with a Failing Heart

Location: Mediterranean 6

Target Audience: PEDS, HF, HTX, MCS, NHSAAH

Chairs: Adam Putschoegl, DO, and Estela Azeka, MD

4:30 PM (377) Survival and Outcome in Pediatric Myocarditis - 3 Year Data from the German Multi-center Prospective Myocarditis Registry: "MYKKE"; S. Schubert¹, B. Opgen-Rhein², M. Böhne³, A. Weigelt⁴, R. Wagner⁵, G. Müller⁶, A. Rentzsch⁷, A. Racolta⁸, K. Papakostas⁹, G. Wiegand¹⁰, B. Ruf¹¹, T. Hannes¹², K. Reineker¹³, D. Kiski¹⁴, M. Khalil¹⁵, M. Steinmetz¹⁶, G. Fischer¹⁷, T. Pickardt¹⁸, K. Klingel¹⁹, D. Messroghli²⁰, F. Degener¹. ¹Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany, ²Klinik für Pädiatrie mit Schwerpunkt Kardiologie, Charité Univ Berlin, Berlin, Germany, ³Pediatric Cardiology, Med Hochschule Hannover, Hannover, Germany, ⁴Pediatric Cardiology, Univ Erlangen, Erlangen, Germany, ⁵Pediatric Cardiology, Herzzentrum Leipzig, Leipzig, Germany, ⁶Pediatric Cardiology, Univ Herzzentrum Hamburg, Hamburg, Germany, ⁷Pediatric Cardiology, Univ des Saarlandes, Homburg, Germany, ⁸Pediatric Cardiology, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany, ⁹Pediatric Cardiology, Klinikum Links der Weser, Bremen, Germany, ¹⁰Pediatric Cardiology, Univ Tübingen, Tübingen, Germany, ¹¹Pediatric Cardiology, Deutsches Herzzentrum München, München, Germany, ¹²Pediatric Cardiology, Uniklinik Köln, Köln, Germany, ¹³Pediatric Cardiology, Univ-Herzzentrum Freiburg Bad Krozingen, Freiburg, Germany, ¹⁴Pediatric Cardiology, Univ Münster, Münster, Germany, ¹⁵Pediatric Cardiology, Univ Gießen, Gießen, Germany, ¹⁶Pediatric Cardiology, Univ Göttingen, Göttingen, Germany, ¹⁷Pediatric Cardiology, Univ Schleswig-Holstein, Kiel, Germany, ¹⁸Kompetenznetz Angeborene Herzfehler, Berlin, Germany, ¹⁹Dept for Pathology, Univ Tübingen, Tübingen, Germany, ²⁰Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

4:45 PM (378) Acute Decompensated Heart Failure in the Pediatric Population: A Report from the Pediatric Cardiac Critical Care Consortium (PC⁴); J. J. Lasa¹, M. Gaies², J. Rossano³, L. Retzloff², W. Zhang², M. Banerjee⁴, J. Elhoff¹, A. Lorts⁵, K. Schumacher², R. Butts⁶, A. Cabrera⁷, J. Alten⁸, J. Price⁷. ¹Critical Care Medicine and Cardiology, Texas Children's Hospital, Houston, TX, ²Cardiology, C.S. Mott Children's Hospital, Univ of Michigan, Ann Arbor, MI, ³Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Institute for Healthcare Policy and Innovation, Univ of Michigan, Ann Arbor, MI, ⁵Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, ⁶Cardiology, Children's Health, UT Southwestern, Dallas, TX, ⁷Cardiology, Texas Children's Hosp, Houston, TX, ⁸Critical Care Medicine, Univ of Alabama-Birmingham, Birmingham, AL

5:00 PM (379) The First Analysis of the International Pediatric Heart Failure Registry (iPHFR) - Heart Failure Hospitalizations; A. I. Dipchand¹, W. Zuckerman², S. Auerbach³, J. Conway⁴, W. Cherikh⁵, D. Peng⁶, A. Barnes⁷, B. Kaufman⁸, P. Thrush⁹, A. Sadavarte⁵, C. Almond⁸, E. Pahl⁹, E. Azeka¹⁰, R. Gajarski¹¹, Y. Law¹², A. Lorts¹³, C. VanderPluym¹⁴, R. Kirk¹⁵. ¹Hosp for Sick Children, Toronto, ON, Canada, ²Morgan Stanley Children's Hospital of New York, Columbia Univ Medical Center, New York, NY, ³Children's Hospital Colorado Heart Institute, Denver, CO, ⁴Stollery Children's Hospital, Edmonton, AB, Canada, ⁵United Network for Organ Sharing, Richmond, VA, ⁶Congenital Heart Center at Mott Children's Hospital, Ann Arbor, MI, ⁷Children's Mercy Hospital and Clinics, Kansas City, MO, ⁸Lucile Packard Children's Hospital at Stanford, Stanford, CA, ⁹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁰Heart Institute (InCor) Univ of São Paulo Medical School, São Paulo, Brazil, ¹¹Nationwide Children's Hospital, Columbus, OH, ¹²Seattle Children's Hospital, Seattle, WA, ¹³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Boston Children's Hospital, Boston, MA, ¹⁵Children's Medical Center, Dallas, TX

5:15 PM (380) Trends in Pediatric Mechanical Circulatory Support: Are Patients, Devices, and Outcomes Changing?; R. S. Cantor¹, D. C. Naftel¹, D. N. Rosenthal², E. D. Blume³, J. K. Kirklin¹. ¹Kirklin Institute for Research in Surgical Outcomes (KIRSO), Univ of Alabama at Birmingham, Birmingham, AL, ²Stanford Univ, Palo Alto, CA, ³Boston Children's Hosp, Boston, MA

5:30 PM (381) Impact of Pre-implant Illness Severity on Outcomes of Pediatric VAD Patients; A. Butto¹, S. A. Teele¹, L. A. Sleeper¹, P. T. Thrush², J. Philip³, M. Lu¹, R. S. Cantor⁴, J. W. Rossano⁵. ¹Dept of Cardiology, Boston Children's Hospital, Boston, MA, ²Division of Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Congenital Heart Center, Univ of Florida, Gainesville, FL, ⁴Kirklin Institute for Research in Surgical Outcomes, Univ of Alabama at Birmingham, Birmingham, AL, ⁵The Cardiac Center, Div of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA

5:45 PM (382) Outcomes of Children With Congenital Heart Disease Implanted With Ventricular Assist Devices: Analysis of the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs); D. M. Peng¹, D. A. Koehl², R. S. Cantor², K. N. McMillan³, A. P. Barnes⁴, P. I. McConnell⁵, J. Jordan¹, N. D. Andersen⁶, J. D. St. Louis⁴, K. Maeda⁷, J. K. Kirklin², S. J. Kindel⁸. ¹*Pediatrics (Cardiology), Univ of Michigan, Ann Arbor, MI*, ²*Univ of Alabama at Birmingham, Birmingham, AL*, ³*Johns Hopkins Univ, Baltimore, MD*, ⁴*Univ of Missouri-Kansas City, Kansas City, MO*, ⁵*Ohio State Univ, Columbus, OH*, ⁶*Harvard Univ, Boston, MA*, ⁷*Stanford Univ, Palo Alto, CA*, ⁸*Medical College of Wisconsin, Milwaukee, WI*

6:15 PM - 7:15 PM

MINI ORAL 13: Mechanical Circulatory Support: Bleeding

Location: Athena

Target Audience: MCS, PHARM

Chairs: Dipanjan Banerjee, MD, and Claudius Mahr, DO

6:15 PM (383) Higher Soluble Thrombomodulin and Angiogenic Markers in LVAD Supported Patients Associate with Arteriovenous Malformation and Non-Surgical Bleeding; K. Muthiah¹, L. L. Dunn², D. Connor³, J. Joseph⁴, D. Robson¹, P. Macdonald¹, R. Stocker², C. S. Hayward¹. ¹Heart Failure and Transplant Unit, St. Vincent's Hospital, Sydney, Sydney, Australia, ²Victor Chang Cardiac Research Institute, Sydney, Australia, ³St. Vincent's Center For Applied Medical Research, Sydney, Australia, ⁴Dept of Haematology, St. Vincent's Hospital, Sydney, Sydney, Australia

6:20 PM (384) Enhanced Thrombin Formation in Patients with Implanted LVADs Experiencing GI and Other Bleeding: Insights from the Multi-center PREVENT Study; W. P. Jeske¹, P. Maia¹, J. Ransom², M. Keebler³, J. Katz⁴, A. Kilic⁵, J. Lindenfeld³, G. Egnaczyk⁶, P. Shah⁷, A. Brieke⁸, N. Uriel⁹, S. Maltais¹⁰, D. Crandall¹¹, K. Sundareswaran¹¹, D. Farrar¹¹, J. Walenga¹. ¹Loyola Univ Medical Center, Maywood, IL, ²Baptist Health Heart and Transplant Institute, Little Rock, AR, ³Vanderbilt Univ, Nashville, TN, ⁴Univ of North Carolina, Chapel Hill, NC, ⁵Ohio State Univ, Columbus, OH, ⁶Christ Hospital, Cincinnati, OH, ⁷Inova Heart and Vascular Institute, Falls Church, VA, ⁸Univ of Colorado, Aurora, CO, ⁹Univ of Chicago, Chicago, IL, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Abbott, Chicago, IL

6:25 PM (385) SSRI/SNRI Therapy is Associated with a Higher Risk of GI Bleed in LVAD Patients; G. Mawardi¹, T. Markman², R. Muslem³, M. Sobhanian⁴, M. Converse⁴, H. Meadows⁴, W. E. Uber⁴, D. P. Judge⁴, R. J. Tedford⁴, B. A. Houston⁴. ¹Internal Medicine, Medical University of South Carolina, Charleston, SC, ²Cardiology, University of Pennsylvania School of Medicine, Philadelphia, PA, ³Cardiology, The Johns Hopkins School of Medicine, Baltimore, MD, ⁴Cardiology, Medical University of South Carolina, Charleston, SC

6:30 PM (386) Impact of Anemia on Survival Among Patients with Durable Ventricular Assist Device: An Analysis of the Prevent Study; S. Zalawadiya¹, A. Shah¹, M. Keebler¹, R. John², I. Gregoric³, A. Kilic⁴, R. Adamson⁵, P. Shah⁶, R. Agarwal⁷, S. Maltais⁸, D. Crandall⁹, K. Sundareswaran⁹, D. Farrar⁹, J. Lindenfeld¹. ¹Vanderbilt, Nashville, TN, ²University of Minnesota, Minneapolis, MN, ³Memorial Hermann, Houston, TX, ⁴Ohio State University, Columbus, OH, ⁵Sharp Memorial, San Diego, CA, ⁶Inova Heart and Vascular Institute, Fall Church, VA, ⁷Allegheny General Hospital, Pittsburgh, PA, ⁸Mayo Clinic, Rochester, MN, ⁹Abbott (formerly St Jude Medical), Chicago, IL

6:35 PM (387) Ticagrelor but not Aspirin Limits Shear-Mediated Platelet Activation; J. Sheriff¹, P. L. Tran², L. Valerio³, M. Hutchinson², D. Bluestein¹, M. J. Slepian⁴. ¹Biomedical Engineering, Stony Brook University, Stony Brook, NY, ²Biomedical Engineering, University of Arizona, Tucson, AZ, ³Electronics, Information, and Bioengineering, Politecnico di Milano, Milan, Italy, ⁴Biomedical Engineering and Sarver Heart Center, University of Arizona, Tucson, AZ

6:40 PM (388) A Prospective Validation of the First Endoscopic Management Algorithm for Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices; J. E. Axelrad¹, A. Pinsino², A. Thanataveerat³, B. Cagliostro², M. A. Flannery², K. Ross², R. T. Te-Frey², L. Effner², A. R. Garan², V. K. Topkara², H. Takayama⁴, K. Takeda⁴, Y. Naka⁴, P. Colombo², T. Gonda¹, M. Yuzepolskaya². ¹Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, ²Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY, ³Epidemiology, Mailman School of Public Health, New York, NY, ⁴Surgery, Columbia University Medical Center, New York, NY

6:45 PM (389) MCS Shear-Medicated Platelet Activation Does not Cause Integrin GPIIb/IIIa Activation, Rather Shedding and Microparticle Generation; Y. Roka-Moii¹, D. E. Palomares¹, J. Sheriff², D. Bluestein², M. J. Slepian¹. ¹Dept of Medicine and Biomedical Engineering, Sarver Heart Center, University of Arizona, Tucson, AZ, ²Dept of Biomedical Engineering, Stony Brook University, Stony Brook, NY

6:50 PM (390) Reduced Rate of Gastrointestinal Bleeding in Recipients of the HeartMate3 Compared to HeartMate II Ventricular Assist Devices; G. Faerber, H. Kirov, T. Sandhaus, S. Tkebuchava, T. Doenst. Univ Clinic Jena, Jena, Germany

6:55 PM (391) Can a More Rapid "Time to Therapeutic INR" Reduce Adverse Events After CF-LVAD Implantation? A Single Center Study; C. Michaud, A. Rosene, N. Manandhar Shrestha, T. Boeve, M. Leacche, S. Jovinge, S. Lee. Spectrum Health, Grand Rapids, MI

7:00 PM (392) Association Between Angiotensin II Receptor Blockade and Recurrent Gastrointestinal Bleeding on Left Ventricular Assist Device Support; J. N. Schultz¹, K. Goodwin², R. John³, T. Alexy⁴, F. Kamdar⁴, C. Martin⁴, R. Cogswell⁴. ¹Dept of Medicine, University of Minnesota, Minneapolis, MN, ²Dept of Surgery, University of Minnesota, Minneapolis, MN, ³Dept of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, ⁴Dept of Cardiology, University of Minnesota, Minneapolis, MN

7:05 PM (393) A Multidisciplinary Continuous Support Heart Team Approach Improves Hemocompatibility Related Outcomes in Continuous Flow LVAD Recipients; A. M. Shah¹, E. Ong¹, D. Sims¹, N. Siddiqi¹, A. Luke¹, O. Saeed¹, S. Patel¹, S. Murthy¹, J. Shin¹, S. Watts¹, W. Jakobleff², S. Forest², S. Vukelic¹, D. Belov¹, Y. Puius³, G. Minamoto³, V. Muggia³, A. Carlese⁴, S. Leung⁴, M. Rahmanian⁴, J. Leff⁵, D. Goldstein², U. Jorde¹. ¹Division of Cardiology, Montefiore Medical Center, Bronx, NY, ²Division of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Bronx, NY, ³Division of Infectious Disease, Montefiore Medical Center, Bronx, NY, ⁴Division of Critical Care Medicine, Montefiore Medical Center, Bronx, NY, ⁵Division of Cardiothoracic Anesthesia, Montefiore Medical Center, Bronx, NY

7:10 PM (394) Omega-3 Reduces Gastrointestinal Bleeding in Patients With Continuous-flow Left Ventricular Assist Device; T. Imamura¹, D. Rodgers¹, G. Kim¹, J. Raikhelkar¹, N. Sarswat¹, S. Kalantari¹, A. Nguyen¹, B. Chung¹, C. Juricek¹, D. Burkhoff², T. Song¹, T. Ota¹, V. Jeevanandam¹, G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY

6:15 PM - 7:15 PM

MINI ORAL 14: Lung Transplantation: Organ Allocation and Candidate Selection

Location: Clio/Thalie/Erato

Target Audience: LTX

Chairs: Olivier Brugière, and Kevin M Chan, MD

6:15 PM (395) Pre-Transplant Evaluation of Patients with History of Skin Cancer: Survey Among Lung Transplant Centers, and The Outcome from a Single Center Intervention; A. M. Emtiazjoo¹, O. Chukwuma², K. Potter², S. Chandrashekar³, H. Alnuaimat¹, A. Pelaez¹, T. Machuca⁴, M. Pipkin⁴, M. I. Longo². ¹University of Florida, Gainesville, FL, ²Dermatology, University of Florida, Gainesville, FL, ³Medicine, University of Florida, Gainesville, FL, ⁴Surgery, University of Florida, Gainesville, FL

6:20 PM (396) Lung Transplantation for Scleroderma Lung Disease: Indications, Survival and Prognosis; P. Pradère¹, I. Tudorache², J. Magnusson³, L. Savale⁴, O. Brugière⁵, B. Douvry⁶, M. Reynaud-Gaubert⁷, J. Claustre⁸, A. Le Borgne⁹, A. M. Holm¹⁰, H. H. Schulz¹¹, C. Knoop¹², L. Godinas¹³, A. Fisher¹⁴, S. Hirschi¹⁵, J. Gottlieb¹⁶, J. Le Pavec¹. ¹Service de chirurgie thoracique, Hôpital Marie Lannelongue, Le Plessis Robinson, France, ²Dept of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hanover, Germany, ³Dept of Internal Medicine/Respiratory Medicine and Allergology, Institute of Medicine, University of Gothenburg, Sweden, ⁴Service de pneumologie, Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France, ⁵Service de pneumologie, Hôpital Bichat, Paris, France, ⁶Service de pneumologie, Hôpital Foch, Suresnes, France, ⁷Service de pneumologie, Marseille North University Hospital, Marseille, France, ⁸Service de pneumologie, Centre Hospitalo-Universitaire, Grenoble, France, ⁹Pôles des voies respiratoires, Hôpital Larrey, Toulouse, France, ¹⁰Dept of Respiratory Medicine, Oslo University Hospital and Institute for Clinical Medicine University of Oslo, Oslo, Norway, ¹¹Dept of Cardiology, Section for lung transplantation, Copenhagen University Hospital, Copenhagen, Denmark, ¹²Brussels Lung Transplant Program, Dept of Chest Medicine, Erasme University, Brussels, Belgium, ¹³Service de pneumologie, Centre Hospitalo-Universitaire UCL, Namur, Belgium, ¹⁴Institute of Transplantation, Newcastle Upon Tyne Hospitals, Newcastle, United Kingdom, ¹⁵Dept of Respiratory Diseases and Lung Transplantation Group, Strasbourg University Hospital, Strasbourg, France, ¹⁶Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany

6:25 PM (397) Outcomes of Lung Transplantation for Patients Undergoing Previous or Simultaneous Cardiac Surgery; H. Niikawa¹, T. Okamoto^{1,2}, L. Thuita³, K. S. Ayyat^{1,4}, Y. Itoda¹, S. Unai¹, D. Johnston¹, U. Ahmad¹, A. Zeeshan¹, E. H. Blackstone³, K. R. McCurry^{1,2}. ¹Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ²Transplant Center, Cleveland Clinic, Cleveland, OH, ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Cardiothoracic Surgery, Zagazig University, Zagazig, Egypt

6:30 PM (398) Lower Six Minute Walk distance or FEV1 Predict a Survival Benefit of Lung Transplantation compared to Medical Management for End Stage COPD; I. Timofte¹, M. Wijesinha², R. Vesselinov³, J. Kim⁴, Z. Kon³, R. Reed⁴, K. Rajagopal⁵, S. Scharf³, R. Wise⁶, A. Sternberg⁷, D. Kaczorowski³, B. Griffith³, M. Terrin⁸, A. Iacono⁹. ¹Pulmonary and Critical Care, University of Maryland School of Medicine, Baltimore, MD, ²Epidemiology & Public Health, UMMC, Baltimore, MD, ³UMMC, Baltimore, MD, ⁴Pulmonary and Critical Care, UMMC, Baltimore, MD, ⁵University of Texas, Houston, TX, ⁶Pulmonary and Critical Care, JHU, Baltimore, MD, ⁷JHU, Baltimore, MD, ⁸Epidemiology and Public Health, UMMC, Baltimore, MD, ⁹University of Maryland School of Medicine, Baltimore, MD

6:35 PM (399) Frailty as a Predictor of Prognostic Outcomes in Patients with Interstitial Lung Disease Referred for Lung Transplantation; E. Montgomery¹, P. Macdonald¹, P. Newton², S. Jha¹, M. Hannu¹, C. Thomson¹, A. Glanville¹, A. Havryk¹, M. Plit¹, R. Pearson¹, M. Benzimra¹, M. Harkess¹, M. Malouf¹. ¹Heart & Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, ²University of Western Sydney, Sydney, Australia

6:40 PM (400) A Nordic Multicenter Study on Size Mismatch in Bilateral Lung Transplantation; H. Auråen¹, A. E. Fiane², O. Geiran², P. Hämmäinen³, M. Perch⁴, H. Larsson⁵, G. Dellgren⁶, M. Durheim¹, A. M. Holm¹. ¹Dept. of Respiratory Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Dept. of Cardiothoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway, ³Dept. of Cardiothoracic Surgery, Helsinki University Hospital, Helsinki, Finland, ⁴Division of Lung Transplantation, Dept. of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, ⁵Division of Respiratory Medicine and Allergology, Dept. of Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden, ⁶Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

6:45 PM (401) Does Gender of the Donor and Recipient Influence Survival After Lung Transplantation?; S. Chandrashekar¹, J. Gregg, L. Mramba, A. Emtiazjoo, H. Alnuaimat, S. Nandavaram, V. Scheuble, M. Pipkin, A. Pelaez, T. Machuca. University Of Florida, Gainesville, FL

6:50 PM (402) Blood Group O is Associated with Decreased Rates of Transplantation and Increased Waitlist Mortality in Lung Transplantation: A Propensity-Matched Registry Analysis; Y. Barac, M. Mulvihill, M. Cox, M. Bishawi, J. Klapper, J. Haney, M. Daneshmand, M. Hartwig. *Duke University Medical Center, Durham, NC*

6:55 PM (403) Geographic Disparities in Donor Lung Availability Impact Waitlist Outcomes in Lung Transplant Candidates: A Retrospective Cohort Study; L. J. Benvenuto¹, D. R. Anderson², H. P. Kim³, J. L. Hook¹, L. Shah¹, H. Robbins¹, F. D'Ovidio⁴, M. Bacchetta⁴, J. R. Sonett⁴, S. M. Arcasoy¹. ¹*Medicine, Columbia University Medical Center, New York, NY*, ²*Dept of Management, Baruch College, New York, NY*, ³*Medicine, New York Presbyterian, New York, NY*, ⁴*Surgery, Columbia University Medical Center, New York, NY*

7:00 PM (404) BLTX on Intraoperative ECMO Sets the New Benchmark for Postoperative Graft Function: Results of a Prospective Trial; K. Hoetzenecker, A. Benazzo, T. Stork, K. Sinn, S. Schwarz, D. Baron, H. Hager, P. Faybik, A. Bacher, C. Krenn, H. Prosch, W. Klepetko. *Medical University of Vienna, Vienna, Austria*

7:05 PM (405) Outcomes of ECMO Bridge to Lung Transplantation are Dependent on Age; M. Caceres Polo¹, A. Iyengar², O. Kwon¹, J. Schaenman¹, R. Biniwale¹, D. Ross¹, E. DePasquale¹, A. Ardehali¹. ¹*University of California - Los Angeles, Los Angeles, CA*, ²*David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA*

7:10 PM (406) Pre-Transplant Opioid Use is Associated with Increased Early Mortality and Readmission after Lung Transplantation; H. Heiney¹, C. J. Iasella¹, C. A. Moore¹, R. Venkataramanan¹, M. R. Morrell¹, J. Hayanga², N. Shigemura³, A. Zeevi¹, J. F. McDyer¹, C. R. Ensor¹. ¹*University of Pittsburgh, Pittsburgh, PA*, ²*West Virginia University, Morgantown, WV*, ³*Temple University, Philadelphia, PA*

6:15 PM - 7:15 PM

MINI ORAL 15: Heart Transplantation: Donor Issues

Location: Uranie/Calliope

Target Audience: HTX, BSTR, EEP, NHSAA, PATH

Chairs: Lars H Lund, MD, PhD, and Alejandro M Bertolotti, MD

6:15 PM (407) *The Effect of Donor Age on Post-Transplant Mortality in a Cohort of Cardiac Transplant Recipients Aged 18 to 45*; A. L. Axtell¹, A. G. Fiedler¹, D. C. Chang², H. Yeh³, G. D. Lewis⁴, M. A. Villavicencio¹, D. A. D'Alessandro¹. ¹Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ²Dept of Surgery, Massachusetts General Hospital, Boston, MA, ³Division of Transplant Surgery, Massachusetts General Hospital, Boston, MA, ⁴Dept of Cardiology, Massachusetts General Hospital, Boston, MA

6:20 PM (408) *Left Ventricular Dysfunction in Potential Heart Donors and Its Impact on Recipient Outcomes*; J. Oras¹, L. Johansson¹, B. Redfors², E. Omerovic², G. Dellgren³. ¹Dept of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, Göteborg, Sweden, ²Dept of Cardiology, Institute of Medicine, Sahlgrenska Academy, Göteborg, Sweden, ³Dept of Cardiothoracic Surgery, Institute of Medicine, Sahlgrenska Academy, Göteborg, Sweden

6:25 PM (409) *Donor Simvastatin Treatment Alters Protein Expression in the Recipient after Heart Transplantation*; J. Lukac¹, E. Holmström¹, S. Joenväärä¹, M. Saraswat¹, R. Krebs¹, T. Tohmola¹, A. Nykänen², R. Renkonen¹, K. Lemström². ¹Cardiopulmonary Research Group, Transplantation Laboratory Univ of Helsinki, Helsinki, Finland, ²Cardiopulmonary Research Group, Transplantation Laboratory Cardiothoracic Surgery, Helsinki Univ Hospital, Helsinki, Finland

6:30 PM (410) *Donor Age and Ischemic Time - Implications for Efficacy of Ex-Vivo Organ Perfusion*; V. Jernryd¹, J. Stehlik², G. J. Smith³, L. H. Lund⁴, B. Andersson⁵, H. Bergenfeldt¹, J. Nilsson¹. ¹Clinical Sciences Lund, Cardiothoracic Surgery, Lund University, Skane Univ Hospital, Lund, Sweden, ²Cardiovascular Medicine, Univ of Utah School of Medicine, Salt Lake City, UT, ³Clinical Sciences Lund, Cardiology, Lund University, Skane Univ Hospital, Lund, Sweden, ⁴Medicine and Heart and Vascular Theme, Karolinska Institutet, Karolinska Univ Hospital, Stockholm, Sweden, ⁵Clinical Sciences Lund, Surgery, Lund Univ, Skane Univ Hospital, Lund, Sweden

6:35 PM (411) *Optimal Characteristics of Donor Hearts With Diminished Left Ventricular Function*; A. B. Davila¹, D. Estevez², L. L. Bailey¹, A. J. Razzouk¹, D. G. Rabkin¹. ¹Cardiovascular and Thoracic Surgery, Loma Linda Univ Medical Center, Loma Linda, CA, ²Research Consulting Group, Loma Linda Univ School of Public Health, Loma Linda, CA

6:40 PM (412) *Survival and Graft Function in Heart Transplant Patients Receiving Adverse Risk Profile Donor Hearts*; K. Berg. Health, AU, Aarhus University, Århus, Denmark

6:45 PM (413) *Coronary Angiography of Potential Cardiac Donors Increases Cardiac Transplantation Rates*; A. Zuckermann¹, K. Auersperg², A. Kaider³, m. De Pauw⁴, Z. Sutlic⁵, J. Gummert⁶, M. Berchtold-Herz⁷, C. Schulze⁸, I. hartyanszky⁹, K. Caliskan¹⁰, I. Knezevic¹¹, J. Smits¹², A. Strēlniece¹³, G. Laufer¹⁴. ¹Medical Univ of Vienna, Vienna, Austria, ²Dept of Cardiac Surgery, Medical Univ of Vienna, Vienna, Austria, ³Institute of Clinical Biometrics, Medical Univ of Vienna, Vienna, Austria, ⁴Dept of Cardiology, Ghent Univ, Vienna, Belgium, ⁵Dept of Cardiac Surgery, Clinical Hospital Dubrava, Zagreb, Croatia, ⁶Klinik für Thorax- und Kardiovaskularchirurgie, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany, ⁷Klinik für Herz-, und Gefäßchirurgie, Herzzentrum Freiburg-Bad Krozingen, Freiburg, Germany, ⁸Klinik für Kardiologie, Univ Jena, Jena, Germany, ⁹Dept of Cardiac Surgery, Semmelweis Medical Univ, Budapest, Hungary, ¹⁰Afdeling Cardiologie, Erasmus MC, Rotterdam, Netherlands, ¹¹Dept of Cardiovascular Surgery, Univ Medical Center Ljubljana, Ljubljana, Slovenia, ¹²Eurotransplant Foundation, Leiden, Netherlands, ¹³Eurotransplant Foundation, Leiden, Netherlands, ¹⁴Dept of Cardiac Surgery, Medical Univ of Vienna, Vienna, Austria

6:50 PM (414) *Using Deep Neural Networks to Simulate Heart Allocation Policies*; D. Medved¹, P. Nugets¹, M. Ohlsson², P. Höglund³, B. Andersson⁴, J. Nilsson⁵. ¹Computer Science, Lund Univ, Lund, Sweden, ²Astronomy and Theoretical Physics, Computational Biology and Biological Physics, Lund Univ, Lund, Sweden, ³Laboratory Medicine, Lund, Clinical Chemistry and Pharmacology, Lund Univ, Skane Univ Hospital, Lund, Sweden, ⁴Clinical Sciences Lund, Surgery, Lund Univ, Skane Univ Hospital, Lund, Sweden, ⁵Clinical Sciences Lund, Cardiothoracic Surgery, Lund Univ, Skane Univ Hospital, Lund, Sweden

6:55 PM (415) Do High Risk Patients Really Achieve a Survival Benefit from Heart Transplantation? A Step Towards a Cardiac Allocation Score; M. Masetti¹, M. Bellettini¹, A. Centritto¹, M. Sabatino¹, A. Russo¹, S. Martin Suarez², A. Loforte², G. Marinelli², F. Grigioni¹, L. Potena¹. ¹Cardiology, Univ of Bologna, Bologna, Italy, ²Cardiac Surgery, Univ of Bologna, Bologna, Italy

7:00 PM (416) National Trends in Heart Donor Utilization Rates: What is in the Numbers?; H. Jaeger¹, T. Hess¹, J. Hermsen², L. Lozonschi², D. Murray¹, T. Kohmoto², R. Dhingra¹. ¹Cardiovascular Medicine, Univ of Wisconsin-Madison, Madison, WI, ²Cardiothoracic Surgery, Univ of Wisconsin-Madison, Madison, WI

7:05 PM (417) The Introduction of a Super-Urgent Heart Allocation Scheme in the United Kingdom; S. Rushton¹, N. Al-Attar², N. Banner³, C. Lewis⁴, S. Schueler⁵, J. Townend⁶, R. Venkateswaran⁷, S. Tsui⁴. ¹NHS Blood and Transplant, Bristol, United Kingdom, ²Golden Jubilee National Hospital, Glasgow, United Kingdom, ³Harefield Hospital, London, United Kingdom, ⁴Papworth Hospital, Cambridge, United Kingdom, ⁵Freeman Hospital, Newcastle, United Kingdom, ⁶Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁷Wythenshawe Hospital, Manchester, United Kingdom

7:10 PM (418) Impact of Donor Smoking History on Graft Survival Following Cardiac Transplantation; H. K. Lamba, D. Yoeli, F. H. Cheema, R. Delgado, L. Simpson, A. Nair, A. B. Civitello, T. Rosengart, O. Frazier, O. Frazier. Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor CoM, Houston, TX

6:15 PM - 7:15 PM

MINI ORAL 16: Basic Science and Infectious Disease Issues

Location: Hermes

Target Audience: ID, BSTR, HTX, LTX, MCS

Chairs: Stephen C Juvet, MD, PhD, FRCPC, and Joanna M Schaeenman, MD, PhD

6:15 PM (419) *Inflammation and Lymphoid Neogenesis Induced by Deletion of Lymphatics in Healed Lung Isografts Show the Importance of Lymphatics in Lung Homeostasis and Function*; L. Wang¹, H. Reed², R. Han¹, M. Kahn², W. W. Hancock¹. ¹Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA

6:20 PM (420) *Circulating Monocyte Subtypes Correlate with Cardiac Allograft Vasculopathy and Differ from Atherosclerotic Disease: A Tool for Monitoring?*; L. Holzhauser¹, K. A. Arnold¹, A. Schroeder¹, T. Imamura¹, A. Nguyen¹, B. Chung¹, N. Narang¹, M. Costanzo², V. Jeevanandam¹, C. Murks¹, T. Riley¹, J. Powers¹, N. Sarswat¹, S. Kalantari¹, J. Raikhelkar¹, G. Sayer¹, G. Kim¹, N. Uriel¹, F. J. Alenghat¹. ¹University of Chicago, Chicago, IL, ²Advocate Health Care, Chicago, IL

6:25 PM (421) *Kidney Allografts Confer Tolerance Upon Co-Transplanted Heart Allografts by Promoting Tregs*; C. Yang¹, T. M. Ashry¹, I. Rosales², J. Ge¹, T. F. O'shea¹, R. White², P. S. Russell¹, J. C. Madsen¹, R. B. Colvin², A. Alessandrini¹. ¹Center for Transplantation Sciences, Dept of Surgery, Massachusetts General Hospital, Boston, MA, ²Dept of Pathology, Massachusetts General Hospital, Boston, MA

6:30 PM (422) *Lung Microbiome and Metabolome Differentiates Allograft from Native Lung in Single Lung Transplant Recipients*; N. S. Sharma¹, K. M. Wille², K. K. Patel¹, M. Pachinbuvaran¹, D. Weill³, J. Deshane⁴. ¹Center for Advanced Lung Diseases, University of South Florida, Tampa, FL, ²Center for Advanced Lung Diseases, UAB, Birmingham, AL, ³Institute for Advanced Organ Disease and Transplantation, University of South Florida, Tampa, FL, ⁴Pulmonary and critical care, UAB, Birmingham, AL

6:35 PM (423) *Superior Isolation of Non-tuberculous Mycobacteria, Including Mycobacterium abscessus Complex, From Lung Transplant Patients Using RGM Medium Compared With Traditional AFB Culture*; A. Perry, D. Stephenson, J. D. Perry, M. Appleby, J. Samuel, F. K. Gould. Microbiology Dept, Freeman Hospital, Newcastle upon Tyne, United Kingdom

6:40 PM (424) *Simkania negevensis and Chronic Lung Allograft Dysfunction in Lung Transplant Recipients*; C. Aguilar¹, Y. Li², T. Martinu³, J. Tikkanen³, W. Kent³, S. Juvet³, A. Humar¹, D. Kumar⁴, J. K. Kolls⁵, S. Keshavjee³, L. G. Singer³, S. Husain¹. ¹Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada, ²Kidney Transplant Program, University Health Network, Toronto, ON, Canada, ³Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ⁴Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada, ⁵Center for Translational Research in Infection and Inflammation, Tulane School of Medicine, New Orleans, LA

6:45 PM (425) *CMV-specific T-cell Response After Lung Transplantation*; V. Rossetti¹, L. Morlacchi¹, G. Lunghi², D. Briganti¹, S. Uceda Renteria², P. Tarsia¹, F. Damarco³, P. Mendogni³, A. Palleschi³. ¹Cardiothoracic Unit and Cystic Fibrosis Adult Centre; Dept of Pathophysiology and Transplantation, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ²Virology Unit, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ³Thoracic and Lung Transplantation Surgery, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

6:50 PM (426) *Cytomegalovirus Donor Seropositivity Negatively Affects Mid- and Long-term Survival After Heart Transplantation*; C. Heim¹, P. Müller², R. Tandler², W. Cherikh³, A. Toll³, A. Kucheryavaya³, K. Kush⁴, M. Weyand², S. M. Ensminger⁵. ¹University of Erlangen Dept of Cardiac Surgery, Erlangen, Germany, ²Dept of Cardiac Surgery, University of Erlangen, Erlangen, Germany, ³UNOS, Richmond, VA, ⁴Stanford University, Palo Alto, CA, ⁵Dept of Cardiac Surgery, HDZ NRW, Bad Oeynhausen, Germany

6:55 PM (427) *Contaminated Ice. How Clean is Your Machine?*; C. Williams, H. Mpofo, J. Samuel, K. Wallace, K. Gould. Microbiology, The Newcastle upon Tyne Hospital Foundation Trust, Newcastle upon Tyne, United Kingdom

7:00 PM (428) Infections and Subsequent Events in the ENDURANCE and ENDURANCE Supplemental Trials; R. L. Kormos¹, J. A. Cowger², K. D. Aaronson³, E. J. Birks⁴, C. H. Selzman⁵, N. A. Mokadam⁶, N. Uriel⁷, F. D. Pagani³, T. A. Vassiliades⁸, J. G. Rogers⁹. ¹University of Pittsburgh, Pittsburgh, PA, ²St. Vincent Heart Center, Indianapolis, IN, ³University of Michigan, Ann Arbor, MI, ⁴University of Louisville, Louisville, KY, ⁵University of Utah, Salt Lake City, UT, ⁶University of Washington, Seattle, WA, ⁷University of Chicago, Chicago, IL, ⁸Medtronic, Framingham, MA, ⁹Duke University, Durham, NC

7:05 PM (429) Preemptive vs. Upfront CMV Prophylaxis Strategies and Risk of Non-CMV Herpesvirus Infections in Intermediate Risk Heart Transplant Recipients; N. Eng¹, C. Chen², M. Aldridge³, A. Osborne⁴, J. Vega⁵, H. Mitchell⁴, A. Smith⁴, M. Hurtik⁴, A. Morris⁶, D. Gupta⁴, K. Bhatt⁷, S. Laskar⁴, R. T. Cole⁴. ¹Emory Univ Sch of Med, Atlanta, GA, ²Internal Medicine, Emory Univ Sch of Med, Atlanta, GA, ³Cardiology, Emory Univ Sch of Med, Atlanta, GA, ⁴Cardiology, Emory Univ Sch of Med, Atlanta, GA, ⁵Cardiothoracic Surgery, Emory Univ Sch of Med, Atlanta, GA, ⁶Cardiology, Emory Univ School of Medicine, Atlanta, GA, ⁷Cardiology, Emory Univ Sch of Med, Atlanta, GA

7:10 PM (430) Preemptive Tuberculosis Prophylaxis vs. Watchful Waiting After Heart Transplantation; G. Poglajen, A. Cerar, S. Frljak, G. Zemljič, V. Andročec, R. Okrajšek, M. Šebeštjen, M. Jaklič, B. Vrtovec. *Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia*

SATURDAY, APRIL 14, 2018

8:15 AM - 9:45 AM

ORAL SESSION 40: Riding the Wave: Hemodynamics in MCS

Location: Athena

Target Audience: MCS, HTX

Chairs: Nicolaas De Jonge, MD, and Nahush A. Mokadam, MD

8:15 AM (431) Right Atrial Pressure is the Best Hemodynamic Predictor of Mortality Among LVAD Recipients: Analysis of the INTERMACS Database; M. Guglin, H. Omar. *University of Kentucky, Lexington, KY*

8:30 AM (432) Hemodynamic Response to Continuous-flow Left Ventricular Assist Device Ramp Test and Volume Loading Predicts Successful Weaning from the Device Support; S. Saito¹, K. Toda¹, S. Miyagawa¹, Y. Yoshikawa¹, H. Hata¹, K. Domae¹, R. Matsuura¹, Y. Sakata², Y. Sawa¹. ¹*Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan*, ²*Cardiovascular Medicine, Osaka Univ Graduate School of Medicine, Suita, Osaka, Japan*

8:45 AM (433) Cardiac Power for Prediction of Outcomes in Patients with LVADs; M. Guglin¹, H. Omar². ¹*University of Kentucky, Lexington, KY*, ²*Mercy Medical Center, Clinton, IA*

9:00 AM (434) Predictors of Hemodynamic Success in Advanced CHF Patients Supported by Ambulatory Counterpulsation; V. Jeevanandam¹, T. Song¹, D. Onsager¹, T. Ota¹, C. Juricek LaBuhn¹, T. Lammy¹, S. Patel-Raman², G. Sayer¹, G. Kim¹, S. Kalantari¹, N. Uriel¹. ¹*University of Chicago Medicine, Chicago, IL*, ²*NuPulseCV, Raleigh, NC*

9:15 AM (435) Usefulness of Analyzing Right Atrial Pressure Waveform to Predict Right Ventricular Failure After Left Ventricular Assist Device Implantation; T. Samura, H. Asanoi, K. Toda, D. Yoshioka, S. Miyagawa, Y. Yoshikawa, H. Hata, S. Saito, K. Domae, R. Matsuura, Y. Sawa. *Dept of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan*

9:30 AM (436) Neurohormonal Blockade Reduces Adverse Events During LVAD Support; P. Mehta¹, T. Imamura², M. N. Belkin¹, D. Rodgers², N. Sarswat², G. Kim², J. Raikhelkar², S. Kalantari², C. Murks², T. Song³, T. Ota³, V. Jeevanandam³, G. Sayer², N. Uriel². ¹*Internal Medicine, University of Chicago, Chicago, IL*, ²*Cardiology, University of Chicago, Chicago, IL*, ³*Cardiac Surgery, University of Chicago, Chicago, IL*

8:15 AM - 9:45 AM

ORAL SESSION 41: Crunching the Numbers: Improving Outcomes in Heart Transplantation

Location: Mediterranean ABC

Target Audience: HTX, BSTR, EEP, HF, ID, NHSAH, PATH, PHARM

Chairs: Alexander M Bernhardt, MD, and Sean P Pinney, MD

8:15 AM (437) Cardiac Allocation Score: A Survival-Benefit Model for Heart Transplantation; E. Z. Xing¹, S. G. Margelis¹, P. L. Karas¹, S. Emmanuel², Y. S. Kim¹, P. Macdonald², K. Dhital². ¹The University of New South Wales, Sydney, Australia, ²Heart & Lung Transplant Unit, St Vincent's Hospital Sydney, Sydney, Australia

8:30 AM (438) Geographic Variation in the Treatment of US Heart Transplant Candidates; W. Parker¹, M. M. Churpek¹, D. Hedeker², E. S. Huang¹, E. R. Garrity Jr¹, M. Siegler¹, A. S. Anderson³. ¹Univ of Chicago Medicine, Chicago, IL, ²Public Health Sciences, Univ of Chicago Medicine, Chicago, IL, ³Medicine, Northwestern Univ, Chicago, IL

8:45 AM (439) Longer Donor Management Time by Organ Procurement Organizations Improves Survival in Heart Transplant Recipients; Y. Xia¹, S. Forest¹, O. Saeed², S. Patel², D. Sims², U. Jorde², D. Goldstein¹. ¹Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, ²Medicine, Cardiology, Montefiore Medical Center, Bronx, NY

9:00 AM (440) A Novel Transplant RiskScore (TRS) Incorporating Recipient and Donor Variables and Center Effect; C. Jasseron¹, C. Legeai¹, C. Jacquelinet¹, K. Nubret-Le Coniat², E. Flecher³, C. Cantrelle¹, B. Audry¹, O. Bastien¹, R. Dorent¹. ¹Agence de la biomedecine, Saint-Denis la plaine, France, ²CHU Bordeaux, Bordeaux, France, ³CHU Rennes, Rennes, France

9:15 AM (441) Changing Trends in Acceptance Criteria for Cardiac Donors: 15 Year UK Experience; A. Page¹, E. Wong², S. Rushton², J. Mehew², M. Berman¹, S. Tsui¹. ¹Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, ²NHS Blood and Transplant, Bristol, United Kingdom

9:30 AM (442) Human Leukocyte Compatibility and Heart Transplant Survival Using a Validated Matching Algorithm; A. Rivard¹, N. Koizumi². ¹Dept of Radiology, Cleveland Clinic, Abu Dhabi, United Arab Emirates, ²George Mason University, Arlington, VA

8:15 AM - 9:45 AM

ORAL SESSION 42: Lung Allocation: New Rules and Old Age

Location: Clio/Thalie/Erato

Target Audience: LTX, EEP

Chairs: Antoine Roux, MD, PhD, and Paul A. Corris, MB FRCP

8:15 AM (443) Lung Transplant Wait list Outcomes After Implementation of the Revised Lung Allocation Score; S. Pasupneti, G. Dhillon, J. Mooney. *Dept of Medicine, Division of Pulmonary and Critical Care, Stanford University School of Medicine, Stanford, CA*

8:30 AM (444) Extremes of Age Decrease Survival After Lung Transplant; C. J. Lehr¹, E. H. Blackstone², K. R. McCurry², L. Thuita², W. M. Tsuang¹, M. Valapour¹. ¹*Respiratory Institute, Cleveland Clinic, Cleveland, OH*, ²*Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH*

8:45 AM (445) The Clinical Trajectory of Frailty in Adults Undergoing Lung Transplantation; A. Venado, A. Soong, P. Shrestha, J. Greenland, R. Shah, S. Hays, L. Leard, J. Golden, J. Kukreja, P. Katz, C. McCulloch, J. Singer. *University of California, San Francisco, San Francisco, CA*

9:00 AM (446) Sarcopenia of the Psoas Muscles Predicts Survival Following Lung Transplantation; J. Hsu¹, A. Krishnan¹, C. T. Lin², P. D. Shah³, S. R. Broderick¹, R. S. Higgins¹, C. A. Merlo³, E. L. Bush¹. ¹*Surgery-Thoracic Surgery, Johns Hopkins Univ School of Medicine, Baltimore, MD*, ²*Radiology, Johns Hopkins Univ School of Medicine, Baltimore, MD*, ³*Medicine-Pulmonary and Critical Care Medicine, Johns Hopkins Univ School of Medicine, Baltimore, MD*

9:15 AM (447) Factors Influencing Outcomes from Listing for Lung Transplantation in the UK; A. Kourliouros¹, R. Hogg², J. Mehew², M. Al-Aloul³, M. Carby⁴, J. Lordan⁵, R. Thompson⁶, S. Tsui¹, J. Parmar¹. ¹*Cardiothoracic Transplantation, Papworth Hospital, Cambridge, United Kingdom*, ²*Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom*, ³*Cardiothoracic Transplantation, Wythenshawe Hospital, Manchester, United Kingdom*, ⁴*Cardiothoracic Transplantation, Harefield Hospital, Harefield, United Kingdom*, ⁵*Cardiothoracic Transplantation, Freeman Hospital, Newcastle, United Kingdom*, ⁶*Cardiothoracic Transplantation, Queen Elizabeth Hospital, Birmingham, United Kingdom*

9:30 AM (448) The Introduction of Urgent and Super-Urgent Lung Allocation Schemes in the United Kingdom; S. Rushton¹, M. Al-Aloul², M. Carby³, S. Clark⁴, R. Thompson⁵, J. Parmar⁶, S. Tsui⁶. ¹*NHS Blood and Transplant, Bristol, United Kingdom*, ²*Wythenshawe Hospital, Manchester, United Kingdom*, ³*Harefield Hospital, London, United Kingdom*, ⁴*Freeman Hospital, Newcastle, United Kingdom*, ⁵*Queen Elizabeth Hospital, Birmingham, United Kingdom*, ⁶*Papworth Hospital, Cambridge, United Kingdom*

8:15 AM - 9:45 AM

ORAL SESSION 43: A Road Less Traveled: Alternative Mechanisms and Treatments for Heart Failure

Location: Uranie/Calliope

Target Audience: HF, BSTR, HTX, MCS, PHARM

Chairs: Ivan Knezevic, MD, and Eileen M Hsich, MD

8:15 AM (449) *Transendocardial Injection of CD34⁺ Cells Targeting Interventricular Septum Improves Right Ventricular Function in Non-ischemic Dilated Cardiomyopathy*; S. Frljak, M. Jaklic, A. Cerar, G. Zemljic, G. Poglajen, B. Vrtovec. *Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia*

8:30 AM (450) *Immunologic Characterization and Clinical Implication of CD4⁺CD57⁺T Cells in Patients with Acute Heart Failure*; J. Youn¹, I. Kim², M. Jung³, S. Kang⁴, E. Shin³. ¹*Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Gyeonggido, Korea, Republic of*, ²*Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of*, ³*Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea, Republic of*, ⁴*Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of*

8:45 AM (451) *Ischemic Heart Failure Induces Simultaneous Downregulation of Myocardial E3 Ligases*; K. Klaeske¹, V. Adams², M. Dix¹, S. Bowen², S. Werner², J. Garbade¹, F. Emrich¹, S. Lehmann¹, K. Jawad¹, M. Borger¹, M. Dieterlen¹. ¹*Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany*, ²*Clinic for Cardiology, Heart Center Leipzig, Leipzig, Germany*

9:00 AM (452) *Hemodynamic Markers of Predominant Right Ventricular Dysfunction are Associated with Paradoxical Decreased Cell-Mediated Immunity in Patients with Advanced Heart Failure*; P. Alvarez¹, T. Kitai², A. Perez³, B. Sperry⁴, W. Tang³. ¹*Medicine, University of Iowa, Iowa City, IA*, ²*Medicine, Kobe City Medical Center General Hospital, Kobe, Japan*, ³*Medicine, Cleveland Clinic, Cleveland, OH*, ⁴*Cleveland Clinic, Cleveland, OH*

9:15 AM (453) *Leptin Modifies the Impact of BMI on Heart Failure Progression: The Obesity Paradox Unraveling*; J. E. Rame¹, J. M. Ortega-Legaspi¹, A. Cappola², K. R. Dumon³, T. P. Cappola¹. ¹*Cardiovascular Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA*, ²*Division of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA*, ³*Division of Bariatric Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA*

9:30 AM (454) *NT-proBNP Levels Are Reduced Following Treatment With Growth Hormone in Chronic Heart Failure Due to Ischemic Heart Disease. A Randomized Double Blind Placebo Controlled Trial*; E. Bobbio¹, J. Isgaard², K. Swedberg³, Å. Hjalmarson³, K. Caidahl⁴, K. Karason¹. ¹*Dept of Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden*, ²*Departement of Medicin, Sahlgrenska University Hospital, Gothenburg, Sweden*, ³*Institute of Medicine, University of Gothenburg, Gothenburg, Sweden*, ⁴*Dept of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden*

8:15 AM - 9:45 AM

ORAL SESSION 44: The Battle for Hearts, Lungs, Minds and Money

Location: Hermes

Target Audience: EEP, HF, HTX, LTX, MCS, NHSAAH

Chairs: Stephen C Clark, MD, and Keki Balsara, MD

8:15 AM (455) *The Opioid Use Crisis and Organ Transplantation: A Comparison of the United States and Europe;* J. Stehlik¹, J. Smits², J. A. Jarcho³, R. Lehman⁴, W. Cherikh⁴, M. R. Mehra³. ¹University of Utah School of Medicine, Salt Lake City, UT, ²Eurotransplant, Leiden, Netherlands, ³Brigham Health Heart and Vascular Center and Harvard Medical School, Boston, MA, ⁴United Network for Organ Sharing, Richmond, VA

8:30 AM (456) *Good or Bad: CMS Flagging is Associated with Fewer Transplants Performed by Repeat Offenders;* J. P. Beller¹, R. B. Hawkins¹, J. H. Mehaffey¹, W. Z. Chancellor¹, R. Teaster¹, D. M. Walters¹, A. S. Krupnick¹, R. D. Davis², C. L. Lau¹. ¹University of Virginia, Charlottesville, VA, ²Florida Hospital, Orlando, FL

8:45 AM (457) *Financial Impact of One Year of Advanced Heart Failure Therapies to a Hospital System;* A. S. Vohra¹, B. Chung², T. Ota³, G. Sayer², V. Jeevanandam³, N. Uriel². ¹Medicine, University of Chicago, Chicago, IL, ²Cardiology, University of Chicago, Chicago, IL, ³Cardiac Surgery, University of Chicago, Chicago, IL

9:00 AM (458) *Family Participation in Daily ECMO Rounds;* M. Stahovich¹, S. Lerum², R. Price², S. Chillcott², R. Adamson², W. Dembitsky². ¹Sharp Memorial Hospital, San Diego, CA, ²Mechanical Circulatory Support, Sharp Memorial Hospital, San Diego, CA

9:15 AM (459) *Race and Baseline Severity of Heart Failure in the Registry Evaluation for Vital Information on VADs in Ambulatory Life (REVIVAL);* D. E. Lanfear¹, R. Forde-McLean², D. Haas³, S. Robinson⁴, J. Thibodeau⁵, J. Teuteberg⁶, U. Jorde⁷, S. Khalatbari⁸, C. Spino⁸, N. Jeffries⁹, L. Stevenson¹⁰, D. Mann¹¹, G. Stewart¹², K. Aaronson⁸. ¹Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, ²Univ of Pennsylvania, Philadelphia, MI, ³Abington Hospital, Abington, PA, ⁴Univ of Maryland, Baltimore, MD, ⁵Univ of Texas Southwestern, Dallas, TX, ⁶Stanford, Palo Alto, CA, ⁷Montefiore, New York, NY, ⁸Univ of Michigan, Ann Arbor, MI, ⁹NHLBI, Bethesda, MD, ¹⁰Vanderbilt Univ, Nashville, MI, ¹¹Washington Univ in St.Louis, St. Louis, MO, ¹²Brigham and Women's Hospital, Boston, MA

9:30 AM (460) *Impact of Socioeconomic Factors on Patient Desire for LVAD Therapy;* I. Tchoukina¹, K. B. Shah¹, J. Thibodeau², J. D. Estep³, A. Lala⁴, D. Lanfear⁵, N. Gilotra⁶, S. Pamboukian⁷, D. A. Horstmanshof⁸, D. McNamara⁹, D. C. Haas¹⁰, U. Jorde¹¹, R. Forde-McLean¹², S. Khalatbari¹³, C. A. Spino¹³, J. Baldwin¹⁴, D. L. Mann¹⁵, K. D. Aaronson¹³, G. C. Stewart¹⁶. ¹Virginia Commonwealth Univ, Richmond, VA, ²Univ of Texas Southwestern Medical Center, Dallas, TX, ³Houston Methodist Research Institute, Houston, TX, ⁴Mount Sinai Hospital, New York, NY, ⁵Henry Ford Hospital, Detroit, MI, ⁶Johns Hopkins Hospital, Baltimore, MD, ⁷Univ of Alabama, Birmingham, AL, ⁸INTEGRIS, Oklahoma City, OK, ⁹Univ of Pittsburgh, Pittsburgh, PA, ¹⁰Abington Hospital - Jefferson Health, Abington, PA, ¹¹Montefiore Medical Center, Bronx, NY, ¹²Univ of Pennsylvania, Philadelphia, PA, ¹³Univ of Michigan, Ann Arbor, MI, ¹⁴National Heart, Lung, and Blood Institute, Bethesda, MD, ¹⁵Washington Univ, St. Louis, MO, ¹⁶Brigham and Women's Hospital, Boston, MA

8:15 AM - 9:45 AM

ORAL SESSION 45: Live Long and Prosper: Long-term Outcomes After Pediatric Heart Transplant

Location: Mediterranean 6

Target Audience: PEDS, HTX, NNSAH, PHARM

Chairs: Robert G. Weintraub, FRACP, FACC, and Ryan Butts, MD

8:15 AM (461) Heart Transplantation in Infants and Children: The Thirty-Year Loma Linda University Experience; M. J. Bock¹, A. Razzouk², R. E. Chinnock³, M. Kuhn¹, T. Martens², T. Shankel³, N. Hasaniya², L. L. Bailey². ¹*Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA*, ²*Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA*, ³*Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA*

8:30 AM (462) Practice Variation in the Diagnosis of Acute Rejection Among Pediatric Heart Transplant Centers: An Analysis of the Pediatric Heart Transplant Study (PHTS) Database; J. Godown¹, E. Pruitt², J. Vo³, D. A. Dodd¹, I. Lytrivi⁴, G. J. Boyle⁵, D. Sutcliffe⁶, J. A. Kleinmahon⁷, R. Shih⁸, S. Urschel⁹, B. Das⁶, W. F. Carlo¹⁰, W. A. Zuckerman¹¹, S. West¹², M. A. McCulloch¹³, M. D. Zinn¹², K. Simpson¹⁴, S. J. Kindel¹⁵, J. R. Szmuszkovicz¹⁶, M. Chrisant¹⁷, S. R. Auerbach⁷, M. P. Carboni¹⁸, D. T. Hsu¹⁹. ¹*Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN*, ²*The Pediatric Heart Transplant Study Group, The University of Alabama at Birmingham, Birmingham, AL*, ³*Pediatric Heart Transplant Study Group, Birmingham, AL*, ⁴*Pediatric Cardiology, Mount Sinai Medical Center, New York, NY*, ⁵*Pediatric Cardiology, Cleveland Clinic, Cleveland, OH*, ⁶*Pediatric Cardiology, UT Southwestern Medical Center, Dallas, TX*, ⁷*Pediatric Cardiology, Children's Hospital Colorado, Aurora, CO*, ⁸*Pediatric Cardiology, University of Florida, Gainesville, FL*, ⁹*Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada*, ¹⁰*Pediatric Cardiology, University of Alabama at Birmingham, Birmingham, AL*, ¹¹*Pediatric Cardiology, Columbia University Medical Center, New York, NY*, ¹²*Pediatric Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA*, ¹³*University of Virginia Children's Heart Center, Charlottesville, VA*, ¹⁴*Pediatric Cardiology, Washington University School of Medicine, St. Louis, MO*, ¹⁵*Pediatric Cardiology, Children's Hospital of Wisconsin, Milwaukee, WI*, ¹⁶*Pediatric Cardiology, Children's Hospital of Los Angeles, Los Angeles, CA*, ¹⁷*Pediatric Cardiology, Joe DiMaggio Children's Hospital, Hollywood, FL*, ¹⁸*Pediatric Cardiology, Duke Children's Hospital, Durham, NC*, ¹⁹*Pediatric Cardiology, Children's Hospital at Montefiore, Bronx, NY*

8:45 AM (463) Intravascular Ultrasound in the Diagnosis of Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients: A 20 Year Single Center Review; M. A. Kuhn¹, B. M. Gordon¹, A. J. Razzouk², M. J. Bock¹, R. E. Chinnock¹, L. L. Bailey². ¹*Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA*, ²*Cardiothoracic Surgery, Loma Linda University Children's Hospital, Loma Linda, CA*

9:00 AM (464) Earlier Cardiac Allograft Vasculopathy and Graft Failure in Pediatric Heart Transplant Recipients After Rejection with Severe Hemodynamic Compromise; J. A. Kleinmahon¹, J. Gralla², S. R. Auerbach¹, G. A. Wallis³, K. Ramakrishnan⁴, R. Singh⁵, R. L. Caldwell⁶, R. Kirk⁷, A. J. Savage⁸, H. T. Henderson⁸, M. D. Everitt¹. ¹*Pediatric Cardiology, Children's Hospital Colorado, Aurora, CO*, ²*Pediatrics, University of Colorado, Denver, Denver, CO*, ³*Pediatric Cardiology, Levine Children's Hospital, Charlotte, NC*, ⁴*Cardiac Surgery, Children's National Health System, Washington, DC*, ⁵*Pediatric Cardiology, Rady Children's Hospital, San Diego, CA*, ⁶*Pediatric Cardiology, Riley Hospital for Children, Indianapolis, IN*, ⁷*Pediatric Cardiology, UT Southwestern, Children's Medical Center, Dallas, TX*, ⁸*Pediatric Cardiology, Medical University of South Carolina, Charleston, SC*

9:15 AM (465) New-Onset Cognitive Impairment after Cardiac Transplantation in Children; R. Rizwan, F. Zafar, C. R. Villa, R. Bryant III, T. D. Ryan, C. Chin, D. L. Morales. *The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

9:30 AM (466) The Reality of Limping to Heart Transplant; K. W. Riggs¹, F. Zafar¹, A. Lorts², C. Chin², R. Bryant III¹, J. S. Tweddell¹, D. L. Morales¹. ¹*Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH*, ²*Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH*

10:00 AM - 12:00 PM
PLENARY 3: Plenary Session

Location: Athena
Target Audience: ALL

Chairs: Jeffrey J Teuteberg, MD, and Lara Danziger-Isakov, MD, MPH

10:00 AM Awards Presentations

Stephan Ensminger, MD, DPhil, Daniel Kreisel, MD, PhD, and Kathleen Grady, PhD, APN, FAAN
Grants & Awards Committee Co-Chairs

10:30 AM *What's Hot, What's New? - Basic Science*

Sonja Schrepfer, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

10:55 AM *What's Hot, What's New? - Clinical Science*

Laurie D Snyder, MD, Duke University Medical Center, Durham, NC, USA

11:20 AM *PRESIDENT'S DEBATE: Dead in Melbourne, Alive in Philadelphia: DCDo's and DCDon'ts - We DCDo*

Gregory I Snell, FRACP, MBBS, Alfred Hospital, Melbourne, Australia

11:35 AM *PRESIDENT'S DEBATE: Dead in Melbourne, Alive in Philadelphia: DCDo's and DCDon'ts - We DCDon't*

Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

11:50 AM *Debate Rebuttal: We DCDo*

Gregory I Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia

11:55 AM *Debate Rebuttal: We DCDon't*

Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

12:15 PM - 1:45 PM

ORAL SESSION 46: Flight Plan: Planning the LVAD Implant

Location: Athena

Target Audience: MCS, NNSAH, PHARM, PH

Chairs: Markus J Wilhelm, MD, and Daniel J Goldstein, MD

12:15 PM (467) Bayesian Model for Predicting 90 Day Event Free Survival in LVAD Patients; M. Kanwar¹, L. Lohmueller², R. Kormos³, C. Mcilvennan⁴, S. Bailey¹, S. Murali¹, J. Antaki². ¹Allegheny General Hospital, Pittsburgh, PA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Colorado, Denver, CO

12:30 PM (468) Impact of Pre-Procedural Planning with 3D Printed Models on Patient Outcomes for Ventricular Assist Device Placement in Adults with Congenital Heart Disease: Rationale and Design of a Multicenter Prospective Registry; K. M. Farooq¹, A. Chelliah¹, P. J. Chai², E. A. Bacha², O. Saeed³, U. P. Jorde³, A. J. Einstein⁴. ¹Pediatrics, Columbia Univ Medical Center, New York, NY, ²Surgery, Columbia Univ Medical Center, New York, NY, ³Medicine, Albert Einstein College of Medicine, Bronx, NY, ⁴Medicine, Columbia Univ Medical Center, New York, NY

12:45 PM (469) The Effects of Concomitant Procedures at the Time of LVAD Implant for Patients in the ENDURANCE and ENDURANCE Supplemental Trials; N. A. Mokadam¹, F. D. Pagani², S. W. Boyce³, M. S. Slaughter⁴, C. H. Selzman⁵, D. T. Pham⁶, K. D. Aaronson², T. A. Vassiliades⁷, C. A. Milano⁸. ¹Univ of Washington, Seattle, WA, ²Univ of Michigan, Ann Arbor, MI, ³MedStar Health, Washington, DC, ⁴Univ of Louisville, Louisville, KY, ⁵Univ of Utah, Salt Lake City, UT, ⁶Northwestern, Chicago, IL, ⁷Medtronic, Framingham, MA, ⁸Duke Univ, Durham, NC

1:00 PM (470) Outcomes of Durable Mechanical Circulatory Support in Myocarditis: Analysis of the IMACS Registry; S. G. Al-Kindi¹, R. Xie², J. K. Kirklin³, G. H. Oliveira¹, T. Krabatsch⁴, T. Nakatani⁵, S. Schueler⁶, A. Leet¹, C. Elamm¹. ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²The University of Alabama at Birmingham, Birmingham, AL, ³Dept of Surgery, The University of Alabama at Birmingham, Birmingham, AL, ⁴Deutsches Herzzentrum Berlin, Berlin, Germany, ⁵Dept of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, ⁶Dept of Cardiothoracic Vascular Surgery, Newcastle/Freeman Hospital, UK, Newcastle, United Kingdom

1:15 PM (471) Pre-implant Phosphodiesterase-5 Inhibitor Use is Associated With Higher Rates of Severe Early Right Heart Failure After LVAD Implantation: An INTERMACS Analysis; G. Gulati¹, E. W. Grandin², K. F. Kennedy³, F. Cabezas², D. DeNofrio¹, R. Kociol², J. E. Rame⁴, F. D. Pagani⁵, J. K. Kirklin⁶, R. L. Kormos⁷, J. Teuteberg⁸, M. S. Kiernan¹. ¹Cardiovascular Center, Tufts Medical Center, Cambridge, MA, ²Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, ³Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Heart and Vascular Institute, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Division of Cardiothoracic Surgery, University of Michigan School of Medicine, Ann Arbor, MI, ⁶Division of Cardiothoracic Surgery, University of Alabama Birmingham School of Medicine, Birmingham, AL, ⁷Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁸Cardiovascular Medicine, Stanford University Medical Center, Palo Alto, CA

1:30 PM (472) Identifying Ambulatory Advanced Heart Failure Patients at High Risk for Death, LVAD or Transplant at 1-year: How Did the REVIVAL Eligibility Criteria Perform?; K. D. Aaronson¹, L. W. Stevenson², F. D. Pagani³, C. Spino⁴, R. L. Kormos⁵, S. Khalatbari⁶, J. T. Baldwin⁷, N. Jeffries⁷, W. C. Taddei-Peters⁷, A. V. Ambardekar⁸, P. Shah⁹, D. McNamara⁵, D. Lanfear¹⁰, J. Gorcsan¹¹, J. Stehlik¹², D. M. Mancini¹³, G. C. Stewart¹⁴, D. L. Mann¹⁵. ¹Division of Cardiovascular Medicine, Univ of Michigan, Ann Arbor, MI, ²Vanderbilt University, Nashville, TN, ³Dept of Cardiac Surgery, University of Michigan, Ann Arbor, MI, ⁴Dept of Biostatistics, Univ of Michigan School of Public Health, Ann Arbor, MI, ⁵Univ of Pittsburgh, Pittsburgh, PA, ⁶Univ of Michigan, Ann Arbor, MI, ⁷National Heart Lung and Blood Institute, NIH, Bethesda, MD, ⁸Univ of Colorado, Aurora, CO, ⁹Inova Heart and Vascular Institute, Falls Church, VA, ¹⁰Henry Ford Hospital, Detroit, MI, ¹¹Washington University in St. Louis, St. Louis, MO, ¹²Division of Cardiology, Univ of Utah, Salt Lake City, UT, ¹³Mount Sinai School of Medicine, New York, NY, ¹⁴Division of Cardiology, Brigham and Women's Hospital, Boston, MA, ¹⁵Division of Cardiology, Washington University in St. Louis, St. Louis, MO

12:15 PM - 1:45 PM

ORAL SESSION 47: A Melange of Outcomes in Heart Transplantation

Location: Mediterranean ABC

Target Audience: HTX, BSTR, EEP, HF, MCS, NHSAA, PATH

Chairs: Marco Masetti, MD, and Eugene C DePasquale, MD

12:15 PM (473) *Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients - 1 Year Follow Up (The HITT Study)*; K. Nytrøen¹, K. Rolid¹, A. K. Andreassen¹, M. Yardley¹, E. Bjørkelund¹, A. R. Authen¹, I. Grov¹, E. Gude¹, J. P. Wigh², C. H. Dall³, F. Gustafsson⁴, K. Karason², L. Gullestad¹. ¹Dept of Cardiology, Oslo University Hospital, Oslo, Norway, ²Sahlgrenska University Hospital, Gothenburg, Sweden, ³Dept of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark, ⁴Rigshospitalet University Hospital, Copenhagen, Denmark

12:30 PM (474) *Trends in Renal Function Among Heart Transplant Recipients of Donors With Hepatitis C*; S. Zalawadiya¹, J. Lindenfeld¹, A. Shah², M. Wigger¹, M. Keebler¹, M. Danter², M. Brinkley¹, J. Menachem¹, S. B. Sacks¹, H. Ooi¹, C. Chung³, R. Perri⁴, J. Awad⁴, S. Smith¹, R. Hayes¹, C. Rueda Rios¹, H. O'Dell⁴, C. Darragh⁵, S. Ruzevich-Scholl¹, K. Schlendorf¹. ¹Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN, ²Cardiothoracic Surgery, Vanderbilt University Medical Center, Nashville, TN, ³Gastroenterology and hepatology, Vanderbilt University Medical Center, Nashville, TN, ⁴Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN, ⁵Vanderbilt University Medical Center, Nashville, TN

12:45 PM (475) *CT Coronary Angiography Predicts Cardiovascular Outcomes after Heart Transplantation*; E. Zambon, G. Karagiannis, P. Kourkouveli, N. Salterain Gonzalez, A. R. Simon, N. R. Banner, T. Mittal. Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom

1:00 PM (476) *Transplant Outcomes of Adult Donor Hearts with Prior Quality-based Offer Refusals*; N. Koizumi¹, A. Rivard². ¹George Mason University, Arlington, VA, ²Cleveland Clinic, Abu Dhabi, United Arab Emirates

1:15 PM (477) *One Year- Outcomes Following Heart Transplantation from Donation After Circulatory Determined Death (DCD) Donors*; V. Hudson¹, S. Messer¹, A. Page¹, M. Berman¹, J. Dunning¹, E. Pavlushkov¹, K. Tweed², J. Parameshwar¹, Y. Abu Omar¹, M. Goddard¹, S. Pettit¹, C. Lewis¹, A. Kydd¹, D. Jenkins¹, C. Sudarshan¹, P. Catarino¹, A. Ali¹, S. Tsui¹, S. R. Large¹, S. Bhagra¹. ¹Dept of Transplantation, Papworth Hospital, Papworth Everard, United Kingdom, ²Dept of Radiology, Papworth Hospital, Papworth Everard, United Kingdom

1:30 PM (478) *Donor-derived Cell Free DNA Correlates More Closely With Intragraft mRNA Transcripts Rather Than Pathology Read Biopsies*; J. A. Kobashigawa¹, J. Patel¹, M. Kittleson¹, L. Czer¹, D. H. Chang¹, E. Kransdorf¹, S. Sana¹, R. Levine¹, S. Dimbil¹, D. Luthringer¹, J. Yee², R. Woodward², P. Halloran³. ¹Cedars-Sinai Heart Institute, Los Angeles, CA, ²CareDx, Inc, Brisbane, CA, ³University of Alberta, Edmonton, AB, Canada

12:15 PM - 1:45 PM

ORAL SESSION 48: Procedures and Standards in Lung Transplantation

Location: Clio/Thalie/Erato

Target Audience: LTX, BSTR, PATH

Chairs: Mark Benzimra, MD, MRCP, and Alice L Gray, MD

12:15 PM (479) *Bronchoalveolar Lavage Practices in Lung Transplantation: Results of a Large-scale International Survey*; A. Koutsokera¹, C. Benden², E. Cantu³, D. Chambers⁴, M. Cypel¹, J. Edelman⁵, A. Emtiazjoo⁶, A. Fisher⁷, J. Greenland⁸, D. Hayes, Jr.⁹, D. Hwang¹⁰, B. C. Keller¹¹, E. D. Lease¹², M. Perch¹³, M. Sato¹⁴, J. Todd¹⁵, S. Verleden¹⁶, J. von der Thüsen¹⁷, S. Weight¹⁸, S. Keshavjee¹, T. Martinu¹, .. On behalf of the BAL standardization workgroup¹. ¹Lung Transplant Program, Toronto General Hospital, UHN, Toronto, ON, Canada, ²Lung Transplant Program, Univ Hospital Zurich, Zurich, Switzerland, ³Dept of Surgery, Univ Hospital of Pennsylvania, Philadelphia, PA, ⁴Lung Transplant Program, The Prince Charles Hospital, Brisbane, Australia, ⁵Lung Transplant Program, Puget Sound VAMC, Seattle, WA, ⁶Lung Transplant Program, Univ of Florida, Gainesville, FL, ⁷Lung Transplant Program, Freeman Hospital, Newcastle, United Kingdom, ⁸Lung Transplant Program, Univ of California, San Fransisco, CA, ⁹Lung Transplant Program, Nationwide Children's Hospital, Columbus, OH, ¹⁰Dept of Pathology, Toronto General Hospital, UHN, Toronto, ON, Canada, ¹¹Lung Transplant Program, Wexner Medical Center, The Ohio State Univ, Columbus, OH, ¹²Division of Pulmonary, Critical Care, and Sleep Medicine, Univ of Washington, Washington, WA, ¹³Lung Transplant Program, Rigshospitalet, Copenhagen, Denmark, ¹⁴Dept of Surgery, Univ of Tokyo, Tokyo, Japan, ¹⁵Lung Transplant Program, Duke Univ Medical Center, Durham, NC, ¹⁶Laboratory of Pulmonology, Katholieke Universiteit, Leuven, Belgium, ¹⁷Dept of Pathology, Erasmus Medical Center, Rotterdam, Netherlands, ¹⁸Lung Transplant Program, UCLA, Los Angeles, CA

12:30 PM (480) *Innate Immune Mediator BAL Concentrations and PGD After Lung Transplantation*; J. M. Diamond, K. Ramphal, E. Cantu, M. Brown, M. K. Porteous, L. Kalman, M. Rushefski, S. Rubin, Z. Penfil, T. DiSanto, M. Oyster, J. D. Christie. *University of Pennsylvania, Philadelphia, PA*

12:45 PM (481) *Efficacy and Safety of Trans-bronchial Cryo in Comparison With Forceps Biopsy in Lung Allograft Recipients: Analysis of 402 Procedures*; E. Gershman. *Pulmonology, Rabin Medical Center, Petah Tikva, Israel*

1:00 PM (482) *Is the Current PGD Grading Still Valid in Modern Lung Transplantation? - A Retrospective Analysis of a High-Volume Center*; S. Schwarz¹, M. Muckenhuber¹, A. Benazzo¹, L. Beer², F. Gittler², O. Bata³, H. Prosch², J. R. Matilla¹, B. Moser¹, G. Lang¹, S. Taghavi¹, W. Klepetko¹, K. Hoetzenecker¹. ¹Thoracic surgery, Medical University of Vienna, Vienna, Austria, ²Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ³Radiology, National Institute of Oncology, Budapest, Hungary

1:15 PM (483) *Implications of the Refusal of Increased Risk Donor Offers on Waitlist Survival in Lung Transplantation*; M. L. Cox¹, M. S. Mulvihill¹, M. Bishawi¹, A. A. Osho², J. Klapper¹, J. C. Haney¹, M. A. Daneshmand¹, M. G. Hartwig¹. ¹Dept of Surgery, Duke University, Durham, NC, ²Dept of Surgery, Massachusetts General Hosp, Boston, MA

1:30 PM (484) *Consequences of Delayed Chest Closure During Lung Transplantation*; S. Rafiroiu¹, U. Ahmad¹, C. E. Koval², H. Hassouna¹, A. Toth³, K. R. McCurry¹, D. R. Johnston¹, M. O. Ibrahim¹, M. M. Budev⁴, E. H. Blackstone¹, G. B. Pettersson¹, M. Z. Tong¹. ¹Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ²Infectious Disease, Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH, ⁴Pulm Medicine, Cleveland Clinic, Cleveland, OH

12:15 PM - 1:45 PM

ORAL SESSION 49: Rocket Fuel and Scaffolding: Alternative Bridges to Heart Transplantation

Location: Uranie/Calliope

Target Audience: HF, HTX, PHARM

Chairs: Gabriela C Lima, and Chetan B Patel, MD

12:15 PM (485) Outcomes Following Mitraclip in Advanced Heart Failure Patients: A Meta-Analysis; M. N. Belkin¹, J. Nnanabu¹, P. P. Mehta¹, T. Feldman², M. Penicka³, C. Giannini⁴, F. Fiorelli⁴, D. Braun⁵, M. Swaans⁶, J. v. Heyden⁶, M. Claeys⁷, M. Orban⁸, S. Kalantari⁹, J. Raikhelkar⁹, N. Sarswat⁹, G. Kim⁹, G. Sayer⁹, N. Uriel⁹. ¹Internal Medicine Residency Program, Dept of Medicine, University of Chicago, Chicago, IL, ²Cardiology, NorthShore University Health System, Evanston, IL, ³Cardiology, OLV Clinic, Aalst, Belgium, ⁴Cardiology, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, ⁵Cardiology, Klinikum der Universität München, Munich, Germany, ⁶Cardiology, St. Antonius Hospital, Nieuwegein, Netherlands, ⁷Cardiology, University Hospital Antwerp, Edegem, Belgium, ⁸Cardiology, Ludwig-Maximilians-Universität München, Munich, Germany, ⁹Cardiology, University of Chicago, Chicago, IL

12:30 PM (486) Echocardiographic Analysis and Outcome in Patients With Functional Mitral Regurgitation Receiving Mitraclip Therapy; D. Reichart, D. Kalbacher, N. Rübsamen, E. Tigges, J. Schirmer, R. Hermann, S. Blankenberg, L. Conradi, U. Schäfer, E. Girdauskas, E. Lubos. Univ Hamburg Heart Center, Hamburg, Germany

12:45 PM (487) Repeated, Planned Levosimendan Infusions in Patients With Advanced Heart Failure Eligible for Heart Transplantation; L. F. Bertoldi, E. Perna, A. Garascia, M. G. Cipriani, G. Masciocco, G. Foti, F. Macera, F. M. Turazza, E. Ammirati, P. Campadello, M. Frigerio. DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy

1:00 PM (488) Intravenous Inotropes, Beta Blockers and Survival in Ambulatory Heart Failure Patients - A Contemporary Analysis of 3,311 Patients; O. Havakuk¹, J. Tran², T. Artig-Brown³, A. Yoon⁴, M. W. Fong⁴, N. Meaux⁵, L. Grazette⁴. ¹Cardiovascular Medicine, Sackler School of Medicine, Tel Aviv Univ, Tel Aviv, Israel, ²Internal Medicine, Keck Medical School of USC, Los Angeles, CA, ³Cardiovascular Medicine, Option Care, Buffalo Grove Illinois, IL, ⁴Cardiovascular Medicine, Keck Medical School of USC, Los Angeles, CA, ⁵Heart Failure, Option Care, Buffalo Grove, IL

1:15 PM (489) Differential Effects of Levosimendan and Dobutamine on GFR in Patients With Heart Failure and Renal Impairment. A Randomized Double-blind Controlled Trial; K. Karason¹, L. Lannemyr², B. Rundqvist³, B. Andersson³, S. Bartfay³, C. Ljungman³, P. Dahlberg³, N. Bergh³, C. Hjalmarsson³, T. Gilljam³, E. Bollano³, S. Ricksten². ¹Dept of Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Dept of Anesthesiology and Intensive Card Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Dept of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

1:30 PM (490) Relevant-HF Repetitive LEvosimendan in AdvANced refracTory Heart Failure: A Multicenter Collaborative Experience; F. Oliva¹, E. Perna², M. Marini³, D. Nassiacos⁴, G. Malfatto⁵, F. Morandi⁶, A. Ciro⁷, I. Caico⁸, R. De Maria⁹. ¹ASST Niguarda, Milan, Italy, ²Cardiovascular, ASST Niguarda, Milan, Italy, ³University Hospital of Ancona, Ancona, Italy, ⁴Saronno General Hospital, Saronno, Italy, ⁵Istituto Auxologico, Milan, Italy, ⁶Circolo Hospital Varese, Varese, Italy, ⁷San Gerardo Hospital, Monza, Italy, ⁸S. Antonio Abate Hospital, Gallarate, Italy, ⁹CNR Clinical Physiology Institute, Milan, Italy

12:15 PM - 1:45 PM

ORAL SESSION 50: What is Really Going On in The Lung Transplant

Location: Hermes

Target Audience: BSTR, LTX, PATH

Chairs: Christine Falk, MD, and Ciara M Shaver, MD, PhD

12:15 PM (491) Gene Expression Profiling in Murine Orthotopic Lung Transplantation Model of Chronic Lung Allograft Dysfunction (CLAD); A. Hata, H. Suzuki, H. Oeda, K. Nishii, T. Kaiho, K. Ohashi, Y. Shiina, Y. Sata, T. Toyoda, Y. Sakairi, H. Tamura, T. Fujiwara, H. Wada, T. Nakajima, Y. Yamada, M. Chiyo, I. Yoshino. *Dept of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan*

12:30 PM (492) Donor Lung Specific Exosome Profiles for Noninvasive Monitoring of Acute Rejection in a Rat Orthotopic Left Lung Transplant Model; A. Habberthuer¹, L. Korutla¹, S. Rostami¹, S. Siddiqui², Y. Xin², R. Rizi², A. Naji³, P. Zielinski¹, R. Hu¹, T. Ochiya⁴, P. Vallabhajosyula¹. ¹*Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA*, ²*Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA*, ³*Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA*, ⁴*Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan*

12:45 PM (493) Bronchoalveolar Lavage Fluid Proteome in Chronic Lung Allograft Dysfunction; J. L. Todd¹, V. Venkat¹, R. Henao¹, C. Brinkley¹, F. L. Kelly¹, C. W. Frankel¹, A. Frear¹, M. A. Moseley¹, J. W. Thompson¹, J. A. Belperio², M. Budev³, P. D. Shah⁴, L. G. Singer⁵, J. M. Reynolds¹, M. W. Foster¹, S. M. Palmer¹. ¹*Duke Univ Med Ctr, Durham, NC*, ²*University of California Los Angeles, Los Angeles, CA*, ³*Cleveland Clinic, Cleveland, OH*, ⁴*Johns Hopkins University, Baltimore, MD*, ⁵*University of Toronto, Toronto, ON, Canada*

1:00 PM (494) Differential Gene Expression Profiling of Reperfusion During Ex Vivo Lung Perfusion and Lung Transplantation in Humans; A. K. Wong¹, R. Zamel², C. Dos Santos³, G. Bader⁴, S. Keshavjee², M. Liu². ¹*Institute of Medical Science, University of Toronto, Toronto, ON, Canada*, ²*Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, Toronto, ON, Canada*, ³*Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada*, ⁴*Molecular Genetics, University of Toronto, Toronto, ON, Canada*

1:15 PM (495) Ex vivo Lung Perfusion Using the Portable OCS Maintains Endothelial Integrity in the Context of Reduced Severe PGD Rates; B. Wiegmann¹, R. BellmasSanz², A. Hitz², I. Tudorache¹, C. Kühn¹, M. Avsar¹, A. Haverich¹, G. Warnecke¹, C. S. Falk². ¹*Dept for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany*, ²*Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany*

1:30 PM (496) Distinct Phenotypic, Molecular and Immune Characteristics of Circulating Exosomes From Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome versus Stable Patients; M. Gunasekaran, M. Sharma, F. Rodriguez, S. Elnahas, R. Hachem, R. Walia, M. Smith, R. Bremner, T. Mohanakumar. *Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

12:15 PM - 1:45 PM

ORAL SESSION 51: I'm at Risk! Outcomes and Novel Risk Stratification in Pulmonary Hypertension

Location: Mediterranean 6

Target Audience: PH, HF

Chairs: Goran Radegran, MD, and Jose M Cifrian, MD

12:15 PM (497) *The United States Pulmonary Hypertension Scientific Registry (USPHSR): Objectives and Preliminary Data*; H. Farber¹, J. Badlam², A. Frost³, R. Benza⁴, E. Austin⁵, D. Badesch², W. Chung⁶, A. Poms⁷, K. Feldkircher⁷, C. Yu⁸, M. Pauciulo⁹, W. Nichols¹⁰, C. Elliott¹¹. ¹Medicine, Boston University School of Medicine, Boston, MA, ²Medicine, University of Colorado, Aurora, CO, ³Medicine, Houston Methodist Hospital & Weill Cornell Medical College, Houston, TX, ⁴Medicine, Allegheny General Hospital, Pittsburgh, PA, ⁵Pediatrics, Vanderbilt University Medical Center, Nashville, TN, ⁶Clinical Genetics and Genomics, New York Presbyterian, Columbia University, New York, NY, ⁷E Squared Trials and Registries, Inc, Half Moon Bay, CA, ⁸Biostatistics, Vanderbilt Institute for Clinical and Translational Research, Nashville, TN, ⁹Cincinnati Children's Hospital Biobank, Cincinnati, OH, ¹⁰Pediatrics, National Biological Sample and Data Repository for PAH, University of Cincinnati, Cincinnati, OH, ¹¹Medicine, Intermountain Medical Center, University of Utah School of Medicine, Murray, UT

12:30 PM (498) *Non-invasive Right Ventricle-pulmonary Artery Coupling Predicts Events in Pulmonary Arterial Hypertension and in Left Heart Disease*; M. Vicenzi¹, R. Casella², G. Deboeck³, R. Naeije⁴, J. Vachiery⁴. ¹Cardiovascular Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ²Cardiovascular Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ³Faculté des Sciences de la Motricité, Dept of Physiology, Université Libre de Bruxelles, Bruxelles, Belgium, ⁴Dept of Cardiology, Cliniques Universitaires de Bruxelles, Hôpital Académique Erasme, Bruxelles, Belgium

12:45 PM (499) *Echocardiography Predicts the Outcome in Pulmonary Arterial Hypertension Patients Treated With Parenteral Prostanoids*; R. Badagliacca, R. Poscia, B. Pezzuto, G. Manzi, S. Papa, M. Minnucci, R. Torre, S. Sciomer, F. Fedele, C. Vizza. Cardiovascular and Respiratory Sciences, Sapienza University of Rome, Rome, Italy

1:00 PM (500) *Stroke Volume Response to Exercise is Dependent on Disease Severity in Pulmonary Arterial Hypertension*; C. Göransson, N. Vejlstrup, J. Carlsen. Dept of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

1:15 PM (501) *Application of Bayesian Model to Predict Outcomes in Pulmonary Arterial Hypertension*; M. Kanwar¹, L. Lohmueller², P. Correa¹, J. Kraisangka³, M. Druzdzal³, J. Antaki², R. Benza¹. ¹Allegheny General Hospital, Pittsburgh, PA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA

1:30 PM (502) *Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis*; R. L. Benza¹, J. Zhang², E. Parsley², P. Klassen², F. Torres³, M. Gombert-Maitland⁴, O. Sitbon⁵, H. A. Ghofrani⁶. ¹Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, ²Arena Pharmaceuticals, San Diego, CA, ³UT Southwestern Medical Center, Dallas, TX, ⁴Dept of Medicine, Section of Cardiology, University of Chicago Medical Center, Chicago, IL, ⁵Centre de Référence de l'Hypertension Pulmonaire Sévère, Service de Pneumologie et Soins Intensifs Hôpital Universitaire de Bicêtre (AP-HP), Le Kremlin-Bicêtre, France, ⁶University of Giessen and Marburg Lung Center, Giessen, Germany

WEDNESDAY, APRIL 11

6:15 PM - 7:15 PM
POSTER SESSION 1

BASIC SCIENCE AND TRANSLATIONAL RESEARCH
(Agora 2)

Poster Discussants: Edward Cantu (USA), Mario Deng (USA), Christine Falk (Germany), Christian Heim (Germany), Eileen Hsich (USA), Howard Huang (USA), Stephen Juvet (Canada), Tomoko Kato (Japan), Pradeep Mammen (USA), Simon Pecha (Germany), Lynn Punnoose (USA), Sonja Schrepfer (USA), Ciara Shaver (USA), Bart M Vanaudenaerde (Belgium), Yoshito Yamada (Switzerland)

(503) Inflammatory Cytokine Profiles in 24-Hour Brain Stem Death Model; A. C. Boon¹, L. E. See Hoe¹, S. E. Pederson¹, N. G. Obonyo¹, M. A. Wells², N. J. Bartnikowski¹, M. R. Passmore¹, L. Marshall³, L. James⁴, J. Tung¹, J. Y. Suen¹, P. S. Macdonald⁵, D. C. McGiffin⁶, J. F. Fraser¹. ¹Critical Care Research Group, The University of Queensland, Chermside, Brisbane, Australia, ²School of Medical Science, Griffith University, Gold Coast, Australia, ³Dept of Cardiothoracic Surgery, The University of Queensland, Chermside, Brisbane, Australia, ⁴Dept of Surgery, The Princess Alexandra Hospital, Brisbane, Australia, ⁵Victor Chang Cardiac Research Institute, Sydney, Australia, ⁶Dept of Cardiothoracic Surgery, The Alfred Hospital, Melbourne, Australia

(504) Extracorporeal Photophoresis Promotes Alveolar Macrophage Production of Anti-fibrogenic Mediators and Prevents Airway Obliteration in a Mouse Lung Allograft Model; Z. Liu¹, Y. Furuya², M. Ibrahim¹, D. Kreisel¹, H. J. Huang³, R. Hachem², A. E. Gelman¹. ¹Dept of Surgery, Washington Univ in St. Louis, St Louis, MO, ²Dept of Medicine, Washington Univ in St. Louis, St. Louis, MO, ³Dept of Pulmonary Medicine, Baylor Univ Med Ctr, Dallas, TX

(505) Toll-like Receptor 4 Signaling Affects Myofibroblasts Expression in Mice Tracheal Allograft; M. Kawashima¹, M. Sato¹, T. Murakawa², M. Anraku¹, C. Konoeda¹, A. Hosoi³, K. Kakimi³, J. Nakajima¹. ¹Dept of Thoracic Surgery, The University of Tokyo, Tokyo, Japan, ²Dept of Thoracic Surgery, Kansai Medical University, Osaka, Japan, ³Dept of Immunotherapeutics, The University of Tokyo, Tokyo, Japan

(506) Overexpression of SOCS3 Attenuates Tracheal Allograft Rejection in the Early Phase After Murine Heterotopic Tracheal Transplantation by the Inhibition of Th1 Response; K. Mesaki¹, S. Sugimoto¹, H. Watanabe², M. Fujisawa², T. Yoshimura¹, T. Kurosaki³, S. Otani³, M. Yamane¹, S. Toyooka¹, A. Matsukawa², T. Oto³. ¹Dept of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Dept of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(507) Accumulation of Intragraft CD15s+Tregs in Long-term Lung Transplant Survivors; B. J. O'Sullivan, P. Hopkins, M. Trotter, A. Fiene, M. Tan, K. Sinclair, D. Chambers. Lung Transplant Research Unit The Prince Charles Hospital, Brisbane, Australia

(508) CD8-Expressing Transitional B Cells Dominate B Cell Reconstitution after Mixed Chimerism Conditioning for Thoracic Organ Transplantation in Monkeys; K. B. Pruner, J. Paster, W. Sommer, J. O. I. Hannekamp, A. Dehnadi, G. Benichou, J. C. Madsen. Center for Transplantation Science, Massachusetts General Hospital, Boston, MA

(509) Recipient Emphysema Differentially Affects Immunologic Responses During Acute Lung Allograft Rejection in a Pre-Clinical Model; K. J. Patel¹, Q. Cheng¹, D. P. Allen¹, A. Aliweah², H. Knochelmann², C. Paulos², M. Goddard³, S. N. Nadig¹, C. Atkinson². ¹Surgery, Medical University of South Carolina, Charleston, SC, ²Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, ³Transplantation, Papworth Hospital NHS Foundation Trust, Cambridgeshire, United Kingdom

(510) After Clinical Lung Transplantation, NK Cells with a Lung-Resident Phenotype Represent the Most Prominent Donor Passenger Leukocyte Subset; R. BellmasSanz¹, B. Wiegmann², K. Bläsing¹, A. Hitz¹, C. Neudörf¹, I. Tudorache², C. Kühn², M. Avsar², A. Haverich², G. Warnecke², C. Falk¹. ¹Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany, ²Dept for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany

(511) Suppression of Recall Alloantibodies by Combined Therapies With Multi Target Approach; G. D. Wu, I. Kim, N. Chai, S. Jordon, A. Klein. *Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA*

(512) Cell Kinetics of Blood Circulating CD38+/CD138+ Plasma Cells During the Development of De Novo Donor Specific Antibody Responses; G. D. Wu, I. Kim, n. Chai, S. Jordon, A. Klein. *Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA*

(513) Evidence of Maturation Stoppage of Peripheral B-cells Induced by Immunosuppression of Recall Alloantibody Responses; G. D. Wu, I. Kim, N. Chai, S. Jordan, A. S. Klein. *Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA*

(514) Increased Phosphorylation of p70S6 Kinase is Associated With CMV Reactivation in Lung Transplant Patients; V. Besa¹, M. Cherneha², G. Weinreich¹, A. Slama³, U. Sommerwerck⁴, C. Taube¹, C. Aigner³, M. Kamler⁵, B. Wilde⁶, O. Witzke². ¹*Pulmonology, Westgerman Center for Lung Transplantation, University Hospital Essen, Essen, Germany*, ²*Infectiology, University Hospital Essen, Essen, Germany*, ³*Thorax Surgery, Westgerman Center for Lung Transplantation, University Hospital Essen, Essen, Germany*, ⁴*Pulmonology, Helios University Hospital Wuppertal, Wuppertal, Germany*, ⁵*Thoracic Transplantation, Westgerman Center for Lung Transplantation, University Hospital Essen, Essen, Germany*, ⁶*Nephrology, University Hospital Essen, Essen, Germany*

(515) Identification of Leukocyte Subpopulations as Potential Biomarkers of Long-term Survival With Normal Allograft Function After Lung Transplantation; A. Mendoza-Valderrey¹, B. Sáez¹, M. P. Hernández-Fuentes², T. Pereira-Veiga¹, R. Escobar¹, C. Berastegui¹, I. Rebollo-Mesa², A. Solé³, F. Zurbano⁴, M. de la Torre⁵, R. Laporta⁶, J. Redel⁷, S. Gómez-Olles⁸, A. Román⁸. ¹*Lung Transplant Unit, Hospital Universitario Vall d'Hebrón, Barcelona, Spain*, ²*Experimental Immunobiology, Div of Transplantation Immunology & Mucosal Biology, Medical Research Council Centre for Transplantation, King's College London, London, United Kingdom*, ³*Cystic Fibrosis and Lung Transplant Unit, Hospital Universitario La Fe, Valencia, Spain*, ⁴*Pulmonology Unit, Hospital Universitario Marqués de Valdecilla, Santander, Spain*, ⁵*Thoracic Surgery Unit, Hospital Universitario A Coruña, A Coruña, Spain*, ⁶*Pulmonology Unit, Hospital Universitario Puerta de Hierro, Madrid, Spain*, ⁷*Lung Transplant Unit, Hospital Universitario Reina Sofía, Córdoba, Spain*, ⁸*Lung Transplant Unit, Hospital Universitario Vall d'Hebrón. Ciber Enfermedades Respiratorias (Ciberes), Barcelona, Spain*

(516) Macrophages Represent the Major Pool of Interleukin-7 Receptor- α Expressing Immune Cells in Patients with Myocarditis; N. Kubin¹, A. Cetinkaya², K. Wörner², P. Löw², M. Schönburg², T. Ziegelhöffer², S. Kostin², M. H. Richter². ¹*Heart and Lung Research, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany*, ²*Cardiac Surgery, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany*

(517) Spred-2 is Necessary to Protect Against Lung Graft Injury After Mouse Lung Transplantation; K. Hashimoto¹, S. Sugimoto¹, T. Kurosaki², S. Otani², M. Yamane¹, S. Toyooka¹, T. Oto². ¹*Dept of Thoracic Surgery, Okayama University Hospital, Okayama, Japan*, ²*Organ Transplant Center, Okayama University Hospital, Okayama, Japan*

(518) Natural Polyreactive Antibodies and Inflammatory Markers Following Left Ventricular Assist Device Implantation; S. B. See¹, A. Pinsino², N. Kunimune³, D. Onat², M. Nasirahmadabadi², M. Yuzefpolskaya², A. R. Garan², V. K. Topkara², Y. Naka⁴, H. Takayama⁴, K. Takeda⁴, P. C. Colombo², E. Zorn¹. ¹*Columbia Center for Translational Immunology, Dept of Medicine, Columbia University, New York, NY*, ²*Division of Cardiology, Dept of Medicine, Columbia University, New York, NY*, ³*Columbia Center for Translational Immunology, Columbia University, New York, NY*, ⁴*Division of Cardiothoracic Surgery, Dept of Surgery, Columbia University, New York, NY*

(519) Frequency of Monocyte Subtypes and TLR4 Expression Correlate with Clinical Outcomes After Mechanical Circulatory Device Implantation; J. M. Schaenman, M. Rossetti, T. Sidwell, V. Groysberg, G. Sunga, E. Liang, S. Vangala, E. Chang, M. Bakir, G. Bondar, M. Cadeiras, M. Kwon, E. F. Reed, M. Deng. *UCLA School of Medicine, Los Angeles, CA*

(520) Immunologic Impacts of Natural Killer Cell-Related Innate Immune Rejection Mediated by CD226 and NKG2D on the Engraftment of Syngeneic Cardiomyocyte Derived from Induced Pluripotent Stem Cell; Y. Nakamura¹, S. Miyagawa¹, S. Yoshida¹, T. Toyofuku², Y. Sawa¹. ¹*Cardiovascular Surgery, Osaka University, Suita, Japan*, ²*Immunology and Regenerative Medicine, Osaka University, Suita, Japan*

(521) Recipient Bone Marrow-derived Cells Are Important Targets of IL-17 in Development of Allograft Fibrosis in the Mouse Intrapulmonary Tracheal Transplantation Model; T. Watanabe¹, K. Boonstra¹, Z. Guan¹, B. Joe¹, M. Maxim¹, J. K. Kolls², S. Keshavjee¹, S. Juvet¹, T. Martinu¹. ¹*Latner Thoracic Surgery Research Laboratories, Toronto Lung Transplant Program / University Health Network, Toronto, ON, Canada*, ²*Medicine and Pediatrics, Tulane School of Medicine, New Orleans, LA*

(522) Alloimmunity Contributes to and is Enhanced by Acute Lung Injury Following Prolonged Ischemia in Mouse Orthotopic Lung Transplantation; T. Watanabe¹, T. Martinu¹, K. Boonstra¹, M. Horie², Z. Guan¹, D. Hwang³, S. Keshavjee¹, S. Juvet¹. ¹Latner Thoracic Surgery Research Laboratories, Toronto Lung Transplant Program / University Health Network, Toronto, ON, Canada, ²Joint Dept of Medical Imaging, University Health Network, Toronto, ON, Canada, ³Dept of Pathology, University Health Network, Toronto, ON, Canada

(523) WITHDRAWN

(524) Bile Acids Aspiration Modulates Cholinergic and Serotonergic Responses of the Distal Airways; A. Urso¹, J. F. Perez-Zoghbi², C. W. Emala², N. W. Bunnett³, F. D'Ovidio¹. ¹Lung Transplant Program, Columbia University, New York, NY, ²Dept of Anesthesiology, Columbia University, New York, NY, ³Dept of Surgery, Columbia University, New York, NY

(525) Intracellular C3 Protects Human Airway Epithelial Cells from Oxidant-Stress Induced Apoptosis: Implications for Lung Allograft Injury; H. S. Kulkarni¹, C. Frakouh², D. E. Byers¹, S. L. Brody¹, A. E. Gelman³, J. P. Atkinson². ¹Medicine, Division of Pulmonary and Critical Care, Washington University in St Louis, Saint Louis, MO, ²Medicine, Division of Rheumatology, Washington University in St Louis, Saint Louis, MO, ³Surgery; Pathology and Immunology, Washington University in St Louis, Saint Louis, MO

(526) Epithelial Cell Death Markers in Bronchoalveolar Lavage Correlate with Chronic Lung Allograft Dysfunction Phenotypes; L. Levy¹, A. Tigert¹, S. Moshkelgosha¹, B. Joe¹, K. Boonstra¹, T. Saito², J. Tikkanen¹, S. Keshavjee¹, S. Juvet¹, T. Martinu¹. ¹Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada, ²Dept of Thoracic Surgery, Kansai Medical University, Hirakata, Japan

(527) Predictive Cytokine Profile for Invasive Aspergillosis in Lung Transplant Recipients in the Setting of Pre-emptive Prophylaxis; S. Herrera¹, W. Gohir¹, C. Aguilar¹, S. Juvet², T. Martinu², L. Singer², S. Keshavjee², C. Rotstein¹, D. Kumar¹, A. Humar¹, S. Husain¹. ¹Infectious diseases, University Health Network, Toronto, ON, Canada, ²Lung Transplant, University Health Network, Toronto, ON, Canada

(528) Longitudinal Mass Cytometric Profiling of BAL Cells in Lung Transplant Recipients; S. Moshkelgosha¹, L. Levy¹, T. Martinu¹, B. Joe¹, C. Guidos², S. Keshavjee¹, S. C. Juvet¹. ¹Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, ²Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, ON, Canada

(529) Organ-specific Differences in a Thymoglobulin and Belatacept-based Protocol for Tolerance Induction in Non-human Primates; W. Sommer, J. M. O., K. Huh, K. A. Robinson, A. Dehnadi, I. M. Hanekamp, I. A. Rosales, K. B. Pruner, J. T. Paster, R. N. Smith, R. B. Colvin, T. Kawai, G. Benichou, J. C. Madsen, J. S. Allan. Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA

(530) Using a Non-supervised Network Analysis to Contextualize a 28 Predictive Gene Classifier Accessing Functional Recovery Potential of Patients Undergoing Mechanical Support; R. Togashi¹, L. Masukawa¹, T. Bao¹, M. Cadeiras¹, J. Schaenman¹, J. Hai¹, D. Chu¹, E. Chang¹, A. Esmaeili², S. Kupiec-Weglinski³, V. Groysberg¹, A. Le¹, R. Dod¹, C. Kahn¹, E. Oh¹, J. Do¹, C. Lumintang¹, T. Grogan¹, J. Meltzer¹, M. Kwon¹, M. Rossetti¹, D. Elashoff¹, E. Reed¹, P. Ping¹, G. Bondar¹, M. Deng¹. ¹University of California, Los Angeles, Los Angeles, CA, ²University of Oklahoma, Oklahoma City, OK, ³Cornell University, Ithaca, NY

(531) Effect of Erythropoietin on Cardiac Allograft Survival in Non-Human Primates; J. O¹, K. A. Robinson¹, W. Sommer¹, K. Pruner¹, J. Paster¹, I. M. Hanekamp¹, A. Dehnadi¹, I. Rosales¹, R. N. Smith¹, P. Cravedi², P. S. Heeger², G. Benichou¹, J. C. Madsen¹. ¹Center for Transplantation Sciences, MGH, Boston, MA, ²Center for Translational Transplant Research, Icahn School of Medicine at Mount Sinai, New York, NY

(532) A Non-cuff Surgical Technique and Potent Peri-Transplant Immunomodulation Together Promote Long-term Survival of Murine Orthotopic Lung Allografts; L. Wang¹, R. Han¹, L. Kobzik², W. W. Hancock¹. ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Harvard School of Public Health & Brigham and Women's Hospital, Boston, MA

(533) Antibodies to Lung Self-antigens in Lung Transplant Recipients and Implications for Outcomes; V. Kaza¹, U. Rao², M. Sharma³, M. Mohanka¹, A. Banga¹, S. Bollineni¹, J. Mullins¹, F. Torres¹, T. Mohanakumar³. ¹UT SW Med Ctr, Coppell, TX, ²Kaiser Permanente San Jose Med Ctr, San Jose, CA, ³St. Joseph's Hospital & Med Ctr, Phoenix, AZ

(534) IL1RN Genotype and Infection Risk in Heart Recipients; I. Ezzahouri, D. Hernandez, C. Rodriguez-Sainz, L. Valor, E. Sarmiento, E. Fernandez-Cruz, J. Carbone. Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

- (535) Comparison of IgG SAB and C1q Assay: A Matter of Complement Fixing or Sensitivity;** C. Murphy¹, J. Rek², M. Kwan², C. Kunavarapu². ¹Southwest Immunodiagnosics, San Antonio, TX, ²Advanced Heart Failure and Transplant Program, Methodist Hospital, San Antonio, TX
- (536) Elamipretide Normalizes Protein and mRNA Expression Levels of Mitofilin in Left Ventricular Myocardium of Dogs with Advanced Heart Failure;** H. N. Sabbah, R. C. Gupta. Henry Ford Health System, Detroit, MI
- (537) Impact of Lung Allograft Position on Lung Quality During Ex Vivo Lung Perfusion;** S. Ordies¹, A. Martens¹, A. E. Frick², B. M. Vanaudenaerde³, S. E. Verleden³, R. Vos³, J. A. Verschakelen⁴, D. E. Van Raemdonck², G. M. Verleden³, A. P. Neyrinck¹. ¹Dept of Cardiovascular Sciences: Anesthesiology and Algology, KU Leuven, Leuven, Belgium, ²Dept of Thoracic Surgery, UZ Leuven, Leuven, Belgium, ³Dept of Chronic Diseases, Metabolism and Ageing: Pneumology, KU Leuven, Leuven, Belgium, ⁴Dept of Radiology, UZ Leuven, Leuven, Belgium
- (538) Ischemia Reperfusion Injury Significantly Differs Between Lung vs. Heart Transplantation with Respect to Lead Cytokines and Correlation to Clinical Outcome;** B. Wiegmann¹, N. Ledwoch², J. Iske², R. BellmasSanz², C. Neudörfel², I. Tudorache¹, C. Kühn¹, T. Kaufeld¹, F. Ius¹, S. RojasHernandez¹, M. Avsar¹, A. Haverich¹, C. Falk², G. Warnecke¹, G. Warnecke¹. ¹Dept for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany
- (539) Cytokine Dynamics Insights into Improved Lung Preservation Using the Organ Care System in a Porcine Transplantation Model in Comparison to the INSPIRE Trial;** T. Siemeni¹, R. Sanz², J. Salman¹, K. Jansson¹, A. Knöfel¹, F. Ius¹, W. Sommer¹, K. Höffler¹, A. Haverich¹, I. Tudorache¹, C. Falk², G. Warnecke¹. ¹Hannover HTTG, Hannover, Germany, ²Institute of Transplant Immunology, Hannover, Germany
- (540) Inflammation and Innate Immune Activation During Ex Vivo Heart Perfusion;** X. Qi¹, S. Hatami¹, C. W. White¹, S. Himmat¹, N. Aboelnazer¹, M. Ondrus¹, Y. Wu², A. Kinnear¹, J. Nagendran¹, D. Freed¹. ¹Surgery, University of Alberta, Edmonton, AB, Canada, ²Physiology, University of Alberta, Edmonton, AB, Canada
- (541) S-Nitroso-Human-Serum-Albumin Administration to Donor Prior to Organ Procurement Attenuates Cardiac Isograft Fibrosis and Alters Myocardial Micro-RNA-126-3p Expression in a Murine Heterotopic Heart Transplant Model;** A. Schaefer¹, A. Kiss¹, A. Oszwald², M. Hackl³, R. Kain², B. K. Podesser¹. ¹Ludwig Boltzmann Cluster for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Vienna, Austria, ²Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, ³TAmiRNA, Vienna, Austria
- (542) Double-Negative $\alpha\beta$ T cells: A Novel Player in Lung Ischemic-Reperfusion Injury;** J. Hsu¹, A. Krishnan¹, S. Lee², J. M. Dodd-o³, B. Kim⁴, A. R. Hamad⁵, H. Rabb², E. L. Bush¹. ¹Surgery-Thoracic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine-Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medicine-Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
- (543) CXCR4 Inhibition Improves Donor Leukocyte Depletion During Ex Vivo Lung Perfusion;** R. Davis, Q. Gao, J. Yerxa, M. Daneshmand, J. Haney, J. Klapper, M. Hartwig, A. Barbas. Dept of Surgery, Duke University, Durham, NC
- (544) Dual Ex-vivo Lung Perfusion Using Human Lungs;** K. Noda¹, S. Tane¹, J. Sembrat^{2,3}, M. Rojas^{2,3}, J. D'Cunha¹, J. D. Luketich¹, N. Shigemura⁴. ¹Dept of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, ³The Dorothy P. and Richard P. Simmons Center For Interstitial Lung Disease, University of Pittsburgh, Pittsburgh, PA, ⁴Cardiovascular Surgery, Temple University, Philadelphia, PA
- (545) Cyclosporine Preconditioning During Ex Vivo Lung Perfusion Improves the Quality of Post Transplant Lung Grafts;** K. Noda¹, S. Haam¹, S. Tane¹, J. D'Cunha¹, J. D. Luketich¹, N. Shigemura². ¹Dept of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Cardiovascular Surgery, Temple University, Philadelphia, PA
- (546) GALA-based SOM (Somah) Protects Coronary Endothelial and Vasomotor Function Following Ex Vivo Heart Perfusion;** R. V. Ribeiro, F. Yu, A. Ghashghai, L. Xin, B. Gellner, G. Ruggeri, J. Alvarez, D. Banner, M. Meineri, V. Rao, M. V. Badiwala. Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada

(547) Mitochondrial Integrity at Early Reperfusion Predicts Post-Ischemic Cardiac Graft Recovery; R. K. Wyss¹, N. Méndez Carmona¹, M. N. Sanz¹, M. Arnold¹, T. P. Carrel¹, S. Djafarzadeh², H. T. Tevaearai¹, S. L. Longnus¹. ¹Dept of Cardiovascular Surgery, University Hospital of Bern, Bern, Switzerland, ²Dept of Intensive Care Medicine, University Hospital of Bern, Bern, Switzerland

(548) Conservation of Hearts from Brain Dead Donors with a Preservation Solution Supplemented by a Conditioned Medium from Mesenchymal Stem Cells, Improves Graft Contractility After Heart Transplantation in Rats; S. Korkmaz-Icöz¹, K. Li¹, M. Ruppert¹, S. Loganathan¹, T. Radovits², P. Brlecic¹, M. Karck¹, G. Szabó¹. ¹Cardiac Surgery, Univ of Heidelberg, Heidelberg, Germany, ²Heart and Vascular Center, Semmelweis Univ, Budapest, Hungary

(549) Twenty-Four Hour Ex Vivo Lung Perfusion: Strategies to Stabilize Extended EVLP in a Pig Model; M. Takahashi, H. Cheung, M. Chen, Y. Watanabe, T. Watanabe, C. Harmantas, H. Gokhale, R. Qaqish, L. Caldarone, Y. Taniguchi, T. K. Waddell, M. Cypel, M. Liu, S. Keshavjee. Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, Toronto, ON, Canada

(550) Nitrite Attenuates Ischemia/Reperfusion (I/R) Injury of Lung by Regulating Endothelial Barrier Function; A. Kumar, K. Noda, B. Philips, M. T. Gladwin, J. D'Cunha. University of Pittsburgh Medical Center, Pittsburgh, PA

(551) Effects of Short and Long Term Cold Static Preservation Followed by Normothermic Ex Vivo Lung Perfusion in a Porcine Model; C. Olbertz¹, N. Pizanis¹, H. Bäumker¹, U. Rauen², I. Nolte³, M. Kamler¹, A. Koch¹. ¹Dept of Thoracic- and cardiovascular surgery, Division of Thoracic Transplantation, University of Essen-Duisburg, Essen, Germany, ²Institute of Physiological Chemistry, University of Essen-Duisburg, Essen, Germany, ³Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany

(552) Cold and Warm Ischemia Result in Different Histological Characteristics of Reperfusion Injury After Lung Transplantation in Mice; X. Wang. Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

(553) Facilitating Donation After Circulatory Death in Heart Transplantation: Effects of Cardioprotective Reperfusion Strategies on Mitochondria; M. N. Sanz, E. Farine, P. Niederberger, N. Méndez-Carmona, R. K. Wyss, M. Arnold, P. Gulak, T. P. Carrel, H. T. Tevaearai Stahel, S. L. Longnus. Dept of Cardiovascular Surgery, Inselspital, Bern University Hospital, Dept for BioMedical Research, University of Bern, Bern, Switzerland

(554) Characterization of Endothelial Function Following Various Ischemic Durations in an Isolated Rat Heart Model of Donation After Circulatory Death; N. Mendez Carmona, R. K. Wyss, M. Arnold, T. P. Carrel, H. T. Tevaearai Stahel, S. L. Longnus. Dept of Cardiovascular Surgery, Bern University Hospital, Bern, Switzerland

(555) Bronchial-arterial-circulation-sparing (BACS) Lung Preservation: A Novel Strategy in Lung Transplantation; S. Tane¹, K. Noda¹, J. D'Cunha¹, J. D. Luketich¹, N. Shigemura². ¹Dept of Cardiothoracic Surgery, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²Division of Cardiovascular Surgery, Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA

(556) Protective Effect of a Hydrogen-Rich Preservation Solution During Cold Ischemia in Rat Lung Transplantation; M. Saito¹, T. Chen-Yoshikawa¹, S. Hirano², H. Kayawake¹, S. Ueda¹, J. Tokuno¹, H. Yamagishi¹, F. Gochi¹, R. Okabe¹, A. Takahagi¹, H. Motoyama¹, M. Hamaji¹, A. Aoyama¹, H. Date¹. ¹Thoracic surgery, Kyoto university, kyoto, Japan, ²Miz company limited., Kamakura, Japan

(557) Functional Decline of the Ex Vivo Perfused Heart is Not Due to Cell Death; S. Hatami¹, X. Qi¹, A. Haromy², N. Aboelnazar³, S. Himmat¹, C. W. White¹, M. Ondrus¹, A. Kinnear¹, A. Wu⁴, M. Buchko¹, J. Nagendran¹, D. H. Freed¹. ¹Dept of Surgery, University of Alberta, Edmonton, AB, Canada, ²Dept of Medicine, University of Alberta, Edmonton, AB, Canada, ³Dept of Medicine, University of Calgary, Edmonton, AB, Canada, ⁴Dept of physiology, University of Alberta, Edmonton, AB, Canada

(558) A New Ex-Vivo Working Heart Model without Ischemia-Reperfusion Damage to Analyze Electrophysiological Properties of a Denervated Heart; A. M. Bernhardt¹, N. Klatt², C. Jungen², K. Scherschel², S. Willems², H. Reichenspurner¹, C. Meyer². ¹Dept of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, ²Dept of Electrophysiology, Univ Heart Ctr Hamburg, Hamburg, Germany

(559) Cell Recovery and Regeneration in Severely Damaged Lungs on Cross-Circulation; B. A. Guenthart¹, J. O'Neill², A. Hozain², Y. Tipograf³, G. Vunjak-Novakovic⁴, M. Bacchetta¹. ¹Surgery and Biomedical Engineering, Columbia Univ Hospital, New York, NY, ²Biomedical Engineering, Columbia Univ Hospital, New York, NY, ³Surgery, Columbia Univ Hospital, New York, NY, ⁴Biomedical Engineering and Medicine, Columbia Univ Hospital, New York, NY

(560) Novel Rat Lung Transplant Model of Primary Graft Dysfunction by Histone Administration; K. Nakao¹, M. Anraku¹, T. Murayama¹, M. Kawashima¹, A. Hosoi², J. Nakajima¹. ¹Dept of Thoracic Surgery, Graduate School of Medicine, Univ of Tokyo, Tokyo, Japan, ²Dept of Immunotherapeutics, Univ of Tokyo Hospital, Tokyo, Japan

(561) Creatine Supplementation Attenuates Apoptosis and Proliferation of Inflammatory Cells in a Lung Transplantation Model; F. M. Almeida¹, A. S. Battochio¹, J. P. Napoli², K. A. Alves², G. S. Balbin², M. Oliveira-Junior³, H. T. Moriya⁴, P. Pego-Fernandes¹, R. P. Vieira⁵, R. Pazetti². ¹Instituto do Coracao (InCor), Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ³Universidade Nove de Julho – UNINOVE, Sao Paulo, Brazil, ⁴Laboratorio de Engenharia Biomedica (LEB), Universidade de Sao Paulo, Sao Paulo, Brazil, ⁵IBEPIPE, School of Medical Sciences of Sao Jose dos Campos Humanitas and Universidade Brazil, Sao Jose dos Campos, Brazil

(562) Optimizing Perfusion of Human DCD Hearts in an Ex-Vivo System, and Histologic Assessment; N. Roy¹, W. Sommer², S. E. Kilmarx², U. J. Dudgeon², M. N. Jodhan², J. M. Camuso², M. A. Villavicencio², J. C. Madsen², S. R. James³, D. A. D'Alessandro². ¹Cardiac Surgery, Boston Children's Hospital, Boston, MA, ²Surgery, Massachusetts General Hospital, Boston, MA, ³Pathology, Massachusetts General Hospital, Boston, MA

(563) 2D Speckle Tracking to Assess Left Ventricular Function in a Model of Ex Vivo Heart Perfusion; G. Ruggeri¹, R. Vanin Pinto Ribeiro², B. Gellner³, L. Xin³, J. Qua Hiansen¹, M. Badiwala², M. Meineri¹. ¹Dept of Anesthesia, Toronto General Hospital, University Health Network, Toronto, ON, Canada, ²Dept of Cardiovascular Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada, ³Dept of Mechanical & Industrial Engineering, University of Toronto, Toronto, ON, Canada

(564) Porcine Model of Sepsis-Induced Systemic Inflammation and Acute Lung Injury: Can Injured Lungs be Recovered with EVLP alone?; A. Menaouar¹, C. Landry¹, J. F. Germain¹, J. F. Cailhier², N. Noiseux¹, P. Laplante², S. Der Sarkissian¹, M. Liberman¹, Y. Berthiaume³, P. Ferraro¹. ¹Dépt. Chirurgie, CHUM Université de Montréal, Montréal, QC, Canada, ²Dépt. Médecine, CHUM Université de Montréal, Montréal, QC, Canada, ³Dépt. Médecine, IRCM Université de Montréal, Montréal, QC, Canada

(565) Ageing and Ischaemic Tolerance in a Rodent Donation After Circulatory Death (DCD) Model; H. Chew, S. Scheuer, L. Gao, J. Villanueva, M. Hicks, A. Jabbour, K. Dhital, P. Macdonald. Transplantation Lab, Victor Chang Cardiac Research Institute, Darlinghurst, Australia

(566) Computed Tomography for Rejection Monitoring in a Murine Orthotopic Lung Transplantation Model; T. Nakagiri¹, L. Ahrens¹, S. Lienenklaus², A. Knöfel¹, D. Jonigk³, N. Madrahimov¹, K. Jansson¹, A. Haverich¹, G. Warnecke¹. ¹Dept of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Institute for Laboratory Animal Science, Hannover Medical School, Hannover, Germany, ³Institute of Pathology, Hannover Medical School, Hannover, Germany

(567) Increased Plasma Levels of Donor-derived Cell-free DNA Correlate With Acute Rejection in the Recipients of Living Donor-lobar Lung Transplantation; S. Tanaka, S. Sugimoto, T. Kurosaki, S. Otani, M. Yamane, S. Toyooka, T. Oto. General Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(568) Intracellular Remodeling in a Rodent Model of Cardiac Mechanical Unloading - Influence of Phospholamban on Expression of Cardiac Ion Currents; S. Westhofen¹, L. Dreher², H. Vitzthum², H. Reichenspurner¹, H. Ehmke², A. P. Schwoerer². ¹Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany, ²Institute for Cellular and Integrative Physiology, UKE, Hamburg, Germany

(569) Mitral Valve 3D Computational Modeling and Simulation Characterized by Left Ventricular Shape Dynamics in Dilated Cardiomyopathy; J. Park¹, P. Bonde². ¹Yale School of Medicine, New Haven, CT, ²Section of Cardiac Surgery, Yale School of Medicine, New Haven, CT

(570) Relationship Between Oral Microbiota, Inflammation and Congestion Among Advanced Heart Failure Patients; R. T. Demmer¹, M. Nasiri², D. Onat², P. Trinh², N. Akter², J. Nwokocha², E. A. Royzman², A. Clemons², A. Pinsino², D. L. Brunjes², A. M. Zuver², A. R. Garan², V. K. Topkara², K. Takeda², H. Takayama², Y. Naka², M. A. Farr², A. Uhlemann², P. C. Colombo², M. Yuzefpolskaya². ¹University of Minnesota, Columbia University, New York, NY, ²Columbia University, New York, NY

(571) Advanced Failing Hearts Have a Wide Range of Fibrosis Including Overlap with Nonfailing Hearts; P. C. Ferrin, S. Navankasattusas, N. A. Diakos, L. McCreath, A. G. Kfoury, D. V. Miller, O. Wever-Pinzon, J. Stehlik, V. Hebl, C. H. Selzman, W. Caine, A. Koliopoulou, E. H. Hammond, S. G. Drakos. *UTAH Cardiac Transplant Program (University of Utah, Intermountain Medical Center, Salt Lake VA Medical Center), Salt Lake City, UT*

(572) A Mouse Model of Recovery from Non-Ischemic Heart Failure; A. S. Cruz-Solbes, K. A. Youker, J. P. Cooke, G. Torre-Amione, B. Trachtenberg, A. Guha, M. H. Park, J. Estep, I. Hussain, A. Bhimaraj. *Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX*

(573) Impaired Mitochondrial Quality Control in African Americans With Chronic Heart Failure; S. Marek-Iannucci, D. Taylor, A. Thomas, B. Coleman, K. Tucker, A. Andres, L. S. Czer, R. A. Gottlieb. *Heart Institute, Cedars Sinai, Los Angeles, CA*

(574) Hyperlipidemia Impairs Autophagy in Chronic Heart Failure; S. Marek-Iannucci, D. Taylor, A. Thomas, K. Tucker, A. Andres, L. S. Czer, R. A. Gottlieb. *Heart Institute, Cedars Sinai, Los Angeles, CA*

(575) Quantification of DNA Damage in Heart Tissue as a Novel Prediction Tool for Therapeutic Prognosis; T. Ko¹, K. Fujita¹, S. Nomura¹, M. Tsuji¹, D. Nitta¹, H. Maki¹, Y. Hosoya¹, E. Amiya¹, M. Hatano¹, M. Ono², I. Komuro¹. ¹*Dept of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan*, ²*Dept of Cardiac & Thoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan*

(576) sCD146 - a Novel Marker of Systemic Venous Congestion - Positively Correlates With Plasma Endothelin-1 - Marker of Vasoconstriction and Inflammation - in Heart Failure; P. C. Colombo¹, M. Yuzefpolskaya¹, M. Nasiri¹, A. Pinsino¹, D. Onat¹, J. Nwokocha¹, A. M. Clemons¹, F. Castagna², A. Kleet¹, K. Axsom¹, E. Lin¹, J. Haythe¹, E. Gayat³, A. Mabaaza³, R. T. Demmer⁴. ¹*Columbia University, New York, NY*, ²*Columbia University/Yale New Haven Bridgeport, New York, NY*, ³*Paris Diderot University, Paris, France*, ⁴*University of Minnesota/Columbia University, New York, NY*

(577) Establishing Chronic Stable Heart Failure in Ovine Model; is It Feasible?; C. Torregroza¹, N. Sadat¹, J. von der Beek², D. Scheiber³, I. J. Knorr², M. Sager², P. Akhyari¹, A. Lichtenberg¹, D. Saeed¹. ¹*Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany*, ²*Dept of Animal Research and Animal Protection Task, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany*, ³*Cardiology, Angiology and Pulmology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany*

(578) Warfarin Genotype Polymorphisms in Kazakhstani Patients with Mechanical Circulatory Support - Left Ventricular Assist Devices; A. R. Akilzhanova¹, S. E. Rakhimova¹, S. A. Andosova², Z. S. Zhumadilov³, M. S. Bekbossynova⁴. ¹*Laboratory of Genomic and Personalised Medicine, National Laboratory Astana, Center for life sciences, Nazarbayev University, Astana, Kazakhstan*, ²*Chronic Heart Failure Dept, National Scientific Cardiac Surgery Center, Astana, Kazakhstan*, ³*National Laboratory Astana, Center for life sciences, Nazarbayev University, Astana, Kazakhstan*, ⁴*National Scientific Cardiac Surgery Center, Astana, Kazakhstan*

(579) Gut Microbiome-Generated Metabolite Trimethylamine-N-Oxide is Reduced After Heart Transplantation and Continuous Flow Left Ventricular Assist Device Therapy in Advanced Heart Failure Patients; M. Yuzefpolskaya, M. Nasiri, D. Onat, E. A. Royzman, J. Nwokocha, A. Pinsino, D. L. Brunjes, P. Trinh, A. M. Zuver, A. R. Garan, V. K. Topkara, H. Takayama, K. Takeda, Y. Naka, M. A. Farr, A. Uhlemann, P. C. Colombo, R. T. Demmer. *Cardiology, Columbia University, New York, NY*

(580) Club Cell Secretory Protein Replacement Therapy in a Murine Lung Transplant Model of Obliterative Bronchiolitis; C. Konoeda¹, Z. Guan¹, T. Watanabe¹, M. Horie², A. Pilon³, M. Liu¹, T. K. Waddell¹, S. C. Juvet¹, S. Keshavjee¹, T. Martinu¹. ¹*Toronto General Hospital, Toronto, ON, Canada*, ²*Joint Dept of Medical Imaging, Toronto General Hospital, Toronto, ON, Canada*, ³*Therabon Therapeutics, Inc., Rockville, MD*

(581) Model of Pediatric Pulmonary Hypertension and Right Heart Failure by Chronic Pulmonary Artery Ligation With Invasive Echocardiographic Evaluation; P. Hala¹, B. Carr², C. Poling², M. Caceres-Quinones², T. Johnson², M. Langley², O. Behbahani-Nejad², P. Yarramilli², A. Prater², R. H. Bartlett², W. R. Lynch², A. Rojas-Pena², R. B. Hirschl². ¹*University of Michigan, ECLS laboratory, Charles University, Homolka Hospital, Ann Arbor, MI*, ²*ECLS laboratory, University of Michigan, Ann Arbor, MI*

ECONOMICS, ETHICS, PUBLIC POLICY

(Muses)

Poster Discussants: John Aubert (Switzerland), Jacob Lavee (Israel)

(582) Acceptable Peri-Operative Risk for Cardiac Transplant: Physician and Patient Perspectives; A. Savtchenko¹, J. Milligan¹, C. Alba², J. Kobulnik³. ¹Core Internal Medicine, University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital: University Health Network, Toronto, ON, Canada, ³Cardiology, Sinai Health System, Toronto, ON, Canada

(583) Elective and Emergency Heart Transplantation: Costs Comparison in a Single Center; M. Farrero Torres, J. L. Pomar, J. Sagarra, E. Santiago, A. Castel, A. Garcia, F. Perez-Villa. *Hospital Clinic, Barcelona, Spain*

(584) Discrepancies Between Costs and Reimbursement Values May Be Associated with Low Heart Transplants Numbers in Brazil; L. Goldraich¹, J. Neyeloff¹, L. M. Zeilmann¹, V. M. Oliveira¹, E. C. Ghisleni², L. C. Hastenteufel², N. Clausell¹. ¹Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ²Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

(585) Impact of the Affordable Care Act on Patients Listed for Cardiac Transplant; M. S. Ising¹, J. R. Trivedi¹, E. J. Birks², R. Vijayakrishnan², B. Alkhalil², M. S. Slaughter³. ¹Dept of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, ²Dept of Medicine, Division of Cardiology, University of Louisville, Louisville, KY, ³Dept of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

(586) The Impact of the Affordable Care Act on Patients Listed for Lung Transplantation; M. S. Ising, J. R. Trivedi, K. Marino, F. P. Matthew, V. van Berkel. *Dept of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY*

(587) Evaluation of the Urgency Based Lung Allocation System in Korea Using the Lung Allocation Score (LAS) System; W. Yu¹, J. Lee², J. Suh², S. Kim³, M. Park³, H. Paik². ¹Dept of Medicine, The Graduate School of Yonsei University, Seoul, Korea, Republic of, ²Dept of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Division of Pulmonology, Dept of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of

(588) Can Prolonged Become Too Long? Medical Futility and Duration of Hospitalization Following Lung Transplantation; A. Courtwright¹, E. Rubin², E. Robinson³, A. Thomasson⁴, S. El-Chemaly⁵, J. Diamond¹, H. Goldberg⁵. ¹Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, ²Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, ³Institute for Patient Care, Massachusetts General Hospital, Boston, MA, ⁴Lung Transplant Institute, University of Pennsylvania, Philadelphia, PA, ⁵Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA

JUNIOR FACULTY CLINICAL CASE REPORTS

(Agora 3)

Poster Discussants: Karen Booth (United Kingdom), Laveena Chhatwani (USA), Hannah Copeland (USA), Jens Gottlieb (Germany), Chi-Hsin Hsu (Taiwan), Manreet Kanwar (USA), Shalika Katugaha, (USA), Sofia Masri (USA), Omar Mohamedaly, (USA), Martha Mooney, (USA), Johan Nilsson (Sweden), Isabelle Opitz (Switzerland), Caroline Patterson (United Kingdom), Stephanie Pouch (USA)

(1288) First in the World Heart Kidney Transplant in HIV Positive Patient; B. Chung¹, J. Powers¹, A. Nguyen¹, N. Narang¹, T. Riley¹, C. Murks¹, M. Reilly¹, V. Jeevanandam², T. Song², T. Ota², S. Kalantari¹, J. Raikhelkar¹, G. Kim¹, N. Sarswat¹, G. Sayer¹, N. Uriel¹. ¹Cardiology, University of Chicago, Chicago, IL, ²Cardiac Surgery, University of Chicago, Chicago, IL

(1289) Isolated IgG4-RD Myocarditis Treated With Heart Transplantation; E. F. Lin, J. R. Cook, J. E. Diamond, N. O. Palmeri. *Medicine, Division of Cardiology, Columbia University, New York, NY*

(1290) Putting Out the Fire: Stabilization of Aggressive Cardiac Allograft Vasculopathy; K. J. Clerkin, M. V. Habal, S. W. Restaino, E. Zorn, M. A. Farr, S. Bokhari. *Cardiology, Columbia University Medical Center, New York, NY*

(1291) Old Before His Time - A Case of Neonatal Myocardial Infarction; A. Pisesky, A. Dipchand, E. Hickey, E. Jean-St-Michel, A. Jeewa. *Paediatric Cardiology, The Hospital for Sick Children, Toronto, ON, Canada*

- (1292) Heart Transplantation After Bridge to Transplant With Novel Approach to Mechanical Circulatory Support in a Patient With d-Transposition of the Great Arteries;** J. A. Gomez-Abraham¹, S. Brann¹, S. Keshavamurthy¹, E. Hamad², R. Alvarez², Y. Toyoda¹. ¹Cardiothoracic Surgery, Temple University School of Medicine Div of Cardiothoracic Surgery, Philadelphia, PA, ²Cardiology, Temple Univ School of Medicine Div of Cardiothoracic Surgery, Philadelphia, PA
- (1293) Acute Necrotizing Eosinophilic Myocarditis Treated With Anti-IL-5 Inhibitor and Mechanical Support;** E. Seif¹, I. Gosev², H. Vidula¹. ¹Cardiology, University of Rochester Medical Center, Rochester, NY, ²Cardiothoracic Surgery, University of Rochester Medical Center, Rochester, NY
- (1294) Autoantibodies Before and After Heart Transplantation. Can They Predict Immunologic Risk?;** N. Aleksova¹, M. Lamacie¹, A. Chruscinski², A. Luk¹, M. Epstein², M. McDonald¹, H. J. Ross¹. ¹Cardiology, University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada
- (1295) Coronary Sinus Injury During Procurement Necessitating Surgical Reconstruction;** N. P. Zwintscher, W. B. Smith, M. J. Bates, P. E. Parrino. Cardiothoracic Surgery, Ochsner Clinic Foundation, New Orleans, LA
- (1296) Extracorporeal Photopheresis (ECP) and Calcineurin Inhibitor (CNI) Delay After Heart Transplantation;** J. Goekler, A. Zuckermann, J. Riebandt, U. Just, N. Worel, R. Knobler, E. Osorio, R. Moayedifar, G. Laufer, A. Aliabadi-Zuckermann. Medical University Vienna, Vienna, Austria
- (1297) Rosai-Dorfman Disease Causing Heart Failure: A Case Report and Review of Literature;** M. P. Laubham¹, A. Darki². ¹Internal Medicine-Pediatrics, Loyola University Medical Center, Chicago, IL, ²Internal Medicine, Loyola University Medical Center, Chicago, IL
- (1298) Cardiac Cells with Hoarding Behavior: An Interesting Case of Heart Failure;** D. F. Miranda¹, K. Mudy², S. M. Mackey-Bojack³, S. O. Sanderson⁴, P. Zimbwa¹. ¹Cardiology Dept, Minneapolis Heart Institute, Minneapolis, MN, ²Division of Surgery, Minneapolis Heart Institute, Minneapolis, MN, ³Medical Director, Jesse E. Edwards Registry of Cardiovascular Disease, Minneapolis, MN, ⁴Pathology Dept, Abbott Northwestern Hospital, Minneapolis, MN
- (1299) Bilateral Sympathectomy for Treatment Refractory Ventricular Tachycardia;** A. Bindra, A. Afzal, T. Gong, M. Assar, M. Assar, D. Mason, A. Donsky, P. Kale, J. Felius, S. Hall. Baylor University Medical Center, Dallas, TX
- (1300) A Successful Case of Heart Transplantation Following Restrictive Cardiomyopathy Due to Systemic Mastocytosis;** A. Braga¹, G. Koukoulis¹, J. Calquinha¹, B. Ferreira², C. Afonso², M. Chorão³, R. Gouveia¹, S. Ramos¹, M. Rebocho¹, M. Abecasis¹, M. Mendes¹, J. Neves¹. ¹Hospital de Santa Cruz, Lisboa, Portugal, ²Hospital de São Francisco Xavier, Lisboa, Portugal, ³Hospital Egaz Moniz, Lisboa, Portugal
- (1301) Persistent Heart Failure Early Post-Transplant Due to Constrictive Pericarditis: Conservative Management and Response;** A. Abbas¹, I. Hussain^{1,2}. ¹Houston Methodist, Houston, TX, ²Houston Methodist Hospital, Houston, TX
- (1302) Serotonin Syndrome from Methylene Blue Administration for Severe Vasoplegia Immediately Post Heart Transplant;** A. Abbas, I. Hussain. Houston Methodist, Houston, TX
- (1303) Familial Dilated Cardiomyopathy in a 32-Year-Old Woman Diagnosed with Mucopolysaccharidosis III by Whole Exome Sequencing;** H. Lee¹, S. Song², S. Kim², J. Shin¹, M. Kwak³, N. Shin⁴, M. Kim⁵, S. Oh¹, N. Jeong¹. ¹Dept of Cardiology, Pusan National University Hospital, Busan, Korea, Republic of, ²Dept of Cardiovascular Surgery, Pusan National University Hospital, Busan, Korea, Republic of, ³Dept of Pediatrics, Pusan National University Hospital, Busan, Korea, Republic of, ⁴Dept of Pathology, Pusan National University Hospital, Busan, Korea, Republic of, ⁵Dept of Pharmacy, Pusan National University Hospital, Busan, Korea, Republic of
- (1304) Takotsubo Cardiomyopathy in a Young Adult With Transplanted Heart: What Happened to Denervation?;** D. De Angelis, M. Chinali, R. Formigari, C. Esposito, A. Franceschini, S. Alfieri, F. Parisi, G. Grutter. Bambino Gesù Children Hospital, Roma, Italy
- (1305) Cardiac Transplantation for Ventricular Tachycardia Storm Due to Cardiac Hemangioma;** F. Scussel¹, M. Krishnan², R. M. Kulchetscki³, S. Mangini¹, F. G. Marcondes-Braga¹, M. S. Ávila¹, L. F. Seguro¹, S. R. Siqueira¹, L. L. Trevizan¹, S. M. Ayub-Ferreira¹, F. Gaiotto¹, F. Bacal¹. ¹Heart Transplant, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil, ²Cardiology, Guthrie Robert Packer Hospital, Sayre, PA, ³Cardiology, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil

- (1306) Tolerability of Sacubitril/Valsartan in Patients with Durable Left Ventricular Assist Devices;** A. Sharma¹, Y. Moayed², S. Duclos¹, R. Lee¹, M. Wheeler¹, W. Hiesinger¹, J. Teuteberg¹, D. Banerjee¹. ¹Cardiology, Stanford University, Menlo Park, CA, ²Cardiology, University of Toronto, Toronto, ON, Canada
- (1307) HVAD as a Bridge to Heart Transplantation in Danon Disease;** P. Chau¹, B. D. Kaufman², J. Kwok², J. Murray², S. Chen², D. N. Rosenthal², S. A. Hollander². ¹Pediatrics, University of Michigan, Ann Arbor, MI, ²Pediatrics, Stanford University, Palo Alto, CA
- (1308) Progressive Cardiomyopathy Requiring Heart Transplant Following Metal-on-Metal Total Hip Arthroplasty;** S. Murphy, J. O'Neill. Mater Misericordiae University Hospital, Dublin, Ireland
- (1309) Early Antibody Mediated Rejection After Heart Transplantation: Successful Treatment Using IgM-enriched Human Intravenous Immunoglobulin;** C. Buchholz¹, A. Bernhardt¹, H. Grahn², M. Rybczynski², H. Reichenspurner¹, M. J. Barten¹. ¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, ²General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
- (1310) Successful Treatment of Mediastinitis After Left Ventricular Assist Device Implantation Using IgM-enriched Human Intravenous Immunoglobulin;** C. Buchholz¹, A. Bernhardt¹, H. Grahn², M. Rybczynski², H. Reichenspurner¹, M. J. Barten¹. ¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, ²General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany
- (1311) Late-Onset Hypertrophic Cardiomyopathy Arising in an Orthotopic Heart Transplant Recipient;** W. A. Parker¹, A. Sinha², H. J. Ramshaw¹, E. K. D'Arcy¹, P. C. Bradley¹, A. Al-Mohammad¹. ¹The Heart & Lung Transplant Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, ²The Medical School, University of Sheffield, Sheffield, United Kingdom
- (1312) Successful Cardiac Retransplantation for Combined Acute and Chronic Rejection in an Allosensitized Recipient: State-of-the-Art Strategies to Improve Donor Organ Availability, Preservation and Immunological Viability;** S. V. Rojas, F. Ius, T. Kaufeld, M. Avsar, C. Bara, A. Haverich, G. Warnecke. Dept of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany
- (1313) Use of Extracorporeal Membrane Oxygenation in a AML Patient With Chemotherapy Induced Acute Heart Failure;** M. Anwer¹, G. Burcu², P. Bonde³. ¹Cardiac Surgery, Yale Sch of Med, New Haven, CT, ²Div of Cardiology, Yale Sch of Med, New Haven, CT, ³Section of Cardiac Surgery, Yale Sch of Med, New Haven, CT
- (1314) Successful Heart Transplantation Alone in a Patient With Congenital Heart Disease and Severe Pulmonary Hypertension;** J. N. Menachem¹, E. Y. Birati², P. Zamani², A. L. Fox², M. Tanna², A. T. Owens², P. Atluri³, N. Hornsby², A. Kayser², D. Drajpuch², L. Tobin², Y. Y. Kim², J. Wald², R. Forde-Mclean², J. E. Rame², L. R. Goldberg², C. E. Mascio⁴, C. A. Bermudez³, M. A. Acker³, J. A. Mazurek². ¹Cardiovascular Division, Vanderbilt University, Nashville, TN, ²Cardiovascular Division, University of Pennsylvania, Philadelphia, PA, ³Cardiovascular Surgery Division, University of Pennsylvania, Philadelphia, PA, ⁴Cardiovascular Surgery Division, Children's Hospital of Philadelphia, Philadelphia, PA
- (1315) An Overlooked Cause of Heart Failure in Patients on Hemodialysis;** H. Keshmiri¹, C. Rajyaguru², S. Danciu¹, S. Pauwaa³, m. Bazavan¹. ¹Advocate Illinois Masonic Medical Center, Chicago, IL, ²UCSF Fresno, Fresno, CA, ³Advocate Christ Medical Center, Oak Lawn, IL
- (1316) WITHDRAWN**
- (1317) Avoiding Cardiac Transplantation With His Bundle Pacing and LVAD Support: A Severe Form of RV Pacing Induced Cardiomyopathy in a Teenager;** S. Bhattacharya¹, M. Caccamo², G. Dandamudi¹, I. Wang¹, B. Angela¹. ¹Krannert Institute of Cardiology, Indiana Univ, Indianapolis, IN, ²Cardiology, West Virginia Univ, Morgantown, WV
- (1318) Is C1q Binding Assay of Donor Specific Anti-HLA Antibodies Useful to Predict Antibody Mediated Rejection in Heart Transplantation?: A Case Report;** Y. Kimura, K. Iwasaki, K. Toda, N. Kikuchi, Y. Kumai, K. Kuroda, Y. Matsumoto, O. Seguchi, S. Fukushima, M. Yanase, T. Fujita, J. Kobayashi, N. Fukushima. Dept of Transplantation, National Cerebral and Cardiovascular Centre, Osaka, Japan
- (1319) Life Threatening Iron Pill Gastritis in Heart Transplant Recipient;** A. Gampa¹, B. Chung¹, A. Nguyen², G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Cardiology, University of Chicago, Chicago, IL
- (1320) WITHDRAWN**

(1321) WITHDRAWN

(1322) **Conduction Dysfunction Then It's Expunction: Giant Cell Myocarditis**; A. Yoruk, C. Gleber, B. I. Goldman, S. J. Cameron, L. Chen. *University of Rochester, Rochester, NY*

(1323) **A Case Report of Severe Antibody Rejection and the Use of Eculizumab and Mechanical Support**; J. C. Krisl, S. Varnado, A. Bhimaraj, A. Guha, J. Estep. *Houston Methodist Hospital, Houston, TX*

(1324) WITHDRAWN

(1325) **Mysterious Multi-Organ Failure in Prior Cardiac Transplant Patient**; S. Byun¹, J. M. Clark², R. J. Alvarez². ¹*Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD*, ²*Advanced Heart Failure/Cardiac Transplantation, Temple University Hospital, Philadelphia, PA*

(1326) **Methotrexate as a Rescue Therapy for Persistent Cellular Rejection and Donor Specific Antibody Reduction**; S. R. Siqueira, S. Mangini, F. Marcondes-Braga, F. Scussel, M. S. Avila, L. L. Trevizan, L. F. Seguro, T. F. Piccirillo, F. Gaiotto, F. Bacal. *Heart Transplant Unit, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil*

(1327) **Managing Hypertrophic Cardiomyopathy in the Setting of Hemorrhaging Placenta Previa**; A. Alam, A. Aboyme, K. Niazi, C. Maulion, D. James, K. Mody, D. Iyer, J. Almendral. *Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ*

(1328) **Pure Red Cellaplasia in Heart Transplant Recipients Secondary to Immunosuppressive Agent**; J. Oh, S. Kang. *Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of*

(1329) **A Rare Case of Large Chylous Pericardial Effusion After Heart Transplantation: Is Pericardiocentesis Indicated**; E. Nachum, Y. Kassif, A. Kogan, D. Freimark, A. Wallner, J. Lavee, Y. Peled. *Sheba Medical Center and Tel-Aviv University, Ramat Gan, Israel*

(1330) **Unique Complication Following Heart Lung Transplantation**; J. Chen¹, K. Rajalingam², G. Dincheva¹, M. Brzezinski³, B. Trinh¹, T. Deuse¹, G. Wieselthaler¹, J. Kukreja¹. ¹*Surgery, Univ of California, San Francisco, CA*, ²*Undergraduate, Univ of California, Berkeley, CA*, ³*Anesthesia, Univ of California, San Francisco, CA*

(1331) **Malakoplakia of the Colon: A Rare Complication After Lung Transplantation**; I. Saba, N. A. Brozzi, D. Fertel, A. Ghodsizad, S. Shafazand, M. Loebe. *University of Miami, Miami, FL*

(1332) **Emergence of Daptomycin Resistant Staphylococcus Epidermidis During Treatment of VAD-Associated Bacteremia**; I. Hollis¹, K. Levinson², M. Jones³, A. Lachiewicz⁴, J. Katz⁵, D. van Duin⁴, L. Bartelt⁴. ¹*Pharmacy, Univ of North Carolina at Chapel Hill, Chapel Hill, NC*, ²*Microbiology, Univ of North Carolina at Chapel Hill, Chapel Hill, NC*, ³*Clinical Microbiology/Immunology, Univ of North Carolina at Chapel Hill, Chapel Hill, NC*, ⁴*Infectious Diseases, Univ of North Carolina at Chapel Hill, Chapel Hill, NC*, ⁵*Cardiology, Univ of North Carolina at Chapel Hill, Chapel Hill, NC*

(1333) **Successful Treatment of Donor-derived Hepatitis C Infection in a Cardiac Transplant Recipient: An Opportunity to Expand Organ Donation**; K. J. Gaj¹, C. K. McIlvennan², M. R. Mehra³, L. R. Baden⁴, D. S. Page³, E. L. Woodcome³, N. E. Ibrahim¹, A. E. Woolley⁴. ¹*Division of Advanced Heart Disease and Cardiac Transplantation, Massachusetts General Hospital, Boston, MA*, ²*Advanced Heart Failure, Mechanical Circulatory Support and Transplantation, Univ of Colorado Denver, Anschutz Med Ctr, Aurora, CO*, ³*Center for Advanced Heart Disease, Brigham and Woman's Hospital, Boston, MA*, ⁴*Transplant Infectious Disease, Brigham and Woman's Hospital, Boston, MA*

(1334) **Treatment of Viral Hepatitis After Lung Transplant**; M. Howsare¹, B. Jalil¹, D. R. Nunley¹, V. Van Berkel², A. Ramirez¹. ¹*Pulmonary, Critical Care, and Sleep Medicine, University of Louisville, Louisville, KY*, ²*Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY*

(1335) **Not Your Usual Chagas Rash: Cutaneous Chagas Reactivation as Violaceous Lesions and Reticular Ulcers Post-Heart Transplantation**; M. Krishnan¹, C. R. Andrade², S. Mangini², F. G. Marcondes-Braga², M. S. Ávila², L. F. Seguro², T. M. Strabelli³, F. Bacal². ¹*Cardiology, Guthrie Robert Packer Hospital, Sayre, PA*, ²*Heart Transplant, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil*, ³*Infection Control Unit, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil*

(1336) WITHDRAWN

- (1337) Time to Relapse: Infection in Destination LVAD Recipients;** M. K. Kim¹, S. B. Katugaha¹, P. Shah², S. Desai², L. Bogar², R. Singh², A. C. Carter². ¹Dept of Medicine, Inova Fairfax Hospital, Falls Church, VA, ²Inova Fairfax Hospital, Falls Church, VA
- (1338) Successful Treatment of De Novo Airway Stent-Associated Mycobacterium abscessus Infection After Lung Transplantation;** M. G. Patel¹, E. Lushin², D. W. Roe¹, C. A. Hage¹. ¹Dept of Pulmonary/Critical Care Medicine, Methodist Hospital, Indiana University Health, Indianapolis, IN, ²Dept of Pharmacy, Methodist Hospital, Indiana University Health, Indianapolis, IN
- (1339) A Wolf in Sheep's Skin: Invasive Abdominal Wall Fungal Infection After LVAD Implantation;** S. Gohar¹, J. P. Herlihy², S. Saatee³, K. Heck⁴, A. Civitello¹, A. Nair¹. ¹Heart Failure/Cardiology, Baylor College of Medicine/Texas Heart institute, Houston, TX, ²Pulm/CC, Baylor College of Medicine, Houston, TX, ³Anesthesia/CC, Baylor College of Medicine/Texas Heart institute, Houston, TX, ⁴Pathology, Baylor College of Medicine/Texas Heart institute, Houston, TX
- (1340) A Case of Persistent Candida Lusitaniae Fungemia in a LVAD Recipient;** K. Kapoor¹, S. Katugaha², D. Nandamuru³, P. Shah², L. Cooper², S. Desai², C. May², A. C. Carter², L. G. Edwards², M. Binetti², M. Kim². ¹University of Miami/Jackson Memorial Hospital, Miami, FL, ²INOVA Heart and Vascular Institute, Falls Church, VA, ³Virginia Commonwealth University School of Medicine, INOVA Campus, Falls Church, VA
- (1341) BK Virus in Cardiac Transplant Patients;** L. Peters, C. McIlveen, L. Allen, A. Ambardekar, P. Khazanie. University of Colorado, Aurora, CO
- (1342) Pseudomonas Aeruginosa Endophthalmitis and Meningitis in a Heart Transplant Patient;** K. Dulnuan, N. Rajagopalan. University of Kentucky, Lexington, KY
- (1343) Post Lung Transplant Recurrence of Diffuse Panbronchiolitis; What Should Be Reconsidered? "Peri-Lung Transplant Management" or "Indication for Lung Transplant"?** R. Waseda, T. Shiraishi, M. Hiratsuka, T. Moroga, S. Miyahara, A. Nagata, A. Iwasaki. Fukuoka University, Fukuoka, Japan
- (1344) Epstein Barr Virus Encephalitis in Heart Transplantation;** P. Avellana, A. Ini, M. Ajzenszlos, D. Radlovachki, S. Belforte, W. Esteban, L. Ahualli. Hospital Cosme Argerich, Buenos Aires, Argentina
- (1345) Simultaneous Bilateral Lung Transplantation and Pectus Excavatum Correction Using the Nuss Technique with Femoro-Femoral ECMO Support;** D. Valdivia, A. Slama, V. Besa, A. Koch, M. Kamler, C. Taube, C. Aigner. West German Center for Lung Transplantation, Essen, Germany
- (1347) Successful Unilateral Lung Transplantation Using Bilateral Upper-lobe Grafts;** Y. Shikatani. Okayama University Hospital, Okayama, Japan
- (1348) Successful Staged Bilateral Lung Retransplant Followed by Living Related Renal Transplant in a Hemodialysis Patient;** E. A. Lendermon, S. Iturra Urriola, M. Morrell, J. D'Cunha. Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
- (1349) Systemic Capillary Leak Syndrome as a Cause of Recurrent Respiratory Failure in a Lung Transplant Recipient;** B. C. Keller¹, S. Kirkby¹, P. Lee², B. Shukrallah², B. A. Whitson², A. Pope-Harman¹. ¹Internal Medicine, The Ohio State University, Columbus, OH, ²Cardiac Surgery, The Ohio State University, Columbus, OH
- (1350) To Treat or Not to Treat: Incidental Bilateral Pan-Lobar Node Negative Mucinous Adenocarcinoma of the Lung;** H. Aziz¹, K. Walker¹, T. Ellison¹, S. Broderick¹, C. Merlo², P. Shah², L. Silhan², P. Illei³, R. Higgins¹, J. Orens¹, E. L. Bush¹. ¹Cardiothoracic Surgery, Johns Hopkins Hospital, Baltimore, MD, ²Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, ³Pathology-Cytopathology, Johns Hopkins Hospital, Baltimore, MD
- (1351) Metastatic Squamous Cell Carcinoma of the Skin in a Lung Transplant Recipient;** G. A. Fernandez Romero¹, C. A. Nieves Prado², S. Tarraf¹, S. Kartik¹. ¹Pulmonary and Critical Care, Temple University Hospital, Philadelphia, PA, ²Internal Medicine, Lansdale Hospital, Philadelphia, PA
- (1352) Marginal Donor for a Marginal Patient: Life Over Lobe;** G. N. Mody¹, S. K. Singh², H. R. Mallidi¹. ¹Thoracic Surgery, Brigham and Women's Hospital, Boston, MA, ²Cardiac Surgery, Brigham and Women's Hospital, Boston, MA

- (1353) Inhaled Epoprostenol-Mediated Shunt in a Lung Transplant Recipient;** L. Cherrier¹, M. A. Smith², S. Biswas Roy³, A. Omar⁴, S. Tokman⁴. ¹St. Joseph's Hospital and Medical Center, Phoenix, AZ, ²Lung Transplantation, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ, ³Internal Medicine, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ, ⁴Advanced Lung Disease, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ
- (1354) Lung Transplantation in a Patient With Burkholderia Ambifaria Infection;** S. Tokman¹, N. Madan², A. Omar¹, J. Huang², R. Walia¹. ¹Advanced Lung Disease, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ, ²Lung Transplantation, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ
- (1355) Extensive Stage Small Cell Lung Cancer Diagnosed on Explant Pathology in a Lung Transplant Recipient;** A. Bery¹, L. Kang², J. P. Gaut², R. Hachem³, P. Aguilar³. ¹Division of Medical Education, Dept of Medicine, Washington University School of Medicine, St. Louis, MO, ²Dept of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, ³Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Washington University School of Medicine, St. Louis, MO
- (1356) Disseminated MAI Infection After Lung Transplant;** A. Bery¹, R. Hachem², P. Aguilar². ¹Division of Medical Education, Dept of Medicine, Washington University School of Medicine, St. Louis, MO, ²Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Washington University School of Medicine, St. Louis, MO
- (1357) Aortic Stenosis and the Sensitized Lung Recipient- What Would You Do?;** A. Siddique¹, M. J. Moulton¹, H. L. Merritt-Genore¹, H. M. Strah². ¹Surgery, University of Nebraska Medical Center, Omaha, NE, ²Medicine, University of Nebraska Medical Center, Omaha, NE
- (1358) Heart-lung Transplantation in an HIV Positive Patient: A Unique Approach to Care;** S. Pasupneti, J. Lee, L. Chhatwani, G. Dhillon. Stanford University Hospitals, Stanford, CA
- (1359) Domino Heart Transplantation: A Feasible Option for a Select Few;** S. Pasupneti, J. Lee, L. Chhatwani. Stanford University Hospitals, Stanford, CA
- (1360) Stealing Home: The Rarest Cause of Pulmonary Hypertension;** Y. Moayed¹, M. M. Aversa², J. G. Duero Posada³, M. Alhussein³, H. J. Ross³, M. Simons⁴, E. M. Horlick³, J. Granton⁵, S. Mak³. ¹Medicine, Stanford Univ, Palo Alto, CA, ²Medicine, Columbia Univ, NYC, NY, ³Medicine, Univ of Toronto, Toronto, ON, Canada, ⁴Radiology, Univ of Toronto, Toronto, ON, Canada, ⁵Pulmonary Medicine, Univ of Toronto, Toronto, ON, Canada
- (1361) Endovascular Treatment of Intracranial Mycotic Aneurysms in Patients With Left Ventricular Assist Devices;** A. Nguyen, B. Chung, N. Narang, S. Kalantari, J. Raikhelkar, N. Sarswat, G. Kim, V. Jeevanandam, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
- (1362) Heartmate II Implantation Technique, Sparing the Sternum and Ascending Aorta;** R. T. Conyer, M. Kawabori, C. Kurihara, T. Sugiura, R. M. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, T. K. Rosengart, O. H. Frazier, J. A. Morgan. Texas Heart Institute/ Baylor College of Medicine, Houston, TX
- (1363) A Hybrid Approach for the Successful Weaning of an EXCOR-LVAD With an Ongoing Intracranial Bleeding;** J. Boehmer¹, B. Soderberg¹, S. Hallhagen². ¹Pediatric Cardiology, The Queen Silvia Children's Hospital, Gothenburg, Sweden, ²Dept of Pediatric Cardiac Surgery, The Queen Silvia Children's Hospital, Gothenburg, Sweden
- (1364) Left Ventricular Noncompaction Dilated Cardiomyopathy in Mucopolysaccharidosis VI;** K. A. Balduf¹, H. J. Mroczkowski², J. A. Towbin¹, J. F. Goldberg¹. ¹Pediatric Cardiology, University of Tennessee School of Health Sciences, Memphis, TN, ²Pediatric Genetics, University of Tennessee School of Health Sciences, Memphis, TN
- (1365) Recurrent Candidal Esophagitis Associated With Dexamethasone Use in a Cardiac Transplant Patient;** J. A. Lee¹, N. D. Hysmith², J. A. Towbin³, J. F. Goldberg³. ¹Pediatric Gastroenterology, University of Tennessee School of Health Sciences, Memphis, TN, ²Pediatric Infectious Diseases, University of Tennessee School of Health Sciences, Memphis, TN, ³Pediatric Cardiology, University of Tennessee School of Health Sciences, Memphis, TN

LUNG TRANSPLANTATION

(Euterpe)

Poster Discussants: Mark Benzimra (Australia), Tobias Deuse (USA), Josh Diamond (USA), Dan Dilling (USA), Alice Gray (USA), Mark Greer (Germany), Matthew Hartwig (USA), Jerome Le Pavec (France), Monique Malouf (Australia)

(589) Lung Transplantation in Jehovah's Witness Patients- A Single Center Experience; S. A. Scheinin¹, T. Majumdar², S. M. Forest¹, H. Seethamraju¹. ¹Ct surgery, Montefiore, Bronx, NY, ²Medicine, Houston Methodist Hospital, Houston, TX

(590) Outcomes of Lung Transplantation in Septuagenarian Recipients; P. R. Aguilar¹, Y. Furuya¹, C. A. Witt¹, D. E. Byers¹, R. Yusen¹, V. Puri², D. Kreisel², E. P. Trulock¹, R. R. Hachem¹. ¹Medicine-Pulmonary/Critical Care Medicine, Washington University School of Medicine, St. Louis, MO, ²Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

(591) Early Survival after Lung Transplantation is Improving in Patients over Age 65; A. Iyengar¹, M. Caceres Polo², E. Aguayo¹, J. Schaenman², R. Biniwale², D. Ross², E. DePasquale², A. Ardehali². ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of California - Los Angeles, Los Angeles, CA

(592) Successful Lung Transplantation for Patients with Graft Versus Host Disease After Bone Marrow Transplantation: An Australian 2 Centre Case Series; D. Abelson¹, S. Kotecha², D. Kliman³, M. A. Malouf¹, D. Ma³, G. I. Snell², A. R. Glanville¹. ¹Lung Transplantation Unit, St Vincent's Hospital, Sydney, Australia, ²Lung Transplantation Service, Alfred Hospital, Melbourne, Australia, ³Dept of Haematology, St Vincent's Hospital, Sydney, Australia

(593) Outcomes After Lung Transplantation in the Elderly; Y. Furuya¹, W. Cherikh², A. Kucheryavaya², E. P. Trulock¹, C. Witt¹, D. Byers¹, R. Yusen¹, P. Aguilar¹, H. Kulkarni¹, A. Gelman³, D. Kreisel³, R. Hachem¹. ¹Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO, ²United Network for Organ Sharing, Richmond, VA, ³Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO

(594) Outcome of Heart-Lung or Double-Lung Transplantation in Pulmonary Hypertension Secondary to Congenital Heart Diseases; S. Hascoet¹, M. Pontailier², O. Mercier², D. Fabre², S. Mussot², M. Humbert³, G. Simonneau³, X. Jais³, O. Sitbon³, E. Fadel². ¹Congenital Heart Diseases, Hopital Marie lannelongue, Plessis-Robinson, France, ²Thoracic surgery, Hopital Marie lannelongue, Plessis-Robinson, France, ³Pulmonary Hypertension, Hopital Kremlin Bicetre, Kremlin-Bicetre, France

(595) The Use of Lung Allocate Score May Improve Postoperative Outcomes in Lung Transplantation?; I. Bello¹, L. Romero¹, A. Jauregui¹, J. Perez¹, V. Monforte², J. Ochoa¹, L. Sánchez¹, F. Ascanio¹, P. Montoya¹, A. Sandiumenge³, J. Sacanell⁴, P. Bascuñana¹, A. Roman², J. Solé¹, M. Deu¹. ¹Thoracic Surgery, Vall d'Hebron University Hospital, Barcelona, Spain, ²Pneumologist, Vall d'Hebron University Hospital, Barcelona, Spain, ³Transplant Coordinator, Vall d'Hebron University Hospital, Barcelona, Spain, ⁴Intensive Care Unit, Vall d'Hebron University Hospital, Barcelona, Spain

(596) Single Center Experience of Controlled Donation After Circulatory Death in Lung Transplantation at Cleveland Clinic; T. Okamoto¹, H. Niiikawa¹, C. Tu², S. Unai¹, A. Zeeshan¹, U. Ahmad¹, M. Tong¹, D. Johnston¹, M. Budev³, K. R. McCurry¹. ¹Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Pulmonary Medicine, Cleveland Clinic, Cleveland, OH

(597) Extra-corporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplantation: Outcomes in the Current Era; S. M. Lari, M. Caceres Polo, A. Iengar, D. J. Ross, S. Weigt, R. Saggat, D. Sayah, M. Shino, A. Der Hovanesian, J. P. Lynch III, J. Belperio, A. Ardehali. Lung Transplant, UCLA, Los Angeles, CA

(598) Improvement of Esophageal Dysmotility with Transelectrical Stimulation (TES) in Lung Transplant Patients; M. Amaris¹, T. Machuca², M. Pipkin², S. Nandavaram³, S. Daouk³, S. Chandrashekar³, A. Emtiazjoo³, C. Eagan³, H. Alnuaimat³, A. Pelaez³. ¹Internal Medicine, Division of Gastroenterology, University of Florida, Gainesville, FL, ²Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL, ³Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL

(599) Prolonged Preservation and Evaluation of Human Lungs With Portable Normothermic EVLP; J. R. Spratt¹, L. M. Mattison², N. K. Kerns¹, S. J. Huddleston¹, L. Meyer³, G. Loo¹, P. A. Iaizzo¹. ¹Dept of Surgery, Univ of Minnesota, Minneapolis, MN, ²Dept of Biomedical Engineering, Univ of Minnesota, Minneapolis, MN, ³LifeSource, Minneapolis, MN

(600) 3-and 5-Year Results of Lung Preservation with the Organ Care System: Insights from a Single-Center Experience; F. Ius¹, W. Sommer¹, J. Salman¹, T. Siemeni¹, C. Kuehn¹, M. Avsar¹, D. Bobylev¹, D. Boethig¹, M. Greer², J. Gottlieb², T. Welte², A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Respiratory Medicine, Hannover Medical School, Hannover, Germany

(601) Extended Clinical Normothermic Ex-Vivo Portable Lung Preservation (>8 Hours) is Feasible and Safe; L. J. Ceulemans¹, A. Neyrinck², R. Vos³, A. Stanzi¹, M. Boada¹, A. Martens², S. Ordies², K. Degezelle⁴, G. Verleden³, D. Van Raemdonck¹. ¹Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ²Anaesthesiology, University Hospitals Leuven, Leuven, Belgium, ³Pneumology, University Hospitals Leuven, Leuven, Belgium, ⁴Perfusion, University Hospitals Leuven, Leuven, Belgium

(602) XPS Jensen Lung as a Low-Cost, High-Fidelity Training Adjunct to Ex-Vivo Lung Perfusion; B. Shukrallah¹, C. Eggeman², D. Mast¹, D. Igoe¹, J. Ralston¹, B. A. Whitson¹. ¹Dept of Surgery, Wexner Med Ctr, Columbus, OH, ²XVIVO Perfusion, Inc., Englewood, CO

(603) Identifying Potential Predictive Biomarkers of Successful Ex-vivo Lung Perfusion; M. I. Morrison¹, J. R. Ferdinand², A. Chhatwal¹, L. A. Borthwick¹, W. E. Scott III¹, M. Clatworthy², A. J. Fisher¹. ¹Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom, ²Molecular Immunity Unit, Dept of Medicine, University of Cambridge, Cambridge, United Kingdom

(604) Impact of Normothermic Ex-vivo-lung Perfusion on Early Post Transplantation Cytomegalovirus Infection; A. Koch¹, N. Pizanis¹, C. Olbertz¹, O. Abou-Issa¹, v. besa², A. Slama³, C. Taube⁴, C. Aigner⁵, H. G. Jakob¹, M. Kamler¹. ¹Dept of Thoracic and cardiovascular surgery, Division of Thoracic Transplantation, University of Essen-Duisburg, Essen, Germany, ²Dept of Pulmonology, University of Essen-Duisburg, Essen, Germany, ³Dept of Thoracic surgery and Surgical Endoscopy, University of Essen-Duisburg, Essen, Germany, ⁴Dept of Pneumology, University of Essen-Duisburg, Essen, Germany, ⁵Dept of Thoracicsurgery and Surgical Endoscopy, University of Essen-Duisburg, Essen, Germany

(605) Organ Sequence Number (SN) is Not a Proxy for Organ Quality; M. Harhay¹, M. J. Crowther², J. M. Diamond¹, T. DiSanto¹, S. Rubin¹, Z. Penfil¹, C. Bermudez¹, J. D. Christie¹, E. Cantu¹. ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Leicester, Leicester, United Kingdom

(606) Size Matters in Single Lung Transplantation for Pulmonary Fibrosis!; K. L. Freystaetter¹, G. Parry², G. Meachery², J. L. Lordan², A. J. Fisher², J. Dark¹, O. Senbaklavaci¹. ¹Dept of Cardiothoracic Surgery, Freeman Hosp, Newcastle Upon Tyne, United Kingdom, ²Inst of Transplantation, Freeman Hosp, Newcastle Upon Tyne, United Kingdom

(607) Using a Computerized Virtual Crossmatch Program for Solid Organ Transplant Donor Selection: Evaluation of VxMatch; D. Chen¹, C. Brack², R. Tian¹, W. Hanshew¹. ¹Duke University Health System, Durham, NC, ²HLA Data Systems, Houston, TX

(608) The Impact of Gender-Age-Physiology (GAP) Stage on Time to Lung Transplantation in Interstitial Lung Disease; M. T. Durheim¹, H. Auråen², I. Leuckfeld¹, H. L. Schultz³, A. M. Holm¹. ¹Dept of Respiratory Medicine, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ²Dept of Cardiothoracic Surgery, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ³Dept of Cardiology, Division of Lung Transplantation, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

(609) Matching Recipient and Donor Risks: Maximizing Benefits from Every Lung Transplant; F. Zafar¹, C. Towe², M. Hossain³, Y. Zhang³, R. Bryant III¹, M. Schecter², D. L. Morales¹. ¹Cardiothoracic Surgery, Children 's Hospital Med Ctr, Cincinnati, OH, ²Pulmonology, Children 's Hospital Med Ctr, Cincinnati, OH, ³Biostatistics and Epidemiology, Children 's Hospital Med Ctr, Cincinnati, OH

(610) A Donor PO₂/FiO₂ Less Than 300 Does Not Determine Graft Function or Survival After Lung Transplantation; H. Whitford¹, C. E. Kure², A. Henriksen¹, J. Hobson¹, G. I. Snell¹, B. J. Levvey¹, S. F. Marasco², J. H. Gooi², A. Zimmet², J. Negri², A. Pick², M. R. Buckland³, T. J. Williams¹, G. P. Westall¹, M. A. Paraskeva¹, C. Martin⁴, D. C. McGiffin². ¹Lung Transplant Service, The Alfred Hospital, Prahran, Australia, ²Dept of Cardiothoracic Surgery, The Alfred Hospital, Prahran, Australia, ³Dept of Anaesthesia, The Alfred Hospital, Prahran, Australia, ⁴Dept of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

(611) Don't Pass the Peanuts: Donor-Derived Nut Allergy in Lung Transplant; R. Bag¹, S. Tlusty², G. Vece², K. Lilly³, T. Peterson⁴, J. Schaeleman⁵, N. Theodoropoulos⁶, M. Michaels⁷, C. R. Wolfe⁸. ¹University of Chicago, Chicago, IL, ²United Network for Organ Sharing, Richmond, VA, ³Lifeline of Georgia, Atlanta, GA, ⁴Baylor University Medical Center, Dallas, TX, ⁵UCLA, Los Angeles, CA, ⁶University of Massachusetts, Worcester, MA, ⁷Children's Hospital of Pittsburgh, UPMC, Pittsburgh, PA, ⁸Duke University Medical Center, Durham, NC

(612) Impact of Allograft Ischemic Time on Short- and Long-term Survival in Lung Transplantation; M. Fakhro¹, H. Ghaidan¹, L. Algotsson², H. Larsson³, S. Lindstedt¹. ¹Cardiothoracic Surgery, Lund University, Lund, Sweden, ²Thoracic Intensive Care and Anesthesia, Lund University, Lund, Sweden, ³Pulmonary Medicine, Lund University, Lund, Sweden

(613) The Feasibility of Lung Transplantation From Donors Mechanically Ventilated for Prolonged Periods; S. Sugimoto¹, M. Yamane¹, T. Kurosaki², S. Otani², S. Toyooka¹, T. Oto². ¹General Thoracic Surgery, Okayama University Hospital, Okayama, Japan, ²Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(614) Temporal Trends and Regional Variation in Multiple Listing among Lung Transplant Recipients in the United States; S. A. Hirji¹, A. Axtell², A. G. Fiedler², A. A. Osho², M. G. Hartwig³, H. Mallidi¹, S. Singh¹. ¹Div of Cardiac Surgery, Dept of Surgery, Brigham and Women's Hospital, Boston, MA, ²Div of Cardiac Surgery, Dept of Surgery, Massachusetts General Hospital, Boston, MA, ³Div of Cardiac Surgery, Dept of Surgery, Duke Univ Medical Center, Durham, NC

(615) Effect of Lung Protective Ventilation on Lung Procurement in a Real-life Setting; c. legeai¹, H. Mal², C. Cantrelle¹, L. Durand¹, G. Cheisson³, L. Saint Marcel⁴, I. Pipien¹, L. Durin¹, O. Bastien¹, R. Dorent¹. ¹Agence de la biomédecine, SAINT-DENIS LA PLAINE, France, ²Hôpital Bichat, APHP, Paris, France, ³Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France, ⁴CH Annecy Gennevois, Annecy, France

(616) Reversibility of Frailty After Lung Transplantation; E. Montgomery¹, P. Macdonald¹, P. Newton², S. Jha¹, M. Hannu¹, C. Thomson¹, A. Glanville¹, A. Havryk¹, M. Pliit¹, R. Pearson¹, M. Benzimra¹, M. Harkess¹, R. Fritis-Lamora¹, N. De Tullio¹, A. Smith¹, M. Malouf¹. ¹Heart & Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, ²University of Western Sydney, Sydney, Australia

(617) Single and Double Redo Lung Transplantation: A Review of UNOS Data; M. A. Kashem¹, H. Zhao², Y. Toyoda³. ¹Cardiovascular Surgery, Temple University, Philadelphia, PA, ²Clinical Science, Temple University, Philadelphia, PA, ³Cardiovascular Surgery, Temple University, PHILA, PA

(618) WITHDRAWN

(619) Donor-recipient Gender-mismatches Correlate With Survival Outcome; J. M. Kwakkel-van Erp¹, H. G. Otten², N. P. van der Kaaij³, S. A. Braithwaite⁴, E. D. Oudijk⁵, D. A. van Kessel⁵, J. C. Grutters⁵, B. Luijk¹, E. A. van de Graaf¹. ¹Respiratory Medicine, Univ Med Ctr Utrecht, Utrecht, Netherlands, ²Immunology, Univ Med Ctr Utrecht, Utrecht, Netherlands, ³Cardio-Thoracic Surgery, Univ Med Ctr Utrecht, Utrecht, Netherlands, ⁴Anesthesiology, Univ Med Ctr Utrecht, Utrecht, Netherlands, ⁵Respiratory Medicine, St. Antonius Hospital, Nieuwegein, Netherlands

(620) Multiple Listing Does Not Improve Outcomes in Lung Transplantation; D. Joyce¹, A. Szabo², Z. Yin², G. Haasler³, K. Presberg⁴, S. Dolan⁴, L. D. Joyce³. ¹Medical College of Wisconsin, Milwaukee, WI, ²Biostatistics, Medical College of Wisconsin, Milwaukee, WI, ³Surgery, Medical College of Wisconsin, Milwaukee, WI, ⁴Medicine, Medical College of Wisconsin, Milwaukee, WI

(621) The Effect of Pre Transplant Donor Specific HLA Antibodies and Antibodies to Ka1-Tubulin on Survival in Lung Transplant Recipients; L. Walsh¹, D. Keegan¹, G. Donnelly¹, K. Khalib², P. Riddell³, J. J. Egan³, K. Redmond⁴, M. Keogan¹. ¹The National Histocompatibility and Immunogenetics Service for Solid Organ Transplantation, Beaumont Hospital, Dublin, Ireland, ²Dept of Clinical Immunology, Beaumont Hospital, Dublin, Ireland, ³The National Lung Transplant Programme, Mater Misericordiae University Hospital, Dublin, Ireland, ⁴Dept of Thoracic Surgery, Mater Misericordiae University Hospital, Dublin, Ireland

(622) Bronchoscopic Management of Bronchial Anastomotic Defects Using Acellular Cadaveric Dermal Grafts; H. Bedi¹, B. D. Shaller¹, D. K. Duong¹, D. Free¹, L. Chhatwani¹, J. J. Mooney¹, G. Dhillon¹, M. J. Simoff². ¹Pulmonary and Critical Care Medicine, Stanford Univ, Stanford, CA, ²Pulmonary and Critical Care Medicine, Henry Ford Hosp, Detroit, MI

(623) Use of Silicon Stents for Stenotic Airway Complications in Lung Transplantation; A. Sundset¹, I. Leuckfeld¹, R. Gagama¹, M. T. Durheim¹, A. E. Fiare², A. M. Holm¹. ¹Dept of Respiratory Medicine, Rikshospitalet, Oslo University Hospital, Oslo, Norway, ²Dept of Thoracic Surgery, Rikshospitalet, Oslo University Hospital, Oslo, Norway

- (624) Bronchial Complications in Contemporary Lung Transplantation: A Rare Event in a 5-Year Single Center Study;** A. Mariscal¹, L. Caldarone¹, J. Tikkanen¹, W. Klement², L. Donahoe¹, J. Yeung¹, K. Yasufuku¹, M. de Perrot¹, A. Pierre¹, M. Binnie¹, C. Chow¹, C. Chaparro¹, L. Singer¹, T. Waddell¹, S. Juvet¹, T. Martinu¹, S. Keshavjee¹, M. Cypel¹. ¹Thoracic Surgery, UHN, Toronto Lung Transplant Program, Toronto, ON, Canada, ²Thoracic Surgery, UHN, Toronto, ON, Canada
- (625) Posterior Reversible Encephalopathy Syndrome After Lung Transplant: Clinical Characteristics and Outcomes;** B. Bottiger¹, J. Klapper², V. Esposito², N. Hashmi³, M. Berger³, P. Smith⁴. ¹Duke University, Durham, NC, ²Dept of Surgery, Duke University, Durham, NC, ³Dept of Anesthesiology, Duke University, Durham, NC, ⁴Dept of Psychiatry and Behavioral Sciences, Duke University, Durham, NC
- (626) Vocal Cord Paralysis After Lung Transplantation Does Not Influence Early Outcome;** B. Seeliger¹, N. Drick¹, B. A. Bollmann¹, M. Avsar², I. Tudorache², J. Gottlieb¹, M. Greer¹. ¹Dep. of Respiratory Medicine, Hannover Medical School, Hannover, Germany, ²Division of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
- (627) Ambulatory Status Improves Outcomes in Patients Bridged to Lung Transplantation with ECMO;** K. L. Bailey, A. Iyengar, O. Kwon, M. Caceras Polo, C. Eisenring, D. Ross, A. Ardehali. David Geffen SoM at UCLA, Los Angeles, CA
- (628) A Study for Bridge to Lung Transplant with Extracorporeal Membrane Oxygenation;** T. Yoshizumi, G. Sunagawa, S. Brann, S. Keshavamurthy, V. Dulam, J. Gomez-Abraham, M. Kashem, K. Minakata, N. Shigemura, Y. Toyoda. Cardiovascular Surgery, Temple University Lewis Katz School of Medicine, Philadelphia, PA
- (629) Prevalence and Treatment Responsiveness of Lung Transplant Recipients with Post Transplant Lymphoproliferative Disease;** O. Berger¹, C. J. Iasella¹, C. A. Moore¹, M. R. Morrell¹, J. Hayanga², N. Shigemura³, A. Zeevi¹, J. F. McDyer¹, C. R. Ensor¹. ¹University of Pittsburgh, Pittsburgh, PA, ²West Virginia University, Morgantown, WV, ³Temple University, Philadelphia, PA
- (630) Outcomes After Lung Transplantation for Patients with Occupational Lung Diseases;** K. D. Joubert¹, C. R. Ensor², D. C. Strollo¹, E. A. Lendermon³, S. A. Yousem⁴, N. Shigemura⁵. ¹Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Dept of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, ³Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Cardiovascular Surgery, Temple University Health System, Philadelphia, PA
- (631) The Role of Diaphragm after Lung Transplantation;** A. Palleschi¹, A. Lo Mauro², E. Privitera¹, M. Vergari³, I. Righi¹, M. Sgroia¹, D. Tosi¹, V. Rossetti⁴, D. F. Briganti⁴, A. Aliverti², C. Colombo⁵, M. Nosotti¹. ¹Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy, ²Dept of Electronic, Information and Bioengineering, Politecnico, Milan, Italy, ³Clinical Center for Neurostimulation, Neurotechnology, and Movement Disorders, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy, ⁴Pneumology Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy, ⁵Pediatric Cystic Fibrosis Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy
- (632) Establishing a Lung Transplant Program in a Resource Constrained Setting;** V. Rahulan¹, A. Jindal¹, S. Attawar², G. Balasubramani³, P. Dutta⁴. ¹Pulmonary, Critical Care & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, ²Cardiac Sciences, Heart & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, ³Cardio-Thoracic Organ Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, ⁴Cardiac Anesthesia, Heart & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India
- (633) Lung Transplantation in Turkey: One Year Balance Sheet;** A. Yeginsu¹, A. E. Tasci¹, M. Vayvada¹, S. Caner², I. Ozmen³, A. Erkilinc⁴, E. Gurcu⁴. ¹Thoracic Surgery, Kartal Kosuyolu Yuksek Ihtisas EAH Kartal, Istanbul, Turkey, ²Chest Disease, Kartal Kosuyolu Yuksek Ihtisas EAH Kartal, Istanbul, Turkey, ³Chest Disease, Sureyyapasa Gogus Hastaliklari EAH Maltepe, Istanbul, Turkey, ⁴Anesthesia and Reanimation, Kartal Kosuyolu Yuksek Ihtisas EAH Kartal, Istanbul, Turkey
- (634) Intraoperative Assessment of Right Ventricular Strain During Lung Transplant Using Tissue Tracking Technology;** A. Berardino¹, J. Qua Hiansen², S. Keshavjee³, M. Meineri⁴. ¹School of Medicine, University of Turin, Torino, Italy, ²Dept of Anaesthesia, Toronto General Hospital, Toronto, ON, Canada, ³Division of Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada, ⁴Dept of Anesthesia and InterDeptal Division of Critical Care, Toronto General Hospital, Toronto, ON, Canada

(635) Outcomes of Combined Patent Foramen Ovale Repair and Lung Transplantation; M. M. El-Sayed Ahmed¹, M. Thomas¹, S. Jacob¹, C. K. Landolfo², E. Lesser³, Z. Li³, E. V. Belli¹, I. A. Makey¹, K. P. Landolfo¹, D. B. Erasmus⁴, C. A. Keller⁴, T. Narula⁴, J. M. Mallea⁴, F. Alvarez⁴, S. M. Pham¹. ¹Thoracic and Cardiovascular surgery, Mayo Clinic, Jacksonville, FL, ²cardiovascular diseases, Mayo Clinic, Jacksonville, FL, ³Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, ⁴Lung Transplant, Mayo Clinic, Jacksonville, FL

(636) Unit, Surgeon and Volume: Equal Contributors to Outcome in Lung Transplantation?; V. Rizzo¹, E. J. Caruana², G. Parry³, S. Clark¹. ¹Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ²Cardiothoracic Surgery, UK, United Kingdom, ³Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(637) Lobar Lung Transplantation from Brain-dead Donors in Pulmonary Hypertension; H. Etienne, O. Mercier, J. Le Pavec, D. Fabre, S. Mussot, D. Mitilian, E. Fadel. Thoracic Surgery, Marie Lannelongue University Hospital, Le Plessis-Robinson, France

(638) Hemi-Diaphragm Paralysis and Diaphragm Plication After Lung Transplant; I. Diaz-Gutierrez¹, S. J. Huddleston², K. R. Kane², A. W. Shaffer², M. Soule², S. J. Shumway², M. Hertz², R. F. Kelly². ¹Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN

(639) Factor VIIa Does not Contribute to Mortality in Lung Transplant Recipients after Adjustment for Packed Red Blood Cell Transfusions; S. J. Huddleston¹, S. Jackson², K. R. Kane¹, A. W. Shaffer¹, M. Soule¹, S. J. Shumway¹, G. Loor³, M. Hertz¹, R. F. Kelly¹. ¹University of Minnesota, Minneapolis, MN, ²Fairview Health Services, Minneapolis, MN, ³Baylor College of Medicine, Houston, TX

(640) Outcomes of Lung Transplantation Following Hematopoietic Stem Cell Transplantation; D. Shitenberg, D. Rozengarten, Y. Shostak, O. Shtraichman, I. Bakal, M. R. Kramer. Pulmonology, Rabin Med Ctr, Petah Tikva, Israel

(641) Rates of Primary Graft Dysfunction and Overall Survival Are Not Affected by the Laterality of the First Implanted Lung in Bilateral Lung Transplantation; A. L. Axtell¹, A. G. Fiedler¹, E. E. Heng¹, S. Melnitchouk¹, D. A. D'Alessandro¹, G. Tolis¹, T. Astor², Y. Raz², I. P. Neuringer², M. A. Villavicencio¹. ¹Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ²Dept of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA

(642) Preoperative Epidural Placement Provides Effective Analgesia Without Added Morbidity in Lung Transplantation; E. E. Heng¹, A. L. Axtell¹, A. G. Fiedler¹, S. Melnitchouk¹, D. A. D'Alessandro¹, G. Tolis¹, G. A. Cudemus², T. Astor³, M. A. Villavicencio¹. ¹Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ²Dept of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, ³Dept of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA

(643) Outcomes Among Lung Transplant Recipients with Elevated Left Heart Filling Pressures and Primary Graft Dysfunction; S. Elnahas¹, R. Panchanathan², M. Olson³, P. Kang⁴, V. Patel⁵, A. Hashimi⁵, J. Huang⁵, H. Abdelrazek⁵, M. A. Smith⁵, R. Walia⁵, A. Omar⁵, R. M. Bremner⁵, A. Kalya⁵. ¹Norton Thoracic Institute, Phoenix, AZ, ²University of Arizona College of Medicine, Phoenix, AZ, ³Grand Canyon University, Phoenix, AZ, ⁴University of Arizona College of Public Health, Phoenix, AZ, ⁵Norton Thoracic Institute, Phoenix, AZ

(644) Right Ventricular Diameter Can Predict Survival in Patients With Severe Lung Diseases Referred to Lung Transplantation; J. U. Nowak, P. Przybyłowski, P. Rozentryt, B. Hudzik, B. Szygula-Jurkiewicz, W. Skowron, M. Ochman, S. Żegleń, J. Wojarski, M. Zembala, M. Gąsior. Silesian Center for Heart Diseases, Zabrze, Poland

MECHANICAL CIRCULATORY SUPPORT **(Muses)**

Poster Discussants: Holger Buchholz (Canada), Sandra Chaparro (USA), Anson Cheung (Canada), Dawn Christensen (USA), Erin Coglianese (USA), Shashank Desai (USA), Anique Ducharme (Canada), Nicolaas De Jonge (Netherlands), Peter Eckman (USA), Daniel Goldstein (USA), Maria Frigerio/Italy, Ranjit John (USA), Markus Wilhelm (Switzerland)

(645) Flow Performance of the CorWave LVAD Membrane Wave Pump; C. N. Botterbusch, P. Monticone, L. Polverelli. Corwave SA, Clichy-Levallois, France

(646) Ambulatory Counter Pulsation at Home- A Dream that Became a Reality; C. LaBuhn¹, N. Uriel², G. Sayer², T. Song¹, D. Onsager¹, G. Kim², T. Lammy¹, J. Raikhelkar², S. Kalantari², V. Jeevanandam¹. ¹Cardiac Surgery, University of Chicago, Chicago, IL, ²Cardiology, University of Chicago, Chicago, IL

(647) Schematic Evaluation and Conservative Management of the Short-To-Shield Phenomenon Circumventing Pump Exchange; A. Ali, B. Hannawi, N. Waxali, A. S. Cruz-Solbes, B. Trachtenberg, J. Estep, M. H. Park, I. Hussain, G. Torre-Amione, A. Bhimaraj, A. Guha. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(648) Augmentation of Right Ventricular Ejection Against Elevated Afterloads Using a Novel Soft Robotic Device; I. Wamala¹, C. J. Payne², M. Saeed³, D. Bautista-Salinas³, D. Van-Story³, T. Thalhofer⁴, M. Horvath⁵, G. Ramirez-Barbieri³, S. J. Staffa⁶, D. Zurakowski⁶, S. J. Ghelani⁷, P. J. del Nido³, C. J. Walsh², N. V. Vasilyev³. ¹Dept of Cardiothoracic and Vascular Surgery, The German Heart Center Berlin, Berlin, Germany, ²Wyss Institute for Biologically Inspired Engineering, Harvard School of Engineering and Applied Sciences, Boston, MA, ³Dept of Cardiac Surgery, Boston Childrens Hospital, Boston, MA, ⁴Technical University Munich, Munich, Germany, ⁵Massachusetts Institute of Technology, Boston, MA, ⁶Dept of Anesthesiology, Perioperative and Pain Medicine Research, Boston Childrens Hospital, Boston, MA, ⁷Dept of Cardiology, Boston Childrens Hospital, Boston, MA

(649) Safe Temperature Limits in Wireless Power Transfer for Ventricular Assist Devices; L. Lucke¹, A. Bartnik¹, B. Doxtater², J. Reibson², W. Weiss², A. McCabe¹. ¹Minnetronix, Inc., St. Paul, MN, ²Penn State Hershey Medical Center, Hershey, PA

(650) Central VA ECMO for Severe Pulmonary Arterial Hypertension: A Novel Cannulation Strategy; Y. Tipograf¹, B. A. Guenthart¹, A. Hozain², E. Berman Rosenzweig³, M. Bacchetta¹. ¹Thoracic Surgery, Columbia University Medical Center, New York, NY, ²Biomedical Engineering, Columbia University Medical Center, New York, NY, ³Pediatrics and Medicine, Columbia University Medical Center, New York, NY

(651) Development of an Ultra Compact Durable ECMO System and Evaluation in a Chronic Animal Experiment for 4 Weeks; D. Akiyama, N. Katagiri, K. Iizuka, T. Mizuno, T. Tsukiya, Y. Takewa, E. Tatsumi. Dept of Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan

(652) A Single Center Experience of the Impella RP in Acute Right Ventricular Failure; A. Proudfoot¹, A. Mulder², S. Maragiri³, E. Pardington³, E. Osip³, T. Ten Brock³, S. VanOosterhout², R. Madder², S. Lee⁴. ¹Perioperative Medicine, St Bartholomew's Hospital, London, United Kingdom, ²Interventional Cardiology, Spectrum Health, Grand Rapids, MI, ³College of Human Medicine, Michigan State University, Grand Rapids, MI, ⁴Advanced Heart Failure, Spectrum Health, Grand Rapids, MI

(653) Hemodynamic Effects of an Intra-aortic Micro-axial Flow Pump in a Swine Model of Ischemic Heart Failure; S. K. Annamalai¹, M. Esposito¹, L. Reyelt¹, P. Natov¹, L. Jorde¹, P. Chouinard², Q. Liu², U. Anand², J. Heuring³, W. Clifton³, N. K. Kapur¹. ¹CardioVascular Center for Research and Innovation, Tufts Medical Center, Boston, MA, ²Boston Scientific, Minneapolis, MN, ³Procyron, Houston, TX

(654) A Prospective Comparison of Venous-Arterial Extra-Corporeal Membrane Oxygenation and a Percutaneous Ventricular Assist Device for Cardiogenic Shock Following Acute Myocardial Infarction; A. R. Garan¹, K. Takeda¹, M. P. Salna², V. K. Topkara¹, S. Sreekanth¹, J. Vandenberg³, M. Yuzefpolskaya¹, Y. Naka¹, P. C. Colombo¹, D. Karpaliotis¹, D. Farrar⁴, A. Kirtane¹, H. Takayama¹, P. Kurlansky¹. ¹Columbia University, New York, NY, ²Stanford University, Stanford, CA, ³University of Vermont, Burlington, VT, ⁴Abbott, Abbott Park, IL

(655) Early Experience of Durable Left Ventricular Assist Devices: Do We Need Bridge to Transplant Strategy in Korea?; J. Lee¹, Y. Cho¹, K. Sung¹, Y. Lee¹, E. Jeon², J. Choi², G. Lee². ¹Thoracic and Cardiovascular Surgery, Samsung Medical Center, Seoul, Korea, Republic of, ²Cardiology, Samsung Medical Center, Seoul, Korea, Republic of

(656) Testing Left Ventricular Assist Device in Argentina; I. G. Berra¹, A. Irusta², A. Diluch², M. Berra³, M. Lewis², G. Berra², S. Berra⁴. ¹Hospital nacional de pediatria J.P. Garrahan, Buenos Aires, Argentina, ²LEW INSUMOS E INNOVACIONES, Buenos Aires, Argentina, ³Hospital nacional Posadas, Buenos Aires, Argentina, ⁴Catedra de Control, Facultad de ingenieria, Universidad de Buenos Aires, Buenos Aires, Argentina

(657) Single-Center Experience with Prolonged Circulatory Support (≥5Years) with a Continuous-Flow Left Ventricular Assist Device; A. Segura¹, A. Nair², A. Civitello², J. Morgan², O. Frazier¹. ¹Texas Heart Institute, Houston, TX, ²Baylor College of Medicine, Houston, TX

(658) Validity of a Novel Institutional Method to Display and Analyze HeartMate II Log Files; C. Holley¹, C. Pierce², A. Ambardekar³, L. A. Allen³, A. Brieke³, E. Benton³, J. C. Cleveland¹, J. D. Pal¹. ¹Surgery, University of Colorado, Aurora, CO, ²University of Colorado Hospital, Aurora, CO, ³Medicine, University of Colorado, Aurora, CO

(659) Comparison of Hemocompatibility-Related Adverse Events in HVAD versus HeartMate II Device; P. Mehta¹, T. Imamura², M. Belkin¹, N. Sarswat², G. Kim², J. Raikhelkar², S. Kalantari², B. Chung², A. Nguyen², T. Song³, C. LaBuhn³, D. Rodgers², T. Ota³, V. Jeevanandam³, G. Sayer², N. Uriel². ¹Internal Medicine, University of Chicago, Chicago, IL, ²Cardiology, University of Chicago, Chicago, IL, ³Cardiac Surgery, University of Chicago, Chicago, IL

(660) Extracorporeal Life Support in Patients with Primary Cardiogenic Shock: Predictors of Recovery and Survival; V. Tarzia¹, L. Bagozzi¹, G. Bortolussi², E. Bellanti¹, F. Zanella¹, R. Bianco¹, C. Guglielmi¹, L. Testolin¹, T. Bottio¹, G. Gerosa¹. ¹Dept of Cardiac, Thoracic and Vascular Sciences, University of Padua, Cardiac Surgery, Padova, Italy, ²University Hospitals Birmingham, Birmingham, United Kingdom

(661) Electrocardiogram-synchronized Rotational Speed Modulation System Can Reduce the Recirculation Due to Aortic Insufficiency in LVAD Support; K. Iizuka¹, D. Akiyama¹, Y. Takewa¹, T. Tsukiya¹, T. Mizuno¹, T. Nishimura², E. Tatsumi¹. ¹Dept of Artificial Organs, National Cerebral and Cardiovascular Center, Osaka, Japan, ²Dept of Cardiovascular Surgery, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan

(662) LVADs as Bridge to Candidacy in the UK; S. M. Shaw¹, R. Venkateswaran¹, S. N. Rushton², R. Hogg², N. Al-Attar³, S. Lim⁴, S. Schueler⁵, J. Parameshwar⁶, N. Banner⁷. ¹Heart and Lung Transplant, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ²Statistics and Clinical Studies, NHSBT, Bristol, United Kingdom, ³Golden Jubilee National Hospital, Glasgow, United Kingdom, ⁴Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁵Cardiothoracic Surgery, Freeman Hospital, Newcastle, United Kingdom, ⁶Papworth, Cambridge, United Kingdom, ⁷Harefield Hospital, London, United Kingdom

(663) Outcomes of Patients Bridged with LVAD to a Repeat Heart Transplant as Compared to Medical Management: Analysis of the UNOS Database; S. Fugar¹, A. K. Okoh², D. Eshun³, M. Schultheis², C. Gidea², M. Russo², M. Zucker², M. Camacho². ¹Internal Medicine, John H Stroger Hospital of Cook County, Chicago, IL, ²Cardiothoracic Surgery, RWJ Barnabas Health, Newark, NJ, ³Internal Medicine, Meharry Medical College, Nashville, TN

(664) IABP as a Bridge to Transplantation: Can we Identify Who May Benefit From a LVAD?; A. Guha, A. Ali, D. Nguyen, B. Bruckner, B. Trachtenberg, E. A. Graviss, A. Bhimaraj, M. H. Park, I. Hussain, E. E. Suarez, G. Torre-Amione, J. Estep. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(665) Patient Survival and Therapeutic Outcomes in the UK Bridge to Heart Transplant Ventricular Assist Device Population; S. Rushton¹, R. Hogg¹, N. Banner², A. Simon², R. Venkateswaran³, S. Shaw³, N. Al-Attar⁴, J. Dalzell⁴, S. Schueler⁵, G. MacGowan⁵, J. Mascaro⁶, L. Sern⁶, S. Tsui⁷, J. Parameshwar⁷. ¹NHS Blood and Transplant, Bristol, United Kingdom, ²Harefield Hospital, London, United Kingdom, ³Wythenshawe Hospital, Manchester, United Kingdom, ⁴Golden Jubilee National Hospital, Glasgow, United Kingdom, ⁵Freeman Hospital, Newcastle, United Kingdom, ⁶Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁷Papworth Hospital, Cambridge, United Kingdom

(666) Patterns of ED Utilization for LVAD Patients Compared to non-LVAD Patients; M. Al-Ani¹, S. Gul², B. Allen², T. Beaver³, G. Arnaoutakis³, E. Jeng³, J. Vilaro¹, J. Aranda, Jr¹, M. Ahmed¹. ¹Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, ²Emergency Medicine, University of Florida, Gainesville, FL, ³Division of Thoracic and Cardiac Surgery, University of Florida, Gainesville, FL

(667) WITHDRAWN

(668) Outcomes of Extended Criteria Cardiac Transplantation versus Destination Left Ventricular Assist Device Therapy; A. Loforte¹, A. Montalto², C. Mariani¹, S. Martin Suarez¹, E. Pilato¹, M. Masetti¹, F. Sbaraglia², P. Lilla Della Monica², F. Grigioni¹, F. Musumeci³, G. Marinelli¹. ¹Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, ²Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy, ³Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy

(669) Computational Fluid Dynamics (CFD) - A Reliable Basis for Therapy and Surgical VAD Strategy?; J. Hochstuhl¹, M. Kassi², S. Elias³, A. Ruhparwar¹, C. Karmonik³, S. Chang². ¹Dept of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany, ²Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, ³MRI Core, Houston Methodist Research Institute, Houston, TX

(670) BOLT Score - A New Prognostic Score for Predicting Survival to Transplant Among Patients on LVAD Support; D. Yoeli¹, H. K. Lamba¹, F. H. Cheema¹, R. M. Delgado², L. Simpson¹, A. P. Nair¹, R. K. Ghanta¹, A. Rana³, R. Civitello¹, T. Rosengart¹, O. Frazier¹, J. A. Morgan¹. ¹Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, ²Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TN, ³Division of Abdominal Transplantation, Baylor College of Medicine, Houston, TX

(671) Cardiac Recovery in Patients with Adriamycin-Induced Cardiomyopathy After Left Ventricular Assist Device Support; E. J. Coromilas, A. R. Garan, M. Yuzefpolskaya, K. Takeda, H. Takayama, M. Farr, Y. Naka, P. C. Colombo, V. K. Topkara. Columbia University, New York, NY

(672) Travel Time Does Not Adversely Effect Outcomes After Ventricular Assist Device; J. Cullen¹, J. Mehaffey¹, R. Hawkins¹, C. Fonner², I. L. Kron¹, J. A. Kern¹, A. Speir³, J. Rich², M. Quader⁴, G. Ailawadi¹, N. Teman¹, L. Yarboro¹. ¹University of Virginia, Charlottesville, VA, ²Virginia Cardiac Services Quality Initiative, Falls Church, VA, ³INOVA Heart and Vascular Institute, Falls Church, VA, ⁴Virginia Commonwealth University, Richmond, VA

(673) Anonymous Survey Reveals Low Controller Change Knowledge Among HeartMate II Patients and Caregivers; M. A. Thompson¹, R. John², L. Hamann¹, J. Schultz³, R. Cogswell⁴. ¹CV Specialty Nursing, University of Minnesota, Minneapolis, MN, ²Cardiovascular Surgery, University of Minnesota, Minneapolis, MN, ³Dept of Medicine, University of Minnesota, Minneapolis, MN, ⁴Cardiology, University of Minnesota, Minneapolis, MN

(674) Prognostic Indicators in Extracorporeal Membrane Oxygenation for Cardiogenic Shock; M. Guglin¹, A. Kolodziej¹, W. Handshoe¹, T. Tribble¹, H. Omar². ¹Univ of Kentucky, Lexington, KY, ²Mercy Medical Center, Clinton, IA

(675) Berlin Heart Excor as Bridge to Heart Transplantation. A Versatile Option in Patients Not Suitable for a Continuous Flow LVAD; S. Bartfay¹, G. Dellgren², P. Dahlberg¹, S. Hallhagen³, B. Redfors⁴, K. Karason⁵. ¹Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden, ²Cardiothoracic Surgery and Transplantation, Sahlgrenska University Hospital, Göteborg, Sweden, ³Pediatric Cardiothoracic Surgery, Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Göteborg, Sweden, ⁴Cardiothoracic anesthesia and intensive care, Sahlgrenska University Hospital, Göteborg, Sweden, ⁵Transplantation, Sahlgrenska University Hospital, Göteborg, Sweden

(676) Continuous-flow Left Ventricular Assist Device Therapy in Adult Patients With Congenital Heart Disease; T. Sugiura, C. Kurihara, M. Kawabori, A. C. Critsinelis, G. Loor, A. B. Civitello, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Houston, TX

(677) Comparison of Sternotomy Versus a Subcostal Approach for Exchange of HeartMate II Continuous Flow-left Ventricular Assist Device; T. Sugiura, C. Kurihara, M. Kawabori, A. C. Critsinelis, G. Loor, R. M. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, T. K. Rosengart, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Houston, TX

(678) The Technical Supervising System Organization of Patients Supported by HVAD in Poland; M. Gawlikowski¹, R. Kustos¹, I. Copik², J. Pacholewicz², M. Zakliczyński², K. Wierzbicki³, B. Kapelak³, P. Siondalski⁴. ¹Artificial Heart Lab., Foundation of Cardiac Surgery Development, Zabrze, Poland, ²Dept of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland, ³Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland, ⁴Dept of Cardiac Surgery, Medical University of Gdansk, Gdansk, Poland

(679) The World's Longest-Supported HeartWare™ Ventricular Assist Device Patient 10 Years & Counting: The Western Australian Experience; H. Hayes, J. Barber, L. Dembo, K. Lam, A. Shah, P. Dias, J. Lambert, R. Larbalestier, J. Baumwol. Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia

(680) Heartmate 3 versus Heartmate 2: Is New Always Better ?; P. Ozturk¹, E. Demir², C. Sahutoglu³, C. Engin¹, T. Yagdi¹, S. Nalbantgil², M. Ozbaran¹. ¹Cardiovascular Surgery, Ege University, Izmir, Turkey, ²Cardiology, Ege University, Izmir, Turkey, ³Anesthesiology, Ege University, Izmir, Turkey

(681) Differences in Fibrin Metabolism Among the Species for Preclinical Large Animal Models for Cardiovascular Device; T. Mizuno, T. Tsukiya, Y. Takewa, E. Tatsumi. Dept. of Artificial organs, Nat'l Cerebral CV Ctr, Suita, Japan

(682) Changes in Glycemic Control and Body Mass Index in Left Ventricular Assist Device Patients with Diabetes; A. R. Vest, C. Chen, J. N. Upshaw, M. S. Kiernan, G. S. Couper, D. DeNofrio. Tufts Medical Center, Boston, MA

- (683) Body Composition Measurement Methods in Systolic Heart Failure Patients Receiving Left Ventricular Assist Devices;** A. R. Vest¹, W. W. Wong², C. Pellows¹, N. Yuen¹, A. DeNofrio¹, S. N. Meltzer¹, M. S. Kiernan¹, D. DeNofrio¹, G. S. Couper¹, E. Saltzman³. ¹Tufts Medical Center, Boston, MA, ²Baylor College of Medicine, Houston, TX, ³Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA
- (684) Inter-facility Collaboration to Decrease Acute Care Length of Stay Post LVAD Implantation;** D. Horstmanshof, S. George, M. Mendenhall, N. Chelikani, M. El Banayosy, C. Gibbs, T. Jacob, A. Patrick, M. Duke, C. Becker, T. Walter, K. Nelson. *Advanced Cardiac Care, INTEGRIS Baptist Medical Center, Oklahoma City, OK*
- (685) Predictive Value of I-CARS for LV Recovery in an Unselected cf-LVAD Cohort;** P. Jain, D. Robson, P. Jansz, C. Hayward. *Heart failure and transplant unit, St Vincent's Hospital, Sydney, Australia*
- (686) Process Improvement for Education and Competency in First Responders Regarding Ventricular Assist Device Emergencies;** S. Stewart¹, C. Chinnici², B. Kim¹, A. Lucev¹, B. Sardanopoli-Heber¹, M. Welch¹, K. Satya¹, R. Berkowitz¹. ¹Heart Failure and Pulmonary Hypertension Program, Hackensack University Medical Center, Hackensack, NJ, ²Emergency Medical Services, Hackensack University Medical Center, Hackensack, NJ
- (687) Safety of Right Heart Catheterization via Brachial Vein Approach in Patients With Left Ventricular Assist Device on Warfarin Therapy;** D. Silber, A. Masoumi, M. B. Collins, P. Green, T. M. Nazif, T. P. Vahl, D. Doshi, A. Patel, K. Ross, A. R. Garan, V. K. Topkara, M. Yuzefpolskaya, P. C. Colombo, A. J. Kirtane. *Columbia University, New York, NY*
- (688) Right Ventricular Failure After LVAD Implantation Occurs in a Pro-inflammatory Environment;** P. C. Tang¹, J. W. Haft¹, M. A. Romano¹, A. Assi¹, R. Hasan², M. Palardy², K. D. Aaronson², F. D. Pagani¹. ¹Cardiac Surgery, University of Michigan-Ann Arbor, Ann Arbor, MI, ²Internal Medicine, University of Michigan-Ann Arbor, Ann Arbor, MI
- (689) High Volume Intraoperative Transfusion is Associated with Decreased Early Survival in Recipients of Ventricular Assist Devices;** S. J. Forest, Y. Xia, J. Leff, U. Jorde, S. Nair, L. Nolasco, O. Saeed, D. B. Sims, S. Patel, W. Jakobleff, J. Shin, S. Murthy, S. Scheinin, D. J. Goldstein. *Montefiore Medical Center, Bronx, NY*
- (690) Right Heart Catheterization with Uninterrupted Anticoagulation via Brachial Vein Approach for Patients with Left Ventricular Assist Device;** T. Hasin¹, B. Ben-Avraham², T. Ben-Gal². ¹Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel, ²Cardiology, Rabin Medical Center, Petach Tiqva, Israel
- (691) Mechanical Unloading Characteristics of the Impella 5.0 Axillary Pump Using a Hemodynamic-Echocardiographic Ramp Protocol;** E. K. Zern¹, A. W. Rottkamp², H. Holmlund², S. S. Mora², S. Sharma¹, N. Roy³, G. Cudemus⁴, K. Shelton⁴, M. Villavicencio-Theoduloz³, D. A. D'Alessandro³, S. S. Thomas². ¹Dept of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Cardiology, Massachusetts General Hospital, Boston, MA, ³Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ⁴Dept of Anesthesia, Critical Care & Pain Medicine, Massachusetts General Hospital, Boston, MA
- (692) Laparoscopic Sleeve Gastrectomy in Morbidly Obese Patients Undergoing Left Ventricular Assist Device Implantation;** I. D. Gregoric¹, R. Radovancevic¹, M. K. Patel¹, M. K. Jezovnik¹, S. S. Nathan¹, B. H. Akkanti¹, M. H. Akay¹, J. Dressel¹, B. Rodgers¹, S. Kumar¹, J. A. Patel¹, S. K. Shah², K. S. Bajwa², B. Kar¹. ¹The University of Texas Health Science Center at Houston, Center for Advanced Heart Failure, Houston, TX, ²The University of Texas Health Science Center at Houston, Advanced Gastrointestinal Surgery, Houston, TX
- (693) Impact of a Novel Shared Healthcare Delivery Model in Remotely Located Patients with Left Ventricular Assist Devices;** M. Yin¹, J. Strega¹, A. Elmer¹, E. Davis¹, E. M. Gilbert¹, S. McKellar², A. Koliopoulou², J. Nativi-Nicolau¹, J. Stehlik¹, J. Fang¹, S. Drakos¹, C. Selzman², O. Wever-Pinzon¹. ¹Cardiology, University of Utah School of Medicine, Salt Lake City, UT, ²Cardiothoracic Surgery, University of Utah School of Medicine, Salt Lake City, UT
- (694) Change in Heart Rate from Pre-Implant to Discharge in Destination Therapy is Associated with Mortality and Admissions in LVAD Patients- A Substudy of the ENDURANCE trial;** E. Y. Birati¹, S. Shore¹, M. A. Acker¹, P. Atluri¹, J. J. Teuteberg², R. L. Kormos³, E. J. Birks⁴, C. Mahr⁵, N. A. Mokadam⁵, F. D. Pagani⁶, J. G. Rogers⁷, T. A. Vassiliades⁸, J. E. Rame¹. ¹University of Pennsylvania, Philadelphia, PA, ²Stanford University, Stanford, CA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Louisville, Louisville, KY, ⁵University of Washington, Seattle, WA, ⁶University of Michigan, Ann Arbor, MI, ⁷Duke University, Durham, NC, ⁸Medtronic, Framingham, MA

- (695) The Ratio of Pulmonary Artery Diameter to Aortic Diameter Can Predict Right Heart Failure After Left Ventricular Assist Device Implantation;** K. Nakamoto¹, T. Ohtani¹, M. Chimura¹, F. Sera¹, Y. Tsukamoto¹, K. Toda², S. Hikoso¹, O. Yamaguchi¹, Y. Sawa², Y. Sakata¹. ¹Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan, ²Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan
- (696) Sex Differences in Reverse Remodeling After Unloading by Contemporary Left Ventricular Assist Devices (LVADs);** B. Kenigsberg¹, D. T. Majure², N. Afari-armah¹, F. H. Sheikh¹, M. R. Hofmeyer¹, M. E. Rodrigo¹, E. J. Molina¹, S. W. Boyce¹, S. S. Najjar¹, S. F. Mohammed¹. ¹MedStar Washington Hospital Center, Washington, DC, ²Northwell Health Physician Partners, Manhasset, NY
- (697) Impact of Creatinine Excretion Rate, a Maker of Sarcopenia, on Prediction of Mortality and Neurological Events in Advanced Heart Failure Patients With Left Ventricular Assist Device;** K. Iwasaki¹, Y. Kimura¹, K. Toda¹, N. Kikuchi¹, Y. Kumai¹, K. Kuroda¹, O. Seguchi¹, M. Yanase¹, Y. Matsumoto², T. Fujita², J. Kobayashi², N. Fukushima¹. ¹Dept of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, ²Dept of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan
- (698) Comparison of Anticoagulation of Patients Who Underwent Left Ventricular Assist Device, Clinical Experience;** U. Köksel, S. Özçobanoglu, C. Kemaloglu, O. Erbasan, I. Gölbası, C. Türkay, O. Bayezid. Cardiovascular Surgery, Akdeniz University, Antalya, Turkey
- (699) Modification of Sleep Disordered Breathing after Increase in LVAD Pump Speed in HF Patients;** N. Bonini¹, C. Vignati¹, A. Apostolo¹, S. Paolillo¹, F. Righini¹, G. Gerosa², T. Bottio², V. Tarzia², J. Bejko², P. Agostoni³. ¹Centro Cardiologico Monzino, IRCCS, Milan, Italy, ²Cardiac Surgery Unit, Dept. of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ³Centro Cardiologico Monzino, IRCCS, Milano, Italy
- (700) LVAD Pump Speed Increase is Associated With Increased Peak VO₂ and Lower Cardiogenic Exercise Limitation;** A. Apostolo¹, C. Vignati¹, N. Bonini¹, S. Paolillo², F. Righini¹, J. Bejko³, V. Tarzia³, T. Bonini³, G. Gerosa³, P. Agostoni⁴. ¹Centro Cardiologico Monzino, IRCCS, Milan, Italy, ²IRCCS SDN, Napoli, Italy, ³Cardiac Surgery Unit, Dept. of Cardiac, Thoracic & Vascular Sciences, Univ of Padua, Padua, Italy, ⁴Centro Cardiologico Monzino, IRCCS, Milano, Italy
- (701) Left Ventricular Assist Device as Bridge-to-Transplant Therapy May Mitigate Elevated Pulmonary Vascular Resistance;** J. J. Han¹, S. Zaheer², J. Chung², C. Chen², R. Kanade³, A. Gaffey², J. E. Rame⁴, M. A. Acker¹, P. Atluri¹. ¹Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic School of Medicine, Rochester, MN, ⁴Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA
- (702) Reducing Days in the Hospital with Cardiomechs Device in Patients with Left Ventricular Assist Device;** A. C. Pandey¹, K. Kheder², M. Pelter³, A. V. Srivastava⁴, J. T. Heywood⁴, R. Mohan⁴. ¹Division of Cardiology, Scripps Clinic/TSRI/STSI, La Jolla, CA, ²Medicine, Scripps Clinic, La Jolla, CA, ³Medicine, Scripps Clinic, La Jolla, CA, ⁴Division of Cardiology, Section of Heart Failure Research and Recovery, Scripps Clinic, La Jolla, CA
- (703) Effects of Right Ventricle Optimization on Post-Operative Outcomes: A Retrospective Comparison;** F. Sagebin¹, B. Ayers¹, B. Barrus¹, S. Prasad¹, H. Vidula², E. Storzynsky², S. Thomas², L. Chen², J. Alexis², I. Gosev¹. ¹Div of Cardiac Surgery, Univ of Rochester, Rochester, NY, ²Div of Cardiology, Univ of Rochester, Rochester, NY
- (704) HeartWare HVAD Log Files Provide Insight into Patient Behavior and Predicts Adverse Events;** K. L. Kiehl¹, R. Pedersen¹, F. X. Downey², J. D. Crouch², N. Sulemanjee¹, O. Cheema¹, T. Hastings¹, E. Roberts¹, V. Thohan¹. ¹Tendick Center for Advanced Heart Failure Therapies, Aurora St. Luke's Medical Center, Milwaukee, WI, ²Aurora Cardiovascular Surgical Services, Aurora St. Luke's Medical Center, Milwaukee, WI
- (705) Glycosylated Hemoglobin (HbA1c) as a Predictor of Adverse Outcomes in Left Ventricular Assist Device (LVAD) Patients;** E. Einarson, A. Eisenbeiss, J. Nelson, K. Graham, R. Alharethi, W. T. Caine, H. Smith, B. B. Reid, M. McCulloch, B. Rasmusson, V. Hebl, A. G. Kfoury. Intermountain Medical Center, Murray, UT
- (706) Reduced 24-hour Blood Pressure Variability is Associated With Lower Pulse Pressure in Patients on Continuous Flow Left Ventricular Assist Device Support;** F. Castagna, A. Pinsino, E. J. Stohr, B. J. McDonnell, D. L. Brunjes, J. K. Nwokocha, J. R. Cockcroft, R. T. Te-Frey, A. R. Garan, V. K. Topkara, H. Takayama, K. Takeda, Y. Naka, P. C. Colombo, M. Yuzefpolskaya. Columbia University, New York, NY

(707) Differences In 24-Hour Vascular Hemodynamic Profiles Among Healthy Subjects, Heart Failure, Left Ventricular Assist Device and Heart Transplant Patients; F. Castagna¹, A. Pinsino², J. Nwokocha², D. L. Brunjes², E. J. Stohr³, B. J. McDonnell⁴, J. R. Cockcroft⁴, C. M. McEniery⁵, M. F. Pineda², A. R. Garan², V. K. Topkara², R. T. Te-Frey¹, H. Takayama², K. Takeda², Y. Naka², P. C. Colombo², M. Yuzefpolskaya². ¹Columbia University/Yale New Haven Bridgeport, New York, NY, ²Columbia University, New York, NY, ³Columbia University/Cardiff Metropolitan, New York, NY, ⁴Cardiff Metropolitan University, Cardiff, United Kingdom, ⁵University of Cambridge, Cambridge, United Kingdom

(708) Does Increasing Experience in Implementing the Blood Pressure Management Protocol in the ENDURANCE Supplemental Trial Result in Better Outcomes?; C. Mahr¹, J. J. Teuteberg², J. D. Vega³, M. N. Walsh⁴, A. K. Ravichandran⁴, W. G. Cotts⁵, N. A. Mokadam¹, T. A. Vassiliades⁶, J. G. Rogers⁷. ¹University of Washington, Seattle, WA, ²Stanford University, Stanford, CA, ³Emory University, Atlanta, GA, ⁴St Vincent Heart Center, Indianapolis, IN, ⁵Advocate Heart Institute, Oak Lawn, IL, ⁶Medtronic, Framingham, MA, ⁷Duke University, Durham, NC

(709) Renal Function is Similar in LVAD Patients Regardless of Hemodynamic Status; M. N. Belkin, S. A. Besser, P. Mehta, B. Chung, S. Kalantari, J. Raikhelkar, N. Sarswat, G. Kim, G. Sayer, N. Uriel. *University of Chicago, Chicago, IL*

(710) Transmission of Pulsatility Into the Brain of Patients with Continuous-Flow Left Ventricular Assist Devices; E. J. Stöhr¹, F. Castagna², A. Pinsino³, J. R. Cockcroft⁴, M. Yuzefpolskaya³, A. R. Garan³, V. K. Topkara³, H. Takayama³, K. Takeda³, Y. Naka³, P. C. Colombo³, J. Z. Willey³, B. J. McDonnell⁴. ¹Cardiology, Columbia University, Cardiff Metropolitan University, New York, Cardiff, NY, ²Cardiology, Columbia University, Yale Bridgeport Hospital, New York, Bridgeport, NY, ³Columbia University, New York, NY, ⁴Cardiff Metropolitan University, Cardiff, United Kingdom

(711) Laterality of Cerebral Artery Hemodynamics in Continuous-Flow LVAD Patients: A Pilot Study in Relation to Stroke; E. J. Stöhr¹, A. Gaudig², A. Pinsino², F. Castagna³, P. C. Colombo², M. Yuzefpolskaya², A. R. Garan², V. K. Topkara², H. Takayama², K. Takeda², Y. Naka², J. R. Cockcroft⁴, B. J. McDonnell⁴, J. Z. Willey². ¹Columbia University, Cardiff Metropolitan University, New York, Cardiff, NY, ²Columbia University, New York, NY, ³Columbia University, Yale Bridgeport Hospital, New York, Bridgeport, NY, ⁴Cardiff Metropolitan University, Cardiff, United Kingdom

(712) Axial Flow Left Ventricular Assist Device is Associated with Progression of Aortic Valve Insufficiency; M. F. Masood¹, I. Fischer¹, K. Kotkar¹, G. A. Ewald², S. C. Silvestry³, K. R. Balsara¹, A. Itoh¹. ¹Surgery, Washington University School of Medicine, Saint Louis, MO, ²Medicine, Washington University School of Medicine, Saint Louis, MO, ³Surgery, Florida Hospital Transplant Institute, Orlando, FL

(713) Outcome of Centrimag Extracorporeal Mechanical Circulatory Support Use in Critical Cardiogenic Shock (INTERMACS 1) Patients; V. Mehta¹, J. Hasan¹, P. Callan², S. Shaw², S. Williams², I. Dimarakis¹, J. Barnard¹, R. V. Venkateswaran³. ¹Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ²Cardiology, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ³Director of Transplantation, Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom

(714) VA-ECMO Cannulation Strategy and Influence on Cerebral Blood Flow Velocities; M. Cevasco, H. Ikegami, J. Willey, A. R. Garan, C. Chan, J. Han, P. Colombo, M. Yusefpolskaya, P. Kurlansky, Y. Naka, H. Takayama, K. Takeda. *Columbia University Medical Center, New York, NY*

(715) Outcomes and Risk Factor of Mechanical Circulatory Support by Periferal Venous-arterial Extracorporeal Membrane Oxygenation at Heart Transplant Candidates Needing Urgent Heart Transplantation; V. N. Poptsov, E. Spirina, S. Uschrenkov, V. Zacharevich, A. Dogonasheva. *Shumakov Centre Heart/Lung Transplant Team, Shumakov Federal Scientific Centre of Transplantology and Artificial Organs, Moscow, Russian Federation*

(716) A Five-year Experience in Periferal Venous-Arterial Extracorporeal Membrane Oxygenation as a Method of Mechanical Circulatory Support in Heart Transplant Candidates; V. N. Poptsov, N. Koloskova, E. Spirina, S. Uschrenkov, A. Dogonasheva, V. Zacharevich. *Shumakov Centre Heart/Lung Transplant Team, Shumakov Federal Scientific Centre of Transplantology and Artificial Organs, Moscow, Moscow, Russian Federation*

(717) Usefulness of Near-infrared Reflectance Spectroscopy to Assess Lower-limb Perfusion on Femoral Venous-arterial Extracorporeal Membrane Oxygenation; C. W. Chan, K. Patton-Rivera, J. R. Beck, K. Fung, A. R. Garan, J. Han, M. Ando, M. Cevasco, P. C. Colombo, Y. Naka, H. Takayama, K. Takeda. *New York Presbyterian - Columbia University Medical Center, New York, NY*

(718) Cardiopulmonary Exercise Testing to Validate Pump Speed Optimization in Patients Implanted With HM 3; A. Montalto, V. Piazza, F. Albi, R. Gherli, F. Musumeci. *San Camillo Hospital, Rome, Italy*

(719) Exercise Capacity and Functional Performance in Patients With an HVAD Left Ventricular Assist Device (LVAD): Development 6 Month After Discharge From Cardiac Rehabilitation; T. Schmidt¹, B. Bjarnason-Wehrens², S. Mommertz¹, A. Nitters-Daske¹, C. Meyer genannt Potthoff¹, S. Schulte-Eistrup¹, N. Reiss¹. ¹Schüchtermann Klinik, Bad Rothenfelde, Germany, ²Institute for Cardiology and Sports Medicine, German Sports University, Cologne, Germany

(720) Can Routine Laboratory Values Predict 30-Day Survival of Patients after Cardiac Surgery Requiring ECMO-Support? N. Neumann¹, S. Zipfel¹, N. Rübsamen², M. Kubik³, M. J. Barten¹, S. Kluge³, H. Reichenspurner¹, A. Bernhardt¹. ¹Cardiac Surgery, Univ Heart Center Hamburg, Hamburg, Germany, ²Cardiology, Univ Heart Center Hamburg, Hamburg, Germany, ³Anesthesiology & Intensive Care Medicine, Univ Hospital Hamburg, Hamburg, Germany

(721) VV-ECMO as a Platform to Evaluate Bronchoscopic Saline Lavage and Surfactant Therapy in Severe ARDS; R. Qaqish¹, L. Del Sorbo², Y. Watanabe¹, M. Galasso¹, C. Summers¹, A. Ali¹, M. Takahashi¹, A. Gazzalle¹, S. Azad¹, M. Liu¹, S. Keshavjee¹, M. Cypel¹. ¹Division of Thoracic Surgery, University of Toronto, Toronto, ON, Canada, ²InterDeptal Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada

(722) Digital Health Monitoring of Physical and Emotional Recovery After LVAD Placement; D. Banerjee¹, D. Beiser², F. Haddad¹. ¹Stanford, Palo Alto, CA, ²University of Chicago, Chicago, IL

(723) Successful Weaning and Explantation of the HeartMate3 Left Ventricular Assist Device Using a Pre-Designed Metal Plug; G. Faerber, H. Kirov, T. Sandhaus, T. Doenst. Univ Clinic Jena, Jena, Germany

(724) Association of Gene Polymorphisms with Thrombosis and Bleeding in Patients with Mechanical Circulatory System; M. Bekbossynova¹, M. Zhalbinova², S. Rakhimova², A. Akilzhanova², S. Andossova¹. ¹National Research Center for Cardiac surgery, Astana, Kazakhstan, ²National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan

(725) Prognostic Implications of Intermediate Hemolysis in Continuous Flow Left Ventricular Assist Device Patients; H. Rosenblum¹, A. Pinsino¹, M. Gavalas², A. Zuver¹, K. Parikh¹, G. Parkis¹, M. Flannery¹, M. Mabasa¹, E. A. Royzman¹, A. Gaudig¹, A. R. Garan¹, V. K. Topkara¹, H. Takayama¹, K. Takeda¹, Y. Naka¹, M. Yuzefpolskaya¹, P. C. Colombo¹. ¹Columbia University, New York, NY, ²Mount Sinai, New York, NY

(726) Does the Type of Mechanical Circulatory Support as a Bridge to Heart Transplant Affect Outcome after Transplant? F. Esmailian, F. Arabia, L. Czer, M. Kittleson, D. Geft, R. Cole, G. Esmailian, M. Rafiei, E. Passano, H. Barone, J. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA

(727) Bridging to Heart Transplantation (BTT) in Seputagenarians with LVADs; A. Salimbanon, D. Vucicevic, M. Kwon, M. Deng, A. Chang, M. Moore, M. Kamath, A. Iyengar, S. Shah, R. Meguerdijian, E. Depasquale. UCLA, Los Angeles, CA

(728) Outcome of CentriMag BiVAD Support for Cardiogenic Shock; D. Schibilsky, A. Page, M. Zho, P. Kaul, S. Messer, S. Bhagra, A. Kydd, S. Pettit, C. Lewis, M. Bermann, A. Ali, Y. Abu-Omar, P. Catarino, C. Sudarshan, D. Jenkins, J. Dunning, J. Parameshwar, S. Tsui. Dept of Transplantation, Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, United Kingdom

(729) Impaired Kidney Function and Impact on Survival After Left Ventricular Assist Device Implantation as a Bridge to Transplantation; D. Vucicevic¹, A. Chang², A. Salimbanon², M. Kamath², E. Moreno², A. Iyengar², S. Shah², M. Cadeiras², A. Ardehali², M. Deng², E. DePasquale². ¹Newark Beth Israel Medical Center, Newark, NJ, ²UCLA, Los Angeles, CA

(730) Is Pre-operative Dialysis a Contraindication to Continuous-flow Left Ventricular Assist Device (CF-LVAD) Implantation? H. Lamba, F. H. Cheema, A. Alnajjar, J. Morgan, G. Loor, T. Rosengart, G. V. Letsou, O. H. Frazier. Surgery, Baylor College of Med, Houston, TX

(731) Long-Term Follow up and Predicting Factors of de Novo Aortic Regurgitation after LVAD Implantation; G. Benedetti¹, P. Mohite¹, H. Small¹, D. Garcia Saez¹, N. P. Patil², M. Husain¹, A. Jothidasan¹, M. Monteagudo-Vela¹, H. A. Hassan³, F. Riesgo Gil¹, O. Dar¹, B. Mahesh¹, N. R. Banner¹, A. R. Simon¹. ¹Transplant Unit, Harefield Hospital, Harefield, United Kingdom, ²Liverpool Heart And Chest Hospital, Liverpool, United Kingdom, ³Menoufia University Hospital, Shibin El Kom, Egypt

(732) Trends and Associations of Serial NT-proBNP Measured After Ventricular Assist Device Implantation; J. M. Camuso¹, C. Dunlap¹, D. McGrath¹, B. Nisraiyya¹, S. Kilmarx¹, K. Milley¹, K. Stettner¹, M. Villavicencio-Theoduloz¹, S. Thomas², G. Lewis², D. D'Alessandro¹, E. E. Coglianesse². ¹Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ²Cardiology, Massachusetts General Hospital, Boston, MA

(733) Safety of Centrifugal Left Ventricular Assist Device Implantation in Patients With Severe Left Ventricular Dysfunction and Secondary Mitral Valve Regurgitation Treated With Mitral Clips; E. Ammirati¹, F. Musca¹, C. M. Van de Heyning², E. Perna¹, M. Cipriani¹, A. Cannata¹, L. D'Angelo¹, F. Milazzo¹, A. Moreo¹, D. De Bock³, C. F. Russo¹, M. Frigerio¹. ¹De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy, ²Dept of Cardiology, Antwerp University Hospital, Edegem, Belgium, ³Dept of Cardiac Surgery, Antwerp University Hospital, Edegem, Belgium

(734) Association between Multidimensional Molecular Biomarkers and Functional Recovery Potential in Advanced Heart Failure; T. Bao¹, R. Togashi¹, M. Cadeiras¹, J. Schaeenman², L. Masukawa¹, J. Hai¹, D. Chu¹, E. Chang¹, S. Kupiec-Weglinski³, V. Groyberg², A. Le¹, R. Dod¹, C. Kahn¹, E. Oh¹, J. Do¹, C. Lumintang¹, T. Grogan², J. Meltzer², M. Kwon², M. Rossetti², D. Elashoff², E. Reed², P. Ping², G. Bondar¹, M. C. Deng¹. ¹Medicine-Cardiology, University of California Los Angeles, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³Cornell University, Ithaca, NY

(735) Heart Failure in Rheumatoid Arthritis Patients: Trend of Admissions and Use of Advanced Heart Failure Therapies; V. Blumer¹, G. A. Hernandez², K. Corbitt¹, M. Ortiz³, S. Chaparro¹. ¹University of Miami, Miami, FL, ²Vanderbilt University, Nashville, TN, ³Universidad Central de Venezuela, Caracas, Venezuela, Bolivarian Republic of

(736) Two Year Outcomes in Patients Successfully Explanted from Durable Left Ventricular Assist Device Support; K. Hryniewicz, C. Weaver, M. Samara, K. Mudy, B. Sun. Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN

(737) Implementation of a Multidisciplinary CODE SHOCK Strategy for Cardiogenic Shock; H. A. Garuba¹, M. Boodhwani², M. Ruel², E. Stadnick¹, R. A. Davies¹, M. Le May¹, B. Bowes³, L. M. Mielniczuk¹, S. Chih¹. ¹Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada, ²Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON, Canada, ³Dept of Clinical Services, University of Ottawa Heart Institute, Ottawa, ON, Canada

(738) Implantation Strategies and Outcomes of Patients Treated with Left Ventricular Assist Devices Awaiting for Heart Transplant in Europe and United States: Data from the TransAtlantic Registry on VAD and Transplant (TRAVIATA); M. Brambatti¹, O. O. Braun¹, E. Ammirati², P. Shah³, L. Klein⁴, E. Perna², C. Van De Heyning⁵, M. Cikes⁶, G. Gjesdal⁷, Y. K. Gernhofer¹, J. Minto³, N. Jakus⁶, C. F. Russo², M. Kassemos⁴, C. Partida⁴, B. Quan¹, D. Milicic⁶, M. Cipriani², L. J. Bogar³, D. De Bock⁵, V. Pretorius¹, J. Nilsson⁷, M. Frigerio², E. Adler¹. ¹University of California San Diego, La Jolla, CA, ²De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy, ³Inova Heart and Vascular Institute, Falls Church, VA, ⁴University of California San Francisco, San Francisco, CA, ⁵Antwerp University Hospital, Edegem, Belgium, ⁶University of Zagreb School of Medicine, Zagreb, Croatia, ⁷Skane University Hospital, Lund, Sweden

(739) Sleep and Life Quality with Left Ventricle Assist Devices or Transplanted Heart: Results from a Multi-Center Observational Study; T. Bottio¹, J. Bejko¹, H. Ocagli¹, M. Carrozzini¹, C. Pagnin¹, V. Tarzia¹, P. Agostoni², D. Bacich³, H. Ortis⁴, U. Livi⁵, M. Maiani⁴, A. Apostolo², G. Di Gianmarco⁶, C. Lanera¹, D. Gregori¹, G. Gerosa¹. ¹Dept of Cardiac Thoracic and Vascular Sciences, Univ of Padua, Padua, Italy, ²Univ of Milano, Padova, Italy, ³Univ Of Padova, Padova, Italy, ⁴Univ of Udine, Padova, Italy, ⁵Univ of Udine, Udine, Italy, ⁶Univ of Chieti, Padova, Italy

NURSING, HEALTH SCIENCES, ALLIED HEALTH **(Gallieni 1-2)**

Poster Discussants: Susan Chernenko (Canada), Pamela Combs (USA), Helen Gibbs (New Zealand), J. Eric Hobson (USA), Christiane Kugler (Germany)

(740) Alleviation of VAD Coordinator Time Burden and Empowerment of HVAD Patients in Order to Improve Outcomes; T. Schläglhofer¹, M. Blood², J. Pietropaolo³, J. Lantz⁴. ¹Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ²Dept of Mechanical Circulatory Support, University of Alabama at Birmingham Hospital, Birmingham, AL, ³Medtronic Inc., Mounds View, MN, ⁴Children's Health, Dallas, TX

(741) Vocal Cord Paralysis and Aspiration Post Ventricular Assist Device Implantation; N. Patel¹, A. Reed², O. Dar², A. Simon³. ¹Speech & Language Therapy, Royal Brompton and Harefield NHS Trust, London, United Kingdom, ²Transplant Medicine, Royal Brompton and Harefield NHS Trust, London, United Kingdom, ³Cardiothoracic Surgery, Royal Brompton and Harefield NHS Trust, London, United Kingdom

(742) The Use of a Bed Bike for Patients Bedbound on Mechanical Circulatory Support: A Case Study; R. Marscheider, F. Nolan. *Rehabilitation, Golden Jubilee National Hospital, Glasgow, United Kingdom*

(743) Medication Adherence: Use of the Beliefs About Medication Questionnaire in Heart and Lung Transplant Patients; L. Painter, I. Fontanilla. *Transplant Psychology, Auckland City Hospital, Auckland, New Zealand*

(744) Predictors for Health Related Quality of Life in De Novo Heart Transplant Recipients; K. Rolid, A. K. Andreassen, M. Yardley, E. Bjørkelund, A. R. Authen, I. Grov, E. Gude, L. Gullestad, K. Nytrøen. *Dept of Cardiology, Oslo University Hospital, Oslo, Norway*

(745) The Relationship Between Peak Cough Flow and Respiratory Function Testing (Spirometry), and the Factors That Influence This, Post Bilateral Sequential Single Lung Transplantation: A Cross-sectional Feasibility Study at a Single Centre Cardiothoracic Transplantation Unit; A. M. Roberts¹, C. L. Pereira¹, M. R. Carby¹, A. R. Simon¹, N. S. Drey², A. K. Reed¹. ¹Royal Brompton and Harefield NHS Foundation Trust, Middlesex, United Kingdom, ²City, University of London, London, United Kingdom

(746) Airway Clearance Following Lung Transplant: Current UK Practice; E. Shkurka¹, H. Spencer², N. Muthialu³. ¹Physiotherapy Dept, Great Ormond Street Hosp for Children NHS Foundation Trust, London, United Kingdom, ²Dept of Cardiothoracic Transplant, Great Ormond Street Hosp for Children NHS Foundation Trust, London, United Kingdom, ³Dept of Cardiothoracic Surgery, Great Ormond Street Hosp for Children NHS Foundation Trust, London, United Kingdom

(747) Assessment of Need for Quality Improvement in Transitional Care; H. M. Lim, E. Estes, M. Zamberlan, K. R. Schumacher, M. K. Cousino. *C.S. Mott Children's Hospital, Congenital Heart Center, Univ of Michigan, Ann Arbor, MI*

(748) Exploring the Relationship Between BMI and Obesogenic Factors Including Nutritional Knowledge, Intake, Psychological Behaviours, Physical Activity and Quality of Life in a Post Heart Transplant Population: A Cross Sectional Study; R. Patel¹, C. Pereira¹, O. Dar¹, N. Banner¹, A. Simon¹, S. Hirani². ¹Royal Brompton and Harefield Hospital, Middlesex, United Kingdom, ²City, University of London, London, United Kingdom

(749) Trajectories of Plasma sST2 by Different Metrics of Clinical Response After Left Ventricular Assist Device Placement; Q. Denfeld¹, J. O. Mudd², J. M. Gelow², S. O. Hiatt¹, S. Florig³, B. A. Habecker³, C. S. Lee¹. ¹School of Nursing, Oregon Health & Science University, Portland, OR, ²Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, ³Physiology & Pharmacology, Oregon Health & Science University, Portland, OR

(750) An International Survey of LVAD Hygiene Practices; A. Kaan¹, B. Cagliostro². ¹Acute Heart Failure Program, St. Paul's Hospital, Vancouver, BC, Canada, ²Bi Campus Mechanical Circulatory Support Program, New York-Presbyterian Hospital, New York, NY

(751) Parallel Improvements in Physical Symptoms and Depression in Response to Left Ventricular Assist Device Implantation; C. S. Lee¹, K. L. Grady², J. M. Gelow³, C. V. Chien⁴, S. O. Hiatt¹, J. O. Mudd³. ¹School of Nursing, Oregon Health & Science Univ, Portland, OR, ²Feinberg Sch of Med, Northwestern Univ, Evanston, IL, ³Knight Cardiovascular Institute, Oregon Health & Science Univ, Portland, OR, ⁴REX Healthcare, Univ of North Carolina, Raleigh, NC

(752) Using Adherence Agreements in Heart Transplant Candidates: What's Important?; A. Kaan, E. Johansson, W. Chiu, C. Cannon, Q. Young, K. Brownjohn. *Acute Heart Failure Program, St. Paul's Hospital, Vancouver, BC, Canada*

(753) Real-world Continuous Physiologic Monitoring in Pediatric Cardiomyopathy Patients: A Safety and Feasibility Study; C. A. Lebo, K. Y. Lin, M. J. O'Connor, H. Griffis, M. McBride, K. D. Miller, R. Ryan, R. E. Shaddy, J. Rossano. *Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA*

(754) Comparison of Different HRQOL Measures Waitlisted Patients for Lung Transplantation; J. Tokuno¹, T. F. Chen-Yoshikawa¹, T. Oga², T. Oto³, T. Okawa³, Y. Okada⁴, M. Akiba⁵, D. Nakajima¹, M. Hamaji¹, H. Motoyama¹, A. Aoyama¹, M. Isomi¹, H. Date¹. ¹Dept of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan, ²Dept of Respiratory Care and Sleep Control Medicine, Kyoto University Hospital, Kyoto, Japan, ³Organ Transplant Center, Okayama University Hospital, Okayama, Japan, ⁴Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, ⁵Division of Organ Transplantation, Tohoku University Hospital, Sendai, Japan

(755) The Effect of Everolimus vs Calcineurin Inhibitors on Quality of Life During 5-6 Years Follow-up After Heart Transplantation: The Results of a Randomized Controlled Trial (SCHEDULE); A. Relbo Authen¹, I. Grov¹, K. Karason², F. Gustafsson³, H. Eiskjær⁴, G. Rådegran⁵, E. Gude¹, K. Jansson⁶, D. Solbu⁷, S. Arora¹, G. Dellgren⁸, A. K. Andreassen¹, L. Gullestad⁹. ¹Dept of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Dept of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Dept of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Dept of Cardiology, Skejby University Hospital, Aarhus, Denmark, ⁵The Section for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, ⁶Dept of Cardiology County Hospital, Linköping University, Linköping, Sweden, ⁷Novartis employee., Novartis Norway AS, Oslo, Norway, ⁸Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁹Dept of Cardiology /K.G.Jebsen Cardiac Research Centre and Center for Heart Failure Research, Oslo University Hospital, Rikshospitalet, Oslo, Norway

(756) Providers Perspectives on Palliative Care Integration in Advanced Heart Failure Care; Y. Quiaoit, M. Molina. Cardiology- Heart failure/transplant, Hospital of the University of Pennsylvania, Philadelphia, PA

(757) WITHDRAWN

(758) Is the VAS Quality of Life Assessment Tool Sensitive to Both Male and Female MCS D Patients?; B. Coleman, R. Levine, F. Arabia, E. Passano, S. Dimbil, H. Barone, C. Runyan, N. Huie, J. Hajj, M. Lindsay, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(759) WITHDRAWN

(760) Adherence to Self-care Behaviors After Left Ventricular Assist Device Implantation; T. Ben Gal¹, N. P. Kato², B. Ben Avraham¹, V. Yaari¹, M. Abu-Hazeira¹, D. Golobov¹, A. Strömberg³, T. Jaarsma². ¹Heart Failure Unit, Cardiology Dept, Rabin Medical Center, Petah Tikva, Israel, ²Dept of social and Welfare studies, Linköping University, Linköping, Sweden, ³Dept of Health Sciences, Linköping University, Linköping, Sweden

(761) Negative Pressure Wound Therapy Applied to Groin Cannulation Incisions Decrease the Incidence and Severity of Seroma Formation; L. J. Bogar¹, L. Cantwell², M. Fregoso³, J. Chun³, R. Singh¹. ¹Cardiac Surgery, INOVA Fairfax Hospital, Falls Church, VA, ²Advanced Heart Failure, INOVA Fairfax Hospital, Falls Church, VA, ³Advanced Lung Center, INOVA Fairfax Hospital, Falls Church, VA

(762) Impact of Massage Therapy in Lung Transplant Recipients; H. Gauchez¹, M. Taharo², A. Sénéchal², C. Cousty³, A. Tiberghien², J. Mornex⁴, P. Boulinguez⁵. ¹Univ Lyon 1, Lyon, France, ²Hospices Civils de Lyon, Lyon, France, ³Hospices Civils de Lyon, Lyon, France, ⁴Univ Lyon 1 & Hospices Civils de Lyon, Lyon, France, ⁵CNRS, Lyon, France

(763) Trajectory Analysis of Self-Reported Adherence to Home Spirometry After Lung Transplantation; A. J. Devito Dabbs¹, M. Dew², M. Alrawashdeh³, D. Zaldonis⁴, J. D'Cuna⁵, J. Pilewski⁶. ¹Nursing, U. Pittsburgh Sch Nursing, Pittsburgh, PA, ²U. Pittsburgh Sch Medicine, Pittsburgh, PA, ³U. Pittsburgh Sch Nursing, Pittsburgh, PA, ⁴CT Transplant, UPMC Health System, Pittsburgh, PA, ⁵CT Surgery, U. Pittsburgh Sch Med, Pittsburgh, PA, ⁶PACCM, U. Pittsburgh Sch Med, Pittsburgh, PA

PATHOLOGY

(Agora 2)

Poster Discussants: Brandon Larsen (USA), Anja Roden (USA)

(764) Vasculitis in Post-Heart Transplant Endomyocardial Biopsy: Possible Relationship with Mixed Rejection, Circulating Donor Specific Antibodies and Worse Outcome; M. Fedrigo¹, A. Romano¹, T. Bottio², G. Toscano², A. Di Francesco¹, G. Feltrin², C. Castellani¹, F. Zanco¹, A. P. Fraiese², A. Veronesi³, G. De Silvestro³, A. Nocco⁴, E. Benazzi⁴, G. Gerosa², G. Thiene¹, A. Angelini¹. ¹Cardiac Thoracic and Vascular Sciences, Pathology, Padua, Italy, ²Cardiac Thoracic and Vascular Sciences, Cardiosurgery, Padua, Italy, ³Regional Laboratory of Transplant, Tranfusion Medicine, Camposampiero, Italy, ⁴Fondazione IRCCS Ca granda, Ospedale Maggiore, Milan, Italy

(765) Pre-transplant Anti-nuclear Antibodies Correlate With Post-transplant Donor-specific Antibodies: A Link between Autoimmunity and Graft Failure?; P. McMullen, J. Xin, N. Brown, A. Husain, N. Uriel, S. Marino. University of Chicago, Chicago, IL

(766) Histologic and Molecular Microscope Determinants of Graft Survival in the INTERHEART Study: The Greater Importance of T Cell-mediated Rejection vs. Antibody-mediated Rejection in Graft Loss; J. Reeve¹, D. H. Kim², M. G. Crespo-Leiro³, J. Kobashigawa⁴, L. Potena⁵, M. Deng⁶, M. Cadeiras⁶, E. C. Depasquale⁶, P. Bruneval⁷, A. Loupy⁸, P. Macdonald⁹, A. Zuckermann¹⁰, A. Z. Aliabadi¹⁰, J. Goekler¹⁰, P. F. Halloran¹. ¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²Univ of Alberta, Edmonton, AB, Canada, ³Complejo Hospitalario Univ A Coruña, A Coruña, Spain, ⁴Cedars-Sinai Heart Institute, Beverly Hills, CA, ⁵Univ of Bologna, Bologna, Italy, ⁶Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁷Hôpital Européen Georges Pompidou, Paris, France, ⁸Hôpital Necker, Paris, France, ⁹The Victor Chang Cardiac Research Institute, Sydney, Australia, ¹⁰Medical Univ of Vienna, Vienna, Austria

(767) Validating the INTERHEART Classifiers for Molecular Diagnosis of Rejection in 558 New Endomyocardial Biopsies; J. Reeve¹, D. H. Kim², M. G. Crespo-Leiro³, J. Kobashigawa⁴, L. Potena⁵, M. Deng⁶, M. Cadeiras⁷, E. C. Depasquale⁶, P. Bruneval⁸, A. Loupy⁹, P. Macdonald¹⁰, A. Zuckermann¹¹, A. Z. Aliabadi¹¹, J. Goekler¹¹, P. F. Halloran¹. ¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁴Cedars-Sinai Heart Institute, Beverly Hills, CA, ⁵University of Bologna, Bologna, Italy, ⁶Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁷Ron, Los Angeles, CA, ⁸Hôpital Européen Georges Pompidou, Paris, France, ⁹Hôpital Necker, Paris, France, ¹⁰The Victor Chang Cardiac Research Institute, Sydney, Australia, ¹¹Medical University of Vienna, Vienna, Austria

(768) Improving the Diagnosis of Rejection by Molecular Phenotype of Endomyocardial Biopsies: Single Center Insights from the Interheart Study; L. Borgese¹, L. Potena¹, O. Leone², V. Agostini², J. Reeve³, M. Masetti¹, A. Russo¹, F. Grigioni¹, P. Halloran³. ¹Cardiology, University of Bologna, Bologna, Italy, ²Pathology, University of Bologna, Bologna, Italy, ³University of Alberta, Edmonton, AB, Canada

(769) NK Cells in Endomyocardial Biopsies From Cardiac Allografts: Detection, Quantification, and Precise Localization Using Multiplex Immunofluorescence; M. Terada¹, M. Rabant², C. Lesaffre¹, J. Duong Van Huyen¹, P. Bruneval¹. ¹INSERM U970, Paris, France, ²INSERM U1151, Paris, France

(770) The Interleukin-33/ST2 Pathway is Expressed in the Failing Human Heart and Associated with Pro-Fibrotic Remodeling of the Myocardium; M. M. Huibers¹, C. C. Tseng², J. van Kuik¹, R. A. de Weger¹, A. Vink¹, N. de Jonge². ¹Pathology, UMC Utrecht, Utrecht, Netherlands, ²Cardiology, UMC Utrecht, Utrecht, Netherlands

(771) Pathological Correlation Between Apical Core Biopsies at the Time of Left Ventricular Assist Device Implantation and Excised Heart at Time of Transplant or Autopsy; M. Alhussein¹, L. Battioni¹, K. Runeckles¹, J. Duero Posada¹, Y. Moayed¹, J. Lombardi¹, H. J. Ross¹, F. Billia¹, V. Rao¹, J. Butany², M. McDonald¹. ¹Division of Cardiology, University Health Network, Toronto, ON, Canada, ²Division of Pathology, Univ Health Network, Toronto, ON, Canada

(772) Characterizing the Airway Inflammatory Milieu in Post-Transplantation Lung Biopsies of Cystic Fibrosis Patients: A Single Institution Study of Acute Cellular Rejection; A. J. McHenry¹, A. Husain², M. Ivanovic³, E. Lowery⁴, D. Dilling⁴, V. Ananthanarayanan⁵. ¹Stritch School of Medicine, Loyola Univ Chicago, Maywood, IL, ²Dept of Pathology, Univ of Chicago, Chicago, IL, ³Dept of Pathology, Univ of Iowa, Iowa City, IA, ⁴Pulmonary and Critical Care Medicine, Loyola Univ Medical Center, Maywood, IL, ⁵Dept of Pathology, Loyola Univ Medical Center, Maywood, IL

(773) miRNA Dysregulation in Chronic Lung Allograft Rejection. A Computational, Quantitative and In Situ Analysis; F. Meloni¹, E. Rossi², S. Inghilleri³, M. Porzio⁴, M. Zorzetto³, R. Kessler⁵, P. Morbini². ¹Internal Medicine, University of Pavia and IRCCS S.Matteo, Pavia, Italy, ²Molecular medicine, University of Pavia and IRCCS S.Matteo, Pavia, Italy, ³Respiratory Diseases, IRCCS S.Matteo, Pavia, Italy, ⁴Hôpital Civil -, Nouvel Hôpital Civil, Strasbourg, France, ⁵PU-PH, NHC, Hôpitaux universitaires de Strasbourg, Nouvel Hôpital Civil, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France

PHARMACY AND PHARMACOLOGY **(Agora 2)**

Poster Discussants: Fay Burrows (Australia), Adam Cochrane (USA), Patricia Ging (Ireland)

(774) Pre-transplant Amiodarone Reduces Weight-based Tacrolimus Dosing Requirements in Heart Transplant Recipients; N. T. Breslin¹, D. Salerno¹, S. Restaino², F. Latif², K. Takeda³, H. Takayama³, M. Farr², P. Colombo², D. L. Jennings¹. ¹Pharmacy, NewYork- Presbyterian, New York, NY, ²Medicine, NewYork- Presbyterian, New York, NY, ³Surgery, NewYork- Presbyterian, New York, NY

- (775) Association Between Tacrolimus Concentration/Dose Ratio and Renal Function Following Cardiac Transplant;** L. M. Lourenco¹, Z. Truman¹, C. Murks², T. Riley², J. Powers², M. Reilly², S. Kalantari², J. Raikhelkar², N. Sarswat², G. Kim², G. Sayer², N. Uriel². ¹Pharmacy Services, University of Chicago Medicine, Chicago, IL, ²Cardiology, University of Chicago Medicine, Chicago, IL
- (776) Use of Oral Milrinone in Ventricular Assist Device Patient with Chronic Right Ventricular Failure: A Single Centre Experience;** H. Lyster¹, E. Zambon¹, L. L.Seuthe@rbht.nhs.uk¹, K. Habibi-Parker¹, P. Ly¹, R. Betmouni¹, N. Leaver², F. Riesgo-Gil¹, O. Dar¹, N. Banner¹. ¹Cardiothoracic transplantation, Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom, ²Immunosuppression Monitoring Service, Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom
- (777) Keeping Tacrolimus Levels Therapeutic: Step-Wise Protocol for Itraconazole Discontinuation;** J. Stephen¹, S. Al-Saleh², L. LeMond³, J. Rosenthal³, D. Steidley³. ¹Pharmacy, Mayo Clinic, Phoenix, AZ, ²Transplant Nursing, Mayo Clinic, Phoenix, AZ, ³Cardiology, Mayo Clinic, Phoenix, AZ
- (778) Safety and Tolerability of High Intensity Statin Therapy in Heart Transplant Patients Receiving Immunosuppression with Tacrolimus;** S. L. Tjugum, S. A. Heeney, M. E. Corkish, I. B. Hollis. University of North Carolina Medical Center, Chapel Hill, NC
- (779) Optimizing Weight-based Enoxaparin Dosing for Lung Transplant Recipients;** T. M. Veasey¹, M. D. Lahey¹, V. Scheuble², J. E. Nelson¹, S. Chandrashekar². ¹Dept of Pharmacy, UF Health Shands Hospital, Gainesville, FL, ²Dept of Medicine, University of Florida, Gainesville, FL
- (780) Conversion to Extended Release Tacrolimus in Early Post Lung Transplantation Period - A Pilot Study;** L. Morlacchi¹, V. Rossetti¹, L. Rosso², A. Pallechi², S. Aliberti¹, R. Carrinola², M. Montoli², M. Nosotti², P. Tarsia¹. ¹Cardiothoracic Unit and Cystic Fibrosis Adult Centre; Dept of Pathophysiology and Transplantation, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ²Thoracic and Lung Transplantation Surgery, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy
- (781) Tacrolimus Trough Monitoring by Mass Spectroscopy is Associated With Acute Kidney Injury in Lung Transplant Recipients;** N. A. Kolaitis, D. Calabrese, P. Ahern, A. Venado-Estrada, R. Florez, H. Lei, K. Isaak, R. J. Shah, L. Leard, M. Kleinhenz, J. Golden, T. De Marco, J. R. Greenland, J. Kukreja, S. R. Hays, P. D. Blanc, J. P. Singer. University of California, San Francisco, San Francisco, CA
- (782) Conversion from Advagraf/Prograf to Envarsus in Stable Lung Transplant Patients;** G. Murakoezy¹, A. Benazzo¹, S. Schwarz¹, S. O. Obermair-Ramp¹, T. Stork², W. Klepetko¹, P. Jaksch¹. ¹Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ²Thoracic Surgery, Medical University of Vienna, Wien, Austria
- (783) INR Remote Monitoring is Associated with Improved Time in Therapeutic Range Following Left Ventricular Assist Device Implantation;** V. N. Nguyen¹, M. Smith², M. Belyk², M. Brambatti³, O. O. Braun³, E. D. Adler³, V. G², M. Mariski¹, C. Stevens¹, A. Feist¹. ¹Pharmacy, UC San Diego Health, San Diego, CA, ²Surgery, UC San Diego Health, San Diego, CA, ³Cardiology, UC San Diego Health, San Diego, CA
- (784) Institution-based, Pharmacist-managed Anticoagulation in Patients with a Left Ventricular Assist Device;** T. J. Bibb¹, L. C. Halder¹, D. L. McDanel¹, A. Briasoulis², P. A. Alvarez², K. E. Horner¹, J. K. Bhamra³, S. B. Larson³. ¹Dept of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, IA, ²Division of Cardiovascular Medicine, Dept of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, ³Division of Cardiothoracic Surgery, Dept of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA
- (785) Reduced Readmissions with Enoxaparin Bridging for Subtherapeutic INR in MCS;** T. Khuu¹, E. DePasquale², A. Salimbanon¹, A. Chang¹, E. Moreno¹, D. Rourke³, J. Creaser³, E. Vandenbogaart³, M. H. Kwon⁴, A. Ardehali⁴, A. Nsair². ¹Transplant Services, UCLA, Los Angeles, CA, ²Medicine - Cardiology, UCLA, Los Angeles, CA, ³Cardiomyopathy, UCLA, Los Angeles, CA, ⁴Surgery - CardioThoracic, UCLA, Los Angeles, CA
- (786) Variability in Anticoagulation Practices With the Impella Percutaneous Ventricular Assist Device: A Survey of High-volume Centers;** B. N. Reed¹, R. J. DiDomenico², J. E. Allender³, J. C. Coons⁴, J. F. Cox⁵, J. D. Moretz⁶, C. S. Oliphant⁷, D. L. Jennings⁸. ¹Pharmacy Practice and Science, Univ of Maryland School of Pharmacy, Baltimore, MD, ²Univ of Illinois Chicago, Chicago, IL, ³WakeMed Health & Hospitals, Raleigh, NC, ⁴Univ of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Palmetto Health, Columbia, SC, ⁶Vanderbilt Univ Medical Center, Nashville, TN, ⁷Methodist Le Bonheur Healthcare, Memphis, TN, ⁸New York-Presbyterian Hospital, Columbia Univ Irving Medical Center, New York City, NY

THURSDAY, APRIL 12

6:15 PM - 7:15 PM
POSTER SESSION 2

HEART FAILURE
(Muses)

Poster Discussants: Sharon Chih (Canada), Savitri Fedson (USA), Pascal Leprince (France), Guy MacGowan (United Kingdom), Alanna Morris (USA), Florian Wagner (Germany)

(787) Gender and Diastolic Dysfunction May be the Driver of Failure of Myocardial Recovery Following LVAD Implantation; K. Stawiariski¹, C. Zogg², J. Park², D. Jacoby², L. Bellumkonda², M. Chen², T. Ahmad², J. Testani², G. McCloskey², L. Sugeng², P. Bonde². ¹Yale New Haven Health Bridgeport Hospital, Bridgeport, CT, ²Yale School of Medicine, New Haven, CT

(788) Which "Roadmap" in Patients With Advanced or Refractory Heart Failure, Eligible for LVAD and Heart Transplantation? L. F. Bertoldi¹, E. Perna¹, A. F. Giglio¹, E. Ammirati¹, M. G. Cipriani¹, A. Garascia¹, F. Macera¹, L. D'Angelo¹, M. Varrenti¹, A. Costetti¹, S. Nonini¹, M. P. Gagliardone¹, C. Russo¹, P. G. Camici², M. Frigerio¹. ¹DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy, ²Cardiothoracic Dept, San Raffaele Hospital, Milan, Italy

(789) Clinical and Humoral Determinants of Congestion-prone Advanced Heart Failure Phenotype; V. Melenovsky¹, J. Benes¹, M. Kotrc¹, A. Jabor¹, J. Kautzner¹, J. Kovar¹, P. Jarolim². ¹Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic, ²Brigham and Women's Hospital, Harvard University, Boston, MA

(790) Outcomes of Long-term Inotrope Therapy as a Bridge to Heart Transplant; E. C. Lee¹, J. Martens¹, J. Alexis¹, I. Gosev², H. Vidula¹. ¹Division of Cardiovascular Medicine, University of Rochester, Rochester, NY, ²Division of Cardiac Surgery, University of Rochester, Rochester, NY

(791) Refusal of Blood Products Should Not be a Contraindication to LVAD Therapy; R. Salabat¹, C. LaBuhn¹, D. Onsager¹, T. Ota¹, G. Sayer², G. Kim², G. Kim², N. Uriel², V. Jeevanandam¹. ¹Cardiothoracic Surgery, University of Chicago, Chicago, IL, ²Medicine, University of Chicago, Chicago, IL

(792) The Significance of NT-proBNP in Patients Assessed for Heart Transplant or LVAD; E. Wolsk, T. Deis, K. Rossing, F. Gustafsson. Dept of Cardiology, Rigshospitalet, Copenhagen, Denmark

(793) The Benefits of Ambulatory Pulmonary Artery Pressure Monitoring in Patients With Heart Failure; H. Patel, S. Phillips. Carillon Clinic - Virginia Tech, Roanoke, VA

(794) Acute Reduction in Pulmonary Artery Pressures with Sacubitril-Valsartan Measured by the CardioMEMS HF Device; L. M. Raj¹, J. McLeod², O. Havakuk¹, A. Wolfson¹, H. Kwong¹, A. Yoon¹, M. Fong¹, D. Shavelle¹, L. Grazette¹. ¹Division of Cardiology, USC, Los Angeles, CA, ²Dept of Medicine, USC, Los Angeles, CA

(795) "There's Always Another Treatment" – The Promise of Cardiac Devices as Barrier to Advance Care Planning in Heart Failure; R. Hadler¹, L. Allen², D. Bekelman³, R. Arnold⁴, N. Goldstein⁵, D. Kavalieratos⁴. ¹Dept of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Dept of Medicine, Division of Cardiology, University of Colorado, Denver, CO, ³Dept of Medicine, Division of Geriatrics, University of Colorado, Denver, CO, ⁴Dept of Medicine, Section of Palliative Care and Medical Ethics, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Dept of Medicine, Mount Sinai School of Medicine, New York, NY

(796) WITHDRAWN

(797) Mobile Integrated Healthcare - Community Paramedicine: An Integrated and Novel Approach to Caring for Heart Failure Patients; G. Reynolds¹, M. Robinson², M. Jernigan², J. Webster², A. Yehya². ¹CV Services, Piedmont Heart, Atlanta, GA, ²Advanced Heart Failure, Piedmont Heart, Atlanta, GA

(798) Transitional Care Service Slashes 30-day Readmission and Mortality Rates: A Single Center Experience; J. N. Patel¹, D. Lewandowski², C. Bhardwaj¹, K. Berkovitz², B. S. Clemson¹. ¹Cardiology (Medicine), University of Illinois College of Medicine - Peoria, Peoria, IL, ²Cardiology (Medicine), OSF St. Francis Medical Center, Peoria, IL

(799) Hospital Pathways Within One Year Before Cardiac Transplantation: A French Nationwide Study; C. Cantrelle¹, R. Dorent¹, O. Bastien¹, T. Damy², C. Legeai¹, P. Tuppin³. ¹Medical & Scientific, Agence de la biomedecine, La Plaine Saint Denis, France, ²Cardiology, Assistance Publique Hôpitaux de Paris - Henri Mondor hospital, Créteil, France, ³Medical & Scientific, Caisse Nationale d'Assurance Maladie des Travailleurs Salariés, Paris, France

(800) Which Advanced Heart Failure Therapy Strategy is Optimal for Patients Over 60 Years Old?; Y. K. Gernhofer¹, O. O. Braun², M. Brambatti², Q. M. Bui², J. Silva Enciso², B. H. Greenberg², E. Adler², V. Pretorius¹. ¹Cardiothoracic Surgery, UC San Diego, San Diego, CA, ²Cardiology, UC San Diego, San Diego, CA

(801) Utility of Intermacs Risk Classification at the Time of Assessment for Advanced Therapies; F. Foroutan¹, E. Friesen¹, J. Krakovsky², S. Chih³, H. J. Ross¹, C. Alba¹. ¹Cardiology, Toronto General Hospital, Toronto, ON, Canada, ²Cardiology, Ottawa Heart Institute, Ottawa, ON, Canada, ³Cardiology, Ottawa Heart Institute, Toronto, ON, Canada

(802) The Association of Global Longitudinal Strain With Clinical Outcomes in Heart Failure Patients With Severe Left Ventricular Systolic Dysfunction; H. Lee¹, J. Sin¹, M. Kim², N. Jeong³, S. Oh³, S. Lee¹, S. Song⁴, S. Kim⁴, M. Kim⁴. ¹Cardiology Dept, Pusan National University Hospital, Busan, Korea, Republic of, ²Dept of Pharmacy, Pusan National University Hospital, Busan, Korea, Republic of, ³Organ Transplantation Center, Pusan National University Hospital, Busan, Korea, Republic of, ⁴Dept of Thoracic Surgery, Pusan National University Hospital, Busan, Korea, Republic of

(803) Feasibility and Effectiveness of a Shock Team Approach in Refractory Cardiogenic Shock: Preliminary Results; I. Taleb, A. Koliopoulou, A. Tandar, S. McKellar, J. Nativi-Nicolau, O. Wever-Pinzon, E. Gilbert, J. Fang, J. Stehlik, J. Tonna, J. Morshedzadeh, B. ko, T. Owan, H. Ibrahim, C. Selzman, F. Welt, S. Drakos. University of Utah, Salt Lake City, UT

(804) Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education; K. Breathett¹, S. Maffett², R. Foraker³, R. Sturdivant⁴, K. Moon⁵, A. Hasan⁶, V. Franco⁶, S. Smith⁶, B. Lampert⁶, S. Emani⁶, G. Haas⁶, R. Kahwash⁶, R. Hershberger⁶, P. Binkley⁶, L. Helmkamp⁷, K. Colborn⁷, P. Peterson⁸, N. Sweitzer¹, W. Abraham⁶. ¹Division of Cardiovascular Medicine, Univ of Arizona, Tuscon, AZ, ²Division of Cardiovascular Medicine, Ohio State Wexer Medical Center, Columbus, OH, ³Institute for Informatics, Univ in St. Louis School of Medicine, St. Louis, MO, ⁴Division of Biostatistics, Azusa Pacific Univ, Azusa, CA, ⁵Division of Cardiovascular Medicine, Univ of Wisconsin, Madison, WI, ⁶Division of Cardiovascular Medicine, Ohio State Univ Wexner Medical Center, Columbus, OH, ⁷Univ of Colorado Adult and Child Consortium for Health Outcomes Research and Delivery Science, Aurora, CO, ⁸Division of Cardiovascular Medicine, Univ of Colorado, Aurora, CO

(805) Quality of Clinical Outcomes and Effectiveness of Heart Failure Exacerbation Management in Emergency Room Observation Unit Versus Coronary Care Unit; F. Al-Saffar¹, S. Ibrahim², P. Patel², J. Ruiz-Morales², J. Sabato², A. Miller². ¹Mayo Clinic, Scottsdale, AZ, ²University of Florida, Jacksonville, FL

(806) Prediction of Mortality in Decompensated Heart Failure by Invasive Hemodynamics Compared to Clinical Assessment; N. Narang¹, B. Chung¹, A. Nguyen¹, D. Rodgers¹, T. Imamura¹, S. Kalantari¹, J. Raikhelkar¹, N. Sarswat¹, G. Kim¹, V. Jeevanandam², G. T. Sayer¹, N. Uriel¹. ¹Cardiology, University of Chicago Medical Center, Chicago, IL, ²Cardiac Surgery, University of Chicago Medical Center, Chicago, IL

(807) Stroke Patterns and Implications for Ventricular Functional Remodeling in Left Ventricular Assist Systems; D. F. Snipelisky¹, P. Ivak², G. Stewart¹, M. Givertz¹, M. Pfeffer¹, J. Groarke¹, S. Singh¹, I. Netuka³, M. Mehra¹. ¹Advanced Heart Failure and Transplantation, Brigham and Women's Hospital, Boston, MA, ²Institute of Clinical and Experimental Medicine, Prague, Czech Republic, ³Institute for Clinical and Experimental Medicine, Prague, Czech Republic

(808) Incidence of Heart Failure in Patients with Cardiac Tumor Surgical Resection: A Single Center Experience; S. H. Ibarra-Cortez, M. J. Reardon. Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

(809) Mitral Regurgitation Due to Ischemic Cardiomyopathy: Insights Using Computational, Robotics Mitral-Papillary-Ventricular Complex; J. Park, P. Bonde. Section of Cardiac Surgery, Yale School of Medicine, New Haven, CT

(810) The Dilemma After CRT Device Removal: A Bi-ventricular Bridging Solution is Needed; L. Castro¹, S. Pecha¹, J. Vogler², N. Gosau², S. Willems², H. Reichenspurner¹, S. Hakmi¹. ¹Dept of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, ²Dept of Cardiology, Electrophysiology, University Heart Center Hamburg, Hamburg, Germany

(811) Neutrophil to Lymphocyte Ratio at the Time of LVAD Implant Predicts 30-day Readmission; N. Ahmed¹, H. Gandhi¹, Y. Kim¹, O. Saeed², S. Patel², S. Murthy², J. Shin², S. Forrest³, D. J. Goldstein³, U. P. Jorde², D. B. Sims². ¹Dept of Medicine, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, ²Division of Cardiology, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, ³Division of Cardiothoracic Surgery, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY

(812) Postcardiotomy Cardiogenic Shock: Characteristics, Management and Prognostic in a Contemporary Cohort; J. Vázquez López-Ibor¹, F. Hernández Pérez¹, J. Goirigolzarri¹, M. Gómez Bueno¹, J. García Suárez², C. Martín López³, L. Alonso-Pulpón¹, J. Segovia Cubero¹. ¹Cardiology, Hospital Puerta de Hierro, Madrid, Spain, ²anesthesiology, Hospital Puerta de Hierro, Madrid, Spain, ³Cardiac surgery, Hospital Puerta de Hierro, Madrid, Spain

(813) Reverse Remodeling Following Ambulatory Counterpulsation; T. Imamura, C. Juricek, T. Song, T. Ota, D. Onsager, B. Bryant, N. Sarswat, G. Kim, J. Raikhelkar, S. Kalantari, G. Sayer, V. Jeevanandam, N. Uriel. *University of Chicago, Chicago, IL*

(814) Comparison of Survival and Readmission Rates in Patients 65 and Older Undergoing Heart Transplantation or LVAD Implantation; T. Imamura¹, C. Murks¹, T. Riley¹, J. Powers¹, B. Chung¹, A. Nguyen¹, D. Rodgers¹, J. Raikhelkar¹, S. Kalantari¹, M. R. Costanzo², U. Jorde³, T. Ota¹, T. Song¹, D. Onsager¹, C. Juricek¹, V. Jeevanandam¹, G. Kim¹, G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Advocate Heart Institute, Naperville, IL, ³Montefiore Medical Center, New York, NY

(815) PAPI Shows a Stronger Correlation With RAP versus RVSWI in Both HFrEF and HFpEF; N. Nair¹, S. Yang², C. Marzbani¹, L. Truong², E. Gongora³. ¹Division of Cardiology, Dept of Internal Medicine, Texas Tech health Sciences Center, Lubbock, TX, ²Dept of Internal Medicine, Texas Tech health Sciences Center, Lubbock, TX, ³Cardiothoracic Surgery, MCVI, Hollywood, FL

(816) Impact of Tandem Heart Use for Heart Failure Patients as a Bridged to Long-term Continuous Flow Left Ventricular Assist Devices; C. Kurihara, M. Kawabori, A. Critsinelis, C. B. Andrew, J. K. George, R. M. Delgado, A. P. Nair, T. Sugiura, L. Gabriel, O. H. Frazier, J. A. Morgan, L. Simpson. *Baylor College of Medicine, Houston, TX*

(817) Genetic Epidemiology of Ventricular Tachycardia in Patients with Cardiomyopathy in Kazakhstan: A Targeted Sequencing Study; M. Bekbossynova¹, A. Akilzhanova², C. Guelly³, Z. Abilova², A. Akhmetova¹, U. Kairov⁴, O. Nuralinov¹, G. Rashbayeva¹, S. Trajanoski³, B. Abdirova¹, Z. Zhumadilov². ¹National Research Center for Cardiac surgery, Astana, Kazakhstan, ²National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, ³Center of Medical Research, Medical University of Graz, Graz, Austria, ⁴Laboratory of Bioinformatics and Computational Systems Biology, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan

(818) Zinc Deficiency and Heart Failure: A Systematic Review of the Literature; H. R. Rosenblum, J. Wessler, A. Gupta, B. Bikdeli. *Columbia University Medical Center, New York, NY*

(819) Ischemic but Not Dilative Cardiomyopathy Impairs the Thioredoxinsystem in the Myocardium; M. Dieterlen, S. Neidhardt, F. Emrich, K. Klaeske, K. Jawad, S. Lehmann, A. Meyer, M. Borger, J. Garbade. *Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany*

(820) IVC Assessment by Ultrasound in Acute and Ambulatory Heart Failure Patients Predictive of Mortality and Readmissions: A Systematic Review; T. Rahman, O. Sheyin, R. Bagur, S. Smith, S. De, R. Davey, R. M. McKelvie. *Cardiology, University of Western Ontario, London, ON, Canada*

(821) The Impact of Hospital Teaching Status on Inpatient Outcomes of Acute Heart Failure Patients in the United States; A. Albaeni¹, M. Sharma¹, S. Raslan², G. A. Al-Dossari³, K. Chatila², W. I. Khalife². ¹Medicine, Heart Failure and Transplant, Univ of Texas Medical Branch, Galveston, TX, ²Medicine, Cardiovascular Medicine, Univ of Texas Medical Branch, Galveston, TX, ³Cardiovascular and Thoracic Surgery, Univ of Texas Medical Branch, Galveston, TX

HEART TRANSPLANTATION (Muses)

Poster Discussants: Amal Alotaibi (USA), David Baran (USA), Lavanya Bellumkonda (USA), Alejandro Bertolotti (Argentina), Agnieszka Ciarka (Belgium), Maria Crespo-Leiro (Spain), Sung-Ho Jung (South Korea), Karl Lemstrom (Finland), Marco Masetti (Italy), Ravi Kumar Ratnagiri (India), Marian Urban (United Kingdom), Rajamiyer Venkateswaran (United Kingdom), Andrae Wasler (Austria)

(822) Donor-recipient Ethnic Matching Impacts Short and Long-term Results of Heart Transplantation; Y. Peled¹, R. Loewenthal¹, E. Raichlin², I. Gueta¹, A. Younis¹, Y. Kassif¹, Y. Har-Zahav¹, E. Nachum¹, D. Freimark¹, I. Goldenberg¹, J. Lavee¹. ¹Sheba Medical Center Tel Hashomer, Ramat Gan, Israel, ²Loyola University Medical Center, Maywood, IL

(823) Recurrent Acute Cellular Rejection Graded ISHLT 1R Early After Heart Transplantation Negatively Affects Long-term Outcomes; Y. Peled¹, E. Raichlin², I. Gueta¹, I. Mazin¹, Y. Kassif¹, Y. Har-Zahav¹, E. Nachum¹, D. Freimark¹, I. Goldenberg¹, J. Lavee¹. ¹Sheba Med Ctr Tel Hashomer, Ramat Gan, Israel, ²Loyola Univ Med Ctr, Maywood, IL

(824) Improved Long Term Outcomes after Heart Transplantation Utilizing Donors with Traumatic Mode of Brain Death; Y. Peled¹, Y. Kassif¹, E. Raichlin², A. Kogan¹, Y. Har-Zahav¹, E. Nachum¹, D. Freimark¹, J. Lavee¹. ¹Sheba Medical Center and Tel-Aviv University, Ramat Gan, Israel, ²Loyola University Medical Center, Maywood, IL

(825) The Role of Loss-of-Function Mutations on Development of Rejection After Heart Transplantation; J. van Setten¹, N. de Jonge¹, B. S. Cole², B. Chang², M. V. Holmes², C. C. Baan³, O. C. Manintveld³, A. M. Peeters³, F. Dominguez⁴, K. K. Kush⁵, P. Garcia-Pavia⁴, J. W. Rossano², R. A. de Weger¹, J. H. Moore², B. Keating², F. W. Asselbergs¹. ¹Univ Medical Center Utrecht, Utrecht, Netherlands, ²Univ of Pennsylvania, Philadelphia, PA, ³Erasmus MC, Rotterdam, Netherlands, ⁴Puerta de Hierro Univ Hospital, Madrid, Spain, ⁵Stanford Univ, Stanford, CA

(826) Donor-derived Cell-free DNA Investigated by Digital PCR After Targeted Pre-Amplification: A Prospective Clinical Study of Heart-transplant Patients; J. Boehmer¹, A. Ricksten², K. Karason³, D. Andersson⁴, A. Stalberg⁴, H. Wahlander¹, J. Asp², C. Wasslavik², J. Sunnegardh¹, G. Dellgren⁵. ¹Pediatric Cardiology, The Queen Silvia Children's Hospital, Gothenburg, Sweden, ²Gene Analysis, Laboratory for Clinical Chemistry, Gothenburg, Sweden, ³Dept of Cardiology, Sahlgrenska Univ Hospital, Gothenburg, Sweden, ⁴Sahlgrenska Cancer Center, Dept of Pathology, Gothenburg, Sweden, ⁵Transplant Institute, Sahlgrenska Univ Hospitalnska Univ Hospital, Gothenburg, Sweden

(827) Ways of Optimizing the Estimation of Results of Endomyocardial Biopsy in the Rejection of the Heart Transplant; T. V. Stavenchuk¹, E. D. Kosmachova², I. A. Shelestova³, A. A. Slavinsky⁴, E. A. Terman⁵, A. A. Verevkin⁶, K. O. Barbuhatty^{7,8,9}, V. A. Porhanov¹⁰. ¹Ultrasound Diagnostic, Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, ²Therapy Dept № 1 FQI and PST "Kuban State medical university", Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, ³cardiology and cardiosurgery FQI and PST "Kuban state medical university", Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, ⁴Pathological anatomy, Kuban State Medical University, Krasnodar, Russian Federation, ⁵Pathomorphology Dept, Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, ⁶Pathological anatomy, Kuban State Medical Academy, Krasnodar, Russian Federation, ⁷Cardiosurgery Dept, Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation, ⁸cardiology and cardiosurgery FQI and PST "Kuban state medical university", Kuban state medical university, Krasnodar, Russian Federation, ⁹cardiology and cardiosurgery FQI and PST, Kuban state medical university, Krasnodar, Russian Federation, ¹⁰Thoracic Surgery Dept, Regional Clinical Hospital n.a. Professor S.V. Ochapovsky of the Ministry of Healthcare of Krasnodar Region, Krasnodar, Russian Federation

(828) De Novo Donor Specific Antibodies as a Risk Marker for Early Antibody Mediated Rejection; D. B. Letchford, S. M. Offen, N. Watson, P. Jain, A. Jabbour, A. Keogh, E. Kotlyar, C. S. Hayward, K. Muthiah, P. MacDonald. Heart failure / transplant, St Vincent's Hospital, Darlinghurst, Australia

(829) Non Invasive Monitoring of Acute Allograft Rejection in Heart Transplantation: Long-term Outcomes of the "No Biopsy Approach"; A. Vallee, L. Houyel, M. Amsallem, N. To, Y. Lepers, R. Ramadan, A. Azmoun, R. Nottin, P. Deleuze, J. Guihaire. Adult Cardiac Surgery, Marie Lannelongue Hospital, Paris Sud Univ, Le Plessis Robinson, France

(830) Elevated Red Cell Distribution Width is Associated with Increased Incidence of Late Allograft Rejection after Heart Transplantation; G. Poglajen, A. Cerar, S. Frljak, G. Zemljič, M. Jaklič, B. Vrtovec. Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia

(831) Safety and Efficacy of Extended Release Tacrolimus After Heart Transplantation; G. Poglajen, S. Frljak, A. Cerar, G. Zemljič, R. Okrajšek, M. Šebeštjen, V. Andročec, M. Jaklič, B. Vrtovec. Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia

- (832) Recipient Age and Acute Cellular Rejection - Implications for Targeted Surveillance After Heart Transplantation;** V. Jernryd¹, J. Wohlfahrt¹, J. Ede¹, G. J. Smith², I. Haugen Lofman³, B. Andersson⁴, J. Nilsson¹. ¹Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, ²Clinical Sciences Lund, Cardiology, Lund University and Skane University Hospital, Lund, Sweden, ³Medicine, Section of Cardiology, Huddinge, Karolinska Institutet, Karolinska Universitetssjukhuset, Stockholm, Sweden, ⁴Surgery, Lund University and Skane University Hospital, Lund, Sweden
- (833) Long Term Graft Survival and Immediate Post-Operative Complications Between Patients with Ischemic and Idiopathic Dilated Cardiomyopathy Undergoing Cardiac Transplantation;** A. K. OKOH, D. Chauhan, M. Schultheis, R. Karanam, C. Gidea, M. Camacho, M. Zucker, M. Russo. RWJ Barnabas Health Newark Beth Israel Medical Center, RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ
- (834) The Use of Cardiac MRI to Detect Myocardial Fibrosis and Development of Restrictive Cardiac Physiology After HTx;** D. Leong, J. Patel, D. Berman, B. Tamarappoo, L. Thomson, M. Kittleson, L. Czer, R. Levine, S. Dimbil, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA
- (835) Pre-Transplant Hemoglobin A1c Predicts Long Term Outcomes Following Heart Transplantation;** L. K. Truby, M. Farr, A. Garan, R. Givens, H. Takayama, K. Takeda, M. Yuzefpolskaya, F. Latif, S. Restaino, K. Axsom, Y. Naka, P. C. Colombo, V. K. Topkara. Columbia University, New York, NY
- (836) Bridge to Transplant with Continuous Flow Left Ventricular Assist Devices Increases Risk for Severe Primary Graft Dysfunction;** L. K. Truby, K. Takeda, V. K. Topkara, H. Takayama, F. Latif, S. Restaino, M. Yuzefpolskaya, K. Axsom, Y. Naka, P. C. Colombo, M. Farr. Columbia University, New York, NY
- (837) Post-Transplant Outcomes of Patients Initially Receiving Left Ventricular Assist Device as Either Bridge to Candidacy or Destination Therapy;** J. Han¹, M. Ando¹, A. R. Garan², M. Farr², P. C. Colombo², H. Takayama¹, Y. Naka¹, K. Takeda¹. ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, ²Division of Cardiology, Columbia University Medical Center, New York, NY
- (838) Survival in Women after Heart Transplant: Do We Really Know How They Perform?;** A. E. Morgan¹, E. Dewey¹, J. Mudd², J. Gelow², J. Davis², H. K. Song³, F. A. Tibayan³, C. M. Bhamidipati³. ¹Surgery, OHSU, Portland, OR, ²Cardiology, OHSU, Portland, OR, ³Cardiac Surgery, OHSU, Portland, OR
- (839) Prognostic Value of Invasive Resting and Exercise Hemodynamics in Long-term Heart-transplanted Patients;** T. S. Clemmensen, H. Eiskjær, B. B. Løgstrup, S. H. Poulsen. Dept of Cardiology, Aarhus University Hospital, Aarhus, Denmark
- (840) Myocardial Perfusion and the Relation to Central Hemodynamics in the Acute Phase After Heart Transplantation;** T. S. Clemmensen¹, S. H. Poulsen¹, B. B. Løgstrup¹, L. P. Tolbod², H. J. Harms², J. Frøkiær², H. Eiskjær¹. ¹Dept of Cardiology, Aarhus University Hospital, Aarhus, Denmark, ²Dept of Nuclear Medicine & PET Center, Aarhus University Hospital, Aarhus, Denmark
- (841) Low Variability in Gene Expression Profile Scores Are Associated With Decreased Risk of Adverse Events Post Heart Transplantation: The Mid America Experience;** S. R. Beauchamp¹, K. R. Carl¹, K. F. Kennedy², B. A. Austin³, M. P. Everley³, T. M. Khumri³, S. L. Lawhorn³, A. Magalski³, B. W. Sperry³, D. Vodnala³, A. M. Borkon⁴, G. Dryton¹, A. Kao³. ¹Surgery, Saint Luke's Hospital, Kansas City, MO, ²Cardiology, Saint Luke's Hospital, Kansas City, MO, ³Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO, ⁴Surgery, Mid America Heart & Lung Surgeons, Kansas City, MO
- (842) Characterization of Circulating Donor Heart Specific Exosomes in Clinical Heart Transplantation;** L. Korutla¹, A. Habertheuer¹, R. Hu¹, P. Zielinski¹, S. Reddy¹, A. Najj², P. Vallabhajosyula¹. ¹Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
- (843) Assessment of Myocardial Strain Using Speckle Tracking Echocardiography Within the First 12 Months After Orthotopic Heart Transplantation;** K. Antończyk¹, T. Niklewski¹, R. Antończyk¹, M. Zakliczyński¹, M. Zembala¹, T. Kukulski². ¹Dept of Cardiac, Vascular and Endovascular Surgery and Transplantology, Silesian Center for Heart Diseases, Zabrze, Poland, ²Dept of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center for Heart Diseases, Zabrze, Poland

(844) Salvage ECMO as Bridge to Heart Transplantation - Single Center Experience; F. Wittmann, J. Riebandt, V. Paspalj, T. Haberl, A. Aliabadi-Zuckermann, G. Laufer, A. Zuckermann. *Cardiac Surgery, Medical University of Vienna, Vienna, Austria*

(845) Gene Expression Profiling for Cardiac Transplant Recipients: Results from the Outcomes AlloMap® Registry; S. A. Hall¹, G. Ewald², P. Berman³, N. Sulemanjee⁴, A. Kao⁵, T. Wolf-Doty⁶, J. Sninsky⁶, J. Yee⁶, J. Kobashigawa⁷. ¹Baylor University Medical Center, Dallas, TX, ²Barnes Jewish Hospital, St. Louis, MO, ³Tampa General Hospital, Tampa, FL, ⁴Aurora St. Luke's Medical Center, Milwaukee, WI, ⁵St. Luke's - Mid-America Heart Institute, Kansas City, MO, ⁶CareDx, Inc, Brisbane, CA, ⁷Cedars-Sinai Medical Center, Los Angeles, CA

(846) WITHDRAWN

(847) Are Protocol Driven Biopsies After Steroid Cessation Necessary?; J. F. Grant, S. Krim, S. Desai, J. B. Biglane, S. Mandras, H. Patel. *Ochsner Clinic, New Orleans, LA*

(848) Contribution of Individual Genes to Longitudinal Variation of Gene Expression Profile Scores; E. C. DePasquale¹, M. Cadeiras¹, D. Hiller², R. N. Woodward², M. Crespo-Leiro³, M. C. Deng¹. ¹UCLA, Los Angeles, CA, ²CareDx, Brisbane, CA, ³Hospital Universitario de A Coruña, La Coruña, Spain

(849) Recipient Working Status is Independently Associated with Outcomes in Heart Transplantation; A. Iyengar¹, M. Caceres Polo², B. Sowell³, O. Kwon², E. Adams¹, L. Reardon², A. Ardehali², E. DePasquale². ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of California - Los Angeles, Los Angeles, CA, ³Wake Forest University School of Medicine, Winston-Salem, NC

(850) Higher Frequency of Surveillance Endomyocardial Biopsies not Associated with Improved Survival After Heart Transplantation; A 10-Year, Single-Center Experience in Thailand; S. Siphurmsukskul¹, P. Ongcharit², S. Siwamogsatham¹, S. Puwanant¹, V. Benjacholamas², A. Ariyachaipanich¹. ¹Division of Cardiovascular Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ²Cardiovascular and Thoracic Surgery Dept, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

(851) Diagnostic Yield of Genetic Testing in Heart Transplant Recipients; H. Boen, B. Loeys, J. Saenen, I. Goovaerts, L. Van Laer, A. Vorlat, T. Vermeulen, C. Franssen, H. Heidbuchel, E. Van Craenenbroeck. *Cardiology, Antwerp University Hospital, Wilrijk, Belgium*

(852) Clinical Characteristics of Sleep Apnea Syndrome in Heart Transplant Recipients; A. Afzal¹, K. Tecson², A. Jamil³, J. Feliu³, H. Qin³, P. Garcha¹, S. A. Hall¹, S. A. Carey¹. ¹Center for Advanced Heart and Lung Disease, Baylor Univ Medical Center, Dallas, TX, ²Baylor Heart and Vascular Inst, Baylor Scott and White Research Inst, Dallas, TX, ³Annette C. and Harold C. Sammons Transplant Inst, Baylor Scott and White Research Inst, Dallas, TX

(853) Model for End-Stage Liver Disease (MELD) Stratification Identifies Two Distinct Cohorts of Arrhythmogenic Right Ventricular Cardiomyopathy Patients Undergoing Transplantation; N. Reza¹, N. Mahmud², M. Molina³, R. McLean¹, L. R. Goldberg¹, M. A. Acker⁴, C. Bermudez⁴, A. Owens¹. ¹Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

(854) Endocrine Profile of Heart Transplant Recipients in an Early Post-transplant Period; M. Jensterle¹, M. Rakusa², G. Poglajen³, A. Janez¹, B. Vrtovec³. ¹Dept of Endocrinology, Diabetes and Metabolic Disease, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Dept of Endocrinology and Diabetology, University Medical Centre Maribor, Maribor, Slovenia, ³Advanced Heart Failure and Transplantation Programme, Dept of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia

(855) Low AlloMap Ordinal and Variability Scores Are Associated with Increased Malignancy Post Heart Transplant; v. cotarlan¹, J. Franzwa², C. Laxson², R. Chawla², Y. Nabeel³, F. Johnson². ¹University of Cincinnati, Cincinnati, OH, ²University of Iowa, Iowa City, IA, ³University of Iowa, Cincinnati, OH

(856) Low AlloMap Variability Score Within the First 3 Years Post Heart Transplant is Associated with the Combined Endpoint of Death, Malignancy and Coronary Vasculopathy Post Heart Transplant; V. Cotarlan¹, C. Laxson², J. Franzwa², R. Chawla³, F. Johnson². ¹University of Cincinnati, Cincinnati, OH, ²University of Iowa, Iowa city, IA, ³University of Iowa, Iowa city, OH

(857) Survival Post Heart Transplant by Listing Strategy; A. Chang, A. Nsair, M. Kwon, M. Kamath, A. Salimbanon, D. Vucicvec, M. Cadeiras, M. Deng, E. Moreno, A. Iyengar, S. Shah, A. Ardehali, E. Depasquale. *Ronald Reagan UCLA Medical Center, Los Angeles, CA*

(858) Evaluating the Impact of Gene Expression Profiling on Tricuspid Regurgitation in Cardiac Transplant Patients; N. Mehta¹, S. Mendelsohn², P. Sharedal², H. Eisen¹. ¹*Cardiovascular Diseases, Drexel University College of Medicine, Philadelphia, PA*, ²*Internal Medicine, Drexel University College of Medicine, Philadelphia, PA*

(859) Risk Factors Associated with Sensitization and Its Correlation with Outcome in Korean Heart Transplantation Patients; G. Oh¹, H. Cho¹, S. Kang², E. Jeon³, J. Kim⁴, H. Lee¹. ¹*Seoul National University Hospital, Seoul, Korea, Republic of*, ²*Severance Hospital, Seoul, Korea, Republic of*, ³*Samsung Medical Center, Seoul, Korea, Republic of*, ⁴*Asan Medical Center, Seoul, Korea, Republic of*

(860) Donor Mechanism of Death (MOD) and Interstitial Fibrin (INTFIB) as Predictors of Outcome After Heart Transplantation; E. H. Hammond¹, M. P. Revelo², D. V. Miller³, G. L. Snow⁴, J. Stehlik⁵, K. M. Molina⁶, R. A. Alharethi⁷, C. H. Selzman⁸, W. Caine⁹, S. G. Drakos⁵, K. Afshar⁷, C. Zollinger¹⁰, A. G. Kfoury⁷. ¹*Intermountain Healthcare and University of Utah, Salt Lake City, UT*, ²*Pathology, University of Utah Medical Center, Salt Lake City, UT*, ³*Pathology, Intermountain Medical Center, Salt Lake City, UT*, ⁴*Statistical Data Center, Intermountain Medical Center, Salt Lake City, UT*, ⁵*Cardiology, University of Utah Medical Center, Salt Lake City, UT*, ⁶*Cardiology, Primary Childrens Medical Center, Salt Lake City, UT*, ⁷*Cardiology, Intermountain Medical Center, Salt Lake City, UT*, ⁸*Cardiovascular Surgery, University of Utah Medical School, Salt Lake City, UT*, ⁹*Cardiovascular Surgery, Intermountain Medical Center, Salt Lake City, UT*, ¹⁰*Intermountain Donor Services, Salt Lake City, UT*

(861) Donor Heart Selection: The Outcome of Cardiac Graft Received After at Least 6 Declines by a Candidate on Medical Grounds: A Single-Center Experience; N. Fukushima¹, M. Yanase¹, O. Seguchi¹, T. Fujita², S. Fukushima³, K. Kuroda¹, Y. Kumai¹, J. Kobayashi¹. ¹*Dept of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan*, ²*Dept of Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Japan*, ³*Dept of Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Japan*

(862) Time Dependent Changes in Thyroid Hormone Levels During Donor Management; A. B. Van Bakel¹, S. A. Moore², D. Welker², M. R. Stroud³, M. L. Craig¹, A. J. Crumbley³, R. M. Sade³. ¹*Medicine/Cardiology, Med Univ of South Carolina, Charleston, SC*, ²*We Are Sharing Hope SC, Charleston, SC*, ³*Surgery/CT Surgery, Med Univ of South Carolina, Charleston, SC*

(862) PROMOTED TO MINI ORAL

(864) Too Big to Fail: Using Obese Donors for Heart Transplantation; N. Rajagopalan, A. E. Shafii, M. E. Sekela. *University of Kentucky, Lexington, KY*

(865) Gender Mismatch with Female Donor Hearts to Male Recipients: A Single Center Analysis; N. Rajagopalan, A. E. Shafii, M. E. Sekela. *University of Kentucky, Lexington, KY*

(866) Increased Use of Multi-organ Transplantation in Heart Transplantation—Time Will Tell; C. Lui, C. D. Fraser III, X. Zhou, A. Suarez-Pierre, J. C. Grimm, R. S. Higgins, K. J. Zehr, A. Kilic. *Division of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD*

(867) Biomarkers and Donor Selection in Heart Transplantation; A. Vorlat¹, N. Dehous¹, A. Vervaecke¹, V. Van Hoof², I. Rodrigus³, T. Vermeulen¹, E. Van Craenenbroeck¹, H. Heidbuchel¹, L. Van Aelst⁴, A. Ancion⁵, M. Claeys¹. ¹*Cardiology, University Hospital of Antwerp, Edegem, Belgium*, ²*Clinical Biology, University Hospital of Antwerp, Edegem, Belgium*, ³*Cardiac Surgery, University Hospital of Antwerp, Edegem, Belgium*, ⁴*Cardiology, University Hospital of Leuven, Leuven, Belgium*, ⁵*Cardiology, University Hospital Sart Tilman, Liege, Belgium*

(868) Do Geographical, Socioeconomic, and Individual Patient Factors Influence Access to Heart Transplant?; M. S. Ising, K. Sell-Dottin, M. S. Slaughter, J. R. Trivedi. *Dept of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY*

(869) Protocol Development for DCD Heart Transplantation; J. W. Smith¹, D. Helderline², A. Stempien-Otero³. ¹*Cardiothoracic Surgery, University of Washington, Seattle, WA*, ²*Division of Cardiology, University of Washington, Seattle, WA*, ³*Cardiology, University of Washington, Seattle, WA*

(870) Early Outcomes Using Hepatitis C-Exposed Donors for Cardiac Transplantation in the Era of Effective Direct-Acting Antiviral Treatments; K. Schlendorf, S. Zalawadiya, A. Shah, M. Wigger, C. Chung, M. Danter, M. Keebler, D. Brinkley, J. Menachem, S. Brown Sacks, H. Ooi, R. Perri, J. Awad, S. Smith, R. Hayes, H. O'dell, C. Darragh, A. Carver, C. Edmonds, S. Ruzevich-Scholl, J. Lindenfeld. *Vanderbilt University Medical Center, Nashville, TN*

(871) Variability in Donor Heart Acceptance Across the United States; K. Khush, R. Ball. *Stanford University, Stanford, CA*

(872) Potential Transplant Recipient Sequence Numbers Do Not Correlate with Worse Patient Outcomes; C. W. Chen¹, J. J. Chung¹, M. Daniel¹, C. Pietras¹, C. Bermudez¹, R. McLean², M. Acker¹, P. Atluri¹. ¹*Dept of Surgery, University of Pennsylvania, Philadelphia, PA*, ²*Dept of Medicine, University of Pennsylvania, Philadelphia, PA*

(873) Analyzing Geographic Disparities in the US Heart Allocation System; A. Rivard¹, F. Karami², M. Gentili², M. Nayeypour³, N. Koizumi³. ¹*Dept of Radiology, Cleveland Clinic, Abu Dhabi, United Arab Emirates*, ²*Industrial Engineering, University of Louisville, Louisville, KY*, ³*Schar School of Policy and Government, George Mason University, Arlington, VA*

(874) A Randomized Comparison of T3 vs. T4 for Management of Hemodynamically Unstable Brain-dead Organ Donors; R. Dhar¹, G. Marklin². ¹*Neurology, Washington University in St. Louis School of Medicine, St Louis, MO*, ²*Mid-America Transplant, St Louis, MO*

(875) New Heart Allocation System to Rescue the Patients With Severe Biventricular Failure; S. Saito, K. Toda, S. Miyagawa, Y. Yoshikawa, H. Hata, K. Domae, R. Matsuura, T. Ueno, T. Kuratani, Y. Sawa. *Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan*

(876) Does Commuting Time to the Transplant Center Affect Compliance with Visits and Outcome after HTx in a big Metropolitan Area?; A. Velleca, J. Patel, M. Kittleson, L. Czer, D. H. Chang, S. Dimbil, R. Levine, A. Patel, D. Geft, A. Hage, T. Kao, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(877) Use of "Needle in the Arm" Donors for Urgent Status Recipients in Heart Transplantation; A. Velleca, M. Kittleson, J. Patel, L. Czer, D. H. Chang, E. Kransdorf, S. Dimbil, R. Levine, S. Mersola, M. Curry, J. Chung, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(878) Longer Waitlist Time Places Blood Group O Patients at Greater Risk of Experiencing a Major CF LVAD Related Complication; O. Saeed¹, S. Cohen¹, E. Borukhov¹, S. Madan¹, S. Rangasamy¹, S. R. Patel¹, J. Shin¹, D. B. Sims¹, D. J. Goldstein², U. P. Jorde¹. ¹*Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY*, ²*Cardiothoracic Surgery, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY*

(879) Donor Pretreatment With Vasopressors: Impact on Outcome after Heart Transplantation; A. Mehdiani, C. Böttger, A. Albert, G. Petrov, H. Dalyanoglu, R. Westenfeld, P. Akhyari, D. Saeed, A. Lichtenberg, U. Boeken. *Cardiovascular Surgery, University Hospital, Duesseldorf, Germany*

(880) Heart Transplantation from Donors with Low Left Ventricle Systolic Function; V. N. Poptsov, N. Koloskova, E. Spirina, V. Zacharevich, A. Dogonacheva, V. Chatutskij. *Shumakov Centre Heart/Lung Transplant Team, Shumakov Federal Scientific Centre of Transplantology and Artificial Organs, Moscow, Russian Federation*

(881) Clinical Outcomes After Tricuspid Annuloplasty Prior to Cardiac Transplantation: A Single Center Experience; G. Rubin, J. Sanchez, J. Bayne, H. Takayama, K. Takeda, Y. Naka, H. Garan, M. Farr, E. Wan. *Columbia University Medical Center, New York, NY*

(882) Influence of Donor Sex and Mechanism of Death on Cardiac Transplant Recipient Early pAMR Incidence and Cardiovascular Death; M. B. Hammond¹, A. Vidic², G. L. Snow³, C. Zollinger⁴, R. A. Alharethi⁵, K. M. Molina⁶, J. Stehlik⁷, C. H. Selzman⁸, B. B. Reid⁹, S. G. Drakos¹⁰, A. G. Kfoury⁵, E. H. Hammond¹¹. ¹*Waterford High School, Salt Lake City, UT*, ²*Cardiology, Florida Hospital, Orlando, FL*, ³*Statistical Data Center, Intermountain Medical Center, Salt Lake City, UT*, ⁴*Intermountain Donor Services, Salt Lake City, UT*, ⁵*Cardiology, Intermountain Medical Center, Salt Lake City, UT*, ⁶*Cardiology, Primary Childrens Medical Center, Salt Lake City, UT*, ⁷*Cardiology, University of Utah Medical Center, Salt Lake City, UT*, ⁸*Cardiovascular Surgery, University of Utah Medical Center, Salt Lake City, UT*, ⁹*Cardiovascular Surgery, Waterford High School, Salt Lake City, UT*, ¹⁰*Cardiology, University of Utah School of Medicine, Salt Lake City, UT*, ¹¹*Intermountain Healthcare and University of Utah, Salt Lake City, UT*

(883) Kinetics of Regulatory CD4 T Cells in Heart Recipients Under Induction Therapy With One-single Dose versus Two-dose Basiliximab; S. Garcia¹, J. Carbone¹, I. Sousa², A. Karinina², E. Zatarain², P. Navas², A. Gallego¹, L. Calahorra¹, R. Lerma¹, E. Sarmiento¹. ¹Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

(884) Predictors of Early and Late Mortality after Heart Transplantation in Patients Bridged with the Total Artificial Heart; E. J. Sawey¹, J. T. Owens¹, I. Tchoukina¹, R. H. Cooke¹, M. A. Quader², R. R. Markley¹, M. C. Smallfield¹, D. G. Tang², K. Desai¹, K. K. Rao¹, M. P. Flattery¹, P. A. Uber¹, V. Kasirajan², K. B. Shah¹. ¹Cardiology, Virginia Commonwealth Univ Health System, Richmond, VA, ²Cardiothoracic Surgery, Virginia Commonwealth Univ Health System, Richmond, VA

(885) Cardiac Allograft Survival Stratified by Preservation Solution: A Multi-Institutional Analysis; C. Pietras¹, A. Thomasson², J. Gordon³, C. Chen¹, J. Chung¹, R. McLean², M. Acker¹, P. Atluri¹. ¹Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, ²Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ³Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

(886) PROMOTED TO MINI ORAL

(887) Salvage of Severe Primary Graft Dysfunction Following Cardiac Transplantation with Extracorporeal Life Support; S. Jacob¹, B. Lima², G. V. Gonzalez-Stawinski², P. Patel³, E. V. Belli¹, M. M. El-Sayed Ahmed¹, I. A. Makey¹, M. Thomas¹, K. Landolfo¹, J. Leoni-Moreno³, D. Yip³, S. M. Pham¹. ¹Cardio-thoracic Surgery, Mayo Clinic, Jacksonville, FL, ²Cardio-thoracic Surgery, Baylor University Medical Center, Dallas, TX, ³Transplant, Mayo Clinic, Jacksonville, FL

(888) Extra Corporeal Membrane Oxygenation (ECMO) for Primary Graft Dysfunction Following Heart Transplantation: A Single Centre Experience; V. Mehta¹, J. Hasan¹, P. Callan², S. Shaw², S. Williams², I. Dimarakis¹, J. Barnard¹, R. Venkateswaran³. ¹Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ²Cardiology, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ³Director of Transplantation, Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom

(889) Heterotopic Cardiac Transplantation: Time for Another Look?; G. V. Letsou¹, F. Musfee¹, F. H. Cheema¹, A. Lee², G. Loor¹, J. Morgan¹, T. Rosengart¹, O. H. Frazier¹. ¹Surgery, Baylor College of Med, Houston, TX, ²Baylor College of Med, Houston, TX

(890) Extracorporeal Membrane Oxygenation for Treatment of Primary Graft Dysfunction in Heart Transplant: Comparison of Central and Peripheral Cannulation; U. Boeken, A. Mehdiani, A. Albert, G. Petrov, B. Sowinski, H. Dalyanoglu, R. Westenfeld, P. Akhyari, D. Saeed, A. Lichtenberg. Cardiovascular Surgery, University Hospital, Duesseldorf, Germany

(891) Primary Graft Failure is More Common in Patients Bridged to Heart Transplant with LVAD: Role of Early Peripheral ECMO; T. Chinnadurai, S. R. Patel, D. Sims, O. Saeed, J. Shin, S. Madan, W. Hanif, S. Vukelic, E. Borukhov, S. Forest, M. Rahmanian, A. Carlese, S. Leung, W. Jakobleff, D. Goldstein, U. P. Jorde. Cardiology, Montefiore Medical Center, Bronx, NY

(892) Donor Right Ventricular Stroke Work Index (RVSWI) is a Poor Predictor of Primary Graft Dysfunction (PGD) After Heart Transplantation; S. Das De¹, S. Avtaar Singh¹, J. Dalzell², H. Doshi², P. Curry², N. Al-Attar², S. Nair². ¹Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, ²Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom

(893) Does a Redo Heart Transplant Decrease the Chance for Primary Graft Dysfunction?; R. Levine¹, J. Patel¹, M. Kittleson¹, L. Czer¹, D. Chang¹, E. Kransdorf¹, S. Dimbil², B. Kearney¹, D. Ramzy¹, F. Esmailian¹, J. A. Kobashigawa¹. ¹Cedars-Sinai Heart Institute, Los Angeles, CA, ²Cedars-Sinai Heart Institute, Beverly Hills, CA

(894) Is Depression After Heart Transplantation (HTX) Associated With Impaired Survival During Long-term Follow-up?; B. S. Bürker¹, L. Gullestad¹, E. Gude², O. E. Havik³, I. Grov², A. Relbo Authen², A. K. Andreassen², I. R. Hebold Haraldsen², A. E. Fiane¹, M. A. Dew⁴, S. Andersson⁵, U. F. Malt¹. ¹University of Oslo and Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³University of Bergen, Bergen, Norway, ⁴University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵University of Oslo, Oslo, Norway

(895) Does Occupation Affect Outcome Following Heart Transplantation; T. Kao, A. Velleca, J. Patel, M. Kittleson, L. Czer, S. Dimbil, R. Levine, A. Sanford, B. Kearney, E. Kransdorf, D. H. Chang, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(896) Relationship Between Patient-Perceived Treatment Burden and Health-Related Quality of Life in Heart Transplant Recipients; K. M. Deininger¹, J. D. Hirsch², S. A. Graveline², A. Feist², S. M. Smith³, J. A. Reich⁴, J. LaFleur⁵, A. V. Ambardekar⁶, J. Lindenfeld⁷, C. L. Aquilante¹. ¹Dept of Pharmaceutical Sciences, University of Colorado, Aurora, CO, ²Division of Clinical Pharmacy, University of California San Diego, La Jolla, CA, ³Dept of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL, ⁴Dept of Sociology, University of Colorado, Denver, CO, ⁵Dept of Pharmacotherapy, University of Utah, Salt Lake City, UT, ⁶Division of Cardiology, University of Colorado, Aurora, CO, ⁷Advanced Heart Failure and Cardiac Transplant Program, Vanderbilt University, Nashville, TN

(897) Outcomes of Heart Transplant Recipients with LVAD Implantation as Destination Therapy versus Bridge to Transplantation; K. Ahmad¹, P. Combs², J. Munro², K. Meehan², K. Jennings², C. Kabir², G. Macaluso¹, S. Pauwaa¹, G. Bhat², A. Tatoes², P. Pappas², A. Andrade², W. Cotts². ¹UIC/Advocate Christ Medical Center, Chicago, IL, ²Advocate Christ Medical Center, Chicago, IL

(898) Changing Donor Profile Over 30 Years of a Heart Transplant Program; J. Alvarez, R. V. Ribeiro, F. Yu, T. Yau, R. J. Cusimano, H. Ross, V. Rao, M. V. Badiwala. Cardiovascular Surgery, Toronto General Hosp, Toronto, ON, Canada

(899) Burden and Consequences of Retained Cardiovascular Implantable Electronic Device Lead Fragments After Heart Transplantation; P. Alvarez¹, B. W. Sperry², A. L. Perez², M. Tong², A. A. Hussein², D. O. Taylor². ¹University of Iowa, Iowa City, IA, ²Cleveland Clinic, Cleveland, OH

(900) Factors Influencing Heart Rate Control After Heart Transplantation; A. H. Christensen¹, S. I. Nygaard¹, K. Rolid², K. Nytrøen², L. Gullestad², A. Fiane³, E. Thaulow¹, G. Døhlen¹, V. B. Wyller⁴. ¹Pediatric Cardiology, Oslo Univ Hospital, Rikshospitalet, Oslo, Norway, ²Cardiology, Oslo Univ Hospital, Rikshospitalet, Oslo, Norway, ³Thoracic Surgery, Oslo Univ Hospital, Rikshospitalet, Oslo, Norway, ⁴Pediatric Cardiology, Akershus Univ Hospital, Oslo, Norway

(901) Older Kidney Donors in Dual Heart-kidney Transplantation: How Do They Stack Up?; S. Dimbil, J. Patel, M. Kittleson, L. Czer, D. H. Chang, E. Kransdorf, R. Levine, J. Baker, R. Bleiker, F. Esmailian, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(902) Predictors and Outcomes of Readmission After Heart Transplantation: An Analysis of UNOS/OPTN Data From 2000 to 2015; R. C. Givens¹, V. K. Topkara¹, D. Edmondson¹, S. W. Restaino¹, P. C. Colombo¹, F. Latif¹, D. Jennings¹, Y. Naka², H. Takayama², K. Takeda², M. A. Farr¹. ¹Medicine, Columbia University Medical Center, New York, NY, ²Surgery, Columbia University Medical Center, New York, NY

(903) The Effect of Dual Renin-angiotensin System Blockade Compared to Conventional Antihypertensive Combination on Blood Pressure and Renal Function After Heart Transplantation: A Randomized Controlled Trial; L. Hoskova¹, I. Malek¹, V. Melenovsky¹, J. Kautzner¹, I. Netuka¹, J. Franekova², A. Jabor². ¹Heart Center, IKEM, Prague, Czech Republic, ²Dept of Laboratory Methods, IKEM, Prague, Czech Republic

INFECTIOUS DISEASES **(Gallieni 1-2/Mykonos)**

Poster Discussants: Saima Aslam (USA), Orla Morrissey (Australia), Stephanie Pouch (USA), Mace Schuurmans (Switzerland), Amparo Sole (Spain)

(904) High Prevalence of BK Virus in Heart Transplant Patients and Effect on Outcomes; A. Nguyen¹, T. Imamura¹, B. Chung¹, C. Murks¹, J. Powers¹, T. Riley¹, D. Onsager¹, T. Song¹, T. Ota¹, S. Kalantari¹, J. Raikhelkar¹, N. Sarswat¹, G. Kim¹, M. Costanzo², U. Jorde³, V. Jeevanandam¹, G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Advocate Medical Group, Chicago, IL, ³Montefiore Medical Center, New York, NY

(905) Impact of Late Onset CMV Replication After Heart Transplant; I. Ponz de Antonio¹, A. Rodriguez Chaverri¹, M. Garcia Cosio¹, C. Ortiz Bautista², L. Moran Fernandez³, J. de Juan Baguda³, F. Lopez Medrano⁴, A. Garcia Reyne⁴, F. Arribas Ynsaurriaga³, J. Delgado Jiménez⁵. ¹Cardiology, University Hospital Doce de Octubre CIBERCV, Madrid, Spain, ²Cardiology, Hospital Universitario Gregorio Marañón, Madrid, Spain, ³Cardiology, University Hospital Doce de Octubre, Madrid, Spain, ⁴Internal Medicine, University Hospital Doce de Octubre, Madrid, Spain, ⁵Cardiology, University 12 de Octubre CIBERCV, Madrid, Spain

(906) Comparison of Prognostic Impact Between Early-onset and Delayed-onset Cytomegalovirus Replication in Heart Transplant Recipients; A. Rodriguez Chaverri¹, I. Ponz de Antonio¹, M. Garcia-Cosio², C. Ortiz Bautista², L. Moran Fernandez², J. de Juan Baguda², N. Carrasco Anton², F. Lopez-Medrano², F. Arribas Ynsaurraga², J. Delgado Jimenez³. ¹Hospital Doce de Octubre, CIBERCV, Madrid, Spain, ²Hospital Doce de Octubre, Madrid, Spain, ³University Hospital Doce de Octubre, CIBERCV, Madrid, Spain

(907) Epstein-Barr Virus Mismatch (Donor+/Recipient-): Is Cancer the Only Risk?; J. Patel, M. Kittleson, L. Czer, D. H. Chang, S. Dimbil, R. Levine, A. Velleca, E. Kransdorf, M. Hamilton, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(908) Preemptive vs. Upfront CMV Prophylaxis Strategies and the Risk of Treated CMV in Intermediate Risk Heart Transplant Recipients; C. Chen¹, N. Eng², M. Aldridge³, H. Mitchell³, A. Osborne³, A. Morris³, M. Hurtik³, D. Gupta³, K. Bhatt³, S. Laskar³, J. Vega⁴, A. Smith³, R. T. Cole³. ¹Emory Univ Sch of Med, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Cardiology, Emory Univ Sch of Med, Atlanta, GA, ⁴Cardiothoracic Surgery, Emory Univ Sch of Med, Atlanta, GA

(909) Multi-Drug Resistant Infection after Heart Transplantation: How Serious is This?; M. Kittleson, J. Patel, L. Czer, D. H. Chang, E. Kransdorf, R. Levine, S. Dimbil, A. Shen, A. Trento, R. Zabner, P. Zakowski, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(910) Rates of CMV Reactivation in Non Mismatched Heart Transplant Patients; S. Offen, D. Letchford, L. Carlos, F. Burrows, A. Jabbour, E. Kotlyar, A. Keogh, C. Hayward, K. Muthiah, P. Macdonald. *Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Darlinghurst, Australia*

(911) Measuring EBV in Lung Transplant Patients - Lessons of 16 Years of Follow Up; E. J. Gore¹, W. van der Bij², C. C. Leer¹, M. E. Erasmus³, C. Gan⁴, E. A. Verschuuren⁵. ¹Medical Microbiology and Virology, University Medical Centre Groningen, Groningen, Netherlands, ²Pulmonary Diseases and Tuberculosis, University Medical Centre Groningen, Groningen, Netherlands, ³Cardiothoracic Surgery, University Medical Centre Groningen, Groningen, Netherlands, ⁴Pulmonary Diseases and Tuberculosis, University Medical Centre Groningen, Groningen, Netherlands, ⁵University Medical Centre Groningen, Groningen, Netherlands

(912) Better Survival Post Lung Transplantation in Cystic Fibrosis Despite Multidrug Antibiotic Resistance in Patients with Previous Achromobacter Colonization; S. Colin de Verdière¹, D. Grenet², S. De Miranda², C. Picard², H. Abdul², M. Stern², M. Le Guen³, E. Sage⁴, A. Roux². ¹Pneumology, Adult CF Center and Lung Transplantation, Hôpital Foch, Suresnes, France, ²Pneumology, Adult CF Center and Lung Transplantation, Foch Hospital, Suresnes, France, ³Anesthesiology, Foch Hospital, Suresnes, France, ⁴Thoracic Surgery, Foch Hospital, Suresnes, France

(913) Impact of Candida Colonization on Lung Transplantation; J. S. Green¹, R. Brown², T. Umeda³, K. Rudser², S. Elde⁴, J. M. Roberts⁴, M. I. Hertz³, J. H. Young¹, R. Tomic³. ¹Medicine, Infectious Diseases, University of Minnesota, Minneapolis, MN, ²Division of Biostatistics, University of Minnesota, Minneapolis, MN, ³Medicine, Pulmonary and Critical Care Medicine, University of Minnesota, Minneapolis, MN, ⁴Medicine, University of Minnesota, Minneapolis, MN

(914) Epidemiology and Risk Factors of Post Operative Pneumonias After Heart Transplantation; C. Vidal, R. Pasqualotto, A. James, A. Bouglé, G. Lebreton, S. Varnous, P. Leprince, J. Amour. *Institut de cardiologie, Hôpital Pitié Salpêtrière, Paris, France*

(915) Brincidofovir - Finally an Option for PML?; J. A. Schneider, T. A. Arbogast, C. R. Wolfe. *Duke University Medical Center, Durham, NC*

(916) Early Rhinovirus Infection After Lung Transplantation - Simply the Innocent Bystander?; T. Thaniyavarn, A. Strand, S. C. Hume, E. K. Maziarz, L. Zaffiri, C. R. Wolfe. *Duke University Medical Center, Durham, NC*

(917) Impact of Cytomegalovirus Transmission on Lung Allograft Survival in the United States; C. Kurihara, R. Fernandez, N. Safaeinili, G. Budinger, M. M. DeCamp, A. Bharat. *Northwestern University, Chicago, IL*

(918) Impact of Donor Lung Pathogenic Bacteria on Patient Outcomes in the Immediate Post-transplant Period; O. Ahmad, A. Shafii, D. Mannino, R. Choate, M. Baz. *University of Kentucky, Lexington, KY*

(919) Mucormycosis in Lung Transplant Recipients: A Systematic Review; O. Wand¹, A. Unterman¹, O. Shtraichman¹, S. Izhakian¹, L. Fridel², M. R. Kramer¹. ¹Pulmonary Medicine, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ²Pathology Institute, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel

(920) Lung Transplantation in Cystic Fibrosis Patients Infected With B.Cepacia Complex: A Single Center Experience; N. Nechaev¹, S. Golovinskiy¹, M. Simonova¹, S. Krasovskiy², V. Poptsov¹, S. Gautier¹. ¹Federal State Budgetary Institution "Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation, Moscow, Russian Federation, ²Federal State Budgetary Institution "Research Institution of Pulmonology" Federal Medical and Biological Agency of the Russian Federation, Moscow, Russian Federation

(921) Ureaplasma spp. and Mycoplasma hominis PCR in Respiratory Samples from Lung Transplant Recipients with Hyperammonemia Syndrome and Cerebral Edema; C. Aguilar¹, W. Gohir¹, J. Tikkanen², L. Del Sorbo³, C. Chaparro², T. Mazzulli⁴, A. Humar¹, D. Kumar¹, M. Cypel², L. G. Singer², S. Keshavjee², S. Husain¹. ¹Transplant Infectious Diseases, Univ Health Network, Toronto, ON, Canada, ²Toronto Lung Transplant Program, Univ Health Network, Toronto, ON, Canada, ³Interdepartmental Division of Critical Care Medicine, Univ Health Network, Toronto, ON, Canada, ⁴Dept of Laboratory Medicine & Pathobiology, Mount Sinai Hospital/ Univ Health Network, Toronto, ON, Canada

(922) The Role of Infections in the Development of de Novo Donor-Specific Antibodies after Lung Transplantation; V. Verplancke¹, S. Husain², K. Tinckam³, L. Singer⁴, S. Keshavjee⁴, J. Tikkanen⁵. ¹Toronto General Hospital, Toronto, ON, Canada, ²Transplant Infectious Disease, Toronto General Hospital, Toronto, ON, Canada, ³Medicine/Nephrology, Toronto General Hospital, Toronto, ON, Canada, ⁴Lung transplantation, Toronto General Hospital, Toronto, ON, Canada, ⁵Lung Transplantation, Toronto General Hospital, Toronto, ON, Canada

(923) Efficacy of Ribavirin in the Treatment of Respiratory Syncytial Virus Infections in Lung-Transplant Recipients; D. Voet¹, J. M. Kwakkel-van Erp², H. D. Luijk², E. A. van de Graaf², F. M. Verduyn Lunel¹. ¹Dept. of Medical Microbiology, Utrecht University Medical Center, Utrecht, Netherlands, ²Dept. of Pulmonology, Utrecht University Medical Center, Utrecht, Netherlands

(924) The Role of Gallium Scans in the Diagnosis of Clinically Suspected Left Ventricular Assist Device Infections in Western Australia; M. Asokendaran¹, Z. AL-Ogaili¹, F. Njue², J. Barber², H. Hayes², K. Lam². ¹Nuclear Medicine Dept, Fiona Stanley Hospital, Perth, Australia, ²Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Perth, Australia

(925) Incidence and Impact of Severe LVAD-related Infections Requiring Surgical Treatment in Obesity Patients on Long-term HeartMate II and HeartWare Support; C. Kurihara, M. Kawabori, A. Critsinelis, T. Sugiura, A. B. Civitello, L. Simpson, J. K. George, R. M. Delgado, A. P. Nair, G. Loor, T. K. Rosengart, O. H. Frazier, J. A. Morgan. Texas Heart Institute/ Baylor College of Medicine, Texas Heart Institute/ Baylor College of Medicine, Houston, TX

(926) Comparative Infection Related Outcomes Between Recipients of an Axial Continuous-flow and an Intrapericardial Centrifugal Continuous-flow Left Ventricular Assist Device: A Single Center Experience; J. Rind¹, A. Faisal¹, J. de Sanctis², S. Lee³, R. Lampen⁴, P. Egeler⁵. ¹Internal Medicine, Spectrum Health/Michigan State University Internal Medicine Residency, Grand Rapids, MI, ²Infectious Disease, Spectrum Health Medical Group Division of Infectious Disease, Grand Rapids, MI, ³Advanced Heart Failure Cardiology, Spectrum Health Medical Group Advanced Heart Failure Cardiology, Grand Rapids, MI, ⁴Infectious Disease, Spectrum Health Medical Group Division of Infectious Disease, Grand Rapids, MI, ⁵Biostatistics, Spectrum Health Bioinformatics Core, Grand Rapids, MI

(927) Conservative Treatment of Driveline Infections: A Single Centre Experience; A. Giacomini¹, T. Nisi¹, E. Lapenna¹, F. Pappalardo², M. Calabrese¹, O. Forma³, A. Castiglioni¹, O. Alfieri¹, M. De Bonis¹. ¹Cardio-Thoracic and Vascular Surgery, San Raffaele Scientific Institute, Milan, Italy, ²Cardiovascular Anesthesia and Intensive Care, San Raffaele Scientific Institute, Milan, Italy, ³Wound Care Unit, San Raffaele Scientific Institute, Milan, Italy

(928) Infection Predisposes to Thrombosis During Long Term VAD Support; J. Castrodeza¹, O. Gonzalez², A. Woods², D. Dobarro¹, M. Urban², N. Robinson-Smith², S. Tovey², A. Koshy³, D. Jakovljevic⁴, J. Samuel⁵, J. Jungschleger², M. Carrasco-Moraleja¹, G. Parry⁶, S. Schueler², G. MacGowan⁶. ¹Cardiology, Hospital Clinico Universitario Valladolid, Valladolid, Spain, ²Cardiothoracic Services, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ³Academic Fellow, Newcastle University, Newcastle Upon Tyne, United Kingdom, ⁴Senior Lecturer, Newcastle University, Newcastle Upon Tyne, United Kingdom, ⁵Microbiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ⁶Institute of Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

(929) Incidence and Management of Device-related Infections With the Jarvik 2000 Axial Flow Pump; M. Gaillard¹, E. M. Flecher², R. Ramadan¹, A. Azmoun¹, Y. Lepers¹, C. Chabanne², R. Nottin¹, A. Anselmi², P. Deleuze¹, J. Guihaire¹. ¹Adult Cardiac Surgery, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France, ²Thoracic and Cardiovascular Surgery, Pontchaillou Hospital, University of Rennes 1, Rennes, France

(930) Favorable Outcomes With Ventricular Assist Device Exchange for Refractory Infections; M. M. Carroll¹, M. Bochan², C. Salerno³, A. Ravichandran³. ¹Indiana University School of Medicine, Evansville, IN, ²Infectious Disease of Indiana and St. Vincent Hospital, Indianapolis, IN, ³St. Vincent Heart Center, Indianapolis, IN

(931) Surgical Debridement of Driveline Infection with Uninterrupted Warfarin Anticoagulation is Associated with Reduced Postoperative Bleeding Events, Blood Transfusion and Shorter Hospital Stay; K. D. Kotkar, S. Anand, I. Fischer, G. Ewald, K. R. Balsara, M. F. Masood, A. Itoh. *Cardiothoracic surgery, Washington university, Saint louis, MO*

(932) Cytomegalovirus (CMV) Infection in Pediatric Solid Organ Transplant Recipients and Role of Prophylaxis; G. Nance¹, A. Serluco¹, S. R. Deshpande², R. Garro³, R. P. George³, M. S. Kelleman⁴, R. Liverman¹. ¹Children's Healthcare of Atlanta, Atlanta, GA, ²Pediatric Cardiology, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, ³Pediatric Nephrology, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory University, Atlanta, GA

JUNIOR FACULTY CLINICAL CASE REPORTS

(Agora 3)

Poster Discussants: Dipanjan Banerjee (USA), Gerard Boyle (USA), Jennifer Conway (Canada), Sitaramesh Emani (USA), Feras Khaliel (Saudi Arabia), Ashwin Ravichandran (USA), Elena Sandoval (Spain), Stephan Schubert (Germany), Palak Shah (USA), Aleem Siddique (USA), Thenappan Thenappan (USA)

(1366) Liver-First Versus Lung-First: A New Dilemma in Combined Organ Transplantation; L. J. Ceulemans¹, R. Vos², A. Neyrinck³, F. Nevens⁴, D. Monbaliu⁵, J. Pirenne⁵, G. Verleden², D. Van Raemdonck¹. ¹Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ²Pneumology, University Hospitals Leuven, Leuven, Belgium, ³Anesthesiology, University Hospitals Leuven, Leuven, Belgium, ⁴Hepatology, University Hospitals Leuven, Leuven, Belgium, ⁵Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium

(1367) Successful LVAD Implantation in a Patient With Hemophilia A: A Case Report and Literature Review; S. Adhikari¹, G. Murtaza¹, W. G. Cotts¹, G. Gavrilos², P. S. Pappas¹, A. Tatoes¹, A. A. Andrade¹. ¹University of Illinois at Chicago-Advocate Christ Medical Center, Oak Lawn, IL, ²Advocate Christ Medical Center, Oak Lawn, IL

(1368) Pumpless Extracorporeal Lung Assist as a Bridge to Medical Therapy in a Teenager With Severe Pulmonary Arterial Hypertension and Partial Anomalous Pulmonary Venous Return; S. Hascoet¹, A. Boet¹, L. Savale², O. Sitbon², X. Jais², M. Humbert², O. Mercier³, L. Houyel¹, J. Horer¹, E. Fadel³. ¹Congenital Heart Diseases, Hopital Marie Lannelongue, Plessis-Robinson, France, ²Pulmonary Hypertension, Hopital Kremlin Bicetre, Kremlin Bicetre, France, ³Thoracic Surgery, Hopital Marie Lannelongue, Plessis-Robinson, France

(1369) Percutaneous Angioplasty of Stenotic HeartMate II Outflow Graft; T. Alnabelsi, R. Wilson, K. Dulnuan, S. Bond, B. George, N. Rajagopalan, A. Shafii, J. Gurley, M. Guglin. *University of Kentucky, Lexington, KY*

(1370) Durable Biventricular Assist Device in a Transplanted Heart; E. Oliveros¹, T. Suboc¹, R. Paliga², A. Tatoes², S. Pauwaa², G. Macaluso², D. Muhyaldeen², P. Pappas², I. Balanlayos², K. Ahmad², G. Bhat², A. Andrade², W. Cotts². ¹Rush University Medical Center, Chicago, IL, ²Advocate Christ Medical Center, Chicago, IL

(1371) Bridge-to-Candidacy With Concomitant Total Artificial Heart and Pulmonary Thromboendarterectomy; A. Mohammed, D. Joyce, N. Gaglianella, D. Ishizawar, G. Dagar, K. Presberg, M. Saltzberg, L. Joyce. *Med College of Wisconsin, Milwaukee, WI*

(1372) Triple Trouble: A Patient with Biventricular Failure, Pectus Excavatum, and Aortic Insufficiency in Shock Requiring Surgical Management; C. Buto-Colletti, M. Quader. *Virginia Commonwealth University, Virginia Commonwealth University, Richmond, VA*

(1373) HeartMate 2 Controller Failure Presenting as Driveline Fault with Repeated Pump Stoppages: Lessons for Detailed Log File Analysis; K. D. Flint¹, W. K. Cornwell¹, C. Pierce², A. Brieke¹, J. C. Cleveland³, J. D. Pal³. ¹Medicine, University of Colorado, Aurora, CO, ²University of Colorado Hospital, Aurora, CO, ³Surgery, University of Colorado, Aurora, CO

(1374) Continuous Flow LVAD Implantation in Patients With Marfan's Syndrome; A. Critsinelis¹, M. Kim¹, C. Kurihara¹, H. Lamba¹, F. H. Cheema¹, M. Kawabori¹, T. Sugiura¹, R. Delgado¹, L. Simpson², J. George², A. Nair², A. Civitello², T. Rosengart³, O. H. Frazier¹, J. Morgan¹. ¹Division of Cardiothoracic Transplantation and Circulatory Support, Baylor College of Medicine, Houston, TX, ²Division of Cardiology, Baylor College of Medicine, Houston, TX, ³Dept of Surgery, Baylor College of Medicine, Houston, TX

- (1375) Minimally Invasive HeartMate 3™ LVAD Implantation in Redo Cases on Impella CP Support;** R. Antończyk, K. Antończyk, K. Filipiak, J. Waszak, I. Copik, P. Przybyłowski, M. Zakliczyński, M. Zembala, M. O. Zembala. *Dept of Cardiac, Vascular and Endovascular Surgery and Transplantology, SMDZ in Zabrze, Medical University of Silesia in Katowice, Silesian Centre for Heart Diseases, Zabrze, Poland, Zabrze, Poland*
- (1376) Acute Pump Failure of Jarvik 2000 LVAD With Development of Cardiogenic Shock Requiring LVAD Exchange - A Novel Approach;** K. A. Sell-Dottin¹, B. Haithcock². ¹Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, ²Cardiothoracic Surgery, University of North Carolina, Chapel Hill, NC
- (1377) Pump Washout Procedure in a Child With Centrifugal-Flow Ventricular Assist Device Support;** S. Choudhry, A. Liou, A. Jeewa, B. A. Elias, I. Adachi. *Texas Children's Hospital, Baylor College of Medicine, Houston, TX*
- (1378) Concomitant Surgical Cryoablation for Refractory Ventricular Tachycardia During Left Ventricular Assist Device Implantation for Ischemic Cardiomyopathy;** G. Sunagawa, M. Mitchell, A. Basil, S. Brann, S. Keshavamurthy, J. Gomez-Abraham, M. Kashem, N. Shigemura, K. Minakata, Y. Toyoda. *Temple Heart and Vascular Institute, Temple University Hospital, Philadelphia, PA*
- (1379) WITHDRAWN**
- (1380) Refractory Traumatic Bronchopleural Fistula: Is Extracorporeal Membrane Oxygenation the New Gold Standard?;** A. A. Grant¹, V. J. Hart², E. B. Lineen², A. Patel³, A. Badiye⁴, M. Loebe⁵, A. Ghodsizad⁵. ¹Dept of Surgery, Jackson Health System, Miami, FL, ²Dept of Surgery, University of Miami, Miami, FL, ³Dept of Cardiothoracic Surgery, University of Miami, Miami, FL, ⁴Dept of Cardiology, University of Miami, Miami, FL, ⁵Dept of Cardiothoracic Surgery, University of Miami, Miami, FL
- (1381) Right Heart Failure and Aortic Regurgitation;** J. Eulert-Grehn, T. Krabatsch, S. Buz, V. Falk, F. Schönraht, E. Potapov. *Cardiac, Thoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany*
- (1382) Pump Fiction: A Tale of Acute Promyelocytic Leukemia Mimicking Pump Thrombosis;** G. A. Hernandez, C. Rueda, J. D. Moretz, S. Brown Sacks, J. Lindenfeld, M. Brinkley. *Advanced Heart Failure and Transplant, Vanderbilt University, Nashville, TN*
- (1383) Implantation of Left Ventricular Assist Device in the Setting of a Heavily Calcified Left Ventricular Apex by Using the Apex Preserving/Telescope/Cerclage Technique (APTC);** I. A. Salas de Armas, J. A. Patel, M. H. Akay, M. K. Jezovnik, R. Radovancevic, B. Kar, I. D. Gregoric. *The University of Texas Health Science Center at Houston, Center for Advanced Heart Failure, Houston, TX*
- (1384) WITHDRAWN**
- (1385) Transcatheter Aortic Valve Replacement as a Bridge to Left Ventricular Device Implantation;** A. Elmously¹, B. Worku¹, S. Wong², A. Salemi¹. ¹Cardiothoracic Surgery, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY, ²Cardiology, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY
- (1386) Percutaneous Deactivation of HeartWare VAD in a Patient Presenting with Significant Pump Thrombosis;** A. Albulushi, M. Hyden, J. Delaney. *Cardiology, University of Nebraska Medical Center, Omaha, NE*
- (1387) Unusual Presentation of Pheochromocytoma in Patient Requiring Ventricular Assist Device Support;** A. Albulushi¹, N. Abdulsalam¹, J. Sullivan², D. Stoller¹. ¹Cardiology, University of Nebraska Medical Center, Omaha, NE, ²Anesthesiology, University of Nebraska Medical Center, Omaha, NE
- (1388) Successful Implantation of a Left Ventricular Assist Device in a Patient With Arrhythmogenic Right Ventricular Cardiomyopathy;** A. Wakamiya, O. Seguchi, Y. Kumai, K. Kuroda, S. Nakajima, M. Yanase, Y. Matsumoto, S. Fukushima, T. Fujita, J. Kobayashi, N. Fukushima. *National Cerebral and Cardiovascular Center, Osaka, Japan*
- (1389) Risk of VAD Thrombosis Due to Left Ventricular Recovery;** D. D. Song¹, A. Lucev², S. Stewart², B. Kim². ¹Dept of Medicine, Rutgers New Jersey Medical School, Jersey City, NJ, ²Division of Heart Failure and Pulmonary Hypertension, Hackensack University Medical Center, Hackensack, NJ
- (1390) Management of Patients With Heparin-Induced Thrombocytopenia Scheduled to Receive a Continuous Flow Left Ventricular Assist Device;** S. R. Maffei, H. Lamba, A. Bracey, F. H. Cheema, A. Civitello, R. Delgado, L.

Simpson, A. P. Nair, O. Frazier, J. Morgan. *Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX*

(1391) Ventricular VADicardias; C. Rueda¹, G. Hernandez¹, H. Keshmiri², K. Patricia³, J. Lindenfeld¹. ¹Vanderbilt University, Nashville, TN, ²Advocate Illinois Masonic Medical Center, Chicago, IL, ³Montana Heart Center, Missoula, IL

(1392) Outflow Graft Compression in a Patient With HeartMate II Left Ventricular Assist Device; P. Pirlamarla¹, V. Rakita¹, A. Lala-Trindade¹, S. Pinney¹, D. Mancini¹, M. Barghash¹, M. Trivieri¹, A. Anyanwu², A. Pawale², N. Moss¹, S. S. Mitter¹. ¹Advanced Heart Failure and Cardiac Transplant, Mount Sinai Hospital, New York, NY, ²Cardiovascular Surgery, Mount Sinai Hospital, New York, NY

(1393) LVAD Masking a Subclavian-Coronary Steal Syndrome; A. Addas¹, M. Kühl², J. Fischer¹, M. Borger¹, J. Garbade¹. ¹Dept of Cardiac Surgery, Leipzig Heart Centre, Leipzig, Germany, ²Dept of Electrophysiology, Leipzig Heart Centre, Leipzig, Germany

(1394) Recurrent Left Ventricular Assist Device Thromboses; T. Artzner, T. Hoang Minh, M. Cristinar, S. Marguerite, G. Ajob, J. Mazzucotelli, A. Ruimy, S. Mebaouj, P. Mertes, M. Kindo. *Strasbourg University Hospital, Strasbourg, France*

(1395) Successful Heart Transplantation After 1 Year of Continuous Vacuum Assisted Therapy in a Case of Severe BIVAD Infection; J. Kremer¹, U. Tochtermann¹, B. Schmack¹, A. Ruhparwar¹, A. Heininger². ¹Cardiac Surgery, Univ Hospital Heidelberg, Heidelberg, Germany, ²Infectious Diseases, Univ Hospital Heidelberg, Heidelberg, Germany

(1396) Extracorporeal Membrane Oxygenation in the Management of Tracheal Tears; J. Tang¹, J. Chen², G. Dincheva², K. Rajalingam³, J. Kratz², M. Brzezinski⁴, J. Kukreja². ¹Chicago Medical School, Rosalind Franklin University, Chicago, IL, ²Surgery, Univ of California, San Francisco, CA, ³Undergraduate, Univ of California, Berkeley, CA, ⁴Anesthesia, Univ of California, San Francisco, CA

(1397) Patient With a Left Ventricular Assist Device and Hypertensive Blood Pressure Response to Activity- Role of Invasive Exercise Hemodynamic Assessment; M. Alhama Belotto, A. Bitar, R. Mohan, J. Heywood, A. Srivastava. *Scripps Clinic, San Diego, CA*

(1398) Left Ventricular Assist Device Inflow Cannula Obstruction Without Hemolysis- Two Cases; K. Mudy, E. Duncanson, T. Knickelbine, J. Lesser, B. Sun, P. Eckman. *Abbott Northwestern Hospital, Minneapolis, MN*

(1399) Unusual Cause of Pneumomediastinum in an LVAD Patient; T. Sugiura, M. Kawabori, C. Kurihara, R. M. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, O. H. Frazier, J. A. Morgan. *Texas Heart Institute, Houston, TX*

(1400) A Case of Suspected Reversible Cerebral Vasoconstriction Syndrome Occurred in a Patient With a Continuous-flow Left Ventricular Assist Device; T. Fujino¹, H. Deguchi², T. Higo², K. Ohtani², K. Hiasa², T. Ushijima³, Y. Tanoue³, H. Tsutsui², A. Shiose³. ¹Dept of Advanced Cardiopulmonary Failure, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ²Dept of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³Dept of Cardiovascular Surgery, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

(1401) "Chronic Ventricular Fibrillation" in a Patient with a Biventricular Assist Device; B. Koell¹, B. Alexander¹, S. Blankenberg², H. Reichenspurner¹, H. Grahn². ¹Dept of Cardiac Surgery, University Heart Center, Hamburg, Germany, Hamburg, Germany, ²Dept of General and Interventional Cardiology, University Heart Center, Hamburg, Germany, Hamburg, Germany

(1402) HeartMate II Implantation Through Mini-Sternotomy in a Low BSA Patient; T. Ushijima¹, Y. Tanoue², K. Hirayama¹, T. Fujino², T. Higo³, H. Tsutsui³, A. Shiose¹. ¹Cardiovascular Surgery, Kyushu University Hospital, Fukuoka, Japan, ²Advanced Cardiopulmonary Failure, Kyushu University Hospital, Fukuoka, Japan, ³Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan

(1403) Cyclophosphamide Myopericarditis: Progression to Cardiac Standstill; E. K. Zern¹, A. J. Coromilas¹, N. Mihatov², J. Mojica³, R. Malhotra², M. Chung⁴, B. R. Dey⁵, S. V. Tsiaras², N. Roy⁶. ¹Dept of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Cardiology, Massachusetts General Hospital, Boston, MA, ³Division of Pulmonary & Critical Care Medicine, Massachusetts General Hospital, Boston, MA, ⁴Dept of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, ⁵Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, ⁶Dept of Surgery, Div of Cardiac Surgery, Massachusetts General Hospital, Boston, MA

- (1404) Left Ventricular Lead On or Off: The Challenge of Cardiac Resynchronization Therapy and Left Ventricular Assist Device Therapy;** N. Patel, D. Konstadina, S. Martin, W. Baker, J. Gluck, J. Radojevic. *Hartford Hosp, Hartford, CT*
- (1405) Awake Venous-Arterial ECMO (VAECMO) Without Mechanical Ventilation as a Bridge to Advanced HF Therapies;** S. M. Rodriguez, V. Luzania, M. Kwan, C. Kunavarapu. *Advanced Heart Failure and Transplant Program, Methodist Hospital, San Antonio, TX*
- (1406) Recurrence of Protein-losing Enteropathy in Fontan Patients After Heart Transplantation;** K. E. Simpson¹, S. C. West², J. N. Johnson³, M. B. Hilscher³, C. D. Castleberry¹, J. Scheel¹, C. E. Canter¹, K. R. Schumacher⁴. ¹*Pediatrics, Washington University in St Louis, Saint Louis, MO*, ²*Pediatrics, University of Pittsburgh, Pittsburgh, PA*, ³*Pediatrics, Mayo Clinic, Rochester, MN*, ⁴*Pediatrics, University of Michigan, Ann Arbor, MI*
- (1407) WITHDRAWN**
- (1408) Dramatic Consequences of Water Pipe Use Following Lung Transplantation;** C. A. Robinson¹, B. Vrugt², M. M. Schuurmans³, C. Benden¹, S. Benussi⁴, I. Inci³, W. Weder³, I. Opitz³. ¹*Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland*, ²*Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland*, ³*Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland*, ⁴*Division of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland*
- (1409) Middle Aortic Syndrome Unmasked After Placement of Berlin LVAD for Dilated Cardiomyopathy;** T. T. Bradford¹, P. Shivaram², E. A. Frazier², X. Garcia², K. R. Knecht². ¹*Arkansas Children's Hospital, Little Rock, AR*, ²*Dept of Pediatrics, Arkansas Children's Hospital, Little Rock, AR*
- (1410) Combined Heart and Kidney Transplantation in a 9 Kilogram Child;** J. J. Parent¹, D. L. Morales², C. Chin², D. Hooper³, T. D. Ryan². ¹*Pediatric Cardiology, Riley Hospital at Indiana University Health, Indianapolis, IN*, ²*The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*, ³*Pediatric Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*
- (1411) Successful Adult to Child Cardiac Transplantation Applying Normothermic Ex Vivo Perfusion in Congenital Heart Disease;** D. Bobylev, S. Rojas, F. Ius, T. Kaufeld, M. Avsar, C. Bara, U. Grosser, H. Koeditz, P. Beerbaum, A. Horke, A. Haverich, G. Warnecke. *Dept of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany*
- (1412) Acute Humoral Rejection in an Infant After Heart Transplantation: Uncommon But Possible;** J. Marcano¹, R. Zea-Vera², H. Tunuguntla³, D. L. Kearney⁴, Z. M. Binsalamah². ¹*Cardiothoracic Surgery, Texas Heart Institute - Baylor College of Medicine, Houston, TX*, ²*Congenital Heart Surgery, Texas Children's Hospital - Baylor College of Medicine, Houston, TX*, ³*Pediatric Cardiology, Texas Children's Hospital - Baylor College of Medicine, Houston, TX*, ⁴*Pathology & Immunology, Texas Children's Hospital - Baylor College of Medicine, Houston, TX*
- (1413) Radiation- Induced Pulmonary Fibrosis After Therapy of Papillary Thyroid Carcinoma With Pulmonary Metastases;** I. Saba, M. Loebe, D. Fertel, S. Shafazand, A. Ghodsizad, N. Brozzi. *University of Miami, Miami, FL*
- (1414) Successful Single Lung Transplant Following Pneumonectomy in a Pediatric Patient With Cystic Fibrosis;** T. Brand, B. E. Haithcock. *Dept of Surgery, University North Carolina, Chapel Hill, NC*
- (1415) Successful Pediatric Heart Transplant in a Patient with Loeys-Dietz;** M. S. Ploutz¹, A. Colon¹, S. Grohall¹, S. Pophal¹, C. F. Lagerstrom², D. A. Velez², S. Zangwill¹. ¹*Cardiology, Phoenix Children's Hospital, Phoenix, AZ*, ²*Cardiovascular Surgery, Phoenix Children's Hospital, Phoenix, AZ*
- (1416) ST Elevation Myocardial Infarction (STEMI) Early After Pediatric Heart Transplantation;** M. Bano¹, V. V. Dimas¹, R. Butts¹, M. Luna², R. Jaquiss³, D. Sutcliffe¹, T. Pirolli³, R. Morrow¹, R. Kirk¹. ¹*Pediatric Cardiology, UT Southwestern, Dallas, TX*, ²*Interventional Cardiology, UT Southwestern, Dallas, TX*, ³*Pediatric Cardiothoracic Surgery, UT Southwestern, Dallas, TX*
- (1417) Arrhythmogenic Cardiomyopathy: Children Don't Always Follow the Rules!;** H. P. Tunuguntla¹, A. Landstrom¹, D. L. Kearney², C. Gates¹, S. Choudhry¹, A. G. Cabrera¹, J. F. Price¹, I. Adachi³, W. J. Dreyer¹, S. W. Denfield¹. ¹*Pediatric Cardiology, Texas Children's Hospital, Houston, TX*, ²*Pathology, Texas Children's Hospital, Houston, TX*, ³*Congenital Heart Surgery, Texas Children's Hospital, Houston, TX*

- (1418) Bivalrudin, Dialysis, and Biventricular Assist Devices: A Pathway to Heart-Kidney Transplant in a HITT Positive Patient;** E. R. Griffiths¹, L. May², K. Molina², A. Lal², A. W. Eckhauser¹. ¹Surgery, University of Utah Primary Children's Hospital, Salt Lake City, UT, ²Pediatrics, University of Utah Primary Children's Hospital, Salt Lake City, UT
- (1419) Successful Bridge to Transplant in the Smallest Pediatric Patient To-Date Using the 50 cc SynCardia® Total Artificial Heart;** G. S. Beasley¹, K. Allen², L. Jackson³, E. Pahl¹, O. Eltayeb⁴, C. L. Backer⁴, M. Monge⁴, P. T. Thrush¹. ¹Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL, ²Pediatric Cardiology and Critical Care Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL, ³Critical Care Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Cardiovascular-Thoracic Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL
- (1420) Acute Coronary Thrombosis in a Child with Kawasaki's Disease and Giant Coronary Aneurysms: BiVAD as a Bridge to Transplantation;** R. A. Murthy¹, G. Vaughn², S. Haldeman², H. El-Said², J. Yeh², J. A. Lamberti¹, J. Nigro¹. ¹Cardiothoracic Surgery, Rady Children's Hospital, University of California San Diego, San Diego, CA, ²Pediatric Cardiology, Rady Children's Hospital, University of California San Diego, San Diego, CA
- (1421) When Two Cardiomyopathies Are Better Than One: Novel Genetic Mutation With LVNC and Unilateral Restrictive Features in a Child;** A. Morrison, P. Baker, A. Hodge, S. Fitzgerald-Butt, R. Gajarski, P. McConnell, D. Nandi. Nationwide Children's Hospital, Columbus, OH
- (1422) High Pulmonary Vascular Resistance and Heart Transplantation;** C. E. Ciccotello¹, K. Kanter², W. T. Mahle³, S. R. Deshpande³. ¹Pediatric Cardiology, Emory University, Atlanta, GA, ²Dept of Cardiothoracic Surgery, Emory University, Atlanta, GA, ³Pediatric Cardiology, Emory University / Children's Healthcare of Atlanta, Atlanta, GA
- (1423) Negative Pressure Wound Therapy Prevents Infection and Allows for Rehabilitation in a Child on Long-Term Mechanical Circulatory Support;** C. S. Jenkins¹, D. J. Kozik¹, A. Lorimer². ¹Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, ²Pediatric Cardiovascular Surgery, Norton Healthcare, Louisville, KY
- (1424) Stable Heart Regraft Function in the Presence of a High Titer Donor Specific Anti-HLA DQA Antibody;** J. A. Spinner¹, P. T. Jindra², R. H. Kerman³, W. J. Dreyer⁴. ¹Section of Pediatric Cardiology, Dept of Pediatrics, Baylor College of Medicine, Houston, TX, ²Immune Evaluation Lab Dept of Surgery, Baylor College of Medicine, Houston, TX, ³Immune Evaluation Lab Dept of Surgery, Baylor College of Medicine, Houston, TX, ⁴Pediatric Cardiology, Texas Children's Hospital, Houston, TX
- (1425) Isolated Pulmonary Artery Vasculitis Leading to Pulmonary Artery Aneurysm Formation;** N. Moghaddam¹, B. Moghaddam¹, N. S. Dehghan², M. T. Janusz³, N. W. Brunner⁴. ¹Dept of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Division of Cardiovascular and Thoracic Surgery, University of British Columbia, Vancouver, BC, Canada, ⁴Division of Cardiology, University of British Columbia, Vancouver, BC, Canada
- (1426) Long Duration PA to LA Pumpless Interventional Lung Assist Device Bridge to Lung Transplantation in a Child with IPAH;** M. Vayvada¹, A. Yeginsu¹, A. E. Tasci¹, S. S. Caner¹, A. Erkilic², E. Gurcu², B. Ozbek³, A. Yildirim⁴. ¹Thoracic Surgery, Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey, ²Anesthesia and Reanimation, Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey, ³Pediatric Cardiovascular Surgery, Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey, ⁴Pediatric Cardiology, Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey
- (1427) Outcome of Lung Transplantation in Sting Syndrome: A Single Case Experience;** A. Hanna, S. Feuillet, J. Le Pavec, A. Crutu, O. Mercier, D. Mitilian, D. Fabre, E. Fadel. Centre Chirurgical Marie Lannelongue, Paris, France
- (1428) Can Bronchoscopic Lung Volume Reduction Be Used to Avoid Transplantation? A Case of Endobronchial Valve Placement in Vanishing Lung;** K. D. Scatliffe, M. Mody, L. Mwamuka, A. Arjuna, H. Nazir, M. Lindner, R. Yanagida, C. Migliore, P. Patel, H. Seethamraju. Pulmonary Critical Care, Newark Beth Israel Medical Center, Newark, NJ
- (1429) Successful Bilateral Lung Transplant for Pulmonary Alveolar Microlithiasis at a Tertiary Care Hospital in India;** A. Jindal¹, V. Rahulan¹, S. Attawar², G. Balasubramani³, P. Dutta¹. ¹Pulmonary, Critical Care & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, ²Cardiac Sciences, Heart & Lung Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India, ³Cardio-Thoracic Organ Transplant, Gleneagles Global Health City, Chennai, Tamil Nadu, India

MECHANICAL CIRCULATORY SUPPORT
(Euterpe)

Poster Discussants: Pavan Atluri (USA), Katherine Fan (Hong Kong), Doug Horstmanshof (USA), Michael Kiernan (USA), Robert Kormos (USA), Sangjin Lee (USA), H. Todd Massey (USA), Christopher Salerno (USA), Thomas Schlöglhofer (Austria), Garrick Stewart (USA), Andre Vincentelli (France)

(933) Clinical Experience With Argatroban as a Therapeutic Option for LVAD Associated Device Thrombosis; M. J. Ruiz-Cano, V. Lauenroth, E. Prashovikj, E. Ljajikj, M. Schoenbrodt, J. Boergemann, L. Paluszkiwicz, J. Gummert, M. Morschuis. *Thorax- und Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Bad Oeynhausen, Germany*

(934) A Novel Predictive Risk Score for Gastrointestinal Bleed Following Implantation of Continuous Flow Left Ventricular Assist Device; M. Yin¹, S. Ruckel¹, S. McKellar², A. Elmer¹, A. Koliopoulou², L. Dranow¹, J. Harry¹, E. Davis¹, E. Gilbert¹, J. Nativi-Nicolau¹, J. Stehlik¹, B. Reid³, J. Fang¹, S. Drakos¹, A. Kfoury³, C. Selzman², O. Wever-Pinzon¹. ¹Cardiology, University of Utah School of Medicine, Salt Lake City, UT, ²Cardiothoracic Surgery, University of Utah School of Medicine, Salt Lake City, UT, ³Intermountain Healthcare, Salt Lake City, UT

(935) Are Elevated Serum Hemolysis Markers a Harbinger of Thromboembolic Events in Heartmate II Patients?; R. Zayat¹, M. A. Khattab¹, U. Ahmad¹, C. Stoppe², L. Tewarie¹, A. Moza¹, A. Goetzenich¹, R. Autschbach¹. ¹Dept of Thoracic and Cardiovascular Surgery, RWTH University Hospital, Aachen, Germany, ²Dept of Intensive Care Medicine, RWTH University Hospital, Aachen, Germany

(936) Fibroblast Growth Factor 23 is a Strong Predictor of Right Ventricular Failure and Postoperative Complications After LVAD Implantation: A Pilot Study; R. Zayat, A. Moza, S. Kraemer, C. Beckers, U. Ahmad, C. Stoppe, R. Autschbach, A. Goetzenich. *Dept of Thoracic & Cardiovascular Surgery, RWTH Univ Hosp, Aachen, Germany*

(937) Platelet Function, von Willebrand Factor and Hemocompatibility-related Adverse Events in Heartmate 3 and Heartmate II Patients: A Propensity Score Matched Study; R. Zayat¹, A. Goetzenich¹, O. Grottke², C. Stoppe³, U. Ahmad¹, M. A. Khattab¹, L. Tewarie¹, A. Moza¹, R. Autschbach¹. ¹Dept of Thoracic and Cardiovascular Surgery, RWTH University Hospital, Aachen, Germany, ²Dept of Anesthesiology, RWTH University Hospital, Aachen, Germany, ³Dept of Intensive Care Medicine, RWTH University Hospital, Aachen, Germany

(938) Predictors for Left Ventricular Assist Device Thrombosis; S. Shore¹, M. Soni², A. Hilbman¹, P. Patel³, J. A. Mazurek¹, C. Justice¹, D. Guarracino¹, M. Molina⁴, J. Wald¹, P. Atluri⁴, C. Bermudez⁴, A. Fox¹, M. Tanna¹, L. R. Goldberg¹, J. Rame¹, E. Y. Birati¹. ¹Cardiology, University of Pennsylvania, Philadelphia, PA, ²Internal Medicine, University of Pennsylvania, Philadelphia, PA, ³School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA

(939) Pump Exchange after Left Ventricular Assist Device Implantation: Indications and Outcomes; S. Shore, M. Soni, A. Hilbman, P. Patel, J. A. Mazurek, C. Justice, A. Fox, M. Tanna, M. Molina, J. Wald, P. Atluri, C. Bermudez, L. R. Goldberg, J. Rame, E. Y. Birati. *Cardiology, University of Pennsylvania, Philadelphia, PA*

(940) Prognostic Significance of Red Cell Distribution Width in Patients with Left Ventricular Assist Devices; R. Butler, S. Shore, A. Hilbmann, J. Mazurek, C. Justice, J. Wald, P. Atluri, L. R. Goldberg, J. E. Rame, E. Y. Birati. *Internal Medicine, University of Pennsylvania, Philadelphia, PA*

(941) Clinical Experience and Outcomes of HeartMate II to HeartWare Left Ventricular Assist Device Exchange: A Multicenter Experience of 24 Cases; R. Agarwal¹, A. Kyvernitakis², B. Soleimani³, C. A. Milano⁴, J. Kennedy⁵, R. L. Benza¹, S. Murali¹, S. H. Bailey⁶. ¹Cardiovascular Disease, Allegheny General Hospital, Pittsburgh, PA, ²Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, ³Cardiothoracic Surgery, Penn State Hershey Heart and Vascular Institute, Hershey, PA, ⁴Cardiothoracic Surgery, Duke Univ Medical Center, Durham, NC, ⁵Cardiovascular Disease, Univ of Virginia Health System, Charlottesville, VA, ⁶Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, PA

(942) Age-Related Risk of Adverse Events after Left Ventricular Assist Device Implantation: A Device-Specific Comparison; S. Poddi¹, V. Tchantchaleishvili¹, R. C. Daly¹, S. M. Dunlay², S. Maltais¹, J. M. Stulak¹. ¹Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ²Cardiovascular Diseases, Mayo Clinic, Rochester, MN

(943) Implication of Pre-Operative Pulmonary Function Testing on Gastrointestinal Bleeding After Continuous Flow LVAD; W. Askar¹, M. Rappelt¹, R. Pedersen², N. Sulemanjee², T. Hastings², O. Cheema², E. Roberts², F. X. Downey³, J. Crouch³, V. Thohan². ¹Aurora Research Institute, Aurora Health Care, Milwaukee, WI, ²Tendick Clinic for Advanced Heart Failure Therapies, Aurora St. Luke's Medical Center, Milwaukee, WI, ³Aurora Cardiovascular Surgical Services, Aurora St. Luke's Medical Center, Milwaukee, WI

(944) Length of Time on Left Ventricular Assist Device Prior to Heart Transplant: Does it Affect Outcome?; A. Nikolova, J. Patel, M. Kittleson, L. Czer, R. Levine, S. Dimbil, D. H. Chang, E. Kransdorf, J. Chung, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(945) WITHDRAWN

(946) Incidence of Early and Late Pump Thrombosis on HeartMate II LVAD Support; J. Schultz¹, A. K. Ho², R. John³, K. Goodwin⁴, A. Kluis⁵, M. Pritzker², E. Missov², K. Liao³, R. Cogswell². ¹Dept of Medicine, University of Minnesota, Minneapolis, MN, ²Dept of Cardiology, University of Minnesota, Minneapolis, MN, ³Dept of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, ⁴Dept of Surgery, University of Minnesota, Minneapolis, MN, ⁵University of Minnesota Medical School, University of Minnesota, Minneapolis, MN

(947) WITHDRAWN

(948) Early Postoperative Heparinization is Crucial for Prevention of Cerebral Vascular Accident in Patients with HeartMate II; Y. Matsumoto, T. Fujita, S. Fukushima, Y. Shimahara, Y. Kume, K. Yamashita, N. Kawamoto, J. Kobayashi. Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

(949) Impact of Late Aortic Regurgitation in Patients with HeartMate II; Y. Matsumoto, T. Fujita, S. Fukushima, Y. Shimahara, Y. Kume, K. Yamashita, N. Kawamoto, J. Kobayashi. Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

(950) A Novel Risk Model to Predict Right Ventricular Failure after Continuous Flow Left Ventricular Assist Device Implantation; A. Loforte¹, A. Montalto², F. Musumeci², C. Mariani¹, V. Polizzi², P. Lilla Della Monica², F. Grigioni¹, G. Marinelli¹. ¹Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, ²Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy

(951) Hemocompatibility Related Adverse Events and Competitive Outcomes of Different Generation of Left Ventricular Assist Devices; A. Loforte¹, A. Montalto², C. Mariani¹, V. Polizzi², M. Masetti¹, P. Lilla Della Monica², F. Grigioni¹, G. Marinelli¹, F. Musumeci². ¹Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, ²Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy

(952) Results of Unplanned Right Ventricular Assist Device for Severe Right Ventricular Failure after Continuous Flow Left Ventricular Assist Device Insertion; A. Loforte¹, A. Montalto², C. Mariani¹, S. Martin Suarez¹, E. Pilato¹, P. Lilla Della Monica², F. Grigioni¹, G. Marinelli¹, F. Musumeci². ¹Cardiovascular Surgery and Transplantation, S. Orsola Hospital, Bologna University, Bologna, Italy, ²Cardiac Surgery and Transplantation, S. Camillo Hospital, Rome, Italy

(953) Durability of Medical Therapy for Heartware LVAD Thrombosis; J. W. Wald¹, C. Justice², D. Guarracino², J. Marble², E. Lavery-Wilson², E. Birati³, C. Bermudez², P. Atluri⁴, M. Acker², E. Rame³. ¹Univ of Pennsylvania Hospital, Philadelphia, PA, ²Cardiothoracic Surgery, Univ of Pennsylvania Hospital, Philadelphia, PA, ³Cardiology, Univ of Pennsylvania Hospital, Philadelphia, PA, ⁴Cardiothoracic Surgery, Univ of Pennsylvania Hospital, Philadelphia, PA

(954) Utility of Hypercoagulable Work-Up in Predicting Post-Operative Complications in Total Artificial Heart (TAH) Implant Patients; L. S. Czer¹, B. Coleman², L. D. Lam³, M. Pollack⁴, D. Collier⁴, R. Lee⁴, D. Mochizuki⁴, L. S. Czer¹, J. Moriguchi¹, J. A. Kobashigawa¹, F. A. Arabia⁵. ¹Cedars Sinai Heart Inst, Cedars Sinai Med Ctr, Los Angeles, CA, ²Biomedical Sciences and Medicine, Cedars Sinai Med Ctr, Los Angeles, CA, ³Cedars Sinai Comprehensive Transplant Center, Cedars Sinai Med Ctr, Los Angeles, CA, ⁴UCSF School of Pharmacy, San Francisco, CA, ⁵CSHI Center for Surgical Device Management of Advanced Heart Disease, Cedars Sinai Med Ctr, Los Angeles, CA

(955) Low Serum TNF- α in a European Cohort Implanted with the HeartMate3 Left Ventricular Assist Device; I. Netuka¹, G. Kim², P. Ivák¹, Z. Tucanova¹, G. Sayer², J. Raikhelkar², S. Kalantari², N. Sarswat², N. Uriel². ¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²University of Chicago, Chicago, IL

(956) Management of Anticoagulation in Patients with LVAD Undergoing Elective Invasive Procedures or Surgeries; M. Guglin, S. Bond, A. Hart. *University of Kentucky, Lexington, KY*

(957) Pump Thrombosis in HeartWare HVAD Left Ventricular Assist Devices: Single Center Experience; E. Demir¹, S. Nalbantgil¹, P. Öztürk², C. Sahutoglu³, Ç. Engin², T. Yagdi², M. Özbaran². ¹Cardiology, Ege University Medicine Faculty, İzmir, Turkey, ²Cardiovascular Surgery, Ege University Medicine Faculty, İzmir, Turkey, ³Anesthesiology, Ege University Medicine Faculty, İzmir, Turkey

(958) Pulmonary Artery Pulsatility Index Predicts Right Ventricular Failure Post-LVAD Implantation in Ischemic Cardiomyopathy; S. Kumar¹, J. S. Josephs¹, K. Kumar², O. Saeed³, S. Patel³, S. Murthy³, J. J. Shin³, S. Forest⁴, D. J. Goldstein⁴, U. P. Jorde³, D. B. Sims³. ¹Dept of Medicine, Montefiore Medical Center (Moses/Weiler Division), Bronx, NY, ²Dept of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL, ³Division of Cardiology, Montefiore Medical Center (Moses/Weiler Division), Bronx, NY, ⁴Division of Cardiothoracic Surgery, Montefiore Medical Center (Moses/Weiler Division), Bronx, NY

(959) Optimizing Hemodynamics Does Not Improve the Pulmonary Artery Pulsatility Index's Post-LVAD Right Ventricular Failure Predictive Value; S. Kumar¹, S. A. Smith², J. S. Josephs¹, K. Kumar³, S. Murthy⁴, S. Patel⁴, O. Saeed⁴, J. J. Shin⁴, S. Forest⁵, D. J. Goldstein⁵, U. P. Jorde⁴, D. B. Sims⁴. ¹Dept of Medicine, Montefiore Medical Center (Moses/Weiler Division), New York, NY, ²Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ³Dept of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL, ⁴Division of Cardiology, Montefiore Medical Center (Moses/Weiler Division), New York, NY, ⁵Division of Cardiothoracic Surgery, Montefiore Medical Center (Moses/Weiler Division), New York, NY

(960) Trends in Utilization, Mortality, and Major Complications After Left Ventricular Assist Device Implantation in the United States (2009-2014); A. Briasoulis, E. Akintoye, P. Alvarez, C. Inampudi, J. Bhama. *Cardiovascular Diseases, University of Iowa, Iowa City, IA*

(961) Temporal Relationship of Early versus Late Right Heart Failure in Patients with Continuous Flow LVADs; W. F. Stendardi¹, O. O. Braun², M. Brambatti², V. Pretorius³, P. Kim², H. Tran², B. Greenberg², E. Adler², J. Silva Enciso². ¹Medicine, UCSD, San Diego, CA, ²Cardiology, UCSD, San Diego, CA, ³Surgery, UCSD, San Diego, CA

(962) Predictors for Early and Late Right Heart Failure After Left Ventricular Assist Device Implantation; W. F. Stendardi¹, O. O. Braun², M. Brambatti², P. Kim², V. Pretorius³, H. Tran², B. Greenberg², E. Adler², J. Silva Enciso². ¹Medicine, UCSD, San Diego, CA, ²Cardiology, UCSD, San Diego, CA, ³Surgery, UCSD, San Diego, CA

(963) Impact of Continuous Flow Left Ventricular Assist Device on Graft Rejection and Donor-specific Antibodies Development After Heart Transplant; M. Carrozzini, J. Bejko, M. Comisso, F. Toto, G. Toscano, V. Tarzia, A. Gambino, E. Cozzi, D. Gregori, T. Bottio, G. Gerosa. *Cardiac, Thoracic and Vascular Sciences, University of Padova, Cardiac Surgery Unit, Padova, Italy*

(964) Administration of Beta-Blockers Early After LVAD Implantation is Not Associated with Early Right Ventricular Failure or Increased Mortality; M. H. Derbala¹, B. Lee¹, M. Alghothani¹, A. McDavid², B. Lampert¹, B. Whitson², R. Hasson², S. Emani¹, A. Hasan¹, A. Kilic², M. Donneyong³, S. A. Smith¹. ¹Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ²Dept of Cardiothoracic Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University College of Pharmacy, Columbus, OH

(965) Predictors of Respiratory Failure in Patients Supported with Continuous Flow Ventricular Assist Devices and the Effect on Survival; F. Sagebin¹, B. Ayers¹, B. Barrus¹, S. Prasad¹, H. Vidula², E. Storzynsky², S. Thomas², L. Chen², J. Alexis², I. Gosev¹. ¹Division of Cardiac Surgery, University of Rochester, Rochester, NY, ²Division of Cardiology, University of Rochester, Rochester, NY

(966) Results of Concomitant Percutaneous Temporary RVAD Support Using the Cardiac Assist TandemHeart With ProtekDuo Cannula in LVAD Patients; B. Schmack¹, J. Kremer¹, A. Brcic², L. Grossekkettler³, R. Goldwasser¹, R. Arif¹, M. Farag¹, H. Schmidt¹, M. Kreusser³, P. W. Raake³, M. Karck¹, A. Ruhparwar¹. ¹Dept of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany, ²Dept of Anaesthesiology, University Hospital Heidelberg, Heidelberg, Germany, ³Dept of Cardiology, University Hospital Heidelberg, Heidelberg, Germany

(967) Impella 5.0 as a Bridge-To Bridge Option after Extracorporeal Life Support. Lessons Learned from the First 15 Cases; S. Zipfel¹, S. Hakmi¹, B. Reiter¹, M. J. Barten¹, M. Rybczinski², M. Kubik³, S. Kluge⁴, H. Reichenspurner¹, A. M. Bernhardt¹. ¹Dept of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, ²Dept of General and

Interventional Cardiology, Univ Heart Ctr Hamburg, Hamburg, Germany, ³Dept of Intensive Care, Univ Heart Ctr Hamburg, Hamburg, Germany, ⁴Dept of Intensive Care, University Hospital Hamburg-Eppendorf, Hamburg, Germany

(968) Hemodynamic Determinants of Decline in Renal Function During Left Ventricular Assist Device Support; A. Pinsino¹, A. Masoumi¹, J. Radhakrishnan¹, E. A. Royzman¹, M. Mabasa¹, F. Castagna², A. M. Zuver¹, M. Nasiri¹, A. R. Garan¹, V. K. Topkara¹, H. Takayama¹, K. Takeda¹, Y. Naka¹, R. T. Demmer³, P. C. Colombo¹, M. Yuzefpolskaya¹. ¹Columbia University, New York, NY, ²Columbia University, Yale Bridgeport Hospital, New York, NY, ³University of Minnesota, Columbia University, New York, NY

(969) Creatinine versus Cystatin C Based Equations for Estimation of Renal Function in Left Ventricular Assist Device Patients; A. Pinsino¹, A. Masoumi¹, J. Radhakrishnan¹, R. T. Demmer², E. A. Royzman¹, M. Mabasa¹, D. L. Brunjes¹, A. M. Clemons¹, B. Cagliostro¹, A. R. Garan¹, V. K. Topkara¹, K. Takeda¹, H. Takayama¹, N. Yoshifumi¹, P. C. Colombo¹, M. Yuzefpolskaya¹. ¹Columbia Univ, New York, NY, ²Univ of Minnesota, Columbia Univ, New York, NY

(970) LVAD versus BiVAD-mediated Allosensitization in Bridge-to-transplant Patients; A. Chaidaroglou¹, M. Bonios², A. Gkouziouta², E. Leontiadis², M. Pantou¹, P. Gourzi¹, A. Kapsalis¹, N. Kogerakis³, G. Stavridis³, S. Adamopoulos², D. Degiannis¹. ¹Molecular Immunopathology and Histocompatibility, Onassis Cardiac Surgery Center, Kallithea, Greece, ²Cardiology, Onassis Cardiac Surgery Center, Kallithea, Greece, ³Cardiothoracic Surgery, Onassis Cardiac Surgery Center, Kallithea, Greece

(971) The Ebb and Flow of Right Heart Failure in INTERMACS: Does Right Heart Failure Get Better or Worse Over Time?; J. Teuteberg¹, G. Studdard², F. Pagani³, M. Kiernan⁴, G. Oliveria⁵, E. Rame⁶, P. Alturi⁶, A. Gaffey⁶, E. Grandin⁷, J. Kirklin², S. Myers², C. Collum², R. L. Kormos⁸. ¹Stanford Univ, Stanford, CA, ²Univ of Alabama, Birmingham, Birmingham, AL, ³Univ of Michigan, Ann Arbor, MI, ⁴Tufts Univ, Boston, MA, ⁵Case Western Univ, Cleveland, OH, ⁶Univ of Pennsylvania, Philadelphia, PA, ⁷Beth Israel Deaconess, Boston, MA, ⁸Univ of Pittsburgh, Pittsburgh, PA

(972) Post-cardiotomy as indication comes with its own predictors of mortality in Venous Arterial Extra Corporal Life Support; A. G. Proudfoot¹, M. Leacche², N. K. Manandhar Shrestha¹, T. A. Timek², C. W. Villekes³, E. T. Murphy², J. S. Fanning², S. Jovinge², T. J. Boeve². ¹Fredrik Meijer Heart and Vascular Institute, Saint Bartholomew's Hospital, Grand Rapids, United Kingdom, ²Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI, ³Fredrik Meijer Heart and Vascular Institute, Saint Bartholomew's Hospital, Grand Rapids, MI

(973) Temporal Predictors of Late Right Heart Failure After LVAD Implantation; H. Vidula, S. McNitt, M. Wang, V. Kutyifa, I. Gosev, J. Alexis. Univ of Rochester, Rochester, NY

(974) Long-Term Impact of Multiple Comorbid Risk Factors on Survival After LVAD Implantation; H. Vidula, B. Johnson, R. Strawderman, D. Harrington, V. Kutyifa, I. Gosev, J. Alexis. Univ of Rochester, Rochester, NY

(975) Correlation of High Molecular Weight Von Willebrand Factor Multimer loss and Rotational Speed During Short Term Mechanical Circulatory Support; L. S. Czer¹, L. Lam¹, R. Hays¹, F. Baiesc¹, A. Kuo¹, S. Hariri¹, J. Moriguchi¹, F. Arabia¹, O. Volod². ¹Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ²Pathology, Cedars-Sinai Medical Center, Los Angeles, CA

(976) Cause of Death Among Bridge to Transplant and Destination Therapy LVAD Patients in a Large, Single Center Cohort; J. N. Schultz¹, R. John², C. Martin³, J. Misialek³, R. Cogswell³. ¹Dept of Medicine, University of Minnesota, Minneapolis, MN, ²Dept of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, ³Dept of Cardiology, University of Minnesota, Minneapolis, MN

(977) Atrial Fibrillation Increases Risk of Recurrent Heart Failure Readmissions in LVAD Patients; R. M. Wehbe¹, A. Tibrewala¹, A. S. Anderson¹, K. Ghafourian¹, I. Okwuosa¹, E. Vorovich¹, J. E. Wilcox¹, C. Yancy¹, D. T. Pham², J. D. Rich¹. ¹Division of Cardiology, Dept of Medicine, Northwestern University, Chicago, IL, ²Division of Cardiac Surgery, Dept of Surgery, Northwestern University, Chicago, IL

(978) Low Incidence of Right Heart Failure During Left Ventricular Assist Device Implantation; G. Faerber, H. Kirov, T. Sandhaus, T. Doenst. Univ Clinic Jena, Jena, Germany

(979) Predicting Acute and Chronic Right Ventricular Failure in Patients Undergoing Left Ventricular Assist Device Implant: The Importance of Right Atrial Strain and Regional Deformation of the Right Ventricular Free Wall; A. Iacovoni¹, D. Bellavia², C. Coronello², M. Simon³, C. Link³, C. Falletta², G. Romano², S. Sciacca², G. Di Gesaro², J. Maalouf⁴, M. Pilato², J. Gorcsan III⁵, A. Terzi¹, F. Clemenza². ¹ASST Papa Giovanni XXIII, Bergamo, Italy, ²ISMETT,

Palermo, Italy, ³Heart and Vascular Institute, Pittsburgh, PA, ⁴Dept of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN, ⁵Washington University, St Louis, MO

(980) Accurate Quantitative Evaluation of Aortic Insufficiency During LVAD Support by Thermodilution Analysis; D. Akiyama¹, T. Nishimura², K. Iizuka¹, T. Mizuno¹, T. Tsukiya¹, Y. Takewa¹, M. Ono³, E. Tatsumi¹. ¹Dept of Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ²Dept of Cardiovascular Surgery, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ³Dept of Cardiac Surgery, The Univ of Tokyo Hospital, Tokyo, Japan

(981) Pattern Discovery of Most Common Sequential Adverse Events after Left Ventricular Assist Device (LVAD) Implant; F. Movahedi¹, L. Lohmueller², L. Sees³, Y. Zhang⁴, M. Kanwar⁵, S. Murali⁵, R. Kormos³, R. Padman⁶, J. Antaki⁷. ¹Electrical Engineering Dept, Univ of Pittsburgh, Pittsburgh, PA, ²Bioengineering Engineering Dept, Univ of Pittsburgh, Pittsburgh, PA, ³Heart and Vascular Institute, Univ of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Weill Cornell Medicine, Cornell Univ, New York, NY, ⁵The Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA, ⁶Heinz College, Carnegie Mellon Univ, Pittsburgh, PA, ⁷Bioengineering Dept, Carnegie Mellon Univ, Pittsburgh, PA

(982) Barriers to Adherence with Early Postoperative Bridging Anticoagulation Protocols Following LVAS Implantation; K. A. Frankel¹, D. M. Nemer², J. Rimsans¹, K. W. Sylvester¹, E. N. Lyons¹, M. Pfeffer³, M. Puligandla⁴, D. S. Neuberger⁴, M. M. Givertz¹, J. M. Connors⁵, G. C. Stewart¹. ¹Brigham & Women's Hospital, Boston, MA, ²Cleveland Clinic Foundation, Cleveland, OH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Dana Farber Cancer Institute, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA

(983) Levosimendan Effects Benefit Weaning From Venous-Arterial Extracorporeal Life Support; S. Zipfel, B. Reiter, M. Barten, M. Rybczynski, B. Schrage, D. Westermann, S. Blankenberg, M. Kubik, S. Kluge, H. Reichenspurner, A. Bernhardt. Hamburg Heart Center, Hamburg, Germany

(984) Echocardiographic Evaluation of Right Ventricular Function during Ex Vivo Heart Perfusion; G. Ruggeri¹, R. Vanin Pinto Ribeiro², B. Gellner³, J. Qua Hiansen¹, M. Badiwala², M. Meineri¹. ¹Dept of Anesthesia, Toronto General Hosp, Univ Health Network, Toronto, ON, Canada, ²Dept of Cardiovascular Surgery, Toronto General Hosp, Univ Health Network, Toronto, ON, Canada, ³Dept of Mechanical & Industrial Engineering, Univ of Toronto, Toronto, ON, Canada

(985) The Obesity Paradox is Lost After LVAD Implant; A. S. Cruz-Solbes, D. Nguyen, E. Graviss, B. Trachtenberg, I. Hussain, A. Bhimaraj, G. Torre-Amione, M. Park, J. Estep, A. Guha. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(986) Impact of Severe Tricuspid Valve Insufficiency on the Performance of Left Ventricular Assist Device; N. Sadat¹, C. Torregroza¹, J. von der Beek², D. Scheiber³, I. J. Knorr², M. Sager², P. Akhyari¹, A. Lichtenberg¹, D. Saeed¹. ¹Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, ²Dept of Animal Research and Animal Protection Task, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, ³Cardiology, Angiology and Pulmology, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

(987) Gender Differences in Cardiac Reverse Remodeling in Mechanically Unloaded Hearts; S. Westhofen, A. Bernhardt, H. Reichenspurner, M. Barten. Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany

(988) Ten-year Experience With CentriMag Ventricular Assist Device Use in Acute Myocardial Infarction and Cardiogenic Shock; J. E. Sanchez, A. R. Garan, V. K. Topkara, J. Han, P. Kurlansky, M. Yuzefpolskaya, P. C. Colombo, Y. Naka, H. Takayama, K. Takeda. Columbia University College of Physicians & Surgeons, New York, NY

(989) Bariatric Surgery in Patients with Continuous Flow Left Ventricular Assist Devices; H. K. Lamba, A. Santiago, C. Kurihara, M. Kawabori, T. Sugiura, J. Eskew, A. Alnajar, F. H. Cheema, A. B. Civitello, R. Delgado, L. Simpson, A. P. Nair, T. K. Rosengart, O. Frazier, J. A. Morgan. Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX

(990) Impact of Hepatic Fibrosis on Outcomes in Patients Undergoing Continuous-Flow LVAD Implantation; H. K. Lamba, M. Kim, C. Kurihara, M. Kawabori, T. Sugiura, A. Alnajar, F. H. Cheema, A. B. Civitello, R. Civitello, L. Simpson, A. P. Nair, T. Rosengart, O. Frazier, J. A. Morgan. Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX

(991) Socioeconomic Disparities Do Not Impact Outcomes After Continuous Flow Left Ventricular Assist Device Implantation; H. K. Lamba, F. Rubio, A. Santiago, A. Alnajar, F. H. Cheema, A. Civitello, R. Delgado, L. Simpson, R. K. Ghanta, T. Rosengart, O. Frazier, J. A. Morgan, S. Chatterjee. Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX

(992) Outcomes of Continuous Flow Left Ventricular Assist Devices: A Single Institutional 18-Year Experience with Over 850 Devices; H. K. Lamba, F. H. Cheema, C. Kurihara, M. Kawabori, T. Sugiura, M. Ono, G. Loo, A. B. Civitello, A. Alnajar, R. Delgado, L. Simpson, A. Nair, S. Oberton, J. George, T. Rosengart, W. E. Cohn, O. Frazier, J. A. Morgan. *Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX*

(993) Use of Advanced Heart Failure Therapies in Duchenne Muscular Dystrophy; C. A. Wittlieb-Weber¹, C. R. Villa², J. Conway³, M. J. Bock⁴, K. E. Gambetta⁵, J. N. Johnson⁶, A. K. Lal⁷, K. R. Schumacher⁸, S. P. Law⁹, S. R. Deshpande¹⁰, S. C. West¹¹, J. M. Friedland-Little¹², I. D. Lytrivi¹³, M. A. McCulloch¹⁴, R. J. Butts¹⁵, D. R. Weber¹, K. R. Knecht¹⁶.
¹Pediatrics, Univ of Rochester Medical Center, Rochester, NY, ²Univ of Cincinnati, Cincinnati, OH, ³Univ of Alberta, Edmonton, AB, Canada, ⁴Loma Linda Univ Health, Loma Linda, CA, ⁵Northwestern Univ Feinberg School of Medicine, Chicago, IL, ⁶Mayo Clinic, Rochester, MN, ⁷Univ of Utah, Salt Lake City, UT, ⁸Univ of Michigan, Ann Arbor, MI, ⁹Columbia Univ Medical Center, New York, NY, ¹⁰Emory Univ School of Medicine, Atlanta, GA, ¹¹Univ of Pittsburgh School of Medicine, Pittsburgh, PA, ¹²Seattle Children's Hospital, Seattle, WA, ¹³Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁴Univ of Virginia Health System, Charlottesville, VA, ¹⁵Univ of Texas Southwestern Medical Center, Dallas, TX, ¹⁶Univ of Arkansas for Medical Sciences, Little Rock, AR

(994) Endomyocardial Biopsy - A Source of Heartache; S. Zangwill¹, K. Stamm², S. Kindel³, D. Mahnke², M. Goetsch⁴, H. Liang⁴, E. Ziegler², A. Tomita-Mitchell⁵, M. E. Mitchell⁶. ¹Phoenix Children's Hosp, Phoenix, AZ, ²TAI Diagnostics, Wauwatosa, WI, ³Children's Hosp of Wisconsin, Milwaukee, WI, ⁴Med College of Wisconsin, Milwaukee, WI, ⁵Children's Hosp of Wisconsin/Med College of Wisconsin, Milwaukee, WI, ⁶Children's Hosp of Wisconsin, Milwaukee, WI

(995) Using Label-free Proteomics to Elucidate Affected Pathways in Pediatric Heart Transplant Rejection; S. R. Deshpande¹, T. Nguyen², A. K. Bhatia³, K. O. Maher¹, D. M. Duong⁴. ¹Pediatric Cardiology, Emory University, Children's Healthcare of Atlanta, Atlanta, GA, ²Emory University, Atlanta, GA, ³Pediatric Cardiology, Stanford University School of Medicine, Stanford, CA, ⁴Integrated Proteomics Core, Emory University, Atlanta, GA

(996) Duchenne Muscular Dystrophy-Related Acute Heart Failure: Multicenter Study of Hospitalizations and Outcomes; S. R. Deshpande¹, C. A. Wittlieb-Weber², K. E. Gambetta³, M. J. Bock⁴, A. K. Lal⁵, J. L. Conway⁶, C. R. Villa⁷, J. N. Johnson⁸, K. R. Schumacher⁹, S. C. West¹⁰, J. M. Friedland-Little¹¹, I. D. Lytrivi¹², M. A. McCulloch¹³, R. J. Butts¹⁴, K. R. Knecht¹⁵, S. Law¹⁶. ¹Pediatric Cardiology, Emory Univ, Children's Healthcare of Atlanta, Atlanta, GA, ²Pediatric Cardiology, Univ of Rochester Medical Center, Rochester, NY, ³Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Pediatric Cardiology, Loma Linda Univ, Loma Linda, CA, ⁵Pediatric Cardiology, Primary Children's Hospital, Univ of Utah, Salt Lake City, UT, ⁶Pediatric Cardiology, Stollery Children's Hospital, Univ of Alberta, Edmonton, AB, Canada, ⁷Pediatric Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Pediatric Cardiology, Mayo Clinic, Rochester, MN, ⁹Pediatric Cardiology, C.S. Mott Children's Hospital / Univ of Michigan, Ann Arbor, MI, ¹⁰Pediatric Cardiology, Univ of Pittsburgh, Pittsburgh, PA, ¹¹Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, ¹²Pediatric Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹³Pediatric Cardiology, Univ of Virginia, Charlottesville, VA, ¹⁴Pediatric Cardiology, UT Southwestern, Dallas, TX, ¹⁵Pediatric Cardiology, Univ of Arkansas, Little Rock, AR, ¹⁶Pediatric Cardiology, Morgan Stanley Children's Hospital, Columbia Univ, New York, NY

(997) Evaluation of Prophylactic Valganciclovir for Cytomegalovirus (CMV) in Pediatric Heart Transplant Recipients; G. Nance¹, A. Serlucio¹, R. S. Liverman¹, M. S. Kelleman², S. R. Deshpande³. ¹Children's Healthcare of Atlanta, Atlanta, GA, ²Emory University, Atlanta, GA, ³Pediatric Cardiology, Emory University / Children's Healthcare of Atlanta, Atlanta, GA

(998) Dynamic Myocardial Response to Exercise in Children with Isolated Non-compaction of the Left Ventricular Myocardium; C. Chen¹, B. Cifra², C. Slorach², S. Fan², C. Manlhiot², B. W. McCrindle², A. Dragulescu², M. K. Friedberg², L. L. Mertens², A. N. Redington³. ¹Cardiology Service, Dept of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore, ²Division of Cardiology, Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Cardiology, Dept of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH

(999) Readmissions for Children Hospitalized with Heart Failure: Are Some Readmissions Preventable?; C. Knoll, J. Dykes, R. Shetty, E. Liu, D. Rosenthal, S. Chen, D. McElhinney, C. Almond. *Pediatric Cardiology, Lucile Packard Children's Hospital Stanford, Palo Alto, CA*

PEDIATRIC TRANSPLANTATION

(Agora 3)

Poster Discussants: Joshua Blatter (USA), Malcolm Brodlie (United Kingdom), Anne Dipchand (Canada), Samuel Goldfarb (USA), Mariska Kemna (USA), Ernestina Melicoff-Portillo (USA), David Morales (USA), Bart Rottier (Netherlands), Rakesh Singh (USA), Tajinder Singh (USA)

(1000) Use of Isosorbide Dinitrate/Hydralazine Combination in Pediatric Patients with Heart Failure; N. Musa¹, Y. Law², N. Richardson³, E. Albers¹, M. Kemna¹, J. Friedland-little¹, B. Hong¹, R. Mazor¹. ¹Dept of Pediatrics, Seattle Childrens Hospital/University of Washington, Seattle, WA, ²Dept of Pediatrics, Seattle Children's Hospital/ University of Washington, Seattle, WA, ³Seattle Children's Hospital, Seattle, WA

(1001) Utilization of Cardiac MRI in Patients with Duchenne Muscular Dystrophy: A Contemporary Multi-Center Cohort; S. C. West¹, C. A. Wittlieb-Weber², C. R. Villa³, C. Cunningham⁴, M. J. Bock⁵, K. E. Gambetta⁶, J. N. Johnson⁷, A. K. Lal⁸, K. R. Schumacher⁹, S. P. Law¹⁰, S. Deshpande¹¹, J. M. Friedland-Little¹², M. A. McCulloch¹³, R. J. Butts¹⁴, K. R. Knecht¹⁵, I. D. Lytrivi¹⁶. ¹Pediatric Cardiology, Children's Hosp of Pittsburgh, Pittsburgh, PA, ²Pediatric Cardiology, Univ of Rochester Medical Center, Rochester, NY, ³Pediatric Cardiology, Cincinnati Children's Hosp, Cincinnati, OH, ⁴Pediatric Cardiology, Stollery Children's Hosp, Edmonton, ON, Canada, ⁵Pediatric Cardiology, Loma Linda Univ Medical Center, Loma Linda, CA, ⁶Pediatric Cardiology, Ann and Robert H. Lurie Children's Hosp of Chicago, Chicago, IL, ⁷Pediatric Cardiology, Mayo Clinic, Rochester, MN, ⁸Pediatric Cardiology, Primary Children's Hosp, Salt Lake City, UT, ⁹Pediatric Cardiology, CS Mott Children's Hosp, Ann Arbor, MI, ¹⁰Pediatric Cardiology, New York-Presbyterian Morgan Stanley Children's Hosp, New York, NY, ¹¹Pediatric Cardiology, Children's Hosp of Atlanta, Atlanta, GA, ¹²Pediatric Cardiology, Seattle Children's Hosp, Seattle, WA, ¹³Pediatric Cardiology, Univ of Virginia Children's Hosp, Charlottesville, VA, ¹⁴Pediatric Cardiology, Univ of Texas Southwestern Children's Medical Center, Dallas, TX, ¹⁵Pediatric Cardiology, Arkansas Children's Hosp, Little Rock, AR, ¹⁶Pediatric Cardiology, Mount Sinai Kravis Children's Hosp, New York, NY

(1002) Echocardiographic Recovery of Function and Survival in Patients with Significant Cardiac Dysfunction from Anthracycline Induced Cardiomyopathy; A. M. Khan¹, A. R. Punnoose², T. Zielke³, N. DeMarais⁴, A. Kuang¹, J. Reichel¹, K. Gambetta¹, E. Pahl¹. ¹Ann and Robert H. Lurie Children's Hospital, Chicago, IL, ²Cardiology, Children's Hospital of Wisconsin, Milwaukee, WI, ³Carroll University, Waukesha, WI, ⁴Rosalind Franklin University of Medicine and Science, Chicago, IL

(1003) Risk Factors for Poor Outcomes in Children Hospitalized With Acute Decompensated Heart Failure; B. Hong¹, J. Friedland-Little¹, E. Albers¹, N. Jorgensen², R. Mazor³, N. Musa³, M. Kemna¹, Y. Law¹. ¹Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, ²Dept of Biostatistics, University of Washington, Seattle, WA, ³Pediatric Critical Care, Seattle Children's Hospital, Seattle, WA

(1004) Long-term Outcomes of Adult Survivors of Pediatric Heart Transplantation; B. Hong¹, N. Jorgensen², E. Albers¹, J. Friedland-Little¹, M. Kemna¹, Y. Law¹. ¹Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, ²Biostatistics, University of Washington, Seattle, WA

(1005) Time and Age Specific Nomogram for Post Transplant Hemodynamics in Children; M. F. Mills¹, J. Long², F. Qin², C. S. Almond¹, D. N. Rosenthal¹, S. Hollander¹. ¹Pediatric Cardiology, Stanford Children's Health - Lucile Packard Children's Hospital, Palo Alto, CA, ²Dept of Medicine, Quantitative Sciences Unit, Stanford University, Palo Alto, CA

(1006) WITHDRAWN

(1007) A New Prediction Model for Quantifying Mortality Risk in Congenital Heart Disease(CHD) Patients after Heart Transplant HTX); L. J. Burchill¹, B. Mueller², C. Fan², C. Manlhiot², H. J. Ross³, A. Alba³. ¹Knight Cardiovascular Institute Adult Congenital Heart Program, Oregon Health Science University, Portland, OR, ²CV Data Management Centre, Hospital for Sick Children, Toronto, ON, Canada, ³Ted Rogers Center of Excellence in Heart Function, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada

(1008) Pediatric Heart Transplantation: Transitioning to Adult Care TRANSIT; E. Pahl¹, A. Andrei², K. Vant Hof¹, M. Liu³, T. Shankel⁴, R. Chinnock⁴, S. Miyamoto⁵, A. V. Ambardekar⁶, A. Anderson², L. J. Addonizio⁷, F. Latif⁷, D. Lefkowitz⁸, L. Goldberg⁹, S. Hollander¹⁰, M. Pham¹⁰, J. Weissberg-Benchell¹¹, N. Cool¹², C. Yancy¹³, K. L. Grady¹³. ¹Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Cardiology, Northwestern Univ Feinberg School of Medicine, Chicago, IL, ³Cardiology, Bluhm Cardiovascular Institute, Chicago, IL, ⁴Cardiology, Loma Linda Univ, Loma Linda, CA, ⁵Pediatric Cardiology, Univ of Colorado, Denver, CO, ⁶Cardiology, Univ of Colorado, Denver, CO, ⁷Cardiology, Columbia Univ, New York, NY, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Univeristy of Pennsylvania, Philadelphia, PA, ¹⁰Stanford Univ, Palo Alto, CA, ¹¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹²Bluhm Cardiovascular Institute, Chicago, IL, ¹³Northwestern Univ Feinberg School of Medicine, Chicago, IL

(1009) Practice Variation in Detection of Coronary Allograft Vasculopathy (CAV) in Children: A Pediatric Heart Transplant Study; E. Pahl¹, D. Nandi², J. Vo³, K. Schumacher⁴, M. Fenton⁵, R. Singh⁶, K. Lin⁷, J. Conway⁸, E. Pruitt³, S. Dahl⁹, J. M. Lamour¹⁰, J. Kirklín³, C. Chin¹¹. ¹Cardiology, Ann & Robert H. Lurie Children's Hosp of Chicago, Northwestern, Chicago, IL, ²Cardiology, Nationwide Children's Hosp, Columbus, OH, ³Cardiology, Univ of Alabama at Birmingham, Birmingham, AL, ⁴Cardiology, Univ of Michigan, CS Mott Children's Hosp, Ann Arbor, MI, ⁵Cardiology, Great Ormond Street Hosp for Children, London, United Kingdom, ⁶Cardiology, UC San Diego, Rady Children's Hosp, San Diego, CA, ⁷Cardiology, Children's Hosp of Philadelphia, Philadelphia, PA, ⁸Cardiology, Univ of Alberta, Edmonton, AB, Canada, ⁹Cardiology, Mayo Clinic (MCR), Rochester, MN, ¹⁰Cardiology, Children's Hosp at Montefiore, Bronx, NY, ¹¹Cardiology, Cincinnati Children's Hosp Medical Center, Cincinnati, OH

(1010) Marijuana in Pediatric and Adult Congenital Heart Transplant Listing: A Survey of Provider Practices and Attitudes; K. A. Phillips¹, P. T. Thrush², A. K. Lal³, S. J. Kindel⁴, C. Castleberry⁵, J. Sparks⁶, K. P. Daly⁷, J. N. Johnson⁸. ¹Mayo Clinic School of Medicine, Rochester, MN, ²Lurie Children's Hospital of Colorado, Chicago, IL, ³Primary Children's Hospital/University of Utah, Salt Lake City, UT, ⁴Children's Hospital of Wisconsin, Milwaukee, WI, ⁵St Louis Children's Hospital, St. Louis, MO, ⁶Norton Children's Hospital, Louisville, KY, ⁷Boston Children's Hospital, Boston, MA, ⁸Mayo Clinic, Rochester, MN

(1011) Outcomes of Myocarditis in Patients with Normal Left Ventricular Systolic Function on Admission; S. B. Barfuss¹, S. R. Deshpande², R. J. Butts³, K. R. Knecht⁴, M. E. Richmond⁵, K. Gambetta⁶, A. K. Lal⁷. ¹Pediatrics, Primary Children's Hospital, University of Utah, Salt Lake City, UT, ²Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA, ³Pediatric Cardiology, Children's Health, UT Southwestern Medical Center, Dallas, TX, ⁴Pediatric Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Pediatric Cardiology, Columbia University Medical Center, New York, NY, ⁶Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Pediatric Cardiology, Primary Children's Hospital, University of Utah, Salt Lake City, UT

(1012) Advanced Parameters of Cardiac Function Out Perform Traditional Echocardiographic Indices in the Identification of Pediatric Patients with Acute Antibody-Mediated Cardiac Transplant Rejection; D. De Angelis, M. Chinali, A. Franceschini, C. Esposito, G. Calcagni, F. Parisi, G. Grutter. Bambino Gesù Children Hospital, Roma, Italy

(1013) Cerebrovascular Autoregulation is Altered During Pediatric cfVAD Support; J. A. Spinner¹, I. Adachi², K. Kibler¹, C. Rusin¹, S. Tume¹, E. Mossad¹, D. Andropoulos¹, B. Elias³, H. Tunuguntla¹, A. Cabrera¹, J. Price¹, S. Denfield¹, W. J. Dreyer¹, K. M. Brady¹. ¹Pediatrics, Baylor College of Medicine, Houston, TX, ²Surgery, Baylor College of Medicine, Houston, TX, ³Texas Children's Hospital, Houston, TX

(1014) High Burden of Diarrhea and Abdominal Pain After Pediatric Heart Transplantation; J. A. Spinner¹, W. J. Dreyer¹, A. G. Cabrera¹, H. Tunuguntla¹, C. Bocchini¹, S. Devaraj², J. Price¹, J. S. Heinle³, I. Adachi³, S. W. Denfield¹. ¹Pediatrics, Baylor College of Medicine, Houston, TX, ²Pathology & Immunology, Baylor College of Medicine, Houston, TX, ³Surgery, Baylor College of Medicine, Houston, TX

(1015) Cystatin C as a Marker of Renal Injury in Pediatric Heart Transplant Recipients; J. F. Goldberg¹, T. A. Street¹, X. Yu², J. Wang³, J. R. Strelsin¹, U. S. Boston⁴, J. A. Towbin¹. ¹Pediatric Cardiology, University of Tennessee School of Health Sciences, Memphis, TN, ²Epidemiology, University of Memphis, Memphis, TN, ³Preventative Medicine, University of Tennessee School of Health Sciences, Memphis, TN, ⁴Pediatric Cardiac Surgery, University of Tennessee School of Health Sciences, Memphis, TN

(1016) Rituximab for the Treatment of Refractory EBV Viremia and Prevention of PTLD in Pediatric Heart Transplant Recipients; M. J. Bock¹, C. Sierra², R. Tan³, T. Shankel⁴, S. Nayak⁴, J. Fitts⁵, R. E. Chinnock⁴. ¹Pediatric Cardiology, Loma Linda University Children's Hospital, Loma Linda, CA, ²Pharmacy, Loma Linda University Children's Hospital, Loma Linda, CA, ³Pharmacy, Loma Linda University Medical Center, Loma Linda, CA, ⁴Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA, ⁵Loma Linda University Transplant Institute, Loma Linda, CA

(1017) Donor-recipient Factors Influencing Early Antibody Mediated Rejection in Children; K. M. Molina, L. May, E. Griffiths, A. Eckhauser. *Univ of Utah Sch of Med, Salt Lake City, UT*

(1018) Center Variation in Listing Parameters Among US Pediatric Heart Transplant Programs; L. M. Barkoff¹, K. Maeda², D. N. Rosenthal³, Y. Zhang⁴, S. A. Hollander³, J. C. Dykes³, S. Chen³, N. A. McDonald¹, S. J. Wilkens³, C. S. Almond³. ¹*Lucile Packard Children's Hospital, Palo Alto, CA*, ²*Dept of Cardiothoracic Surgery, Stanford University, Palo Alto, CA*, ³*Dept of Pediatrics (Cardiology), Stanford University, Palo Alto, CA*, ⁴*Heart Center Clinical and Translational Research Unit, Stanford University, Palo Alto, CA*

(1019) Pediatric Heart Transplantation in Spain. Data From the National Registry; L. G. Guereta¹, M. Camino², M. Tejero³, D. Albert⁴, S. Marcos⁵, A. Cano⁶. ¹*Hospital Universitario De La Paz, Madrid, Spain*, ²*Hospital Universitario Gregorio Marañón, Madrid, Spain*, ³*Pediatric Cardiology, Hospital Universitario Reina Sofía, Cordoba, Spain*, ⁴*Pediatric cardiology, Hospital Vall d'Hebron, Barcelona, Spain*, ⁵*pediatric Cardiology, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain*, ⁶*Pediatric Cardiology, Hospital Universitari i Politècnic La Fe, Valencia, Spain*

(1020) Duration of ECMO Support Predicts Survival in Transplant Patients; J. Grijalva¹, B. Keeshan¹, J. Dentel², J. Chen¹, D. McMullan¹. ¹*Seattle Children's Hospital, Seattle, WA*, ²*Surgery, Seattle Children's Hospital, Seattle, WA*

(1021) The Utility of Right Atrial Strain to Evaluate for Transplant Co-morbidities in Pediatric Heart Transplant Recipients; K. Watanabe¹, M. Schäfer², C. Cassidy¹, S. D. Miyamoto¹, P. Jone¹. ¹*School of Medicine, University of Colorado, Aurora, CO*, ²*Dept of Bioengineering, University of Colorado, Aurora, CO*

(1022) Post-transplant Mortality and the Components of Donor Organ Ischemic Time in Pediatric Heart Transplantation; R. R. Davies¹, T. J. Pirolli¹, M. Bano², R. J. Butts², D. L. Sutcliffe², R. Kirk², R. D. Jaquiss¹. ¹*Pediatric Cardiothoracic Surgery, UT Southwestern - Children's Health Dallas, Dallas, TX*, ²*Pediatric Cardiology, UT Southwestern - Children's Health Dallas, Dallas, TX*

(1023) When Critically Ill: Broaden Your Horizons for Acceptable Weight; K. W. Riggs¹, R. Rizwan¹, C. M. Giannini², A. Lorts³, C. Chin³, R. Bryant III¹, D. L. Morales¹, F. Zafar¹. ¹*Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH*, ²*Univ of Cincinnati, Cincinnati, OH*, ³*Pediatric Cardiology, Cincinnati Children's Hospital, Cincinnati, OH*

(1024) The Effect of Inflammation and Severity of Cardiac Allograft Vasculopathy on Coronary Artery Distensibility After Paediatric Heart Transplantation; S. A. Rosen¹, M. Burch², M. Fenton². ¹*University College London, London, United Kingdom*, ²*Great Ormond Street Hospital, London, United Kingdom*

(1025) Center Variation in Indication and Survival after Pediatric Heart Transplantation: Analysis of a Merged UNOS-PHIS Cohort; M. J. O'Connor, H. Griffis, D. Dai, Y. Li, J. W. Rossano, K. Y. Lin, D. Burstein, B. Fisher, K. Getz, Y. Huang, R. Aplenc. *The Children's Hospital of Philadelphia, Philadelphia, PA*

(1026) The Use of Virtual Heart Transplantation Will Allow for a Broader Donor Pool in Pediatric Heart Transplantation for Dilated Cardiomyopathy; N. Szugye¹, A. Lorts¹, M. Taylor¹, F. Zafar², D. Morales², R. Bryant III², J. Broderick¹, R. Moore¹. ¹*Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*, ²*Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

(1027) Supplemental Use of Blood Cardioplegia Before Graft Implantation in Pediatric Heart Transplantation; M. Ramaswamy¹, A. Beeman¹, S. Henwood¹, A. Hawkyard¹, A. Robertson¹, D. Ridout², A. Walker², R. Patel², J. Simmonds¹, N. Muthialu¹. ¹*Great Ormond Street Hospital for Children, London, United Kingdom*, ²*University College London, London, United Kingdom*

(1028) Early Changes in Donor Fraction Cell-free DNA in Newly Transplanted Pediatric Heart Transplant Patients; S. Kindel¹, W. Ragalie², S. Zangwill³, R. Katz⁴, A. Tomita-Mitchell⁵, K. Stamm⁶, M. E. Mitchell⁷. ¹*Cardiology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI*, ²*Surgery, Medical College of Wisconsin, Milwaukee, WI*, ³*Cardiology, Phoenix Children's Hospital, Phoenix, AZ*, ⁴*University of Washington, Seattle, WA*, ⁵*Medical College of Wisconsin, Milwaukee, WI*, ⁶*TAI Diagnostics, Wauwatosa, WI*, ⁷*Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI*

(1029) Pretransplant Amiodarone Use and Post-transplant Outcomes in Pediatric Heart Transplant: A Propensity Score Analysis of the ISHLT Transplant Registry; R. Butts¹, A. Dipchand², D. Sutcliffe¹, M. Bano¹, R. Morrow³, R. Kirk¹. ¹*Pediatrics, University of Texas Southwestern, Dallas, TX*, ²*Pediatrics, SickKids Hospital of Toronto, Toronto, ON, Canada*, ³*Pediatrics, Children's Medical Center of Dallas, Dallas, TX*

(1030) Fifty Years of Pediatric Heart Transplantation - The First Successful Case and Results of the Early Era; C. R. Kirk¹, R. J. Butts¹, A. I. Dipchand². ¹Heart Center, UTSW Medical, Dallas, TX, ²Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

(1031) Preoperative Use of Amiodarone is Associated With Perioperative Morbidity, But Not Mortality in Pediatric Heart Transplant Recipients; S. M. Amdani¹, A. Dalal¹, K. Simpson¹, J. Scheel¹, P. Eghtesady², A. Abarbanell², C. Canter¹, C. Castleberry¹. ¹Pediatric Cardiology, St. Louis Children's Hospital, St. Louis, MO, ²Pediatric Cardiothoracic Surgery, St. Louis Children's Hospital, St. Louis, MO

(1032) The Outcome of Cardiac Transplantation in Patients With Down Syndrome; E. Khoshbin¹, Z. Reinhardt², R. Kirk³, G. Parry⁴, S. Schueler¹, A. Hasan¹. ¹Dept of Cardiac Surgery and Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ²Dept of Paediatric Cardiology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ³Dept of Paediatric Cardiology, Childrens Medical Centre, Dallas, TX, ⁴Dept of Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

(1033) Comparing Outcomes and Resource Utilization Among Pediatric Heart Transplant Indications Using a Novel, Merged Data Set from the United Network for Organ Sharing and the Pediatric Health Information System (UNOS-PHIS) Databases; D. Burstein¹, Y. Li², K. Getz³, Y. Huang⁴, J. W. Rossano¹, M. J. O'Connor¹, K. Y. Lin¹, R. Aplenc¹. ¹Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Biostatistics, Epidemiology, and Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Healthcare Analytics Unit, Children's Hospital of Philadelphia, Philadelphia, PA

(1034) Exercise Training in Pediatric Ventricular Assist Device Recipients; D. S. Burstein, M. McBride, J. W. Rossano, M. J. O'Connor, K. Y. Lin, S. M. Paridon. Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA

(1035) Description of Longitudinal Measurement of Donor Fraction of Cell-Free DNA Following Rejection Treatment and Correlation to Clinical Outcomes; W. Ragalie¹, S. Kindell², S. Zangwill³, M. E. Mitchell⁴. ¹Surgery, Medical College of Wisconsin, Milwaukee, WI, ²Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ³Pediatrics, Pheonix Children's Hospital, Pheonix, AZ, ⁴Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI

(1036) Pediatric Donor-Recipient Size Matching - Seeing is Believing, Or is it?; J. Plasencia¹, J. R. Ryan², D. Velez², K. Lagerstrom², J. J. Nigro³, T. Karamlou², Y. Kamarianakis¹, D. H. Frakes¹, S. G. Pophal², S. D. Zangwill². ¹Arizona State University, Tempe, AZ, ²Phoenix Children's Hospital, Phoenix, AZ, ³Rady Children's Hospital, San Diego, CA

(1037) Hybrid Stage 1 Palliation as a Bridge to Cardiac Transplantation in Patients With High Risk Single Ventricle Physiology; B. H. Marray¹, E. L. Albers¹, T. K. Jones¹, M. S. Kemna¹, L. C. Permut², Y. M. Law¹. ¹Pediatrics, Seattle Children's Hospital, Seattle, WA, ²Cardiothoracic Surgery, Seattle Children's Hospital, Seattle, WA

(1038) Narrative Review of Ethical Considerations in Pediatric Heart Transplantation; S. J. Wilkens¹, P. Smith², A. Patel³. ¹Pediatric Cardiology, Stanford Univ, Lucile Packard Children's Hospital, Palo Alto, CA, ²Northwestern Univ, Chicago, IL, ³Pediatric Cardiology, Northwestern Univ, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

(1039) Intellectual Disability and Pediatric Lung Transplantation; A. Iyengar¹, A. Goel¹, M. Caceres Polo², O. Kwon², C. Eisenring², R. Biniwale², E. DePasquale², A. Ardehali². ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of California - Los Angeles, Los Angeles, CA

(1040) Living-donor Lobar Lung Transplantation Outcomes in Pediatric Patients; S. Ueda, T. F. Chen-Yoshikawa, H. Kayawake, J. Tokuno, H. Yamagishi, F. Gochi, R. Okabe, M. Saito, A. Takahagi, D. Nakajima, H. Motoyama, M. Hamaji, A. Aoyama, H. Date. Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

(1041) Lung Transplantation in Children and Young Adults in Czech Republic: A Single Center Experience; T. Dousova¹, J. Havlin², L. Fila³, J. Kolařík², M. Svorcova², L. Valentova-Bartakova³, J. Pozniak², J. Simonek², R. Lischke². ¹Dept of Pediatric Pneumology, Motol University Hospital, Prague, Czech Republic, ²3rd Dept of Surgery, Lung and Thoracic Division, Motol University Hospital, Prague, Czech Republic, ³Dept of Pneumology, Motol University Hospital, Prague, Czech Republic

(1042) Hospital Costs for Pediatric Patients With Temporary Ventricular Assist Devices: A Multicenter Study From the Pediatric Interagency Registry for Mechanically Assisted Circulatory Support (Pedimacs) and the Pediatric Health Information System (PHIS); J. W. Rossano¹, R. S. Cantor², D. Dai¹, P. Shamszad¹, Y. Huang¹, M. Hall³, K. Y. Lin¹, M. Zinn⁴, E. Edens⁵, E. Parrino⁶, J. K. Kirklin². ¹Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Surgery, University of Alabama at Birmingham, Birmingham, AL, ³Children's Hospital Association, Lenexa, KS, ⁴Cardiology, Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁵Cardiology, University of Iowa, Iowa City, IA, ⁶Ochsner Medical Center, New Orleans, LA

(1043) Characteristics and Outcomes of Pediatric Patients Supported with Ventricular Assist Device - A Multi-institutional Analysis; K. Puri¹, J. C. Causey², S. C. Tume², B. S. Moffett³, M. Anders². ¹Cardiology, Texas Children's Hospital, Houston, TX, ²Critical Care Medicine, Texas Children's Hospital, Houston, TX, ³Pain Medicine, Texas Children's Hospital, Houston, TX

(1044) Iron Deficiency is Associated with Adverse Outcomes in Pediatric Heart Failure; K. Puri¹, J. A. Spinner¹, M. D. Shah², J. M. Powers², S. W. Denfield¹, A. G. Cabrera¹, H. P. Tunuguntla¹, W. J. Dreyer¹, J. F. Price¹. ¹Cardiology, Texas Children's Hospital, Houston, TX, ²Hematology-Oncology, Texas Children's Hospital, Houston, TX

(1045) BMI and Association with Outcomes in Pediatric Patients on Durable Ventricular Assist Device Support; K. Puri¹, A. Jimenez Gomez², I. Adachi³, S. W. Denfield¹, A. G. Cabrera¹, B. A. Elias³, J. F. Price¹, W. J. Dreyer¹, S. Choudhry¹, H. P. Tunuguntla¹. ¹Cardiology, Texas Children's Hospital, Houston, TX, ²Neurology, Texas Children's Hospital, Houston, TX, ³Congenital Heart Surgery, Texas Children's Hospital, Houston, TX

(1046) Mechanical Support in Children with Restrictive Left Ventricle - Single Centre Experience; A. Mahmood, M. Johnson, A. Khushnood, M. Burch, A. Karimova. Cardiothoracic Unit, Great Ormond Street Hospital for Children, London, United Kingdom

(1047) Quality Improvement for VA ECMO in Pediatric Hospitals- A 20-Year Analysis of Neonatal and Pediatric VA ECMO Complications in North America; A. Kiankhooy, W. H. Gray, C. J. Baker, S. R. Kumar, V. A. Starnes, A. E. Hackmann. Division of Cardiac Surgery, Dept of Surgery, Keck School of Medicine of University of Southern California; The Heart Institute, Children's Hospital of Los Angeles, Los Angeles, CA

(1048) Quality of Outpatient INR Control in Children Supported on a Ventricular Assist Device; J. Murray¹, S. Chen¹, J. Lee¹, J. Dykes¹, S. Wilkens¹, D. Rosenthal¹, A. Shin², C. S. Almond². ¹Lucile Packard Children's Hospital, Palo Alto, CA, ²Dept of Pediatrics Stanford University, Lucile Packard Children's Hospital Stanford, Palo Alto, CA

(1049) Ex vivo Effects of a Pediatric Extracorporeal Membrane Oxygenation (ECMO) Circuit on the Sequestration of Mycophenolate Mofetil and Tacrolimus; C. S. Heith¹, J. R. Hume², L. Hansen³, R. M. Bakken⁴, S. L. Ritter⁵, L. Zhang⁶, B. R. Long⁴, M. E. Steiner¹, G. A. Fischer¹. ¹Pediatric Critical Care, Univ of Minnesota, Minneapolis, MN, ²Pediatric Critical Care, Univ of Minnesota, Minneapolis, MN, ³Pharmacy, Univ of Minnesota, Minneapolis, MN, ⁴Cardiopulmonary and ECMO Services, Fairview- Univ Medical Center, Minneapolis, MN, ⁵Cardiopulmonary and ECMO Services, Univ of Minnesota Masonic Children's Hospital, Minneapolis, MN, ⁶Clinical Translational and Science Institute, Univ of Minnesota, Minneapolis, MN

(1050) Quantification and Distribution of Thrombus Burden in Berlin Heart Pumps; S. Shea¹, K. Spitzer², M. Carroll³, D. N. Ku⁴, S. R. Deshpande⁵. ¹Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ²Perfusion Services, Children's Healthcare of Atlanta, Atlanta, GA, ³VAD Program, Children's Healthcare of Atlanta, Atlanta, GA, ⁴Institute of Bioengineering and Biotechnology, Georgia Institute of Technology, Atlanta, GA, ⁵Pediatric Cardiology, Emory University / Children's Healthcare of Atlanta, Atlanta, GA

(1051) Early Implantation of Ventricular Assisted Devices (VADs) in Failing Single Ventricle Physiology Patients Can Lead to Better Outcomes in Pediatric Heart Transplantation; R. Shih, J. Phillips, M. Tsifansky, D. Machado, M. Ebraheem, G. Venkata, K. Sullivan, D. Gupta, K. Reyes, B. Pietra, F. J. Fricker, M. Bleiweis. Congenital Heart Center, University of Florida, Gainesville, FL

(1052) Is Low-rpm a Risk Factor for Pump Thrombosis in Pediatric Patients with HeartWare HVAD?; S. Kocabeyoglu¹, U. Kervan¹, D. Sert¹, E. Aygun¹, A. Pac², D. Eris², A. Temizhan³, U. Unal¹, M. Pac¹. ¹Cardiovascular Surgery, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ²Pediatric Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ³Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey

(1053) Survival and Neurological Outcome after Extracorporeal Cardiopulmonary Resuscitation in Children; P. Kramer, A. Mommsen, F. Berger, K. R. Schmitt. *Congenital Heart Disease, Deutsches Herzzentrum Berlin, Berlin, Germany*

(1054) Long Term Results of Mechanical Circulatory Support as Bridge to Transplant in Severe Heart Failure Pediatric Patients; M. Taira, T. Ueno, T. Kido, T. Kanaya, N. Okuda, Y. Matsunaga, K. Toda, T. Kuratani, Y. Sawa. *Dept of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan*

(1055) Prolonged but Successful Weaning from Berlin Heart EXCOR After a Long-term Mechanical Unloading in Infantile DCM; J. Narita¹, S. Kogaki¹, S. Ishigaki¹, F. Torigoe¹, R. Ishii¹, H. Ishida¹, K. Ozono¹, M. Taira², T. Ueno², Y. Sawa². ¹*Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan*, ²*Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan*

(1056) Long-term Results of Berlin Heart EXCOR Pediatric Implantation in Japan; M. Ono¹, Y. Sawa², N. Fukushima³, H. Ichikawa⁴, M. Ueno², Y. Hirata¹, K. Sakamoto⁵, T. Suzuki⁶, Y. Kaneko⁷. ¹*Dept. of Cardiac Surg., Univ. of Tokyo Hospital, Tokyo, Japan*, ²*Dept. of Cardiovascular Surg., Osaka Univ. Hospital, Osaka, Japan*, ³*Dept. of Organ Transplantation, National Cerebral and Cardiovascular Research Center, Osaka, Japan*, ⁴*Dept. of Pediatric Cardiac Surg., National Cerebral and Cardiovascular Research Center, Osaka, Japan*, ⁵*Dept. of Cardiovascular Surg., Mt. Fuji Shizuoka Children's Hospital, Shizuoka, Japan*, ⁶*Dept. of Pediatric Cardiac Surg., Saitama International Medical Center, Saitama, Japan*, ⁷*Division of Cardiovascular Surg., National Medical Center for Children and Mothers, Tokyo, Japan*

(1057) Intra-corporeal Biventricular Assist Devices Using the HVAD in Children; M. Schweiger¹, C. Mascio², K. Kanter³, S. Marasco⁴, P. Eghtesady⁵, M. Hübler¹, M. Kavarana⁶. ¹*Dept of Congenital Pediatric Surgery, Children's Hospital Zurich, Zurich, Switzerland*, ²*Pediatric Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA*, ³*Emory University School of Medicine, Children's Healthcare of Atlanta Pediatric Cardiac Surgery, Atlanta, GA*, ⁴*Cardiothoracic Surgical Unit, The Alfred, Melbourne, Australia*, ⁵*Pediatric Cardiothoracic Surgery, Washington University in St. Louis and St. Louis Children's Hospital, St. Louis, MO*, ⁶*Division of Pediatric Cardiothoracic Surgery, Charleston, SC*

FRIDAY, APRIL 13

6:15 PM - 7:15 PM
POSTER SESSION 3

HEART TRANSPLANTATION
(Muses)

Poster Discussants: Alexander Bernhardt (Germany), Eric Epailly (France), Marta Farrero Torres (Spain), Livia Goldraich (Brazil), Manon Huibers (Netherlands), Jama Jahanyar (USA), Nandkishore Kapadia (India), Ivan Knezevic (Slovenia), Jose Luis Lambert (Spain), Clive Lewis (United Kingdom), Javier Segovia (Spain), Jorge Silva Enciso (USA)

(1058) Hemodynamic and Functional Analysis of Human DCD Hearts Undergoing Normothermic Ex Vivo Perfusion; W. Sommer, N. Roy, S. E. Kilmarx, J. M. O, J. S. Titus, M. Villavicencio, J. R. Stone, J. C. Madsen, D. A. D'Alessandro. *Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA*

(1059) Heart Preservation With the Organ Care System in Germany - Revival in High Risk Recipients; F. Ius¹, M. Berchtold-Herz², S. V. Rojas¹, T. Kaufeld¹, J. Scheumann², M. Avsar¹, J. Salman¹, C. Bara¹, F. Beyersdorf², A. Haverich¹, M. Siepe², G. Warnecke¹. ¹*Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany*, ²*Thoracic and Cardiovascular Surgery, University of Freiburg, Freiburg, Germany*

(1060) Does Ex Vivo Perfusion Lead to More or Less Intimal Thickening in the First-year Post-Heart Transplantation?; T. Sato¹, B. Azarbal¹, R. Cheng¹, F. Esmailian¹, J. Patel¹, M. Kittleson¹, L. Czer¹, R. Levine¹, S. Dimbil¹, T. Khayal², J. A. Kobashigawa¹. ¹*Cedars-Sinai Heart Institute, Los Angeles, CA*, ²*Transmedics, Andover, MA*

(1061) Combined Heart and Kidney Transplantation - Is There a Protective Effect Against Cardiac Allograft Vasculopathy Using Intravascular Ultrasound?; T. Sato, B. Azarbal, R. Cheng, M. Kittleson, J. Patel, L. Czer, R. Levine, S. Dimbil, T. Kao, E. Kransdorf, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(1062) Heart Transplantation Using the Normothermic Ex-Vivo Perfusion Device Organ Care System for Donor Heart Preservation - Long-term Outcomes; B. Fujita, A. Sievert, J. Sunavsky, J. Börgermann, U. Fuchs, J. Gummert, U. Schulz, S. Ensminger. *Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany*

(1063) Prevalence of Microvascular Cardiac Allograft Vasculopathy Following Heart Transplantation; K. J. Clerkin, J. H. Lee, S. W. Restaino, F. Latif, M. Yuzefpolskaya, P. C. Colombo, M. A. Farr, S. Bokhari. *Cardiology, Columbia University Medical Center, New York, NY*

(1064) Baseline and 1-year Follow-up Serial Optical Coherence Tomography Evaluation of Coronary Plaques in Heart Transplant Recipients; Y. Tsukamoto¹, T. Ohtani¹, T. Shiraki¹, Y. Ichibori¹, S. Saito², S. Hikoso¹, K. Toda², O. Yamaguchi¹, Y. Sawa², Y. Sakata¹. ¹*Dept of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan*, ²*Dept of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan*

(1065) Short Term Clinical Outcomes of Percutaneous Coronary Intervention in Heart Transplant Recipients in the US - Result from Largest Inpatient Registry (2005-2014); P. Patel¹, A. Kaneria¹, E. Koman², J. Hoosain², H. Patel³, F. Hasni², G. Ledley², A. Badheka⁴, S. Hankins², H. Eisen². ¹*Dept of Internal Medicine, Drexel University College of Medicine/Hahnemann University Hospital, Philadelphia, PA*, ²*Dept of Cardiology, Drexel University College of Medicine, Philadelphia, PA*, ³*Pramukhswami Medical College, Anand, India*, ⁴*Dept of Cardiology, The Everett Clinic, Everett, WA*

(1066) Variability of Gene Expression Profile Scores Does Not Predict Coronary Allograft Vasculopathy as Detected by Intravascular Ultrasound One Year Post Heart Transplant: The Mid America Experience; S. R. Beauchamp¹, K. F. Kennedy², H. Brandt², D. M. Safley², B. A. Austin³, M. P. Everley³, T. M. Khumri³, S. L. Lawhorn³, A. Magalski³, B. W. Sperry³, D. Vodnala³, A. M. Borkon⁴, K. R. Carl¹, G. Dryton¹, A. Kao³. ¹*Surgery, Saint Luke's Hospital, Kansas City, MO*, ²*Cardiology, Saint Luke's Hospital, Kansas City, MO*, ³*Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO*, ⁴*Surgery, Mid America Heart & Lung Surgeons, Kansas City, MO*

- (1067) Biomarker Discovery in Cardiac Allograft Vasculopathy: Novel Aptamer Proteomic and MicroRNA Profiling;** A. Almufleh¹, K. Rayner², L. Zhang³, L. Susser², L. Mielniczuk¹, E. Stadnick¹, R. Davies¹, P. Liu¹, S. Chih¹. ¹Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada, ²Cardiometabolic microRNA Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada, ³Cardiac Function Laboratory, University of Ottawa Heart Institute, Ottawa, ON, Canada
- (1068) The Presence of Microchannel in Optical Coherence Tomography is Associated With the Plaque Volume of Cardiac Allograft Vasculopathy After Heart Transplantation;** D. Nitta¹, K. Kinugawa², J. Yokota³, M. Endo⁴, M. Tsuji¹, A. Saito¹, S. Minatsuki¹, E. Amiya¹, M. Hatano⁵, M. Ono⁶, I. Komuro¹. ¹Dept of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan, ²Dept of Internal Medicine 2, The University of Toyama Hospital, Toyama, Japan, ³Dept of Medical Engineering, The University of Tokyo Hospital, Tokyo, Japan, ⁴Dept of Organ transplantation, The University of Tokyo Hospital, Tokyo, Japan, ⁵Dept of Therapeutic Strategy for Heart Failure, The University of Tokyo Hospital, Tokyo, Japan, ⁶Dept of Cardiothoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan
- (1069) Impact of Coronary Artery Calcification of the Donor Heart on Transmitted Coronary Artery Disease in Heart Transplant Recipients;** Y. Kimura¹, O. Seguchi¹, K. Iwasaki¹, K. Toda¹, N. Kikuchi¹, Y. Kumai¹, K. Kuroda¹, Y. Matsumoto², S. Fukushima², M. Yanase¹, T. Fujita², J. Kobayashi², N. Fukushima¹. ¹Dept of Transplantation, National Cerebral and Cardiovascular Centre, Osaka, Japan, ²Dept of Cardiovascular Surgery, National Cerebral and Cardiovascular Centre, Osaka, Japan
- (1070) To IVUS or Not for CAV? A Single Center Experience;** S. R. Krim, M. Hasan, M. F. Becnel, S. Mohareb, J. Grant, J. Biglane, S. Desai, S. Mandras, H. Patel, C. Eiswirth, H. O. Ventura. *Cardiology, 1514 Jefferson Highway, New Orleans, LA*
- (1071) Immunosuppression Impact in Heart Transplant Recipients with Chagas' Disease in the Development of Cardiac Allograft Vasculopathy Data of an Argentine Center;** M. A. Peradejordi, L. Favaloro, D. Absi, M. Lopez Rosetti, R. Ratto, M. F. Renedo, E. Giordanino, P. Morejon, R. R. Favaloro, A. Bertolotti. *Intrathoracic Transplantation and Heart Failure Division, Favaloro Foundation - University Hospital, Buenos Aires, Argentina*
- (1072) Pre-Transplant Neutrophil to Lymphocyte Ratio Predicts 30-day Readmission for Patients Undergoing Cardiac Transplantation;** N. Ahmed¹, Y. Kim¹, H. Gandhi¹, O. Saeed², S. Patel², S. Murthy², J. Shin², S. Forrester³, D. J. Goldstein³, U. P. Jorde², D. B. Sims². ¹Dept of Medicine, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, ²Division of Cardiology, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY, ³Division of Cardiothoracic Surgery, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, NY
- (1073) Precision Medicine for Tacrolimus Dosing in Heart Transplant Recipients;** Y. Yang, N. Sulejmani, A. Jantz, B. Summers, A. Dhanekula, C. Williams, H. Nemeh, D. Lanfear. *Henry Ford Hospital, Detroit, MI*
- (1074) The Effect of Everolimus vs Calcineurin Inhibitors on Left Ventricular Mass in De Novo Heart Transplant Recipients After 3 Years Follow-Up - Results From the Randomized Controlled SCHEDULE Trial;** K. Murbræch¹, R. Massey¹, K. Karason², F. Gustafsson³, H. Eiskjær⁴, G. Rådegran⁵, D. Solbu⁶, K. Broch¹, E. Gude¹, A. Andreassen¹, L. Gullestad¹. ¹Cardiology, Oslo Univ Hospital, Oslo, Norway, ²Cardiology, Sahlgrenska Univ Hospital, Gothenburg, Sweden, ³Cardiology, Copenhagen Univ Hospital, Copenhagen, Denmark, ⁴Cardiology, Skejby Univ Hospital, Aarhus, Denmark, ⁵Clinic for Heart Failure and Valvular Disease, Skåne Univ Hospital, Lund, Sweden, ⁶Novartis, Oslo, Norway
- (1075) Dynamic Phenomapping and HLA Class I and II Antibodies for Heart Transplant Outcomes;** M. Bakir¹, N. Jackson², S. Han², E. Chang¹, C. Tseng², T. Khuu¹, A. Bui², J. Zhang², E. Reed², M. Deng¹, M. Cadeiras¹. ¹Cardiology, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, CA
- (1076) Initial Experience with Bosentan for the Management of Pulmonary Hypertension after Heart Transplantation;** E. Santiago¹, M. Farrero¹, J. Ivey-Miranda², M. Castel¹, A. García-Álvarez¹, F. Perez-Villa¹. ¹Heart Failure and Heart Transplantation Program, Hospital Clínic, Barcelona, Spain, ²Hospital de Cardiología, Centro Médico Nacional Siglo XXI, Mexico city, Mexico
- (1077) Longitudinal Development in Left Ventricular Volume, Mass and Function in Heart Transplant Recipients - Results From the NOCTET Trial;** K. Broch, R. J. Massey, K. Murbræch, E. Gude, A. K. Andreassen, L. Gullestad. *Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway*
- (1078) Questioning the Tacrolimus Dogma: Does Early Dose Control Matter?;** W. L. Baker¹, S. Steiger², S. Martin², N. Patel², J. Radojevic², K. Darsaklis², L. O'Bara², H. Kutzler², J. Dougherty², A. Feingold², J. Hammond², D. Fusco², J. A. Gluck². ¹University of Connecticut, Storrs, CT, ²Hartford Hospital, Hartford, CT

- (1079) Increased Risk of Rejection Following Itraconazole vs Nebulised Amphotericin For Fungal Prophylaxis After Heart Transplant;** F. S. Burrows, L. Carlos, S. Rao, A. Jabbour, E. Kotlyar, A. Keogh, C. Hayward, P. Macdonald. *St. Vincent's Hospital, Sydney, Australia*
- (1080) Low-dose Prothrombin Complex Concentrates for Warfarin Reversal Prior to Heart Transplantation;** M. R. Wanek¹, K. Hodges², R. Persaud³, N. Moazami⁴. ¹Dept of Pharmacy, Cleveland Clinic, Cleveland, OH, ²Dept of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ³Dept of Pharmacy, Florida Hospitals, Orlando, FL, ⁴Dept of Cardiothoracic Surgery, New York University Langone Health, New York, NY
- (1081) Phosphodiesterase-type 5 Inhibition for Refractory Pre-capillary PH in Advanced Heart Failure is Associated with Increased Early Mortality Post Heart Transplant;** M. Ayers¹, K. A. Clark², J. A. Mazurek³, P. Zamani³, A. Fox³, R. Forde-McLean³, J. E. Rame³. ¹Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ²Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
- (1082) High Variability in Tacrolimus Trough Levels is Associated With Rejections After Heart Transplantation;** I. Gueta¹, N. Markovits¹, H. Bilavsky-Yarden¹, E. Raichlin², I. Mazin¹, D. Freimark¹, J. Lavee¹, R. Leobstein¹, Y. Peled¹. ¹Sheba Medical Center Tel Hashomer, Ramat Gan, Israel, ²Loyola University Medical Center, Maywood, IL
- (1083) Giant-cell Myocarditis: A Case Series from the Perspective of a United Kingdom Cardiac Transplantation Centre;** N. Okonkwo, H. Enab, A. Tindale, O. Dar. *Royal Brompton & Harefield NHS Trust, London, United Kingdom*
- (1084) The Optimal Initial Immunosuppressive Strategy for Orthotopic Heart Transplantation in Renal Dysfunction - A Comparison of Commonly Used Regimes;** J. Mundisugih, H. Fernando, P. Bergin, J. Hare, D. M. Kaye, A. S. Leet, A. J. Taylor. *Dept of Cardiovascular Medicine, The Alfred Hospital, Melbourne, Australia*
- (1085) Average Daily Dose of Mycophenolate Mofetil in the First Post-transplant Year and Long Term Clinical Outcomes: A Single Center Retrospective Study;** K. WONG¹, N. Pereira², S. Kushwaha¹. ¹Dept of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Dept of Cardiovascular Diseases; Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN
- (1086) One Tac Trial: Renal Function After Conversion from Twice Daily to Extended Release Tacrolimus;** D. A. Baran¹, E. Menchavez², M. J. Zucker², C. Gidea³, M. Camacho³. ¹Advanced Heart Failure and Transplant, Sentara Heart Hospital, Norfolk, VA, ²Heart Failure and Transplant, Newark Beth Israel Medical Center, Newark, NJ, ³Newark Beth Israel Medical Center, Newark, NJ
- (1087) Liver Fibrosis Predicts Survival After Heart Transplant;** E. Kransdorf, D. H. Chang, K. Nguyen, T. Tran, A. Patel, R. Levine, S. Dimbil, J. Patel, D. Ramzy, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*
- (1088) Does a History of Malignancy Prior to Heart-transplant Increase Post-transplant Risk?;** E. Kransdorf, J. Patel, M. Kittleson, L. Czer, D. Chang, S. Dimbil, R. Levine, A. Hsu, T. Davis, K. Norland, A. Trento, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*
- (1089) Variability in Trust in the Heart Transplant Team Internationally and Its Relation to Patient and Center Level Factors in Heart Transplant Centers: The International Cross-Sectional BRIGHT Study;** X. Luta¹, K. Iglesias², I. Peytremann-Bridevaux³, R. Helmy¹, K. Denhaerynk¹, F. Dobbels⁴, C. Russell⁵, S. De Geest¹. ¹Institute of Nursing Science, Dept of Public Health, University of Basel, Basel, Switzerland, ²School of Health Sciences (HEdS-FR), University of Applied Sciences and Arts of Western Switzerland (HES-SO), Fribourg, Switzerland, ³Institute of Social and Preventive Medicine, University Hospital, Lausanne, Switzerland, ⁴Academic Centre for Nursing and Midwifery, Dept of Public Health and Primary Care, Katholieke Universiteit Leuven, Leuven, Belgium, ⁵School of Nursing and Health Studies, University of Missouri-Kansas City, Kansas City, MO
- (1090) Discrepancy Between Heart Rate Response and Indices of Autonomic Cardiovascular Control One Year After Heart Transplantation;** S. I. Nygaard¹, A. H. Christensen¹, K. Rolid¹, K. Nytroen¹, L. Gullestad¹, A. Fiane¹, E. Thaulow¹, G. Dohlen¹, V. B. Wyller². ¹Oslo Univ Hospital, Oslo, Norway, ²Akershus Univ Hospital, Lørenskog, Norway
- (1091) Comparison of Heart Transplantation Outcomes Between Adult Congenital Heart Disease and Matched Adult Cardiac Patients in a Single Quaternary Reference Centre;** A. Kinsella¹, J. S. Alvarez¹, R. V. Ribeiro¹, F. Yu¹, J. Heggie², M. Badiwala¹, V. Rao¹. ¹Cardiac Surgery, Toronto General Hospital, Toronto, ON, Canada, ²Anaesthesia, Toronto General Hospital, Toronto, ON, Canada

(1092) Cardiac Transplantation and Mechanical Circulatory Support in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC); S. Madan¹, J. Cress², D. B. Sims¹, S. R. Patel¹, O. Saeed¹, S. Forest³, W. Jakobleff³, S. Murthy¹, J. J. Shin¹, D. J. Goldstein³, U. P. Jorde¹. ¹Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

(1093) Giant Cell Myocarditis Patients Undergoing Heart Transplantation Have High Rates of Rejection, Infection and Cardiac Allograft Vasculopathy: Case Series; H. S. Lumish, K. J. Clerkin, C. Marboe, J. Han, F. Latif, S. W. Restaino, M. A. Farr, E. F. Lin, H. Takayama, K. Takeda, Y. Naka, P. C. Colombo, M. Yuzefpolskaya. *Columbia University, New York, NY*

(1094) Effect of Different Treatment Modalities for End-stage Renal Disease After Heart Transplantation; S. Roest¹, D. A. Hesselink², I. Kardys¹, K. Caliskan¹, J. J. Brugts¹, A. P. Maat³, A. A. Constantinescu¹, O. C. Manintveld¹. ¹Dept of Cardiology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Dept of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Dept of Cardiothoracic Surgery, Erasmus MC, University Medical Center, Rotterdam, Netherlands

(1095) WITHDRAWN

(1096) Risk of Post-Transplant De Novo Donor Specific Antibodies in Patients Receiving Transfusions Perioperatively; I. Mahoney¹, A. Young¹, N. Shekiladze², A. Morris³, D. Gupta³, K. Bhatt³, S. Laskar³, A. Smith³, J. Vega⁴, R. T. Cole³. ¹Emory Univ Sch of Med, Atlanta, GA, ²Memorial Hospital, Savannah, GA, ³Cardiology, Emory Univ Sch of Med, Atlanta, GA, ⁴Cardiothoracic Surgery, Emory Univ Sch of Med, Atlanta, GA

(1097) Survival Post Heart Transplant by Era in Recipients \geq 65y Bridged with Mechanical Circulatory Support; A. Salimbanon, M. Kwon, D. Vucicevic, A. Chang, M. Moore, M. Kamath, S. Shah, M. Deng, A. Iyengar, E. Depasquale. *UCLA, Los Angeles, CA*

(1098) Transplant Center Volume Impacts Survival Among ACHD Patients Undergoing Heart Transplantation - An Analysis of the UNOS Registry; J. N. Menachem¹, J. Lindenfeld¹, K. Schlendorf¹, A. S. Shah¹, D. P. Bichell¹, W. Book², D. Brinkley¹, M. Danter¹, B. Frischhertz¹, M. Keebler¹, B. Kogon³, B. Mettler¹, J. Rossano⁴, S. Brown Sacks¹, T. Young⁵, M. Wigger¹, S. Zalawadiya¹. ¹Vanderbilt Univ Med Ctr, Nashville, TN, ²Emory Univ, Atlanta, GA, ³Univ of Mississippi, Jackson, MS, ⁴Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Ochsner Health System, New Orleans, LA

(1099) Novel Technique to Reduce Warm Ischemic Time During Cardiac Implantation; K. Morcos¹, S. Singh¹, S. Das De¹, H. AlHaideri¹, Y. Hegazy¹, J. Dalzell², S. Nair¹, H. Doshi¹, N. Al-Attar¹, P. Curry¹. ¹Cardiac Surgery and Transplant, Golden Jubilee National Hospital, Glasgow, United Kingdom, ²Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom

(1100) Combined Heart and Lung Transplant: Improved Survival After Implementation of Exclusion and Inclusion Criteria; A. S. Cruz-Solbes, I. Hussain, B. Trachtenberg, A. Bhimaraj, A. Guha, M. Park, G. Torre-Amione, T. Kaleekal, J. Estep. *Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX*

(1101) Improving Utility of MELD-XI Prognostication in Heart Transplant; R. Meguerdijian¹, A. Chang¹, E. Moreno¹, A. Salimbanon¹, M. Kamath¹, T. Khuu¹, M. Kwon¹, M. Moore¹, A. Nsair¹, K. Pandya¹, D. Vucicevic¹, A. Ardehali¹, M. C. Deng¹, E. C. DePasquale². ¹UCLA, Los Angeles, CA, ²David Geffen School of Medicine, Los Angeles, CA

(1102) Safety and Efficacy of Mechanical Circulatory Support as a Bridge to Heart-Kidney Transplant; R. Araujo-Gutierrez, J. Gardner, B. Trachtenberg, A. Bhimaraj, M. Park, I. Hussain, G. Ashrith, E. E. Suarez, B. Bruckner, J. Estep. *Houston Methodist DeBakey Cardiology Associates, Houston Methodist Research Institute, Houston, TX*

(1103) Simultaneous Heart-Liver Transplant is Associated with Excellent Outcomes Independent of MELD Score; R. Araujo-Gutierrez, J. Gardner, B. Trachtenberg, A. Bhimaraj, I. Hussain, M. Park, G. Ashrith, E. E. Suarez, B. Bruckner, J. Estep. *DeBakey Heart & Vascular Center, Houston Methodist Research Institute, Houston, TX*

(1104) Trends in Heart Transplantation in Patients with History of Prior Malignancy; M. S. Panhwar¹, S. Al-Kindi², M. Ginwalla², G. Oliveira². ¹Internal Medicine, Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH, ²Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH

(1105) Effect of Donor Renal Function on Heart Transplant Outcomes; M. S. Panhwar, M. Ginwalla. *Case Western Reserve Univ/Univ Hospitals of Cleveland, Cleveland, OH*

(1106) Relation of Age to Risk of Major Rejections, Allograft Vasculopathy, and Long-term Mortality in a Contemporary Cohort of Patients Undergoing Heart Transplantation; Y. Peled¹, J. Lavee¹, M. Arad¹, E. Raichlin², N. Shlomo¹, Y. Har-Zahav¹, Y. Kassif¹, E. Nachum¹, D. Freimark¹, I. Goldenberg¹, I. Mazin¹. ¹Sheba Medical Center and Tel Aviv University, Ramat Gan, Israel, ²Loyola University Medical Center, Maywood, IL

(1107) Long Term Survival Outcomes Following Heart Transplantation are Significantly Impacted by Recipient Smoking Status; D. Yoeli¹, H. Lamba¹, F. H. Cheema¹, R. M. Delgado¹, L. Simpson¹, A. B. Civitello², A. Nair¹, T. K. Rosengart¹, O. Frazier¹, J. Morgan¹. ¹Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, ²Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, VA

(1108) Implementing the Index for Mortality Prediction After Cardiac Transplantation Risk Scores to Optimize Resources; E. I. Jeng¹, P. Lipori², D. J. Hall¹, L. Duce³, M. M. Ahmed⁴, J. Vilaro⁴, J. M. Aranda⁴, T. M. Beaver¹, G. J. Arnaoutakis¹. ¹Surgery, University of Florida, Gainesville, FL, ²Finance, University of Florida, Gainesville, FL, ³Anesthesiology, University of Florida, Gainesville, FL, ⁴Medicine, University of Florida, Gainesville, FL

(1109) Ex-situ Intra-vascular Ultrasound (IVUS) May Allow Safe Access to Extended Criteria DCD Heart Donors; S. Messer¹, A. Page¹, M. Berman¹, S. Tsui¹, S. Large¹, S. Hoole². ¹Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom, ²Cardiology, Papworth Hospital, Cambridgeshire, United Kingdom

(1110) Survival Post Heart Transplant by Era in Recipients ≥ 65 ; M. Moore¹, S. Fraschilla², A. Chang², A. Salimbanon², M. Kamath³, A. Nsair³, L. Sweet², E. DePasquale³. ¹Heart and Lung Transplant, UCLA, Venice, CA, ²Heart and Lung Transplant, UCLA, Los Angeles, CA, ³Dept of Medicine, Division of Cardiology, UCLA, Los Angeles, CA

(1111) Benefit of Modified Bicaval Anastomosis Technique for Orthotopic Heart Transplantation From Size-mismatch Marginal Donor; T. Kakuta, T. Fujita, S. Fukushima, N. Kawamoto, Y. Matsumoto, K. Yamashita, Y. Kume, Y. Shimahara, N. Fukushima, S. Kitamura, J. Kobayashi. Cardiovascular Surgery, National Cerebral and Cardiovascular Research Center, Suita, Japan

(1112) Perioperative Ischemic Reperfusion Injury, Aggravated by Prolonged Cardiac Ischemic Time, May Cause Temporary Deterioration of Allograft Function; Y. Nakamura, S. Saito, S. Miyagawa, Y. Yoshikawa, K. Domae, R. Matsuura, K. Toda, Y. Sawa. Cardiovascular Surgery, Osaka University, Suita, Japan

(1113) Redo Heart Transplantation: The Comparison of Survival Based on the Time Interval Between Transplants; D. Vucicevic¹, A. Salimbanon², A. Chang², E. Moreno², M. Kamath², A. Iyengar², S. Shah², M. Deng², A. Ardehali², M. Cadeiras², E. DePasquale². ¹Newark Beth Israel Medical Center, Newark, NJ, ²UCLA, Los Angeles, CA

(1114) The Comparison of Survival in Patients with Redo Heart Transplantation by Era; D. Vucicevic¹, A. Chang², A. Salimbanon², E. Moreno², M. Kamath², S. Shah², A. Iyengar², M. Cadeiras², A. Ardehali², M. Deng², E. DePasquale². ¹Newark Beth Israel Medical Center, Newark, NJ, ²UCLA, Los Angeles, CA

(1115) Advanced Heart Failure Therapies in Patients Aged ≥ 65 Years: Ventricular Assist Device vs. Heart Transplantation; D. M. Harmon¹, K. M. Tecson², A. K. Jamil¹, H. Qin¹, J. Felius¹, B. Lima¹, G. V. Gonzalez-Stawinski¹, S. M. Joseph¹, S. A. Hall¹. ¹Baylor University Medical Center, Dallas, TX, ²Baylor Heart and Vascular Institute, Dallas, TX

(1116) Combined Heart-Kidney Transplantations: Is it necessary?; O. Konukoglu¹, Y. Saltan², G. Tellioglu³, D. Mansuroglu¹, M. Balkanay¹. ¹Cardiovascular Surgery, Gaziosmanpasa Hospital, Istanbul, Turkey, ²Cardiology, Gaziosmanpasa Hospital, Istanbul, Turkey, ³Kidney Transplantation, General Surgery, Gaziosmanpasa Hospital, Istanbul, Turkey

(1117) Incidence and Outcomes of Cardiac Surgery After Orthotopic Heart Transplantation; M. T. Simpson¹, H. Takayama¹, J. Han¹, P. Kurlansky¹, A. R. Garan², M. A. Farr², P. C. Colombo², Y. Naka¹, K. Takeda¹. ¹Dept of Surgery, Columbia Univ Medical Center, New York, NY, ²Dept of Medicine, Columbia Univ Medical Center, New York, NY

(1118) Outcome of Cardiac Retransplantation for Late Allograft Failure: A Fifteen-Year Single Center Experience; M. T. Simpson¹, H. Takayama¹, J. Han¹, P. Kurlansky¹, A. R. Garan², M. A. Farr², P. C. Colombo², Y. Naka¹, K. Takeda¹. ¹Dept of Surgery, Columbia University College of Physicians & Surgeons, New York, NY, ²Dept of Medicine, Columbia University College of Physicians & Surgeons, New York, NY

(1119) Mechanical Circulatory Support for Late Cardiac Allograft Failure; M. T. Simpson¹, H. Takayama¹, J. Han¹, M. Ando¹, M. Cevasco¹, P. Kurlansky¹, A. R. Garan², M. A. Farr², P. C. Colombo², Y. Naka¹, K. Takeda¹. ¹Dept of Surgery, Columbia University College of Physicians & Surgeons, New York, NY, ²Dept of Medicine, Columbia University College of Physicians & Surgeons, New York, NY

(1120) Characterization of Vasoplegia Immediately After Heart Transplantation; F. Esmailian, J. Patel, M. Kittleson, L. Czer, S. Dimbil, R. Levine, F. DeLeon, A. Hage, J. Chung, D. H. Chang, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(1121) Thoracic Organ Transplantation in Patients With Congenitally Corrected Transposition of the Great Arteries; D. Schibilsky¹, M. Rafiq¹, L. Kenny², C. Lewis¹, C. Burt³, J. Dunning¹, C. Sudarshan¹, A. Hasan², D. Crossland², L. Coats², S. Tsui¹, J. Parameshwar¹, M. Berman¹. ¹Dept of Transplantation, Papworth NHS Trust, Papworth Everard, Cambridge, United Kingdom, ²Adult Congenital and Children's Heart Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ³Dept of Anaesthesia, Papworth NHS Trust, Papworth Everard, Cambridge, United Kingdom

(1122) Jehovah Witness Patients: Should We Liberalize Criteria for Heart Transplantation?; R. Sharoff, J. Patel, M. Kittleson, L. Czer, R. Levine, S. Dimbil, N. Musto, D. H. Chang, E. Kransdorf, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(1123) Transplant Outcomes in Destination Therapy vs Bridge to Transplant LVAD Patients; R. J. Miller¹, Y. Moyaedi¹, A. Sharma¹, S. Zarafshar¹, B. Varr², F. Haddad¹, W. Hiesinger¹, D. Banerjee¹. ¹Stanford, Palo Alto, CA, ²Kaiser Permanente, Santa Clara, CA

(1124) The Effect of Preoperative use of Mechanical Circulatory Support on Survival After Heart Transplantation in Finland; K. B. Lemström¹, A. Nykänen², C. Stark², K. Lemström². ¹Cardiac Surgery, Helsinki University Hospital, Helsinki, Finland, ²Helsinki University Hospital, Helsinki, Finland

(1125) Low Volume Centers have Inferior Post-Heart Transplant Survival; H. K. Lamba¹, D. Yoeli¹, F. H. Cheema¹, R. Delgado¹, L. Simpson¹, A. Nair¹, A. B. Civitello¹, A. Rana², T. Rosengart¹, O. Frazier¹, J. A. Morgan¹. ¹Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, ²Division of Abdominal Transplantation, Texas Heart Institute at Baylor College of Medicine, Houston, TX

(1126) Recipient Cardiac Enzymes: An Early Indicator of Primary Graft Dysfunction; J. J. Martinez, M. Peltz, J. E. Pruszynski, L. C. Huffman, P. Bajona, M. A. Wait, J. S. Murala, M. E. Jessen, W. S. Ring. Cardiothoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX

(1127) The Impact of Gender Mismatch on Survival After Heart Transplantation; S. Avtaar Singh¹, S. Das De¹, C. Berry², N. Banner³, N. Al-Attar⁴. ¹Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, ²Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ³Cardiology and Mechanical Circulatory Support, Harefield Hospital, London, United Kingdom, ⁴Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom

(1128) Center Characteristics Play a Leading Role in Geographic Disparities in Access to Heart Transplantation in France; C. Cantrelle¹, R. Dorent¹, E. Savoye¹, P. Tuppin², G. Lebreton³, C. Legeai¹, O. Bastien¹. ¹Medical & Scientific, Agence de la biomedecine, La Plaine Saint Denis, France, ²Medical & Scientific, Caisse Nationale d'Assurance Maladie des Travailleurs Salariés, Paris, France, ³Medical & Scientific, Assistance Publique Hôpitaux de Paris - Hôpital de la Pitié Salpêtrière, Paris, France

(1129) Ideal Body Weight May Be A Better Comparative Variable than Actual Body Weight for Donor-Recipient Matching in Orthotopic Heart Transplantation; B. Hoemann, M. Cevasco, H. Takayama, J. Han, P. Kurlansky, P. Colombo, M. Farr, Y. Naka, K. Takeda. Columbia University College of Physicians and Surgeons, New York City, NY

(1130) Survival in Re-Do Heart Transplant: Does Dual Organ Allocation Make a Difference?; M. Y. Kamath, N. Bassi, J. Wilson, N. Bellam, T. Khuu, A. Iyengar, D. Vucicevic, M. Deng, A. Ardehali, E. Depasquale. UCLA, Los Angeles, CA

(1131) Pathology Antibody-Mediated Rejection Plus Circulating Donor-Specific Antibodies Increase Development of Cardiac Allograft Vasculopathy After Heart Transplantation; M. Kittleson, J. Patel, L. Czer, D. Chang, S. Dimbil, R. Levine, N. Lam, R. Bleiker, D. Geft, D. Ramzy, X. Zhang, D. Luthringer, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(1132) The Clinical Impact of Early vs Late HLA Donor-Specific Antibody Development After Heart Transplantation; M. Kittleson, J. Patel, L. Czer, D. H. Chang, E. Kransdorf, S. Dimbil, R. Levine, J. Davis, M. Hamilton, A. Trento, X. Zhang, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(1133) Is the Luminex 1:8 Dilution Truly the Poor Man's C1q for Patients Awaiting Heart Transplantation?; M. Kittleson, J. Patel, L. Czer, D. H. Chang, S. Dimbil, R. Levine, R. Bleiker, E. Kransdorf, F. Esmailian, X. Zhang, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(1134) Is First-year DSA After Heart Transplantation Truly a Biomarker for the Development of Cardiac Allograft Vasculopathy?; J. Patel, M. Kittleson, L. Czer, D. H. Chang, R. Levine, S. Dimbil, J. Olive, M. Curry, D. Ramzy, A. Hage, X. Zhang, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(1135) Does ATG Induction Prevent Donor-specific Antibodies After Heart Transplantation?; J. Patel, M. Kittleson, L. Czer, D. H. Chang, E. Kransdorf, S. Dimbil, R. Levine, K. Norland, A. Hage, D. Ramzy, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(1136) Novel Methods for Assessing Response to Desensitization; E. Kransdorf¹, J. Patel¹, X. Zhang¹, M. Pando², M. Kittleson¹, L. Czer¹, D. H. Chang¹, S. Dimbil¹, R. Levine¹, K. Norland¹, M. Hamilton¹, J. Chung¹, J. A. Kobashigawa¹. ¹*Cedars-Sinai Heart Institute, Los Angeles, CA*, ²*Baylor Scott and White Health, Temple, TX*

(1137) Pre-Transplant Memory/Antibody Status Predicts Rejection Risk in the First-Year After Heart Transplantation; J. Patel, M. Kittleson, L. Czer, D. H. Chang, S. Dimbil, R. Levine, J. MacKinnon, A. Velleca, A. Hage, J. Chung, X. Zhang, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

(1138) In Sensitized Pre-Transplant Patients, Does IVIG after Heart Transplant Have any Benefit?; J. Patel, M. Kittleson, L. Czer, D. Geft, S. Dimbil, R. Levine, B. Kearney, E. Kransdorf, F. Esmailian, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

LUNG TRANSPLANTATION **(Euterpe)**

Poster Discussants: Clemens Aigner (Germany), Michael Durheim (USA), Are Holm (Norway), Tereza Martinu (Canada), Josh Mooney (USA), Pali Shah (USA), Aida Venado (USA), Erik Verschuuren (Netherlands), Keith Wille (USA)

(1139) Long Distance Relationships - Does the Geographic Distance From the Transplant Centre Affect Lung Transplant Outcomes?; E. Khoshbin¹, J. Battle¹, H. Muse², K. Wallace², G. Ditchburn³, G. Parry², S. Clark¹. ¹*Dept of Cardiac Surgery and Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom*, ²*Dept of Cardiothoracic Transplantation, Freeman Hospital, Newcastle Upon Tyne, United Kingdom*, ³*IAS Medical, London, United Kingdom*

(1140) High Body Mass Index is a Risk Factor for Acute Cellular Rejection in Lung Transplant Recipients; F. S. Nunes, C. S. King, S. D. Nathan, M. Fregoso, K. Ahmad, S. Aryal, A. W. Brown, S. D. Barnett, O. A. Shlobin, A. Vester. *Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA*

(1141) Hyaluronan in Acute Rejection After Lung Transplantation; J. L. Todd¹, M. L. Neely¹, C. Brinkley¹, F. L. Kelly¹, C. W. Frankel¹, J. Kirchner¹, J. A. Belperio², M. Budev³, P. D. Shah⁴, L. G. Singer⁵, J. M. Reynolds¹, S. M. Palmer¹. ¹*Duke Univ Med Ctr, Durham, NC*, ²*University of California Los Angeles, Los Angeles, CA*, ³*Cleveland Clinic, Cleveland, OH*, ⁴*Johns Hopkins University, Baltimore, MD*, ⁵*University of Toronto, Toronto, ON, Canada*

(1142) Early Acute Cellular Rejection in Lung Transplant Recipients is Associated with Greater Variation in the Lung Allograft Microbiome; C. J. Iasella¹, C. R. Ensor¹, A. Morris², B. Methé², J. F. McDyer². ¹*Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA*, ²*Medicine, University of Pittsburgh, Pittsburgh, PA*

(1143) Untreated Subclinical Minimal Acute Rejection Does Not Increase the Risk for Chronic Lung Allograft Dysfunction and Death After Lung Transplantation; L. Levy¹, W. Klement¹, E. Huszti², M. Ahmed¹, J. Tikkanen¹, R. Zamel¹, S. Azad¹, P. Fiset³, D. Hwang³, G. Tomlinson², S. Keshavjee¹, L. Singer¹, S. Juvet¹, T. Martinu¹. ¹*Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada*, ²*Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada*, ³*Dept of Pathology, University Health Network, University of Toronto, Toronto, ON, Canada*

- (1144) Risks and Benefits of Surveillance Transbronchial Biopsy after Lung Transplantation: A Single Center Experience;** D. Tosi, R. Carrinola, L. Morlacchi, P. Tarsia, S. Sarzana, F. Damarco, M. Cattaneo, A. Palleschi, M. Nosotti. *Fondazione Ca' Granda IRCCS Policlinico Milan, Milano, Italy*
- (1145) Selection of Lung Transplant Candidates: A Look Behind the Scene;** A. Lenoir, C. Perez-Valdes, J. D. Aubert. *Service de Pneumologie, Lausanne University Hospital, Lausanne, Switzerland*
- (1146) Presence of de Novo Donor-Specific Antibodies to HLA-DQ in Lung Transplant Recipients Predicts Poor Survival;** E. A. Belloli¹, L. Fitzgerald², D. Lyu¹, O. Moussa³, K. Chan¹. ¹Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²Pharmacy, Michigan Medicine, Ann Arbor, MI, ³Pathology, Michigan Medicine, Ann Arbor, MI
- (1147) HLA Donor Specific Antibody and HLA Antigen Bias are Independent Risk Factors for Chronic Lung Allograft Dysfunction;** T. K. Roberts¹, M. Steele², D. Nunley³. ¹Dept of Pathology, University of Louisville, Louisville, KY, ²Trager Transplant Center, KentuckyOne Jewish Hospital, Louisville, KY, ³Dept of Internal Medicine, Lung Transplantation, University of Louisville, Louisville, KY
- (1148) The Effect of CLAD Phenotypes on Survival After Lung Transplantation: A Single-centre Study;** A. Van Herck, A. Sacreas, S. E. Verleden, B. Vanaudenaerde, G. M. Verleden, R. Vos. *Dept of Chronic Diseases, Metabolism & Ageing (CHROMETA), University of Leuven, Leuven, Belgium*
- (1149) Early Detection of Chronic Lung Allograft Dysfunction After Bilateral Living Donor Lobar Lung Transplantation by Computed Tomographic Scanning Scoring Method;** E. Niman, K. Miyoshi, S. Namura, T. Kurosaki, S. Ohtani, S. Sugimoto, M. Yamane, S. Toyooka, T. Oto. *Dept of Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama city, Japan*
- (1150) High Circulating CD4⁺CD25^{hi}FOXP3⁺ T Cell Subpopulation Early After Lung Transplantation is Associated With Development of Bronchiolitis Obliterans Syndrome;** M. Durand¹, P. Lacoste², R. Danger¹, A. Tissot¹, C. Brosseau¹, N. Degauque¹, A. Magnan², S. Brouard¹. ¹INSERM UMR 1064, Centre de Recherche en Transplantation et Immunologie, Nantes, France, ²INSERM UMR 1087, Institut du Thorax, Nantes, France
- (1151) Lung Tissue Telomere Length in Chronic Lung Allograft Dysfunction;** A. Sacreas¹, E. J. Lammertyn¹, S. Everaerts¹, D. S. Martens², J. E. McDonough¹, T. S. Nawrot², G. M. Verleden¹, S. E. Verleden¹, R. Vos¹, B. M. Vanaudenaerde¹. ¹Dept of Chronic diseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium, ²Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium
- (1152) The Incidence of Chronic Lung Allograft Dysfunction After Cadaveric Lobar Lung Transplantation is Comparable to Conventional Lung Transplantation;** I. Inci¹, M. Schuurmans², I. Iskender¹, S. Hillinger¹, I. Opitz¹, D. Schneider¹, C. Caviezel¹, C. Benden², W. Weder¹. ¹Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, ²Pulmonology, University Hospital Zurich, Zurich, Switzerland
- (1153) Circulating CD9⁺ B Cells: Biomarker of Long-term BOS-free Survival After Lung Transplantation;** A. Tissot¹, M. Durand¹, E. Durand¹, A. Foureau², R. Danger¹, A. Magnan², S. Brouard¹. ¹INSERM UMR1064, Centre de Recherche en Transplantation et Immunologie, Nantes, France, ²INSERM UMR1087, Institut du Thorax, Nantes, France
- (1154) Bronchiolitis Obliterans Syndrome in Lung Transplantation: A Predictive Model;** A. Khurshudyan¹, A. Iyengar², O. Kwon², M. Caceres², C. Eisenring², D. Ross², A. Ardehali². ¹University of Illinois College of Medicine, Chicago, IL, ²David Geffen School of Medicine at UCLA, Los Angeles, CA
- (1155) Comparison of Extracorporeal Photopheresis and Thymoglobulin for the Treatment of Chronic Lung Allograft Dysfunction;** N. Martos Gisbert¹, M. Aguilar¹, R. Laporta¹, M. Lázaro¹, S. Aguado¹, R. Sandoval², M. Ussetti Gil¹. ¹Pneumology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²Pneumology, Instituto Nacional de Enfermedades Respiratorias, Ciudad de Mexico, Mexico
- (1156) Predictors of Long Term Survival in Patients With Cystic Fibrosis Following Lung Transplantation;** C. A. Robinson¹, A. Deibel¹, M. M. Schuurmans¹, I. Inci², C. Benden¹. ¹Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland, ²Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
- (1157) Standardizing and Improving the Classification for Causes of Death Post Lung Transplantation;** K. Levin, M. Paraskeva, G. Westall, B. Levvey, G. Snell. *Dept of General Respiratory and Lung Transplantation, The Alfred Hospital, Melbourne, Australia*

- (1158) Psoas Muscle Mass Predicts Early Postoperative Outcomes and Survival in Lung Transplantation;** J. Suh¹, J. Lee¹, H. Paik¹, K. Narm¹, M. Park², S. Kim². ¹thoracic surgery, Yonsei University college of medicine, seoul, Korea, Republic of, ²Internal medicine, Yonsei University college of medicine, seoul, Korea, Republic of
- (1159) Characteristics of De Novo Donor-specific Anti-HLA Antibodies (DSAs) in Living-donor Lobar and Cadaveric Lung Transplantation;** F. Gochi, T. Chen-Yoshikawa, J. Tokuno, S. Ueda, H. Kayawake, H. Yamagishi, R. Okabe, A. Takahagi, M. Saito, D. Nakajima, H. Motoyama, M. Hamaji, A. Aoyama, H. Date. Dept of Thoracic Surgery, Graduate School of Medicine, Kyoto University Hospital, kyoto, Japan
- (1160) “My Best Spirometry Numbers- What Do They Mean?”;** M. R. Mohanka, R. Kanade, H. Garcia, J. Mullins, S. Bollineni, V. Kaza, F. Torres, A. Banga. UT Southwestern Medical Center, Dallas, TX
- (1161) Air Trapping on Lung Scintigraphy After Lung Transplantation: Predictors and Association with Survival;** H. Garcia, R. Kanade, L. D. Mahan, S. Castillo, D. Pinho, V. Kaza, M. Mohanka, D. Mathews, F. Torres, A. Banga. UT Southwestern Medical Center, Dallas, TX
- (1162) Role of dd-cfDNA in Predicting Early Post-operative Course in Lung Transplant Recipients;** A. W. Brown¹, S. Agbor-Enoh², P. Shah³, I. Timofte⁴, J. Orens³, A. Iacono⁴, M. Lemma¹, S. Barnett¹, F. Soares¹, S. D. Nathan¹, K. Ahmad¹, H. Valentine². ¹Inova Fairfax Hospital, Falls Church, VA, ²National Heart, Lung, and Blood Institute, Bethesda, MD, ³John Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, MD
- (1163) Predicting Risk of Early Readmission in Lung Transplant Recipients Using dd-cfDNA;** K. Ahmad¹, S. Agbor-Enoh², P. Shah³, I. Timofte⁴, J. Orens³, A. Iacono⁴, M. Lemma¹, S. Aryal¹, A. Cochrane¹, F. Soares¹, S. Nathan¹, A. W. Brown¹, H. Valentine². ¹Inova Fairfax Hospital, Falls Church, VA, ²National Heart, Lung, and Blood Institute, Bethesda, MD, ³John Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, MD
- (1164) Predictors of Airway Dehiscence Following Lung Transplantation;** X. Zhou, C. D. Fraser, III, A. Suarez-Pierre, C. Lui, S. R. Broderick, R. S. Higgins, C. A. Merlo, E. L. Bush. Johns Hopkins Hospital, Baltimore, MD
- (1165) Cryotherapy of Airway Stenosis after Lung Transplant;** N. Zwintscher¹, H. Koopercamp¹, M. Gaudet¹, R. Rampolla-Selles², M. J. Bates¹. ¹Cardiothoracic Surgery, Ochsner Health System, New Orleans, LA, ²Transplant Pulmonology, Ochsner Health System, New Orleans, LA
- (1166) Incidence and Outcomes of Post-lymphoproliferative Disorder in Lung Transplant Recipients. Analysis of the ISHLT Registry;** L. Zaffiri¹, M. Neely², W. Cherikh³, J. Stehlik⁴, L. Snyder¹. ¹Pulmonary and Critical Care, Duke University, Durham, NC, ²Biostatistics & Bioinformatics, Duke University, Durham, NC, ³UNOS, Richmond, VA, ⁴University of Utah, Salt Lake City, UT
- (1167) Low Correlation Between PCWP and LVEDP in Patients With End-Stage Lung Disease;** A. Kafi¹, B. Lindgren¹, G. Chaux¹, J. Mirocha², W. Cheng³, D. Ramzy³, J. Falk¹. ¹Pulmonary and Critical Care, Cedars Sinai Medical Center, Los angeles, CA, ²Biostatistics and Bioinformatics, Cedars Sinai Medical Center, Los angeles, CA, ³Cardiothoracic Surgery, Cedars Sinai Medical Center, Los angeles, CA
- (1168) Role for Assessment of Diaphragm Function Prior to Lung Transplant;** S. E. Cohen¹, D. S. Tabari², N. Patel², G. E. Chaux¹. ¹Pulmonary and Critical Care, Cedars-Sinai Medical Center, Los Angeles, CA, ²Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
- (1169) Single and Double Lung Transplantation in Idiopathic Pulmonary Fibrosis: A Review of Pulmonary Artery Mean Pressure;** M. A. Kashem, S. Keshavamurthy, J. Gomez-Abraham, Y. Toyoda. Cardiovascular Surgery, Temple University, Philadelphia, PA
- (1170) Prevalence and Predictors of Coronary Artery Disease in Patients Evaluated for Lung Transplantation;** H. Fernando¹, S. Noaman¹, G. Snell², A. Dart¹, J. Shaw¹, W. Chan¹. ¹Cardiology, Alfred Hospital, Prahran, Australia, ²Lung Transplant, Alfred Hospital, Prahran, Australia
- (1171) Prevalence of Post-transplant Diabetes Mellitus (PTDM) and Cardiovascular (CV) Risk Factors After Lung Transplantation;** J. M. Leung¹, B. Paty¹, M. Almehtel¹, N. Partovi², J. Yee³, R. D. Levy⁴. ¹Dept of Medicine, Division of Endocrinology, The University of British Columbia, Vancouver, BC, Canada, ²Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, ³Dept of Surgery, Division of Thoracic Surgery, The University of British Columbia, Vancouver, BC, Canada, ⁴Dept of Medicine, Division of Respiriology, The University of British Columbia, Vancouver, BC, Canada

(1172) Diagnostic Value of Peripheral and Bronchoalveolar Leukocyte Profile in Lung Transplant Recipients After Alemtuzumab Induction Therapy. A Single Center Experience; Z. Á. Kováts¹, A. Bohacs¹, Z. I. Komlosi¹, A. Bikov¹, Z. Süttö¹, G. Lang², G. Losonczy¹, V. Müller¹. ¹Dept of Pulmonology, Semmelweis University, Budapest, Hungary, ²Dept of Thoracic Surgery, Semmelweis University, Budapest, Hungary

(1173) Short Term Outcomes After Lung Transplantation: Sternotomy Offers Advantages Over Clamshell Approach; G. N. Mody¹, D. Larios Chavez¹, D. Varon², C. Kerwin¹, A. Coppolino¹, R. Madathil¹, S. Singh¹, P. Camp¹, H. Goldberg³, H. R. Mallidi¹. ¹Surgery, Brigham and Women's Hospital, Boston, MA, ²Medical School, University of Michigan, Ann Arbor, MI, ³Medicine, Brigham and Women's Hospital, Boston, MA

(1174) Sternal Closure by Rigid Plate Fixation versus Traditional Technique After Clamshell Incision for Bilateral Lung Transplantation; M. N. Samano¹, H. F. Costa¹, L. M. Fernandes¹, L. Abdalla¹, O. Gomes Jr.¹, D. C. Mondadori¹, S. V. Campos², R. M. Carraro², P. M. Pego-Fernandes¹. ¹Thoracic Surgery Division, Heart Institute (InCor) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pulmonology Division, Heart Institute (InCor) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

(1175) Cardiopulmonary Bypass Use Does Not Affect Outcomes in Single Lung Transplantation; A. Iyengar¹, A. Khurshudyan², O. Kwon³, M. Caceres Polo³, C. Eisenring³, R. Biniwale³, D. Ross³, A. Ardehali³. ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of Illinois College of Medicine, Chicago, IL, ³University of California - Los Angeles, Los Angeles, CA

(1176) Recipient Working Status is Independently Associated with Outcomes in Lung Transplantation; A. Iyengar¹, M. Caceres Polo², O. Kwon², N. Faiq¹, R. Biniwale², E. DePasquale², A. Ardehali². ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of California - Los Angeles, Los Angeles, CA

(1177) Single vs. Double Lung Transplantation in Patients over Age 65; A. Iyengar¹, M. Caceres Polo², O. Kwon², J. Schaanman², R. Biniwale², D. Ross², E. DePasquale², A. Ardehali². ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²University of California - Los Angeles, Los Angeles, CA

(1178) Bilateral Living-donor Lobar Lung Transplantation May Deliver Potential Lung Function; H. Kayawake, T. F. Chen-Yoshikawa, S. Ueda, J. Tokuno, R. Okabe, F. Gochi, H. Yamagishi, A. Takahagi, M. Saito, H. Motoyama, M. Hamaji, D. Nakajima, A. Aoyama, H. Date. Dept of Thoracic Surgery, Kyoto University, Kyoto, Japan

(1179) Desensitization in Lung Transplant Recipients with a Positive Virtual Crossmatch; S. Hammad, B. Ravichandran, J. Kim, D. KuKuruga, M. McLennon, Z. Kon. University of Maryland Medical Center, Baltimore, MD

(1180) Effect of Rabbit Anti-Thymocyte Globulin Induction Therapy on the Incidence of Acute Cellular Rejection and Infection Complications After Lung Transplantation; J. Havlin¹, D. Paugsch¹, T. Dousova², J. Kolarik¹, M. Svorcova¹, L. Valentova-Bartakova³, J. Pozniak¹, J. Simonek¹, R. Lischke¹. ¹3rd Dept of Surgery, Motol University Hospital, Prague 5, Czech Republic, ²Dept of Pediatric Pneumology, Motol University Hospital, Prague 5, Czech Republic, ³Dept of Pneumology, Motol University Hospital, Prague 5, Czech Republic

(1181) The Impact of Azithromycin on the Post Lung Transplant Microbiome; S. E. Verleden¹, C. Spence², G. Einarsson², E. Johnston², A. J. Lee³, B. Vanaudenaerde¹, S. Elborn², D. Gilpin², R. Vos¹, M. Tunney². ¹KU Leuven, Leuven, Belgium, ²Queen's University, Belfast, United Kingdom, ³Queen's University, Belfast, Ireland

(1182) Safety of Early Sirolimus Immunosuppression in Lung Transplantation; J. Wojarski, S. Zeglen, M. Ochman, W. Karolak. Dept of Cardiac Surgery and Transplantology, Silesian Center for Heart Disease, Zabrze, Poland

(1183) Experience of Using mTOR Inhibitor in Lung Transplant at Recipients With Lymphangiomyomatosis; T. Kurosaki, S. Otani, S. Sugimoto, K. Miyoshi, H. Yamamoto, S. Tanaka, Y. Shikatani, K. Mesaki, K. Hashimoto, M. Yamane, S. Toyooka, T. Oto. Thoracic surgery, Okayama University, Okayama prefecture, Japan

(1184) Single Lung Transplantation in Patients with Severe Secondary Pulmonary Hypertension; B. S. Nasir, M. S. Mulvihill, M. Bishawi, M. L. Cox, D. J. Megna, J. C. Haney, J. A. Klapper, M. A. Daneshmand, M. G. Hartwig. Duke University Medical Center, Durham, NC

(1185) Does Center Volume Affect Failure to Rescue Rates in Lung Transplantation? A U.S. Nationwide Analysis; A. A. Osho¹, M. Bishawi², S. Hirji³, M. Mulvihill⁴, A. Axtell¹, S. Melnitchouk⁵, D. D'Alessandro⁵, T. Astor⁶, M. Hartwig², M. Villavicencio⁵. ¹Dept of General Surgery, Massachusetts General Hospital, Boston, MA, ²Dept of Cardiothoracic Surgery, Duke University School of Medicine, Durham, NC, ³Dept of General Surgery, Brigham and Women's Hospital, Boston, MA, ⁴Dept of General Surgery, Duke University School of Medicine, Durham, NC, ⁵Dept of Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, ⁶Dept of Medicine, Massachusetts General Hospital, Boston, MA

(1186) Outcomes Following Use of a Novel Treatment Protocol for Antibody Mediated Rejection After Lung Transplantation; V. Rusanov¹, K. M. Wille¹, N. S. Sharma², C. B. Baker³, A. H. Johnson⁴, S. B. Pruitt⁵, N. J. Bush⁵, B. Wei⁴, C. W. Hoopes⁴, S. R. Duncan¹, V. G. Valentine¹. ¹Medicine, Univ of Alabama at Birmingham, Birmingham, AL, ²Medicine, Univ of South Florida, Tampa, FL, ³Pharmacy, Virginia Commonwealth University, Richmond, VA, ⁴Surgery, Univ of Alabama at Birmingham, Birmingham, AL, ⁵Univ of Alabama at Birmingham, Birmingham, AL

(1187) Use of Sirolimus in Patients with Lymphangiomyomatosis (LAM) on Waiting Lists for Lung Transplant LTX; D. F. Dilling¹, A. Nair², C. J. Gries³, L. E. Leard⁴, A. J. Fisher², S. R. Johnson⁵, F. X. McCormack⁶. ¹Division of Pulmonary and Critical Care, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, ²Institute of Transplantation, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ³Florida Hospital, Orlando, FL, ⁴Dept of Medicine, University of California San Francisco, San Francisco, CA, ⁵Division of Respiratory Medicine, The University of Nottingham, Nottingham, United Kingdom, ⁶Division of Pulmonary & Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, OH

(1188) Cardiovascular Autonomic Control in End Stage Lung Disease Before Lung Transplantation; L. Morlacchi¹, A. Monti², E. Tobaldini², V. Rossetti¹, S. Henchi¹, I. Righi³, S. Aliberti¹, P. Tarsia¹, N. Montano². ¹Cardiothoracic Unit and Cystic Fibrosis Adult Centre; Dept of Pathophysiology and Transplantation, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ²Dept of Internal Medicine; Dept of Clinical Sciences and Community Health, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ³Thoracic and Lung Transplantation Surgery, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

(1189) Elevated Pre-transplant Left Ventricular End Diastolic Pressure is Associated With Increased Risk of Primary Graft Dysfunction in Lung Transplant Recipients; D. Li, J. Weinkauf, A. Kapasi, A. Hirji, J. Nagendran, D. Lien, J. Ezekowitz, K. Halloran. University of Alberta, Edmonton, AB, Canada

(1190) MiRNA's Profiling and Primary Graft Dysfunction: Novel Non-invasive Biomarkers; A. Palleschi¹, V. Vaira², G. Gaudio², M. Formica², V. Musso¹, R. Carrinola¹, L. Morlacchi³, P. Tarsia³, A. Terrasi², L. Rosso¹, S. Ferrero². ¹Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy, ²Division of Pathology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy, ³Pneumology Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy

(1191) Impact of Ischemic Time on Primary Graft Dysfunction: A National Analysis; K. Anderson¹, A. Rucker¹, M. Mulvihill², B. Yerokun², M. Hartwig². ¹Duke University School of Medicine, Durham, NC, ²Surgery, Duke University Medical Center, Durham, NC

(1192) Negative Impact of Primary Graft Dysfunction Grade 3 within the Initial 72 Hours on Short and Long Term Clinical Outcomes in Standard Criteria Double Lung Transplants: Prospective Evidence from the OCS Lung INSPIRE International Trial Results; A. Ardehali¹, D. Van Raemdonck², J. Kukreja³, M. Smith⁴, G. Looor⁵, F. Rea⁶, G. Massard⁷, F. De Robertis⁸, J. Nagendran⁹, J. Moradiellos¹⁰, K. Dhital¹¹, C. Knosalla¹², C. Bermudez¹³, S. Tsui¹⁴, J. Madsen¹⁵, I. Wang¹⁶, K. McCurry¹⁷, T. Deuse¹⁸, P. Thomas¹⁹, I. Tudorache²⁰, B. Wiegmann²⁰, M. Schiavon⁶, F. Calabrese⁶, N. Santelmo⁷, A. Olland⁷, P. Falcoz⁷, A. Varela¹⁰, M. Hertz⁵, A. Simon⁸, H. Resichenspurner²¹, A. Haverich²⁰, G. Warnecke²⁰. ¹UCLA Sch of Med, Los Angeles, CA, ²Leuven University Hospital, Leuven, Belgium, ³University of California San Francisco Medical Center (UCSF), San Francisco, CA, ⁴St. Joseph's Medical Center, Phoenix, AZ, ⁵University of Minnesota Medical Center, Minneapolis, MN, ⁶University of Padua Hospital, Padua, Italy, ⁷University Hospital of Strasbourg, Strasbourg, France, ⁸Harefield Hospital, London, United Kingdom, ⁹University of Alberta Medical Center, Edmonton, AB, Canada, ¹⁰University Puerta de Hierro Hospital, Madrid, Spain, ¹¹St. Vincent's Hospital, Sydney, Australia, ¹²German Heart Institute, Berlin, Germany, ¹³University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, ¹⁴Papworth Hospital, Cambridge, United Kingdom, ¹⁵Massachusetts General Hospital, Boston, MA, ¹⁶Indiana University Health Methodist Hospital, Indianapolis, IN, ¹⁷Cleveland Clinic Foundation, Cleveland, OH, ¹⁸University of Hamburg, Hamburg, Germany, ¹⁹University Hospitals of Marseille, Marseille, France, ²⁰Hannover Medical School, Hannover, Germany, ²¹Hamburg University Hospital, Hamburg, Germany

(1193) The Use of Inhaled Nitric Oxide versus Inhaled Epoprostenol in High Risk Lung Transplant Recipients; A. Wexler¹, M. Patel², J. Rusinak¹, E. Mancl¹, S. Quddus². ¹Pharmacy, Loyola University Medical Center, Maywood, IL, ²Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL

(1194) Prognostic Value of Pao2/Fio2 Ratio at the End of Double-Lung Transplantation; J. Thes¹, J. Fessler¹, R. Pirracchio², A. Roux¹, E. Sage¹, C. Cerf¹, M. Fischler¹, M. Le Guen¹. ¹Foch Lung Transplant Team, Suresnes, France, ²Hopital Europeen Georges Pompidou, Paris, France

(1195) Inhaled Nitric Oxide Dependency at the End of Double-Lung Transplantation: A Boosted Propensity Score Cohort Analysis; M. Godement¹, J. Fessler¹, E. Sage¹, A. Roux¹, C. Cerf¹, R. Pirracchio², M. Fischler¹, M. Le Guen¹. ¹Foch Lung Transplant Team, Suresnes, France, ²Hopital Europeen Georges Pompidou, Paris, France

(1196) Preoperative Epidural Use in Lung Transplantation: A New Frontier in Pain Management?; A. Krishnan¹, J. Hsu¹, N. Weltman², J. Orens³, P. Shah³, R. S. Higgins¹, S. R. Broderick¹, C. A. Merlo³, M. N. Hanna², E. L. Bush¹. ¹Surgery- Thoracic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine- Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

(1197) Comparison of Extra Corporeal Membrane Oxygenation versus Cardiopulmonary Bypass Support for Lung Transplantation; V. Mehta¹, J. Hasan¹, J. Salaie¹, E. Milser², K. Santhanakrishnan³, M. Al-Aloul³, I. Dimarakis¹, J. Barnard¹, R. Venkateswaran⁴. ¹Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ²Blood Transfusion Practitioner, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ³Respiratory/Transplant Physician, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ⁴Director of Transplantation, Cardiothoracic Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom

(1198) Bile Acid Aspiration is Associated with Airway Infections: A Targeted Metabolomic Approach; A. Urso¹, D. F. Briganti¹, J. Costa¹, R. Nandakumar², H. Robbins¹, L. Shah¹, J. R. Sonett¹, S. Cremers², S. Arcasoy¹, F. D'Ovidio¹. ¹Lung Transplant Program, Columbia Univ, New York, NY, ²Pathology, Columbia Univ Medical Center, New York, NY

MECHANICAL CIRCULATORY SUPPORT

(Agora 3)

Poster Discussants: Maya Guglin (USA), Maryl Johnson (USA), Minoru Ono (Japan), Nicola Robinson Smith (United Kingdom), Keyur Shah (USA), Cumara Sivathanan (Singapore), Mary Cristy Smith (USA), Benjamin Sun (USA), Veli Topkara (USA), Patricia Uber (USA), Richard Wampler (USA), Melana Yuzefpolskaya (USA)

(1199) Bridge to Cancer Therapy: Can LVAD Support Allow Advanced Heart Failure Patients to Survive Cancer Treatment?; J. Raikhelkar¹, P. Ivak², C. LaBuhn³, B. Chung¹, A. Nguyen¹, N. Narang¹, S. Kalantari¹, N. Sarswat¹, G. Kim¹, G. Sayer¹, T. Song³, T. Ota³, V. Jeevanandam³, J. Maly², I. Netuka², N. Uriel¹. ¹Cardiology, University of Chicago, Chicago, IL, ²Cardiac Surgery, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic, ³Cardiac Surgery, University of Chicago, Chicago, IL

(1200) A Risk Model Incorporating Pectoralis Muscle Measures More Accurately Risk Predicts Mortality after Left Ventricular Assist Device Implantation; L. M. Teigen¹, C. P. Earthman¹, J. Hodges², J. Shultz³, C. Martin⁴, R. John⁵, R. Cogswell⁴. ¹Food Science and Nutrition, University of Minnesota, St. Paul, MN, ²Dept of Biostatistics, University of Minnesota, Minneapolis, MN, ³Dept of Medicine, University of Minnesota, Minneapolis, MN, ⁴Dept of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, ⁵Dept of Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

(1201) Predicting Post-LVAD Mortality Across a Diverse HF Population Using Bayesian Analysis; M. Kanwar¹, L. Lohmueller², S. Bailey¹, C. McIlvannan³, R. Kormos⁴, S. Murali¹, J. Antaki². ¹Allegheny General Hospital, Pittsburgh, PA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of Colorado, Denver, CO, ⁴University of Pittsburgh, Pittsburgh, PA

(1202) Prognostic Value of the Nutritional Risk Index in Candidates for Continuous Flow Left Ventricular Assist Device Therapy; A. Uribarri, S. V. Rojas, J. S. Hanke, G. Dogan, T. Siemeni, T. Kaufeld, T. Goecke, S. Rojas-Hernandez, G. Warnecke, C. Bara, M. Avsar, J. D. Schmitto, A. Haverich. Dept of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany

(1203) After the Referral: How Patients Fare After Evaluation for Left Ventricular Assist Device Placement; S. N. Yu, M. Cevasco, J. Han, M. Flannery, P. C. Colombo, H. Takayama, Y. Naka, K. Takeda. *Columbia University Medical Center, New York, NY*

(1204) Preoperative Predictors of Early Right Ventricular Failure After Left Ventricular Assist Device Implantation for Stable Patients in Intermacs 3-5 Status; M. J. Ruiz-Cano, E. Ljajikj, L. Paluszkiwicz, J. Boergermann, M. Schoenbrodt, V. Lauenroth, E. Prashovikj, J. Gummert, M. Morshuis. *Thorax- und Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Bad Oeynhausen, Germany*

(1205) Blood Group O Heart Transplant Waitlist Mortality in the Ventricular Assist Device Era; J. Trivedi¹, R. Vijayakrishnan², M. Slaughter¹, E. Birks², D. Abramov³. ¹Dept of Cardiovascular and Thoracic Surgery, Louisville Univ, Louisville, KY, ²Dept of Cardiology, Louisville Univ, Louisville, KY, ³Cardiology, Loma Linda Univ, Loma Linda, CA

(1206) Systems Biological Identification of an Age-related Predictor of Functional Recovery Potential in Advanced Heart Failure; G. Bondar¹, T. Bao¹, R. Manoharan², R. Togashi¹, N. Agrawal², S. Ramachandrala², J. Hai¹, D. Chu¹, L. Masukawa¹, M. Cadeiras¹, J. Schaeenman¹, E. Chang¹, A. Le¹, R. Dod¹, C. Kahn¹, E. Oh¹, J. Do¹, C. Lumintang¹, S. Kupiec-Weglinski³, V. Groysberg⁴, T. Grogan⁴, M. Rossetti⁴, D. Elashoff⁴, E. Reed⁴, P. Ping⁴, M. Deng¹. ¹Medicine-Cardiology, University of California Los Angeles, Los Angeles, CA, ²Strand NGS Avadis, Bangalore, India, ³Cornell University, Ithaca, NY, ⁴University of California Los Angeles, Los Angeles, CA

(1207) Heart Failure Clinicians Want to Revive the REVIVE-IT Study Following the Results of the MOMENTUM 3 and ENDURANCE Supplement Trials; G. Sayer¹, A. Anderson², E. Raichlin³, C. Gupta⁴, G. Kim¹, J. Raikhelkar¹, E. Vorovich², D. Pham⁵, V. Jeevanandam⁶, T. Song⁶, D. Onsager⁶, D. Rodgers¹, N. Uriel¹. ¹Cardiology, University of Chicago, Chicago, IL, ²Cardiology, Northwestern University, Chicago, IL, ³Cardiology, Loyola University, Chicago, IL, ⁴Cardiology, NorthShore University HealthSystem, Chicago, IL, ⁵Cardiac Surgery, Northwestern University, Chicago, IL, ⁶Cardiac Surgery, University of Chicago, Chicago, IL

(1208) Early Postoperative Organ Function Recovery Score and Long-term Survival in Advanced Heart Failure Patients Undergoing Mechanical Circulatory Support; L. M. Masukawa¹, T. Bao¹, R. Dod¹, R. Togashi¹, M. Cadeiras¹, J. Schaeenman¹, J. Hai¹, D. Chu¹, E. Chang¹, S. Kupiec-Weglinski², V. Groysberg¹, A. Le¹, C. Kahn¹, E. Oh¹, J. Do¹, C. Lumintang¹, T. Grogan¹, J. Meltzer¹, M. Kwon¹, M. Rossetti¹, D. Elashoff¹, E. Reed¹, P. Ping¹, G. Bondar¹, M. C. Deng¹. ¹Medicine/Cardiology, Univ of California, Los Angeles, Los Angeles, CA, ²Medicine/Cardiology, Cornell Univ, Ithaca, NY

(1209) Predictors of Survival to Discharge After VA-ECMO Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock; J. A. Fried¹, K. Takeda², K. Clerkin¹, M. Ando², A. Masoumi¹, V. Topkara¹, D. Burkhoff¹, M. Yuzefpolskaya¹, A. Kirtane¹, D. Karpalotis¹, P. C. Colombo¹, Y. Naka², H. Takayama², A. Garan¹. ¹Medicine, Columbia University, New York, NY, ²Surgery, Columbia University, New York, NY

(1210) A Comparison of Renal Outcomes in Patients With LVAD and Heart Transplantation; A. Arshad, E. Kew, N. Howell, A. Ranasinghe, J. Mascaró, S. Lim. *University Hospital Birmingham, Birmingham, United Kingdom*

(1211) Psoas Muscle Diameter in Patients Undergoing Left Ventricular Assist Device Implantation; G. Yost, G. Bhat, M. Nagarkatte, A. Bhan, B. Kyi, S. Asokan, P. Pappas, A. Tatoes. *Heart Institute, Advocate Christ Medical Center, Chicago, IL*

(1212) Pre-Operative Pectoralis Muscle Measures by Computed Tomography Predict Early Right Heart Failure Deaths After Left Ventricular Assist Device; R. Cogswell¹, L. Teigen², J. Schultz³, T. Thenappan¹, L. Lin⁴, J. Kealhofer¹, C. Martin¹, R. John⁵. ¹Dept of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, ²Food Science and Nutrition, University of Minnesota, Minneapolis, MN, ³Dept of Medicine, University of Minnesota, Minneapolis, MN, ⁴Dept of Medicine, University of Minnesota, Minneapolis, MN, ⁵Dept of Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

(1213) Socioeconomic Status Influences Outcomes for Patients Undergoing Heart Transplantation But Not LVAD Implantation; A. C. Coniglio¹, J. N. Katz², R. Watkins³, S. B. Waters², M. E. Andrews², B. C. Jensen², L. J. Rose-Jones², P. P. Chang¹. ¹Internal Medicine, University of North Carolina, Durham, NC, ²Cardiology, University of North Carolina, Durham, NC, ³University of North Carolina, Durham, NC

(1214) Is Pre-Operative Colonoscopy Screening for LVAD Therapy Needed for Higher INTERMACS Profile Patients in the Current Era?; A. Bansal¹, K. Marz², S. Desai², J. Bhama³. ¹Cardiothoracic Surgery, Ochsner Clinic Foundation, New Orleans, LA, ²Heart Failure and Heart Transplant, Ochsner Clinic Foundation, New Orleans, LA, ³Cardiothoracic Surgery, University of Iowa Health Care, Iowa City, IA

(1215) Right Ventricular Function Assessment Using Gated Blood-Pool SPECT Ventriculography in Patients with Advanced Heart Failure; V. Melenovsky, M. Tupy, L. Mlateckova, M. Buncova, J. Ters, J. Kidery, I. Netuka, J. Kautzner. *Institute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic*

(1216) Predictors of Neurologic Outcomes After Extracorporeal Cardiopulmonary Resuscitation; J. Han¹, M. Ando¹, M. Cevasco¹, P. A. Kurlansky¹, A. R. Garan², P. C. Colombo², H. Takayama¹, Y. Naka¹, K. Takeda¹. ¹*Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY*, ²*Division of Cardiology, Columbia University Medical Center, New York, NY*

(1217) Use of Veno-arterial ECMO as Salvage Treatment in Patients With Refractory Post-cardiotomy Shock: Single Center Experience; K. Mudy¹, H. Tavangar², K. Hryniewicz¹, K. Wilson², R. Garberich², B. Sun¹. ¹*Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN*, ²*Minneapolis Heart Institute Foundation, Minneapolis, MN*

(1218) Outcomes After Left Ventricular Assist Device Implant in Patients Requiring Peri-operative Dialysis; G. A. Hernandez, C. Rueda, J. Boone, J. Lindenfeld, M. A. Wigger. *Advanced Heart Failure and Transplant, Vanderbilt University, Nashville, TN*

(1219) Pre-implantation Hepatic Imaging as a Predictor of LVAD Morbidity; C. J. van Niekerk¹, A. C. Pandey², J. T. Heywood³, A. V. Srivastava³, R. Mohan³. ¹*Medicine, Scripps Clinic, La Jolla, CA*, ²*Div of Cardiology, Scripps Clinic/TSRI/STSI, La Jolla, CA*, ³*Div of Cardiology, Section of Heart Failure Research and Recovery, Scripps Clinic, La Jolla, CA*

(1220) Mid-term Survival after Ventricular Assist Device Implantation in Patients \geq 70 Years; N. Pizanis¹, H. Carstens¹, A. Koch¹, P. Luedike², T. Rassaf², M. Kamler¹. ¹*Thoracic and Cardiovascular Surgery, West German Heart Center Essen, Essen, Germany*, ²*Cardiology, West German Heart Center Essen, Essen, Germany*

(1221) Sex-Related Differences in Patients Undergoing Left Ventricular Assist Device Implantation as Destination Therapy: A Single Center Experience; A. K. OKOH, M. Schultheis, C. Gidea, M. Russo, M. Zucker, M. Camacho. *RWJ Barnabas Health Newark Beth Israel Medical Center, Newark, NJ*

(1222) WITHDRAWN

(1223) Time is on Your Side: A Comparison of OR Times with ECMO Survival in Post Cardiotomy Patients; A. Luksan¹, D. B. Berkheim², T. Ryan², E. Lyden³, J. Y. Um², A. Siddique², M. J. Moulton², H. Merritt². ¹*Anesthesiology, University of Nebraska Medical Center, Omaha, NE*, ²*Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE*, ³*University of Nebraska Medical Center, Omaha, NE*

(1224) Spousal Support Does Not Affect Outcomes in Patients with Continuous Flow Left Ventricular Assist Device; A. Topoll, A. Althouse, K. Lockard, E. Dunn, N. Kunz, M. Dew, A. Kilic, C. Sciortino, M. Mathier, M. Shullo, R. Kormos, G. Hickey. *HVI, UPMC Presbyterian Hospital, Pittsburgh, PA*

(1225) SIPAT May Predict Clinical Outcomes in Patients With Left Ventricular Assist Device (LVAD); Q. M. Bui, O. O. Braun, M. Brambatti, Y. Ko, H. Hernandez, N. Wettersten, H. A. Tran, V. Pretorius, E. Adler. *University of California San Diego, La Jolla, CA*

(1226) Unique Predictors of 12 Month Mortality in Ischemic and Non-Ischemic LVAD Patients; C. Khoo¹, M. Kanwar², L. E. Lohmueller¹, S. Murali², J. Antaki¹. ¹*Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA*, ²*Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA*

(1227) Pre-Transplant Proteinuria Predicts Post-Transplant Renal Replacement Therapy and Mortality in Patients Bridged with Left Ventricular Assist Devices; L. K. Truby, A. Garan, R. Givens, H. Takayama, K. Takeda, M. Yuzefpolskaya, F. Latif, S. Restaino, M. Farr, Y. Naka, P. C. Colombo, V. K. Topkara. *Columbia University, New York, NY*

(1228) Left Ventricular Assist Devices in INTERMACS 1 Acute Cardiogenic Shock Patients; C. Louis¹, U. Daimee², I. Gosev¹, S. Prasad¹, S. McNitt², A. Papernov², J. Alexis³, V. Kutiyifa². ¹*Cardiothoracic Surgery, UPMC, Rochester, NY*, ²*Heart Research Follow-up Program, UPMC, Rochester, NY*, ³*Cardiology, UPMC, Rochester, NY*

(1229) Impact of Contemporary Ventricular Assist Device Therapy on Renal Outcomes in End Stage Heart Failure; P. Z. Xu¹, S. Wu¹, H. Tun¹, G. Adenuga², M. Fong². ¹*LAC USC Medical Center, Los Angeles, CA*, ²*Keck Medical Center, Los Angeles, CA*

(1230) Psychosocial Outcome Categories to Better Understand Outcomes After VAD; M. G. Dickinson, C. E. Kelty, E. A. Crittenden, D. K. Donahue, E. R. Thomas, J. R. Everly, M. D. Sligh, A. N. Lewandowski, L. R. Ebels, J. I. Schuitema, M. M. Lypka, N. K. Manandhar Shrestha, S. Jovinge. *Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI*

(1231) PROMOTED TO MINI ORAL

(1232) Adverse Events and Their Effect on Quality of Life and Functional Capacity in the ENDURANCE and ENDURANCE Supplemental Trials; J. G. Rogers¹, C. A. Milano¹, S. V. Pamboukian², M. S. Slaughter³, E. J. Birks³, S. W. Boyce⁴, S. S. Najjar⁴, A. Itoh⁵, B. B. Reid⁶, N. A. Mokadam⁷, K. D. Aaronson⁸, T. A. Vassiliades⁹, F. D. Pagani¹⁰. ¹*Duke Univ, Durham, NC*, ²*Univ of Alabama, Birmingham, AL*, ³*Univ of Louisville, Louisville, KY*, ⁴*MedStar Health, Washington, DC*, ⁵*Washington Univ in St Louis, St Louis, MO*, ⁶*Intermountain Health Care, Murray, UT*, ⁷*Univ of Washington, Seattle, WA*, ⁸*Univ of Michigan, Ann Arbor, IL*, ⁹*Medtronic, Framingham, MA*, ¹⁰*Univ of Michigan, Ann Arbor, MI*

(1233) Overall Satisfaction and Adjustment After LVAD Using the QOLVAD; M. Soni¹, K. Sandau², R. Garberich³, B. A. Hognlund⁴, J. Cowger⁵, E. Y. Birati⁶. ¹*Medicine, University of Pennsylvania, Philadelphia, PA*, ²*Nursing, Bethel Univ, St. Paul, MN*, ³*Cardiovascular Medicine, Minneapolis Heart Institute, Minneapolis, MN*, ⁴*Metropolitan State Univ, St. Paul, MN*, ⁵*St. Vincent, Indianapolis, IN*, ⁶*Cardiovascular Medicine, Univ of Pennsylvania, Philadelphia, PA*

(1234) Stability of Patient Values in the Face of Invasive Therapies for Life-threatening Illness: Insights from the DECIDE-LVAD Trial; L. A. Allen¹, C. E. Knoepke², E. C. Leister², J. S. Thompson², C. K. McIlvennan¹, A. V. Ambardekar¹, R. M. Arnold³, D. D. Matlock². ¹*Division of Cardiology, University of Colorado School of Medicine, Aurora, CO*, ²*Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado School of Medicine, Aurora, CO*, ³*University of Pittsburgh, Pittsburgh, PA*

(1235) Impact of the Thoracotomy Implant Approach on Patient Self-Reported Quality of Life in the HVAD LATERAL Trial; A. Cheung¹, M. R. Danter², N. A. Mokadam³, C. Mahr³, M. S. Kiernan⁴, D. T. Pham⁵, T. Boeve⁶, S. S. Najjar⁷, T. A. Vassiliades⁸, E. McGee⁹. ¹*University of British Columbia, Vancouver, BC, Canada*, ²*Vanderbilt University Medical Center, Nashville, TN*, ³*University of Washington, Seattle, WA*, ⁴*Tufts Medical Center, Boston, MA*, ⁵*Northwestern, Chicago, IL*, ⁶*Spectrum Health, Grand Rapids, MO*, ⁷*MedStar Health, Washington, DC*, ⁸*Medtronic, Framingham, MA*, ⁹*Loyola University Medical Center, Maywood, IL*

(1236) Life During Long Term LVAD Support; C. J. LaBuhn, V. Jeevanandam, D. Rodgers, T. Ota, G. Sayer, G. Kim, N. Uriel. *Cardiac Surgery, University of Chicago, Chicago, IL*

(1237) Spiritual Well-Being in LVAD Recipients Measured by FACIT-Sp is Comparable to Patients with Malignancy; P. M. Eckman¹, R. Garberich¹, C. E. Weaver¹, S. Joseph², S. Carey², S. Hall², J. Cowger³, S. P. Chaudhry³, S. Schroeder⁴, E. Birati⁵, M. Soni⁵, J. Marble⁵, B. Hognlund⁶, K. E. Sandau⁷. ¹*Minneapolis Heart Institute, Minneapolis, MN*, ²*Baylor Univ Medical Center, Dallas, TX*, ³*St. Vincent Heart Center, Indianapolis, IN*, ⁴*Bryan Heart Center, Lincoln, NE*, ⁵*Univ of Pennsylvania, Philadelphia, PA*, ⁶*Metropolitan State Univ, Saint. Paul, MN*, ⁷*Bethel Univ, Saint Paul, MN*

(1238) Restoring Quality of Life - Untethered LVAD Swimming; J. Webster, A. Krishnamoorthy, T. Hrobowski, A. Yehya, A. Darlington, C. Marti, D. Dean. *Advanced Heart Failure, Piedmont Heart, Atlanta, GA*

(1239) Quality of Life with a Ventricular Assist Device (QOLVAD) Questionnaire: Preliminary Psychometrics for a New Measure; K. E. Sandau¹, B. Pozehl², C. Y. Jurgens³, R. Garberich⁴, C. E. Weaver⁵, B. A. Hognlund⁶, S. Joseph⁷, S. Carey⁷, S. Hall⁷, J. Cowger⁸, S. P. Chaudhry⁸, S. Schroeder⁹, E. Y. Birati¹⁰, M. Soni¹⁰, J. Marble¹⁰, P. Eckman⁴. ¹*Bethel Univ/Allina Health, St. Paul, MN*, ²*College of Nursing, Univ of Nebraska Medical Center, Omaha, NE*, ³*School of Nursing, Stony Brook Univ, New York City, NY*, ⁴*Minneapolis Heart Institute, Minneapolis, MN*, ⁵*Abbott Northwestern Hospital/ Minneapolis Heart Institute, Minneapolis, MN*, ⁶*Metropolitan State Univ, St. Paul, MN*, ⁷*Baylor Univ Medical Center, Dallas, TX*, ⁸*St. Vincent Heart Ctr, Indianapolis, IN*, ⁹*Bryan Heart Center, Lincoln, NE*, ¹⁰*Univ of Pennsylvania, Philadelphia, PA*

(1240) Interval Depression Screening and Quality of Life Relationships in Ventricular Assist Device Patients; S. E. Schroeder¹, B. J. Pozehl², K. E. Sandau³, A. T. Lundstrom⁴. ¹*MCS Nurse Practitioner and Program Coordinator, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE*, ²*Nursing/Cardiology, University of Nebraska Medical Center, Omaha, NE*, ³*Nursing, Bethel University, St. Paul, MN*, ⁴*MCS RN Coordinator, Cardiothoracic Surgery, Bryan Heart, Lincoln, NE*

(1241) Improvement of Quality of Life and Mental Recovery after Left Ventricular Assist Device Implantation compared to Heart Transplantation; M. J. Barten¹, S. Gasser¹, A. Bernhardt¹, C. Buchholz¹, M. Rybczynski², H. Grahn², H. Reichenspurner¹. ¹*Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany*, ²*General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany*

(1242) Palliative Care Consultation in Cardiogenic Shock Requiring Short-term Mechanical Circulatory Support- A Retrospective, Description of Timing and Utilization From a Single Institution; S. Nakagawa, A. R. Garan, K. Takeda, V. K. Topkara, H. Takayama, M. Yuzefpolskaya, P. C. Colombo, Y. Naka, C. D. Blinderman. *Columbia University Medical Center, New York, NY*

(1243) Depressive Symptoms Among Women and Men After Left Ventricular Assist Device; J. Marble¹, R. Garberich², P. Eckman², C. E. Weaver³, S. Joseph⁴, S. Carey⁴, S. Hall⁴, J. Cowger⁵, S. P. Chaudhry⁵, S. Schroeder⁶, E. Y. Birati¹, M. Soni¹, B. A. Hoglund⁷, K. E. Sandau⁸. ¹*University of Pennsylvania, Philadelphia, PA*, ²*Minneapolis Heart Institute, Minneapolis, MN*, ³*Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN*, ⁴*Baylor University Medical Center, Dallas, TX*, ⁵*St. Vincent Heart Center, Indianapolis, IN*, ⁶*Bryan Heart Center, Lincoln, NE*, ⁷*Metropolitan State University, St. Paul, MN*, ⁸*Bethel University/Allina Health, St. Paul, MN*

(1244) The HeartWare HVAD System for the Treatment of Advanced Biventricular Heart Failure; S. Marasco¹, A. R. Simon², S. Tsui³, D. McGiffin¹, M. Pac⁴, U. Kervan⁴, A. E. Fiane⁵, J. D. Schmitto⁶. ¹*The Alfred Hospital, Melbourne, Australia*, ²*Royal Brompton and Harefield NHS Trust, Harefield, United Kingdom*, ³*Papworth Hospital, Cambridge, United Kingdom*, ⁴*Turkiye Yuksek Ihtisas Education & Research Hospital, Ankara, Turkey*, ⁵*Oslo University Hospital, Oslo, Norway*, ⁶*Hannover Medical School, Hannover, Germany*

(1245) A Novel Driveline Stabilisation Technique for VAD; S. Özçobanoglu, C. Kemaloglu, U. Koksel, O. Erbasan, I. Golbasi, C. Turkey, O. Bayezid. *Cardiovascular Surgery, Akdeniz University Faculty of Medicine, Antalya, Turkey*

(1246) PROMOTED TO ORAL

(1247) Recovery Plug for HeartMate 3 Left Ventricular Assist Device; J. Mulzer, E. Potapov, F. Kaufmann, M. Müller. *HTG, German Heart Institute, Berlin, Germany*

(1248) Less Invasive Left Ventricular Assist Device Implantation; Single Center Experience; D. Saeed, A. Albert, R. Wieloch, L. Ghari, B. Sowinski, U. Boeken, R. Westenfeld, P. Akhyari, A. Lichtenberg. *Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany*

(1249) Durability of Aortic Valve Repair with Park Stitch in Patients with Continuous Flow LVADS; E. Konik, J. Stulak, J. Schirger, A. Briasoulis. *Mayo Clinic, Rochester, MN*

(1250) Effect of Aortic Cross-clamping During Left Ventricular Assist Device Implantation: A Single Institutional 13-year Experience Over 500 Implantations; M. Kawabori, C. Kurihara, T. Sugiura, M. R. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, T. K. Rosengart, O. H. Frazier, J. A. Morgan. *Texas Heart Institute/ Baylor College of Medicine, Houston, TX*

(1251) Outcomes Using HVAD for Long-term Biventricular Support; M. Kawabori, C. Kurihara, T. Sugiura, R. M. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, T. K. Rosengart, O. H. Frazier, J. A. Morgan. *Texas Heart Institute/ Baylor College of Medicine, Houston, TX*

(1252) Mortality From Neurological Complications While on Continuous-flow Left Ventricular Assist Device Support; M. Kawabori, C. Kurihara, T. Sugiura, R. M. Delgado, L. Simpson, A. P. Nair, A. B. Civitello, T. K. Rosengart, O. H. Frazier, J. A. Morgan. *Texas Heart Institute/ Baylor College of Medicine, Texas Heart Institute/ Baylor College of Medicine, Houston, TX*

(1253) Pre-Cannulation SOFA Score is a Strong Predictor of Vasoplegia in Venous-Arterial Extra-Corporeal Life Support Patients; M. Leacche, N. Manandhar Shresta, C. E. Kelty, T. J. Boeve, S. Jovinge. *Fredrik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI*

(1254) Totally Implantable Ventricular Assist Devices: Wireless Powering over Sub-Meter Distances; J. Park, P. Bonde. *Section of Cardiac Surgery, Yale School of Medicine, New Haven, CT*

(1255) A Co-Rhythmic, Isolable, Self-Maintenance, Assist (CoRISMA) Device for Class III Heart Failure; J. Park, P. Bonde. *Yale School of Medicine, New Haven, CT*

(1256) Recovery or Remission? Changes in Cardiac Function After LVAD Explantation; P. Chavez¹, O. Saeed¹, U. Jorde¹, D. Goldstein², S. Patel¹. ¹*Cardiology, Montefiore Medical Center, New York, NY*, ²*Cardiovascular and Thoracic Surgery, Montefiore Medical Center, New York, NY*

(1257) Differential Effects of Carvedilol vs. Metoprolol on Mortality and Adverse Events in Left Ventricular Assist Device Patients; A. Pinsino¹, D. L. Jennings¹, J. Z. Willey¹, E. A. Royzman¹, M. Mabasa¹, F. Castagna², A. R. Garan¹, K. Ross¹, L. Effner¹, V. K. Topkara¹, Y. Naka¹, H. Takayama¹, K. Takeda¹, B. J. McDonnell³, J. R. Cockcroft³, P. C. Colombo¹, M. Yuzefpolskaya¹. ¹Columbia University, New York, NY, ²Yale Bridgeport Hospital, Bridgeport, CT, ³Cardiff Metropolitan University, Cardiff, United Kingdom

(1258) Neurohormonal Blockade with Sacubitril/Valsartan in Left Ventricular Assist Device (LVAD) Patients; E. Njue¹, K. Collins², H. Hayes¹, J. Barber¹, K. Lam¹. ¹Advanced Heart Failure and cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia, ²Cardiology, Fiona Stanley Hospital, Murdoch, Australia

(1259) Preoperative Patient Optimization Using Low Dose Levosimendan Improves Outcomes of Patients After Left Ventricular Assist Device Implantation; S. Kocabeyoglu¹, M. Pac¹, U. Kervan¹, M. Karahan¹, E. Aygun¹, O. Beyazal¹, U. Unal¹, Y. Guray², B. Demirkan². ¹Cardiovascular Surgery, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, ²Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey

(1260) Length of Stay, Hospitalization Cost and Disposition in U.S. Adult inpatients after Left Ventricular Assist Device Implantation (2009-2014); A. Briasoulis, P. Alvarez, I. Inampudi, E. Akintoye, J. Bhamra. University of Iowa, Iowa City, IA

(1261) Decoupling Between Diastolic Pulmonary Artery and Pulmonary Capillary Wedge Pressures at Incremental LVAD Speeds is a Poor Prognostic Factor Following LVAD Implantation; T. Imamura¹, D. Rodgers¹, G. Kim¹, J. Raikhelkar¹, N. Sarswat¹, S. Kalantari¹, A. Nguyen¹, B. Chung¹, C. Juricek¹, D. Burkhoff², T. Song¹, T. Ota¹, V. Jeevanandam¹, G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY

(1262) Estimation of Central Venous Pressure by Pacemaker Lead Impedances in LVAD Patients; T. Imamura¹, D. Rodgers¹, G. Kim¹, J. Raikhelkar¹, N. Sarswat¹, S. Kalantari¹, A. Nguyen¹, B. Chung¹, C. Juricek¹, D. Burkhoff², T. Song¹, T. Ota¹, V. Jeevanandam¹, G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY

(1263) Optimal Hemodynamics During LVAD Support Are Associated With Reduced Readmission Rate; T. Imamura¹, J. Raikhelkar¹, N. Sarswat¹, D. Rodgers¹, S. Kalantari¹, A. Nguyen¹, B. Chung¹, N. Narang¹, G. Kim¹, C. Juricek¹, C. Murks¹, T. Ota¹, T. Song¹, M. R. Costanzo², D. Burkhoff³, U. Jorde⁴, V. Jeevanandam¹, G. Sayer¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Advocate Heart Institute, Naperville, IL, ³Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY, ⁴Montefiore Medical Center, Bronx, NY

PULMONARY HYPERTENSION AND CTEPH **(Gallieni 1-2)**

Poster Discussants: Roberto Badagliacca (Italy), Marco Caccamo (USA), Elie Fadel (France), Stefan Soderberg (Sweden)

(1264) Impact of Right Ventricular Function and Pulmonary Hypertension Therapy on Graft Dysfunction and Death in Lung Transplant Recipients; M. Thornberg¹, C. J. Iasella¹, S. A. Esper¹, C. A. Moore¹, M. R. Morrell¹, J. Hayanga², N. Shigemura³, A. Zeevi¹, J. F. McDyer¹, C. R. Ensor¹. ¹University of Pittsburgh, Pittsburgh, PA, ²West Virginia University, Morgantown, WV, ³Temple University, Philadelphia, PA

(1265) The Pathology of Thromboendarterectomy Specimens from 50 Chronic Thromboembolic Pulmonary Hypertension Patients; E. R. Rodriguez¹, N. G. Smedira², G. A. Heresi³, C. D. Tan¹. ¹Pathology, The Cleveland Clinic, Cleveland, OH, ²Heart and Vascular Institute, The Cleveland Clinic, Cleveland, OH, ³Respiratory Institute, The Cleveland Clinic, Cleveland, OH

(1266) A "Thrombo-Endarterectomy" Approach: Establishing a New Center for CTEPH Patients; Y. Toyoda¹, M. A. Kashem¹, G. Ramakrishnan¹, A. Vaidya², P. Forfia². ¹Cardiovascular Surgery, Temple University, Philadelphia, PA, ²Cardiology, Temple University, Philadelphia, PA

(1267) Extracorporeal Life Support After Pulmonary Thromboendarterectomy: Single Institutions Outcome; J. R. Higgins¹, V. G. Pretorius¹, T. Fernandes¹, N. H. Kim², K. Kerr², D. Poch², D. Papamatheakis², M. Madani¹. ¹Cardiothoracic Surgery, UCSD Medical Center, La Jolla, CA, ²Pulmonary Medicine, UCSD Medical Center, La Jolla, CA

- (1268) Should Right Heart Hemodynamics be the Primary Guide for Operability for Pulmonary Thromboendarterectomy?**; D. Joyce¹, R. Frantz², S. Kushwaha², B. Lahr³, L. Joyce⁴. ¹Medical College of Wisconsin, Milwaukee, WI, ²Cardiovascular Medicine, Mayo Clinic, Rochester, MN, ³Surgery, Mayo Clinic, Rochester, MN, ⁴Surgery, Medical College of Wisconsin, Milwaukee, WI
- (1269) WITHDRAWN**
- (1270) Influence of Age on Pulmonary Vascular Function in Systemic Sclerosis: A Case Controlled Study;** A. Rimouche¹, S. Caravita², L. Dewachter³, A. Bondue¹, J. Vachieri¹. ¹Cardiology, Erasme, Brussels, Belgium, ²Cardiology, Ospedale S Luca IRCCS Istituto Auxologico Italiano, Milano, Italy, ³ULB, Brussels, Belgium
- (1271) Simple Echocardiographic Parameters to Capture Acute Changes in Right Ventricle-Pulmonary Artery Coupling in a Large Animal Model of Pulmonary Hypertension;** D. Boulate¹, M. Amsallem², G. Giraldeau³, B. Decante¹, E. Fadel¹, T. Kouznetsova⁴, F. Haddad², O. Mercier¹. ¹Laboratory of Surgical Research, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, ²Cardiovascular Institute, Stanford University, Palo Alto, CA, ³Cardiology, Institut de Cardiologie, Montreal, QC, Canada, ⁴Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven, Leuven, Belgium
- (1272) Moderate to Severe Right Ventricular Failure in the Setting of Pulmonary Hypertension Resolves in Most Patients After Lung Transplantation;** M. M. El-Sayed Ahmed¹, M. Thomas¹, S. Jacob¹, E. Lesser², Z. Li², C. K. Landolfo³, I. A. Makey¹, E. V. Belli¹, K. P. Landolfo¹, J. M. Mallea⁴, D. B. Erasmus⁴, F. Alvarez⁴, C. A. Keller⁴, T. Narula⁴, S. M. Pham¹. ¹Thoracic and Cardiovascular Surgery, Mayo Clinic, Jacksonville, FL, ²Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, ³Cardiovascular Diseases, Mayo Clinic, Jacksonville, FL, ⁴Lung Transplant, Mayo Clinic, Jacksonville, FL
- (1273) Predictors of Mortality in Acute Right Ventricular Failure in Severe Pre-capillary Pulmonary Hypertension Treated by Dobutamine;** M. Rietz. Cardiology, Hôpital Universitaire Erasme, Univ Libre de Bruxelles, Brussels, Belgium
- (1274) The Successful Transition from Injectable to Inhaled Prostacyclins in the Outpatient Setting for Patients with Pulmonary Arterial Hypertension;** L. Kimmig¹, C. Liao², R. Bag¹. ¹Pulmonary and Critical Care Medicine, University of Chicago Medicine, Chicago, IL, ²University of Chicago, Chicago, IL
- (1275) Cardiovascular Magnetic Resonance Imaging for Risk Assessment and Prediction of Clinical Worsening in Pulmonary Arterial Hypertension;** C. Göransson, N. Vejlstrop, J. Carlsen. Dept of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
- (1276) The Clinical Features of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease in Japan;** H. Maki¹, M. Hatano², S. Minatsuki¹, I. Komuro¹. ¹Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan, ²Therapeutic Strategy for Heart Failure, The University of Tokyo, Tokyo, Japan
- (1277) Clinical Classification and Prevalence of Pulmonary Hypertension in Rural;** L. Mirfakhraie¹, T. Dirks², S. Ebnet¹, P. Eckman³, B. Cabuay³, R. Garberich², S. Reed², P. J. Stokman², E. R. Fenstad². ¹Minneapolis Heart Institute Foundation, Minneapolis, MN, ²Minneapolis Heart Institute, Baxter, MN, ³Minneapolis Heart Institute, Minneapolis, MN
- (1278) Fluid Challenge During Right Heart Catheterization: An Experience From a Tertiary Pulmonary Hypertension Referral Centre;** N. Moghaddam¹, J. Swiston², R. D. Levy², V. F. Huckell³, N. W. Brunner³. ¹Dept of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Division of Respiriology, University of British Columbia, Vancouver, BC, Canada, ³Division of Cardiology, University of British Columbia, Vancouver, BC, Canada
- (1279) Characteristics of Cardiopulmonary Exercise Testing in Patients with Combined Post-capillary and Pre-capillary Pulmonary Hypertension (Cpc-PH) Due to Left Heart Disease;** A. Goda, K. Takeuchi, H. Kikuchi, T. Inami, T. Satoh, H. Yoshino. Kyorin University Hospital, Tokyo, Japan
- (1280) Reversibility of Pulmonary Hypertension with LVAD Support; A Meta-Analysis of Published Reports;** P. L. Tremblay, C. R. Herman, R. J. Baskett. Dept of Surgery, Dalhousie University, Halifax, NS, Canada
- (1281) Long-Term Changes in Pulmonary Haemodynamics after Continuous-Flow Left Ventricular Assist Device Implantation in Advanced Heart Failure Patients;** A. F. Giglio¹, L. F. Bertoldi², E. Perna¹, E. Ammirati¹, F. Macera¹, M. G. Cipriani¹, A. Garascia¹, F. Oliva¹, C. Russo¹, M. Frigerio¹. ¹ASST Niguarda, Milan, Italy, ²San Raffaele, Milan, Italy

(1282) Double-Lung versus Heart-Lung Transplantation for Pulmonary Hypertension - A Single-Center Experience; J. Brouckaert¹, S. Verleden², T. Verbelen³, P. De Leyn¹, W. Coosemans¹, H. Decaluwé¹, L. Depypere¹, P. Nafteux¹, H. Van Veer¹, B. Meyns³, F. Rega³, M. Van De Velde⁴, G. Poortmans⁴, S. Rex⁴, A. Neyrinck⁴, G. Van den Berghe⁵, M. Schetz⁵, D. Vlasselaers⁵, J. Van Cleemput⁶, W. Budts⁶, R. Vos⁷, C. Belge⁷, M. Delcroix⁷, G. M. Verleden⁷, D. E. Van Raemdonck¹. ¹Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ²Pneumology, Catholic University Leuven, Leuven, Belgium, ³Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium, ⁴Anesthesiology, University Hospitals Leuven, Leuven, Belgium, ⁵Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium, ⁶Cardiology, University Hospitals Leuven, Leuven, Belgium, ⁷Pneumology, University Hospitals Leuven, Leuven, Belgium

(1283) Unexpected Autopsy Finding as a Cause of Fatal Pulmonary Hypertension Post Transplant; X. Garcia¹, L. Gonzalez-Krellwitz², N. Gokden², E. Frazier¹. ¹Pediatric Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR, ²Pathology, University of Arkansas for Medical Sciences, Little Rock, AR


(1284) Evaluation of the Prognostic Factor and the Treatment Efficacy of Inhaled Iloprost in Patients with Group 3 Pulmonary Hypertension; P. Su, C. Hsu. National Cheng Kung University Hospital, Tainan, Taiwan

(1285) Quality of Life in Children and Young Adults With Pulmonary Hypertension and Its Association With Clinical Features; P. Chau¹, K. R. Schumacher¹, K. Uzark¹, R. G. Grifka¹, C. Miller¹, S. Yu¹, R. Lowery¹, J. M. Friedland-Little². ¹Pediatrics, University of Michigan, Ann Arbor, MI, ²Pediatrics, University of Washington, Seattle, WA

(1286) Rapid Transition from Parenteral to Oral Treprostinil in Pulmonary Hypertension is Feasible and Safe: A Retrospective Cohort Study; H. Jarrett¹, A. K. Jonnalagadda¹, S. D. Liu¹, A. J. Bagnola², D. Lewis³, O. A. Shlobin³, C. F. Barnett¹. ¹Heart and Vascular Institute, MedStar Washington Hospital Center / MedStar Georgetown University Hospital, Washington, DC, ²Division of Pharmacy, Inova Fairfax Hospital, Falls Church, VA, ³Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA

(1287) Double Lungtransplantation In Patients with End-Stage Pulmonary Arterial Hypertension or End-Stage Inoperable Chronic Thromboembolic Pulmonary Hypertension; A. Rinaldi¹, A. Dell'Amore², S. Pastore³, A. Rocca⁴, D. Giunta⁵, M. Palazzini¹, A. Manes¹, F. Dardi¹, E. Gotti¹, N. Galiè¹. ¹Cardiology, University of Bologna, Dept of Experimental, Diagnostic and Specialty Medicine - DIMES, Bologna, Italy, ²Thoracic Surgery, Bologna University Hospital, Bologna, Italy, ³Anesthesiology, Bologna University Hospital, Bologna, Italy, ⁴Pneumology, University of Bologna, Dept of Experimental, Diagnostic and Specialty Medicine - DIMES, Bologna, Italy, ⁵Thoracic Surgery, University of Bologna, Dept of Experimental, Diagnostic and Specialty Medicine - DIMES, Bologna, Italy


POSTER SESSION 1
WEDNESDAY, APRIL 11
GALLIENI 1-2
NNSAH



POSTER SESSION 1

WEDNESDAY, APRIL 11
AGORA 2


BSTR, PATH, PHARM




POSTER SESSION 1

WEDNESDAY, APRIL 11
AGORA 2


JFTC



POSTER SESSION 1
WEDNESDAY, APRIL 11
MUSES / EUTERPE
LTX, MCS




POSTER SESSION 2
THURSDAY, APRIL 12
GALLIENI 1-2
ID



POSTER SESSION 2

THURSDAY, APRIL 12
MUSES / EUTERPE


HF, HTX, MCS



POSTER SESSION 3

FRIDAY, APRIL 13
GALLIENI 1-2

PH, CTEPH





CORE COMPETENCIES IN HEART FAILURE AND CARDIAC TRANSPLANTATION

**Tuesday, April 10, 2018
7:55 AM – 5:30 PM
Mediterranee ABC**

Scientific Program Committee

Chair: Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
Co-Chair: Lavanya Bellumkonda, MD, Yale School of Medicine, New Haven, CT, USA
Co-Chair: Eric Epailly, MD, Les Hopitaux University, Strasbourg, France

Faculty

David Baran, MD, Newark Beth Israel Hospital, Newark, NJ, USA
Lavanya Bellumkonda, MD, Yale School of Medicine, New Haven, CT, USA
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA
Eugene DePasquale, MD, David Geffen School of Medicine, Los Angeles, CA, USA
Eric Epailly, MD, Les Hopitaux University, Strasbourg, France
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain
Maria Frigerio, MD, A.O. Niguarda-Ca'Granda, Milan, Italy
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, USA
Ranjit John, MD, University of Minnesota, Minneapolis, MN, USA
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy
Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FLA, USA
Jean Luc Vachieri, MD, Erasme University Hospital, Brussels, Belgium
Andre Vincentelli, CHU Regional de Lille Hospital Cardiologique, Lille, France

Practice Gaps

Heart failure is a leading cause of morbidity and mortality world-wide, and significant advances have occurred that are still not consistently implemented in every day practice. Clinicians need to understand the principles of acute and chronic heart failure disease management, including advanced treatment options, in order to deliver optimal care to these complex patients.

Target Audience

While all members are invited to enroll, this course is primarily designed to be of benefit for health care professionals who are in the early stages of their careers or who are in training, or who are part of a new program, or who desire an update on the current state of the field. The information presented is intended to provide a strong foundation of the core competencies of heart failure, cardiac transplantation and mechanical circulatory support, rather than as a detailed update for those who are already proficient in the field.

Educational Need

This course is designed to meeting the practitioner's education need for a targeted review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients with heart failure, cardiac transplantation, and mechanical circulatory support devices.

Learning Objectives

At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Understand the general concepts, definitions and management principles of patients with heart failure.
2. Understand the general concepts, indications, contraindications and management principles of patients who are evaluated for and receive cardiac transplant.

3. Understand the general concepts, indications, contraindications and management principles of patients who are evaluated for and receive mechanical circulatory support devices.

Course Summary

This course is designed for early career professionals with an interest in congestive heart failure, cardiac transplantation, and mechanical circulatory support. Each section is designed with focused, didactic lectures followed by Q&A. The first section will cover the general topics of heart failure – definitions, epidemiology, pathophysiology, etiology. It will then move to signs and symptoms, diagnostic process and management and treatment modalities, followed by a focus on the acute decompensated heart – challenges in recognition and treatment as well as new developments. The second section will review updates in the understanding and treatment of heart failure with preserved ejection fraction HFpEF, and pulmonary hypertension with an emphasis on its relationship with heart failure. The third section will encompass the cardiac transplant patient, from evaluation of the recipient candidate and donor, to perioperative management principles, immunology, immunosuppression, rejection, and common long-term challenges. The final section will review the history and development of mechanical circulatory support and management of common complications.

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 7.50 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This course is co-provided by AMEDCO and ISHLT. Maximum of 7.50 contact hours.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Faculty/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

SCIENTIFIC PROGRAM SCHEDULE

7:00 AM – 7:55 AM
REGISTRATION & MORNING COFFEE

7:55 AM – 8:00 AM
WELCOME AND OVERVIEW OF COURSE
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA

8:00 AM – 9:00 AM
SESSION 1: HEART FAILURE: OVERVIEW AND EVALUATION
Chair: Shelley Hall, MD

8:00 AM *Heart Failure: General Overview and Concepts*
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA

8:15 AM *Evaluation of Patients with Heart Failure*
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

8:30 AM *Heart Failure Tests*
Eugene DePasquale, MD, David Geffen School of Medicine, Los Angeles, CA, USA

8:45 AM Q&A with Panel

9:00 AM – 10:00 AM
SESSION 2: MANAGEMENT OF PATIENTS WITH CHRONIC HFrEF
Chair: Eric Epailly, MD

9:00 AM *Non-Pharmacologic and Pharmacologic Management*
Lavanya Bellumkonda, MD, School of Medicine, New Haven, CT, USA

9:15 AM *Principles for Arrhythmia Management and Electrical Devices*
Maria Frigerio, MD, A.O. Niguarda-Ca'Granda, Milan, Italy

9:30 AM *Surgical Management of Heart Failure*
Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FL, USA

9:45 AM Q&A with Panel

10:00 AM – 10:30 AM
COFFEE BREAK

10:30 AM – 11:30 AM
SESSION 3: ACUTE DECOMPENSATED HEART FAILURE
Chair: Lavanya Bellumkonda, MD

10:30 AM *Epidemiology and Pharmacologic Management*
David Baran, MD, Newark Beth Israel Hospital, Newark, NJ, USA

10:45 AM *Cardiogenic Shock*
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA

11:00 AM *Transitions of Care*
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA

11:15 AM Q&A with Panel

11:30 AM – 1:00 PM
LUNCH BREAK

1:00 PM – 2:00 PM

SESSION 4: HFPEF AND PULMONARY HYPERTENSION

Chair: Shelley Hall, MD

1:00 PM *HFpEF*

Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

1:20 PM *Pulmonary Hypertension: PAH in Heart Failure*

Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium

1:40 PM Q&A with Panel

2:00 PM – 3:00 PM

SESSION 5: HEART TRANSPLANTATION 101

Chair: Lavanya Bellumkonda, MD

2:00 PM *Evaluation of the Transplant Candidate*

Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

2:15 PM *Perioperative Management*

Ranjit John, MD, University of Minnesota, Minneapolis, MN, USA

2:30 PM *Chronic Care of the Transplant Recipient*

Eric Epailly, MD, Les Hopitaux University, Strasbourg, France

2:45 PM Q&A with Panel

3:00 PM – 3:30 PM

COFFEE BREAK

3:30 PM – 4:30 PM

SESSION 6: MECHANICAL CIRCULATORY SUPPORT

Chair: Eric Epailly, MD

3:30 PM *Current Devices and Outcomes*

Scott Silvestry, MD, Florida Hospital Transplant Institute, Orlando, FLA, USA

3:50 PM *Chronic Complications in MCS*

Andre Vincentelli, CHU Regional de Lille Hospital Cardiologique, Lille, France

4:10 PM Q&A with panel

4:30 PM – 5:30 PM

SESSION 7: CASE PRESENTATIONS

Chairs: Shelley Hall MD; Lavanya Bellumkonda, MD; Eric Epailly MD

4:30 PM *Cardiogenic Shock Case*

David Baran MD, Newark Beth Israel Hospital, NJ, USA

4:45 PM *Transplant vs VAD Case*

Susan Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

5:00 PM Q&A with Panel

5:15 PM – 5:30 PM

COURSE SUMMARY AND EVALUATION

Shelley Hall MD, Baylor University Medical Center, Dallas, TX, USA

5:30 PM

ADJORN



CORE COMPETENCIES IN LUNG TRANSPLANTATION

**Tuesday, April 10, 2018
7:55 AM – 5:45 PM
Hermes**

Scientific Program Committee

Chair: Lorriana Leard, MD, University of California San Francisco, CA, USA
Co-Chair: Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden
Co-Chair: Daniel Dilling, MD, Loyola University Medical Center, Maywood, IL, USA

Faculty

Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden
Daniel Dilling, MD, Loyola University Medical Center, Maywood, IL, USA
Mark Greer, MB Bch, Hannover Medical School, Hannover, Germany
Allan R. Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia
Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA
Matthew Hartwig, MD, Duke University, Durham, NC, USA
Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN, USA
David Hormuth, MD, St. Mary's Medical Group, Indianapolis, IN, USA
Lorriana Leard, MD, University of California San Francisco, CA, USA
Erika D. Lease, MD, University of Washington, Seattle, WA, USA
Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, Canada
Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA
Sofya Tokman, MD, Norton Thoracic Institute, Phoenix, AZ, USA
Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
Robin Vos, MD, PhD, KU Leuven, Leuven, Belgium

Practice Gaps

1. The technology available to support the clinical practice of lung transplantation has progressed significantly in the past 7 years with advanced innovations available to support patients undergoing lung transplantation, to evaluate donor lungs, and to support patients in the immediate post-operative period. This course will address the application of these technologies in clinical practice.
2. Advanced understanding of the presentations of both acute and chronic allograft dysfunction has led to improved description and recognition of antibody mediated rejection, obstructive chronic lung allograft dysfunction and restrictive allograft syndrome that all specialists caring for lung transplantation need to be able to recognize.
3. Clinicians involved in the care of lung transplant patients are seeking a comprehensive review of the available evidence and consensus opinion about the evaluation and management of lung transplant patients.

Target Audience

While all members are invited to enroll, this course is primarily designed to be of benefit for health care professionals who are in the early stages of their careers or who are in training, or who are part of a new program, or who desire an update on the current state of the field. The information presented is intended to provide a strong foundation of the core competencies of lung transplantation, rather than as a detailed update for those who are already proficient in the field.

Educational Need

This course meets the practitioner's educational need for a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of lung transplantation.

Learning Objectives

At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Explain in detail how to evaluate and list potential candidates for lung transplantation.
2. Discuss perioperative management of the donor, lung procurement, and operative strategies including use of extracorporeal life support and ex vivo lung perfusion.
3. Recognize the most common post-transplant complications including immediate post-operative complications, acute and chronic allograft dysfunction, infections, and other systemic complications.
4. Describe the immunosuppressive and preventative medication regimens that utilized in lung transplant recipients, the rationale for their use, and their potential complications.

Course Summary

The Core Competency Course in Lung Transplantation will provide a detailed examination of the clinical practice of lung transplantation today. Through focused presentations with an emphasis on clinical practice, the course will provide a historical context, cover candidate selection, donor management and organ procurement, post-transplant management and complications.

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 7.25 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This course is co-provided by AMEDCO and ISHLT. Maximum of 7.25 contact hours.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

SCIENTIFIC PROGRAM SCHEDULE

7:00 AM – 7:55 AM
REGISTRATION AND MORNING COFFEE

7:55 AM – 8:00 AM
WELCOME AND OVERVIEW
Lorriana Leard, MD, University of California San Francisco, CA, USA

8:00 AM - 9:00 AM
SESSION 1: LUNG TRANSPLANTATION: GETTING FROM HERE TO THERE – HISTORY, CANDIDATE AND DONOR SELECTION
Chair: Lorriana Leard, MD

8:00 AM History of Lung Transplantation
Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN, USA

8:15 AM Lung Transplant Candidacy, Selection, and Listing, Including Allocation Systems
Allan R. Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

8:30 AM Lung Allograft Donation and Procurement
Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden

8:45 AM Q&A with Panel

9:00 AM – 10:00 AM
SESSION 2: SURGICAL AND POST-OPERATIVE MANAGEMENT OF LUNG TRANSPLANT RECIPIENTS
Chair: Göran Dellgren, MD, PhD

9:00 AM Surgical Options and Procedural Issues in Lung Transplantation
David Hormuth, MD, St. Mary's Medical Group, Indianapolis, IN, USA

9:15 AM The Role of ECMO - To ECMO or not the ECMO, that is the Question!
Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, SWEDEN

9:30 AM Surgical Complications and Post-OP Management after Lung Transplantation
Matthew Hartwig, MD, Duke University, Durham, NC, USA

9:45 AM Q&A with Panel

10:00 AM – 10:30 AM
COFFEE BREAK

10:30 AM – 11:30 AM
SESSION 3: DEALING WITH REJECTION
Chair: Daniel Dilling, MD

10:30 AM Acute Cellular Rejection (ACR)
Mark Greer, MB Bch, Hannover Medical School, Hannover, Germany

10:45 AM Antibody Mediated Rejection (AMR)
Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA

11:00 AM Chronic Lung Allograft Dysfunction (CLAD)
Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

11:15 AM Q&A with Panel

11:30 AM – 1:00 PM
LUNCH BREAK

1:00 PM – 2:00 PM

SESSION 4: MANAGING THE MEDS – IMMUNOSUPPRESSION AND THE SYSTEMIC EFFECTS

Chair: Lorriana Leard, MD

1:00 PM Induction and Maintenance Immunosuppression

Daniel Dilling, MD, Loyola University Medical Center, Maywood, Illinois, USA

1:15 PM Hematologic Disorders Following Lung Transplant

Lorriana Leard, MD, University of California San Francisco, CA, USA

1:30 PM Gastrointestinal Issues Post Lung Transplant

Matthew Hartwig, MD, Duke University, Durham, NC, USA

1:45 PM Q&A with Panel

2:00 PM – 3:00 PM

SESSION 5: BUGS AND THEIR DRUGS – PROPHYLAXIS, DIAGNOSIS AND MANAGEMENT OF INFECTIONS AFTER LUNG TRANSPLANT

Chair: Göran Dellgren, MD, PhD

2:00 PM Bacterial and Mycobacterial Infections in Lung Transplantation

Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

2:15 PM Fungal Infections in Lung Transplant Recipients

Erika D. Lease, MD, University of Washington, Seattle, WA, USA

2:30 PM Viral Pathogens from A to V (Adenovirus, CMV, EBV, HSV, RSV, and VZV)

Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA

2:45 PM Q&A with Panel

3:00 PM – 3:30 PM

COFFEE BREAK

3:30 PM – 4:30 PM

SESSION 6 – MALEVOLENT MALIGNANCIES

Chair: Daniel Dilling, MD

3:30 PM Skin Cancer in Lung Transplant Recipients

Sofya Tokman, MD, Norton Thoracic Institute, Phoenix, AZ, USA

3:45 PM Post Transplant Lymphoproliferative Disease (PTLD) in Thoracic Transplantation

Laurie D. Snyder, MD, Duke University Medical Center, Durham, NC, USA

4:00 PM Lung Cancer and Other Malignancies in Lung Transplant Recipients

Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

4:15 PM Q&A with Panel

4:30 PM – 5:30 PM

SESSION 7 – LIFE AFTER TRANSPLANT

Chair: Lorriana Leard, MD

4:30 PM Management of the Metabolic Complications – Diabetes, Hypertension, and Osteoporosis

Daniel Dilling, MD, Loyola University Medical Center, Maywood, Illinois, USA

4:45 PM Reproductive Health after Lung Transplantation – Contraception, Fertility, and Pregnancy

Robin Vos, MD, PhD, KU Leuven, Leuven, Belgium

5:00 PM This is My Life – Outcomes and Quality of Life Post Transplant

Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, Canada

5:15 PM Q&A with Panel

5:30 PM – 5:45 PM

COURSE SUMMARY AND ASSESSMENT

Lorriana Leard, MD, University of California San Francisco, CA, USA

5:45 PM

ADJORN



CORE COMPETENCIES IN MECHANICAL CIRCULATORY SUPPORT

**Tuesday, April 10, 2018
8:00 AM – 5:30 PM
Athena**

Scientific Program Committee

Chair: Diyar Saeed, MD, PhD, Heinrich-Heine University, Dusseldorf, Germany
Co-Chair: Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA, USA
Co-Chair: Jennifer Cook, MD, University of Arizona Heart Center, Tucson, AZ, USA

Faculty

Saima Aslam, MD, MS, University of California San Diego, San Diego, CA, USA
Jennifer Cook, MD, University of Arizona Heart Center, Tucson, AZ, USA
Michael Dickinson, MD, Spectrum Health, Grand Rapids, MI, USA
Jens Garbade, University of Leipzig, Leipzig, Germany
Jonathan Haft, MD, University of Michigan, Ann Arbor, MI, USA
Douglas Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA
Susan M. Joseph, MD, Baylor University Medical Center, Dallas, TX, USA
Antonio Loforte, MD, PhD, S. Orsola Hospital, Bologna, Italy
Kavitha Muthiah, MBChB, St. Vincent's Hospital, Sydney, Australia
Samer Najjar, MD, Medstar Heart Institute, Washington, DC, USA
Evgenij Potapov, MD, PhD, Deutsches Herzzentrum, Berlin, Germany
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada
Ryan Tedford, MD, Medical University of South Carolina, Charleston, SC, USA
Diyar Saeed, MD, PhD, Heinrich-Heine University, Dusseldorf, Germany
Christopher Salerno, MD, St Vincent Heart Center of Indiana, Indianapolis, IN, USA.
Thomas Schloeglhofer, BSc, Medical University of Vienna, Vienna, Austria
Stephan Schueler, MD, PhD, FRCS, Newcastle Upon Tyne Hospital, Newcastle Upon Tyne, United Kingdom
Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA, USA
Lynne Warner Stevenson, MD, Vanderbilt University, Nashville, TN, USA

Practice Gaps

The field of the mechanical circulatory support systems experienced steady growth during the last years. The management of these complex patients remains challenging and starts prior to the surgical procedures. There is still lack of adequate knowledge of proper patient selection, right ventricular assessment, and proper management of device-related complications. This Course will address all important aspects in the management of these patients starting from patient selection and preparation for the assist device implantation. Further, several alternative implantation approaches and surgical pitfalls are presented. Finally, issues related to the home transition and adequate state of art management strategies of assist device related complication management are addressed.

Target Audience

While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training and/or are part of a new program or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of mechanical support, rather than as a detailed update for those who are already proficient experts in the field.

Educational Need

This course is designed to meeting the practitioner's educational need for a targeted review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients with mechanical circulatory support devices.

Learning Objectives

At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Explain how to risk stratify patient with advanced heart failure in order to assess MCS surgical risk and optimally time mechanical circulatory support (MCS) implantation.
2. Discuss the medical and social factors which impact patient outcomes during short- and long-term MCS.
3. Recognize the various types of MCS support available for patients with advanced single or biventricular heart failure and the technological differences that may impact pump selection and patient/device management.
4. Identify MCS implantation techniques and patient/pump management during the index admission intensive care unit and inpatient general care periods.
5. Describe how to manage patients and the MCS during outpatient long-term support with an understanding of interventions that can reduce patient- and device-related adverse events during MCS.
6. Diagnose and manage common clinical dilemmas and adverse encountered after MCS.

Course Summary

The purpose of this Core Competency Course is to provide a concise review of clinical knowledge and outline of the essential professional skills for candidate assessment and longitudinal support for mechanical circulatory support patients. This Course should serve programs providing mechanical circulatory support with a tool to review their standards of care, develop protocols, and implement guidelines established in management of mechanical circulator support patients.

The Course consists of six plenary sessions; in the first session, the current state of mechanical circulatory support systems are reviewed, followed by the challenging task of adequate patient selection and preoperative preparation including proper assessment tools of right ventricular function. In the third session all surgical aspects and alternative approaches of assist device implantation are addressed, followed by immediate postoperative care related issues and management of right ventricular insufficiency. The fifth session addresses the preparation strategies for proper and safe patient transition to home. In the final session, adequate management of device related long term complications are presented.

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 8.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This course is co-provided by AMEDCO and ISHLT. Maximum of 8.00 contact hours.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

SCIENTIFIC PROGRAM SCHEDULE

7:00 AM – 8:00 AM

MORNING COFFEE AND REGISTRATION

8:00 AM – 8:05 AM

WELCOME AND OVERVIEW

Diyar Saeed, MD, PhD, Heinrich-Heine University, Dusseldorf, Germany

8:05 AM – 9:15 AM

SESSION 1 – REVIEW OF THE CURRENT STATE OF MCS

Chair: Diyar Saeed, MD, PhD

8:05 AM MCS Technology 101

Evgenij Potapov, MD, PhD, Deutsches Herzzentrum, Berlin, Germany

8:25 AM BTT and DT Outcome

Lynne Warner Stevenson, MD, Vanderbilt University, Nashville, TN, USA

8:40 AM Short-term Support and Shock

Jonathan Haft, MD, University of Michigan, Ann Arbor, MI, USA

9:00 AM Q&A with panel

9:15 AM – 10:30 AM

SESSION 2 – PATIENT SELECTION

Chair: Palak Shah, MD, MS

9:15 AM When Should Patients be Referred: Warning Signs

Douglas Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA

9:35 AM Assessing and Optimizing RV Function Preoperatively

Ryan Tedford, MD, Medical University of South Carolina, Charleston, SC, USA

9:55 AM Quality of Life After VAD and the Impact of Frailty and Social Behaviors on VAD Success

Susan M. Joseph, MD, Baylor University Medical Center, Dallas, TX, USA

10:15 AM Q&A with panel

10:30 AM – 10:45 AM

COFFEE BREAK

10:45 AM – NOON

SESSION 3: SURGICAL CONSIDERATIONS

Chair: Diyar Saeed, MD, PhD

10:45 AM Key Surgical Aspects of Implantation

Jens Garbade, University of Leipzig, Leipzig, Germany

11:05 AM How Much Else is Too Much?

Stephan Schueler, MD, PhD, FRCS, Newcastle Upon Tyne Hospital, Newcastle Upon Tyne, UK

11:25 AM Tailoring Pumps to Patients

Diyar Saeed, MD, Heinrich-Heine University, Dusseldorf, Germany

11:45 AM Q&A with panel

NOON – 1:00 PM

LUNCH BREAK

1:00 PM – 2:15 PM

SESSION 4: POSTOPERATIVE CARE

Chair: Jennifer Cook, MD

1:00 PM Managing the RV Postop

Christopher Salerno, MD, St Vincent Heart Center of Indiana, Indianapolis, Indiana, USA.

1:20 PM Anticoagulation and Antiplatelet Therapy

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Canada

1:40 PM Pump Speed Optimization: The Role of Imaging and Hemodynamics

Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, Virginia, USA

2:00 PM Q&A with panel

2:15 – 3:15 PM

SESSION 5: TRANSITION TO HOME

Chair: Jennifer Cook, MD

2:15 PM VAD Education: Patient/Caregiver Assessments and Strategies for Successful VAD Self-Care

Thomas Schloeglhofer, BSc, Medical University of Vienna, Vienna, Austria

2:30 PM Starting New: How to Start and Succeed in MCS

Michael Dickinson, MD, Spectrum Health, Grand Rapids, MI, USA

2:45 PM Optimal Outpatient Management of VAD Recipients

Antonio Loforte, MD, PhD, S. Orsola Hospital, , Bologna, Italy

3:00 PM Q&A with panel

3:15 PM – 3:30 PM

COFFEE BREAK

3:30 PM – 5:20 PM

SESSION 6: LONG TERM MANAGEMENT OF PATIENTS AND COMPLICATIONS

Chair: Palak Shah, MD, MS

3:30 PM LVAD Infections: Prevention, Diagnosis, and Management

Saima Aslam, MD, MS, University of California San Diego, San Diego, CA, USA

3:50 PM Stroke: Risk factors for Hemorrhagic and Embolic CNS Complications and Management Strategies

Samer Najjar MD, Medstar Heart Institute, Washington, DC, USA

4:10 PM Pump Thrombosis: Diagnostic Strategies and Management Algorithms

Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, Virginia, USA

4:30 PM Aortic Insufficiency in LVAD Recipients: Incidence, Screening, and Management

Jennifer Cook, MD, University of Arizona Heart Center, Tucson, AZ, USA

4:50 PM GI Bleeding

Kavitha Muthiah, MBChB, St. Vincent's Hospital, Sydney, Australia

5:10 PM Q&A with panel

5:20 PM – 5:30 PM

COURSE SUMMARY AND ASSESSMENT

Palak Shah, MD, MS

5:30 PM

ADJORN



MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT

**Tuesday, April 10, 2018
Clio, Thalie**

Scientific Program Committee

Chair: Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA

Co-Chair: Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Faculty

Meredith Brisco, MD, MSCE, Temple University, Philadelphia, PA, USA

Igor Gregoric, MD, Center for Advanced Heart Failure, Houston, TX, USA

JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

Bart Meyns, MD, PhD, Uz, K Uleuven, Leuven, Belgium

Jerry Estep, MD, The Methodist, Hospital, Houston, TX, USA

Finn Gustafson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

Snehal Patel, MD, Montefiore Medical Center, Bronx, NY, USA

Course Summary

The MCS Master Class is intended for members with higher levels of expertise (completed the core curriculum course on MCS and/or primary practice in MCS \geq 5 years). The course setting will generate a highly interactive environment composed of a small group of individuals and designed to enhance individual expertise and network development. Utilizing the concept of “convergent discussion” and the technique of “audience response system”, faculty moderators will use complex situations and controversial statements during practical case presentations in order to lead the group through active audience participation, towards specific answers based on practice gaps and learning objectives. The MCS Master Class is arranged in advanced breakout sessions for every participant to take full advantage of an integrated curriculum and the exceptional networking opportunity. The specific topics are devised according to defined clinical practice gaps in this fast developing specialty.

Practice Gaps

1. The outcomes of cardiogenic shock have remained poor, large randomized trials are scarce and the management of these patients remains challenging. Comprehensive clinical expertise of advanced usage of evolving MCS options including patient and device selection and transition to next step therapies constitute currently major limitations in the care of these critically ill patients.
2. Structures to seamlessly communicate events occurring in and outside of the operating room to ensure optimal performance by providers in each setting are lacking. Surgeons, cardiologist, and critical care practitioner often lack in depth insight of decision algorithms employed by their counterparts before, during, and after device implant and explant procedures.
3. The outcome impact and preferred technique of ancillary procedures - such as valve repair / replacement or left atrial appendage occlusion - during LVAD implantation has not been established.
4. The diagnosis and management of complex and combined adverse events such as cerebrovascular hemorrhagic accidents, device thrombosis and gastrointestinal bleeding is challenging and practitioners often face difficulties in developing effective strategies to appropriately identify and treat these adverse events.
5. The diagnostic and therapeutic approaches for early and late right ventricular failure in MCS patients has been evolving with the introduction of new diagnostic criteria and new technologies/therapeutic options. Such practice gaps in specialist knowledge and clinical skills constitute major limitations in the care of MCS patients.

6. The use of extracorporeal membrane oxygenation is growing rapidly both as a bridge to decision tool before LVAD/HTX and as a rescue bridge to recovery tool in the setting of primary graft failure, yet outcomes of patients transitioned from ECMO to LVAD or HTX remain poor and MCS based PGF treatment strategies have not been developed.

Target Audience

The target audience for this class includes cardiothoracic surgeons and cardiologists with MCS experience, specialists in heart failure care, allied health professionals with involvement in MCS patients, VAD coordinators, transplant coordinators, critical care specialists, and heart transplant professionals.

Educational Need

Mechanical circulatory support is a relatively new and rapidly evolving therapy for advanced congestive heart failure. Multiple device technologies are now in use for short and long term support and patient outcomes are highly dependent on in-depth understanding of device-induced changes in physiology as well as device specific serious adverse events. Multidisciplinary teams are an essential part of modern day mechanical circulatory support management. This Class is designed to meet the target audience's need for an advanced learning opportunity that explores and seeks to address the unique clinical challenges faced by specialists and developing experts in the field of MCS for treatment of heart failure patients.

Learning Objectives

Upon completion of the Master Class, participants will be able to:

- 1: Identify the challenges during the diagnosis and management of complex cardiogenic shock patients and the potential benefits of a multidisciplinary team approach
- 2: Explain how to appropriately select patients for long-term MCS options with particular consideration of the need for / utility of ancillary procedures
- 3: Enhance understanding of the bidirectional impact of surgical and medical technique and management approaches
- 4: Describe how to develop a systematic approach to diagnosis and therapy of complex and combined adverse events such as device thrombosis, recurrent gastrointestinal bleeding and stroke
- 5: Name the diagnostic and therapeutic challenges of early and late RV failure
6. Acquire in depth understanding of ECMO placement, management, and explant in combination with LVAD or heart transplantation

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credits*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This course is co-provided by AMEDCO and ISHLT. Maximum of 4.25 contact hours.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

MORNING SCIENTIFIC PROGRAM SCHEDULE

8:00 AM – 8:10 AM

WELCOME AND OVERVIEW

Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA

Ivan Netuka, MD, PhD, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

8:10 AM – 10:15 AM

SMALL GROUP INTERACTIVE DISCUSSION A: ACUTE MCS FOR SHOCK

Moderator: Finn Gustafson, MD

CASE SCENARIO A1: IABP to non-ECMO percutaneous MCS transition

Finn Gustafson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

CASE SCENARIO A2: ECMO

Bart Meyns, MD, PhD, Uz, K Uleuven, Leuven, Belgium

SMALL GROUP INTERACTIVE DISCUSSION B: BLEEDING AND THROMBOSIS

Moderator: Jerry Estep, MD

CASE SCENARIO B1: Recurrent GI Bleeding and Pump Thrombosis

Snehal Patel, MD, Montefiore Medical Center, Bronx, NY, USA

CASE SCENARIO B2: Management of cerebrovascular hemorrhagic accidents

Jerry Estep, MD, The Methodist, Hospital, Houston, TX, USA

10:15 AM – 10:45 AM

COFFEE BREAK

10:45 AM – 12:50 PM

SMALL GROUP INTERACTIVE DISCUSSION C: ANCILLARY PROCEDURES IN LVAD

Moderator: Igor Gregoric, MD

CASE SCENARIO C1: A patient with atrial fibrillation and severe mitral regurgitation

Igor Gregoric, MD, Center for Advanced Heart Failure, Houston, TX, USA

CASE SCENARIO C2: A patient with prior sternotomy and severe tricuspid regurgitation

Meredith Brisco, MD, MSCE, Temple University, Philadelphia, PA, USA

SMALL GROUP INTERACTIVE DISCUSSION D: BAILOUT STRATEGIES FOR ECMO / BYPASS WEANING FAILURE

Moderator: JoAnn Lindenfeld, MD

CASE SCENARIO D1: ECMO weaning failure – transition to durable device or “high risk organ”?

JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

CASE SCENARIO D2: Primary graft failure – ECMO?

Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

12:50 PM – 1:00 PM

COURSE SUMMARY AND ASSESSMENT

Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA

Ivan Netuka, MD, PhD, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

1:00 PM

ADJOURN

AFTERNOON SCIENTIFIC PROGRAM SCHEDULE

2:00 PM – 2:10 PM

WELCOME AND OVERVIEW

Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA

Ivan Netuka, MD, PhD, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

2:10 PM – 4:15 PM

SMALL GROUP INTERACTIVE DISCUSSION A: ACUTE MCS FOR SHOCK

Moderator: Finn Gustafson, MD

CASE SCENARIO A1: IABP to non-ECMO percutaneous MCS transition

Finn Gustafson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

CASE SCENARIO A2: ECMO

Bart Meyns, MD, PhD, Uz, K Uleuven, Leuven, Belgium

SMALL GROUP INTERACTIVE DISCUSSION B: BLEEDING AND THROMBOSIS

Moderator: Jerry Estep, MD

CASE SCENARIO B1: Recurrent GI Bleeding and Pump Thrombosis

Snehal Patel, MD, Montefiore Medical Center, Bronx, NY, USA

CASE SCENARIO B2: Management of cerebrovascular hemorrhagic accidents

Jerry Estep, MD, The Methodist, Hospital, Houston, TX, USA

4:15 PM – 4:45 PM

COFFEE BREAK

4:45 PM – 6:50 PM

SMALL GROUP INTERACTIVE DISCUSSION C: ANCILLARY PROCEDURES IN LVAD

Moderator: Igor Gregoric, MD

CASE SCENARIO C1: A patient with atrial fibrillation and severe mitral regurgitation

Igor Gregoric, MD, Center for Advanced Heart Failure, Houston, TX, USA

CASE SCENARIO C2: A patient with prior sternotomy and severe tricuspid regurgitation

Meredith Brisco, MD, MSCE, Temple University, Philadelphia, PA, USA

SMALL GROUP INTERACTIVE DISCUSSION D: BAILOUT STRATEGIES FOR ECMO / BYPASS WEANING FAILURE

Moderator: JoAnn Lindenfeld, MD

CASE SCENARIO D1: ECMO weaning failure – transition to durable device or “high risk organ”?

JoAnn Lindenfeld, MD, Vanderbilt University, Nashville, TN, USA

CASE SCENARIO D2: Primary graft failure – ECMO?

Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

6:50 PM – 7:00 PM

COURSE SUMMARY AND ASSESSMENT

Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA

Ivan Netuka, MD, PhD, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

7:00 PM

ADJOURN



MASTER CLASS IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Tuesday, April 10, 2018
2:00 PM – 7:00 PM
Erato, Uranie

Scientific Program Committee

Chair: David Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom
Co-Chair: Mardi Gomberg-Maitland MD, MSc, Inova Heart and Vascular Institute, Falls Church, VA, USA

Faculty

William Auger, MD, UCSD Medical Center, San Diego, CA, USA
Raymond Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
John Cannon, FRCP, Papworth Hospital, Cambridge, United Kingdom
Duane Davis, MD, MBA, Florida Hospital, Orlando, FL, USA
Marion Delcroix, MD, PhD, University Hospital Leuven, Leuven, Belgium
Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada
Elie Fadel, MD, Hospital Marie Lannelongue, La Plessis-Robinson, France
Deepa Gopalan, MD, Papworth Hospital, Cambridge, United Kingdom
Irene Lang, MD, Medical University of Vienna, Vienna, Austria
Michael Madani, MD, University of California San Diego Medical Center, San Diego, CA, USA
Takeshi Ogo, National Cerebral and Cardiovascular Center, Osaka, Japan
Joanna Pepke-Zaba, PhD, Papworth Hospital NHS Trust, Cambridge, United Kingdom

Course Summary

The four topics covered in Class include: Diagnostic challenges/modalities utilized for CTEPH, management strategies of the complex CTEPH patient, interventional approaches, and mechanical support and surgery for CTEPH. The topics cover the major aspects of CTEPH and highlight the significant differences in the diagnosis and management of these entities. Utilizing the concept of “convergent discussion” and audience response system techniques, faculty moderators will use complex clinical situations and controversial statements during practical case presentations in order to direct active audience participation. The aim is to provide specific insights based on current practice gaps and achieve selected learning objectives.

Practice Gaps

1. The multidisciplinary team approach is needed to properly diagnose, assess, and determine operability for CTEPH. The correct interpretation of imaging to select patients who will get a good technical response is not always easy to determine. Therefore, clinical decisions and whether or not to provide operative interventions need to be made with a deep understanding of the pathophysiology of the disease. The established risks and potential benefits that CTEPH treatment may offer, including surgery in this setting are discussed.
2. The current evidence base regarding the use of vasodilator drugs in technically operable patients, instead of or in addition to surgery, is in evolution. The timing and use in general of these pharmaceutical agents is controversial. The criteria for decision making, including, clot burden, anatomy of obstruction, and the individual patients’ co-morbidities are controversial.
3. Although the interventionalists have improved their techniques and understanding of balloon pulmonary angioplasty (BPA) there is still uncertainty surrounding the selection of patients for surgery versus performing BPA versus medical therapy. There is uncertainty as to the best approach in “segmental CTEPH disease”. This is an area that warrants further studies and discussions by a multidisciplinary group of experts.

4. Surgical techniques for CETEPH patients have improved. Advanced endarterectomy techniques, however, may be utilized without a clear standardization of approach. A discussion of these techniques risk/benefit is required. Understanding these newer approaches will help the team determine the best approach medical, surgical, interventional or a hybrid approach. The peri-operative care techniques and coordination is integral to surgical success. This may not be usually standardized or discussed in detail. There is a clear need to focus on this aspect of the procedure.

Target Audience

The Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Master Class is an ISHLT educational event intended for specialists with advanced levels of expertise. Ideally, participants will have completed the core competency course on Pulmonary Hypertension (PH) and/or have primary practice in thoracic, cardiothoracic surgery or medical treatment of PH ≥ 5 years) and will have managed patients with one or more of the topics intended for discussion.

Pulmonologists/respirologists, cardiologists, thoracic surgeons, cardiothoracic surgeons, interventional radiologists, interventional cardiologists, nurses, physician assistants, and allied health professionals with experience in CTEPH. The course is mainly intended for health care whose primary practice includes care of CTEPH patients and providers who are developing programs for medical, surgical or interventional treatment in this field.

Educational Need

The field of chronic thromboembolic disease is a changing landscape with increasing evidence for new therapies. With improved diagnostic tools, surgical techniques, use of interventional approaches, and the approval of medical therapies, the disease requires a multi-disciplinary team approach and training to understand contemporary decision making. This Class is designed to meet the target audience's need for an advanced learning opportunity that explores and seeks to address the unique clinical challenges faced by those caring for patients with CTEPH.

Learning Objectives

After completion of this Master Class, the participant will have improved competence and professional performance in their ability to:

1. understand the imaging features that indicate operability in CTEPH patients
2. differentiate low and high risk scenarios for CETEPH interventions
3. appreciate the evidence gaps relating to the use of vasodilator drugs in CTEPH
4. acknowledge the overlap in the use of BPA and PEA in patients with segmental CTEPH disease dependent on institutional experience and hence the uncertainty in the current guidelines
5. understand the advanced technical endarterectomy procedure and care of patients with perioperative complications

Accreditation Statement

The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

ISHLT designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credits*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit

AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This course is co-provided by AMEDCO and ISHLT. The maximum credit is 4.25 contact hours.

Disclosure

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.

SCIENTIFIC PROGRAM SCHEDULE

2:00 PM – 2:10 PM

WELCOME AND OVERVIEW

David Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom

Mardi Gomberg-Maitland MD, MSc, Inova Heart and Vascular Institute, Falls Church, VA, USA

2:10 PM – 4:15 PM

SMALL GROUP INTERACTIVE DISCUSSION A: DIAGNOSIS AND ASSESSMENT OF OPERABILITY IN CTEPH

Moderator: Raymond Benza, MD

CASE SCENARIO A1: 'Proximal' CTEPH with expected good response from PEA

Deepa Gopalan, MD, Papworth Hospital, Cambridge, United Kingdom

CASE SCENARIO A2: Mixed pattern CTEPH with likely residual PH after PEA

William Auger, MD, UCSD Medical Center, San Diego, CA, USA

SMALL GROUP INTERACTIVE DISCUSSION B: USE OF VASODILATOR DRUGS PRE-AND POST-PEA

Moderator: Joanna Pepke-Zaba, PhD

CASE SCENARIO B1: Patient with severe PH 'bridged' with vasodilators prior to PEA

Marion Delcroix, MD, PhD, University Hospital Leuven, Leuven, Belgium

CASE SCENARIO B2: Patient with residual PH post PEA

John Cannon, FRCP, Papworth Hospital, Cambridge, United Kingdom

4:15 PM – 4:45 PM

COFFEE BREAK

4:45 PM – 6:50 PM

SMALL GROUP INTERACTIVE DISCUSSION C: SELECTION OF PATIENTS TO BENEFIT FROM BPA

Moderator: Duane Davis, MD, MBA

CASE SCENARIO C1: Typical patient with sub-segmental disease with expected good outcome from BPA

Irene Lang, MD, Medical University of Vienna, Vienna, Austria

CASE SCENARIO C2: Higher risk patient with less predictable result from BPA

Takeshi Ogo, National Cerebral and Cardiovascular Center, Osaka, Japan

SMALL GROUP INTERACTIVE DISCUSSION D: ADVANCED PEA TECHNIQUES AND PERI-OPERATIVE CARE

Moderator: Michael Madani, MD

CASE SCENARIO D1: Successful surgery in a patient with segmental/sub segmental disease

Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada

CASE SCENARIO D2: Complexities of post-operative care, dealing with complications and residual PH in the early post-operative period

Elie Fadel, MD, Hospital Marie Lannelongue, La Plessis-Robinson, France

6:50 PM – 7:00 PM

COURSE SUMMARY AND ASSESSMENT

David Jenkins, FRCS, Papworth Hospital, Cambridge, United Kingdom

Mardi Gomberg-Maitland MD, MSc, Inova Heart and Vascular Institute, Falls Church, VA, USA

7:00 PM

ADJOURN

AFFILIATE EVENTS

Coming Soon...

CORPORATE EVENTS AND INDUSTRY THEATERS LISTINGS

The following approved Corporate Events and Industry Theaters are taking place during the ISHLT Annual Meeting. All events are taking place at the Acropolis Congr s Centre unless noted as off-site. The Industry Theaters will take place inside the Rhodes Exhibit Hall in the Risso 6 Room.

Coming Soon...

EXHIBIT HALL FLOORPLAN




Exhibit Hall Floor Plan

2018 EXHIBITORS AND BOOTH NUMBERS

40	Abbott
48	Abiomed
31	ActiCare Health
33	Alere Home Monitoring
43, 44	Bayer AG
53	Bellerophon Therapeutics
37	Berlin Heart GMBH
49, 50, 51	Biotest AG
34	Bridge to Life (Europe) Ltd
41, 42	CareDx
5, 6	Carmat
32	Elsevier
7, 8	Evaheart, Inc.
15	Getinge
30	Hibernicor LLC.
4	ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)
12	Institut Georges Lopez
3	ISHLT Registries
10	Jarvik Heart, Inc.
39	Mallinckrodt Pharmaceuticals/Therakos UK (Ltd)
38	Medtronic
29	Millar, Inc.
45, 46	One Lambda, A Thermo Fisher Scientific Brand
14	Paragonix Technologies
52	Pulmonary Hypertension Association
9	Scanlan International, Inc.
13	SynCardia Systems, LLC
11	TAI Diagnostics, Inc
35	Tandem Life
36	Transmedics, Inc.
47	XVIVO Perfusion AB

2018 EXHIBITOR PRODUCT DESCRIPTIONS

ABBOTT Booth #40
Avenue Da Vincilaan 11
Zaychtem, Belgium B-1935
www.sjm.com

ABBOTT HAS LONG BEEN IN THE BUSINESS OF LIFE

At Abbott, we're all about helping you live the best life you can through good health. We keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines and breakthroughs to manage your health. Every day and around the world, we're discovering new ways to make life better.

ABIOMED Booth #48
Neuenhofer Weg 26
Aachen, Germany 52074
www.abiomed.com

Abiomed manufactures the Impella® family of the world's smallest heart pumps that provide temporary circulatory support, enabling the heart to rest and potentially recover its native function. The Impella pumps both unload the heart and stabilize the patient's hemodynamics before or during a percutaneous coronary intervention (PCI) procedure and during cardiogenic shock. With this minimally invasive intervention, Abiomed aims to change the standard of care for hemodynamic support by „Recovering hearts, saving lives™“.

Visit us at: www.abiomed.com

Learn more about Protected PCI at: www.protectedpci.com | www.protectedpci.eu

ACTICARE HEALTH Booth #31
6111 Southfront Road, Suite M
Livermore, CA 94551
<http://acticarehealth.com>

ActiCare Health (Booth #31) offers the first and only VAD, heart transplant and lung transplant tele-health and advanced monitoring platform with 24x7 support, empowering both patients and clinicians to achieve remarkable outcomes with reduced stress. In response to the immense administrative and operational challenges faced by VAD and transplant departments, we've designed a program to provide enhanced visibility into patients' health status, modernize patient safety and communication, optimize discharge plan adherence, and minimize adverse clinical and financial events. Our program is designed to positively affect health outcomes and quality of life, enhance care coordination and staff efficiency, and reduce costs.

ALERE HOME MONITORING Booth #33
6465 National Drive
Livermore, CA 94550

BAYER AG Booth #43, 44
Muellerstr. 178
13342 Berlin, Germany
www.bayer.com

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. For more information, go to www.bayer.com.

BELLEROPHON THERAPEUTICS Booth #53

184 Liberty Corner

Warren, NJ 07059

BERLIN HEART GMBH Booth #37

Wiesenweg 10

Berlin, Germany 12247

www.berlinheart.de

Berlin Heart is the only company worldwide that develops, produces, and distributes implantable and paracorporeal ventricular assist devices for patients of every age and body size. EXCOR® is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns, children, adolescents, and adults. INCOR® is an implantable axial-flow LVAD for adults. The Berlin Heart EXCOR® Pediatric Ventricular Assist Device is approved for use in the US. All other products are not FDA approved.

BIOTEST AG Booth #49,50,51

Landsteinerstraße 5

63303 Dreieich, Germany

www.biotest.de

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies.

BRIDGE TO LIFE (EUROPE) LTD Booth #34

LU311 The Light Bult, 1 Filament Walk

Wandsworth, United Kingdom SW18 4GQ

CAREDX, INC. Booth #41, 42

3260 Bayshore Blvd.

Brisbane, CA

www.caredx.com

CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.

CARMAT Booth #5, 6

36 Avenue De L'Europe – CS 40533

Vélizy-Villacoublay, France

www.carmatsa.com

CARMAT (contraction of founders' names Professor **C**arpentier and **M**atra – now part of Airbus Group) develops a bioprosthetic implantable artificial heart with its power supply and monitoring systems. Key differentiating features of this device are: use of bovine pericardium for most parts in contact with blood, which potentially reduces thromboembolic risks, and automatically adjustable pulsatile flow in response to patients' physiological needs thanks to embedded sensors and electronics. **CARMAT heart is an investigational device only and is not commercially available. The First-in-Man feasibility study was completed early in 2016. A CE MARK pivotal study is currently ongoing in Europe.**

ELSEVIER Booth #32
230 Park Avenue, Suite 800
New York, NY 10169
www.elsevier.com

Elsevier is a world-leading provider of information solutions that help you make better decisions, deliver better care, and sometimes make groundbreaking discoveries in science, health, and technology. We provide web-based, digital solutions — among them [ScienceDirect](#), [Scopus](#), [Evolve](#), [Knovel](#), [Reaxys](#) and [ClinicalKey](#) — and publish over 2,500 [journals](#) and more than 33,000 [book titles](#).

EVAHEART, INC. Booth #7, 8
6655 TRAVIS ST. STE 590
HOUSTON, TX 77030 USA
www.evaheart-usa.com

The EVAHEART Left Ventricular Assist System (LVAS)[™] is a continuous-flow, hydraulically levitated centrifugal pump designed to support patients with end-stage heart failure as bridge-to-transplant therapy. The EVAHEART LVAS has been commercially available in Japan since 2010, and has successfully obtained CE marking approval.

Evaheart, Inc. (EVI) is a medical device company based in the Texas Medical center of Houston. EVI was established to gain regulatory approval and commercialize the EVAHEART LVAS in North America and to start distribution in Europe. Under an FDA-approved IDE, a bridge-to-transplant (BTT) clinical trial of the EVAHEART LVAS is ongoing in the US.

GETINGE Booth #15
Kehlerst 31
Rastatt, Germany 76437

The CARDIOHELP System is a compact heart-lung support system suitable for all indications requiring extracorporeal circulation for cardiopulmonary support. Although extracorporeal life support provided by the CARDIOHELP System is not a therapy itself, it acts as a bridge for recovery or transplantation, enabling caregivers to optimize the patient's therapy. In cases of respiratory support, the extracorporeal circuit provided in a critical care unit enables the use of ultra-protective ventilation to optimize the therapy of acute respiratory distress syndromes (ARDS). The CARDIOHELP System can also act as cardiac support system until the myocardium recovers after an acute myocardial infarction.

HIBERNICOR LLC Booth #30
253 Ridge Drive
Jackson, MS 39216
769-257-6146
www.hibernicor.com/asporto/

Right now, world-wide greater than 6000 patients with end-stage heart failure are waiting for a donated heart. Many donated hearts – about 20 percent – are not used. The hearts are deemed unusable because the current ice cooler method only allows 3-4 hours of transport time. The solution to this problem is Asporto; an microcomputer controlled lightweight device which pumps cardioplegic to the donor heart during hypothermic storage. It is designed to improve the quality of the donor heart; thus allowing a greater transport distance. Hibernicor is a startup company developing the Asporto device - currently in pre-clinical research and development. For more information: www.hibernicor.com

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT REGISTRY (IMACS) Booth #4
701 19TH Street South, LHRB 790
Birmingham, AL 35294
<http://www.isHLT.org/registries/mcsdDatabase.asp>

IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place.

The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCS D data that allows participating centers to engage in important outcomes research about mechanical support devices.

INSTITUT GEORGES LOPEZ Booth #12

Parc Tertiaire du Bois Dieu
RN6 - 1 Allée des Chevreuils
Lissieu, France 69380
www.groupe-igl.com

Institut Georges Lopez consists of a network of subsidiaries located worldwide. This means we are never far from our customers. IGL design, manufacture, and market proprietary and equivalent products for organ preservation classified as drugs or medical devices. We represent a key player in the world of organ preservation, uniquely positioned by providing a comprehensive offer for the organ storage. We strive to be the worldwide reference in organ preservation technologies. Our work is inspired by our commitment to consistently meeting customer and regulatory requirements, to delivering quality products and to providing an innovative and comprehensive offer for organ preservation.”

ISHLT INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY Booth #3

700 N 4th Street
Richmond, VA 23219
www.ishlt.org

The ISHLT International Pediatric Heart Failure Registry (iPHFR) is an international registry intended to enroll and follow pediatric patients with heart failure in the setting of either congenital or acquired heart disease in all countries and hospitals that wish to participate. The primary goal is to collect and analyze clinically relevant data on pediatric heart failure patients in order to better understand the natural history and response to current treatment regimens.

ISHLT INTERNATIONAL REGISTRY FOR HEART AND LUNG TRANSPLANTATION Booth #3

700 N 4th Street
Richmond, VA 23219
www.ishlt.org

The ISHLT International Registry for Heart and Lung Transplantation was created for the purpose of providing on-going, current information on the worldwide thoracic organ transplantation experience. The collected data is made available to ISHLT members and the public via online quarterly data reports and annual data slides. The Annual ISHLT Registry Report includes survival data, risk factor data, and other outcome data in thoracic transplantation for a variety of demographic criteria.

JARVIK HEART, INC. Booth #10

333 West 52nd St
New York, NY 10019
www.jarvikheart.com

Jarvik Heart, Inc. is a privately held, New York City based company that develops, manufactures and sells unique cardiac assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery- powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available* for the long-term treatment of Heart Failure. The New Jarvik 15mm VAD has been designed for pediatric and small patients and will enter clinical trials in the USA and EU in 2018.

*Jarvik 2000 available, in US, only in FDA clinical trial.

MALLINCKRODT PHARMACEUTICALS/THERAKOS UK (LTD) Booth #39
3 Lotus Park, The Causeway
Staines-upon-Thames, Surrey, TW18 3AG, United Kingdom
www.therakos.co.uk

Mallinckrodt is focused on providing innovative therapeutic platforms and comprehensive support services to better enable healthcare professionals to deliver optimised ECP Immunomodulation to patients. The THERAKOS™ CELLEX™ Photopheresis system, the only integrated ECP platform, represents our latest advancement in ECP Immunomodulation technology.

THERAKOS ECP Immunomodulation™ employs the patient's own immune cells to modulate dysregulated immune function. The therapy consists of extracorporeally treating a small fraction of the patient's own leukocytes by exposing them to UVA light in the presence of a photosensitizing agent. This treatment induces apoptosis, which in turn initiates a cascade of immunomodulatory activities involving regulation of important immune cells and cytokines.

MEDTRONIC Booth #38
710 Medtronic Parkway
Minneapolis, MN 55432-5604
www.medtronic.com

Patients are at the center of everything we do —and we believe medical technology can play an even greater role in improving people's lives.

Medtronic Mechanical Circulatory Support is committed to continuous learning and innovation, to further advance the treatment of end-stage heart failure. We strive to improve patient outcomes and the clinical experience of your practice. Stop by the Medtronic booth to learn more and to see the latest HeartWare™ HVAD™ System enhancements.

Join us in our commitment to take healthcare Further, Together. Be inspired at medtronic.com.

MILLAR, INC. Booth #29
6001-A Gulf Freeway
Houston, TX 77023
www.millar.com

Millar is committed to making the improbable possible in cardiovascular diagnostics and research by delivering products that enable a deeper understanding of hemodynamic function. From accurate, pressure waveforms with the Mikro-Cath™ pressure catheter to plotting the complete cardiac cycle with the Inca® PV Loop System, expert insight is within reach. Millar is a unique provider of cardiovascular products that cover device and drug development from the first animal model through the final clinical trial. Millar OEM also serves the medical device and life sciences industries through our MEMS pressure sensors, ISO 13485 precision manufacturing and wireless power technology.

ONE LAMBDA, A THERMO FISHER SCIENTIFIC BRAND Booth #45, 46
21001 Kittridge Street
Canoga Park, CA 91303
www.onelambda.com

One Lambda, a brand of Thermo Fisher Scientific, is the global leader in transplant diagnostics. For over 30 years we remain committed to the global scientific and transplant communities; improving the standard of care for transplant patients and their families worldwide. We offer a broad range of HLA typing and antibody detection products, laboratory instrumentation, software and reagents to support clinicians and laboratories in the management of transplant patients.

PARAGONIX TECHNOLOGIES Booth #14
Paragonix Technologies, Inc.
c/o Vaughn & Associates
639 Granite Street
Braintree, MA 02184
www.paragonixtechnologies.com

PULMONARY HYPERTENSION ASSOCIATION Booth #52
801 Roeder Road, Ste. 1000
Silver Spring, MD 20910
www.PHAssociation.org

SCANLAN INTERNATIONAL, INC. Booth #9
One Scanlan Plaza
Saint Paul, MN 55107
info@scanlangroup.com
www.scanlaninternational.com

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, Scanlan® SUPER CUT™ and PREMIER Scissors. Full line of VATS / MIS Thoracoscopic instruments including the Chitwood Aortic Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter; Axial Handle needle holders and forceps. Single-use products include: Scanlan® VASCU-STATT® bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

SYNCARDIA SYSTEMS, LLC Booth #13
1992 E. Silverlake Road
Tucson, AZ 85713
www.syncardia.com

The SynCardia temporary Total Artificial Heart (TAH-t), the world's most used artificial heart, is now available in two sizes to serve more patients. The 70cc TAH-t is FDA, Health Canada and CE approved as a bridge to transplant for patients with end-stage biventricular failure. The smaller 50cc TAH-t, approved in Europe and Canada and undergoing an Investigational Device Exemption clinical study in the U.S., is designed for patients of smaller stature, including women and adolescents. Stable patients can be discharged to wait for a matching donor heart at home using the Freedom® portable driver. Visit our booth to learn more.

TAI DIAGNOSTICS, INC. Booth #11
10101 Innovation Drive, Suite 600
Wauwatosa, WI, 53226
www.taidiagnostics.com

TAI Diagnostics, Inc. is a leading biotechnology company focused on providing non-invasive and highly sensitive diagnostic tests to monitor the health of transplanted organs in patients who have received solid organ transplants.

The myTAI_{HEART}™ test aids in identifying heart transplant recipients with a low probability of acute cellular rejection and can be used on patients as young as two months of age, and as early as one week post-transplant. myTAI_{HEART} is non-invasive, requiring only a small sample of blood with actionable results available the next business day.

TANDEM LIFE Booth #35
240 Alpha Drive
Pittsburgh, PA 15238

One Pump. Massive Potential. TandemLife (formerly, CardiacAssist, Inc.) exists to deliver Life Support Simplified, with one small pump enabling any type of extracorporeal circulatory support your patients may need. The TandemHeart pump was the driving force behind the world's first percutaneous left heart support system. We've added on to this legacy of innovation by developing three new product lines with the same reliability you've come to expect; TandemLife, TandemLung, and Protek Duo. Visit us to learn how we can empower your program to deliver breakthrough performance in extracorporeal support.

TRANSMEDICS, INC. Booth #36
200 Minuteman Road, Suite 302
Andover, MA 01810
www.transmedics.com

TransMedics Inc. is a global leader in the field of ex-vivo physiologic organ preservation for lung, heart and liver transplantation using the Organ Care System (OCS™) technology. The OCS™ is the only portable multi-organ platform for ex-vivo preservation, optimization and assessment of donor organs for transplantation.

XVIVO PERFUSION AB Booth #47
Box 53015
SE-400 14 Gothenburg, Sweden
www.xvivoperfusion.com

XVIVO Perfusion manufactures and markets solutions and systems for transplantation:

- Perfadex® and Perfadex® Plus for hypothermic flushing and preservation of donor lungs during transport
- STEEN Solution™ for normothermic *ex vivo* lung perfusion and evaluation
- XPS™ and LS™ platforms for warm perfusion and evaluation of lungs *ex vivo*, after donation and prior to transplantation

XPS™, disposables and the perfusates are CE-marked, approved in Canada, Australia and US. LS™ and disposables are approved in Europe, Canada and Australia.

XVIVO aims to increase the number of organs available for transplantation and transplantation success rates using new transplantation concepts and techniques.

FUTURE ANNUAL MEETINGS

2019
39th Annual Meeting and Scientific Sessions
Orlando, FL, USA
April 3-6 2019

2020
40th Annual Meeting and Scientific Sessions
Montreal, Canada
April 2020

2021
41st Annual Meeting and Scientific Sessions
Sydney, Australia
April 2021



International Society for Heart and Lung
Transplantation
14673 Midway Road, Suite 200
Addison, TX 75001 USA
972-490-9495
www.isHLT.org